Polynucleotides encoding interleukin-12 (IL12) and uses thereof

ABSTRACT

The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Application No.PCT/US2017/033422, filed May 18, 2017, which claims the benefit of U.S.Provisional Patent Application Ser. No. 62/338,483, filed May 18, 2016,and U.S. Provisional Patent Application Ser. No. 62/443,693, filed Jan.7, 2017. The entire contents of the above-referenced patent applicationsare incorporated herein by this reference.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. The name of the text file containing theSequence Listing is Said ASCII copy, created on Nov. 15, 2018, is namedMDN_714PCCN_Sequence_Listing and is 390121 bytes in size.

BACKGROUND

Interleukin-12 (IL12) is a pro-inflammatory cytokine that plays animportant role in innate and adaptive immunity. Gately, M K et al., AnnuRev Immunol. 16: 495-521 (1998). IL12 functions primarily as a 70 kDaheterodimeric protein consisting of two disulfide-linked p35 and p40subunits. IL12 p40 homodimers do exist, but other than functioning as anantagonist that binds the IL12 receptor, they do not appear to mediate abiologic response. Id. The precursor form of the IL12 p40 subunit(NM_002187; P29460; also referred to as IL12B, natural killer cellstimulatory factor 2, cytotoxic lymphocyte maturation factor 2) is 328amino acids in length, while its mature form is 306 amino acids long.The precursor form of the IL12 p35 subunit (NM_000882; P29459; alsoreferred to as IL12A, natural killer cell stimulatory factor 1,cytotoxic lymphocyte maturation factor 1) is 219 amino acids in lengthand the mature form is 197 amino acids long. Id. The genes for the IL12p35 and p40 subunits reside on different chromosomes and are regulatedindependently of each other. Gately, M K et al., Annu Rev Immunol. 16:495-521 (1998). Many different immune cells (e.g., dendritic cells,macrophages, monocytes, neutrophils, and B cells) produce IL12 uponantigenic stimuli. The active IL12 heterodimer is formed followingprotein synthesis. Id.

Due to its ability to activate both NK cells and cytotoxic T cells, IL12protein has been studied as a promising anti-cancer therapeutic since1994. See Nastala, C. L. et al., J Immunol 153: 1697-1706 (1994). Butdespite high expectations, early clinical studies did not yieldsatisfactory results. Lasek W. et al., Cancer Immunol Immunother 63:419-435, 424 (2014). Repeated administration of IL12, in most patients,led to adaptive response and a progressive decline of IL12-inducedinterferon gamma (IFN-γ) levels in blood. Id. Moreover, while it wasrecognized that IL12-induced anti-cancer activity is largely mediated bythe secondary secretion of IFNγ, the concomitant induction of IFN-γalong with other cytokines (e.g., TNF-α) or chemokines (IP-10 or MIG) byIL12 caused severe toxicity. Id.

In addition to the negative feedback and toxicity, the marginal efficacyof the IL12 therapy in clinical settings may be caused by the strongimmunosuppressive environment in humans. Id. To minimize IFN-γ toxicityand improve IL12 efficacy, scientists tried different approaches, suchas different dose and time protocols for IL12 therapy. See Sacco, S. etal., Blood 90: 4473-4479 (1997); Leonard, J. P. et al., Blood 90:2541-2548 (1997); Coughlin, C. M. et al., Cancer Res. 57: 2460-2467(1997); Asselin-Paturel, C. et al., Cancer 91: 113-122 (2001); andSaudemont, A. et al., Leukemia 16: 1637-1644 (2002). Nonetheless, theseapproaches have not significantly impacted patient survival. Kang, W.K., et al., Human Gene Therapy 12: 671-684 (2001).

Currently, a number of IL12 clinical trials are on-going. Though thesemultiple clinical trials have been on-going for nearly 20 years sincethe first human clinical trial of IL12 in 1996, an FDA-approved IL12product is still not available. Thus, there is a need in the art for animproved therapeutic approach for using IL12 to treat tumors.

BRIEF SUMMARY

The present disclosure provides mRNA therapeutics for the treatment ofcancer. The mRNA therapeutics of the disclosure are particularlywell-suited for the treatment of cancer as the technology provides forthe intracellular delivery of mRNA encoding immune modulatingpolypeptides (for example, immune stimulating polypeptides, such asIL-12, and the like, useful in immuno-oncology (“IO”)), followed by denovo synthesis of functional proteins within target cells, e.g., withintarget cells in tumors. The disclosure features therapeutic mRNAs havingmodified nucleotides to (1) minimize unwanted immune activation (e.g.,the innate immune response associated with in vivo introduction offoreign nucleic acids) and (2) optimize the translation efficiency ofmRNA to protein. Exemplary aspects of the disclosure feature therapeuticmRNAs having a combination of nucleotide modifications to reduce theinnate immune response and sequence optimization, in particular, withinthe open reading frame (ORF) of therapeutic mRNAs encoding immunemodulating polypeptides (e.g., immune stimulating polypeptides such asIL-12) to enhance protein expression.

In other aspects, the mRNA therapeutic technology of the disclosurefeatures delivery of mRNA(s) encoding immune modulating (e.g., immunestimulating) polypeptides via a lipid nanoparticle (LNP) deliverysystem. In exemplary embodiments, the mRNA therapeutic technology of thedisclosure features delivery of mRNA(s) encoding immune modulatingpolypeptides into tumors via a lipid nanoparticle (LNP) delivery system.The disclosure also features novel ionizable lipid-based LNPs which haveimproved properties when combined with mRNA(s) encoding immunemodulating (e.g., immune stimulating) polypeptides and administered invivo, for example, cellular uptake, intracellular transport and/orendosomal release or endosomal escape. The LNP formulations of thedisclosure also demonstrate reduced immunogenicity associated with thein vivo administration of LNPs.

Certain aspects of the present disclosure are directed to a method ofreducing the size of a tumor or inhibiting growth of a tumor in asubject in need thereof comprising administering to the subject aneffective amount of a composition comprising one or more polynucleotidesencoding an IL-12 polypeptide, wherein the polynucleotide comprises anopen reading frame (“ORF”) encoding an interleukin 12 p40 subunit(“IL12B”) polypeptide and an interleukin 12 p35 subunit (“IL12A”)polypeptide. In some embodiments, the method further comprisesadministering to the subject an effective amount of a compositioncomprising a polynucleotide comprising an ORF encoding a checkpointinhibitor polypeptide or an effective amount of a composition comprisinga checkpoint inhibitor polypeptide. In some embodiments, the checkpointinhibitor polypeptide inhibits PD1, PD-L1, CTLA-4, or a combinationthereof. In certain embodiments, the checkpoint inhibitor polypeptidecomprises an antibody. In some embodiments, administering thecomposition activates T cells in the subject.

Another aspect of the present disclosure is directed to a method ofactivating T cells in a subject in need thereof comprising administeringto the subject an effective amount of a composition comprising one ormore polynucleotides encoding an IL-12 polypeptide, wherein thepolynucleotide comprises an ORF encoding an IL12B polypeptide and anIL12A polypeptide. In some embodiments, the T cell activation comprisesinducing T cell proliferation. In some embodiments, the T cellactivation comprises inducing T cell infiltration in the tumor orincreasing the number of tumor-infiltrating T cells. In someembodiments, the T cell activation comprises inducing a memory T cellresponse. In some embodiments, the activated T cells comprise CD4⁺ Tcells, CD8⁺ T cells, or both. In certain embodiments, administering thecomposition alone or in combination with a composition comprising apolynucleotide comprising an ORF encoding a checkpoint inhibitorpolypeptide or a composition comprising a checkpoint inhibitorpolypeptide increases an effector to suppressor T cell ratio in thetumor. In some embodiments, administering the composition furtherincreases the number of activated NK cells in the subject. In someembodiments, administering the composition increases cross-presentingdendritic cells in the tumor of the subject. In some embodiments,administering the composition reduces the size of a distal tumor orinhibits growth of a distal tumor in the subject.

Another aspect of the present disclosure is directed to a method ofincreasing an effector to suppressor T cell ratio in a tumor of asubject in need thereof comprising administering to the subject aneffective amount of a composition comprising one or more polynucleotidesencoding an IL-12 polypeptide, wherein the polynucleotide comprises anORF encoding an IL12B polypeptide and an IL12A polypeptide. In someembodiments, the effector to suppressor T cell ratio is a CD8⁺ T cells:Tregulatory (Treg) cells ratio.

Another aspect of the present disclosure is directed to a method ofincreasing the number of activated Natural Killer (NK) cells in asubject in need thereof comprising administering to the subject aneffective amount of a composition comprising one or more polynucleotidesencoding an IL-12 polypeptide, wherein the polynucleotide comprises anORF encoding an IL12B polypeptide and an IL12A polypeptide.

Another aspect of the present disclosure is directed to a method ofincreasing cross-presenting dendritic cells in a tumor of a subject inneed thereof comprising administering to the subject an effective amountof a composition comprising one or more polynucleotides encoding anIL-12 polypeptide, wherein the polynucleotide comprises an ORF encodingan IL12B polypeptide and an IL12A polypeptide. In some embodiments, thecross-presenting dendritic cells are CD103⁺ cells.

Another aspect of the present disclosure is directed to a lipidnanoparticle comprising a polynucleotide encoding a human IL12polypeptide, wherein the polynucleotide comprises an ORF encoding ahuman IL12B polypeptide operably linked to a human IL12A polypeptide.

In some embodiments, the IL12B polypeptide and the IL12A polypeptide arefused directly or by a nucleic acid encoding a linker. In someembodiments, the IL12B polypeptide comprises an amino acid sequence atleast 80%, at least 90%, at least 95%, or at least 98% identical toamino acids 23 to 328 of SEQ ID NO: 48, wherein the amino acid sequencehas IL12B activity. In some embodiments, the IL12A polypeptide comprisesan amino acid sequence at least 80%, at least 90%, at least 95%, or atleast 98% identical to amino acids 336 to 532 of SEQ ID NO: 48, whereinthe amino acid sequence has IL12A activity. In some embodiments, thepolynucleotide comprises a nucleotide sequence encoding a signalpeptide. In some embodiments, the signal peptide is an IL12B signalpeptide.

In some embodiments, the composition comprises a polynucleotidecomprising an ORF encoding an IL12B polypeptide operably linked via alinker to an IL12A polypeptide. In some embodiments, the compositioncomprises a polynucleotide comprising an ORF encoding an IL12B signalpeptide, an IL12B polypeptide, a linker and an IL12A polypeptide. Insome embodiments, the linker comprises a Gly/Ser linker.

In some embodiments, the IL12 polypeptide comprises an amino acidsequence at least 80%, at least 90%, at least 95%, or at least 98%identical to SEQ ID NO: 48. the polynucleotide comprises a nucleotidesequence at least 60%, at least 70%, at least 80%, at least 90%, atleast 95%, at least 98%, or at least 99% identical to a nucleotidesequence selected from the group consisting of SEQ ID NOs: 5 to 44, 236,and 237. In some embodiments, the polynucleotide comprises a nucleotidesequence at least 60%, at least 70%, at least 80%, at least 90%, atleast 95%, at least 98%, or at least 99% identical to SEQ ID NO: 236 or237.

In some embodiments, the polynucleotide comprises an ORF comprising atleast one chemically modified nucleoside. In some embodiments, the atleast one chemically modified nucleoside is selected from the groupconsisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine,5-methoxyuridine, and a combination thereof. In some embodiments, thechemically modified nucleosides in the ORF are selected from the groupconsisting of uridine, adenine, cytosine, guanine, and any combinationthereof.

In some embodiments, the polynucleotide comprises a miRNA binding site.In some embodiments, the miRNA binding site is a miR-122 binding site.In some embodiments, the miRNA binding site is a miR-122-3p ormiR-122-5p binding site. In certain embodiments, the miRNA binding sitecomprises a nucleotide sequence at least about 80%, at least about 85%,at least about 90%, at least about 95%, or about 100% identical toaacgccauua ucacacuaaa ua (SEQ ID NO: 51), wherein the miRNA binding sitebinds to miR-122. In certain embodiments, the miRNA binding sitecomprises a nucleotide sequence at least about 80%, at least about 85%,at least about 90%, at least about 95%, or about 100% identical touggaguguga caaugguguu ug (SEQ ID NO: 53), wherein the miRNA binding sitebinds to miR-122. In certain embodiments, the miRNA binding sitecomprises a nucleotide sequence at least about 80%, at least about 85%,at least about 90%, at least about 95%, or about 100% identical tocaaacaccau ugucacacuc ca (SEQ ID NO: 54), wherein the miRNA binding sitebinds to miR-122.

In some embodiments, the polynucleotide comprises a 5′ untranslatedregion (UTR). In certain embodiments, the 5′ UTR comprises a nucleicacid sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a sequence listed in Table 3. In some embodiments, thepolynucleotide comprises a 3′ untranslated region (UTR). In certainembodiments, the 3′ UTR comprises a nucleic acid sequence at least 90%,95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table4A or 4B. In some embodiments, the polynucleotide comprises a miRNAbinding site within the 3′ UTR. In some embodiments, the polynucleotidecomprises a nucleotide spacer sequence fused to the miRNA binding site.In some embodiments, the polynucleotide comprises a 5′ terminal capstructure. In some embodiments, the polynucleotide comprises a 3′ polyAtail. In some embodiments, the polynucleotide comprises a codonoptimized ORF. In certain embodiments, the polynucleotide is in vitrotranscribed (IVT) polynucleotide. In certain embodiments, thepolynucleotide is circular.

In certain aspects, the polynucleotide is formulated with a deliveryagent. In some embodiments, the delivery agent comprises a lipidoid, aliposome, a lipoplex, a lipid nanoparticle, a polymeric compound, apeptide, a protein, a cell, a nanoparticle mimic, a nanotube, or aconjugate. In some embodiments, the delivery agent is a lipidnanoparticle. In some embodiments, the delivery agent comprises acompound having formula (I)

or a salt or stereoisomer thereof, wherein

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′; R₂ and R₃ are independently selected from thegroup consisting of H, C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and—R*OR″, or R₂ and R₃, together with the atom to which they are attached,form a heterocycle or carbocycle; R₄ is selected from the groupconsisting of a C₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR,—CQ(R)₂, and unsubstituted C₁₋₆ alkyl, where Q is selected from acarbocycle, heterocycle, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃,—CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R,—N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, and —C(R)N(R)₂C(O)OR, and each n isindependently selected from 1, 2, 3, 4, and 5; each R₅ is independentlyselected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H;each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂— an aryl group, and a heteroaryl group; R₇ is selected from thegroup consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl, and H; each R isindependently selected from the group consisting of C₁₋₃ alkyl, C₂₋₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H; each R″is independently selected from the group consisting of C₃₋₁₄ alkyl andC₃₋₁₄ alkenyl; each R* is independently selected from the groupconsisting of C₁₋₁₂ alkyl and C₂₋₁₂ alkenyl; each Y is independently aC₃₋₆ carbocycle; each X is independently selected from the groupconsisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9,10, 11, 12, and 13; and provided when R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, or —CQ(R)₂, then (i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5,or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.

In some embodiments, the compound is of Formula (IA):

or a salt or stereoisomer thereof, wherein 1 is selected from 1, 2, 3,4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which n is 1, 2, 3, 4,or 5 and Q is OH, —NHC(S)N(R)₂, or —NHC(O)N(R)₂; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—,an aryl group, and a heteroaryl group; and R₂ and R₃ are independentlyselected from the group consisting of H, C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In some embodiments, the compound is of Formula (II):

or a salt or stereoisomer thereof, wherein 1 is selected from 1, 2, 3,4, and 5;

M₁ is a bond or M′; R₄ is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, inwhich n is 2, 3, or 4 and Q is OH, —NHC(S)N(R)₂, or —NHC(O)N(R)₂; M andM′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—P(O)(OR′)O—, an aryl group, and a heteroaryl group; and R₂ and R₃ areindependently selected from the group consisting of H, C₁₋₁₄ alkyl, andC₂₋₁₄ alkenyl.

In some embodiments, the compound is selected from Compound 1 toCompound 147, and salts and stereoisomers thereof. In some embodiments,the delivery agent comprises a compound having the formula (I)

or a salt or stereoisomer thereof, wherein R₁ is selected from the groupconsisting of C₅₃₀ alkyl, C₅₂₀ alkenyl, —R*YR″, —R″, and R″M′R′; R₂ andR₃ are independently selected from the group consisting of H, C₁₁₄alkyl, C₂₁₄ alkenyl, R*YR″, YR″, and R*OR″, or R₂ and R₃, together withthe atom to which they are attached, form a heterocycle or carbocycle;R₄ is selected from the group consisting of a C₃₆ carbocycle,(CH₂)_(n)Q, —(CH₂)_(n)CHQR, CHQR, CQ(R)₂, and unsubstituted C₁₆ alkyl,where Q is selected from a carbocycle, heterocycle, —OR,—(CH₂)_(n)N(R)₂, —(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂,—OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR,—N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5; each R₅ is independently selected from the group consisting ofC₁₃ alkyl, C₂₃ alkenyl, and H; each R₆ is independently selected fromthe group consisting of C₁₃ alkyl, C₂₃ alkenyl, and H; M and M′ areindependently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—(O)—, —C(S)—, —C(S)S—, —SC(S)—, —(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—,an aryl group, and a heteroaryl group; R₇ is selected from the groupconsisting of C₁₃ alkyl, C₂₃ alkenyl, and H; R₈ is selected from thegroup consisting of C₃₋₆ carbocycle and heterocycle; R₉ is selected fromthe group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR, —S(O)₂R,—S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle; each R isindependently selected from the group consisting of C₁₃ alkyl, C₂₃alkenyl, and H; each R′ is independently selected from the groupconsisting of C₁₁₈ alkyl, C₂₁₈ alkenyl, R*YR″, YR″, and H; each R″ isindependently selected from the group consisting of C₃₁₄ alkyl and C₃₁₄alkenyl; each R* is independently selected from the group consisting ofC₁₁₂ alkyl and C₂₁₂ alkenyl; each Y is independently a C₃₆ carbocycle;each X is independently selected from the group consisting of F, Cl, Br,and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; andprovided that when R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂,then (i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5,6, or 7-membered heterocycloalkyl when n is 1 or 2.

In some embodiments, the delivery agent further comprises aphospholipid. In some embodiments, the phospholipid is selected from thegroup consisting of 1,2 dilinoleoyl sn glycero 3 phosphocholine (DLPC),1,2 dimyristoyl sn glycero phosphocholine (DMPC), 1,2 dioleoyl snglycero 3 phosphocholine (DOPC), 1,2 dipalmitoyl sn glycero 3phosphocholine (DPPC), 1,2 distearoyl sn glycero 3 phosphocholine(DSPC), 1,2 diundecanoyl sn glycero phosphocholine (DUPC), 1 palmitoyl 2oleoyl sn glycero 3 phosphocholine (POPC), 1,2 di O octadecenyl snglycero 3 phosphocholine (18:0 Diether PC), 1 oleoyl 2cholesterylhemisuccinoyl sn glycero 3 phosphocholine (OChemsPC), 1hexadecyl sn glycero 3 phosphocholine (C16 Lyso PC), 1,2 dilinolenoyl snglycero 3 phosphocholine, 1,2 diarachidonoyl sn glycero 3phosphocholine, 1,2 didocosahexaenoyl sn glycero 3 phosphocholine, 1,2dioleoyl sn glycero 3 phosphoethanolamine (DOPE), 1,2 diphytanoyl snglycero 3 phosphoethanolamine (ME 16:0 PE), 1,2 distearoyl sn glycero 3phosphoethanolamine, 1,2 dilinoleoyl sn glycero 3 phosphoethanolamine,1,2 dilinolenoyl sn glycero 3 phosphoethanolamine, 1,2 diarachidonoyl snglycero 3 phosphoethanolamine, 1,2 didocosahexaenoyl sn glycero 3phosphoethanolamine, 1,2 dioleoyl sn glycero 3 phospho rac (1 glycerol)sodium salt (DOPG), sphingomyelin, and mixtures thereof. In someembodiments, the phospholipid is selected from the group consisting of 1myristoyl 2 palmitoyl sn glycero 3 phosphocholine (14:0-16:0 PC, MPPC),1 myristoyl 2 stearoyl sn glycero 3 phosphocholine (14:0-18:0 PC, MSPC),1 palmitoyl 2 acetyl sn glycero 3 phosphocholine (16:0-02:0 PC), 1palmitoyl 2 myristoyl sn glycero 3 phosphocholine (16:0-14:0 PC, PMPC),1 palmitoyl 2 stearoyl sn glycero 3 phosphocholine (16:0-18:0 PC, PSPC),1 palmitoyl 2 oleoyl sn glycero 3 phosphocholine (16:0-18:1 PC, POPC), 1palmitoyl 2 linoleoyl sn glycero 3 phosphocholine (16:0-18:2 PC, PLPC),1 palmitoyl 2 arachidonoyl sn glycero 3 phosphocholine (16:0-20:4 PC), 1palmitoyl 2 docosahexaenoyl sn glycero 3 phosphocholine (14:0-22:6 PC),1 stearoyl 2 myristoyl sn glycero 3 phosphocholine (18:0-14:0 PC, SMPC),1 stearoyl 2 palmitoyl sn glycero 3 phosphocholine (18:0-16:0 PC, SPPC),1 stearoyl 2 oleoyl sn glycero 3 phosphocholine (18:0-18:1 PC, SOPC), 1stearoyl 2 linoleoyl sn glycero 3 phosphocholine (18:0-18:2 PC), 1stearoyl 2 arachidonoyl sn glycero 3 phosphocholine (18:0-20:4 PC), 1stearoyl 2 docosahexaenoyl sn glycero 3 phosphocholine (18:0-22:6 PC), 1oleoyl 2 myristoyl sn glycero 3 phosphocholine (18:1-14:0 PC, OMPC), 1oleoyl 2 palmitoyl sn glycero 3 phosphocholine (18:1-16:0 PC, OPPC), 1oleoyl 2 stearoyl sn glycero 3 phosphocholine (18:1-18:0 PC, OSPC), 1palmitoyl 2 oleoyl sn glycero 3 phosphoethanolamine (16:0-18:1 PE,POPE), 1 palmitoyl 2 linoleoyl sn glycero 3 phosphoethanolamine(16:0-18:2 PE), 1 palmitoyl 2 arachidonoyl sn glycero 3phosphoethanolamine (16:0-20:4 PE), 1 palmitoyl 2 docosahexaenoyl snglycero 3 phosphoethanolamine (16:0-22:6 PE), 1 stearoyl 2 oleoyl snglycero 3 phosphoethanolamine (18:0-18:1 PE), 1 stearoyl 2 linoleoyl snglycero 3 phosphoethanolamine (18:0-18:2 PE), 1 stearoyl 2 arachidonoylsn glycero 3 phosphoethanolamine (18:0-20:4 PE), 1 stearoyl 2docosahexaenoyl sn glycero 3 phosphoethanolamine (18:0-22:6 PE), 1oleoyl 2 cholesterylhemisuccinoyl sn glycero 3 phosphocholine(OChemsPC), and any combination thereof.

In some embodiments, the delivery agent further comprises a structurallipid. In some embodiments, the delivery agent further comprises a PEGlipid. In some embodiments, the delivery agent further comprises anionizable lipid selected from the group consisting of 3 (didodecylamino)N1,N1,4 tridodecyl 1 piperazineethanamine (KL10), N1 [2(didodecylamino)ethyl] N1,N4,N4 tridodecyl 1,4 piperazinediethanamine(KL22), 14,25 ditridecyl 15,18,21,24-tetraaza-octatriacontane (KL25),1,2 dilinoleyloxy N,N dimethylaminopropane (DLin-DMA), 2,2 dilinoleyl 4dimethylaminomethyl [1,3]dioxolane (DLin-K-DMA), heptatriaconta6,9,28,31 tetraen 19 yl 4 (dimethylamino)butanoate (DLin-MC3-DMA), 2,2dilinoleyl 4 (2 dimethylaminoethyl) [1,3] dioxolane (DLin-KC2-DMA), 1,2dioleyloxy N,N dimethylaminopropane (DODMA), 2 ({8 [(3β) cholest 5 en 3yloxy]octyl}oxy) N,N dimethyl 3 [(9Z,12Z) octadeca 9,12 dien 1yloxy]propan 1 amine (Octyl-CLinDMA), (2R) 2 ({8 [(3β) cholest 5 en 3yloxy]octyl}oxy) N,N dimethyl 3 [(9Z,12Z) octadeca 9,12 dien 1yloxy]propan 1 amine (Octyl-CLinDMA (2R)), and (2S) 2 ({8 [(3β) cholest5 en 3 yloxy]octyl}oxy) N,N dimethyl 3 [(9Z,12Z) octadeca 9,12 dien 1yloxy]propan 1 amine (Octyl-CLinDMA (2S)).

In some embodiments, the delivery agent further comprises a quaternaryamine compound. In certain embodiments, the quaternary amine compound isselected from the group consisting of1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride (DOTMA),1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride(DOTIM),2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide(DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DORIE),N,N-dioleyl-N,N-dimethylammonium chloride (DODAC),

1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC),1,2-distearoyl-3-trimethylammonium-propane (DSTAP),1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP),1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP),1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC),1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC),1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC),1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC),1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC),1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0-18:1 EPC),and any combination thereof.

In certain aspects, the composition is formulated for in vivo delivery.In some aspects, the composition is formulated for intramuscular,subcutaneous, intratumoral, or intradermal delivery.

In certain aspects, the administration treats a cancer. In someembodiments, the cancer is selected from the group consisting of adrenalcortical cancer, advanced cancer, anal cancer, aplastic anemia, bileductcancer, bladder cancer, bone cancer, bone metastasis, brain tumors,brain cancer, breast cancer, childhood cancer, cancer of unknown primaryorigin, Castleman disease, cervical cancer, colon/rectal cancer,endometrial cancer, esophagus cancer, Ewing family of tumors, eyecancer, gallbladder cancer, gastrointestinal carcinoid tumors,gastrointestinal stromal tumors, gestational trophoblastic disease,Hodgkin disease, Kaposi sarcoma, renal cell carcinoma, laryngeal andhypopharyngeal cancer, acute lymphocytic leukemia, acute myeloidleukemia, chronic lymphocytic leukemia, chronic myeloid leukemia,chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma(HCC), non-small cell lung cancer, small cell lung cancer, lungcarcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiplemyeloma, myelodysplastic syndrome, nasal cavity and paranasal sinuscancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oralcavity and oropharyngeal cancer, osteosarcoma, ovarian cancer,pancreatic cancer, penile cancer, pituitary tumors, prostate cancer,retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma inadult soft tissue, basal and squamous cell skin cancer, melanoma, smallintestine cancer, stomach cancer, testicular cancer, throat cancer,thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvarcancer, Waldenstrom macroglobulinemia, Wilms tumor, secondary cancerscaused by cancer treatment, and any combination thereof.

In certain aspects, the composition is administered by a devicecomprising a pump, patch, drug reservoir, short needle device, singleneedle device, multiple needle device, micro-needle device, jetinjection device, ballistic powder/particle delivery device, catheter,lumen, cryoprobe, cannula, microcanular, or devices utilizing heat, RFenergy, electric current, or any combination thereof. In some aspects,the effective amount is between about 0.10 mg/kg to about 1,000 mg/kg.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

FIG. 1 shows (1) the wild-type IL12B amino acid sequence, (2) thewild-type nucleic acid encoding the wtIL12B, (3) the wild-type IL12Aamino acid sequence, (4) the wild-type nucleic acid encoding thewtIL12A, (5) the wild-type IL12B signal peptide amino acid sequence, and(6) the wild-type nucleic acid encoding the wtIL12B signal peptide.

FIGS. 2A-2B. FIG. 2A is a graph depicting the higher AUC and C_(max) forIL12 plasma levels observed following intravenous administration of IL12mRNA in lipid nanoparticle (LNP) compared to the corresponding IL12recombinant protein. FIG. 2B is a graph depicting the higher AUC andC_(max) for IFNγ plasma levels observed following intravenousadministration of IL12 mRNA administered in lipid nanoparticle (LNP)compared to IL12 recombinant protein.

FIG. 3 is a graph depicting the robust efficacy of a single intravenous(IV) dose of IL12 mRNA in lipid nanoparticle (LNP), at doses of 0.1mg/kg (Group 4) and 0.05 mg/kg (Group 5) (as indicated by lines with theinverted triangles), compared to Groups 1 (PBS), 2 (IL12 protein), 7 and8 (controls NST-FIX, 0.1 mg/kg and 0.05 mg/kg, respectively).

FIGS. 4A-4F are graphs depicting the mean tumor volume and the number ofcomplete responses (CR) seen following administration of a singleintravenous (IV) dose of: IL12 mRNA in lipid nanoparticle (LNP), atdoses of 0.1 mg/kg (Group 4) (FIG. 4F) and 0.05 mg/kg (Group 5) (FIG.4E), PBS (Group 1) (FIG. 4A), IL12 protein (Group 2) (FIG. 4D), controlsNST-FIX, 0.1 mg/kg and 0.05 mg/kg (Groups 7 and 8, respectively) (FIG.4C and FIG. 4B, respectively). Complete responses (CRs) are shown inFIGS. 4E and 4F only. FIG. 4E shows that 6 of 8 CRs were seen in Group 5(IL12 mRNA in lipid nanoparticle (LNP), at a dose of 0.05 mg/kg). FIG.4F shows that 5 of 9 CRs were seen in Group 4 (IL12 mRNA in lipidnanoparticle (LNP), at a dose of 0.1 mg/kg). Aside from the IL12 mRNAgroups, all other groups did not observe any CRs.

FIG. 5 is a graph depicting the survival benefit at day 47 posttumor-implantation from a single intravenous (IV) dose of IL12 mRNA inlipid nanoparticle (LNP) at a dose of 0.05 mg/kg (Group 5) and a dose of0.1 mg/kg (Group 4) compared to a single IV dose of IL12 protein at 1 μg(˜0.05 mg/kg) (Group 2), NST-FIX at 0.1 mg/kg (Group 7) or 0.05 mg/kg(Group 8), or PBS (Group 1).

FIGS. 6A-6B are graphs showing the in vivo anti-tumor efficacy of asingle intratumoral dose of IL12 mRNA (4 μg) in a lipid nanoparticle(LNP) administered to mice bearing adenocarcinoma (MC38) tumors. FIG. 6Ashows the tumor volume means (mm³), up to day 24, starting at day 10post implantation. Group 1 (circles) represents mice (n=7) administered4 μg IL12 mRNA LNP at day 10 post-implantation; Group 2 (squares)represents mice (n=7) administered 4 μg of control mRNA encodingnon-translated factor IX (NST-FIX LNP); and Group 3 (triangles)represents another control group of mice (n=7) administered PBS. FIG. 6Bshows the individual tumor volumes (mm³) for each group of mice, up today 47, starting at day 10 post implantation. Complete responses (CR)were achieved in 3 of 7 (44%) animals administered 4 μg IL12 mRNA LNP(circles).

FIGS. 7A-7B are graphs showing the in vivo anti-tumor efficacy of anintratumoral dose of IL12 mRNA (5 μg) in MC3-based lipid nanoparticle(LNP) administered to mice bearing A20 B-cell lymphoma tumors. FIG. 7Ashows the individual tumor volume (mm³) for mice (n=12) administered 5μg non-translated control mRNA (NST). FIG. 7B shows the individual tumorvolumes for mice (n=12) administered 5 μg of IL12 (miRless) mRNA.Complete responses (CR) were achieved in 5 of 12 animals that receivedIL12 mRNA.

FIG. 7C is a graph showing comparable in vivo anti-tumor efficacy ofIL12 mRNA (5 μg) containing a miR122 binding site (FIG. 7C) in a B-celllymphoma tumor model (A20). Both IL12 mRNAs (with miR122 binding siteand without (i.e., miRless)) were formulated in an MC3-based lipidnanoparticle (LNP). The IL12 mRNAs were administered to mice bearing A20B-cell lymphoma tumors. Complete responses (CR) were achieved in 6 outof 12 mice in the IL12 miR122 group (FIG. 7C).

FIGS. 8A-8B are graphs showing in vivo anti-tumor efficacy of a singledose of 0.5 μg IL12 mRNA in MC3-based lipid nanoparticle (LNP)administered to mice bearing A20 B-cell lymphoma tumors. Completeresponses (CR) were achieved in 4 of 12 mice in the IL12 miRless (0.5μg) group (FIG. 8A) and 3 of 12 mice in the IL12 miR122 (0.5 μg) group(FIG. 8B).

FIG. 8C is a graph showing enhanced in vivo anti-tumor efficacy in aB-cell lymphoma tumor model (A20) by administering multiple doses of 0.5μg IL12 mRNA in MC3-based lipid nanoparticle (LNP) to mice bearing A20tumors. Complete responses (CR) were achieved in 5 out of 12 miceadministered weekly dosing of 0.5 μg IL12 miR122 for seven (7) days×6.

FIG. 8D is a graph showing that the in vivo anti-tumor efficacy ofweekly intratumoral doses of 0.5 μg IL12 mRNA in lipid nanoparticle(LNP) (i.e., Compound 18) administered to mice bearing A20 B-celllymphoma tumors is similar to the in vivo anti-tumor efficacy of 0.5 μgIL12 mRNA in MC3-based LNP. FIG. 14 shows the individual tumor volumesfor 12 mice administered 0.5 μg of IL12 mRNA in Compound 18-based LNPfor 7 days×6. Complete responses (CR) were also achieved in 5 out of 12animals.

FIGS. 8E-8F are graphs showing tumor growth in mice bearing A20 tumorsadministered weekly dosing (7 days×6) of 0.5 μg non-translated negativecontrol mRNA (NST) in MC3-based lipid nanoparticle (LNP) (FIG. 8E) and0.5 μg non-translated negative control mRNA (NST) in Compound 18-basedLNP (FIG. 8F).

FIGS. 9A-9B are graphs showing dose-dependent levels of IL12 in plasma(FIG. 9A) and tumor (FIG. 9B) at 6 hours and 24 hours followingintratumoral administration of the indicated doses of IL12 mRNA inMC3-based LNPs to mice bearing A20 tumors. From left to right, the micewere given (i) PBS, (ii) 0.5 μg NST, (iii) 2.5 μg NST, (iv) 5 g NST, (v)0.5 μg IL12, (vi) 2.5 μg IL12, (vii) 5 μg IL12, (viii) 0.5 μg IL12miR122, (ix) 2.5 μg IL12 miR122, and (x) 5 μg IL12 miR122.

FIGS. 9C-9D are graphs showing elevated levels of IL12 in plasma andtumor following administration of indicated doses of IL12 mRNA inCompound 18-based LNPs compared to IL12 mRNA in MC3-based LNPs. FIG. 9Cshows plasma IL12 levels at 6 hours and 24 hours; FIG. 9D shows tumorIL12 levels at 6 hours and 24 hours. From left to right, the mice weregiven (i) PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 μg NST in MC3, (iv) 0.5μg IL12 miR122 in MC3, (v) 2.5 μg IL12 miR122 in MC3, (vi) 0.5 μg NST inCompound 18, (vii) 2.5 μg NST in Compound 18, (viii) 5 μg IL12 miR122,(ix) 0.5 μg IL12 miR122 in Compound 18, and (x) 2.5 μg IL12 miR122 inCompound 18.

FIGS. 9E-9F are graphs showing increased levels of IFNγ at 6 hours and24 hours in plasma (FIG. 9E) and in tumor (FIG. 9F) followingadministration of IL12 mRNA to mice bearing A20 tumors. From left toright, the mice were given (i) PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 μgNST in MC3, (iv) 5 μg NST in MC3, (v) 0.5 μg IL12 in MC3, (vi) 2.5 μgIL12 in MC3, (vii) 5 μg IL12 in MC3, (viii) 0.5 μg IL12 miR122 in MC3,(ix) 2.5 g IL12 miR122 in MC3, (x) 5 μg IL12 miR122 in MC3, (xi) 0.5 μgNST in Compound 18, (xii) 2.5 μg NST in Compound 18, (xiii) 0.5 μg IL12miR122 in Compound 18, and (xiv) 2.5 μg IL12 miR122 in Compound 18.

FIGS. 9G-9H are graphs showing increased levels of IP10 at 6 hours and24 hours in plasma (FIG. 9G) and in tumor (FIG. 9H) followingadministration of IL12 mRNA to mice bearing A20 tumors. From left toright, the mice were given (i) PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 μgNST in MC3, (iv) 5 μg NST in MC3, (v) 0.5 μg IL12 in MC3, (vi) 2.5 μgIL12 in MC3, (vii) 5 μg IL12 in MC3, (viii) 0.5 μg IL12 miR122 in MC3,(ix) 2.5 g IL12 miR122 in MC3, (x) 5 μg IL12 miR122 in MC3, (xi) 0.5 μgNST in Compound 18, (xii) 2.5 μg NST in Compound 18, (xiii) 0.5 μg IL12miR122 in Compound 18, and (xiv) 2.5 μg IL12 miR122 in Compound 18.

FIGS. 9I-9J are graphs showing decreased levels of IL6 at 6 hours and 24hours in plasma (FIG. 9I) and in tumor (FIG. 9J) followingadministration of IL12 mRNA. From left to right, the mice were given (i)PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 μg NST in MC3, (iv) 5 μg NST inMC3, (v) 0.5 μg IL12 in MC3, (vi) 2.5 μg IL12 in MC3, (vii) 5 g IL12 inMC3, (viii) 0.5 μg IL12 miR122 in MC3, (ix) 2.5 μg IL12 miR122 in MC3,(x) 5 μg IL12 miR122 in MC3, (xi) 0.5 μg NST in Compound 18, (xii) 2.5μg NST in Compound 18, (xiii) 0.5 μg IL12 miR122 in Compound 18, and(xiv) 2.5 μg IL12 miR122 in Compound 18.

FIGS. 9K-9L are graphs showing decreased levels of G-CSF at 6 hours and24 hours in plasma (FIG. 9K) and in tumor (FIG. 9L) followingadministration of IL12 mRNA. From left to right, the mice were given (i)PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 g NST in MC3, (iv) 5 μg NST inMC3, (v) 0.5 μg IL12 in MC3, (vi) 2.5 μg IL12 in MC3, (vii) 5 μg IL12 inMC3, (viii) 0.5 μg IL12 miR122 in MC3, (ix) 2.5 μg IL12 miR122 in MC3,(x) 5 μg IL12 miR122 in MC3, (xi) 0.5 μg NST in Compound 18, (xii) 2.5μg NST in Compound 18, (xiii) 0.5 μg IL12 miR122 in Compound 18, and(xiv) 2.5 g IL12 miR122 in Compound 18.

FIGS. 9M-9N are graphs showing decreased levels of GROα at 6 hours andat 24 hours in plasma (FIG. 9M) and tumor (FIG. 9N) followingadministration of IL12 mRNA. From left to right, the mice were given (i)PBS, (ii) 0.5 μg NST in MC3, (iii) 2.5 g NST in MC3, (iv) 5 μg NST inMC3, (v) 0.5 μg IL12 in MC3, (vi) 2.5 μg IL12 in MC3, (vii) 5 μg IL12 inMC3, (viii) 0.5 μg IL12 miR122 in MC3, (ix) 2.5 μg IL12 miR122 in MC3,(x) 5 μg IL12 miR122 in MC3, (xi) 0.5 μg NST in Compound 18, (xii) 2.5μg NST in Compound 18, (xiii) 0.5 μg IL12 miR122 in Compound 18, and(xiv) 2.5 g IL12 miR122 in Compound 18.

FIGS. 10A-10B are graphs showing individual tumor volumes through day 35post disease induction with A20 tumor following treatment withIL12_miR122 mRNA (FIG. 10B) compared to negative control mRNA (FIG.10A).

FIGS. 10C-10D are graphs showing body weight measurements of micethrough day 35 post disease induction with A20 tumor following treatmentwith IL12_miR122 mRNA (FIG. 10D) compared to negative control mRNA (FIG.10C).

FIG. 11A is a graph depicting bioluminescence (BL) as a surrogate fortumor burden at day 22 post disease induction with a luciferase-enabledMC38 colon cancer cell line in mice. From left to right, mice wereadministered no treatment, 2 μg mIL12_miRless, 2 μg mIL12_miR122, 2 μgNST_OX40L_122, 4 μg mIL12_miRless, 4 g mIL12_miR122, 4 g NST_OX40L_122,and 1 μg rm IL12.

FIG. 11B is a Kaplan-Meier curve showing the percent survival of micetreated with LNPs carrying IL12 mRNA compared to NST-OX40L negativecontrols. The graph shows survival to day 150 post implantation with A20tumor.

FIG. 12A shows uracil (U) metrics corresponding to wild type IL12B and20 sequence optimized IL12B polynucleotides (hIL12AB_001 tohIL12AB_020). FIG. 12B shows guanine (G) metrics corresponding to wildtype IL12B and 20 sequence optimized IL12B polynucleotides (hIL12AB_001to hIL12AB_020). FIG. 12C shows cytosine (C) metrics corresponding towild type IL12B and 20 sequence optimized IL12B polynucleotides(hIL12AB_001 to hIL12AB_020). FIG. 12D shows guanine plus cytosine (G/C)metrics corresponding to wild type IL12B and 20 sequence optimized IL12Bpolynucleotides (hIL12AB_001 to hIL12AB_020).

FIG. 13A shows uracil (U) metrics corresponding to wild type IL12B and20 sequence optimized IL12B polynucleotides (hIL12AB_021 tohIL12AB_040). FIG. 13B shows guanine (G) metrics corresponding to wildtype L12B and 20 sequence optimized IL12B polynucleotides (hIL12AB_021to hIL12AB_040). FIG. 13C shows cytosine (C) metrics corresponding towild type IL12B and 20 sequence optimized IL12B polynucleotides(hIL12AB_021 to hIL12AB_040). FIG. 13D shows guanine plus cytosine (G/C)metrics corresponding to wild type IL12B and 20 sequence optimized IL12Bpolynucleotides (hIL12AB_021 to hIL12AB_040).

FIG. 14A shows uracil (U) metrics corresponding to wild type IL12A and20 sequence optimized IL12A polynucleotides (hIL12AB_001 tohIL12AB_020). FIG. 14B shows guanine (G) metrics corresponding to wildtype L12A and 20 sequence optimized IL12A polynucleotides (hIL12AB_001to hIL12AB_020). FIG. 14C shows cytosine (C) metrics corresponding towild type IL12A and 20 sequence optimized IL12A polynucleotides(hIL12AB_001 to hIL12AB_020). FIG. 14D shows guanine plus cytosine (G/C)metrics corresponding to wild type IL12A and 20 sequence optimized IL12Apolynucleotides (hIL12AB_001 to hIL12AB_020).

FIG. 15A shows uracil (U) metrics corresponding to wild type IL12A and20 sequence optimized IL12A polynucleotides (hIL12AB_021 tohIL12AB_040). FIG. 15B shows guanine (G) metrics corresponding to wildtype L12A and 20 sequence optimized IL12A polynucleotides (hIL12AB_021to hIL12AB_040). FIG. 15C shows cytosine (C) metrics corresponding towild type IL12A and 20 sequence optimized IL12A polynucleotides(hIL12AB_021 to hIL12AB_040). FIG. 15D shows guanine plus cytosine (G/C)metrics corresponding to wild type IL12A and 20 sequence optimized IL12Apolynucleotides (hIL12AB_021 to hIL12AB_040). The column labeled “G/CContent (%)” corresponds to % G/Cm.

FIG. 16A shows a comparison between the G/C compositional bias for codonpositions 1, 2, 3 corresponding to the wild type IL12B and 20 sequenceoptimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). FIG. 16Bshows a comparison between the G/C compositional bias for codonpositions 1, 2, 3 corresponding to the wild type IL12B and 20 sequenceoptimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). FIG. 16Cshows a comparison between the G/C compositional bias for codonpositions 1, 2, 3 corresponding to the wild type IL12A and 20 sequenceoptimized IL12A polynucleotides (hIL12AB_0-1 to hIL12AB_020). FIG. 16Dshows a comparison between the G/C compositional bias for codonpositions 1, 2, 3 corresponding to the wild type IL12A and 20 sequenceoptimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040).

FIG. 17A is a graph showing dose-dependent levels of IL12 in plasma at24 hours following intratumoral administration of the indicated doses ofIL12 mRNA to mice bearing tumors. From left to right, the mice weregiven (i) no treatment, (ii) 5 μg NST, (iii) 0.05 μg IL12 miR122, (iv)0.5 μg IL12 miR122, (v) 5 μg IL12 miR122, (vi) 5 μg NST, (vii) 0.5 μgIL12 miR122 (4 doses), (viii) 2.5 μg IL12 miR122 (4 doses), and (ix) 5 gIL12 miR122 (4 doses).

FIG. 17B is a graph showing increased levels of IFNγ in plasma at 24hours following intratumoral administration of IL12 mRNA to mice bearingtumors. From left to right, the mice were given (i) no treatment, (ii) 5μg NST, (iii) 0.05 μg IL12 miR122, (iv) 0.5 μg IL12 miR122, (v) 5 μgIL12 miR122, (vi) 5 μg NST, (vii) 0.5 μg IL12 miR122 (4 doses), (viii)2.5 μg IL12 miR122 (4 doses), and (ix) 5 μg IL12 miR122 (4 doses).

FIGS. 18A-18B are graphs showing increased levels of IL12 in plasma(FIG. 18A) and IFNγ in plasma (FIG. 18B) over the course of 200 hoursfollowing intraperitoneal administration of IL12 mRNA to mice bearingMC38 tumors. Mice were given (i) no treatment, (ii) 2 μg IL12 miRless,(iii) 2 μg IL12 miR122, (iv) 4 μg IL12 miRless, (v) 4 μg miR122, (vi) 1μg IL12 protein, (vii) 2 μg NST_OX40L_122, or (viii) 4 μg NST_OX40L_122.

FIGS. 19A-19B are graphs showing individual tumor volumes through day 90post disease induction with A20 tumor following treatment with 0.5 μgIL12_miR122 mRNA in a Compound 18-based lipid nanoparticle (LNP) (FIG.19B) compared to negative control mRNA (FIG. 19A).

FIGS. 19C-19D are graphs showing individual tumor volumes through day 60post disease induction with A20 tumor in naïve mice (FIG. 19C) or incomplete responder mice previously treated with IL12_miR122 mRNA andrechallenged (FIG. 19D).

FIGS. 20A-20D are graphs showing individual tumor volumes through 80days following a single intratumoral dose of IL12 mRNA to mice bearingMC38-S tumors. Mice were given 0.05 μg IL12 mRNA (FIG. 20A), 0.5 μg IL12mRNA (FIG. 20B), 5 μg IL12 mRNA (FIG. 20C), or NST (FIG. 20D).

FIGS. 21A-21F are graphs showing individual tumor volumes through 80days following a single dose or multiple doses of IL12 mRNA to micebearing MC38-S tumors. Mice were given a single dose of 0.05 μg IL12mRNA (FIG. 21A), a single dose of 0.5 μg IL12 mRNA (FIG. 21B), a singledose of 5 μg IL12 mRNA (FIG. 21C), two doses of 0.05 μg IL12 mRNA (FIG.21D), two doses of 0.5 μg IL12 mRNA (FIG. 21E), two doses of 5 μg IL12mRNA (FIG. 21F).

FIG. 22 is a Kaplan-Meier curve showing the percent survival of micetreated with LNPs carrying IL12 mRNA compared to NST-FIX negativecontrols. The graph shows survival to day 80 post implantation withMC38-S tumor.

FIG. 23A-23D are graphs showing individual tumor volumes through 75 daysfollowing a single dose of IL12 mRNA to mice bearing MC38-R tumors. Micewere given 0.05 μg IL12 mRNA (FIG. 23A), 0.5 μg IL12 mRNA (FIG. 23B), 5μg IL12 mRNA (FIG. 23C), or NST (FIG. 23D).

FIG. 23E-23J are graphs showing individual tumor volumes through 75 daysfollowing a single dose or multiple doses of IL12 mRNA to mice bearingMC38-R tumors. Mice were given a single dose of 0.05 μg IL12 mRNA (FIG.23E), a single dose of 0.5 μg IL12 mRNA (FIG. 23F), a single dose of 5μg IL12 mRNA (FIG. 23G), multiple doses of 0.05 μg IL12 mRNA (FIG. 23H),multiple doses of 0.5 μg IL12 mRNA (FIG. 23I), or multiple doses of 5 μgIL12 mRNA (FIG. 23J).

FIG. 24 is a Kaplan-Meier curve showing the percent survival of micetreated with LNPs carrying IL12 mRNA compared to NST-OX40L negativecontrols. The graph shows survival to day 80 post implantation withMC38-R tumor.

FIG. 25 is a graph showing depletion of CD8+ T cells over the course of28 days.

FIGS. 26A-26E are graphs showing individual tumor volumes through 90days following CD8+ T cell depletion and subsequent administration of asingle dose of IL12 mRNA to mice bearing MC38-R tumors. Mice were givenan antibody control for CD8+ T cell depletion and then 0.5 μg negativecontrol mRNA (FIG. 26A), an antibody control for CD8+ T cell depletionand then 0.5 μg IL12 mRNA (FIG. 26B), CD8+ T cell-depleting antibodyclone 24.3 and then 0.5 μg negative control mRNA (FIG. 26C), or CD8+ Tcell-depleting antibody clone 24.3 and then 0.5 μg IL12 mRNA (FIG. 26D).

FIG. 26E is a Kaplan-Meier curve showing the percent survival of micetreated with IL12 mRNA absent CD8+ T cell depletion compared to micetreated with IL12 mRNA after CD8+ T cell depletion. The graph showssurvival to day 90 post implantation with MC38-R tumor.

FIGS. 27A-27B are graphs showing the percent of CD1 lb+ myeloid cellsstaining positive for PDL1 expression in MC38-R (FIG. 27A) andB16F10-AP3 (FIG. 27B) tumors 24 hours or 72 hours after no treatment,treatment with an NST negative control or two different intratumoraldoses of IL12 mRNA. Statistical significance is indicated by asterisks.

FIGS. 28A-28B are graphs showing CD8+ T cells in tumors as a proportionof the immune infiltrate (CD45+ cells) (left panels) and per mg of tumor(right panels) in MC38-R (FIG. 28A) and B16F10-AP3 (FIG. 28B) tumors 7days after no treatment, treatment with an NST negative control or twodifferent doses of IL12 mRNA. Statistical significance is indicated byasterisks.

FIGS. 29A-29B are graphs showing ratio of CD8+ T cells to Treg cells inMC38-R (FIG. 29A) and B16F10-AP3 (FIG. 29B) tumors 7 days after notreatment, treatment with an NST negative control or two different dosesof IL12 mRNA. Statistical significance is indicated by asterisks.

FIGS. 30A-30B are graphs showing the percent of cells CD8+ T cellsstaining positive for the early activation marker CD69 in MC38-R (FIG.30A) and B16F10-AP3 (FIG. 30B) tumors 24 hours after no treatment,treatment with an NST negative control or two different doses of IL12mRNA. Statistical significance is indicated by asterisks.

FIGS. 31A-31B are graphs showing the percent of NK cells stainingpositive for the early activation marker CD69 in MC38-R (FIG. 31A) andB16F10-AP3 (FIG. 31B) tumors 24 hours or 72 hours after no treatment,treatment with an NST negative control or two different doses of IL12mRNA. Statistical significance is indicated by asterisks.

FIGS. 32A-32B are graphs showing the number of CD103+ classicaldendritic cells per mg of MC38-R (FIG. 32A) and B16F10-AP3 (FIG. 32B)tumors 7 days after no treatment, treatment with an NST negative controlor two different doses of IL12 mRNA.

FIG. 32C is a graph showing the percent of CD8+ classical dendriticcells staining positive for CD86 in the tumor draining lymph node (LN)of a B16F10-AP3 tumor 24 hours, 72 hours, or 7 days after no treatment,treatment with an NST negative control or two different dose of IL12mRNA. Statistical significance is indicated by asterisks.

FIGS. 33A-33B are graphs showing individual tumor volumes through 55days following administration of anti-PD-L1 antibody to mice bearingMC38-R tumors. Mice were given an antibody control (FIG. 33A) or ananti-PD-L1 antibody (clone 80) (FIG. 33B). FIGS. 33C-33G are graphsshowing individual tumor volumes in mice bearing MC38-R tumors through90 days following administration of IL12 mRNA alone or in combinationwith an anti-PD-L1 antibody. Mice were given (i) a single iTu dose of0.5 g IL12 mRNA as a monotherapy (FIG. 33C), (ii) a single iTu dose of5.0 μg IL12 miR122 as a monotherapy (FIG. 33D), (iii) a single iTu doseof 0.5 μg IL12 miR122 in combination with multiple intraperitoneal dosesof anti-PD-L1 antibody (FIG. 33E), (iv) a single iTu dose of 5.0 μg IL12mRNA in combination with multiple intraperitoneal doses of anti-PD-L1antibody (FIG. 33F); or (v) multiple intraperitoneal doses of anti-PD-L1antibody (FIG. 33G).

FIGS. 34A-34C are graphs showing individual tumor volumes through 75days. Mice bearing MC38-R tumors were treated 10 days post implant withan anti-PD-L1 antibody alone (FIG. 34A), 0.5 μg IL12 mRNA alone (FIG.34B), or both an anti-PD-L1 antibody and 0.5 μg IL12 mRNA (FIG. 34C).The anti-PD-L1 antibody was administered over 6 doses. Vertical dashedlines indicate dose days.

FIGS. 35A-35D are graphs showing individual tumor volumes through 70days. Mice bearing B16F10-AP3 tumors were treated 10 days post implantwith a negative control (FIG. 35A), an anti-PD-L1 antibody alone (FIG.35B), a single dose of 0.5 μg IL12 mRNA alone (FIG. 35C), or with bothan anti-PD-L1 antibody and 0.5 μg IL12 mRNA (FIG. 35D). The anti-PD-L1antibody was administered over 6 doses. Vertical dashed lines indicatedose days.

FIG. 36A is a drawing of a mouse implanted bilaterally with tumor cells.FIGS. 36B-36G are graphs showing individual tumor volumes in bilaterallyimplanted MC38-S mice through 60 days in treated (FIGS. 36B, 36D, and36F) and distal (FIGS. 36C, 36E, and 36G) tumors following treatmentwith a negative control (NST mRNA plus isotype antibody control) (FIGS.36B-36C), 0.5 μg IL12 mRNA (FIG. 36D-36E), or 5 μg IL12 mRNA (FIGS.36F-36G). Vertical dashed lines indicate dose days.

FIGS. 37A-37F are graphs showing individual tumor volumes in bilaterallyimplanted MC38-S mice through 60 days following treatment with no activemRNA (NST mRNA) (FIGS. 37A-37B), 0.5 μg IL12 mRNA (FIG. 37C-37D), or 5μg IL12 mRNA (FIGS. 37E-37F), combined with either an isotype controlantibody (FIG. 37A, 37C, or 37E) or an anti-PD-L1 antibody (FIG. 37B,37D, or 37F). Vertical dashed lines indicate dose days.

FIG. 38 is a graph showing human IL-12 expression in vitro and in vivoby wild-type and codon optimized IL-12 mRNA constructs.

DETAILED DESCRIPTION

The present disclosure provides a new approach to treat cancer involvingthe prevention or treatment of disease with substances (e.g., mRNAsencoding IL12) that stimulate the immune response, i.e., immunotherapy.

In one aspect, the disclosure relates to methods of treating cancerusing a polynucleotide encoding IL12. An IL12 polypeptide as disclosedherein comprises IL12A, IL12B, or both IL12A and IL12B. In anotheraspect, the disclosure provides methods of treating cancer using acombination approach that features mRNAs encoding IL12 and ananti-cancer agent, e.g., an immune-checkpoint inhibitor, e.g., anti-PD-1antibody, anti-PD-L1 antibody, and/or anti-CTLA-4 antibody. Withoutbeing bound by any theory, it is believed that priming of an anti-cancerimmune response is possible by administering, e.g., intratumorally,mRNAs encoding IL12 in the stimulation of, for example, T-cells and/ornatural killer cells. Therefore, an mRNA encoding IL12 is believed toprovide a first stimulation signal to the immune system, for example,within the tumor environment, e.g., via intratumoral injection of themRNA. IL12 can also stimulate the production of interferon-gamma (IFN-γ)and tumor necrosis factor-alpha (TNF-α) from T cells and natural killer(NK) cells. As disclosed herein, IL12, either directly or indirectlythrough IFN-γ, can also increase expression of PD-L1 in tumor cells,which can impair local tumor immunity. Therefore, in some aspects, thedisclosure provides a method of treating tumor comprising administeringa polynucleotide (e.g., mRNA) encoding IL12 in combination with ananti-PD-1 antibody or anti-PD-L1 antibody to block the interactionbetween PD-L1 and its receptor, i.e., PD-1. In other aspects, thedisclosure includes a method of treating tumor comprising administeringa polynucleotide (e.g., mRNA) encoding IL2 in combination with ananti-CTLA-4 antibody. In further aspects, the disclosure provides amethod of treating tumor comprising administering a polynucleotide(e.g., mRNA) encoding IL2 in combination with an anti-PD-1 antibody oranti-PD-L1 antibody and an anti-CTLA-4 antibody. Some aspects of thedisclosure also include additional agents, e.g., OX40L, a polynucleotideencoding OX40L, or mRNA encoding an OX40L. In other aspects, theanti-PD-1 antibody or anti-PD-L1 antibody can be administered in theform of a polynucleotide. Similarly, the anti-CTLA-4 antibody can beadministered in the form of a polynucleotide. Exemplary aspects featuretreatment with lipid nanoparticle-(LNP-) encapsulated mRNAs. Exemplaryaspects feature intratumoral administration of mRNAs in cationiclipid-based LNPs.

1. Methods of Treating Cancer

Certain aspects of the present disclosure are directed to methods ofreducing or decreasing size, mass, and/or volume of a tumor orpreventing the growth of a tumor in a subject in need thereof comprisingadministering a polynucleotide, e.g., mRNA, encoding an IL12B and/orIL12A polypeptide disclosed herein, or a vector or a host cellcomprising the polynucleotide, or an IL12B and/or IL12A polypeptideencoded by the polynucleotide. In certain embodiments, thepolynucleotide encodes an IL-12 polypeptide, wherein the polynucleotidecomprises an ORF encoding an IL12B and an IL12A polypeptides. In someembodiments, the methods of reducing the size (including mass and/orvolume) of a tumor or inhibiting growth of a tumor in a subject in needthereof comprise administering to the subject an effective amount of acomposition comprising one or more polynucleotides. In some embodiments,the one or more polynucleotides encode an IL-12 polypeptide. In someembodiments, the one or more polynucleotides comprise an ORF encoding anIL12B polypeptide. In some embodiments, the one or more polynucleotidescomprise an ORF encoding an IL12A polypeptide. In certain embodiments,the one or more polynucleotides comprise an ORF encoding an IL12Bpolypeptide and an IL12A polypeptide.

In some embodiments, the methods further comprise administering a secondagent. In some embodiments, the second agent comprises an effectiveamount of a composition comprising a polynucleotide comprising an ORFencoding a checkpoint inhibitor polypeptide. In some embodiments, thesecond agent comprises an effective amount of a composition comprising acheckpoint inhibitor polypeptide. In some embodiments, the checkpointinhibitor is any checkpoint inhibitor known in the art or describedherein. In some embodiments, the checkpoint inhibitor is an anti-PD-1antibody. In other embodiments, the checkpoint inhibitor is ananti-PD-L1 antibody. In other embodiments, the checkpoint inhibitor isan anti-CTLA-4 antibody. In some embodiments, the second agent comprisesan effective amount of a composition comprising a polynucleotidecomprising an ORF encoding OX40L. In some embodiments, the checkpointinhibitor is selected from an anti-PD-1 antibody, an anti-PD-L1antibody, and/or an anti-CTLA-4 antibody, or a polynucleotide encodingOX40L or any other agents disclosed herein. In certain embodiments, thecomposition comprising a checkpoint inhibitor comprises more than onecheckpoint inhibitor. In one particular embodiment, the method comprisesadministering (i) an mRNA, encoding an IL12B and/or IL12A polypeptidedisclosed herein, and (ii) an anti-PD-L1 antibody, an anti-PD-1antibody, an anti-CTLA-4 antibody, a polynucleotide encoding OX40L, orany combination thereof.

In some embodiments, the methods reduce the size of a tumor in a subjectas compared to the size of the tumor before the administration. Incertain embodiments, the size of the tumor is reduced by at least about5%, at least about 10%, at least about 15%, at least about 20%, at leastabout 25%, at least about 30%, at least about 35%, at least about 40%,at least about 45%, at least about 50%, least about 60%, at least about70%, at least about 80%, at least about 90%, or about 100%. In certainembodiments, the subject exhibits a partial response. In certainembodiments, the subject exhibits a complete response.

In some embodiments, the methods of the present disclosure inhibit, stopor delay tumor growth in a subject in need thereof. In certainembodiments, the tumor growth is inhibited, stopped or delayed for atleast about 1 week, at least about 2 weeks, at least about 3 weeks, atleast about 1 month, at least about 2 months, at least about 3 months,at least about 4 months, at least about 5 months, at least about 6months, at least about 9 months, at least about 12 months, at leastabout 15 months, at least about 18 months, at least about 24 months, orat least about 36 months. In other embodiments, the tumor growth isinhibited indefinitely.

In other embodiments, the present disclosure provides methods ofpromoting an anti-tumor effect (e.g., induce T cell proliferation,induce T cell infiltration in a tumor, induce a memory T cell response,increasing the number of NK cells, etc.) by administering thepolynucleotide (e.g., mRNA) encoding IL12 alone or the polynucleotide incombination with any agents disclosed herein.

In one embodiment, the present disclosure provides a method ofactivating T cells in a subject in need thereof, inducing T cellproliferation in a subject in need thereof, inducing T cell infiltrationin a tumor of a subject in need thereof, and/or inducing a memory T cellresponse in a subject in need thereof, comprising administering to thesubject a composition disclosed herein, e.g., a polynucleotide (e.g.,mRNA) encoding IL12, alone or in combination with composition comprisinga second agent, e.g., a checkpoint inhibitor polypeptide or apolynucleotide comprising an ORF encoding a checkpoint inhibitorpolypeptide, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/oran anti-CTLA-4 antibody, or a polynucleotide encoding OX40L or any otheragents disclosed herein. In certain embodiments, the intratumoraladministration of the polynucleotide (e.g., mRNA) encoding IL12 alone orin combination with a second agent can increase the efficacy of theanti-tumor effect (e.g., T cell infiltration in a tumor) compared toother routes of administration.

In some embodiments, the administering of the compositions describedherein, e.g., a polynucleotide encoding an IL12, alone or in combinationwith a composition comprising a polynucleotide comprising an ORFencoding a checkpoint inhibitor polypeptide or a composition comprisinga checkpoint inhibitor polypeptide, activates T cells in the subject. Tcell activation can be characterized in any way known in the art. Insome embodiments, the activated T cells express CD4. In someembodiments, the activated T cells express CD8. In certain embodimentsthe activated T cells express CD4 and CD8. In certain embodiments, theactivated T cells comprise CD4⁺ T cells, CD8⁺ T cells, or both CD4⁺ Tcells and CD8⁺ T cells.

In one embodiment, activated T cells in the subject reduce the size of atumor or inhibit the growth of a tumor in the subject. Activation of Tcells can be measured using applications in the art such as measuring Tcell proliferation; measuring cytokine production with enzyme-linkedimmunosorbant assays (ELISA) or enzyme-linked immunospot assays(ELISPOT); or detection of cell-surface markers associated with T cellactivation (e.g., CD69, CD40L, CD137, CD25, CD71, CD26, CD27, CD28,CD30, CD154, and CD134) with techniques such as flow cytometry.

In some embodiments, T cell activation comprises inducing T cellproliferation. In some embodiments, T cell proliferation is increased byat least about 1.5 fold, at least about 2 fold, at least about 3 fold,at least about 4 fold, at least about 5 fold, at least about 6 fold, atleast about 7 fold, at least about 8 fold, at least about 9 fold, atleast about 10 fold, at least about 20 fold, at least about 30 fold, atleast about 50 fold, or at least about 100 fold, as compared to thelevel of T cell proliferation prior to the administration of the IL12encoding polynucleotide (e.g., mRNA).

In one embodiment, T cell proliferation in the subject is directed to ananti-tumor immune response in the subject. In another aspect, the T cellproliferation in the subject reduces or decreases the size of a tumor orinhibits the growth of a tumor in the subject. T cell proliferation canbe measured using applications in the art such as cell counting,viability staining, optical density assays, or detection of cell-surfacemarkers associated with T cell activation (e.g., CD69, CD40L, CD137,CD25, CD71, CD26, CD27, CD28, CD30, CD154, and CD134) with techniquessuch as flow cytometry.

In some embodiments, T cell activation comprises induction of T cellinfiltration of the tumor. In some embodiments, T cell infiltration inthe tumor is increased by at least about 2 fold, at least about 3 fold,at least about 4 fold, at least about 5 fold, at least about 6 fold, atleast about 7 fold, at least about 8 fold, at least about 9 fold, atleast about 10 fold, at least about 20 fold, at least about 30 fold, atleast about 50 fold, or at least about 100 fold, as compared to thelevel of T cell infiltration of the tumor prior to the administration ofthe IL12 encoding polynucleotide (e.g., mRNA).

In some embodiments, T cell activation comprises increasing the numberof tumor-infiltrating T cells. In certain embodiments, the number oftumor-infiltrating T cells in the tumor is increased by at least about 2fold, at least about 3 fold, at least about 4 fold, at least about 5fold, at least about 6 fold, at least about 7 fold, at least about 8fold, at least about 9 fold, at least about 10 fold, at least about 20fold, at least about 30 fold, at least about 50 fold, or at least about100 fold, as compared to the number of tumor infiltrating T cells in thetumor prior to the administration of the IL12 encoding polynucleotide(e.g., mRNA)

In one embodiment, T cell infiltration in a tumor of the subject isdirected to an anti-tumor immune response in the subject. In anotheraspect, the T cell infiltration in a tumor of the subject reduces ordecreases the size of a tumor or inhibits the growth of a tumor in thesubject. T cell infiltration in a tumor can be measured usingapplications in the art such as tissue sectioning and staining for cellmarkers, measuring local cytokine production at the tumor site, ordetection of T cell-surface markers with techniques such as flowcytometry.

In some embodiments, T cell activation comprises inducing a memory Tcell response in a subject in need thereof. In certain embodiments, thememory T cell response is increased by at least about 2 fold, at leastabout 3 fold, at least about 4 fold, at least about 5 fold, at leastabout 6 fold, at least about 7 fold, at least about 8 fold, at leastabout 9 fold, at least about 10 fold, at least about 20 fold, at leastabout 30 fold, at least about 50 fold, or at least about 100 fold, ascompared to the memory T cell response prior to the administration ofthe IL12 encoding polynucleotide (e.g., mRNA).

In one embodiment, the memory T cell response in the subject is directedto an anti-tumor immune response in the subject. In another aspect, thememory T cell response in the subject reduces or decreases the size of atumor or inhibits the growth of a tumor in the subject. A memory T cellresponse can be measured using applications in the art such as measuringT cell markers associated with memory T cells, measuring local cytokineproduction related to memory immune response, or detecting memory Tcell-surface markers with techniques such as flow cytometry.

In some embodiments, the administering of the compositions describedherein, e.g., a polynucleotide encoding an IL12, alone or in combinationwith a composition comprising a polynucleotide comprising an ORFencoding a checkpoint inhibitor polypeptide or a composition comprisinga checkpoint inhibitor polypeptide, increases an effector to suppressorT cell ratio in the tumor. In certain embodiments, the effector tosuppressor T cell ratio is characterized by the ratio of (i) CD8+, CD4+,or CD8+/CD4+ T cells to (ii) Treg cells in a subject. In certainembodiments, the increase in the effector to suppressor T cell ratiocorrelates with an increase in the number of CD8+ T cells. In someembodiments, the increase in the effector to suppressor T cell ratiocorrelates with an increase in the number of CD4+ T cells. In someembodiments, the increase in the effector to suppressor T cell ratiocorrelates with an increase in the number of CD8+/CD4+ T cells. In someembodiments, the increase in the effector to suppressor T cell ratiocorrelates with a decrease in the number of Treg cells.

In some embodiments, the effector to suppressor T cell ratio, e.g., theCD8⁺ T cell to Treg cell ratio, following administration of the IL12encoding polynucleotide (e.g., mRNA) (alone or in combination with ananti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, ora polynucleotide encoding OX40L) is at least about 1.5:1, at least about2:1, at least about 2.5:1, at least about 3:1, at least about 3.5:1, atleast about 3.5:1, at least about 4:1, at least about 4.5:1, at leastabout 5:1, at least about 6:1, at least about 7:1, at least about 8:1,at least about 9:1, at least about 10:1, at least about 15:1, at leastabout 20:1, at least about 25:1, at least about 30:1, at least about35:1, at least about 40:1, at least about 45:1, at least about 50:1, atleast about 60:1, at least about 70:1, at least about 80:1, at leastabout 90:1, at least about 100:1, at least about 110:1, at least about120:1, at least about 130:1, at least about 140:1, at least about 150:1,at least about 200:1, at least about 250:1, or at least about 500:1.

In some embodiments, the effector to suppressor T cell ratio, e.g., theCD8⁺ T cell to Treg cell ratio, following administration of the IL12encoding polynucleotide (e.g., mRNA) (alone or in combination with ananti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, ora polynucleotide encoding OX40L) is at least about 1.5, at least about2, at least about 2.5, at least about 3, at least about 3.5, at leastabout 3.5, at least about 4, at least about 4.5, at least about 5, atleast about 6, at least about 7, at least about 8, at least about 9, atleast about 10, at least about 15, at least about 20, at least about 25,at least about 30, at least about 35, at least about 40, at least about45, at least about 50, at least about 60, at least about 70, at leastabout 80, at least about 90, at least about 100, at least about 110, atleast about 120, at least about 130, at least about 140, at least about150, at least about 200, at least about 250, or at least about 500.

In one embodiment, the increase in the effector to suppressor T cellratio in the tumor is directed to an anti-tumor immune response in thesubject. In another aspect, the increase in the effector to suppressor Tcell ratio in the tumor reduces or decreases the size of a tumor orinhibits the growth of a tumor in the subject. The effector tosuppressor T cell ratio in the tumor can be measured using applicationsin the art such as measuring the ratio of CD8+, CD4+, or CD8+/CD4+ Tcells to Treg cells, using any methods known in the art including IHCand/or flow cytometry.

In certain embodiments, the activated T cells by the present methods areCD4⁺ cells, CD8⁺ cells, CD62⁺ (L-selectin⁺) cells, CD69⁺ cells, CD40L⁺cells, CD137⁺ cells, CD25⁺ cells, CD71⁺ cells, CD26⁺ cells, CD27⁺ cells,CD28⁺ cells, CD30⁺ cells, CD45⁺ cells, CD45RA⁺ cells, CD45RO⁺ cells,CD11b⁺ cells, CD154⁺ cells, CD134⁺ cells, CXCR3⁺ cells, CCR4⁺ cells,CCR6⁺ cells, CCR7⁺ cells, CXCR5⁺ cells, Crth2⁺ cells, gamma delta Tcells, or any combination thereof. In some embodiments, the activated Tcells by the present methods are Th₁ cells. In other embodiments, the Tcells activated by the present methods are Th₂ cells. In otherembodiments, the T cells activated by the present disclosure arecytotoxic T cells.

In some embodiments, the infiltrating T cells by the present methods areCD4⁺ cells, CD8⁺ cells, CD62⁺ (L-selectin⁺) cells, CD69⁺ cells, CD40L⁺cells, CD137⁺ cells, CD25⁺ cells, CD71⁺ cells, CD26⁺ cells, CD27⁺ cells,CD28⁺ cells, CD30⁺ cells, CD45⁺ cells, CD45RA⁺ cells, CD45RO⁺ cells,CD11b⁺ cells, CD154⁺ cells, CD134⁺ cells, CXCR3⁺ cells, CCR4⁺ cells,CCR6⁺ cells, CCR7⁺ cells, CXCR5⁺ cells, Crth2⁺ cells, gamma delta Tcells, or any combination thereof. In some embodiments, the infiltratingT cells by the present methods are Th₁ cells. In other embodiments, theinfiltrating T cells by the present methods are Th₂ cells. In otherembodiments, the infiltrating T cells by the present disclosure arecytotoxic T cells.

In some embodiments, the memory T cells induced by the present methodsare CD4⁺ cells, CD8⁺ cells, CD62⁺ (L-selectin⁺) cells, CD69⁺ cells,CD40L⁺ cells, CD137⁺ cells, CD25⁺ cells, CD71⁺ cells, CD26⁺ cells, CD27⁺cells, CD28⁺ cells, CD30⁺ cells, CD45⁺ cells, CD45RA⁺ cells, CD45RO⁺cells, CD11b⁺ cells, CD154⁺ cells, CD134⁺ cells, CXCR3⁺ cells, CCR4⁺cells, CCR6⁺ cells, CCR7⁺ cells, CXCR5⁺ cells, Crth2⁺ cells, gamma deltaT cells, or any combination thereof. In some embodiments, the memory Tcells by the present methods are Th₁ cells. In other embodiments, thememory T cells by the present methods are Th₂ cells. In otherembodiments, the memory T cells by the present disclosure are cytotoxicT cells.

In certain embodiments, the disclosure includes a method of inducing anadaptive immune response, an innate immune response, or both adaptiveand innate immune response against tumor comprising administering apolynucleotide, e.g., mRNA, encoding IL12 alone or in combination with asecond agent, e.g., a checkpoint inhibitor, e.g., an anti-PD-1 antibody,an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, a polynucleotideencoding OX40L, and/or any other agents disclosed herein.

The present disclosure further provides a method of increasing thenumber of Natural Killer (NK) cells in a subject in need thereofcomprising administering a polynucleotide comprising an mRNA encodingIL12 alone or in combination with a second agent, e.g., a checkpointinhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/oran anti-CTLA-4 antibody, a polynucleotide encoding OX40L, and/or anyother agents disclosed herein. In one aspect, the increase in the numberof NK cells in the subject is directed to an anti-tumor immune responsein the subject. In another aspect, the increase in the number of NKcells in the subject reduces or decreases the size of a tumor orinhibits the growth of a tumor in the subject. Increases in the numberof NK cells in a subject can be measured using applications in the artsuch as detection of NK cell-surface markers (e.g., CD335/NKp46;CD336/NKp44; CD337/NPp30) or intracellular NK cell markers (e.g.,perforin; granzymes; granulysin).

In some embodiments, the administering of the compositions describedherein, e.g., a polynucleotide (e.g., mRNA) encoding an IL12, alone orin combination with a composition comprising a polynucleotide comprisingan ORF encoding a checkpoint inhibitor polypeptide or a compositioncomprising a checkpoint inhibitor polypeptide, increases the number ofactivated NK cells in the subject as compared to the number of activatedNK cells prior to the administration. In some embodiments, the number ofactivated NK cells is increased by at least about 1.5 fold, at leastabout 2 fold, at least about 3 fold, at least about 4 fold, at leastabout 5 fold, at least about 6 fold, at least about 7 fold, at leastabout 8 fold, at least about 9 fold, at least about 10 fold, at leastabout 15 fold, at least about 20 fold, at least about 25 fold, at leastabout 30 fold, at least about 35 fold, at least about 40 fold, at leastabout 45 fold, at least about 50 fold, at least about 60 fold, at leastabout 70 fold, at least about 80 fold, at least about 90 fold, or atleast about 100 fold. In some embodiments, the increase in activated NKcells is maintained for at least about 1 day, at least about 2 days, atleast about 3 days, at least about 4 days, at least about 5 days, atleast about 6 days, at least about 7 days, at least about 8 days, atleast about 9 days, at least about 10 days, at least about 11 days, atleast about 12 days, at least about 13 days, at least about 14 days, atleast about 15 days, at least about 16 days, at least about 17 days, atleast about 18 days, at least about 19 days, at least about 20 days, atleast about 21 days, or at least about 28 days.

In some embodiments, the administering of the compositions describedherein, e.g., a polynucleotide (e.g., mRNA) encoding an IL12, alone orin combination with a composition comprising a polynucleotide comprisingan ORF encoding a checkpoint inhibitor polypeptide or a compositioncomprising a checkpoint inhibitor polypeptide, increases the number ofcross-presenting dendritic cells in the tumor of the subject as comparedto the number of cross-presenting dendritic cells in the tumor prior tothe administration. In some embodiments, the number of cross-presentingdendritic cells in the tumor is increased by at least about 1.5 fold, atleast about 2 fold, at least about 3 fold, at least about 4 fold, atleast about 5 fold, at least about 6 fold, at least about 7 fold, atleast about 8 fold, at least about 9 fold, at least about 10 fold, atleast about 15 fold, at least about 20 fold, at least about 25 fold, atleast about 30 fold, at least about 35 fold, at least about 40 fold, atleast about 45 fold, at least about 50 fold, at least about 60 fold, atleast about 70 fold, at least about 80 fold, at least about 90 fold, orat least about 100 fold. In some embodiments, the increase incross-presenting dendritic cells in the tumor is maintained for at leastabout 1 day, at least about 2 days, at least about 3 days, at leastabout 4 days, at least about 5 days, at least about 6 days, at leastabout 7 days, at least about 8 days, at least about 9 days, at leastabout 10 days, at least about 11 days, at least about 12 days, at leastabout 13 days, at least about 14 days, at least about 15 days, at leastabout 16 days, at least about 17 days, at least about 18 days, at leastabout 19 days, at least about 20 days, at least about 21 days, or atleast about 28 days.

In certain embodiments, the present disclosure is also directed to amethod of increasing IFNγ expression in a subject having tumorcomprising administering a polynucleotide, e.g., mRNA, encoding IL12alone or in combination with a second agent, e.g., a checkpointinhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/oran anti-CTLA-4 antibody, a polynucleotide encoding OX40L, and/or anyother agents disclosed herein.

Other embodiments also include a method of increasing expression ofIFNγ, TNFα, IL-10, IL-13, IL-15/15R, IL-27, MIP-1β, MIP-1α, MCP-1,MCP-3, M-CSF, IL-4, IL-5, or any combination thereof in a subject havingtumor comprising administering a polynucleotide, e.g., mRNA, encodingIL12 alone or in combination with another agent disclosed herein. In yetother embodiments, the methods of the present disclosure can includemethods of inducing expression of GM-CSF, IL-18, IL-3, RANTES, IL-6, orany combination thereof.

The polynucleotide encoding IL12 can be formulated as a pharmaceuticalcomposition that is suitable for administration either directly orindirectly to tumors. The term “tumor” is used herein in a broad senseand refers to any abnormal new growth of tissue that possesses nophysiological function and arises from uncontrolled usually rapidcellular proliferation. The term “tumor” as used herein relates to bothbenign tumors and to malignant tumors.

Certain aspects of the disclosure provide methods of intratumorallyadministering a single administration dose of a polynucleotide, e.g.,mRNA, encoding IL12 alone or in combination with any agents disclosedherein. In such embodiments, an mRNA encoding IL12 can be administeredonly once while the other agent can be administered regularly, followingits regular dosing schedule. In certain embodiments, a checkpointinhibitor, e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/oran anti-CTLA-4 antibody, is administered prior to administration of apolynucleotide, e.g., mRNA, encoding 1L12. In some embodiments, thepolynucleotide is formulated in a lipid nanoparticle, e.g., Compound 18,disclosed herein. Not being bound by any theory, in some aspects, theintratumoral delivery of a polynucleotide encoding IL12 and/or the lipidnanoparticle formulation disclosed herein allow single doseadministration that is sufficient for the dose to trigger anti-tumorefficacy and treat tumor. Given the potential toxicity of IFNγ inducedby IL-12, this single dosing regimen of the disclosed polynucleotide canbe beneficial to the subjects in need of the treatment.

In certain embodiments, the method comprises administering a single doseof a polynucleotide encoding IL12 in combination with a second agent,e.g., an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or ananti-CTLA-4 antibody, which can be given also in single administrationor multiple administrations following its regular (e.g., approved)schedule. In other embodiments, the method comprises not more than twoadministrations of a polynucleotide encoding IL2, not more than threeadministrations of a polynucleotide encoding IL12, not more than fouradministrations of a polynucleotide encoding IL12, or not more than fiveadministrations of a polynucleotide encoding IL12, optionally incombination with a checkpoint inhibitor, e.g., an anti-PD-1 antibody, ananti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, or a polynucleotideencoding an OX40L polypeptide.

In other embodiments, the present methods can result in abscopaleffects, e.g., a treatment of tumor where localized treatment of atumor, e.g., intratumoral delivery, by a polynucleotide, e.g., mRNA,encoding IL2 causes not only a shrinking of the treated tumor, but alsoa shrinking of tumors outside the scope of the localized treatment(“distal tumor”).

In some embodiments, the administering of the compositions describedherein, e.g., a polynucleotide encoding an IL12 polypeptide, alone or incombination with a composition comprising a polynucleotide comprising anORF encoding a checkpoint inhibitor polypeptide or a compositioncomprising a checkpoint inhibitor polypeptide, reduces the size of adistal tumor. In certain embodiments, the administering is intratumoralto a first tumor, and the administering reduces the size of a second,distal tumor. In some embodiments, the size of the distal tumor isreduced by at least about 10%, at least about 20% at least about 30%, atleast about 40%, at least about 50%, at least about 60%, at least about70%, at least about 80%, at least about 90%, at least about 95%, orabout 100%.

In certain embodiments, the administering of the compositions describedherein, e.g., a polynucleotide encoding an IL12 polypeptide, alone or incombination with a composition comprising a polynucleotide comprising anORF encoding a checkpoint inhibitor polypeptide or a compositioncomprising a checkpoint inhibitor polypeptide, inhibits the growth of adistal tumor. In certain embodiments, the administering is intratumoralto a first tumor, and the administering inhibits the growth of a second,distal tumor. In some embodiments, the growth of the distal tumor isinhibited for at least about 7 days, at least about 14 days, at leastabout 21 days, at least about 28 days, at least about 2 months, at leastabout 3 months, at least about 4 months, at least about 5 months, atleast about 6 months, at least about 7 months, at least about 8 months,at least about 9 months, at least about 10 months, at least about 11months, at least about 12 months, at least about 18 months, at leastabout 24 months, at least about 30 months, at least about 36 months, atleast about 4 years, or at least about 5 years.

The delivery of the polynucleotide encoding IL12 to a tumor using apharmaceutical compositions for intratumoral administration disclosedherein can:

-   (i) increase the retention of the polynucleotide in the tumor;-   (ii) increase the levels of expressed polypeptide in the tumor    compared to the levels of expressed polypeptide in peritumoral    tissue;-   (iii) decrease leakage of the polynucleotide or expressed product to    off-target tissue (e.g., peritumoral tissue, or to distant    locations, e.g., liver tissue); or,-   (iv) any combination thereof,    wherein the increase or decrease observed for a certain property is    relative to a corresponding reference composition (e.g., composition    in which compounds of formula (I) are not present or have been    substituted by another ionizable amino lipid, e.g., MC3).

In one embodiment, a decrease in leakage can be quantified as decreasein the ratio of polypeptide expression in the tumor to polypeptideexpression in non-tumor tissues, such as peritumoral tissue or toanother tissue or organ, e.g., liver tissue.

Delivery of a polynucleotide encoding IL12 to a tumor involvesadministering a pharmaceutical composition disclosed herein, e.g., innanoparticle form, including the polynucleotide encoding IL12 to asubject, where administration of the pharmaceutical composition involvescontacting the tumor with the composition.

In the instance that the polynucleotide encoding IL12 is an mRNA, uponcontacting a cell in the tumor with the pharmaceutical composition, atranslatable mRNA may be translated in the cell to produce a polypeptideof interest. However, mRNAs that are substantially not translatable mayalso be delivered to tumors. Substantially non-translatable mRNAs may beuseful as vaccines and/or may sequester translational components of acell to reduce expression of other species in the cell.

The pharmaceutical compositions disclosed herein can increase specificdelivery. As used herein, the term “specific delivery,” means deliveryof more (e.g., at least 1.5 fold more, at least 2-fold more, at least3-fold more, at least 4-fold more, at least 5-fold more, at least 6-foldmore, at least 7-fold more, at least 8-fold more, at least 9-fold more,at least 10-fold more) of a polynucleotide encoding an IL12Bpolypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides bypharmaceutical composition disclosed herein (e.g., in nanoparticle form)to a target tissue of interest (e.g., a tumor) compared to an off-targettissue (e.g., mammalian liver).

The level of delivery of a nanoparticle to a particular tissue may bemeasured, for example, by comparing

-   (i) the amount of protein expressed from a polynucleotide encoding    IL12 in a tissue to the weight of the tissue;-   (ii) comparing the amount of the polynucleotide in a tissue to the    weight of the tissue; or-   (iii) comparing the amount of protein expressed from a    polynucleotide encoding IL12 in a tissue to the amount of total    protein in the tissue.

Specific delivery to a tumor or a particular class of cells in the tumorimplies that a higher proportion of pharmaceutical composition includinga polynucleotide encoding an IL12B polypeptide, IL12A polypeptide, orboth IL12B and IL12A polypeptides is delivered to the target destination(e.g., target tissue) relative to other off-target destinations uponadministration of a pharmaceutical composition to a subject.

The present disclosure also provides methods to deliver intratumorally apolynucleotide encoding an IL12B polypeptide, IL12A polypeptide, or bothIL12B and IL12A polypeptides when a pharmaceutical compositioncomprising the polynucleotides disclosed herein (e.g., in nanoparticleform) are administered to a tumor. The intratumoral administration canshow one or more properties selected from the group consisting of:

-   (i) increased retention of the polynucleotide encoding an IL12B    polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides    in the tumor;-   (ii) increased levels of expressed polypeptide in the tumor compared    to the levels of expressed polypeptide in peritumoral tissue;-   (iii) decreased leakage of the polynucleotide or expressed product    to off-target tissue (e.g., peritumoral tissue, or to distant    locations, e.g., liver tissue); and,-   (iv) any combination thereof,    wherein the increase or decrease observed for a certain property is    relative to a corresponding reference composition (e.g., composition    in which compounds of formula (I) are not present or have been    substituted by another ionizable amino lipid, e.g., MC3).

In one embodiment, a decrease in leakage can be quantified as decreasein the ratio of polypeptide expression in the tumor to polypeptideexpression in non-tumor tissues, such as peritumoral tissue or toanother tissue or organ, e.g., liver tissue.

In some embodiments, another property in delivery caused as a result ofusing the pharmaceutical compositions disclosed herein is a reduction inimmune response with respect to the immune response observed when otherlipid components are used to deliver the same a therapeutic agent orpolynucleotide encoding a therapeutic agent.

Accordingly, the present disclosure provides a method of increasingretention of a therapeutic agent (e.g., a polynucleotide or apolypeptide administered as part of the pharmaceutical composition or apolypeptide expressed as a result of the administration) in a tumortissue in a subject, comprising administering intratumorally to thetumor tissue a pharmaceutical composition disclosed herein, wherein theretention of the therapeutic agent in the tumor tissue is increasedcompared to the retention of the therapeutic agent in the tumor tissueafter administering a corresponding reference composition (e.g., MC3).

Also provided is a method of increasing retention of a polynucleotide ina tumor tissue in a subject, comprising administering intratumorally tothe tumor tissue a pharmaceutical composition disclosed herein, whereinthe retention of the polynucleotide in the tumor tissue is increasedcompared to the retention of the polynucleotide in the tumor tissueafter administering a corresponding reference composition (e.g., MC3).

Also provided is a method of increasing retention of an expressedpolypeptide in a tumor tissue in a subject, comprising administering tothe tumor tissue a pharmaceutical composition disclosed herein, whereinthe pharmaceutical composition comprises a polynucleotide encoding theexpressed polypeptide, and wherein the retention of the expressedpolypeptide in the tumor tissue is increased compared to the retentionof the polypeptide in the tumor tissue after administering acorresponding reference composition (e.g., MC3).

The present disclosure also provides a method of decreasing expressionleakage of a polynucleotide administered intratumorally to a subject inneed thereof, comprising administering said polynucleotideintratumorally to the tumor tissue as a pharmaceutical compositiondisclosed herein, wherein the expression level of the polypeptide innon-tumor tissue is decreased compared to the expression level of thepolypeptide in non-tumor tissue after administering a correspondingreference composition (e.g., MC3).

Also provided is a method of decreasing expression leakage of atherapeutic agent (e.g., a polypeptide administered as part of thepharmaceutical composition) administered intratumorally to a subject inneed thereof, comprising administering the therapeutic agentintratumorally to the tumor tissue as a pharmaceutical compositiondisclosed herein, wherein the amount of therapeutic agent in non-tumortissue is decreased compared to the amount of therapeutic in non-tumortissue after administering a corresponding reference composition (e.g.,MC3).

Also provided is a method of decreasing expression leakage of anexpressed polypeptide in a tumor in a subject, comprising administeringto the tumor tissue a pharmaceutical composition disclosed herein,wherein the pharmaceutical composition comprises a polynucleotideencoding the expressed polypeptide, and wherein the amount of expressedpolypeptide in non-tumor tissue is decreased compared to the amount ofexpressed polypeptide in non-tumor tissue after administering acorresponding reference composition (e.g., MC3).

In some embodiments, the non-tumoral tissue is peritumoral tissue. Inother embodiments, the non-tumoral tissue is liver tissue.

The present disclosure also provides a method to reduce or prevent theimmune response caused by the intratumoral administration of apharmaceutical composition, e.g., a pharmaceutical compositioncomprising lipids known in the art, by replacing one or all the lipidsin such composition with a compound of Formula (I). For example, theimmune response caused by the administration of a polynucleotideencoding an IL12B polypeptide, IL12A polypeptide, or both IL12B andIL12A polypeptides in a pharmaceutical composition comprising MC3 (orother lipids known in the art) can be prevented (avoided) or amelioratedby replacing MC3 with a compound of Formula (I), e.g., Compound 18.

In some embodiments, the immune response observed after a polynucleotideencoding an IL12B polypeptide, IL12A polypeptide, or both IL12B andIL12A polypeptides is administered in a pharmaceutical compositiondisclosed herein is not elevated compared to the immune responseobserved when the therapeutic agent or a polynucleotide encoding anIL12B polypeptide, IL12A polypeptide, or both IL12B and IL12Apolypeptides is administered in phosphate buffered saline (PBS) oranother physiological buffer solution (e.g., Ringer's solution, Tyrode'ssolution, Hank's balanced salt solution, etc.).

In some embodiments, the immune response observed after a therapeuticagent or a polynucleotide encoding an IL12B polypeptide, IL12Apolypeptide, or both IL12B and IL12A polypeptides is administered in apharmaceutical composition disclosed herein is not elevated compared tothe immune response observed when PBS or another physiological buffersolution is administered alone.

In some embodiments, no immune response is observed when apharmaceutical composition disclosed herein is administeredintratumorally to a subject.

Accordingly, the present disclosure also provides a method of deliveringa therapeutic agent or a polynucleotide encoding an IL12B polypeptide,IL12A polypeptide, or both IL12B and IL12A polypeptides to a subject inneed thereof, comprising administering intratumorally to the subject apharmaceutical composition disclosed herein, wherein the immune responsecaused by the administration of the pharmaceutical composition is notelevated compared to the immune response caused by the intratumoraladministration of

-   (i) PBS alone, or another physiological buffer solution (e.g.,    Ringer's solution, Tyrode's solution, Hank's balanced salt solution,    etc.);-   (ii) the therapeutic agent or polynucleotide encoding an IL12B    polypeptide, IL12A polypeptide, or both IL12B and IL12A polypeptides    in PBS or another physiological buffer solution; or,-   (iii) a corresponding reference composition, i.e., the same    pharmaceutical composition in which the compound of Formula (I) is    substituted by another ionizable amino lipid, e.g., MC3.

In certain embodiments, the administration treats a cancer.

The polynucleotide (e.g., mRNA) of the present disclosure can beadministered in any route available, including, but not limited to,intratumoral, enteral, gastroenteral, epidural, oral, transdermal,epidural (peridural), intracerebral (into the cerebrum),intracerebroventricular (into the cerebral ventricles), epicutaneous(application onto the skin), intradermal, (into the skin itself),subcutaneous (under the skin), nasal administration (through the nose),intravenous (into a vein), intraperitoneal (into the peritoneum),intraarterial (into an artery), intramuscular (into a muscle),intracardiac (into the heart), intraosseous infusion (into the bonemarrow), intrathecal (into the spinal canal), intraperitoneal, (infusionor injection into the peritoneum), intravesical infusion, intravitreal,(through the eye), intracavernous injection, (into the base of thepenis), intravaginal administration, intrauterine, extra-amnioticadministration, transdermal (diffusion through the intact skin forsystemic distribution), transmucosal (diffusion through a mucousmembrane), insufflation (snorting), sublingual, sublabial, enema, eyedrops (onto the conjunctiva), or in ear drops. In other embodiments, themRNA of the present disclosure is administered parenterally (e.g.,includes subcutaneous, intravenous, intraperitoneal, intratumoral,intramuscular, intra-articular, intra-synovial, intrasternal,intrathecal, intrahepatic, intralesional and intracranial injection orinfusion techniques), intraventricularly, orally, by inhalation spray,topically, rectally, nasally, buccally, vaginally or via an implantedreservoir. In particular embodiments, the polynucleotide, composition,or polypeptide is administered subcutaneously, intravenously,intraperitoneally, intratumorally, intramuscularly, intra-articularly,intra-synovially, intrasternally, intrathecally, intrahepatically,intradermally, intralesionally, intracranially, intraventricularly,orally, by inhalation spray, topically, rectally, nasally, buccally,vaginally or via an implanted reservoir. In one particular embodiment,the polynucleotide (e.g., mRNA) of the present disclosure isadministered intratumorally.

In some embodiments, the polynucleotide is delivered by a devicecomprising a pump, patch, drug reservoir, short needle device, singleneedle device, multiple needle device, micro-needle device, jetinjection device, ballistic powder/particle delivery device, catheter,lumen, cryoprobe, cannula, microcanular, or devices utilizing heat, RFenergy, electric current, or any combination thereof.

Other aspects of the present disclosure relate to transplantation ofcells containing polynucleotides to a mammalian subject. Administrationof cells to mammalian subjects is known to those of ordinary skill inthe art, and includes, but is not limited to, local implantation (e.g.,topical or subcutaneous administration), organ delivery or systemicinjection (e.g., intravenous injection or inhalation), and theformulation of cells in pharmaceutically acceptable carriers.

In some embodiments, the polynucleotide, e.g., mRNA, is administered atan amount between about 0.10 μg/kg and about 1000 mg/kg.

In some embodiments, the administration of the polynucleotide,pharmaceutical composition or formulation of the disclosure results inexpression of IL12 in cells of the subject. In some embodiments,administering the polynucleotide, pharmaceutical composition orformulation of the disclosure results in an increase of IL12 activity inthe subject. For example, in some embodiments, the polynucleotides ofthe present disclosure are used in methods of administering acomposition or formulation comprising an mRNA encoding an IL12Bpolypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides toa subject, wherein the method results in an increase of IL12 activity inat least some cells of a subject.

In some embodiments, the administration of a composition or formulationcomprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, andboth IL12B and IL12A polypeptides to a subject results in an increase ofIL12 activity in cells subject to a level at least 10%, at least 15%, atleast 20%, at least 25%, at least 30%, at least 35%, at least 40%, atleast 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, or to 100% or more of the activity level expected in a normalsubject.

Other embodiments of the disclosure also provide a method of treating acancer in a subject in need thereof comprising administering (e.g.,intratumorally, intraperitoneally, or intravenously) a polynucleotidecomprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, andboth IL12B and IL12A polypeptides with one or more anti-cancer agents tothe subject.

In some embodiments, the polynucleotides (e.g., mRNA) encoding an IL12Bpolypeptide, IL12A polypeptide, and both IL12B and IL12A polypeptides ofthe present disclosure can be used to reduce the size of a tumor orinhibit tumor growth in a subject in need thereof.

In some embodiments, the tumor is associated with a disease, disorder,and/or condition. In a particular embodiment, the disease, disorder,and/or condition is a cancer. Thus, in one aspect, the administration ofthe polynucleotide (e.g., mRNA) encoding an IL12B polypeptide, IL12Apolypeptide, and both IL12B and IL12A polypeptides treats a cancer.

A “cancer” refers to a broad group of various diseases characterized bythe uncontrolled growth of abnormal cells in the body. Unregulated celldivision and growth results in the formation of malignant tumors thatinvade neighboring tissues and can also metastasize to distant parts ofthe body through the lymphatic system or bloodstream. A “cancer” or“cancer tissue” can include a tumor at various stages. In certainembodiments, the cancer or tumor is stage 0, such that, e.g., the canceror tumor is very early in development and has not metastasized. In someembodiments, the cancer or tumor is stage I, such that, e.g., the canceror tumor is relatively small in size, has not spread into nearby tissue,and has not metastasized. In other embodiments, the cancer or tumor isstage II or stage III, such that, e.g., the cancer or tumor is largerthan in stage 0 or stage I, and it has grown into neighboring tissuesbut it has not metastasized, except potentially to the lymph nodes. Inother embodiments, the cancer or tumor is stage IV, such that, e.g., thecancer or tumor has metastasized. Stage IV can also be referred to asadvanced or metastatic cancer.

In some aspects, the cancer can include, but is not limited to, adrenalcortical cancer, advanced cancer, anal cancer, aplastic anemia, bileductcancer, bladder cancer, bone cancer, bone metastasis, brain tumors,brain cancer, breast cancer, childhood cancer, cancer of unknown primaryorigin, Castleman disease, cervical cancer, colon/rectal cancer,endometrial cancer, esophagus cancer, Ewing family of tumors, eyecancer, gallbladder cancer, gastrointestinal carcinoid tumors,gastrointestinal stromal tumors, gestational trophoblastic disease,Hodgkin disease, Kaposi sarcoma, renal cell carcinoma, laryngeal andhypopharyngeal cancer, acute lymphocytic leukemia, acute myeloidleukemia, chronic lymphocytic leukemia, chronic myeloid leukemia,chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma(HCC), non-small cell lung cancer, small cell lung cancer, lungcarcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiplemyeloma, myelodysplastic syndrome, nasal cavity and paranasal sinuscancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oralcavity and oropharyngeal cancer, osteosarcoma, ovarian cancer,pancreatic cancer, penile cancer, pituitary tumors, prostate cancer,retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma inadult soft tissue, basal and squamous cell skin cancer, melanoma, smallintestine cancer, stomach cancer, testicular cancer, throat cancer,thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvarcancer, Waldenstrom macroglobulinemia, Wilms tumor, secondary cancerscaused by cancer treatment, and any combination thereof.

In some aspects, the tumor is a solid tumor. A “solid tumor” includes,but is not limited to, sarcoma, melanoma, carcinoma, or other solidtumor cancer. “Sarcoma” refers to a tumor which is made up of asubstance like the embryonic connective tissue and is generally composedof closely packed cells embedded in a fibrillar or homogeneoussubstance. Sarcomas include, but are not limited to, chondrosarcoma,fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma,Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft partsarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma,chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrialsarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblasticsarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma,idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcomaof B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen'ssarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma,leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma,reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovialsarcoma, or telangiectaltic sarcoma.

The term “melanoma” refers to a tumor arising from the melanocyticsystem of the skin and other organs. Melanomas include, for example,acra-lentiginous melanoma, amelanotic melanoma, benign juvenilemelanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma,juvenile melanoma, lentigo maligna melanoma, malignant melanoma,metastatic melanoma, nodular melanoma, subungal melanoma, or superficialspreading melanoma.

The term “carcinoma” refers to a malignant new growth made up ofepithelial cells tending to infiltrate the surrounding tissues and giverise to metastases. Exemplary carcinomas include, e.g., acinarcarcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cysticcarcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolarcarcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinomabasocellulare, basaloid carcinoma, basosquamous cell carcinoma,bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogeniccarcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorioniccarcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma,cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum,cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma,carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoidcarcinoma, carcinoma epitheliale adenoides, exophytic carcinoma,carcinoma ex ulcere, carcinoma fibrosum, gelatiniform carcinoma,gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare,glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma,hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma,hyaline carcinoma, hypemephroid carcinoma, infantile embryonalcarcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelialcarcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cellcarcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatouscarcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullarycarcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma,carcinoma muciparum, carcinoma mucocellulare, mucoepidernoid carcinoma,carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes,naspharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans,osteoid carcinoma, papillary carcinoma, periportal carcinoma,preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma,renal cell carcinoma of kidney, reserve cell carcinoma, carcinomasarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinomascroti, signet-ring cell carcinoma, carcinoma simplex, small-cellcarcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cellcarcinoma, carcinoma spongiosum, squamous carcinoma, squamous cellcarcinoma, string carcinoma, carcinoma telangiectaticum, carcinomatelangiectodes, transitional cell carcinoma, carcinoma tuberosum,tuberous carcinoma, verrucous carcinoma, or carcinoma viflosum.

Additional cancers that can be treated include, e.g., Leukemia,Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma,neuroblastoma, breast cancer, ovarian cancer, lung cancer,rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia,small-cell lung tumors, primary brain tumors, stomach cancer, coloncancer, malignant pancreatic insulanoma, malignant carcinoid, urinarybladder cancer, premalignant skin lesions, testicular cancer, lymphomas,thyroid cancer, papillary thyroid cancer, neuroblastoma, neuroendocrinecancer, esophageal cancer, genitourinary tract cancer, malignanthypercalcemia, cervical cancer, endometrial cancer, adrenal corticalcancer, prostate cancer, Müllerian cancer, ovarian cancer, peritonealcancer, fallopian tube cancer, or uterine papillary serous carcinoma.

2. Combination Therapy

The disclosure further includes a polynucleotide comprising an ORF(e.g., mRNA) encoding an IL12B polypeptide, IL12A polypeptide, or bothIL12B and IL12A polypeptide or uses thereof as a combination therapy,i.e., with any other anti-cancer agent in combination. In certainembodiments, the polynucleotide encodes an IL-12 polypeptide, whereinthe polynucleotide comprises an ORF encoding an IL12B polypeptide and anIL12A polypeptide or uses thereof as a combination therapy, i.e., withany other anti-cancer agent in combination.

In certain embodiments, the disclosure is directed to a polynucleotidecomprising an mRNA encoding an IL12B polypeptide, IL12A polypeptide, orboth IL12B and IL12A polypeptide in combination with one or moreanti-cancer agents or uses of the polynucleotide in combination with oneor more anti-cancer agents to the subject. In one embodiment, thecombination therapy can be a combination of the polynucleotide encodingIL12 and one or more standard therapy. In another embodiment, themethods of the disclosure include two additional anti-cancer agents,three additional agents, four additional agents, etc. The additionalanti-cancer agents can be a protein, e.g., an antibody, or apolynucleotide, e.g., mRNA. In some embodiments, the one or moreanti-cancer agents are an mRNA. In certain embodiments, the one or moreanti-cancer agents are an mRNA encoding a tumor antigen. In otherembodiments, the one or more anti-cancer agents are not a tumor antigenor an mRNA encoding a tumor antigen. In other embodiments, the one ormore anti-cancer agents are a protein, e.g., an antibody.

In some embodiments, the one or more anti-cancer agents are an approvedagent by the United States Food and Drug Administration. In otherembodiments, the one or more anti-cancer agents are a pre-approved agentby the United States Food and Drug Administration.

One skilled in the art would also appreciate that alternativeembodiments of the present disclosure include a combination therapy ofIL12 and any other agents, e.g., an anti-PD-1 antibody, an anti-PD-L1antibody, and/or an anti-CTLA-4 antibody, or OX40L as polynucleotidesand/or proteins. For example, the present disclosure encompassescombination therapy of (i) a polynucleotide (e.g., mRNA) encoding IL2and a protein comprising an anti-PD-1 antibody or an anti-PD-L1antibody; (iii) a polynucleotide (e.g., mRNA) encoding IL12 and a secondprotein comprising an anti-CTLA-4 antibody, or (iv) a polynucleotide(e.g., mRNA) encoding IL12 and a second protein comprising OX40L. Inother embodiments, the IL12 can also be administered as a protein.

In other embodiments, the additional agents can be formulated togetherwith the polynucleotide encoding IL12, e.g., mRNA, or separately.Moreover, even when formulated separately, the additional agents can beadministered concurrently with the polynucleotide encoding IL12 orsequentially. In one embodiment, the polynucleotide encoding IL12 isadministered prior to the second agent. In another embodiment, thepolynucleotide encoding IL12 is administered after the second agent.

In certain embodiments, the additional agents, e.g., any antibodydisclosed herein or a polynucleotide encoding OX40L, are alsoadministered intratumorally. In other embodiments, the second agents,e.g., any antibody disclosed herein or a polynucleotide encoding OX40L,are administered via different routes, e.g., intravenously,subcutaneously, intraperitoneally, etc.

In some aspects, the subject for the present methods or compositions hasbeen treated with one or more standard of care therapies. In otheraspects, the subject for the present methods or compositions has notbeen responsive to one or more standard of care therapies or anti-cancertherapies. In one aspect, the subject has been previously treated withan IL2 protein or an IL2 DNA gene therapy. In another aspect, thesubject is treated with an anti-PD-1 antagonist or an anti-CTLA-4antagonist prior to the polynucleotide of the present disclosure. Inanother aspect, the subject has been treated with a monoclonal antibodythat binds to PD-1 prior to the polynucleotide of the present disclosureand/or a monoclonal antibody that binds to CTLA-4 prior to thepolynucleotide of the present disclosure. In another aspect, the subjecthas been treated with an anti-PD-1 monoclonal antibody and/oranti-CTLA-4 monoclonal antibody therapy prior to the polynucleotide ofthe present methods or compositions.

In recent years, the introduction of immune checkpoint inhibitors fortherapeutic purposes has revolutionized cancer treatment. Of interestare therapies featuring combinations of checkpoint inhibitors with othercostimulatory or inhibitory molecules.

T cell regulation, i.e., activation or inhibition is mediated viaco-stimulatory or co-inhibitory signals. This interaction is exerted vialigand/receptor interaction. T cells harbor a myriad of both activatingreceptors, such as OX40, and inhibitory receptors (i.e., immunecheckpoints) such as programmed death receptor 1 (PD-1) or cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) (Mellman et al. 2011 Nature;480:480-489). Activation of this immune checkpoints results in T celldeactivation and commandeering these pathways by tumor cells contributesto their successful immune escape.

In some embodiments, the methods of reducing the size of a tumor orinhibiting growth of a tumor in a subject in need thereof compriseadministering to the subject an effective amount of a compositioncomprising one or more polynucleotides. In some embodiments, the one ormore polynucleotides encode an IL-12 polypeptide. In some embodiments,the one or more polynucleotides comprise an open reading frame (“ORF”)encoding an IL12B polypeptide. In some embodiments, the one or morepolynucleotides comprise an ORF encoding an IL12A polypeptide. Incertain embodiments, the one or more polynucleotides comprise an ORFencoding an IL12B polypeptide and an IL12A polypeptide.

In some embodiments, the methods further comprise administering a secondagent. In some embodiments, the second agent comprises an effectiveamount of a composition comprising a polynucleotide comprising an ORFencoding a checkpoint inhibitor polypeptide. In some embodiments, thesecond agent comprises an effective amount of a composition comprising acheckpoint inhibitor polypeptide. In some embodiments, the checkpointinhibitor is any checkpoint inhibitor known in the art or describedherein. In some embodiments, the checkpoint inhibitor is an anti-PD-1antibody. In other embodiments, the checkpoint inhibitor is ananti-PD-L1 antibody. In other embodiments, the checkpoint inhibitor isan anti-CTLA-4 antibody. In some embodiments, the second agent comprisesan effective amount of a composition comprising a polynucleotidecomprising an ORF encoding OX40L. In some embodiments, the checkpointinhibitor is selected from the group consisting of an anti-PD-1antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, apolynucleotide encoding OX40L any other agents disclosed herein, and anycombination thereof. In certain embodiments, the composition comprisinga checkpoint inhibitor comprises more than one checkpoint inhibitor. Inone particular embodiment, the method comprises administering (i) anmRNA, encoding an IL12B and/or IL12A polypeptide disclosed herein, and(ii) an anti-PD-L1 antibody, an anti-PD-1 antibody, anti-CTLA-4antibody, a polynucleotide encoding OX40L, or any combination thereof.

In some embodiments, the checkpoint inhibitor comprises an antigenbinding fragment of an antibody. In some embodiments, the antibody is ananti-CTLA-4 antibody or antigen-binding fragment thereof thatspecifically binds CTLA-4, an anti-PD-1 antibody or antigen-bindingfragment thereof that specifically binds PD-1, an anti-PD-L1 antibody orantigen-binding fragment thereof that specifically binds PD-L1, or acombination thereof. In one embodiment, the antibody is an anti-CTLA4antibody or antigen-binding fragment thereof that specifically bindsCTLA4. In another embodiment, the antibody is an anti-PD-1 antibody orantigen-binding fragment thereof that specifically binds PD-1. Inanother embodiment, the antibody is an anti-PD-L1 antibody orantigen-binding fragment thereof that specifically binds PD-L1.

Immune checkpoint inhibitors such as pembrolizumab or nivolumab, whichtarget the interaction between programmed death receptor i/programmeddeath ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved forthe treatment of various malignancies and are currently beinginvestigated in clinical trials for cancers including melanoma, head andneck squamous cell carcinoma (HNSCC). Data available from these trialsindicate substantial activity accompanied by a favorable safety andtoxicity profile in these patient populations.

For example, checkpoint inhibitors have been tested in clinical trialsfor the treatment of melanoma. In particular, phase III clinical trialshave revealed that therapies such as ipilimumab and pembrolizumab, whichtarget the CTLA-4 and PD-1 immune checkpoints, respectively, have raisedthe three-year survival of patients with melanoma to ˜70%, and overallsurvival (>5 years) to ˜30%.

Likewise, checkpoint inhibitors have been tested in clinical trials forthe treatment of head and neck cancer. In preclinical studies, it hadbeen shown that that 45-80% of HNSCC tumors express programmed deathligand 1 (PD-L1) (Zandberg et al. (2014) Oral Oncol. 50:627-632).Currently there are dozens of clinical trials evaluating the efficacyand safety of immune checkpoint inhibitors as monotherapy or incombination regimens in HNSCC. For example, clinical trials with PD 1,PD-L1, and CTLA-4 inhibitors are being tested in HNSCC. Data that thePD-1 antibody pembrolizumab might be effective in metastatic/recurrent(R/M) HNSCC patients were generated in the phase 1b Keynote-012 phaseI/II trial (Cheng. ASCO 2015, oral presentation). More recently the dataof the randomized CheckMate-141 phase III clinical trial were presented(Gillison. AACR 2016, oral presentation). This study investigated theefficacy of the monoclonal PD-1 antibody nivolumab given every 2 weeksin platinum-refractory R/M HNSCC patients. The study was stopped earlydue to superiority of the nivolumab arm of the study.

In one aspect, the subject has been previously treated with a PD-1antagonist prior to the polynucleotide of the present disclosure. Inanother aspect, the subject has been treated with a monoclonal antibodythat binds to PD-1 prior to the polynucleotide of the presentdisclosure. In another aspect, the subject has been treated with ananti-PD-1 monoclonal antibody therapy prior to the polynucleotide of thepresent methods or compositions. In other aspects, the anti-PD-1monoclonal antibody therapy comprises nivolumab, pembrolizumab,pidilizumab, or any combination thereof. In another aspect, the subjecthas been treated with a monoclonal antibody that binds to PD-L1 prior tothe polynucleotide of the present disclosure. In another aspect, thesubject has been treated with an anti-PD-L1 monoclonal antibody therapyprior to the polynucleotide of the present methods or compositions. Inother aspects, the anti-PD-L1 monoclonal antibody therapy comprisesdurvalumab, avelumab, MEDI473, BMS-936559, aezolizumab, or anycombination thereof.

In some aspects, the subject has been treated with a CTLA-4 antagonistprior to treatment with the compositions of present disclosure. Inanother aspect, the subject has been previously treated with amonoclonal antibody that binds to CTLA-4 prior to the compositions ofthe present disclosure. In another aspect, the subject has been treatedwith an anti-CTLA-4 monoclonal antibody prior to the polynucleotide ofthe present disclosure. In other aspects, the anti-CTLA-4 antibodytherapy comprises ipilimumab or tremelimumab.

In some aspects, the disclosure is directed to a method of treatingcancer and/or a method of immunotherapy in a subject in need thereofcomprising administering to the subject (e.g., intratumorally,intraperitoneally, or intravenously) the polynucleotide (e.g., RNA,e.g., mRNA) encoding an IL12 polypeptide in combination with a PD-L1antagonist, e.g., an antibody or antigen-binding portion thereof thatspecifically binds to PD-L1, e.g., an anti-PD-L1 monoclonal antibody,e.g., an anti-PD-L1 monoclonal antibody comprises Durvalumab, Avelumab,MEDI473, BMS-936559, Atezolizumab, or any combination thereof.

In certain embodiments, the anti-PD-L1 antibody useful for thedisclosure is MSB0010718C (also called Avelumab; See US 2014/0341917) orBMS-936559 (formerly 12A4 or MDX-1105) (see, e.g., U.S. Pat. No.7,943,743; WO 2013/173223). In other embodiments, the anti-PD-L1antibody is atezolizumab (also known as TECENTRIQ®). In otherembodiments, the anti-PD-L1 antibody is MPDL3280A (also known asatezolizumab, TECENTRIQ®, and RG7446) (see, e.g., Herbst et al. (2013) JClin Oncol 3 (suppl):3000. Abstract; U.S. Pat. No. 8,217,149), MEDI4736(also called Durvalumab; Khleif (2013) In: Proceedings from the EuropeanCancer Congress 2013; Sep. 27-Oct. 1, 2013; Amsterdam, The Netherlands.

In some aspects, the disclosure is directed to a method of treatingcancer and/or a method of immunotherapy in a subject in need thereofcomprising administering to the subject (e.g., intratumorally,intraperitoneally, or intravenously) the polynucleotide (e.g., RNA,e.g., mRNA) encoding an IL12 polypeptide, in combination with a PD-1antagonist, e.g., an antibody or antigen-binding portion thereof thatspecifically binds to PD-1, e.g., an anti-PD-1 monoclonal antibody.

In one embodiment, the anti-PD-1 antibody (or an antigen-binding portionthereof) useful for the disclosure is pembrolizumab. Pembrolizumab (alsoknown as “KEYTRUDA®”, lambrolizumab, and MK-3475) is a humanizedmonoclonal IgG4 antibody directed against human cell surface receptorPD-1 (programmed death-1 or programmed cell death-1). Pembrolizumab isdescribed, for example, in U.S. Pat. No. 8,900,587; see alsohttp://www.cancer.gov/drugdictionary?cdrid=695789 (last accessed: Dec.14, 2014). Pembrolizumab has been approved by the FDA for the treatmentof relapsed or refractory melanoma and advanced NSCLC.

In another embodiment, the anti-PD-1 antibody useful for the disclosureis nivolumab. Nivolumab (also known as “OPDIVO®”; formerly designated5C4, BMS-936558, MDX-1106, or ONO-4538) is a fully human IgG4 (S228P)PD-1 immune checkpoint inhibitor antibody that selectively preventsinteraction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking thedown-regulation of antitumor T-cell functions (U.S. Pat. No. 8,008,449;Wang et al., 2014 Cancer Immunol Res. 2(9):846-56). Nivolumab has shownactivity in a variety of advanced solid tumors including renal cellcarcinoma (renal adenocarcinoma, or hypernephroma), melanoma, andnon-small cell lung cancer (NSCLC) (Topalian et al., 2012a; Topalian etal., 2014; Drake et al., 2013; WO 2013/173223.

In other embodiments, the anti-PD-1 antibody is MEDI0680 (formerlyAMP-514), which is a monoclonal antibody against the PD-1 receptor.MEDI0680 is described, for example, in U.S. Pat. No. 8,609,089B2 or inhttp://www.cancer.gov/drugdictionary?cdrid=756047 (last accessed Dec.14, 2014).

In certain embodiments, the anti-PD-1 antibody is BGB-A317, which is ahumanized monoclonal antibody. BGB-A317 is described in U.S. Publ. No.2015/0079109.

In certain embodiments, a PD-1 antagonist is AMP-224, which is a B7-DCFc fusion protein. AMP-224 is discussed in U.S. Publ. No. 2013/0017199or inhttp://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=700595(last accessed Jul. 8, 2015).

In other embodiments, the disclosure includes a method of treatingcancer and/or a method of immunotherapy in a subject in need thereofcomprising administering to the subject (e.g., intratumorally,intraperitoneally, or intravenously) the polynucleotide (e.g., RNA,e.g., mRNA) encoding an IL12 polypeptide together with an antibody or anantigen binding portion thereof that specifically binds to PD-1, e.g.,an anti-PD-1 monoclonal antibody, e.g., an anti-PD-1 monoclonal antibodycomprises Nivolumab, Pembrolizumab, Pidilizumab, or any combinationthereof.

In other aspects, the disclosure is directed to a method of treatingcancer and/or a method of immunotherapy in a subject in need thereofcomprising administering to the subject (e.g., intratumorally,intraperitoneally, or intravenously) the polynucleotide (e.g., RNA,e.g., mRNA) encoding an IL12 polypeptide in combination with a CTLA-4antagonist, e.g., an antibody or antigen-binding portion thereof thatspecifically binds to CTLA-4, e.g., an anti-CTLA-4 monoclonal antibody,e.g., an anti-CTLA-4 monoclonal antibody comprises Ipilimumab orTremelimumab, or any combination thereof.

An exemplary clinical anti-CTLA-4 antibody is the human mAb 10D1 (nowknown as ipilimumab and marketed as YERVOY®) as disclosed in U.S. Pat.No. 6,984,720. Another anti-CTLA-4 antibody useful for the presentmethods is tremelimumab (also known as CP-675,206). Tremelimumab ishuman IgG2 monoclonal anti-CTLA-4 antibody. Tremelimumab is described inWO/2012/122444, U.S. Publ. No. 2012/263677, or WO Publ. No. 2007/113648A2.

In one embodiment, a first polynucleotide (e.g. a first mRNA) encodingIL12 and a second polynucleotide (e.g., a second mRNA) encoding an OX40Lpolypeptide are administered in combination. In another embodiment, thefirst polynucleotide (e.g. a first mRNA) encoding IL12 and the secondpolynucleotide (e.g. a second mRNA) encoding an OX40L polypeptide areadministered in combination with an antibody or an antigen-bindingportion thereof which specifically binds to CTLA-4, an antibody orantigen-binding portion thereof which specifically binds to a PD-1receptor, or an antibody or antigen-binding portion thereof whichspecifically binds to a PD-L1 receptor.

In one embodiment, a first polynucleotide (e.g. a first mRNA) encodingan IL12 polypeptide and a second polynucleotide (e.g. a second mRNA)encoding an OX40L polypeptide are administered in combination with anantibody or an antigen-binding portion thereof that specifically bindsto a PD-1 or PD-L1 receptor or a polynucleotide encoding the same.

In another embodiment, a first polynucleotide (e.g. a first mRNA)encoding an IL12 polypeptide and a second polynucleotide (e.g. a secondmRNA) encoding an OX40L polypeptide are administered in combination withan antibody or an antigen-binding portion thereof that specificallybinds to a CTLA-4 or a polynucleotide encoding the same.

In yet another embodiment, a first polynucleotide (e.g. a first mRNA)encoding an IL12 polypeptide and a second polynucleotide (e.g. a secondmRNA) encoding an OX40L polypeptide are administered in combination withan antibody or an antigen-binding portion thereof that specificallybinds to a PD-1 or PD-L1 receptor and an antibody or an antigen-bindingportion thereof that specifically binds to a CTLA-4 (or polynucleotidesof the same).

In some embodiments, the compositions disclosed herein comprise (i) afirst polynucleotide (e.g. a first mRNA) encoding IL12 and (ii) a secondpolynucleotide (e.g. a second mRNA) encoding an antibody or an antigenbinding portion thereof which specifically binds to CTLA-4 in a singleformulation.

In some embodiments, the compositions disclosed herein comprise apolynucleotide encoding IL12 and a polynucleotide encoding an OX40Lprotein in a single formulation.

Human OX40L was first identified on the surface of human lymphocytesinfected with human T-cell leukemia virus type-I (HTLV-I) by Tanaka etal. (Tanaka et al., International Journal of Cancer (1985),36(5):549-55). OX40L is the ligand for OX40 (CD134). OX40L has also beendesignated CD252 (cluster of differentiation 252), tumor necrosis factor(ligand) superfamily, member 4, tax-transcriptionally activatedglycoprotein 1, TXGP1, or gp34. Human OX40L is 183 amino acids in lengthand contains three domains: a cytoplasmic domain of amino acids 1-23; atransmembrane domain of amino acids 24-50, and an extracellular domainof amino acids 51-183.

In some embodiments, a polynucleotide encoding OX40L that can becombined with the polynucleotide encoding IL12 comprises an mRNAencoding a mammalian OX40L polypeptide. In some embodiments, themammalian OX40L polypeptide is a murine OX40L polypeptide. In someembodiments, the mammalian OX40L polypeptide is a human OX40Lpolypeptide. In some embodiments, the OX40L polypeptide comprises anamino acid sequence set forth in Table 1.

In some embodiments, each polynucleotide of the disclosure comprises anmRNA, i.e., an mRNA encoding an IL12 polypeptide and an mRNA encoding anOX40L polypeptide. In some embodiments, the mRNA encoding an IL12polypeptide encodes a mammalian IL12 polypeptide. In some embodiments,the mRNA encoding an OX40L polypeptide encodes a mammalian OX40Lpolypeptide. In some embodiments, the mRNA encoding an IL12 polypeptideencodes a murine IL12 polypeptide. In some embodiments, the mRNAencoding an OX40L polypeptide encodes a murine OX40L polypeptide. Insome embodiments, the mRNA encoding an IL12 polypeptide encodes a humanIL12 polypeptide. In some embodiments, the mRNA encoding an OX40Lpolypeptide encodes a human OX40L polypeptide.

In some embodiments, the IL12 polypeptide comprises a human amino acidsequence set forth in Table 4. In other embodiments, the OX40Lpolypeptide comprises a human amino acid sequence set forth in Table 1.

In some embodiments, the OX40L polypeptide comprises an amino acidsequence at least 50%, at least 60%, at least 70%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 99%, or 100% identicalto an amino acid sequence listed in Table 1 or an amino acid sequenceencoded by a nucleotide sequence listed in Table 1, wherein the aminoacid sequence is capable of binding to an OX40 receptor.

In certain embodiments, the OX40L polypeptide encoded by apolynucleotide of the disclosure comprises an amino acid sequence listedin Table 1 with one or more conservative substitutions, wherein theconservative substitutions do not significantly affect the bindingactivity of the OX40L polypeptide to its receptor, i.e., the OX40Lpolypeptide binds to the OX40 receptor after the substitutions.

In other embodiments, a nucleotide sequence (i.e., mRNA) encoding anOX40L polypeptide comprises a sequence at least 50%, at least 60%, atleast 70%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 99%, or 100% identical to a nucleic acid sequence listed inTable 1. One skilled in the art would know that if a sequence is writtenin DNA form (containing thymidine) in the present application, thecorresponding RNA sequence would contain uridine instead of thymidine.

In some embodiments, the polynucleotide (e.g., mRNA) useful for themethods and compositions comprises an open reading frame encoding anextracellular domain of OX40L. In other embodiments, the polynucleotide(e.g., mRNA) comprises an open reading frame encoding a cytoplasmicdomain of OX40L. In some embodiments, the polynucleotide (e.g., mRNA)comprises an open reading frame encoding a transmembrane domain ofOX40L. In certain embodiments, the polynucleotide (e.g., mRNA) comprisesan open reading frame encoding an extracellular domain of OX40L and atransmembrane of OX40L. In other embodiments, the polynucleotide (e.g.,mRNA) comprises an open reading frame encoding an extracellular domainof OX40L and a cytoplasmic domain of OX40L. In yet other embodiments,the polynucleotide (e.g., mRNA) comprises an open reading frame encodingan extracellular domain of OX40L, a transmembrane of OX40L, and acytoplasmic domain of OX40L.

Table 1 presents, e.g., precursor and mature sequences for OX40L as wellas constructs comprising the OX40L sequences. Furthermore, a constructcomprising a polynucleotide encoding OX40L and further comprisingcomponents such 3′ UTR and 5′ UTR would be considered an OX40L encodingpolynucleotide. A person of skill in the art would understand that inaddition to the native signal sequences and propeptide sequencesdisclosed in Table 1 (sequences present in the precursor for and absentin the mature corresponding form) and the non-native signal peptidedisclosed in Table 1, other signal sequences can be used. Accordingly,references to an OX40L polypeptide or polynucleotide according to Table1 encompass variants in which an alternative signal peptide (or encodingsequence) known in the art has been attached to the OX40L polypeptide(or polynucleotide). It is also understood that references to thesequences disclosed in Table 1 through the application are equallyapplicable and encompass orthologs and functional variants (for examplepolymorphic variants) and isoforms of those sequences known in the artat the time the application was filed.

TABLE 1 OX40L Polypeptide and Polynucleotide sequences Encoded SEQ IDPolypeptide Description Sequence NO: OX40L TumorMERVQPLEENVGNAARPRFERNKLLLVASVIQGLGLLLCFTYICLHFSA SEQ ID (TNFSF4)necrosis factor LQVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCD NO:178 ligand GFYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKD 183 aasuperfamily KVYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL member 4 isoform 1[Homo sapiens] NP_003317 OX40L TNFSF4MVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDG SEQ ID (TNFSF4)isoform 2 FYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDK NO: 179[Homo VYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL 133 aa sapiens] NP_001284491OX40L TNFSF4 MEGEGVQPLDENLENGSRPRFKWKKTLRLVVSGIKGAGMLLCFIYVCLQ SEQ ID(TNFSF4) [Mus LSSSPAKDPPIQRLRGAVTRCEDGQLFISSYKNEYQTMEVQNNSVVIKC NO: 180musculus] DGLYIIYLKGSFFQEVKIDLHFREDHNPISIPMLNDGRRIVFTVVASLA 198 aaNP_033478 FKDKVYLTVNAPDTLCEHLQINDGELIVVQLTPGYCAPEGSYHSTVNQV PL OX40LTNFSF4, ORF AUGGAAAGGGUCCAACCCCUGGAAGAGAAUGUG SEQ ID (TNFSF4) [HomoGGAAAUGCAGCCAGGCCAAGAUUCGAGAGGAAC NO: 181 sapiens]AAGCUAUUGCUGGUGGCCUCUGUAAUUCAGGGA 552ntsCUGGGGCUGCUCCUGUGCUUCACCUACAUCUGC CUGCACUUCUCUGCUCUUCAGGUAUCACAUCGGUAUCCUCGAAUUCAAAGUAUCAAAGUACAAUUU ACCGAAUAUAAGAAGGAGAAAGGUUUCAUCCUCACUUCCCAAAAGGAGGAUGAAAUCAUGAAGGUG CAGAACAACUCAGUCAUCAUCAACUGUGAUGGGUUUUAUCUCAUCUCCCUGAAGGGCUACUUCUCC CAGGAAGUCAACAUUAGCCUUCAUUACCAGAAGGAUGAGGAGCCCCUCUUCCAACUGAAGAAGGUC AGGUCUGUCAACUCCUUGAUGGUGGCCUCUCUGACUUACAAAGACAAAGUCUACUUGAAUGUGACC ACUGACAAUACCUCCCUGGAUGACUUCCAUGUGAAUGGCGGAGAACUGAUUCUUAUCCAUCAAAAU CCUGGUGAAUUCUGUGUCCUU OX40L TNFSF4,GGCCCUGGGACCUUUGCCUAUUUUCUGAUUGAU SEQ ID (TNFSF4) transcriptAGGCUUUGUUUUGUCUUUACCUCCUUCUUUCUG NO: 182 variant 1,GGGAAAACUUCAGUUUUAUCGCACGUUCCCCUU 3484 nts mRNAUUCCAUAUCUUCAUCUUCCCUCUACCCAGAUUG NM_003326UGAAGAUGGAAAGGGUCCAACCCCUGGAAGAGA AUGUGGGAAAUGCAGCCAGGCCAAGAUUCGAGAGGAACAAGCUAUUGCUGGUGGCCUCUGUAAUUC AGGGACUGGGGCUGCUCCUGUGCUUCACCUACAUCUGCCUGCACUUCUCUGCUCUUCAGGUAUCAC AUCGGUAUCCUCGAAUUCAAAGUAUCAAAGUACAAUUUACCGAAUAUAAGAAGGAGAAAGGUUUCA UCCUCACUUCCCAAAAGGAGGAUGAAAUCAUGAAGGUGCAGAACAACUCAGUCAUCAUCAACUGUG AUGGGUUUUAUCUCAUCUCCCUGAAGGGCUACUUCUCCCAGGAAGUCAACAUUAGCCUUCAUUACC AGAAGGAUGAGGAGCCCCUCUUCCAACUGAAGAAGGUCAGGUCUGUCAACUCCUUGAUGGUGGC CUCUCUGACUUACAAAGACAAAGUCUACUUGAAUGUGACCACUGACAAUACCUCCCUGGAUGAC UUCCAUGUGAAUGGCGGAGAACUGAUUCUUAUCCAUCAAAAUCCUGGUGAAUUCUGUGUCCUUU GAGGGGCUGAUGGCAAUAUCUAAAACCAGGCACCAGCAUGAACACCAAGCUGGGGGUGGACAGG GCAUGGAUUCUUCAUUGCAAGUGAAGGAGCCUCCCAGCUCAGCCACGUGGGAUGUGACAAGAAG CAGAUCCUGGCCCUCCCGCCCCCACCCCUCAGGGAUAUUUAAAACUUAUUUUAUAUACCAGUUA AUCUUAUUUAUCCUUAUAUUUUCUAAAUUGCCUAGCCGUCACACCCCAAGAUUGCCUUGAGCCU ACUAGGCACCUUUGUGAGAAAGAAAAAAUAGAUGCCUCUUCUUCAAGAUGCAUUGUUUCUAUUG GUCAGGCAAUUGUCAUAAUAAACUUAUGUCAUUGAAAACGGUACCUGACUACCAUUUGCUGGAA AUUUGACAUGUGUGUGGCAUUAUCAAAAUGAAGAGGAGCAAGGAGUGAAGGAGUGGGGUUAUGA AUCUGCCAAAGGUGGUAUGAACCAACCCCUGGAAGCCAAAGCGGCCUCUCCAAGGUUAAAUUGA UUGCAGUUUGCAUAUUGCCUAAAUUUAAACUUUCUCAUUUGGUGGGGGUUCAAAAGAAGAAUCA GCUUGUGAAAAAUCAGGACUUGAAGAGAGCCGUCUAAGAAAUACCACGUGCUUUUUUUCUUUAC CAUUUUGCUUUCCCAGCCUCCAAACAUAGUUAAUAGAAAUUUCCCUUCAAAGAACUGUCUGGGG AUGUGAUGCUUUGAAAAAUCUAAUCAGUGACUUAAGAGAGAUUUUCUUGUAUACAGGGAGAGUG AGAUAACUUAUUGUGAAGGGUUAGCUUUACUGUACAGGAUAGCAGGGAACUGGACAUCUCAGGG UAAAAGUCAGUACGGAUUUUAAUAGCCUGGGGAGGAAAACACAUUCUUUGCCACAGACAGGCAA AGCAACACAUGCUCAUCCUCCUGCCUAUGCUGAGAUACGCACUCAGCUCCAUGUCUUGUACACA CAGAAACAUUGCUGGUUUCAAGAAAUGAGGUGAUCCUAUUAUCAAAUUCAAUCUGAUGUCAAAU AGCACUAAGAAGUUAUUGUGCCUUAUGAAAAAUAAUGAUCUCUGUCUAGAAAUACCAUAGACCA UAUAUAGUCUCACAUUGAUAAUUGAAACUAGAAGGGUCUAUAAUCAGCCUAUGCCAGGGCUUCA AUGGAAUAGUAUCCCCUUAUGUUUAGUUGAAAUGUCCCCUUAACUUGAUAUAAUGUGUUAUGCU UAUGGCGCUGUGGACAAUCUGAUUUUUCAUGUCAACUUUCCAGAUGAUUUGUAACUUCUCUGUG CCAAACCUUUUAUAAACAUAAAUUUUUGAGAUAUGUAUUUUAAAAUUGUAGCACAUGUUUCCCU GACAUUUUCAAUAGAGGAUACAACAUCACAGAAUCUUUCUGGAUGAUUCUGUGUUAUCAAGGAA UUGUACUGUGCUACAAUUAUCUCUAGAAUCUCCAGAAAGGUGGAGGGCUGUUCGCCCUUACACU AAAUGGUCUCAGUUGGAUUUUUUUUUCCUGUUUUCUAUUUCCUCUUAAGUACACCUUCAACUAU AUUCCCAUCCCUCUAUUUUAAUCUGUUAUGAAGGAAGGUAAAUAAAAAUGCUAAAUAGAAGAAA UUGUAGGUAAGGUAAGAGGAAUCAAGUUCUGAGUGGCUGCCAAGGCACUCACAGAAUCAUAAUC AUGGCUAAAUAUUUAUGGAGGGCCUACUGUGGACCAGGCACUGGGCUAAAUACUUACAUUUACA AGAAUCAUUCUGAGACAGAUAUUCAAUGAUAUCUGGCUUCACUACUCAGAAGAUUGUGUGUGUG UUUGUGUGUGUGUGUGUGUGUGUAUUUCACUUUUUGUUAUUGACCAUGUUCUGCAAAAUUGCAG UUACUCAGUGAGUGAUAUCCGAAAAAGUAAACGUUUAUGACUAUAGGUAAUAUUUAAGAAAAUG CAUGGUUCAUUUUUAAGUUUGGAAUUUUUAUCUAUAUUUCUCACAGAUGUGCAGUGCACAUGCA GGCCUAAGUAUAUGUUGUGUGUGUUGUUUGUCUUUGAUGUCAUGGUCCCCUCUCUUAGGUGCUC ACUCGCUUUGGGUGCACCUGGCCUGCUCUUCCCAUGUUGGCCUCUGCAACCACACAGGGAUAUU UCUGCUAUGCACCAGCCUCACUCCACCUUCCUUCCAUCAAAAAUAUGUGUGUGUGUCUCAGUCC CUGUAAGUCAUGUCCUUCACAGGGAGAAUUAACCCUUCGAUAUACAUGGCAGAGUUUUGUGGGA AAAGAAUUGAAUGAAAAGUCAGGAGAUCAGAAUUUUAAAUUUGACUUAGCCACUAACUAGCCAU GUAACCUUGGGAAAGUCAUUUCCCAUUUCUGGGUCUUGCUUUUCUUUCUGUUAAAUGAGAGGAA UGUUAAAUAUCUAACAGUUUAGAAUCUUAUGCUUACAGUGUUAUCUGUGAAUGCACAUAUUAAA UGUCUAUGUUCUUGUUGCUAUGAGUCAAGGAGUGUAACCUUCUCCUUUACUAUGUUGAAUGUAU UUUUUUCUGGACAAGCUUACAUCUUCCUCAGCCAUCUUUGUGAGUCCUUCAAGAGCAGUUAUCA AUUGUUAGUUAGAUAUUUUCUAUUUAGAGAAUGCUUAAGGGAUUCCAAUCCCGAUCCAAAUCAU AAUUUGUUCUUAAGUAUACUGGGCAGGUCCCCUAUUUUAAGUCAUAAUUUUGUAUUUAGUGCUU UCCUGGCUCUCAGAGAGUAUUAAUAUUGAUAUUAAUAAUAUAGUUAAUAGUAAUAUUGCUAUUU ACAUGGAAACAAAUAAAAGAUCUCAGAAUUCACUAAAAAAAAAAA OX40L Mus musculus AUUGCUUUUUGUCUCCUGUUCUGGGACCUUUA SEQ ID(TNFSF4) Tnfsf4, mRNA UCUUCUGACCCGCAGGCUUGACUUUGCCCUUA NO: 183 NM_009452UUGGCUCCUUUGUGGUGAAGAGCAGUCUUCCC 1609 ntsCCAGGUUCCCCGCCACAGCUGUAUCUCCUCUG CACCCCGACUGCAGAGAUGGAAGGGGAAGGGGUUCAACCCCUGGAUGAGAAUCUGGAAAACGGA UCAAGGCCAAGAUUCAAGUGGAAGAAGACGCUAAGGCUGGUGGUCUCUGGGAUCAAGGGAGCAG GGAUGCUUCUGUGCUUCAUCUAUGUCUGCCUGCAACUCUCUUCCUCUCCGGCAAAGGACCCUCC AAUCCAAAGACUCAGAGGAGCAGUUACCAGAUGUGAGGAUGGGCAACUAUUCAUCAGCUCAUAC AAGAAUGAGUAUCAAACUAUGGAGGUGCAGAACAAUUCGGUUGUCAUCAAGUGCGAUGGGCUUU AUAUCAUCUACCUGAAGGGCUCCUUUUUCCAGGAGGUCAAGAUUGACCUUCAUUUCCGGGAGGA UCAUAAUCCCAUCUCUAUUCCAAUGCUGAACGAUGGUCGAAGGAUUGUCUUCACUGUGGUGGCC UCUUUGGCUUUCAAAGAUAAAGUUUACCUGACUGUAAAUGCUCCUGAUACUCUCUGCGAACACC UCCAGAUAAAUGAUGGGGAGCUGAUUGUUGUCCAGCUAACGCCUGGAUACUGUGCUCCUGAAGG AUCUUACCACAGCACUGUGAACCAAGUACCACUGUGAAUUCCACUCUGAGGGUGGACGGGACAC AGGUUCUUUCUCGAGAGAGAUGAGUGCAUCCUGCUCAUGAGAUGUGACUGAAUGCAGAGCCUAC CCUACUUCCUCACUCAGGGAUAUUUAAAUCAUGUCUUACAUAACAGUUGACCUCUCAUUCCCAG GAUUGCCUUGAGCCUGCUAAGAGCUGUUCUGGGAAUGAAAAAAAAAAUAAAUGUCUCUUCAAGA CACAUUGCUUCUGUCGGUCAGAAGCUCAUCGUAAUAAACAUCUGCCACUGAAAAUGGCGCUUGA UUGCUAUCUUCUAGAAUUUUGAUGUUGUCAAAAGAAAGCAAAACAUGGAAAGGGUGGUGUCCAC CGGCCAGUAGGAGCUGGAGUGCUCUCUUCAAGGUUAAGGUGAUAGAAGUUUACAUGUUGCCUAA AACUGUCUCUCAUCUCAUGGGGGGCUUGGAAAGAAGAUUACCCCGUGGAAAGCAGGACUUGAAG AUGACUGUUUAAGCAACAAGGUGCACUCUUUUCCUGGCCCCUGAAUACACAUAAAAGACAACUU CCUUCAAAGAACUACCUAGGGACUAUGAUACCCACCAAAGAACCACGUCAGCGAUGCAAAGAAA ACCAGGAGAGCUUUGUUUAUUUUGCAGAGUAUACGAGAGAUUUUACCCUGAGGGCUAUUUUUAU UAUACAGGAUGAGAGUGAACUGGAUGUCUCAGGAUAAAGGCCAAGAAGGAUUUUUCACAGUCUG AGCAAGACUGUUUUUGUAGGUUCUCUCUCCAAAACUUUUAGGUAAAUUUUUGAUAAUUUUAAAA UUUUUAGUUAUAUUUUUGGACCAUUUUCAAUAGAAGAUUGAAACAUUUCCAGAUGGUUUCAUAU CCCCACAAG Human mRNAGGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGA SEQ ID OX40L sequence:AAUAUAAGAGCCACCAUGGAAAGGGUCCAACC NO: 184 HumanCCUGGAAGAGAAUGUGGGAAAUGCAGCCAGGC OX40L withCAAGAUUCGAGAGGAACAAGCUAUUGCUGGUG 5′-UTR, 3′-GCCUCUGUAAUUCAGGGACUGGGGCUGCUCCU UTR, andGUGCUUCACCUACAUCUGCCUGCACUUCUCUG miR-122CUCUUCAGGUAUCACAUCGGUAUCCUCGAAUU binding siteCAAAGUAUCAAAGUACAAUUUACCGAAUAUAA GAAGGAGAAAGGUUUCAUCCUCACUUCCCAAAAGGAGGAUGAAAUCAUGAAGGUGCAGAACAAC UCAGUCAUCAUCAACUGUGAUGGGUUUUAUCUCAUCUCCCUGAAGGGCUACUUCUCCCAGGAAG UCAACAUUAGCCUUCAUUACCAGAAGGAUGAGGAGCCCCUCUUCCAACUGAAGAAGGUCAGGUC UGUCAACUCCUUGAUGGUGGCCUCUCUGACUUACAAAGACAAAGUCUACUUGAAUGUGACCACU GACAAUACCUCCCUGGAUGACUUCCAUGUGAAUGGCGGAGAACUGAUUCUUAUCCAUCAAAAUC CUGGUGAAUUCUGUGUCCUUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUG GGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUC CAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGG CMurine mRNA GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAA SEQ ID OX40L sequence:AUAUAAGAGCCACCAUGGAAGGGGAAGGGGUUC NO: 185 murineAACCCCUGGAUGAGAAUCUGGAAAACGGAUCAA OX40L withGGCCAAGAUUCAAGUGGAAGAAGACGCUAAGGC 5′-UTR, 3′-UGGUGGUCUCUGGGAUCAAGGGAGCAGGGAUGC UTR, andUUCUGUGCUUCAUCUAUGUCUGCCUGCAACUCU miR-122CUUCCUCUCCGGCAAAGGACCCUCCAAUCCAAA binding siteGACUCAGAGGAGCAGUUACCAGAUGUGAGGAUG GGCAACUAUUCAUCAGCUCAUACAAGAAUGAGUAUCAAACUAUGGAGGUGCAGAACAAUUCGGUUG UCAUCAAGUGCGAUGGGCUUUAUAUCAUCUACCUGAAGGGCUCCUUUUUCCAGGAGGUCAAGAUUG ACCUUCAUUUCCGGGAGGAUCAUAAUCCCAUCUCUAUUCCAAUGCUGAACGAUGGUCGAAGGAUUG UCUUCACUGUGGUGGCCUCUUUGGCUUUCAAAGAUAAAGUUUACCUGACUGUAAAUGCUCCUGAUA CUCUCUGCGAACACCUCCAGAUAAAUGAUGGGGAGCUGAUUGUUGUCCAGCUAACGCCUGGAUACU GUGCUCCUGAAGGAUCUUACCACAGCACUGUGAACCAAGUACCACUGUGAUAAUAGGCUGGAGCCU CGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACC CCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC hOX40L CodonATGGAAAGGGTCCAACCCCTGGAAGAGAATGTGGGAAATGCAGCCAGGC SEQ ID miR-122optimized CAAGATTCGAGAGGAACAAGCTATTGCTGGTGGCCTCTGTAATTCAGGG NO: 186human OX40L ACTGGGGCTGCTCCTGTGCTTCACCTACATCTGCCTGCACTTCTCTGCT sequencesCTTCAGGTATCACATCGGTATCCTCGAATTCAAAGTATCAAAGTACAATTTACCGAATATAAGAAGGAGAAAGGTTTCATCCTCACTTCCCAAAAGGAGGATGAAATCATGAAGGTGCAGAACAACTCAGTCATCATCAACTGTGATGGGTTTTATCTCATCTCCCTGAAGGGCTACTTCTCCCAGGAAGTCAACATTAGCCTTCATTACCAGAAGGATGAGGAGCCCCTCTTCCAACTGAAGAAGGTCAGGTCTGTCAACTCCTTGATGGTGGCCTCTCTGACTTACAAAGACAAAGTCTACTTGAATGTGACCACTGACAATACCTCCCTGGATGACTTCCATGTGAATGGCGGAGAACTGATTCTTATCCATCAAAATCCTGGTGAATT CTGTGTCCTT mOX40L +Codon ATGGAAGGGGAAGGGGTTCAACCCCTGGATGAGAATCTGGAAAACGGAT SEQ ID miR-122optimized CAAGGCCAAGATTCAAGTGGAAGAAGACGCTAAGGCTGGTGGTCTCTGG NO: 187mouse OX40L GATCAAGGGAGCAGGGATGCTTCTGTGCTTCATCTATGTCTGCCTGCAA sequencesCTCTCTTCCTCTCCGGCAAAGGACCCTCCAATCCAAAGACTCAGAGGAGCAGTTACCAGATGTGAGGATGGGCAACTATTCATCAGCTCATACAAGAATGAGTATCAAACTATGGAGGTGCAGAACAATTCGGTTGTCATCAAGTGCGATGGGCTTTATATCATCTACCTGAAGGGCTCCTTTTTCCAGGAGGTCAAGATTGACCTTCATTTCCGGGAGGATCATAATCCCATCTCTATTCCAATGCTGAACGATGGTCGAAGGATTGTCTTCACTGTGGTGGCCTCTTTGGCTTTCAAAGATAAAGTTTACCTGACTGTAAATGCTCCTGATACTCTCTGCGAACACCTCCAGATAAATGATGGGGAGCTGATTGTTGTCCAGCTAACGCCTGGATACTGTGCTCCTGAAGGATCTTACCACAGCACTGTGAACCAAGTA CCACTG OX40L Codon-AUGGAGAGAGUGCAGCCCCUGGAGGAGAACGUG SEQ ID (TNFSF4) optimizedGGCAACGCCGCCAGACCCAGAUUCGAGAGAAAC NO: 188 sequence 1 forAAGCUGCUGCUGGUGGCCAGCGUGAUCCAGGGC ENSP 281834CUGGGCCUGCUGCUGUGCUUCACCUACAUCUGC CUGCACUUCAGCGCCCUGCAGGUGAGCCACAGAUACCCCAGAAUCCAGAGCAUCAAGGUGCAGUUC ACCGAGUACAAGAAGGAGAAGGGCUUCAUCCUGACCAGCCAGAAGGAGGACGAGAUCAUGAAGGUG CAGAACAACAGCGUGAUCAUCAACUGCGACGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGC CAGGAGGUGAACAUCAGCCUGCACUACCAGAAGGACGAGGAGCCCCUGUUCCAGCUGAAGAAGGUG AGAAGCGUGAACAGCCUGAUGGUGGCCAGCCUGACCUACAAGGACAAGGUGUACCUGAACGUGACC ACCGACAACACCAGCCUGGACGACUUCCACGUGAACGGCGGCGAGCUGAUCCUGAUCCACCAGAAC CCCGGCGAGUUCUGCGUGCUG OX40L Codon-AUGGAGCGUGUGCAGCCUCUUGAGGAGAAUGUG SEQ ID (TNFSF4) optimizedGGAAAUGCAGCCCGGCCUCGAUUCGAACGUAAU NO: 189 sequence 2 forAAACUCCUGCUCGUGGCCUCCGUGAUCCAGGGU ENSP 281834CUCGGUUUAUUGCUGUGUUUUACCUAUAUAUGC UUACACUUUAGUGCAUUACAGGUCUCACACCGGUACCCUCGCAUUCAGUCUAUAAAAGUGCAGUUU ACCGAGUAUAAGAAGGAGAAAGGUUUUAUACUGACUUCUCAGAAAGAGGACGAGAUCAUGAAGGUG CAGAAUAAUAGCGUCAUUAUCAACUGCGAUGGAUUCUAUCUAAUUUCCCUAAAGGGGUACUUCAGC CAGGAGGUCAAUAUAUCACUGCACUAUCAAAAGGACGAGGAGCCCCUGUUUCAACUGAAGAAAGUG CGAUCAGUUAACUCUCUGAUGGUUGCCUCUCUGACCUAUAAGGACAAAGUCUACUUGAACGUGACA ACUGACAACACCUCACUGGAUGACUUUCAUGUGAAUGGGGGGGAACUGAUUCUUAUCCAUCAGAAU CCAGGAGAAUUCUGUGUGCUC OX40L Codon-AUGGAGCGGGUGCAGCCCCUGGAGGAGAAUGUG SEQ ID (TNFSF4) optimizedGGCAAUGCUGCCCGGCCCAGGUUUGAAAGAAAC NO: 190 sequence 3 forAAGCUGCUGCUGGUGGCCAGCGUCAUCCAGGGC ENSP 281834CUGGGCCUGCUGCUGUGCUUCACCUACAUCUGC CUGCACUUCAGCGCCCUGCAGGUGAGCCACCGCUACCCCCGCAUCCAGAGCAUCAAGGUGCAGUUC ACAGAGUACAAGAAGGAGAAGGGCUUCAUCCUGACCAGCCAGAAGGAGGAUGAGAUCAUGAAGGUG CAGAACAACAGCGUCAUCAUCAACUGUGAUGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGC CAGGAGGUGAACAUCAGCCUGCACUACCAGAAGGAUGAGGAGCCCCUCUUCCAGCUGAAGAAGGUG CGCUCUGUGAACAGCCUGAUGGUGGCCAGCCUGACCUACAAGGACAAGGUGUACCUGAAUGUGACC ACAGACAACACCAGCCUGGAUGACUUCCACGUGAAUGGAGGAGAGCUGAUCCUGAUCCACCAGAAC CCUGGAGAGUUCUGUGUGCUG OX40L Codon-AUGGAGCGGGUGCAGCCCCUGGAGGAGAACGUG SEQ ID (TNFSF4) optimizedGGCAACGCCGCCCGCCCGCGUUUUGAGCGAAAU NO: 191 sequence 4 forAAGUUACUGCUUGUUGCAUCUGUGAUACAGGGG ENSP 281834UUGGGUUUACUUCUUUGCUUUACAUAUAUUUGU CUCCACUUUAGUGCGCUUCAGGUAUCCCAUCGGUACCCGCGCAUCCAGUCAAUCAAGGUCCAGUUC ACUGAAUAUAAAAAGGAGAAAGGAUUCAUUCUGACUUCACAAAAAGAGGACGAAAUCAUGAAAGUG CAGAACAACUCUGUAAUUAUAAACUGCGAUGGGUUCUAUCUGAUCAGUCUGAAGGGAUAUUUUAGC CAGGAAGUAAAUAUUUCACUACAUUAUCAGAAGGACGAAGAACCACUUUUUCAACUGAAGAAAGUC CGGUCCGUGAACUCCCUGAUGGUUGCUAGCCUUACCUACAAGGAUAAAGUCUAUUUAAACGUCACA ACAGAUAACACUAGCCUCGACGAUUUCCAUGUGAACGGAGGUGAACUGAUAUUGAUCCAUCAAAAC CCCGGCGAGUUCUGCGUUUUA OX40L Codon-AUGGAGCGGGUCCAGCCCCUCGAGGAGAACGUU SEQ ID (TNFSF4) optimizedGGUAAUGCCGCACGUCCCAGGUUUGAACGCAAC NO: 192 sequence 5 forAAGCUGCUGUUGGUGGCCAGCGUCAUUCAGGGG ENSP 281834CUGGGUUUGUUGCUGUGCUUCACUUACAUCUGU CUGCAUUUUAGUGCACUCCAGGUGUCCCACCGCUACCCCCGUAUCCAAUCCAUUAAAGUCCAAUUU ACCGAAUACAAAAAAGAGAAGGGUUUCAUUCUUACCUCCCAGAAGGAGGAUGAAAUUAUGAAGGUG CAGAACAAUUCUGUUAUCAUCAACUGUGACGGAUUCUAUCUGAUUUCACUGAAGGGAUACUUUUCC CAGGAGGUGAACAUCAGUCUGCAUUAUCAGAAGGACGAAGAACCGCUUUUUCAACUGAAGAAGGUU AGGAGUGUGAACUCCUUAAUGGUAGCCAGCCUGACAUAUAAGGACAAGGUAUAUCUGAACGUCACC ACUGAUAACACCUCUUUAGACGAUUUUCAUGUAAAUGGGGGAGAAUUGAUACUCAUUCACCAGAA UCCGGGUGAGUUUUGUGUUCUG OX40L Codon-AUGGUGAGCCACAGAUACCCCAGAAUCCAGAGCA SEQ ID (TNFSF4) optimizedUCAAGGUGCAGUUCACCGAGUACAAGAAGGAGAA NO: 193 sequence 1 forGGGCUUCAUCCUGACCAGCCAGAAGGAGGACGAG ENSP 356691AUCAUGAAGGUGCAGAACAACAGCGUGAUCAUCA ACUGCGACGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGCCAGGAGGUGAACAUCAGCCUGCAC UACCAGAAGGACGAGGAGCCCCUGUUCCAGCUGAAGAAGGUGAGAAGCGUGAACAGCCUGAUGGUGGC CAGCCUGACCUACAAGGACAAGGUGUACCUGAACGUGACCACCGACAACACCAGCCUGGACGACUUCC ACGUGAACGGCGGCGAGCUGAUCCUGAUCCACCAGAACCCCGGCGAGUUCUGCGUGCUG OX40L Codon-AUGGUUUCUCACCGUUACCCACGGAUCCAGUCUA SEQ ID (TNFSF4) optimizedUCAAGGUUCAGUUUACCGAGUACAAAAAGGAAAA NO: 194 sequence 2 forAGGGUUCAUCCUCACCUCUCAGAAAGAGGACGAA ENSP 356691AUCAUGAAGGUGCAGAAUAACUCUGUAAUCAUUA AUUGCGACGGUUUUUAUCUGAUUUCACUGAAGGGCUACUUUAGUCAGGAAGUUAAUAUUAGUUUGCAC UACCAAAAGGACGAGGAGCCUCUCUUCCAACUAAAAAAGGUAAGAUCCGUUAAUUCCCUUAUGGUGGC CUCCUUAACUUAUAAGGACAAGGUGUAUCUGAAUGUGACCACAGAUAACACAUCCCUGGACGACUUUC AUGUAAAUGGCGGCGAGUUAAUUCUGAUACACCAGAACCCUGGCGAGUUCUGCGUGCUG OX40L Codon-AUGGUGAGCCACCGCUACCCCCGCAUCCAGAGCA SEQ ID (TNFSF4) optimizedUCAAGGUGCAGUUCACAGAGUACAAGAAGGAGAA NO: 195 sequence 3 forGGGCUUCAUCCUGACCAGCCAGAAGGAGGAUGAG ENSP 356691AUCAUGAAGGUGCAGAACAACAGCGUCAUCAUCA ACUGUGAUGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGCCAGGAGGUGAACAUCAGCCUGCAC UACCAGAAGGAUGAGGAGCCCCUCUUCCAGCUGAAGAAGGUGCGCUCUGUGAACAGCCUGAUGGUGGC CAGCCUGACCUACAAGGACAAGGUGUACCUGAAUGUGACCACAGACAACACCAGCCUGGAUGACUUCC ACGUGAAUGGAGGAGAGCUGAUCCUGAUCCACCAGAACCCUGGAGAGUUCUGUGUGCUG OX40L Codon-AUGGUGAGCCACCGGUACCCCCGGAUCCAGAGCA SEQ ID (TNFSF4) optimizedUCAAGGUGCAGUUCACCGAAUACAAGAAGGAGAA NO: 196 sequence 4 forGGGUUUUAUCCUGACGAGCCAGAAGGAAGACGAG ENSP 356691AUUAUGAAGGUCCAAAACAACUCAGUCAUCAUAA ACUGCGAUGGAUUUUACCUGAUCUCUCUGAAAGGGUACUUCUCCCAGGAAGUGAAUAUUAGCUUGCAC UAUCAAAAAGAUGAGGAGCCUCUAUUCCAGCUCAAGAAGGUCAGAAGCGUCAAUAGUCUGAUGGUCGC AUCAUUAACCUAUAAAGACAAAGUAUAUCUAAAUGUGACGACAGACAAUACAUCCCUCGAUGAUUUUC ACGUCAACGGAGGCGAACUCAUUCUGAUCCACCAGAAUCCAGGGGAAUUUUGCGUGCUG OX40L Codon-AUGGUCUCACACCGGUACCCCCGUAUCCAGAGUA SEQ ID (TNFSF4) optimizedUUAAGGUGCAAUUCACGGAGUAUAAAAAAGAAAA NO: 197 sequence 5 forGGGAUUCAUUCUGACGUCUCAGAAGGAAGAUGAG ENSP 356691AUCAUGAAGGUCCAGAACAAUUCUGUGAUCAUUA AUUGCGAUGGAUUUUAUCUGAUUUCACUUAAAGGAUAUUUUUCCCAGGAGGUUAAUAUCAGUUUGCAC UAUCAGAAAGACGAGGAGCCAUUAUUCCAGCUGAAGAAGGUGAGAUCAGUGAAUAGCCUGAUGGUUGC GUCACUGACGUAUAAAGACAAAGUUUAUCUAAACGUUACCACUGAUAAUACAUCCCUUGAUGAUUUUC AUGUGAACGGGGGUGAACUGAUCCUUAUACACCAGAACCCCGGAGAGUUCUGUGUGUUG OX40L Codon-AUGGUGAGCCACAGAUACCCCAGAAUCCAGAGCAU SEQ ID (TNFSF4) optimizedCAAGGUGCAGUUCACCGAGUACAAGAAGGAGAAG NO: 198 sequence 1 forGGCUUCAUCCUGACCAGCCAGAAGGAGGACGAGA ENSP 439704UCAUGAAGGUGCAGAACAACAGCGUGAUCAUCAA CUGCGACGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGCCAGGAGGUGAACAUCAGCCUGCACU ACCAGAAGGACGAGGAGCCCCUGUUCCAGCUGAAGAAGGUGAGAAGCGUGAACAGCCUGAUGGUGGCC AGCCUGACCUACAAGGACAAGGUGUACCUGAACGUGACCACCGACAACACCAGCCUGGACGACUUCCA CGUGAACGGCGGCGAGCUGAUCCUGAUCCACCAGAACCCCGGCGAGUUCUGCGUGCUG OX40L Codon- AUGGUGUCACACCGGUACCCUCGGAUCCAGUCUASEQ ID (TNFSF4) optimized UUAAAGUUCAAUUUACGGAGUACAAGAAAGAAAA NO: 199sequence 2 for AGGCUUUAUCCUUACAAGCCAAAAGGAAGACGAG ENSP 439704AUCAUGAAAGUGCAAAACAACAGUGUGAUUAUAA AUUGUGAUGGCUUCUACCUUAUUAGUCUGAAGGGCUACUUUAGUCAGGAAGUCAAUAUUAGCCUACAC UACCAGAAAGACGAGGAGCCCCUCUUUCAACUGAAAAAGGUGCGCUCCGUGAAUUCGUUGAUGGUCGC CUCUCUGACCUACAAAGAUAAGGUGUAUCUUAACGUUACUACCGACAAUACUAGUCUGGACGACUUUC ACGUCAACGGAGGCGAACUUAUUCUGAUCCACCAGAACCCCGGCGAAUUCUGCGUGCUG OX40L Codon-AUGGUGAGCCACCGCUACCCCCGCAUCCAGAGCA SEQ ID (TNFSF4) optimizedUCAAGGUGCAGUUCACAGAGUACAAGAAGGAGAA NO: 200 sequence 3 forGGGCUUCAUCCUGACCAGCCAGAAGGAGGAUGAG ENSP 439704AUCAUGAAGGUGCAGAACAACAGCGUCAUCAUCA ACUGUGAUGGCUUCUACCUGAUCAGCCUGAAGGGCUACUUCAGCCAGGAGGUGAACAUCAGCCUGCAC UACCAGAAGGAUGAGGAGCCCCUCUUCCAGCUGAAGAAGGUGCGCUCUGUGAACAGCCUGAUGGUGGC CAGCCUGACCUACAAGGACAAGGUGUACCUGAAUGUGACCACAGACAACACCAGCCUGGAUGACUUCC ACGUGAAUGGAGGAGAGCUGAUCCUGAUCCACCAGAACCCUGGAGAGUUCUGUGUGCUG OX40L Codon-AUGGUGAGCCACCGGUACCCCCGGAUCCAGAGCA SEQ ID (TNFSF4) optimizedUCAAGGUGCAGUUCACAGAGUACAAGAAGGAGAA NO: 201 sequence 4 forGGGAUUUAUUCUCACAAGUCAGAAAGAAGAUGAG ENSP 439704AUCAUGAAGGUUCAGAACAACUCAGUCAUUAUUA AUUGCGACGGAUUCUAUCUCAUUAGCCUCAAAGGCUAUUUCAGCCAGGAGGUCAAUAUCAGCCUGCAC UACCAGAAGGAUGAGGAACCUCUCUUUCAGCUGAAAAAAGUCCGCUCUGUGAAUUCCCUCAUGGUCGC UUCCCUGACCUACAAGGAUAAAGUUUAUUUGAACGUUACAACAGAUAAUACAUCGCUGGACGACUUCC AUGUGAAUGGUGGCGAACUAAUUCUAAUACACCAAAAUCCAGGCGAAUUUUGUGUCCUU OX40L Codon-AUGGUAUCCCAUAGAUACCCACGUAUUCAAAGCA SEQ ID (TNFSF4) optimizedUUAAGGUGCAGUUCACAGAGUACAAAAAGGAGAA NO: 202 sequence 5 forGGGUUUCAUACUGACGUCACAGAAGGAGGACGAG ENSP 439704AUAAUGAAGGUGCAGAAUAAUAGUGUGAUCAUCA AUUGUGAUGGAUUCUAUUUGAUCAGCCUCAAAGGUUAUUUCUCACAGGAAGUCAACAUUUCCCUGCAC UACCAGAAGGACGAAGAGCCUUUGUUUCAGCUGAAGAAGGUGCGCUCAGUGAACAGUUUGAUGGUAGC CUCCCUAACUUAUAAAGAUAAAGUUUAUCUGAACGUGACAACCGAUAACACAUCCCUGGACGACUUUC ACGUCAAUGGAGGUGAGUUAAUCCUGAUCCAUCAGAAUCCCGGAGAAUUCUGCGUUCUU

3. Interleukin-12 (IL12)

IL12 (also shown as IL-12) is a pleiotropic cytokine, the actions ofwhich create an interconnection between innate and adaptive immunity.IL12 functions primarily as a 70 kDa heterodimeric protein consisting oftwo disulfide-linked p35 and p40 subunits. The precursor form of theIL12 p40 subunit (NM_002187; P29460; also referred to as IL12B, naturalkiller cell stimulatory factor 2, cytotoxic lymphocyte maturation factor2) is 328 amino acids in length, while its mature form is 306 aminoacids long. The precursor form of the IL12 p35 subunit (NM_000882;P29459; also referred to as IL12A, natural killer cell stimulatoryfactor 1, cytotoxic lymphocyte maturation factor 1) is 219 amino acidsin length and the mature form is 197 amino acids long. Id. The genes forthe IL12 p35 and p40 subunits reside on different chromosomes and areregulated independently of each other. Gately, M K et al., Annu RevImmunol. 16: 495-521 (1998). Many different immune cells (e.g.,dendritic cells, macrophages, monocytes, neutrophils, and B cells)produce IL12 upon antigenic stimuli. The active IL12 heterodimer isformed following protein synthesis. Id.

IL12 is composed of a bundle of four alpha helices. It is aheterodimeric cytokine encoded by two separate genes, IL12A (p35) andIL12B (p40). The active heterodimer (referred to as ‘p70’), and ahomodimer of p40 are formed following protein synthesis.

Therefore, in some embodiments, the IL12 polypeptide of the presentdisclosure comprises a single polypeptide chain comprising the IL12B andIL12A fused directly or by a linker. In other embodiments, the IL12polypeptide of the present disclosure comprises two polypeptides, thefirst polypeptide comprising IL12B and the second polypeptide comprisingIL12A. In certain aspects, the disclosure provides an IL12A polypeptideand an IL12B polypeptide, wherein the IL12A and IL12B polypeptides areon the same chain or different chains. In some embodiments, the IL12A orIL12B polypeptide of the disclosure is a variant, a peptide or apolypeptide containing a substitution, and insertion and/or an addition,a deletion and/or a covalent modification with respect to a wild-typeIL12A or IL12B sequence. In some embodiments, sequence tags (such asepitope tags, e.g., a V5 tag) or amino acids, can be added to thesequences encoded by the polynucleotides of the disclosure (e.g., at theN-terminal or C-terminal ends), e.g., for localization. In someembodiments, amino acid residues located at the carboxy, amino terminal,or internal regions of a polypeptide of the disclosure can optionally bedeleted providing for fragments.

In some embodiments, the IL12A and/or IL12B polypeptide encoded by apolynucleotide of the disclosure (e.g., a RNA, e.g., an mRNA) comprisesa substitutional variant of an IL12A and/or IL12B sequence, which cancomprise one, two, three or more than three substitutions. In someembodiments, the substitutional variant can comprise one or moreconservative amino acids substitutions. In other embodiments, thevariant is an insertional variant. In other embodiments, the variant isa deletional variant.

In other embodiments, the IL12A and/or IL12B polypeptide encoded thepolynucleotide (e.g., a RNA, e.g., an mRNA) comprises a linker fusingthe IL12A and IL12B polypeptides. Non-limiting examples of linkers aredisclosed elsewhere herein.

Some aspects of the present disclosure are directed to a lipidnanoparticle comprising a polynucleotide (e.g., mRNA) encoding a humanIL12 polypeptide, wherein the polynucleotide comprises an ORF encoding ahuman IL12B polypeptide operably linked to a human IL12A polypeptide. Insome embodiments, the IL12B polypeptide is operably linked to the IL12Apolypeptide by a peptide linker. In some embodiments, the IL12Bpolypeptide is located at the 5′ terminus of the IL12A polypeptide orthe peptide linker. In other embodiments, the IL12A polypeptide islocated at the 5′ terminus of the IL12B polypeptide or the peptidelinker.

As recognized by those skilled in the art, IL12 protein fragments,functional protein domains, variants, and homologous proteins(orthologs) are also considered to be within the scope of the IL12polypeptides of the disclosure. Nonlimiting examples of polypeptidesencoded by the polynucleotides of the disclosure are shown in FIGS. 1 to2. For example, Table 2 shows the correlating amino acid numbering inSEQ ID NOs, nucleotide numbering in SEQ ID NOs, and the 5′ UTR, IL12Bsignal peptide, mature IL12A and IL12B peptides, and linker.

TABLE 2 Domains of IL12. Amino acids Nucleotides Signal Peptide IL12B1-22 of SEQ ID NO: 48 1-66 of SEQ ID NOs: 5-44 Mature IL12B 23-328 ofSEQ ID NO: 48 67-984 of SEQ ID NOs: 5-44 Linker 329-335 of SEQ ID NO: 48985-1005 of SEQ ID NOs: 5-44 Mature IL12A 336-532 of SEQ ID NO: 481006-1596 of SEQ ID NOs: 5-44

4. Polynucleotides and Open Reading Frames (ORFS)

In certain aspects, the disclosure provides polynucleotides (e.g., aRNA, e.g., an mRNA) that comprise a nucleotide sequence (e.g., an ORF,e.g., mRNA) encoding one or more IL12 polypeptides. In certainembodiments, the polynucleotides encode an IL-12 polypeptide, whereinthe polynucleotides comprise a single ORF encoding an IL12B polypeptideand an IL12A polypeptide. In some embodiments, the polynucleotide (e.g.,a RNA, e.g., an mRNA) of the disclosure encodes a single IL12polypeptide chain comprising an IL12B polypeptide and an IL12Apolypeptide, which are fused directly or by a linker, wherein the IL12Bpolypeptide is selected from the group consisting of:

-   (i) the full-length IL12B polypeptide (e.g., having the same or    essentially the same length as wild-type IL12B);-   (ii) a functional fragment of the full-length IL12B polypeptide    (e.g., a truncated (e.g., deletion of carboxy, amino terminal, or    internal regions) sequence shorter than an IL12B wild-type; but    still retaining IL12B enzymatic activity);-   (iii) a variant thereof (e.g., full length or truncated IL12B    proteins in which one or more amino acids have been replaced, e.g.,    variants that retain all or most of the IL12B activity of the    polypeptide with respect to the wild type IL12B polypeptide (such    as, e.g., V33I, V298F, or any other natural or artificial variants    known in the art); and-   (iv) a fusion protein comprising (i) a full length IL12B wild-type,    a functional fragment or a variant thereof, and (ii) a heterologous    protein; and/or    wherein the IL12A polypeptide is selected from the group consisting    of:-   (v) the full-length IL12A polypeptide (e.g., having the same or    essentially the same length as wild-type IL12A);-   (vi) a functional fragment of the full-length IL12A polypeptide    (e.g., a truncated (e.g., deletion of carboxy, amino terminal, or    internal regions) sequence shorter than an IL12A wild-type; but    still retaining IL12A enzymatic activity);-   (vii) a variant thereof (e.g., full length or truncated IL12A    proteins in which one or more amino acids have been replaced, e.g.,    variants that retain all or most of the IL12A activity of the    polypeptide with respect to the wtIL12A polypeptide (such as natural    or artificial variants known in the art); and-   (viii) a fusion protein comprising (i) a full length IL12A    wild-type, a functional fragment or a variant thereof, and (ii) a    heterologous protein.

In other embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure encodes two polypeptide chains, the first chaincomprising an IL12B polypeptide and the second chain comprising an IL12Apolypeptide, wherein the IL12B polypeptide is selected from the groupconsisting of:

-   (i) the mature IL12B polypeptide (e.g., having the same or    essentially the same length as wild-type IL12B) with or without a    signal peptide;-   (ii) a functional fragment of any of the mature IL12B polypeptide    (e.g., a truncated (e.g., deletion of carboxy, amino terminal, or    internal regions) sequence shorter than an IL12B wild-type; but    still retaining IL12B enzymatic activity);-   (iii) a variant thereof (e.g., full length, mature, or truncated    IL12B proteins in which one or more amino acids have been replaced,    e.g., variants that retain all or most of the IL12B activity of the    polypeptide with respect to the wild type IL12B polypeptide (such    as, e.g., V33I, V298F, or any other natural or artificial variants    known in the art); and-   (iv) a fusion protein comprising (i) a mature IL12B wild-type, a    functional fragment or a variant thereof, with or without a signal    peptide and (ii) a heterologous protein; and/or    wherein the IL12A is selected from the group consisting of:-   (v) the mature IL12A polypeptide (e.g., having the same or    essentially the same length as wild-type IL12A) with or without a    signal peptide;-   (vi) a functional fragment of any of the wild-type IL12A polypeptide    (e.g., a truncated (e.g., deletion of carboxy, amino terminal, or    internal regions) sequence shorter than an IL12A wild-type; but    still retaining IL12A enzymatic activity);-   (vii) a variant thereof (e.g., full length, mature, or truncated    IL12A proteins in which one or more amino acids have been replaced,    e.g., variants that retain all or most of the IL12A activity of the    polypeptide with respect to a reference isoform (such as natural or    artificial variants known in the art); and-   (viii) a fusion protein comprising (i) a mature IL12A wild-type, a    functional fragment or a variant thereof, with or without a signal    peptide and (ii) a heterologous protein.

In certain embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA)of the disclosure encodes a mammalian IL12 polypeptide, such as a humanIL12 polypeptide, a functional fragment or a variant thereof.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure increases IL12B and/or IL12A protein expression levelsand/or detectable IL12 enzymatic activity levels in cells whenintroduced in those cells, e.g., by at least 10%, at least 15%, at least20%, at least 25%, at least 30%, at least 35%, at least 40%, at least45%, at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least95%, or at least 100%, compared to IL12B and/or IL12A protein expressionlevels and/or detectable IL12 enzymatic activity levels in the cellsprior to the administration of the polynucleotide of the disclosure.IL12B and/or IL12A protein expression levels and/or IL12 enzymaticactivity can be measured according to methods known in the art. In someembodiments, the polynucleotide is introduced to the cells in vitro. Insome embodiments, the polynucleotide is introduced to the cells in vivo.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprise a nucleotide sequence (e.g., an ORF) thatencodes a wild-type human IL12B and/or IL12A, (see FIG. 1).

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a codon optimized nucleic acid sequence,wherein the open reading frame (ORF) of the codon optimized nucleicsequence is derived from a wild-type IL12A and/or IL12B sequence.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprise a nucleotide sequence encoding IL12B and/orIL12A having the full length sequence of human IL12B and/or IL12A (i.e.,including the initiator methionine and the signal peptides). In maturehuman IL12B and/or IL12A, the initiator methionine and/or signalpeptides can be removed to yield a “mature IL12B” and/or “mature IL12A”comprising amino acid residues of SEQ ID NO: 1 and SEQ ID NO: 3,respectively. SEQ ID NO: 1 corresponds to amino acids 23 to 328 of SEQID NO: 48, and SEQ ID NO: 3 corresponds to amino acids 336 to 532 of SEQID NO: 48, respectively. The teachings of the present disclosuredirected to the full sequence of human IL12B and/or IL12A are alsoapplicable to the mature form of human IL12B and/or IL12A lacking theinitiator methionine and/or the signal peptide. Thus, in someembodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) of thedisclosure comprise a nucleotide sequence encoding IL12B and/or IL12Ahaving the mature sequence of human IL12B and/or IL12A. In someembodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) of thedisclosure comprising a nucleotide sequence encoding IL12B and/or IL12Ais sequence optimized.

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprise a nucleotide sequence (e.g., an ORF) encoding amutant IL12B and/or IL12A polypeptide. In some embodiments, thepolynucleotides of the disclosure comprise an ORF encoding an IL12Band/or IL12A polypeptide that comprises at least one point mutation, atleast two point mutations, at least three mutations, at least fourmutations, at least five mutations, at least six mutations, at leastseven mutations, at least eight mutations, at least nine mutations, orat least ten mutations in the IL12B and/or IL12A sequence and retainsIL12B and/or IL12A enzymatic activity. In some embodiments, the mutantIL12B and/or IL12A polypeptide has an IL12B and/or IL12A activity whichis at least 10%, at least 15%, at least 20%, at least 25%, at least 30%,at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, or at least 100% of the IL12Band/or IL12A activity of the corresponding wild-type IL12B and/or IL12A(i.e., the same IL12B and/or IL12A but without the mutation(s)). In someembodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) of thedisclosure comprising an ORF encoding a mutant IL12B and/or IL12Apolypeptide is sequence optimized.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) thatencodes an IL12B and/or IL12A polypeptide with mutations that do notalter IL12B and/or IL12A enzymatic activity. Such mutant IL12B and/orIL12A polypeptides can be referred to as function-neutral. In someembodiments, the polynucleotide comprises an ORF that encodes a mutantIL12B and/or IL12A polypeptide comprising one or more function-neutralpoint mutations.

In some embodiments, the mutant IL12B and/or IL12A polypeptide hashigher IL12B and/or IL12A enzymatic activity than the correspondingwild-type IL12B and/or IL12A. In some embodiments, the mutant IL12Band/or IL12A polypeptide has an IL12B and/or IL12A activity that is atleast 10%, at least 15%, at least 20%, at least 25%, at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, or at least 100% higher than theactivity of the corresponding wild-type IL12B and/or IL12A (i.e., thesame IL12B and/or IL12A but without the mutation(s)).

In some embodiments, the polynucleotides (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprise a nucleotide sequence (e.g., an ORF) encoding afunctional IL12B and/or IL12A fragment, e.g., where one or morefragments correspond to a polypeptide subsequence of a wild type IL12Band/or IL12A polypeptide and retain IL12B and/or IL12A enzymaticactivity. In some embodiments, the IL12B and/or IL12A fragment has anIL12B and/or IL12A activity which is at least 10%, at least 15%, atleast 20%, at least 25%, at least 30%, at least 35%, at least 40%, atleast 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, or at least 100% of the IL12 activity of the correspondingfull length IL12B and/or IL12A. In some embodiments, the polynucleotide(e.g., a RNA, e.g., an mRNA) of the disclosure comprising an ORFencoding a functional IL12B and/or IL12A fragment is sequence optimized.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B and/or IL12A fragment that has higher IL12B and/or IL12Aenzymatic activity than the corresponding full length IL12B and/orIL12A. Thus, in some embodiments the IL12B and/or IL12A fragment has anIL12B and/or IL12A activity which is at least about 10%, at least about15%, at least about 20%, at least about 25%, at least about 30%, atleast about 35%, at least about 40%, at least about 45%, at least about50%, at least about 55%, at least about 60%, at least about 65%, atleast about 70%, at least about 75%, at least about 80%, at least about85%, at least about 90%, at least about 95%, or about 100% higher thanthe IL12B and/or IL12A activity of the corresponding full length IL12Band/or IL12A.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B and/or IL12A fragment that is at least about 1%, 2%, 3%, 4%,5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%,20%, 21%, 22%, 23%, 24% or 25% shorter than wild-type IL12B and/orIL12A.

In other embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B polypeptide, which has:

-   (i) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_007, hIL12AB_010, or hIL12AB_012;-   (ii) at least about 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_018 or hIL12AB_019;-   (iii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    67-984 of hIL12AB_008;-   (iv) at least about 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,    96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides 67-984    of hIL12AB_005, hIL12AB_013, or hIL12AB_017 or nucleotides 70-987 of    hIL12AB_004;-   (v) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_001 or hIL12AB_009;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_022 or hIL12AB_038;-   (viii) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,    99%, or 100% sequence identity to nucleotides 67-984 of hIL12AB_024,    hIL12AB_031, hIL12AB_032, or hIL12AB_036;-   (ix) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 67-984 of hIL12AB_021,    hIL12AB_023, hIL12AB_025, hIL12AB_026, hIL12AB_027, hIL12AB_029,    hIL12AB_030, hIL12AB_034, hIL12AB_039, or hIL12AB_040;-   (x) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_016, hIL12AB_035,    or hIL12AB_037;-   (xi) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_011, hIL12AB_028,    or hIL12AB_033;-   (xii) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_015;-   (xiii) at least about 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_020; or-   (xiv) 100% sequence identity to nucleotides 67-984 of hIL12AB_006.

In other embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12A polypeptide, which has:

-   (i) at least about 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,    87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_010;-   (ii) at least about 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,    88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_019;-   (iii) at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,    90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_013;-   (iv) at least about 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,    91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_007 or hIL12AB_014;-   (v) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_002, hIL12AB_008;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    1006-1596 of hIL12AB_001, or hIL12AB_009 or nucleotides 1009-1589 of    hIL12AB_004;-   (viii) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,    97%, 98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_17;-   (ix) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_029 or hIL12AB_027;-   (x) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,    or 100% sequence identity to nucleotides 1006-1596 of hIL12AB_039 or    hIL12AB_040;-   (xi) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_036,    hIL12AB_034, hIL12AB_016, hIL12AB_023, hIL12AB_030, hIL12AB_031,    hIL12AB_025, or hIL12AB_035;-   (xii) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_021,    hIL12AB_024, hIL12AB_032, hIL12AB_033, hIL12AB_037, or hIL12AB_022;-   (xiii) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_020,    hIL12AB_026, or hIL12AB_038;-   (xiv) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_015, hIL12AB_011, or    hIL12AB_028; or-   (xv) about 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_003.

In certain embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA)of the disclosure comprises a single ORF encoding IL12B and IL12A,wherein the ORF comprises a sequence that has:

-   (i) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_007, hIL12AB_010, or hIL12AB_012;-   (ii) at least about 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_018 or hIL12AB_019;-   (iii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    67-984 of hIL12AB_008;-   (iv) at least about 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,    96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides 67-984    of hIL12AB_005, hIL12AB_013, or hIL12AB_017 or nucleotides 70-987 of    hIL12AB_004;-   (v) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_001 or hIL12AB_009;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_022 or hIL12AB_038;-   (viii) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,    99%, or 1009% sequence identity to nucleotides 67-984 of    hIL12AB_024, hIL12AB_031, hIL12AB_032, or hIL12AB_036;-   (ix) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 67-984 of hIL12AB_021,    hIL12AB_023, hIL12AB_025, hIL12AB_026, hIL12AB_027, hIL12AB_029,    hIL12AB_030, hIL12AB_034, hIL12AB_039, or hIL12AB_040;-   (x) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_016, hIL12AB_035,    or hIL12AB_037;-   (xi) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_011, hIL12AB_028,    or hIL12AB_033;-   (xii) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_015;-   (xiii) at least about 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_020; or-   (xiv) about 100% sequence identity to nucleotides 67-984 of    hIL12AB_006; and    a sequence that has:-   (i) at least about 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,    87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_010;-   (ii) at least about 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,    88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_019;-   (iii) at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,    90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_013;-   (iv) at least about 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,    91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_007 or hIL12AB_014;-   (v) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_002, hIL12AB_008;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    1006-1596 of hIL12AB_001, or hIL12AB_009 or nucleotides 1009-1599 of    hIL12AB_004;-   (viii) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,    97%, 98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_17;-   (ix) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_029 or hIL12AB_027;-   (x) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,    or 100% sequence identity to nucleotides 1006-1596 of hIL12AB_039 or    hIL12AB_040;-   (xi) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_036,    hIL12AB_034, hIL12AB_016, hIL12AB_023, hIL12AB_030, hIL12AB_031,    hIL12AB_025, or hIL12AB_035;-   (xii) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_021,    hIL12AB_024, hIL12AB_032, hIL12AB_033, hIL12AB_037, or hIL12AB_022;-   (xiii) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_020,    hIL12AB_026, or hIL12AB_038;-   (xiv) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_015, hIL12AB_011, or    hIL12AB_028; or-   (xv) about 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_003.

In certain embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA)of the disclosure comprises a first ORF encoding IL12B and a second ORFencoding IL12A or, wherein the first ORF comprises a sequence that has:

-   (i) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_007, hIL12AB_010, or hIL12AB_012;-   (ii) at least about 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_018 or hIL12AB_019;-   (iii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    67-984 of hIL12AB_008;-   (iv) at least about 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,    96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides 67-984    of hIL12AB_005, hIL12AB_013, or hIL12AB_017 or nucleotides 70-987 of    hIL12AB_004;-   (v) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_001 or hIL12AB_009;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 67-984 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 67-984 of    hIL12AB_022 or hIL12AB_038;-   (viii) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,    99%, or 1009% sequence identity to nucleotides 67-984 of    hIL12AB_024, hIL12AB_031, hIL12AB_032, or hIL12AB_036;-   (ix) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 67-984 of hIL12AB_021,    hIL12AB_023, hIL12AB_025, hIL12AB_026, hIL12AB_027, hIL12AB_029,    hIL12AB_030, hIL12AB_034, hIL12AB_039, or hIL12AB_040;-   (x) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_016, hIL12AB_035,    or hIL12AB_037;-   (xi) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 67-984 of hIL12AB_011, hIL12AB_028,    or hIL12AB_033;-   (xii) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_015;-   (xiii) at least about 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 67-984 of hIL12AB_020; or-   (xiv) about 100% sequence identity to nucleotides 67-984 of    hIL12AB_006; and/or    wherein the second ORF comprises a sequence that has:-   (i) at least about 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,    87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_010;-   (ii) at least about 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,    88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_019;-   (iii) at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,    90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_013;-   (iv) at least about 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,    91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_007 or hIL12AB_014;-   (v) at least about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,    93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_002, hIL12AB_008;-   (vi) at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,    94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to    nucleotides 1006-1596 of hIL12AB_012 or hIL12AB_005;-   (vii) at least about 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,    95%, 96%, 97%, 98%, 99%, or 100% sequence identity to nucleotides    1006-1596 of hIL12AB_001, or hIL12AB_009 or nucleotides 1009-1599 of    hIL12AB_004;-   (viii) at least about 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,    97%, 98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_17;-   (ix) at least about 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,    98%, 99%, or 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_029 or hIL12AB_027;-   (x) at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,    or 100% sequence identity to nucleotides 1006-1596 of hIL12AB_039 or    hIL12AB_040;-   (xi) at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or    100% sequence identity to nucleotides 1006-1596 of hIL12AB_036,    hIL12AB_034, hIL12AB_016, hIL12AB_023, hIL12AB_030, hIL12AB_031,    hIL12AB_025, or hIL12AB_035;-   (xii) at least about 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_021,    hIL12AB_024, hIL12AB_032, hIL12AB_033, hIL12AB_037, or hIL12AB_022;-   (xiii) at least about 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%    sequence identity to nucleotides 1006-1596 of hIL12AB_020,    hIL12AB_026, or hIL12AB_038;-   (xiv) at least about 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence    identity to nucleotides 1006-1596 of hIL12AB_015, hIL12AB_011, or    hIL12AB_028; or-   (xv) about 100% sequence identity to nucleotides 1006-1596 of    hIL12AB_003.

In some embodiments, the polynucleotide sequence comprises an ORFcomprising the sequence set forth as hIL12AB_002 (SEQ ID NO: 6) or anucleotide sequence at least about 60%, 65%, 70%, 75%, 76%, 77%, 78%,79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity tohIL12AB_002 (SEQ ID NO: 6).

In one embodiment, the first nucleotide sequence (e.g, first ORF)encoding the IL12B polypeptide and the second nucleotide sequence (e.g.,second ORF) encoding the IL12A polypeptide are fused directly or by alinker. In another embodiment, the first nucleotide sequence (e.g, firstORF) encoding the IL12B polypeptide and the second nucleotide sequence(e.g., second ORF) encoding the IL12A polypeptide are not fused to eachother.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B-IL12A fusion polypeptide (e.g., the wild-type sequence,functional fragment, or variant thereof), wherein the nucleotidesequence has at least about 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identityto a sequence selected from the group consisting of SEQ ID NOs: 5 to 44.See Table 4.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B-IL12A fusion polypeptide (e.g., the wild-type sequence,functional fragment, or variant thereof), wherein the nucleotidesequence has 70% to 100%, 75% to 100%, 80% to 100%, 85% to 100%, 70% to95%, 80% to 95%, 70% to 85%, 75% to 90%, 80% to 95%, 70% to 75%, 75% to80%, 80% to 85%, 85% to 90%, 90% to 95%, or 95% to 100%, sequenceidentity to a sequence selected from the group consisting of SEQ ID NOs:5 to 44. See Table 4.

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises from about 900 to about 100,000 nucleotides(e.g., from 900 to 1,000, from 900 to 1,100, from 900 to 1,200, from 900to 1,300, from 900 to 1,400, from 900 to 1,500, from 1,000 to 1,100,from 1,000 to 1,100, from 1,000 to 1,200, from 1,000 to 1,300, from1,000 to 1,400, from 1,000 to 1,500, from 1,083 to 1,200, from 1,083 to1,400, from 1,083 to 1,600, from 1,083 to 1,800, from 1,083 to 2,000,from 1,083 to 3,000, from 1,083 to 5,000, from 1,083 to 7,000, from1,083 to 10,000, from 1,083 to 25,000, from 1,083 to 50,000, from 1,083to 70,000, or from 1,083 to 100,000).

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B-IL12A fusion polypeptide (e.g., the wild-type sequence,functional fragment, or variant thereof), wherein the length of thenucleotide sequence (e.g., an ORF) is at least 500 nucleotides in length(e.g., at least or greater than about 500, 600, 700, 80, 900, 1,000,1,050, 1,083, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800,1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800,2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800,3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800,4,900, 5,000, 5,100, 5,200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800,5,900, 6,000, 7,000, 8,000, 9,000, 10,000, 20,000, 30,000, 40,000,50,000, 60,000, 70,000, 80,000, 90,000 or up to and including 100,000nucleotides).

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B and/or IL12A polypeptide (e.g., the wild-type sequence,functional fragment, or variant thereof) further comprises at least onenucleic acid sequence that is noncoding, e.g., a miRNA binding site.

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) comprises a nucleotide sequence (e.g., an ORF) encodingan IL12B and/or IL12A polypeptide that is single stranded or doublestranded.

In some embodiments, the polynucleotide of the disclosure comprising anucleotide sequence (e.g., an ORF) encoding an IL12B and/or IL12Apolypeptide (e.g., the wild-type sequence, functional fragment, orvariant thereof) is DNA or RNA. In some embodiments, the polynucleotideof the disclosure is RNA. In some embodiments, the polynucleotide of thedisclosure is, or functions as, a messenger RNA (mRNA). In someembodiments, the mRNA comprises a nucleotide sequence (e.g., an ORF)that encodes at least one IL12B and/or IL12A polypeptide, and is capableof being translated to produce the encoded IL12B and/or IL12Apolypeptide in vitro, in vivo, in situ or ex vivo.

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) comprises a sequence-optimized nucleotide sequence (e.g.,an ORF) encoding an IL12B and/or IL12A polypeptide (e.g., the wild-typesequence, functional fragment, or variant thereof), wherein thepolynucleotide comprises at least one chemically modified nucleobase,e.g., 5-methoxyuracil. In some embodiments, the polynucleotide furthercomprises a miRNA binding site, e.g., a miRNA binding site that binds tomiR-122. In some embodiments, the polynucleotide disclosed herein isformulated with a delivery agent, e.g., a compound having Formula (I),e.g., any of Compounds 1-147 or any of Compounds 1-232.

The polynucleotides (e.g., a RNA, e.g., an mRNA) of the disclosure canalso comprise nucleotide sequences that encode additional features thatfacilitate trafficking of the encoded polypeptides to therapeuticallyrelevant sites. One such feature that aids in protein trafficking is thesignal sequence, or targeting sequence. The peptides encoded by thesesignal sequences are known by a variety of names, including targetingpeptides, transit peptides, and signal peptides. In some embodiments,the polynucleotide (e.g., a RNA, e.g., an mRNA) comprises a nucleotidesequence (e.g., an ORF) that encodes a signal peptide operably linked anucleotide sequence that encodes an IL12B and/or IL12A polypeptidedescribed herein.

In some embodiments, the “signal sequence” or “signal peptide” is apolynucleotide or polypeptide, respectively, which is from about 9 to200 nucleotides (3-70 amino acids) in length that, optionally, isincorporated at the 5′ (or N-terminus) of the coding region or thepolypeptide, respectively. Addition of these sequences results intrafficking the encoded polypeptide to a desired site, such as theendoplasmic reticulum or the mitochondria through one or more targetingpathways. Some signal peptides are cleaved from the protein, for exampleby a signal peptidase after the proteins are transported to the desiredsite.

In some embodiments, the polynucleotide of the disclosure comprises anucleotide sequence encoding an IL12B and/or IL12A polypeptide, whereinthe nucleotide sequence further comprises a 5′ nucleic acid sequenceencoding a native signal peptide. In another embodiment, thepolynucleotide of the disclosure comprises a nucleotide sequenceencoding an IL12B and/or IL12A polypeptide, wherein the nucleotidesequence lacks the nucleic acid sequence encoding a native signalpeptide.

In some embodiments, the polynucleotide of the disclosure comprises anucleotide sequence encoding an IL12B and/or IL12A polypeptide, whereinthe nucleotide sequence further comprises a 5′ nucleic acid sequenceencoding a heterologous signal peptide.

In some embodiments, the polynucleotide further comprises a nucleic acidsequence encoding a signal peptide that is located at the 5′ terminus ofthe first ORF.

In some embodiments, the first ORF comprises a nucleic acid sequenceencoding a signal peptide.

In some embodiments, the signal peptide is a human IL12B signal peptide.

In some embodiments, the signal peptide comprises a sequence at leastabout 80%, at least about 90%, at least about 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100% identical to amino acids1 to 22 of SEQ ID NO: 48.

Based on the RNA sequences provided, a person of ordinary skill in theart would understand the corresponding DNA sequence (e.g., conversion ofuracil to thymine). Likewise, based on the DNA sequences provided, aperson of ordinary skill in the art would understand the correspondingRNA sequence (e.g., conversion of thymine to uracil).

5. Chimeric Proteins

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) can comprise more than one nucleic acid sequence (e.g.,more than one ORF) encoding one or more polypeptide of interest. In someembodiments, polynucleotides of the disclosure comprise a single ORFencoding an IL12B and/or IL12A polypeptide, a functional fragment, or avariant thereof. However, in some embodiments, the polynucleotide of thedisclosure can comprise more than one nucleotide sequence, for example,a first nucleotide sequence encoding an IL12B polypeptide (a firstpolypeptide of interest), a functional fragment, or a variant thereof, asecond nucleotide sequence encoding an IL12A polypeptide (a secondpolypeptide of interest), a functional fragment, or a variant thereof,and a third nucleotide sequence expressing a third polypeptide ofinterest (e.g., a polypeptide heterologous to IL12). In one embodiment,the third polypeptide of interest can be fused to the IL12B polypeptidedirectly or by a linker. In another embodiment, the third polypeptide ofinterest can be fused to the IL12A polypeptide directly or by a linker.In other embodiments, the third polypeptide of interest can be fused toboth the IL12B polypeptide and the IL12A polypeptide directly or by alinker. In further embodiments, the polynucleotide of the disclosure cancomprise more than three nucleotide sequences, for example, a firstnucleotide sequence encoding an IL12B polypeptide (a first polypeptideof interest), a functional fragment, or a variant thereof, a secondnucleotide sequence encoding an IL12A polypeptide (a second polypeptideof interest), a functional fragment, or a variant thereof, a thirdnucleotide sequence expressing a third polypeptide of interest, and afourth nucleotide sequence expressing a fourth polypeptide of interest.In other embodiments, the third polypeptide of interest is fused to theIL12A polypeptide directly or by a linker, and the fourth polypeptide ofinterest is fused to the IL12B polypeptide directly or by a linker. Insome embodiments, two or more polypeptides of interest can begenetically fused, i.e., two or more polypeptides can be encoded by thesame nucleotide sequence. In some embodiments, the polynucleotide cancomprise a nucleic acid sequence encoding a linker (e.g., a G₄S peptidelinker or another linker known in the art) between two or morepolypeptides of interest.

In some embodiments, a polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) can comprise two, three, four, or more nucleotidesequences, each expressing a polypeptide of interest.

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) can comprise a first nucleic acid sequence (e.g., a firstORF) encoding an IL12B polypeptide, IL12A polypeptide, or both IL12B andIL12A polypeptides and a second nucleic acid sequence (e.g., a secondORF) encoding a second polypeptide of interest.

6. Linker

In one aspect, the IL12B and/or IL12A can be fused directly or by alinker. In other embodiments, the IL12B and/or IL12A can be fuseddirectly to by a linker to a heterologous polypeptide. The linkerssuitable for fusing the IL12B to IL12A or the IL12B and/or IL12A to aheterologous polypeptide can be a polypeptide (or peptide) moiety or anon-polypeptide moiety.

Some aspects of the present disclosure are directed to a lipidnanoparticle comprising a polynucleotide encoding a human IL12polypeptide, wherein the polynucleotide comprises an ORF encoding ahuman IL12B polypeptide operably linked to a human IL12A polypeptide. Insome embodiments, the IL12B polypeptide is operably linked to the IL12Apolypeptide by a peptide linker. In some embodiments, the IL12Bpolypeptide is located at the 5′ terminus of the IL12A polypeptide orthe peptide linker. In other embodiments, the IL12A polypeptide islocated at the 5′ terminus of the IL12B polypeptide or the peptidelinker.

In some embodiments, the linker is a peptide linker, including from oneamino acid to about 200 amino acids. In some embodiments, the linkercomprises at least 1, at least 2, at least 3, at least 4, at least 5, atleast 6, at least 7, at least 8, at least 9, at least 10, at least 11,at least 12, at least 13, at least 14, at least 15, at least 16, atleast 17, at least 18, at least 19, at least 20, at least 21, at least22, at least 23, at least 24, at least 25, at least 26, at least 27, atleast 28, at least 29, at least 30, at least 31, at least 32, at least33, at least 34, at least 35, at least 36, at least 37, at least 38, atleast 39, or at least 40 amino acids.

In some embodiments, the linker can be GS (Gly/Ser) linkers, forexample, comprising (G_(n)S)_(m), wherein n is an integer from 1 to 20and m is an integer from 1 to 20. In some embodiments, the Gly/Serlinker comprises (G_(n)S)_(m) (SEQ ID NO: 203), wherein n is 1, 2 3, 4,5, 6, 7, 8, 9, 10, 15, or 20 and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,or 20. In some embodiments, the GS linker can comprise (GGGGS)_(o) (SEQID NO: 204), wherein o is an integer from 1 to 5. In some embodiments,the GS linker can comprise GGSGGGGSGG (SEQ ID NO: 205), GGSGGGGG (SEQ IDNO: 206), or GSGSGSGS (SEQ ID NO: 207). In certain embodiments, theGly/Ser linker comprises (G_(n)S)_(m), wherein n is 6 and m is 1.

In some embodiments, the linker suitable for the disclosure can be aGly-rich linker, for example, comprising (Gly)_(p) (SEQ ID NO: 208),wherein p is an integer from 1 to 40. In some embodiments, a Gly-richlinker can comprise GGGGG, GGGGGG, GGGGGGG or GGGGGGGG.

In some embodiments, the linker suitable for the disclosure can comprise(EAAAK)_(q) (SEQ ID NO: 209), wherein q is an integer from 1 to 5. Inone embodiment, the linker suitable for the disclosure can comprise(EAAAK)₃.

Further exemplary linkers include, but not limited to, GGGGSLVPRGSGGGGS(SEQ ID NO: 210), GSGSGS (SEQ ID NO: 211), GGGGSLVPRGSGGGG (SEQ ID NO:212), GGSGGHMGSGG (SEQ ID NO: 213), GGSGGSGGSGG (SEQ ID NO: 214), GGSGG(SEQ ID NO: 215), GSGSGSGS (SEQ ID NO: 216), GGGSEGGGSEGGGSEGGG (SEQ IDNO: 217), AAGAATAA (SEQ ID NO: 218), GGSSG (SEQ ID NO: 219), GSGGGTGGGSG(SEQ ID NO: 220), GSGSGSGSGGSG (SEQ ID NO: 221), GSGGSGSGGSGGSG (SEQ IDNO: 222), and GSGGSGGSGGSGGS (SEQ ID NO: 223).

The nucleotides encoding the linkers can be constructed to fuse thenucleotide sequences of the present disclosure. Based on the RNAsequences provided, a person of ordinary skill in the art wouldunderstand the corresponding DNA sequence (e.g., conversion of uracil tothymine). Likewise, based on the DNA sequences provided, a person ofordinary skill in the art would understand the corresponding RNAsequence (e.g., conversion of thymine to uracil).

7. Sequence Optimization of Nucleotide Sequence Encoding an IL12Polypeptide

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure is sequence optimized. In some embodiments, thepolynucleotide (e.g., a RNA, e.g., an mRNA) of the disclosure comprisesa nucleotide sequence (e.g., an ORF) encoding an IL12B and/or IL12Apolypeptide, a nucleotide sequence (e.g., an ORF) encoding anotherpolypeptide of interest, a 5′-UTR, a 3′-UTR, a miRNA, a nucleotidesequence encoding a linker, or any combination thereof that is sequenceoptimized.

A sequence-optimized nucleotide sequence, e.g., an codon-optimized mRNAsequence encoding an IL12B and/or IL12A polypeptide, is a sequencecomprising at least one synonymous nucleobase substitution with respectto a reference sequence (e.g., a wild type nucleotide sequence encodingan IL12B and/or IL12A polypeptide).

A sequence-optimized nucleotide sequence can be partially or completelydifferent in sequence from the reference sequence. For example, areference sequence encoding polyserine uniformly encoded by TCT codonscan be sequence-optimized by having 100% of its nucleobases substituted(for each codon, T in position 1 replaced by A, C in position 2 replacedby G, and T in position 3 replaced by C) to yield a sequence encodingpolyserine which would be uniformly encoded by AGC codons. Thepercentage of sequence identity obtained from a global pairwisealignment between the reference polyserine nucleic acid sequence and thesequence-optimized polyserine nucleic acid sequence would be 0%.However, the protein products from both sequences would be 100%identical.

Some sequence optimization (also sometimes referred to codonoptimization) methods are known in the art (and discussed in more detailbelow) and can be useful to achieve one or more desired results. Theseresults can include, e.g., matching codon frequencies in certain tissuetargets and/or host organisms to ensure proper folding; biasing G/Ccontent to increase mRNA stability or reduce secondary structures;minimizing tandem repeat codons or base runs that can impair geneconstruction or expression; customizing transcriptional andtranslational control regions; inserting or removing protein traffickingsequences; removing/adding post translation modification sites in anencoded protein (e.g., glycosylation sites); adding, removing orshuffling protein domains; inserting or deleting restriction sites;modifying ribosome binding sites and mRNA degradation sites; adjustingtranslational rates to allow the various domains of the protein to foldproperly; and/or reducing or eliminating problem secondary structureswithin the polynucleotide. Sequence optimization tools, algorithms andservices are known in the art, non-limiting examples include servicesfrom GeneArt (Life Technologies), DNA2.0 (Menlo Park Calif.) and/orproprietary methods.

Codon options for each amino acid are given in Table 3.

TABLE 3 Codon Options Single Letter Amino Acid Code Codon OptionsIsoleucine I ATT, ATC, ATA Leucine L CTT, CTC, CTA, CTG, TTA, TTG ValineV GTT, GTC, GTA, GTG Phenylalanine F TTT, TTC Methionine M ATG CysteineC TGT, TGC Alanine A GCT, GCC, GCA, GCG Glycine G GGT, GGC, GGA, GGGProline P CCT, CCC, CCA, CCG Threonine T ACT, ACC, ACA, ACG Serine STCT, TCC, TCA, TCG, AGT, AGC Tyrosine Y TAT, TAC Tryptophan W TGGGlutamine Q CAA, CAG Asparagine N AAT, AAC Histidine H CAT, CAC Glutamicacid E GAA, GAG Aspartic acid D GAT, GAC Lysine K AAA, AAG Arginine RCGT, CGC, CGA, CGG, AGA, AGG Selenocysteine Sec UGA in mRNA in presenceof Selenocysteine insertion element (SECTS) Stop codons Stop TAA, TAG,TGA

In some embodiments, a polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a sequence-optimized nucleotide sequence (e.g.,an ORF) encoding an IL12B and/or IL12A polypeptide, a functionalfragment, or a variant thereof, wherein the IL12B and/or IL12Apolypeptide, functional fragment, or a variant thereof encoded by thesequence-optimized nucleotide sequence has improved properties (e.g.,compared to an IL12B and/or IL12A polypeptide, functional fragment, or avariant thereof encoded by a reference nucleotide sequence that is notsequence optimized), e.g., improved properties related to expressionefficacy after administration in vivo. Such properties include, but arenot limited to, improving nucleic acid stability (e.g., mRNA stability),increasing translation efficacy in the target tissue, reducing thenumber of truncated proteins expressed, improving the folding or preventmisfolding of the expressed proteins, reducing toxicity of the expressedproducts, reducing cell death caused by the expressed products,increasing and/or decreasing protein aggregation.

In some embodiments, the sequence-optimized nucleotide sequence is codonoptimized for expression in human subjects, having structural and/orchemical features that avoid one or more of the problems in the art, forexample, features which are useful for optimizing formulation anddelivery of nucleic acid-based therapeutics while retaining structuraland functional integrity; overcoming a threshold of expression;improving expression rates; half-life and/or protein concentrations;optimizing protein localization; and avoiding deleterious bio-responsessuch as the immune response and/or degradation pathways.

In some embodiments, the polynucleotides of the disclosure comprise anucleotide sequence (e.g., a nucleotide sequence (e.g., an ORF) encodingan IL12B and/or IL12A polypeptide, a nucleotide sequence (e.g., an ORF)encoding an additional polypeptide of interest, a 5′-UTR, a 3′-UTR, amicroRNA, a nucleic acid sequence encoding a linker, or any combinationthereof) that is sequence-optimized according to a method comprising:

-   (i) substituting at least one codon in a reference nucleotide    sequence (e.g., an ORF encoding an IL12B and/or IL12A polypeptide)    with an alternative codon to increase or decrease uridine content to    generate a uridine-modified sequence;-   (ii) substituting at least one codon in a reference nucleotide    sequence (e.g., an ORF encoding an IL12B and/or IL12A polypeptide)    with an alternative codon having a higher codon frequency in the    synonymous codon set;-   (iii) substituting at least one codon in a reference nucleotide    sequence (e.g., an ORF encoding an IL12B and/or IL12A polypeptide)    with an alternative codon to increase G/C content; or-   (iv) a combination thereof.

In some embodiments, the sequence-optimized nucleotide sequence (e.g.,an ORF encoding an IL12B and/or IL12A polypeptide) has at least oneimproved property with respect to the reference nucleotide sequence.

In some embodiments, the sequence optimization method is multiparametricand comprises one, two, three, four, or more methods disclosed hereinand/or other optimization methods known in the art.

Features, which can be considered beneficial in some embodiments of thedisclosure, can be encoded by or within regions of the polynucleotideand such regions can be upstream (5′) to, downstream (3′) to, or withinthe region that encodes the IL12B and/or IL12A polypeptide. Theseregions can be incorporated into the polynucleotide before and/or aftersequence-optimization of the protein encoding region or open readingframe (ORF). Examples of such features include, but are not limited to,untranslated regions (UTRs), microRNA sequences, Kozak sequences,oligo(dT) sequences, poly-A tail, and detectable tags and can includemultiple cloning sites that may have XbaI recognition.

In some embodiments, the polynucleotide of the disclosure comprises a 5′UTR, a 3′ UTR and/or a miRNA binding site. In some embodiments, thepolynucleotide comprises two or more 5′ UTRs and/or 3′ UTRs, which canbe the same or different sequences. In some embodiments, thepolynucleotide comprises two or more miRNA binding sites, which can bethe same or different sequences. Any portion of the 5′ UTR, 3′ UTR,and/or miRNA binding site, including none, can be sequence-optimized andcan independently contain one or more different structural or chemicalmodifications, before and/or after sequence optimization.

In some embodiments, after optimization, the polynucleotide isreconstituted and transformed into a vector such as, but not limited to,plasmids, viruses, cosmids, and artificial chromosomes. For example, theoptimized polynucleotide can be reconstituted and transformed intochemically competent E. coli, yeast, neurospora, maize, drosophila, etc.where high copy plasmid-like or chromosome structures occur by methodsdescribed herein.

8. Sequence-Optimized Nucleotide Sequences Encoding IL12 Polypeptides

In some embodiments, the polynucleotide of the disclosure comprises asequence-optimized nucleotide sequence encoding an IL12B and/or IL12Apolypeptide disclosed herein. In some embodiments, the polynucleotide ofthe disclosure comprises an open reading frame (ORF) encoding an IL12Band/or IL12A polypeptide, wherein the ORF has been sequence optimized.

Exemplary sequence-optimized nucleotide sequences encoding human IL12Band/or IL12A are shown in Tables 4A-4D. In some embodiments, thesequence optimized IL12B and/or IL12A sequences in Table 4A-4D,fragments, and variants thereof are used to practice the methodsdisclosed herein. In some embodiments, the sequence optimized IL12Band/or IL12A sequences in Table 4A-4D, fragments and variants thereofare combined with or alternatives to the wild-type sequences disclosedin FIG. 1. Based on the RNA sequences provided, a person of ordinaryskill in the art would understand the corresponding DNA sequence (e.g.,conversion of uracil to thymine). Likewise, based on the DNA sequencesprovided, a person of ordinary skill in the art would understand thecorresponding RNA sequence (e.g., conversion of thymine to uracil).

TABLE 4A Sequence optimized Open Reading Frame sequences for humanIL12 > hIL12AB_001 (SEQ ID NO: 5)ATGTGTCACCAGCAGCTGGTCATTAGCTGGTTTAGCCTTGTGTTCCTGGCCTCCCCCCTTGTCGCTATTTGGGAGCTCAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCAGACGCGCCCGGAGAGATGGTAGTTCTGACCTGTGATACCCCAGAGGAGGACGGCATCACCTGGACTCTGGACCAAAGCAGCGAGGTTTTGGGCTCAGGGAAAACGCTGACCATCCAGGTGAAGGAATTCGGCGACGCCGGACAGTACACCTGCCATAAGGGAGGAGAGGTGCTGAGCCATTCCCTTCTTCTGCTGCACAAGAAAGAGGACGGCATCTGGTCTACCGACATCCTGAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTGAGGTGCGAGGCCAAGAACTACTCCGGCAGGTTCACTTGTTGGTGGCTGACCACCATCAGTACAGACCTGACTTTTAGTGTAAAAAGCTCCAGAGGCTCGTCCGATCCCCAAGGGGTGACCTGCGGCGCAGCCACTCTGAGCGCTGAGCGCGTGCGCGGTGACAATAAAGAGTACGAGTACAGCGTTGAGTGTCAAGAAGACAGCGCTTGCCCTGCCGCCGAGGAGAGCCTGCCTATCGAGGTGATGGTTGACGCAGTGCACAAGCTTAAGTACGAGAATTACACCAGCTCATTCTTCATTAGAGATATAATCAAGCCTGACCCACCCAAGAACCTGCAGCTGAAGCCACTGAAAAACTCACGGCAGGTCGAAGTGAGCTGGGAGTACCCCGACACCTGGAGCACTCCTCATTCCTATTTCTCTCTTACATTCTGCGTCCAGGTGCAGGGCAAGAGCAAGCGGGAAAAGAAGGATCGAGTCTTCACCGACAAAACAAGCGCGACCGTGATTTGCAGGAAGAACGCCAGCATCTCCGTCAGAGCCCAGGATAGATACTATAGTAGCAGCTGGAGCGAGTGGGCAAGCGTGCCCTGTTCCGGCGGCGGGGGCGGGGGCAGCCGAAACTTGCCTGTCGCTACCCCGGACCCTGGAATGTTTCCGTGTCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGTCGAATATGCTCCAGAAGGCCCGGCAGACCCTTGAGTTCTACCCCTGTACCAGCGAAGAGATCGATCATGAGGACATCACGAAAGACAAGACTTCCACCGTCGAGGCTTGTCTCCCGCTGGAGCTGACCAAGAACGAGAGCTGTCTGAATAGCCGGGAGACATCTTTCATCACGAATGGTAGCTGTCTGGCCAGCAGGAAAACTTCCTTCATGATGGCTCTCTGCCTGAGCTCTATCTATGAAGATCTGAAGATGTATCAGGTGGAGTTTAAGACTATGAACGCCAAACTCCTGATGGACCCAAAAAGGCAAATCTTTCTGGACCAGAATATGCTGGCCGTGATAGACGAGCTGATGCAGGCACTGAACTTCAACAGCGAGACAGTGCCACAGAAATCCAGCCTGGAGGAGCCTGACTTTTACAAAACTAAGATCAAGCTGTGTATCCTGCTGCACGCCTTTAGAATCCGTGCCGTGACTATCGACAGGGTGATGTCATACCTCAACGCTTCA > hIL12AB_002(SEQ IDNO: 6)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCCGACGCCCCCGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGATGCGAGGCCAAGAACTACAGCGGCAGATTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGCGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACAGAGTGTTCACCGACAAGACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGAGCCCAGGACAGATACTACAGCAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCAGACAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGACCACGAGGACATCACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGACAGATCTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGAATCAGAGCCGTGACCATCGACAGAGTGATGAGCTACCTGAACGCCAGC > hIL12AB_003(SEQ IDNO: 7)ATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTCCCCTCGTGGCCATATGGGAACTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGTATCCGGATGCCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCGCTCCTGCTGCTTCACAAAAAGGAAGATGGAATTTGGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCAGTGTCAAAAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACACTCTCTGCAGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCCAGCTGCTGAGGAGAGTCTGCCCATTGAGGTCATGGTGGATGCCGTTCACAAGCTCAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAACTTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAGAGCAAGAGAGAAAAGAAAGATAGAGTCTTCACGGACAAGACCTCAGCCACGGTCATCTGCCGCAAAAATGCCAGCATTAGCGTGCGGGCCCAGGACCGCTACTATAGCTCATCTTGGAGCGAATGGGCATCTGTGCCCTGCAGTGGCGGAGGGGGCGGAGGGAGCAGAAACCTCCCCGTGGCCACTCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGGCCAGACAAACTTTAGAATTTTACCCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCCAGAGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGACCTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTTTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCGGACTTCTACAAGACCAAGATCAAGCTCTGCATACTTCTTCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCC > hIL12AB_004 (SEQ IDNO: 8)ATGGGCTGCCACCAGCAGCTGGTCATCAGCTGGTTCTCCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAAGATGTCTATGTTGTAGAGCTGGACTGGTACCCAGATGCTCCTGGAGAAATGGTGGTTCTCACCTGTGACACGCCAGAAGAAGATGGCATCACCTGGACGCTGGACCAGAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACAGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGCAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGGGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGACTCGGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAAGTGGAAGTTTCCTGGGAGTACCCAGACACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACAGACAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTGCACCACAGCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCAAGACAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGACATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGAGACAAATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGACTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGC > hIL12AB_005 (SEQID NO: 9)ATGTGCCACCAGCAGCTGGTCATCAGCTGGTTCTCCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAAGATGTCTATGTTGTAGAGCTGGACTGGTACCCAGATGCTCCTGGAGAAATGGTGGTTCTCACCTGTGACACGCCAGAAGAAGATGGCATCACCTGGACGCTGGACCAGAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACAGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGCAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGGGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGACTCGGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAAGTGGAAGTTTCCTGGGAGTACCCAGACACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACAGACAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTGCACCACAGCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCAAGACAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGACATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGAGACAAATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGACTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGC > hIL12AB_006 (SEQ IDNO: 10)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCCGACGCCCCCGGCGAGATGGTGGTGCTGACCTGTGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGGGACGCCGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATCTGGAGCACAGATATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGATGCGAGGCCAAGAACTACAGCGGCAGATTCACCTGCTGGTGGCTGACCACCATCAGCACAGACTTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGGGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCCGACCCGCCGAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACAGAGTGTTCACAGATAAGACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGAGCCCAGGACAGATACTACAGCAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCAGACAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGACCACGAGGACATCACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAATGAAAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGACAGATCTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGAATCAGAGCCGTGACCATCGACAGAGTGATGAGCTACCTGAACGCCAGC > hIL12AB_007 (SEQ IDNO: 11)ATGTGCCACCAGCAGCTTGTCATCTCCTGGTTCTCTCTTGTCTTCCTTGCTTCTCCTCTTGTGGCCATCTGGGAGCTGAAGAAGGATGTTTATGTTGTGGAGTTGGACTGGTACCCTGATGCTCCTGGAGAAATGGTGGTTCTCACCTGTGACACTCCTGAGGAGGATGGCATCACCTGGACTTTGGACCAGTCTTCTGAGGTTCTTGGCAGTGGAAAAACTCTTACTATTCAGGTGAAGGAGTTTGGAGATGCTGGCCAGTACACCTGCCACAAGGGTGGTGAAGTTCTCAGCCACAGTTTACTTCTTCTTCACAAGAAGGAGGATGGCATCTGGTCTACTGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAGACTTTCCTTCGTTGTGAAGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTTACTACTATTTCTACTGACCTTACTTTCTCTGTGAAGTCTTCTCGTGGCTCTTCTGACCCTCAGGGTGTCACCTGTGGGGCTGCTACTCTTTCTGCTGAGCGTGTGCGTGGGGACAACAAGGAGTATGAATACTCGGTGGAGTGCCAGGAGGACTCTGCCTGCCCTGCTGCTGAGGAGTCTCTTCCTATTGAGGTGATGGTGGATGCTGTGCACAAGTTAAAATATGAAAACTACACTTCTTCTTTCTTCATTCGTGACATTATAAAACCTGACCCTCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACTCTCGTCAGGTGGAGGTGTCCTGGGAGTACCCTGACACGTGGTCTACTCCTCACTCCTACTTCTCTCTTACTTTCTGTGTCCAGGTGCAGGGCAAGTCCAAGCGTGAGAAGAAGGACCGTGTCTTCACTGACAAGACTTCTGCTACTGTCATCTGCAGGAAGAATGCATCCATCTCTGTGCGTGCTCAGGACCGTTACTACAGCTCTTCCTGGTCTGAGTGGGCTTCTGTGCCCTGCTCTGGCGGCGGCGGCGGCGGCAGCAGAAATCTTCCTGTGGCTACTCCTGACCCTGGCATGTTCCCCTGCCTTCACCACTCGCAGAACCTTCTTCGTGCTGTGAGCAACATGCTTCAGAAGGCTCGTCAGACTTTAGAATTCTACCCCTGCACTTCTGAGGAGATTGACCATGAAGACATCACCAAGGACAAGACTTCTACTGTGGAGGCCTGCCTTCCTTTAGAGCTGACCAAGAATGAATCCTGCTTAAATTCTCGTGAGACTTCTTTCATCACCAATGGCAGCTGCCTTGCCTCGCGCAAGACTTCTTTCATGATGGCTCTTTGCCTTTCTTCCATCTATGAAGACTTAAAAATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTTCTCATGGACCCCAAGCGTCAGATATTTTTGGACCAGAACATGCTTGCTGTCATTGATGAGCTCATGCAGGCTTTAAACTTCAACTCTGAGACTGTGCCTCAGAAGTCTTCTTTAGAAGAGCCTGACTTCTACAAGACCAAGATAAAACTTTGCATTCTTCTTCATGCTTTCCGCATCCGTGCTGTGACTATTGACCGTGTGATGTCCTACTTAAATGCTTCT > hIL12AB_008 (SEQ IDNO: 12)ATGTGTCATCAACAACTCGTGATTAGCTGGTTCAGTCTCGTGTTCCTGGCCTCTCCGCTGGTGGCCATCTGGGAGCTTAAGAAGGACGTGTACGTGGTGGAGCTCGATTGGTACCCCGATGCTCCTGGCGAGATGGTGGTGCTAACCTGCGATACCCCCGAGGAGGACGGGATCACTTGGACCCTGGATCAGAGTAGCGAAGTCCTGGGCTCTGGCAAGACACTCACAATCCAGGTGAAGGAATTCGGAGACGCTGGTCAGTACACTTGCCACAAGGGGGGTGAAGTGCTGTCTCACAGCCTGCTGTTACTGCACAAGAAGGAGGATGGGATCTGGTCAACCGACATCCTGAAGGATCAGAAGGAGCCTAAGAACAAGACCTTTCTGAGGTGTGAAGCTAAGAACTATTCCGGAAGATTCACTTGCTGGTGGTTGACCACAATCAGCACTGACCTGACCTTTTCCGTGAAGTCCAGCAGAGGAAGCAGCGATCCTCAGGGCGTAACGTGCGGCGCGGCTACCCTGTCAGCTGAGCGGGTTAGAGGCGACAACAAAGAGTATGAGTACTCCGTGGAGTGTCAGGAGGACAGCGCCTGCCCCGCAGCCGAGGAGAGTCTGCCCATCGAGGTGATGGTGGACGCTGTCCATAAGTTAAAATACGAAAATTACACAAGTTCCTTTTTCATCCGCGATATTATCAAACCCGATCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAATAGCCGACAGGTGGAAGTCTCTTGGGAGTATCCTGACACCTGGTCCACGCCTCACAGCTACTTTAGTCTGACTTTCTGTGTCCAGGTCCAGGGCAAGAGCAAGAGAGAGAAAAAGGATAGAGTGTTTACTGACAAGACATCTGCTACAGTCATCTGCAGAAAGAACGCCAGTATCTCAGTGAGGGCGCAGGACAGATACTACAGTAGTAGCTGGAGCGAATGGGCTAGCGTGCCCTGTTCAGGGGGCGGCGGAGGGGGCTCCAGGAATCTGCCCGTGGCCACCCCCGACCCTGGGATGTTCCCTTGCCTCCATCACTCACAGAACCTGCTCAGAGCAGTGAGCAACATGCTCCAAAAGGCCCGCCAGACCCTGGAGTTTTACCCTTGTACTTCAGAAGAGATCGATCACGAAGACATAACAAAGGATAAAACCAGCACCGTGGAGGCCTGTCTGCCTCTAGAACTCACAAAGAATGAAAGCTGTCTGAATTCCAGGGAAACCTCCTTCATTACTAACGGAAGCTGTCTCGCATCTCGCAAAACATCATTCATGATGGCCCTCTGCCTGTCTTCTATCTATGAAGATCTCAAGATGTATCAGGTGGAGTTCAAAACAATGAACGCCAAGCTGCTGATGGACCCCAAGAGACAGATCTTCCTGGACCAGAACATGCTGGCAGTGATCGATGAGCTGATGCAAGCCTTGAACTTCAACTCAGAGACAGTGCCGCAAAAGTCCTCGTTGGAGGAACCAGATTTTTACAAAACCAAAATCAAGCTGTGTATCCTTCTTCACGCCTTTCGGATCAGAGCCGTGACTATCGACCGGGTGATGTCATACCTGAATGCTTCC > hIL12AB_009 (SEQ IDNO: 13)ATGTGCCACCAGCAGCTGGTCATCAGCTGGTTTAGCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAAGATGTCTATGTTGTAGAGCTGGACTGGTACCCAGATGCTCCTGGAGAAATGGTGGTTCTCACCTGCGACACGCCAGAAGAAGATGGCATCACCTGGACGCTGGACCAGAGCAGCGAAGTACTGGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGCGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTACTGAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACCGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCGAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACCGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGTAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGCGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGACTCGGCCTGCCCGGCGGCAGAAGAAAGTCTGCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCAGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAAGTGGAAGTTTCCTGGGAGTACCCAGACACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACCGACAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCAAGCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTTCCGTGCCTGCACCACAGCCAAAATTTATTACGAGCTGTTAGCAACATGCTGCAGAAAGCAAGACAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGACATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAACGAGAGCTGCCTCAATAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATCTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGAGACAAATATTCCTCGACCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGACTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGC > hIL12AB_010 (SEQ IDNO: 14)ATGTGCCACCAGCAGCTTGTCATCTCCTGGTTTTCTCTTGTCTTCCTCGCTTCTCCTCTTGTGGCCATCTGGGAGCTGAAGAAAGATGTCTATGTTGTAGAGCTGGACTGGTACCCGGACGCTCCTGGAGAAATGGTGGTTCTCACCTGCGACACTCCTGAAGAAGATGGCATCACCTGGACGCTGGACCAAAGCAGCGAAGTTTTAGGCTCTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGCGACGCTGGCCAGTACACGTGCCACAAAGGAGGAGAAGTTTTAAGCCACAGTTTACTTCTTCTTCACAAGAAAGAAGATGGCATCTGGAGTACGGACATTTTAAAAGACCAGAAGGAGCCTAAGAACAAAACCTTCCTCCGCTGTGAAGCTAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTCACCACCATCTCCACTGACCTCACCTTCTCTGTAAAATCAAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCAGCGCTGAAAGAGTTCGAGGCGACAACAAGGAATATGAATATTCTGTGGAATGTCAAGAAGATTCTGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGACGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATTCGTGACATCATCAAACCAGACCCTCCTAAGAACCTTCAGTTAAAACCGCTGAAGAACAGCAGACAAGTGGAAGTTTCCTGGGAGTACCCGGACACGTGGAGTACGCCGCACTCCTACTTCAGTTTAACCTTCTGTGTACAAGTACAAGGAAAATCAAAAAGAGAGAAGAAAGATCGTGTCTTCACTGACAAAACATCTGCCACGGTCATCTGCCGTAAGAACGCTTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTTCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCCGCAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTTCACCACTCGCAAAATCTTCTTCGTGCTGTTTCTAACATGCTGCAGAAGGCGAGACAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATAGACCATGAAGACATCACCAAGGACAAAACCAGCACGGTGGAGGCCTGCCTTCCTTTAGAACTTACTAAGAACGAAAGTTGCCTTAACAGCCGTGAGACCAGCTTCATCACCAATGGCAGCTGCCTTGCTAGCAGGAAGACCAGCTTCATGATGGCGCTGTGCCTTTCTTCCATCTATGAAGATCTTAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAGAGACAAATATTCCTCGACCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAAACTGTTCCCCAGAAGTCATCTTTAGAAGAACCGGACTTCTACAAAACAAAAATAAAACTCTGCATTCTTCTTCATGCCTTCCGCATCCGTGCTGTCACCATTGACCGTGTCATGTCCTACTTAAATGCTTCT > hIL12AB_011 (SEQ IDNO: 15)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCGCCGGGGGAGATGGTGGTGCTGACGTGCGACACGCCGGAGGAGGACGGGATCACGTGGACGCTGGACCAGAGCAGCGAGGTGCTGGGGAGCGGGAAGACGCTGACGATCCAGGTGAAGGAGTTCGGGGACGCGGGGCAGTACACGTGCCACAAGGGGGGGGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGGATCTGGAGCACGGACATCCTGAAGGACCAGAAGGAGCCGAAGAACAAGACGTTCCTGAGGTGCGAGGCGAAGAACTACAGCGGGAGGTTCACGTGCTGGTGGCTGACGACGATCAGCACGGACCTGACGTTCAGCGTGAAGAGCAGCAGGGGGAGCAGCGACCCGCAGGGGGTGACGTGCGGGGCGGCGACGCTGAGCGCGGAGAGGGTGAGGGGGGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCGTGCCCGGCGGCGGAGGAGAGCCTGCCGATCGAGGTGATGGTGGACGCGGTGCACAAGCTGAAGTACGAGAACTACACGAGCAGCTTCTTCATCAGGGACATCATCAAGCCGGACCCGCCGAAGAACCTGCAGCTGAAGCCGCTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCGGACACGTGGAGCACGCCGCACAGCTACTTCAGCCTGACGTTCTGCGTGCAGGTGCAGGGGAAGAGCAAGAGGGAGAAGAAGGACAGGGTGTTCACGGACAAGACGAGCGCGACGGTGATCTGCAGGAAGAACGCGAGCATCAGCGTGAGGGCGCAGGACAGGTACTACAGCAGCAGCTGGAGCGAGTGGGCGAGCGTGCCGTGCAGCGGGGGGGGGGGGGGGGGGAGCAGGAACCTGCCGGTGGCGACGCCGGACCCGGGGATGTTCCCGTGCCTGCACCACAGCCAGAACCTGCTGAGGGCGGTGAGCAACATGCTGCAGAAGGCGAGGCAGACGCTGGAGTTCTACCCGTGCACGAGCGAGGAGATCGACCACGAGGACATCACGAAGGACAAGACGAGCACGGTGGAGGCGTGCCTGCCGCTGGAGCTGACGAAGAACGAGAGCTGCCTGAACAGCAGGGAGACGAGCTTCATCACGAACGGGAGCTGCCTGGCGAGCAGGAAGACGAGCTTCATGATGGCGCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACGATGAACGCGAAGCTGCTGATGGACCCGAAGAGGCAGATCTTCCTGGACCAGAACATGCTGGCGGTGATCGACGAGCTGATGCAGGCGCTGAACTTCAACAGCGAGACGGTGCCGCAGAAGAGCAGCCTGGAGGAGCCGGACTTCTACAAGACGAAGATCAAGCTGTGCATCCTGCTGCACGCGTTCAGGATCAGGGCGGTGACGATCGACAGGGTGATGAGCTACCTGAACGCGAGC > hIL12AB_012 (SEQ IDNO: 16)ATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTCGTGTTTCTGGCCAGCCCCCTGGTGGCCATTTGGGAACTCAAGAAGGACGTGTATGTAGTGGAACTCGACTGGTACCCTGACGCCCCAGGCGAAATGGTGGTCTTAACCTGCGACACCCCTGAGGAGGACGGAATCACCTGGACCTTGGACCAGAGCTCCGAGGTCCTCGGCAGTGGCAAGACCCTGACCATACAGGTGAAAGAATTTGGAGACGCAGGGCAATACACATGTCACAAGGGCGGGGAGGTTCTTTCTCACTCCCTTCTGCTTCTACATAAAAAGGAAGACGGAATTTGGTCTACCGACATCCTCAAGGACCAAAAGGAGCCTAAGAATAAAACCTTCTTACGCTGTGAAGCTAAAAACTACAGCGGCAGATTCACTTGCTGGTGGCTCACCACCATTTCTACCGACCTGACCTTCTCGGTGAAGTCTTCAAGGGGCTCTAGTGATCCACAGGGAGTGACATGCGGGGCCGCCACACTGAGCGCTGAACGGGTGAGGGGCGATAACAAGGAGTATGAATACTCTGTCGAGTGTCAGGAGGATTCAGCTTGTCCCGCAGCTGAAGAGTCACTCCCCATAGAGGTTATGGTCGATGCTGTGCATAAACTGAAGTACGAAAACTACACCAGCAGCTTCTTCATTCGGGACATTATAAAACCTGACCCCCCCAAGAACCTGCAACTTAAACCCCTGAAAAACTCTCGGCAGGTCGAAGTTAGCTGGGAGTACCCTGATACTTGGTCCACCCCCCACTCGTACTTCTCACTGACTTTCTGTGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAAAAAGATCGTGTATTCACAGACAAGACCTCTGCCACCGTGATCTGCAGAAAAAACGCTTCCATCAGTGTCAGAGCCCAAGACCGGTACTATAGTAGTAGCTGGAGCGAGTGGGCAAGTGTCCCCTGCTCTGGCGGCGGAGGGGGCGGCTCTCGAAACCTCCCCGTCGCTACCCCTGATCCAGGAATGTTCCCTTGCCTGCATCACTCACAGAATCTGCTGAGAGCGGTCAGCAACATGCTGCAGAAAGCTAGGCAAACACTGGAGTTTTATCCTTGTACCTCAGAGGAGATCGACCACGAGGATATTACCAAGGACAAGACCAGCACGGTGGAGGCCTGCTTGCCCCTGGAACTGACAAAGAATGAATCCTGCCTTAATAGCCGTGAGACCTCTTTTATAACAAACGGATCCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTCTGCCTGTCCTCAATCTACGAAGACCTGAAGATGTACCAGGTGGAATTTAAAACTATGAACGCCAAGCTGTTGATGGACCCCAAGCGGCAGATCTTTCTGGATCAAAATATGCTGGCTGTGATCGACGAACTGATGCAGGCCCTCAACTTTAACAGCGAGACCGTGCCACAAAAGAGCAGTCTTGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTCCTTCATGCCTTCAGGATAAGAGCTGTCACCATCGACAGAGTCATGAGTTACCTGAATGCATCC > hIL12AB_013 (SEQ IDNO: 17)ATGTGCCACCAGCAGCTGGTCATCTCCTGGTTCAGTCTTGTCTTCCTGGCCTCGCCGCTGGTGGCCATCTGGGAGCTGAAGAAAGATGTTTATGTTGTAGAGCTGGACTGGTACCCAGATGCTCCTGGAGAAATGGTGGTCCTCACCTGTGACACGCCAGAAGAAGATGGCATCACCTGGACGCTGGACCAGAGCAGTGAAGTTCTTGGAAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGAGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGTTTATTATTACTTCACAAGAAAGAAGATGGCATCTGGTCCACGGACATTTTAAAAGACCAGAAGGAGCCCAAAAATAAAACATTTCTTCGATGTGAGGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTGACCACCATCTCCACAGACCTCACCTTCAGTGTAAAAAGCAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCTCTGCAGAAAGAGTTCGAGGGGACAACAAAGAATATGAGTACTCGGTGGAATGTCAAGAAGACTCGGCCTGCCCAGCTGCTGAGGAGAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAACCTGACCCGCCCAAGAACTTACAGCTGAAGCCGCTGAAAAACAGCAGACAAGTAGAAGTTTCCTGGGAGTACCCGGACACCTGGTCCACGCCGCACTCCTACTTCTCCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACGGACAAAACATCAGCCACGGTCATCTGCAGGAAAAATGCCAGCATCTCGGTGCGGGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTGCCCTGCAGTGGTGGTGGGGGTGGTGGCAGCAGAAACCTTCCTGTGGCCACTCCAGACCCTGGCATGTTCCCGTGCCTTCACCACTCCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCAAGACAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATTGACCATGAAGACATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTCTTCCTTTAGAGCTGACCAAAAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCTCCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTCAGCTCCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAGAGGCAGATATTTTTAGATCAAAACATGCTGGCAGTTATTGATGAGCTCATGCAAGCATTAAACTTCAACAGTGAGACTGTACCTCAAAAAAGCAGCCTTGAAGAGCCGGACTTCTACAAAACCAAGATCAAACTCTGCATTTTACTTCATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCTCG > hIL12AB_014 (SEQ IDNO: 18)ATGTGCCACCAGCAGCTTGTGATTTCTTGGTTCTCTCTTGTGTTCCTTGCTTCTCCTCTTGTGGCTATTTGGGAGTTAAAAAAGGACGTGTACGTGGTGGAGCTTGACTGGTACCCTGATGCTCCTGGCGAGATGGTGGTGCTTACTTGTGACACTCCTGAGGAGGACGGCATTACTTGGACTCTTGACCAGTCTTCTGAGGTGCTTGGCTCTGGCAAGACTCTTACTATTCAGGTGAAGGAGTTCGGGGATGCTGGCCAGTACACTTGCCACAAGGGCGGCGAGGTGCTTTCTCACTCTCTTCTTCTTCTTCACAAGAAGGAGGACGGCATTTGGTCTACTGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAGACTTTCCTTCGTTGCGAGGCCAAGAACTACTCTGGCCGTTTCACTTGCTGGTGGCTTACTACTATTTCTACTGACCTTACTTTCTCTGTGAAGTCTTCTCGTGGCTCTTCTGACCCTCAGGGCGTGACTTGTGGGGCTGCTACTCTTTCTGCTGAGCGTGTGCGTGGGGACAACAAGGAGTACGAGTACTCTGTGGAGTGCCAGGAGGACTCTGCTTGCCCTGCTGCTGAGGAGTCTCTTCCTATTGAGGTGATGGTGGATGCTGTGCACAAGTTAAAATACGAGAACTACACTTCTTCTTTCTTCATTCGTGACATTATTAAGCCTGACCCTCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACTCTCGTCAGGTGGAGGTGTCTTGGGAGTACCCTGACACTTGGTCTACTCCTCACTCTTACTTCTCTCTTACTTTCTGCGTGCAGGTGCAGGGCAAGTCTAAGCGTGAGAAGAAGGACCGTGTGTTCACTGACAAGACTTCTGCTACTGTGATTTGCAGGAAGAATGCATCTATTTCTGTGCGTGCTCAGGACCGTTACTACTCTTCTTCTTGGTCTGAGTGGGCTTCTGTGCCTTGCTCTGGCGGCGGCGGCGGCGGCTCTAGAAATCTTCCTGTGGCTACTCCTGACCCTGGCATGTTCCCTTGCCTTCACCACTCTCAGAACCTTCTTCGTGCTGTGAGCAACATGCTTCAGAAGGCTCGTCAGACTCTTGAGTTCTACCCTTGCACTTCTGAGGAGATTGACCACGAGGACATCACCAAGGACAAGACTTCTACTGTGGAGGCTTGCCTTCCTCTTGAGCTTACCAAGAATGAATCTTGCTTAAATTCTCGTGAGACTTCTTTCATCACCAACGGCTCTTGCCTTGCCTCGCGCAAGACTTCTTTCATGATGGCTCTTTGCCTTTCTTCTATTTACGAGGACTTAAAAATGTACCAGGTGGAGTTCAAGACTATGAATGCAAAGCTTCTTATGGACCCCAAGCGTCAGATTTTCCTTGACCAGAACATGCTTGCTGTGATTGACGAGCTTATGCAGGCTTTAAATTTCAACTCTGAGACTGTGCCTCAGAAGTCTTCTCTTGAGGAGCCTGACTTCTACAAGACCAAGATTAAGCTTTGCATTCTTCTTCATGCTTTCCGTATTCGTGCTGTGACTATTGACCGTGTGATGTCTTACTTAAATGCTTCT > hIL12AB_015 (SEQ IDNO: 19)ATGTGTCACCAGCAGCTGGTGATCAGCTGGTTTAGCCTGGTGTTTCTGGCCAGCCCCCTGGTGGCCATATGGGAACTGAAGAAAGATGTGTATGTGGTAGAACTGGATTGGTATCCGGATGCCCCCGGCGAAATGGTGGTGCTGACCTGTGACACCCCCGAAGAAGATGGTATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAAACCCTGACCATCCAAGTGAAAGAGTTTGGCGATGCCGGCCAGTACACCTGTCACAAAGGCGGCGAGGTGCTAAGCCATTCGCTGCTGCTGCTGCACAAAAAGGAAGATGGCATCTGGAGCACCGATATCCTGAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATAGCGGCCGTTTCACCTGCTGGTGGCTGACGACCATCAGCACCGATCTGACCTTCAGCGTGAAAAGCAGCAGAGGCAGCAGCGACCCCCAAGGCGTGACGTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGCGACAACAAGGAGTATGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGATGCCGTGCACAAGCTGAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAACCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAATAGCAGACAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCATAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAAAAGAAAGATAGAGTGTTCACGGACAAGACCAGCGCCACGGTGATCTGCAGAAAAAATGCCAGCATCAGCGTGAGAGCCCAGGACAGATACTATAGCAGCAGCTGGAGCGAATGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAAAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCAGACAAACCCTGGAATTTTACCCCTGCACCAGCGAAGAGATCGATCATGAAGATATCACCAAAGATAAAACCAGCACCGTGGAGGCCTGTCTGCCCCTGGAACTGACCAAGAATGAGAGCTGCCTAAATAGCAGAGAGACCAGCTTCATAACCAATGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTTATGATGGCCCTGTGCCTGAGCAGCATCTATGAAGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCCAAGCTGCTGATGGATCCCAAGAGACAGATCTTTCTGGATCAAAACATGCTGGCCGTGATCGATGAGCTGATGCAGGCCCTGAATTTCAACAGCGAGACCGTGCCCCAAAAAAGCAGCCTGGAAGAACCGGATTTTTATAAAACCAAAATCAAGCTGTGCATACTGCTGCATGCCTTCAGAATCAGAGCCGTGACCATCGATAGAGTGATGAGCTATCTGAATGCCAGC > hIL12AB_016 (SEQ IDNO: 20)ATGTGCCACCAGCAGCTGGTCATCAGCTGGTTCAGCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGATGTTTATGTTGTGGAGCTGGACTGGTACCCAGATGCCCCTGGGGAGATGGTGGTGCTGACCTGTGACACCCCAGAAGAGGATGGCATCACCTGGACCCTGGACCAGAGCTCAGAAGTGCTGGGCAGTGGAAAAACCCTGACCATCCAGGTGAAGGAGTTTGGAGATGCTGGCCAGTACACCTGCCACAAGGGTGGTGAAGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACAGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTTCGCTGTGAAGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTGACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCAGAGGCAGCTCAGACCCCCAGGGTGTCACCTGTGGGGCGGCCACGCTGTCGGCGGAGAGAGTTCGAGGGGACAACAAGGAGTATGAATACTCGGTGGAGTGCCAGGAGGACTCGGCGTGCCCGGCGGCAGAAGAGAGCCTGCCCATAGAAGTGATGGTGGATGCTGTGCACAAGCTGAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGAGACATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGACAAGTGGAGGTTTCCTGGGAGTACCCAGACACGTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGTGTCCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACAGAGTCTTCACAGACAAGACCTCGGCCACGGTCATCTGCAGAAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACAGATACTACAGCAGCAGCTGGTCAGAATGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTGCCTGTTGCCACCCCAGACCCTGGGATGTTCCCCTGCCTGCACCACAGCCAGAACTTATTACGAGCTGTTTCTAACATGCTGCAGAAGGCCAGACAAACCCTGGAGTTCTACCCCTGCACCTCAGAAGAGATTGACCATGAAGACATCACCAAGGACAAGACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAATGAAAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAATGGAAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTATGAAGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTGCTGATGGACCCCAAGAGACAAATATTTTTGGACCAGAACATGCTGGCTGTCATTGATGAGCTGATGCAGGCCCTGAACTTCAACTCAGAAACTGTACCCCAGAAGAGCAGCCTGGAGGAGCCAGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTTCATGCTTTCAGAATCAGAGCTGTCACCATTGACCGCGTGATGAGCTACTTAAATGCCTCG > hIL12AB_017 (SEQ IDNO: 21)ATGTGCCACCAGCAGCTGGTAATCAGCTGGTTTTCCCTCGTCTTTCTGGCATCACCCCTGGTGGCTATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGATTGGTACCCTGACGCCCCGGGGGAAATGGTGGTGTTAACATGCGACACGCCTGAGGAGGACGGCATCACCTGGACACTGGACCAGAGCAGCGAGGTGCTTGGGTCTGGTAAAACTCTGACTATTCAGGTGAAAGAGTTCGGGGATGCCGGCCAATATACTTGCCACAAGGGTGGCGAGGTGCTTTCTCATTCTCTGCTCCTGCTGCACAAGAAAGAAGATGGCATTTGGTCTACTGATATTCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGATGCGAGGCTAAAAACTACAGCGGAAGATTTACCTGCTGGTGGCTGACCACAATCTCAACCGACCTGACATTTTCAGTGAAGTCCAGCAGAGGGAGCTCCGACCCTCAGGGCGTGACCTGCGGAGCCGCCACTCTGTCCGCAGAAAGAGTGAGAGGTGATAATAAGGAGTACGAGTATTCAGTCGAGTGCCAAGAGGACTCTGCCTGCCCAGCCGCCGAGGAGAGCCTGCCAATCGAGGTGATGGTAGATGCGGTACACAAGCTGAAGTATGAGAACTACACATCCTCCTTCTTCATAAGAGACATTATCAAGCCTGACCCACCTAAAAATCTGCAACTCAAGCCTTTGAAAAATTCAAGACAGGTGGAGGTGAGCTGGGAGTACCCTGATACTTGGAGCACCCCCCATAGCTACTTTTCGCTGACATTCTGCGTCCAGGTGCAGGGCAAGTCAAAGAGAGAGAAGAAGGATCGCGTGTTCACTGATAAGACAAGCGCCACAGTGATCTGCAGAAAAAACGCTAGCATTAGCGTCAGAGCACAGGACCGGTATTACTCCAGCTCCTGGAGCGAATGGGCATCTGTGCCCTGCAGCGGTGGGGGCGGAGGCGGATCTAGAAACCTCCCCGTTGCCACACCTGATCCTGGAATGTTCCCCTGTCTGCACCACAGCCAGAACCTGCTGAGAGCAGTGTCTAACATGCTCCAGAAGGCCAGGCAGACCCTGGAGTTTTACCCCTGCACCAGCGAGGAAATCGATCACGAGGACATCACCAAAGATAAAACCTCCACCGTGGAGGCCTGCCTGCCCCTGGAACTGACCAAAAACGAGAGCTGCCTGAATAGCAGGGAGACCTCCTTCATCACCAACGGCTCATGCCTTGCCAGCCGGAAAACTAGCTTCATGATGGCCCTGTGCCTGTCTTCGATCTATGAGGACCTGAAAATGTACCAGGTCGAATTTAAGACGATGAACGCAAAGCTGCTGATGGACCCCAAGCGGCAGATCTTTCTGGACCAGAACATGCTGGCAGTCATAGATGAGTTGATGCAGGCATTAAACTTCAACAGCGAGACCGTGCCTCAGAAGTCCAGCCTCGAGGAGCCAGATTTTTATAAGACCAAGATCAAACTATGCATCCTGCTGCATGCTTTCAGGATTAGAGCCGTCACCATCGATCGAGTCATGTCTTACCTGAATGCTAGC > hIL12AB_018 (SEQ IDNO: 22)ATGTGTCACCAACAGTTAGTAATCTCCTGGTTTTCTCTGGTGTTTCTGGCCAGCCCCCTCGTGGCCATCTGGGAGCTTAAAAAGGATGTGTACGTGGTGGAGCTGGACTGGTATCCCGATGCACCAGGCGAAATGGTCGTGCTGACCTGCGATACCCCTGAAGAAGATGGCATCACCTGGACTCTGGACCAGTCTTCCGAGGTGCTTGGATCTGGCAAGACTCTGACAATACAAGTTAAGGAGTTCGGGGACGCAGGACAGTACACCTGCCACAAAGGCGGCGAGGTCCTGAGTCACTCCCTGTTACTGCTCCACAAGAAAGAGGACGGCATTTGGTCCACCGACATTCTGAAGGACCAGAAGGAGCCTAAGAATAAAACTTTCCTGAGATGCGAGGCAAAAAACTATAGCGGCCGCTTTACTTGCTGGTGGCTTACAACAATCTCTACCGATTTAACTTTCTCCGTGAAGTCTAGCAGAGGATCCTCTGACCCGCAAGGAGTGACTTGCGGAGCCGCCACCTTGAGCGCCGAAAGAGTCCGTGGCGATAACAAAGAATACGAGTACTCCGTGGAGTGCCAGGAAGATTCCGCCTGCCCAGCTGCCGAGGAGTCCCTGCCCATTGAAGTGATGGTGGATGCCGTCCACAAGCTGAAGTACGAAAACTATACCAGCAGCTTCTTCATCCGGGATATCATTAAGCCCGACCCTCCTAAAAACCTGCAACTTAAGCCCCTAAAGAATAGTCGGCAGGTTGAGGTCAGCTGGGAATATCCTGACACATGGAGCACCCCCCACTCTTATTTCTCCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGTAAACGGGAGAAAAAGGACAGGGTCTTTACCGATAAAACCAGCGCTACGGTTATCTGTCGGAAGAACGCTTCCATCTCCGTCCGCGCTCAGGATCGTTACTACTCGTCCTCATGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGTGGAGGCGGATCCAGAAATCTGCCTGTTGCCACACCAGACCCTGGCATGTTCCCCTGTCTGCATCATAGCCAGAACCTGCTCAGAGCCGTGAGCAACATGCTCCAGAAGGCCAGGCAGACATTGGAGTTCTACCCGTGTACATCTGAGGAAATCGATCACGAAGATATAACCAAGGACAAAACCTCTACAGTAGAGGCTTGTTTGCCCCTGGAGTTGACCAAAAACGAGAGTTGCCTGAACAGTCGCGAGACAAGCTTCATTACTAACGGCAGCTGTCTCGCCTCCAGAAAGACATCCTTCATGATGGCCCTGTGTCTTTCCAGCATATACGAAGACCTGAAAATGTACCAGGTCGAGTTCAAAACAATGAACGCCAAGCTGCTTATGGACCCCAAGAGACAGATCTTCCTCGACCAAAACATGCTCGCTGTGATCGATGAGCTGATGCAGGCTCTCAACTTCAATTCCGAAACAGTGCCACAGAAGTCCAGTCTGGAAGAACCCGACTTCTACAAGACCAAGATTAAGCTGTGTATTTTGCTGCATGCGTTTAGAATCAGAGCCGTGACCATTGATCGGGTGATGAGCTACCTGAACGCCTCG > hIL12AB_019 (SEQ IDNO: 23)ATGTGCCACCAGCAGCTTGTCATCTCCTGGTTTTCTCTTGTCTTCCTGGCCTCGCCGCTGGTGGCCATCTGGGAGCTGAAGAAAGATGTCTATGTTGTAGAGCTGGACTGGTACCCAGATGCTCCTGGAGAAATGGTGGTTCTCACCTGTGACACTCCTGAAGAAGATGGCATCACCTGGACGCTGGACCAAAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACGTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGTTTACTTCTTCTTCACAAGAAAGAAGATGGCATCTGGTCCACGGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTCCGCTGTGAGGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTCACCACCATCTCCACTGACCTCACCTTCTCTGTAAAAAGCAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCTCGGCAGAAAGAGTTCGAGGGGACAACAAGGAATATGAATATTCTGTGGAATGTCAAGAAGATTCTGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATTCGTGACATCATCAAACCAGACCCGCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACAGCAGACAAGTAGAAGTTTCCTGGGAGTACCCGGACACGTGGTCCACGCCGCACTCCTACTTCAGTTTAACCTTCTGTGTACAAGTACAAGGAAAATCAAAAAGAGAGAAGAAAGATCGTGTCTTCACTGACAAAACATCTGCCACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTTCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCCGCAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTTCACCACTCCCAAAATCTTCTTCGTGCTGTTTCTAACATGCTGCAGAAGGCGCGCCAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATAGACCATGAAGACATCACCAAAGATAAAACCAGCACGGTGGAGGCCTGCCTTCCTTTAGAGCTGACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCTCGCGCAAGACCAGCTTCATGATGGCGCTGTGCCTTTCTTCCATCTATGAAGATTTAAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAAAGACAAATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAAACTGTTCCCCAGAAGTCATCTTTAGAAGAGCCGGACTTCTACAAAACAAAAATAAAACTCTGCATTCTTCTTCATGCCTTCCGCATCCGTGCTGTCACCATTGACCGTGTCATGTCCTACTTAAATGCTTCT > hIL12AB_020 (SEQ IDNO: 24)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCTAGCCCTCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTAGACTGGTACCCCGACGCTCCCGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGGATCACCTGGACCCTGGATCAGTCAAGCGAGGTGCTGGGAAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAATACACTTGCCACAAGGGAGGCGAGGTGCTGTCCCACTCCCTCCTGCTGCTGCACAAAAAGGAAGACGGCATCTGGAGCACCGACATCCTGAAAGACCAGAAGGAGCCTAAGAACAAGACATTCCTCAGATGCGAGGCCAAGAATTACTCCGGGAGATTCACCTGTTGGTGGCTGACCACCATCAGCACAGACCTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGTGGCGCCGCCACCCTGAGCGCCGAAAGAGTGCGCGGCGACAACAAGGAGTACGAGTACTCCGTGGAATGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCTCTAGCTTCTTCATCCGGGACATCATCAAGCCCGATCCCCCCAAGAACCTGCAGCTGAAACCCCTGAAGAACAGCAGACAGGTGGAGGTGAGCTGGGAGTATCCCGACACCTGGTCCACCCCCCACAGCTATTTTAGCCTGACCTTCTGCGTGCAAGTGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACCGCGTGTTCACCGACAAAACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGGGCCCAGGATAGATACTACAGTTCCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGGGGAGGCTCTAGAAACCTGCCCGTGGCTACCCCCGATCCCGGAATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGGGCGGTGTCCAACATGCTTCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGTACCTCTGAGGAGATCGATCATGAGGACATCACAAAGGACAAAACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGCCTGAACTCCCGCGAGACCAGCTTCATCACGAACGGCAGCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAAATGTACCAGGTGGAGTTTAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAAATCTTCCTGGACCAGAACATGCTGGCAGTGATCGACGAGCTCATGCAGGCCCTGAACTTCAATAGCGAGACAGTCCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTTTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTTAGAATCCGTGCCGTGACCATTGACAGAGTGATGAGCTACCTGAATGCCAGC > hIL12AB_021(SEQ IDNO: 25)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCTCTGGTTGCCATCTGGGAGCTGAAGAAAGACGTGTACGTCGTGGAACTGGACTGGTATCCGGACGCCCCGGGCGAGATGGTGGTGCTGACCTGTGACACCCCCGAGGAGGACGGCATCACCTGGACGCTGGACCAATCCTCCGAGGTGCTGGGAAGCGGCAAGACCCTGACCATCCAGGTGAAGGAATTCGGGGACGCCGGGCAGTACACCTGCCACAAGGGGGGCGAAGTGCTGTCCCACTCGCTGCTGCTCCTGCATAAGAAGGAGGATGGAATCTGGTCCACCGACATCCTCAAAGATCAGAAGGAGCCCAAGAACAAGACGTTCCTGCGCTGTGAAGCCAAGAATTATTCGGGGCGATTCACGTGCTGGTGGCTGACAACCATCAGCACCGACCTGACGTTTAGCGTGAAGAGCAGCAGGGGGTCCAGCGACCCCCAGGGCGTGACGTGCGGCGCCGCCACCCTCTCCGCCGAGAGGGTGCGGGGGGACAATAAGGAGTACGAGTACAGCGTGGAATGCCAGGAGGACAGCGCCTGCCCCGCCGCGGAGGAAAGCCTCCCGATAGAGGTGATGGTGGACGCCGTGCACAAGCTCAAGTATGAGAATTACACCAGCAGCTTTTTCATCCGGGACATTATCAAGCCCGACCCCCCGAAGAACCTCCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAAGTCTCCTGGGAGTATCCCGACACCTGGAGCACCCCGCACAGCTACTTCTCCCTGACCTTCTGTGTGCAGGTGCAGGGCAAGTCCAAGAGGGAAAAGAAGGACAGGGTTTTCACCGACAAGACCAGCGCGACCGTGATCTGCCGGAAGAACGCCAGCATAAGCGTCCGCGCCCAAGATAGGTACTACAGCAGCTCCTGGAGCGAGTGGGCTAGCGTGCCCTGCAGCGGGGGCGGGGGTGGGGGCTCCAGGAACCTGCCAGTGGCGACCCCCGACCCCGGCATGTTCCCCTGCCTCCATCACAGCCAGAACCTGCTGAGGGCCGTCAGCAATATGCTGCAGAAGGCCAGGCAGACCCTGGAATTCTACCCCTGCACGTCGGAGGAGATCGATCACGAGGATATCACAAAAGACAAGACTTCCACCGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAGTCCTGTCTGAACTCCCGGGAAACCAGCTTCATCACCAACGGGTCCTGCCTGGCCAGCAGGAAGACCAGCTTTATGATGGCCCTGTGCCTGTCGAGCATCTACGAGGACCTGAAGATGTACCAGGTCGAGTTCAAGACAATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAAATCTTCCTGGACCAGAATATGCTTGCCGTCATCGACGAGCTCATGCAGGCCCTGAACTTCAACTCCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCGTTCAGGATCCGGGCAGTCACCATCGACCGTGTGATGTCCTACCTGAACGCCAGC > hIL12AB_022(SEQID NO: 26)ATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTCGCCTCTCCCCTGGTGGCCATCTGGGAGCTCAAAAAGGACGTGTACGTGGTGGAGCTCGACTGGTACCCAGACGCCCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAAGAAGACGGCATCACGTGGACCCTCGACCAGTCCAGCGAGGTGCTGGGGAGCGGGAAGACTCTGACCATCCAGGTCAAGGAGTTCGGGGACGCCGGGCAGTACACGTGCCACAAGGGCGGCGAAGTCTTAAGCCACAGCCTGCTCCTGCTGCACAAGAAGGAGGACGGGATCTGGTCCACAGACATACTGAAGGACCAGAAGGAGCCGAAGAATAAAACCTTTCTGAGGTGCGAGGCCAAGAACTATTCCGGCAGGTTCACGTGCTGGTGGCTTACAACAATCAGCACAGACCTGACGTTCAGCGTGAAGTCCAGCCGCGGCAGCAGCGACCCCCAGGGGGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGCGGGTGCGCGGGGACAACAAGGAGTACGAGTACTCCGTGGAGTGCCAGGAAGACAGCGCCTGTCCCGCCGCCGAAGAGAGCCTGCCTATCGAGGTCATGGTAGATGCAGTGCATAAGCTGAAGTACGAGAACTATACGAGCAGCTTTTTCATACGCGACATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTTAAGCCCCTGAAGAATAGCCGGCAGGTGGAGGTCTCCTGGGAGTACCCCGACACCTGGTCAACGCCCCACAGCTACTTCTCCCTGACCTTTTGTGTCCAAGTCCAGGGAAAGAGCAAGAGGGAGAAGAAAGATCGGGTGTTCACCGACAAGACCTCCGCCACGGTGATCTGCAGGAAGAACGCCAGCATCTCCGTGAGGGCGCAAGACAGGTACTACTCCAGCAGCTGGTCCGAATGGGCCAGCGTGCCCTGCTCCGGCGGCGGGGGCGGCGGCAGCCGAAACCTACCCGTGGCCACGCCGGATCCCGGCATGTTTCCCTGCCTGCACCACAGCCAGAACCTCCTGAGGGCCGTGTCCAACATGCTGCAGAAGGCCAGGCAGACTCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGATCACGAGGACATCACCAAGGATAAGACCAGCACTGTGGAGGCCTGCCTTCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTGAACTCCAGGGAGACCTCATTCATCACCAACGGCTCCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCCTTGTGTCTCAGCTCCATCTACGAGGACCTGAAGATGTATCAGGTCGAGTTCAAGACAATGAACGCCAAGCTGCTGATGGACCCCAAAAGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTCATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACGGTGCCCCAGAAAAGCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGGATCAGGGCAGTGACCATCGACCGGGTGATGTCATACCTTAACGCCAGC > hIL12AB_023(SEQID NO: 27)ATGTGCCATCAGCAGCTGGTGATCTCCTGGTTCAGCCTGGTGTTTCTGGCCTCGCCCCTGGTCGCCATCTGGGAGCTGAAGAAAGACGTGTACGTCGTCGAACTGGACTGGTACCCCGACGCCCCCGGGGAGATGGTGGTGCTGACCTGCGACACGCCGGAGGAGGACGGCATCACCTGGACCCTGGATCAAAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAAGTGAAGGAATTCGGCGATGCCGGCCAGTACACCTGTCACAAAGGGGGCGAGGTGCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACCGATATCCTGAAGGACCAGAAAGAGCCCAAGAACAAGACGTTCCTGAGGTGCGAGGCCAAGAACTACAGCGGTAGGTTCACGTGTTGGTGGCTGACCACCATCAGCACCGACCTGACGTTCAGCGTGAAGAGCTCCAGGGGCAGCTCCGACCCACAGGGGGTGACGTGCGGGGCCGCAACCCTCAGCGCCGAAAGGGTGCGGGGGGACAACAAGGAGTACGAATACTCCGTGGAGTGCCAGGAAGATTCGGCCTGCCCCGCCGCGGAGGAGAGCCTCCCCATCGAGGTAATGGTGGACGCCGTGCATAAGCTGAAGTACGAGAACTACACCAGCTCGTTCTTCATCCGAGACATCATCAAACCCGACCCGCCCAAAAATCTGCAGCTCAAGCCCCTGAAGAACTCCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCGCACAGCTACTTCTCCCTGACATTCTGCGTGCAGGTGCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCCGAAAGAACGCCAGCATCTCGGTGCGCGCCCAGGATAGGTACTATTCCAGCTCCTGGAGCGAGTGGGCCTCGGTACCCTGCAGCGGCGGCGGGGGCGGCGGCAGTAGGAATCTGCCCGTGGCTACCCCGGACCCGGGCATGTTCCCCTGCCTCCACCACAGCCAGAACCTGCTGAGGGCCGTGAGCAACATGCTGCAGAAGGCCAGACAGACGCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGACCACGAGGACATCACCAAGGATAAAACTTCCACCGTCGAGGCCTGCCTGCCCTTGGAGCTGACCAAGAATGAATCCTGTCTGAACAGCAGGGAGACCTCGTTTATCACCAATGGCAGCTGCCTCGCCTCCAGGAAGACCAGCTTCATGATGGCCCTCTGTCTGAGCTCCATCTATGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGCTGCTGATGGACCCCAAGAGGCAGATCTTCCTGGATCAGAATATGCTGGCGGTGATCGACGAGCTCATGCAGGCCCTCAATTTCAATAGCGAGACAGTGCCCCAGAAGTCCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGTATCCTGCTGCACGCCTTCCGGATCCGGGCCGTCACCATCGACCGGGTCATGAGCTACCTCAATGCCAGC > hIL12AB_024(SEQID NO: 28)ATGTGCCACCAGCAGCTGGTGATCTCCTGGTTCTCCCTGGTGTTCCTGGCCTCGCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTCGTGGAGCTCGACTGGTACCCCGACGCCCCTGGCGAGATGGTGGTGCTGACCTGCGACACCCCAGAGGAGGATGGCATCACCTGGACCCTGGATCAGTCCTCCGAGGTGCTGGGCTCCGGCAAGACGCTGACCATCCAAGTGAAGGAGTTCGGTGACGCCGGACAGTATACCTGCCATAAGGGCGGCGAGGTCCTGTCCCACAGCCTCCTCCTCCTGCATAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGGTGCGAGGCCAAGAACTACAGCGGCCGATTCACCTGCTGGTGGCTCACCACCATATCCACCGACCTGACTTTCTCCGTCAAGTCCTCCCGGGGGTCCAGCGACCCCCAGGGAGTGACCTGCGGCGCCGCCACCCTCAGCGCCGAGCGGGTGCGGGGGGACAACAAGGAGTACGAATACTCCGTCGAGTGCCAGGAGGACTCCGCCTGCCCGGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTCGACGCGGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGTTTCTTCATCAGGGATATCATCAAGCCAGATCCCCCGAAGAATCTGCAACTGAAGCCGCTGAAAAACTCACGACAGGTGGAGGTGAGCTGGGAGTACCCCGACACGTGGAGCACCCCACATTCCTACTTCAGCCTGACCTTCTGCGTGCAGGTCCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACGGATAAGACCAGTGCCACCGTGATCTGCAGGAAGAACGCCTCTATTAGCGTGAGGGCCCAGGATCGGTATTACTCCTCGAGCTGGAGCGAATGGGCCTCCGTGCCCTGCAGTGGGGGGGGTGGAGGCGGGAGCAGGAACCTGCCCGTAGCAACCCCCGACCCCGGGATGTTCCCCTGTCTGCACCACTCGCAGAACCTGCTGCGCGCGGTGAGCAACATGCTCCAAAAAGCCCGTCAGACCTTAGAGTTCTACCCCTGCACCAGCGAAGAAATCGACCACGAAGACATCACCAAGGACAAAACCAGCACCGTGGAGGCGTGCCTGCCGCTGGAGCTGACCAAGAACGAGAGCTGCCTCAACTCCAGGGAGACCAGCTTTATCACCAACGGCTCGTGCCTAGCCAGCCGGAAAACCAGCTTCATGATGGCCCTGTGCCTGAGCTCCATTTACGAGGACCTGAAGATGTATCAGGTGGAGTTCAAGACCATGAATGCCAAACTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCGGTGATCGATGAGCTGATGCAGGCCCTGAACTTTAATAGCGAGACCGTGCCCCAGAAAAGCAGCCTGGAGGAGCCGGACTTCTACAAGACCAAAATCAAGCTGTGCATCCTGCTCCACGCCTTCCGCATCCGGGCCGTGACCATCGACAGGGTGATGAGCTACCTGAACGCCAGC > hIL12AB_025(SEQID NO: 29)ATGTGCCATCAGCAGCTGGTGATTTCCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTCGTGGCGATCTGGGAGCTAAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCACCCGGCGAGATGGTCGTTCTGACCTGCGATACGCCAGAGGAGGACGGCATCACCTGGACCCTCGATCAGAGCAGCGAGGTCCTGGGGAGCGGAAAGACCCTGACCATCCAGGTCAAGGAGTTCGGCGACGCCGGCCAGTACACCTGCCACAAAGGTGGCGAGGTCCTGAGCCACTCGCTGCTGCTCCTGCATAAGAAGGAGGACGGAATCTGGAGCACAGACATCCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAGAACTACAGCGGGCGCTTCACGTGCTGGTGGCTGACCACCATCAGCACGGACCTCACCTTCTCCGTGAAGAGCAGCCGGGGATCCAGCGATCCCCAAGGCGTCACCTGCGGCGCGGCCACCCTGAGCGCGGAGAGGGTCAGGGGCGATAATAAGGAGTATGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCGGCCGCCGAGGAGTCCCTGCCAATCGAAGTGATGGTCGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCCGGGATATCATCAAGCCCGATCCCCCGAAGAACCTGCAGCTGAAGCCCCTCAAGAACAGCCGGCAGGTGGAGGTGAGTTGGGAGTACCCCGACACCTGGTCAACGCCCCACAGCTACTTCTCCCTGACCTTCTGTGTGCAGGTGCAGGGAAAGAGCAAGAGGGAGAAGAAAGACCGGGTCTTCACCGACAAGACCAGCGCCACGGTGATCTGCAGGAAGAACGCAAGCATCTCCGTGAGGGCCCAGGACAGGTACTACAGCTCCAGCTGGTCCGAATGGGCCAGCGTGCCCTGTAGCGGCGGCGGGGGCGGTGGCAGCCGCAACCTCCCAGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAATCTGCTGAGGGCCGTGAGTAACATGCTGCAGAAGGCAAGGCAAACCCTCGAATTCTATCCCTGCACCTCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCAGCACCGTCGAGGCCTGTCTCCCCCTGGAGCTGACCAAGAATGAGAGCTGCCTGAACAGCCGGGAGACCAGCTTCATCACCAACGGGAGCTGCCTGGCCTCCAGGAAGACCTCGTTCATGATGGCGCTGTGCCTCTCAAGCATATACGAGGATCTGAAGATGTACCAGGTGGAGTTTAAGACGATGAACGCCAAGCTGCTGATGGACCCGAAGAGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATAGACGAGCTCATGCAGGCCCTGAACTTCAACTCCGAGACCGTGCCGCAGAAGTCATCCCTCGAGGAGCCCGACTTCTATAAGACCAAGATCAAGCTGTGCATCCTGCTCCACGCCTTCCGGATAAGGGCCGTGACGATCGACAGGGTGATGAGCTACCTTAACGCCAGC > hIL12AB_026(SEQID NO: 30)ATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCCCTGGTGTTTCTCGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCTGACGCCCCGGGGGAGATGGTCGTGCTGACCTGCGACACCCCCGAAGAGGACGGTATCACCTGGACCCTGGACCAGTCCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACTATTCAAGTCAAGGAGTTCGGAGACGCCGGCCAGTACACCTGCCACAAGGGTGGAGAGGTGTTATCACACAGCCTGCTGCTGCTGCACAAGAAGGAAGACGGGATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAAAACAAGACCTTCCTGCGGTGCGAGGCCAAGAACTATTCGGGCCGCTTTACGTGCTGGTGGCTGACCACCATCAGCACTGATCTCACCTTCAGCGTGAAGTCCTCCCGGGGGTCGTCCGACCCCCAGGGGGTGACCTGCGGGGCCGCCACCCTGTCCGCCGAGAGAGTGAGGGGCGATAATAAGGAGTACGAGTACAGCGTTGAGTGCCAGGAAGATAGCGCCTGTCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTATGAGAACTACACCTCAAGCTTCTTCATCAGGGACATCATCAAACCCGATCCGCCCAAGAATCTGCAGCTGAAGCCCCTGAAAAATAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCCCATAGCTATTTCTCCCTGACGTTCTGCGTGCAGGTGCAAGGGAAGAGCAAGCGGGAGAAGAAGGACCGGGTGTTCACCGACAAGACCTCCGCCACCGTGATCTGTAGGAAGAACGCGTCGATCTCGGTCAGGGCCCAGGACAGGTATTACAGCAGCAGCTGGAGCGAGTGGGCGAGCGTGCCCTGCTCGGGCGGCGGCGGCGGCGGGAGCAGAAATCTGCCCGTGGCCACCCCAGACCCCGGAATGTTCCCCTGCCTGCACCATTCGCAGAACCTCCTGAGGGCCGTGAGCAACATGCTGCAGAAGGCCCGCCAGACGCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAAACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAAAACGAATCCTGCCTCAACAGCCGGGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCCGAAAGACCTCCTTCATGATGGCCCTCTGCCTGAGCAGCATCTATGAGGATCTGAAGATGTATCAGGTGGAGTTCAAGACCATGAATGCCAAGCTGCTGATGGACCCCAAGAGGCAGATATTCCTGGACCAGAATATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTCCCCCAGAAGTCCAGCCTGGAGGAGCCGGACTTTTACAAAACGAAGATCAAGCTGTGCATACTGCTGCACGCCTTCAGGATCCGGGCCGTGACAATCGACAGGGTGATGTCCTACCTGAACGCCAGC > hIL12AB_027(SEQID NO: 31)ATGTGTCACCAGCAGCTGGTGATCAGCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTCAAGAAGGACGTCTACGTCGTGGAGCTGGATTGGTACCCCGACGCTCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACGCTGGACCAGAGCTCAGAGGTGCTGGGAAGCGGAAAGACACTGACCATCCAGGTGAAGGAGTTCGGGGATGCCGGGCAGTATACCTGCCACAAGGGCGGCGAAGTGCTGAGCCATTCCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATATGGTCCACCGACATCCTGAAGGATCAGAAGGAGCCGAAGAATAAAACCTTCCTGAGGTGCGAGGCCAAGAATTACAGCGGCCGATTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGTGTGAAGTCCTCACGGGGCAGCTCAGATCCCCAGGGCGTGACCTGCGGGGCCGCGACACTCAGCGCCGAGCGGGTGAGGGGTGATAACAAGGAGTACGAGTATTCTGTGGAGTGCCAGGAAGACTCCGCCTGTCCCGCCGCCGAGGAGTCCCTGCCCATCGAGGTGATGGTGGACGCCGTGCATAAACTGAAGTACGAGAACTACACCTCCAGCTTCTTCATCCGGGATATAATCAAGCCCGACCCTCCGAAAAACCTGCAGCTGAAGCCCCTTAAAAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCATAGCTATTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGGAAGTCCAAGCGCGAGAAAAAGGACCGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCCGGAAGAACGCCAGTATAAGCGTAAGGGCCCAGGATAGGTACTACAGCTCCAGCTGGTCGGAGTGGGCCTCCGTGCCCTGTTCCGGCGGCGGGGGGGGTGGCAGCAGGAACCTCCCCGTGGCCACGCCGGACCCCGGCATGTTCCCGTGCCTGCACCACTCCCAAAACCTCCTGCGGGCCGTCAGCAACATGCTGCAAAAGGCGCGGCAGACCCTGGAGTTTTACCCCTGTACCTCCGAAGAGATCGACCACGAGGATATCACCAAGGATAAGACCTCCACCGTGGAGGCCTGTCTCCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTTAACAGCAGAGAGACCTCGTTCATAACGAACGGCTCCTGCCTCGCTTCCAGGAAGACGTCGTTCATGATGGCGCTGTGCCTGTCCAGCATCTACGAGGACCTGAAGATGTATCAGGTCGAGTTCAAAACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAAACCGTGCCCCAGAAGTCAAGCCTGGAGGAGCCGGACTTCTATAAGACCAAGATCAAGCTGTGTATCCTGCTACACGCTTTTCGTATCCGGGCCGTGACCATCGACAGGGTTATGTCGTACTTGAACGCCAGC > hIL12AB_028(SEQID NO: 32)ATGTGCCACCAACAGCTCGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCGCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCCGACGCCCCCGGCGAGATGGTGGTCCTGACCTGCGACACGCCGGAAGAGGACGGCATCACCTGGACCCTGGATCAGTCCAGCGAGGTGCTGGGCTCCGGCAAGACCCTGACCATTCAGGTGAAGGAGTTCGGCGACGCCGGTCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTACTGCTCCTGCACAAAAAGGAGGATGGAATCTGGTCCACCGACATCCTCAAGGACCAGAAGGAGCCGAAGAACAAGACGTTCCTCCGGTGCGAGGCCAAGAACTACAGCGGCAGGTTTACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACATTTTCCGTGAAGAGCAGCCGCGGCAGCAGCGATCCCCAGGGCGTGACCTGCGGGGCGGCCACCCTGTCCGCCGAGCGTGTGAGGGGCGACAACAAGGAGTACGAGTACAGCGTGGAATGCCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGAGCCTGCCAATCGAGGTCATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACGAGCAGCTTCTTCATCAGGGACATCATCAAACCGGACCCGCCCAAGAACCTGCAGCTGAAACCCTTGAAAAACAGCAGGCAGGTGGAAGTGTCTTGGGAGTACCCCGACACCTGGTCCACCCCCCACAGCTACTTTAGCCTGACCTTCTGTGTGCAGGTCCAGGGCAAGTCCAAGAGGGAGAAGAAGGACAGGGTGTTCACCGACAAAACCAGCGCCACCGTGATCTGCAGGAAGAACGCCTCCATCAGCGTGCGGGCCCAGGACAGGTATTACAGCTCGTCGTGGAGCGAGTGGGCCAGCGTGCCCTGCTCCGGGGGAGGCGGCGGCGGAAGCCGGAATCTGCCCGTGGCCACCCCCGATCCCGGCATGTTCCCGTGTCTGCACCACAGCCAGAACCTGCTGCGGGCCGTGAGCAACATGCTGCAGAAGGCCCGCCAAACCCTGGAGTTCTACCCCTGTACAAGCGAGGAGATCGACCATGAGGACATTACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTCGAGCTCACAAAGAACGAATCCTGCCTGAATAGCCGCGAGACCAGCTTTATCACGAACGGGTCCTGCCTCGCCAGCCGGAAGACAAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAAATGTACCAAGTGGAGTTCAAAACGATGAACGCCAAGCTGCTGATGGACCCCAAGCGCCAGATCTTCCTGGACCAGAACATGCTGGCCGTCATCGACGAGCTCATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACGAAGATCAAGCTCTGCATCCTGCTGCACGCTTTCCGCATCCGCGCGGTGACCATCGACCGGGTGATGAGCTACCTCAACGCCAGT > hIL12AB_029(SEQID NO: 33)ATGTGCCACCAACAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTTCTGGCCTCCCCTCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCTGACGCCCCCGGCGAAATGGTGGTGCTGACGTGCGACACCCCCGAGGAGGATGGCATCACCTGGACCCTGGACCAAAGCAGCGAGGTCCTCGGAAGCGGCAAGACCCTCACTATCCAAGTGAAGGAGTTCGGGGATGCGGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGTCTCATAGCCTGCTGCTCCTGCATAAGAAGGAAGACGGCATCTGGAGCACCGACATACTGAAGGATCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAGAACTACTCCGGGCGCTTCACCTGTTGGTGGCTGACCACCATCTCCACCGACCTGACCTTCAGCGTGAAGAGCAGCAGGGGGAGCAGCGACCCCCAGGGGGTGACCTGCGGAGCCGCGACCTTGTCGGCCGAGCGGGTGAGGGGCGACAATAAGGAGTACGAGTACTCGGTCGAATGCCAGGAGGACTCCGCCTGCCCCGCCGCCGAGGAGTCCCTCCCCATCGAAGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATACGGGATATCATCAAGCCCGACCCCCCGAAGAACCTGCAGCTGAAACCCTTGAAGAACTCCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCGCACTCATACTTCAGCCTGACCTTCTGTGTACAGGTCCAGGGCAAGAGCAAGAGGGAAAAGAAGGATAGGGTGTTCACCGACAAGACCTCCGCCACGGTGATCTGTCGGAAAAACGCCAGCATCTCCGTGCGGGCCCAGGACAGGTACTATTCCAGCAGCTGGAGCGAGTGGGCCTCCGTCCCCTGCTCCGGCGGCGGTGGCGGGGGCAGCAGGAACCTCCCCGTGGCCACCCCCGATCCCGGGATGTTCCCATGCCTGCACCACAGCCAAAACCTGCTGAGGGCCGTCTCCAATATGCTGCAGAAGGCGAGGCAGACCCTGGAGTTCTACCCCTGTACCTCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCTCCACGGTCGAGGCGTGCCTGCCCCTGGAGCTCACGAAGAACGAGAGCTGCCTTAACTCCAGGGAAACCTCGTTTATCACGAACGGCAGCTGCCTGGCGTCACGGAAGACCTCCTTTATGATGGCCCTATGTCTGTCCTCGATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGATCCCAAGAGGCAGATTTTCCTGGACCAGAACATGCTGGCCGTGATTGACGAGCTGATGCAGGCGCTGAACTTCAACAGCGAGACAGTGCCGCAGAAGAGCTCCCTGGAGGAGCCGGACTTTTACAAGACCAAGATAAAGCTGTGCATCCTGCTCCACGCCTTCAGAATACGGGCCGTCACCATCGATAGGGTGATGTCTTACCTGAACGCCTCC > hIL12AB_030(SEQID NO: 34)ATGTGCCACCAGCAGCTGGTGATTAGCTGGTTTAGCCTGGTGTTCCTGGCAAGCCCCCTGGTGGCCATCTGGGAACTGAAAAAGGACGTGTACGTGGTCGAGCTGGATTGGTACCCCGACGCCCCCGGCGAAATGGTGGTGCTGACGTGTGATACCCCCGAGGAGGACGGGATCACCTGGACCCTGGATCAGAGCAGCGAGGTGCTGGGGAGCGGGAAGACCCTGACGATCCAGGTCAAGGAGTTCGGCGACGCTGGGCAGTACACCTGTCACAAGGGCGGGGAGGTGCTGTCCCACTCCCTGCTGCTCCTGCATAAGAAAGAGGACGGCATCTGGTCCACCGACATCCTCAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGCGGTGTGAGGCGAAGAACTACAGCGGCCGTTTCACCTGCTGGTGGCTGACGACAATCAGCACCGACTTGACGTTCTCCGTGAAGTCCTCCAGAGGCAGCTCCGACCCCCAAGGGGTGACGTGCGGCGCGGCCACCCTGAGCGCCGAGCGGGTGCGGGGGGACAACAAGGAGTACGAGTACTCCGTGGAGTGCCAGGAGGACAGCGCCTGTCCCGCAGCCGAGGAGTCCCTGCCCATCGAAGTCATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCCGCGATATCATCAAGCCCGATCCCCCCAAAAACCTGCAACTGAAGCCGCTGAAGAATAGCAGGCAGGTGGAGGTGTCCTGGGAGTACCCGGACACCTGGAGCACGCCCCACAGCTATTTCAGCCTGACCTTTTGCGTGCAGGTCCAGGGGAAGAGCAAGCGGGAGAAGAAGGACCGCGTGTTTACGGACAAAACCAGCGCCACCGTGATCTGCAGGAAGAACGCCAGCATCAGCGTGAGGGCCCAGGACAGGTACTACAGCAGCTCCTGGAGCGAGTGGGCCTCCGTGCCCTGTTCCGGAGGCGGCGGGGGCGGTTCCCGGAACCTCCCGGTGGCCACCCCCGACCCGGGCATGTTCCCGTGCCTGCACCACTCACAGAATCTGCTGAGGGCCGTGAGCAATATGCTGCAGAAGGCAAGGCAGACCCTGGAGTTTTATCCCTGCACCAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAGACCAGCACAGTGGAGGCCTGCCTGCCCCTGGAACTGACCAAGAACGAGTCCTGTCTGAACTCCCGGGAAACCAGCTTCATAACCAACGGCTCCTGTCTCGCCAGCAGGAAGACCAGCTTCATGATGGCCCTGTGCCTCAGCTCCATCTACGAGGACCTCAAGATGTACCAGGTTGAGTTCAAGACCATGAACGCCAAGCTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAATATGCTGGCCGTGATCGATGAGTTAATGCAGGCGCTGAACTTCAACAGCGAGACGGTGCCCCAAAAGTCCTCGCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTCCTGCACGCCTTCCGAATCCGGGCCGTAACCATCGACAGGGTGATGAGCTATCTCAACGCCTCC > hIL12AB_031(SEQID NO: 35)ATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCGCTTGTGTTCCTGGCCTCCCCCCTCGTCGCCATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCGGGGGAGATGGTGGTGCTGACCTGCGACACCCCGGAAGAGGACGGCATCACCTGGACGCTCGACCAGTCGTCCGAAGTGCTGGGGTCGGGCAAGACCCTCACCATCCAGGTGAAGGAGTTCGGAGACGCCGGCCAGTACACCTGTCATAAGGGGGGGGAGGTGCTGAGCCACAGCCTCCTGCTCCTGCACAAAAAGGAGGACGGCATCTGGAGCACCGATATCCTCAAGGACCAGAAGGAGCCCAAGAACAAGACGTTCCTGAGGTGTGAGGCCAAGAACTACAGCGGGCGGTTCACGTGTTGGTGGCTCACCACCATCTCCACCGACCTCACCTTCTCCGTGAAGTCAAGCAGGGGCAGCTCCGACCCCCAAGGCGTCACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGGGTCAGGGGGGATAACAAGGAATACGAGTACAGTGTGGAGTGCCAAGAGGATAGCGCCTGTCCCGCCGCCGAAGAGAGCCTGCCCATCGAAGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCTCCAGCTTCTTCATCAGGGATATCATCAAGCCCGATCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTATCCCGACACGTGGAGCACCCCGCACAGCTACTTCTCGCTGACCTTCTGCGTGCAGGTGCAAGGGAAGTCCAAGAGGGAGAAGAAGGATAGGGTGTTCACCGACAAAACGAGCGCCACCGTGATCTGCCGGAAGAATGCCAGCATCTCTGTGAGGGCCCAGGACAGGTACTATTCCAGCTCCTGGTCGGAGTGGGCCAGCGTGCCCTGTAGCGGCGGGGGCGGGGGCGGCAGCAGGAACCTCCCGGTTGCCACCCCCGACCCCGGCATGTTTCCGTGCCTGCACCACTCGCAAAACCTGCTGCGCGCGGTCTCCAACATGCTGCAAAAAGCGCGCCAGACGCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGATCATGAAGATATCACCAAAGACAAGACCTCGACCGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAACGAAAGCTGCCTGAACAGCAGGGAGACAAGCTTCATCACCAACGGCAGCTGCCTGGCCTCCCGGAAGACCAGCTTCATGATGGCCCTGTGCCTGTCCAGCATCTACGAGGATCTGAAGATGTACCAAGTGGAGTTTAAGACCATGAACGCCAAGCTGTTAATGGACCCCAAAAGGCAGATCTTCCTGGATCAGAACATGCTGGCCGTCATCGACGAGCTGATGCAAGCCCTGAACTTCAACAGCGAGACGGTGCCCCAGAAGAGCAGCCTCGAGGAGCCCGACTTCTATAAGACCAAGATAAAGCTGTGCATTCTGCTGCACGCCTTCAGAATCAGGGCCGTGACCATCGATAGGGTGATGAGCTACCTGAACGCCAGC > hIL12AB_032(SEQID NO: 36)ATGTGTCACCAGCAGCTGGTGATTTCCTGGTTCAGTCTGGTGTTTCTTGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAAGACGTATACGTCGTGGAGCTGGACTGGTATCCCGACGCTCCCGGCGAGATGGTGGTCCTCACCTGCGACACCCCAGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCTCCGAGGTCCTGGGCAGCGGTAAGACCCTCACCATCCAGGTGAAGGAGTTTGGTGATGCCGGGCAGTATACCTGCCACAAGGGCGGCGAGGTGCTGTCCCACAGCCTCCTGTTACTGCATAAGAAGGAGGATGGCATCTGGAGCACCGACATCCTCAAGGACCAGAAAGAGCCCAAGAACAAGACCTTTCTGCGGTGCGAGGCGAAAAATTACTCCGGCCGGTTCACCTGCTGGTGGCTGACCACCATCAGCACGGACCTGACGTTCTCCGTGAAGTCGAGCAGGGGGAGCTCCGATCCCCAGGGCGTGACCTGCGGCGCGGCCACCCTGAGCGCCGAGCGCGTCCGCGGGGACAATAAGGAATACGAATATAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCGGCCGAGGAGAGCCTCCCGATCGAGGTGATGGTGGATGCCGTCCACAAGCTCAAATACGAAAACTACACCAGCAGCTTCTTCATTAGGGACATCATCAAGCCCGACCCCCCCAAAAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGCCAGGTCGAGGTGTCATGGGAGTACCCAGACACCTGGAGCACCCCCCACTCCTACTTCAGCCTGACCTTCTGCGTCCAGGTGCAGGGAAAGTCCAAACGGGAGAAGAAGGATAGGGTCTTTACCGATAAGACGTCGGCCACCGTCATCTGCAGGAAGAACGCCAGCATAAGCGTGCGGGCGCAGGATCGGTACTACAGCTCGAGCTGGTCCGAATGGGCCTCCGTGCCCTGTAGCGGAGGGGGTGGCGGGGGCAGCAGGAACCTGCCCGTGGCCACCCCGGACCCGGGCATGTTTCCCTGCCTGCATCACAGTCAGAACCTGCTGAGGGCCGTGAGCAACATGCTCCAGAAGGCCCGCCAGACCCTGGAGTTTTACCCCTGCACCAGCGAAGAGATCGATCACGAAGACATCACCAAAGACAAGACCTCCACCGTGGAGGCCTGTCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTGAACAGCAGGGAGACCTCCTTCATCACCAACGGCTCCTGCCTGGCATCCCGGAAGACCAGCTTCATGATGGCCCTGTGTCTGAGCTCTATCTACGAGGACCTGAAGATGTACCAGGTCGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGACAGATATTCCTGGACCAGAACATGCTCGCCGTGATCGATGAACTGATGCAAGCCCTGAACTTCAATAGCGAGACCGTGCCCCAGAAAAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAACTGTGCATACTGCTGCACGCGTTCAGGATCCGGGCCGTCACCATCGACCGGGTGATGTCCTATCTGAATGCCAGC > hIL12AB_033(SEQID NO: 37)ATGTGCCACCAGCAGCTCGTGATTAGCTGGTTTTCGCTGGTGTTCCTGGCCAGCCCTCTCGTGGCCATCTGGGAGCTGAAAAAAGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCCCCCGGCGAGATGGTGGTGCTGACGTGCGACACCCCGGAAGAGGACGGCATCACCTGGACCCTGGACCAGTCATCCGAGGTCCTGGGCAGCGGCAAGACGCTCACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAGTACACATGCCATAAGGGCGGGGAGGTGCTGAGCCACAGCCTGCTCCTCCTGCACAAGAAGGAGGATGGCATCTGGTCTACAGACATCCTGAAGGACCAGAAAGAGCCCAAGAACAAGACCTTCCTCCGGTGCGAGGCCAAGAACTACTCCGGGCGGTTTACTTGTTGGTGGCTGACCACCATCAGCACCGACCTCACCTTCAGCGTGAAGAGCTCCCGAGGGAGCTCCGACCCCCAGGGGGTCACCTGCGGCGCCGCCACCCTGAGCGCCGAGCGGGTGAGGGGCGACAACAAGGAGTATGAATACAGCGTGGAATGCCAAGAGGACAGCGCCTGTCCCGCGGCCGAGGAAAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAACTCAAGTACGAGAACTACACCAGCAGTTTCTTCATTCGCGACATCATCAAGCCGGACCCCCCCAAAAACCTGCAGCTCAAACCCCTGAAGAACAGCAGGCAGGTGGAGGTCAGCTGGGAGTACCCGGACACCTGGAGCACCCCCCATAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAACGCGAGAAGAAGGACCGGGTGTTTACCGACAAGACCAGCGCCACGGTGATCTGCCGAAAGAATGCAAGCATCTCCGTGAGGGCGCAGGACCGCTACTACTCTAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGTGGCGGCGGAGGCGGCAGCCGTAACCTCCCCGTGGCCACCCCCGACCCCGGCATGTTCCCGTGTCTGCACCACTCCCAGAACCTGCTGAGGGCCGTCAGCAATATGCTGCAGAAGGCCCGGCAGACGCTGGAGTTCTACCCCTGCACCTCCGAGGAGATCGACCATGAGGACATTACCAAGGACAAGACGAGCACTGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAAAACGAGAGCTGCCTGAATAGCAGGGAGACGTCCTTCATCACCAACGGCAGCTGTCTGGCCAGCAGGAAGACCAGCTTCATGATGGCCCTGTGCCTCTCCTCCATATATGAGGATCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGATCCCAAGAGGCAGATCTTCCTGGACCAGAATATGCTGGCCGTGATTGACGAGCTGATGCAGGCCCTGAACTTTAATAGCGAGACCGTCCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTATAAGACCAAGATCAAGCTGTGCATACTGCTGCACGCGTTTAGGATAAGGGCCGTCACCATCGACAGGGTGATGAGCTACCTGAATGCCAGC > hIL12AB_034(SEQID NO: 38)ATGTGCCACCAACAGCTGGTGATCTCCTGGTTCAGCCTGGTGTTCCTCGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCCGGCGAGATGGTCGTGCTGACCTGCGACACCCCGGAGGAGGACGGCATCACCTGGACCCTGGATCAGTCCTCCGAGGTGCTGGGCAGCGGGAAGACCCTGACCATCCAGGTGAAAGAGTTCGGAGATGCCGGCCAGTATACCTGTCACAAGGGGGGTGAGGTGCTGAGCCATAGCCTCTTGCTTCTGCACAAGAAGGAGGACGGCATCTGGTCCACCGACATCCTCAAGGACCAAAAGGAGCCGAAGAATAAAACGTTCCTGAGGTGCGAAGCCAAGAACTATTCCGGACGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTCACCTTCTCCGTAAAGTCAAGCAGGGGCAGCTCCGACCCCCAGGGCGTGACCTGCGGAGCCGCCACCCTGAGCGCAGAGAGGGTGAGGGGCGACAACAAGGAGTACGAATACTCCGTCGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAAAGTCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTCAAATACGAGAACTACACCAGCAGCTTCTTCATCCGGGATATCATCAAGCCCGACCCTCCAAAGAATCTGCAGCTGAAACCCCTTAAGAACAGCAGGCAGGTGGAGGTCAGCTGGGAGTACCCCGACACCTGGAGCACGCCCCACTCCTACTTTAGCCTGACCTTTTGCGTGCAGGTGCAGGGGAAAAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACCGATAAGACCTCCGCTACCGTGATCTGCAGGAAGAACGCCTCAATCAGCGTGAGGGCCCAGGATCGGTACTACTCCAGCTCCTGGAGCGAGTGGGCCAGCGTGCCCTGCTCTGGCGGTGGCGGCGGGGGCAGCCGGAACCTGCCGGTGGCCACTCCCGACCCGGGCATGTTCCCGTGCCTCCACCATTCCCAGAACCTGCTGCGGGCCGTGTCCAATATGCTCCAGAAGGCAAGGCAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGATCACGAGGACATCACCAAAGACAAAACCAGCACGGTCGAGGCCTGCCTGCCCCTGGAACTCACCAAGAACGAAAGCTGTCTCAACAGCCGCGAGACCAGCTTCATAACCAACGGTTCCTGTCTGGCCTCCCGCAAGACCAGCTTTATGATGGCCCTCTGTCTGAGCTCCATCTATGAAGACCTGAAAATGTACCAGGTGGAGTTCAAAACCATGAACGCCAAGCTTCTGATGGACCCCAAGAGGCAGATCTTCCTGGATCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTTAACTCCGAGACCGTGCCCCAGAAAAGCAGCCTGGAAGAGCCCGATTTCTACAAAACGAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCCGGATCCGTGCGGTGACCATCGATAGGGTGATGAGCTACCTGAACGCCAGC > hIL12AB_035(SEQID NO: 39)ATGTGCCACCAACAGCTGGTAATCAGCTGGTTCAGCCTGGTTTTCCTCGCGTCGCCCCTGGTGGCCATCTGGGAGTTAAAGAAGGACGTGTACGTGGTGGAGCTGGATTGGTACCCCGACGCCCCGGGCGAGATGGTCGTGCTCACCTGCGATACCCCCGAGGAGGACGGGATCACCTGGACCCTGGACCAATCCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATACAGGTGAAGGAATTTGGGGACGCCGGGCAGTACACCTGCCACAAGGGCGGGGAAGTGCTGTCCCACTCCCTCCTGCTGCTGCATAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAAAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAAAACTATTCCGGCCGCTTTACCTGTTGGTGGCTGACCACCATCTCCACCGATCTGACCTTCAGCGTGAAGTCGTCTAGGGGCTCCTCCGACCCCCAGGGCGTAACCTGCGGCGCCGCGACCCTGAGCGCCGAGAGGGTGCGGGGCGATAACAAAGAGTACGAGTACTCGGTGGAGTGCCAGGAGGACAGCGCCTGTCCGGCGGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGTTCGTTCTTCATCAGGGACATCATCAAGCCGGACCCCCCCAAGAACCTCCAGCTGAAGCCCCTGAAGAACAGCAGGCAGGTGGAAGTGTCCTGGGAGTATCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTTTGCGTGCAGGTGCAGGGCAAAAGCAAGAGGGAAAAGAAGGACCGGGTGTTCACCGATAAGACGAGCGCCACCGTTATCTGCAGGAAGAACGCCTCCATAAGCGTGAGGGCGCAGGACCGTTACTACAGCAGCAGCTGGAGTGAGTGGGCAAGCGTGCCCTGTAGCGGCGGGGGCGGGGGCGGGTCCCGCAACCTCCCCGTCGCCACCCCCGACCCAGGCATGTTTCCGTGCCTGCACCACAGCCAGAACCTGCTGCGGGCCGTTAGCAACATGCTGCAGAAGGCCAGGCAGACCCTCGAGTTCTATCCCTGCACATCTGAGGAGATCGACCACGAAGACATCACTAAGGATAAGACCTCCACCGTGGAGGCCTGTCTGCCCCTCGAGCTGACCAAGAATGAATCCTGCCTGAACAGCCGAGAGACCAGCTTTATCACCAACGGCTCCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTGTGCCTCTCCAGCATCTACGAGGATCTGAAGATGTACCAGGTAGAGTTCAAGACGATGAACGCCAAGCTCCTGATGGACCCCAAGAGGCAGATATTCCTGGACCAGAACATGCTGGCGGTGATCGACGAGCTGATGCAGGCCCTGAATTTCAACAGCGAGACGGTGCCACAGAAGTCCAGCCTGGAGGAGCCAGACTTCTACAAGACCAAGATCAAACTGTGCATCCTCCTGCACGCGTTCAGGATCCGCGCCGTCACCATAGACAGGGTGATGAGTTATCTGAACGCCAGC > hIL12AB_036(SEQID NO: 40)ATGTGCCATCAGCAGCTGGTAATCAGCTGGTTTAGCCTGGTGTTCCTGGCCAGCCCACTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAACTGGACTGGTACCCCGACGCCCCTGGCGAGATGGTGGTACTGACCTGTGACACCCCGGAGGAAGACGGTATCACCTGGACCCTGGATCAGAGCTCCGAGGTGCTGGGCTCCGGCAAGACACTGACCATCCAAGTTAAGGAATTTGGGGACGCCGGCCAGTACACCTGCCACAAGGGGGGCGAGGTGCTGTCCCACTCCCTGCTGCTTCTGCATAAGAAGGAGGATGGCATCTGGTCCACCGACATACTGAAGGACCAGAAGGAGCCCAAGAATAAGACCTTCCTGAGATGCGAGGCCAAGAACTACTCGGGAAGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCTCCGTGAAGAGCTCCCGGGGCAGCTCCGACCCCCAGGGCGTAACCTGTGGGGCCGCTACCCTGTCCGCCGAGAGGGTCCGGGGCGACAACAAGGAATACGAGTACAGCGTGGAGTGCCAGGAGGACTCCGCCTGCCCCGCCGCCGAGGAGTCGCTGCCCATAGAGGTGATGGTGGACGCCGTGCACAAGCTCAAGTACGAGAATTACACCAGCAGCTTCTTTATCAGGGACATAATTAAGCCGGACCCCCCAAAGAATCTGCAGCTGAAGCCCCTGAAGAATAGCCGGCAGGTGGAAGTGTCCTGGGAGTACCCCGACACCTGGAGCACCCCCCACTCCTATTTCTCACTGACATTCTGCGTGCAGGTGCAAGGGAAAAGCAAGAGGGAGAAGAAGGATAGGGTGTTCACCGACAAGACAAGCGCCACCGTGATCTGCCGAAAAAATGCCAGCATCAGCGTGAGGGCCCAGGATCGGTATTACAGCAGCTCCTGGAGCGAGTGGGCCAGCGTGCCCTGTTCCGGCGGGGGAGGGGGCGGCTCCCGGAACCTGCCGGTGGCCACCCCCGACCCTGGCATGTTCCCCTGCCTGCATCACAGCCAGAACCTGCTCCGGGCCGTGTCGAACATGCTGCAGAAGGCCCGGCAGACCCTCGAGTTTTACCCCTGCACCAGCGAAGAGATCGACCACGAAGACATAACCAAGGACAAGACCAGCACGGTGGAGGCCTGCCTGCCCCTGGAGCTTACCAAAAACGAGTCCTGCCTGAACAGCCGGGAAACCAGCTTCATAACGAACGGGAGCTGCCTGGCCTCCAGGAAGACCAGCTTCATGATGGCGCTGTGTCTGTCCAGCATATACGAGGATCTGAAGATGTATCAGGTGGAATTCAAAACTATGAATGCCAAGCTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTAGCCGTGATCGACGAGCTGATGCAGGCCCTCAACTTCAACTCGGAGACGGTGCCCCAGAAGTCCAGCCTCGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATACTGCTGCATGCCTTCAGGATAAGGGCGGTGACTATCGACAGGGTCATGTCCTACCTGAACGCCAGC > hIL12AB_037(SEQID NO: 41)ATGTGCCACCAACAACTGGTGATCAGCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTCAAAAAAGACGTGTACGTGGTGGAGCTCGATTGGTACCCAGACGCGCCGGGGGAAATGGTGGTGCTGACCTGCGACACCCCAGAGGAGGATGGCATCACGTGGACGCTGGATCAGTCCAGCGAGGTGCTGGGGAGCGGCAAGACGCTCACCATCCAGGTGAAGGAATTTGGCGACGCGGGCCAGTATACCTGTCACAAGGGCGGCGAGGTGCTGAGCCACTCCCTGCTGCTGCTGCACAAGAAGGAGGATGGGATCTGGTCAACCGATATCCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGCGCTGCGAGGCCAAGAACTATAGCGGCAGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGCGTGAAATCCTCCAGGGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGTGCCGCCACGCTCTCCGCCGAGCGAGTGAGGGGTGACAACAAGGAGTACGAGTACAGCGTGGAATGTCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGTCGCTGCCCATCGAGGTGATGGTCGACGCGGTGCACAAGCTCAAATACGAGAATTACACCAGCAGCTTCTTCATCAGGGACATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCTTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCGGACACCTGGAGCACCCCCCACTCCTACTTCAGCCTGACGTTCTGTGTGCAGGTGCAGGGGAAGTCCAAGAGGGAGAAGAAGGACCGGGTGTTCACCGACAAGACCAGCGCCACCGTGATATGCCGCAAGAACGCGTCCATCAGCGTTCGCGCCCAGGACCGCTACTACAGCAGCTCCTGGTCCGAATGGGCCAGCGTGCCCTGCAGCGGTGGAGGGGGCGGGGGCTCCAGGAATCTGCCGGTGGCCACCCCCGACCCCGGGATGTTCCCGTGTCTGCATCACTCCCAGAACCTGCTGCGGGCCGTGAGCAATATGCTGCAGAAGGCCAGGCAGACGCTCGAGTTCTACCCCTGCACCTCCGAAGAGATCGACCATGAGGACATCACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTCCCCCTGGAGCTGACCAAAAACGAGAGCTGCCTGAACTCCAGGGAGACCAGCTTTATAACCAACGGCAGCTGCCTCGCCTCCAGGAAGACCTCGTTTATGATGGCCCTCTGCCTGTCCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGTTGCTCATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCGGTGATCGACGAGCTGATGCAAGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAAGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCCGGATCCGGGCCGTGACCATCGACAGGGTGATGAGCTACCTCAACGCCTCC > hIL12AB_038(SEQID NO: 42)ATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCCCTCGTCTTCCTGGCCTCCCCGCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCCGGCGAGATGGTGGTGCTGACGTGCGACACACCAGAAGAGGACGGGATCACATGGACCCTGGATCAGTCGTCCGAGGTGCTGGGGAGCGGCAAGACCCTCACCATCCAAGTGAAGGAGTTCGGGGACGCCGGCCAGTACACCTGCCACAAGGGCGGGGAGGTGCTCTCCCATAGCCTGCTCCTCCTGCACAAAAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACATTTCTCAGGTGTGAGGCCAAGAACTATTCGGGCAGGTTTACCTGTTGGTGGCTCACCACCATCTCTACCGACCTGACGTTCTCCGTCAAGTCAAGCAGGGGGAGCTCGGACCCCCAGGGGGTGACATGTGGGGCCGCCACCCTGAGCGCGGAGCGTGTCCGCGGCGACAACAAGGAGTACGAGTATTCCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGTCCCTGCCCATAGAGGTGATGGTGGACGCCGTCCACAAGTTGAAGTACGAAAATTATACCTCCTCGTTCTTCATTAGGGACATCATCAAGCCTGACCCCCCGAAGAACCTACAACTCAAGCCCCTCAAGAACTCCCGCCAGGTGGAGGTGTCCTGGGAGTACCCCGACACCTGGTCCACCCCGCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTCCAGGGGAAGAGCAAGCGTGAAAAGAAAGACAGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCAGGAAAAACGCCTCCATCTCCGTGCGCGCCCAGGACAGGTACTACAGTAGCTCCTGGAGCGAATGGGCCAGCGTGCCGTGCAGCGGCGGGGGAGGAGGCGGCAGTCGCAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCATGCCTGCACCACAGCCAGAACCTGCTGAGGGCAGTCAGCAATATGCTGCAGAAGGCCAGGCAGACCCTGGAGTTTTATCCCTGCACCAGCGAGGAGATCGACCACGAGGACATCACCAAGGACAAGACCTCCACCGTCGAGGCCTGCCTGCCACTGGAGCTGACCAAAAACGAGAGCTGCCTGAACTCCAGGGAGACCTCCTTCATCACCAACGGGAGCTGCCTGGCCAGCCGGAAGACCAGCTTCATGATGGCGCTGTGCCTCAGCAGCATCTACGAGGATCTCAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATTGACGAGCTCATGCAGGCCCTGAACTTCAATAGCGAGACCGTCCCCCAAAAGAGCAGCCTGGAGGAACCCGACTTCTACAAAACGAAGATCAAGCTCTGCATCCTGCTGCACGCCTTCCGGATCCGGGCCGTGACCATCGATCGTGTGATGAGCTACCTGAACGCCTCG > hIL12AB_039(SEQID NO: 43)ATGTGCCACCAGCAGCTCGTCATCTCCTGGTTTAGCCTGGTGTTTCTGGCCTCCCCCCTGGTCGCCATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCTCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCTCCGAGGTGCTGGGGAGCGGCAAGACCCTGACCATTCAGGTGAAAGAGTTCGGCGACGCCGGCCAATATACCTGCCACAAGGGGGGGGAGGTCCTGTCGCATTCCCTGCTGCTGCTTCACAAAAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAAGAACCCAAGAACAAGACGTTCCTGCGCTGCGAGGCCAAGAACTACAGCGGCCGGTTCACCTGTTGGTGGCTGACCACCATCTCCACCGACCTGACTTTCTCGGTGAAGAGCAGCCGCGGGAGCAGCGACCCCCAGGGAGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAAAGGGTGAGGGGCGACAATAAAGAGTACGAGTATTCCGTGGAGTGCCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGTCCCTGCCTATCGAGGTGATGGTCGACGCGGTGCACAAGCTCAAGTACGAAAACTACACCAGCAGCTTTTTCATCAGGGATATCATCAAACCAGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAAAACAGCAGGCAGGTGGAAGTGAGCTGGGAATACCCCGATACCTGGTCCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGGAAGTCCAAGCGGGAGAAGAAAGATCGGGTGTTCACGGACAAGACCAGCGCCACCGTGATTTGCAGGAAAAACGCCAGCATCTCCGTGAGGGCTCAGGACAGGTACTACAGCTCCAGCTGGAGCGAGTGGGCCTCCGTGCCTTGCAGCGGGGGAGGAGGCGGCGGCAGCAGGAATCTGCCCGTCGCAACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAATCTGCTGCGAGCCGTGAGCAACATGCTCCAGAAGGCCCGGCAGACGCTGGAGTTCTACCCCTGCACCTCCGAGGAGATCGACCACGAGGACATCACCAAGGATAAGACGAGCACCGTCGAGGCCTGTCTCCCCCTGGAGCTCACCAAGAACGAGTCCTGCCTGAATAGCAGGGAGACGTCCTTCATAACCAACGGCAGCTGTCTGGCGTCCAGGAAGACCAGCTTCATGATGGCCCTCTGCCTGAGCTCCATCTACGAGGACCTCAAGATGTACCAGGTCGAGTTCAAGACCATGAACGCAAAACTGCTCATGGATCCAAAGAGGCAGATCTTTCTGGACCAGAACATGCTGGCCGTGATCGATGAACTCATGCAGGCCCTGAATTTCAATTCCGAGACCGTGCCCCAGAAGAGCTCCCTGGAGGAACCCGACTTCTACAAAACAAAGATCAAGCTGTGTATCCTCCTGCACGCCTTCCGGATCAGGGCCGTCACCATTGACCGGGTGATGTCCTACCTGAACGCCAGC > hIL12AB_040(SEQID NO: 44)ATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTCGTGTTCCTCGCCAGCCCCCTCGTGGCCATCTGGGAGCTGAAAAAGGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCGGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATTACCTGGACACTGGACCAGAGCAGCGAGGTCCTGGGCAGCGGGAAGACCCTGACAATTCAGGTGAAGGAGTTCGGCGACGCCGGACAGTACACGTGCCACAAGGGGGGGGAGGTGCTGTCCCACAGCCTCCTCCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGATCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGATGCGAGGCCAAGAATTACAGCGGCCGTTTCACCTGCTGGTGGCTCACCACCATCAGCACCGACCTGACCTTCAGCGTGAAATCCTCCAGGGGCTCCTCCGACCCGCAGGGAGTGACCTGCGGCGCCGCCACACTGAGCGCCGAGCGGGTCAGAGGGGACAACAAGGAGTACGAGTACAGCGTTGAGTGCCAGGAGGACAGCGCCTGTCCCGCGGCCGAGGAATCCCTGCCCATCGAGGTGATGGTGGACGCAGTGCACAAGCTGAAGTACGAGAACTATACCTCGAGCTTCTTCATCCGGGATATCATTAAGCCCGATCCCCCGAAGAACCTGCAGCTCAAACCCCTGAAGAACAGCAGGCAGGTGGAGGTCTCCTGGGAGTACCCCGACACATGGTCCACCCCCCATTCCTATTTCTCCCTGACCTTTTGCGTGCAGGTGCAGGGCAAGAGCAAGAGGGAGAAAAAGGACAGGGTGTTCACCGACAAGACCTCCGCCACCGTGATCTGCCGTAAGAACGCTAGCATCAGCGTCAGGGCCCAGGACAGGTACTATAGCAGCTCCTGGTCCGAGTGGGCCAGCGTCCCGTGCAGCGGCGGGGGCGGTGGAGGCTCCCGGAACCTCCCCGTGGCCACCCCGGACCCCGGGATGTTTCCCTGCCTGCATCACAGCCAGAACCTGCTGAGGGCCGTGTCCAACATGCTGCAGAAGGCCAGGCAGACACTCGAGTTTTACCCCTGCACCAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAGACCTCCACCGTGGAGGCATGCCTGCCCCTGGAGCTGACCAAAAACGAAAGCTGTCTGAACTCCAGGGAGACCTCCTTTATCACGAACGGCTCATGCCTGGCCTCCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCTCCATCTACGAGGACTTGAAAATGTACCAGGTCGAGTTCAAGACCATGAACGCCAAGCTGCTCATGGACCCCAAAAGGCAGATCTTTCTGGACCAGAATATGCTGGCCGTGATCGACGAGCTCATGCAAGCCCTGAATTTCAACAGCGAGACCGTGCCCCAGAAGTCCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATACTCCTGCACGCGTTTAGGATCAGGGCGGTGACCATCGATAGGGTGATGAGCTACCTGAATGCCTCC > hIL12AB_002(SEQ ID NO: 236)ATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCCGACGCCCCCGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGATGCGAGGCCAAGAACTACAGCGGCAGATTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGCGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAAGATAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAAGATAGAGTGTTCACCGACAAGACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGAGCCCAAGATAGATACTACAGCAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGACCACGAAGATATCACCAAAGATAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGAATCAGAGCCGTGACCATCGACAGAGTGATGAGCTACCTGAACGCCAGC

TABLE 4B Sequence Optimized Polynucleotides Comprising 5′ UTR, ORF,3′ UTR hIL12AB_001TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAGCAGCTGGTCATTAGCTGGTTTAGCCTTGTGTTCCTGGCCTCCCCCCTTGTCGCTNO: 55)ATTTGGGAGCTCAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCAGACGCGCCCGGAGAGATGGTAGTTCTGACCTGTGATACCCCAGAGGAGGACGGCATCACCTGGACGCTGGACCAAAGCAGCGAGGTTTTGGGCTCAGGGAAAACGCTGACCATCCAGGTGAAGGAATTCGGCGACGCCGGGCAGTACACCTGCCATAAGGGAGGAGAGGTGCTGAGCCATTCCCTTCTTCTGCTGCACAAGAAAGAGGACGGCATCTGGTCTACCGACATCCTGAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTGAGGTGCGAGGCCAAGAACTACTCCGGCAGGTTCACTTGTTGGTGGCTGACCACCATCAGTACAGACCTGACTTTTAGTGTAAAAAGCTCCAGAGGCTCGTCCGATCCCCAAGGGGTGACCTGCGGCGCAGCCACTCTGAGCGCTGAGCGCGTGCGCGGTGACAATAAAGAGTACGAGTACAGCGTTGAGTGTCAAGAAGATAGCGCTTGCCCTGCCGCCGAGGAGAGCCTGCCTATCGAGGTGATGGTTGACGCAGTGCACAAGCTTAAGTACGAGAATTACACCAGCTCATTCTTCATTAGAGATATAATCAAGCCTGACCCACCCAAGAACCTGCAGCTGAAGCCACTGAAAAACTCACGGCAGGTCGAAGTGAGCTGGGAGTACCCCGACACCTGGAGCACTCCTCATTCCTATTTCTCTCTTACATTCTGCGTCCAGGTGCAGGGCAAGAGCAAGCGGGAAAAGAAGGATCGAGTCTTCACCGACAAAACAAGCGCGACCGTGATTTGCAGGAAGAACGCCAGCATCTCCGTCAGAGCCCAGGATAGATACTATAGTAGCAGCTGGAGCGAGTGGGCAAGCGTGCCCTGTTCCGGCGGCGGGGGCGGGGGCAGCCGAAACTTGCCTGTCGCTACCCCGGACCCTGGAATGTTTCCGTGTCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGTCGAATATGCTCCAGAAGGCCCGGCAGACCCTTGAGTTCTACCCCTGTACCAGCGAAGAGATCGATCATGAAGATATCACGAAAGATAAAACATCCACCGTCGAGGCTTGTCTCCCGCTGGAGCTGACCAAGAACGAGAGCTGTCTGAATAGCCGGGAGACGTCTTTCATCACGAATGGTAGCTGTCTGGCCAGCAGGAAAACTTCCTTCATGATGGCTCTCTGCCTGAGCTCTATCTATGAAGATCTGAAGATGTATCAGGTGGAGTTTAAAACAATGAACGCCAAACTCCTGATGGACCCAAAAAGGCAAATCTTTCTGGACCAGAATATGCTGGCCGTGATAGACGAGCTGATGCAGGCACTGAACTTCAACAGCGAGACGGTGCCACAGAAATCCAGCCTGGAGGAGCCTGACTTTTACAAAACTAAGATCAAGCTGTGTATCCTGCTGCACGCCTTTAGAATCCGTGCCGTGACTATCGACAGGGTGATGTCATACCTCAACGCTTCATGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_002TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCNO: 56)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCCGACGCCCCCGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGATGCGAGGCCAAGAACTACAGCGGCAGATTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGCGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAAGATAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAAGATAGAGTGTTCACCGACAAGACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGAGCCCAAGATAGATACTACAGCAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGACCACGAAGATATCACCAAAGATAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGAATCAGAGCCGTGACCATCGACAGAGTGATGAGCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_003TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTCCCCTCGTGGCCNO: 57)ATCTGGGAACTGAAGAAAGACGTTTACGTTGTAGAATTGGATTGGTATCCGGACGCTCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAAGAAGACGGAATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCGCTCCTGCTGCTTCACAAAAAGGAAGATGGAATTTGGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCAGTGTCAAAAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACACTCTCTGCAGAGAGAGTCAGAGGTGACAACAAGGAGTATGAGTACTCAGTGGAGTGCCAGGAAGATAGTGCCTGCCCAGCTGCTGAGGAGAGTCTGCCCATTGAGGTCATGGTGGATGCCGTTCACAAGCTCAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAACCTGACCCACCCAAGAACTTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAGAGCAAGAGAGAAAAGAAAGATAGAGTCTTCACAGATAAGACCTCAGCCACGGTCATCTGCCGCAAAAATGCCAGCATTAGCGTGCGGGCCCAGGACCGCTACTATAGCTCATCTTGGAGCGAATGGGCATCTGTGCCCTGCAGTGGCGGAGGGGGCGGAGGGAGCAGAAACCTCCCCGTGGCCACTCCAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAACCTGCTGAGGGCCGTCAGCAACATGCTCCAGAAGGCCCGGCAAACTTTAGAATTTTACCCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCCAGAGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGACCTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGATTTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTTTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACGGTGCCACAAAAATCCTCCCTTGAAGAACCAGATTTCTACAAGACCAAGATCAAGCTCTGCATACTTCTTCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_004TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGGGCTGCCACCAGCAGCTGGTCATCAGCTGGTTCTCCCTGGTCTTCCTGGCCAGCCCCCTGGTGNO: 58)GCCATCTGGGAGCTGAAGAAAGACGTCTACGTAGTAGAGTTGGATTGGTACCCAGACGCACCTGGAGAAATGGTGGTTCTCACCTGTGACACGCCAGAAGAAGACGGTATCACCTGGACGCTGGACCAGAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACAGATATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGCAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGTGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGATTCGGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAAGTTTCCTGGGAGTACCCAGATACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACAGATAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTGCACCACAGCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCACGGCAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGATATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGCGGCAGATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGATTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_005TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTCATCAGCTGGTTCTCCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCNO: 59)ATCTGGGAGCTGAAGAAAGACGTCTACGTAGTAGAGTTGGATTGGTACCCAGACGCACCTGGAGAAATGGTGGTTCTCACCTGTGACACGCCAGAAGAAGACGGTATCACCTGGACGCTGGACCAGAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACAGATATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGCAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGTGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGATTCGGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAAGTTTCCTGGGAGTACCCAGATACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACAGATAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTGCACCACAGCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCACGGCAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGATATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGCGGCAGATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGATTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_006TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCNO: 60)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCCGACGCCCCCGGCGAGATGGTGGTGCTGACCTGTGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGGGACGCCGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATCTGGAGCACAGATATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGATGCGAGGCCAAGAACTACAGCGGCAGATTCACCTGCTGGTGGCTGACCACCATCAGCACAGATTTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGTGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAAGATAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCCGACCCGCCGAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAAGATAGAGTGTTCACAGATAAGACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGAGCCCAAGATAGATACTACAGCAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGACCACGAAGATATCACCAAAGATAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAATGAAAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGAATCAGAGCCGTGACCATCGACAGAGTGATGAGCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_007TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTTGTCATCTCCTGGTTCTCTCTTGTCTTCCTTGCTTCTCCTCTTGTGGCCNO: 61)ATCTGGGAGCTGAAGAAGGACGTTTACGTAGTGGAGTTGGATTGGTACCCTGACGCACCTGGAGAAATGGTGGTTCTCACCTGTGACACTCCTGAGGAGGACGGTATCACCTGGACGTTGGACCAGTCTTCTGAGGTTCTTGGCAGTGGAAAAACTCTTACTATTCAGGTGAAGGAGTTTGGAGATGCTGGCCAGTACACCTGCCACAAGGGTGGTGAAGTTCTCAGCCACAGTTTACTTCTTCTTCACAAGAAGGAGGATGGCATCTGGTCTACTGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACATTCCTTCGTTGTGAAGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTTACTACTATTTCTACTGACCTTACTTTCTCTGTGAAGTCTTCTCGTGGCTCTTCTGACCCTCAGGGTGTCACCTGTGGGGCTGCTACTCTTTCTGCTGAGCGTGTGCGTGGTGACAACAAGGAGTATGAATACTCGGTGGAGTGCCAGGAAGATTCTGCCTGCCCTGCTGCTGAGGAGTCTCTTCCTATTGAGGTGATGGTGGATGCTGTGCACAAGTTAAAATATGAAAACTACACTTCTTCTTTCTTCATTCGTGACATTATAAAACCTGACCCTCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACTCTCGTCAGGTGGAGGTGTCCTGGGAGTACCCTGACACGTGGTCTACTCCTCACTCCTACTTCTCTCTTACTTTCTGTGTCCAGGTGCAGGGCAAGTCCAAGCGTGAGAAGAAGGACCGTGTCTTCACTGACAAAACATCTGCTACTGTCATCTGCAGGAAGAATGCATCCATCTCTGTGCGTGCTCAGGACCGTTACTACAGCTCTTCCTGGTCTGAGTGGGCTTCTGTGCCCTGCTCTGGCGGCGGCGGCGGCGGCAGCAGAAATCTTCCTGTGGCTACTCCTGACCCTGGCATGTTCCCCTGCCTTCACCACTCGCAGAACCTTCTTCGTGCTGTGAGCAACATGCTTCAGAAGGCTCGTCAAACTTTAGAATTCTACCCCTGCACTTCTGAGGAGATTGACCATGAAGATATCACCAAAGATAAAACATCTACTGTGGAGGCCTGCCTTCCTTTAGAGCTGACCAAGAATGAATCCTGCTTAAATTCTCGTGAGACGTCTTTCATCACCAATGGCAGCTGCCTTGCCTCGCGCAAAACATCTTTCATGATGGCTCTTTGCCTTTCTTCCATCTATGAAGATTTAAAAATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTTCTCATGGACCCCAAGCGTCAGATATTTTTGGACCAGAACATGCTTGCTGTCATTGATGAGCTCATGCAGGCTTTAAACTTCAACTCTGAGACGGTGCCTCAGAAGTCTTCTTTAGAAGAGCCTGACTTCTACAAGACCAAGATAAAACTTTGCATTCTTCTTCATGCTTTCCGCATCCGTGCTGTGACTATTGACCGTGTGATGTCCTACTTAAATGCTTCTTGATAATAGGCTGGAGCCTCGGTGGCCAAGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_008TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCATCAACAACTCGTGATTAGCTGGTTCAGTCTCGTGTTCCTGGCCTCTCCGCTGGTGGCCNO: 62)ATCTGGGAGCTTAAGAAGGACGTGTACGTGGTGGAGCTCGATTGGTACCCCGACGCACCTGGCGAGATGGTGGTGCTAACCTGCGATACCCCCGAGGAGGACGGGATCACTTGGACCCTGGATCAGAGTAGCGAAGTCCTGGGCTCTGGCAAAACACTCACAATCCAGGTGAAGGAATTCGGAGACGCTGGTCAGTACACTTGCCACAAGGGGGGTGAAGTGCTGTCTCACAGCCTGCTGTTACTGCACAAGAAGGAGGATGGGATCTGGTCAACCGACATCCTGAAGGATCAGAAGGAGCCTAAGAACAAGACCTTTCTGAGGTGTGAAGCTAAGAACTATTCCGGAAGATTCACTTGCTGGTGGTTGACCACAATCAGCACTGACCTGACCTTTTCCGTGAAGTCCAGCAGAGGAAGCAGCGATCCTCAGGGCGTAACGTGCGGCGCGGCTACCCTGTCAGCTGAGCGGGTTAGAGGCGACAACAAAGAGTATGAGTACTCCGTGGAGTGTCAGGAAGATAGCGCCTGCCCCGCAGCCGAGGAGAGTCTGCCCATCGAGGTGATGGTGGACGCTGTCCATAAGTTAAAATACGAAAATTACACAAGTTCCTTTTTCATCCGCGATATTATCAAACCCGATCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAATAGCCGACAGGTGGAAGTCTCTTGGGAGTATCCTGACACCTGGTCCACGCCTCACAGCTACTTTAGTCTGACTTTCTGTGTCCAGGTCCAGGGCAAGAGCAAGAGAGAGAAAAAGGATAGAGTGTTTACTGACAAAACATCTGCTACAGTCATCTGCAGAAAGAACGCCAGTATCTCAGTGAGGGCGCAAGATAGATACTACAGTAGTAGCTGGAGCGAATGGGCTAGCGTGCCCTGTTCAGGGGGCGGCGGAGGGGGCTCCAGGAATCTGCCCGTGGCCACCCCCGACCCTGGGATGTTCCCTTGCCTCCATCACTCACAGAACCTGCTCAGAGCAGTGAGCAACATGCTCCAAAAGGCCCGCCAGACCCTGGAGTTTTACCCTTGTACTTCAGAAGAGATCGATCACGAAGATATAACAAAGGATAAAACCAGCACCGTGGAGGCCTGTCTGCCTCTGGAACTCACAAAGAATGAAAGCTGTCTGAATTCCAGGGAAACCTCCTTCATTACTAACGGAAGCTGTCTCGCATCTCGCAAAACATCATTCATGATGGCCCTCTGCCTGTCTTCTATCTATGAAGATCTCAAGATGTATCAGGTGGAGTTCAAAACAATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCAGTGATCGATGAGCTGATGCAAGCCTTGAACTTCAACTCAGAGACGGTGCCGCAAAAGTCCTCGTTGGAGGAACCAGATTTTTACAAAACCAAAATCAAGCTGTGTATCCTTCTTCACGCCTTTCGGATCAGAGCCGTGACTATCGACCGGGTGATGTCATACCTGAATGCTTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_009TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTCATCAGCTGGTTTAGCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCNO: 63)ATCTGGGAGCTGAAGAAAGACGTCTACGTAGTAGAGTTGGATTGGTACCCAGACGCACCTGGAGAAATGGTGGTTCTCACCTGCGACACGCCAGAAGAAGACGGTATCACCTGGACGCTGGACCAGAGCAGCGAAGTACTGGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGCGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTACTGAGCCACAGCCTGCTGCTGCTGCACAAGAAAGAAGATGGCATCTGGAGCACCGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTTCGATGTGAGGCGAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTCACCACCATCAGCACCGACCTCACCTTCTCGGTGAAGAGCAGCCGTGGTAGCTCAGACCCCCAAGGAGTCACCTGTGGGGCGGCCACGCTGTCGGCAGAAAGAGTTCGAGGCGACAACAAGGAATATGAATACTCGGTGGAATGTCAAGAAGATTCGGCCTGCCCGGCGGCAGAAGAAAGTCTGCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCAGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAAGTTTCCTGGGAGTACCCAGATACGTGGAGCACGCCGCACAGCTACTTCAGCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACCGACAAAACCTCGGCGACGGTCATCTGCAGGAAGAATGCAAGCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTTCCGTGCCTGCACCACAGCCAAAATTTATTACGAGCTGTTAGCAACATGCTGCAGAAAGCACGGCAAACTTTAGAATTCTACCCCTGCACCTCAGAAGAAATAGACCATGAAGATATCACCAAAGATAAAACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAACGAGAGCTGCCTCAATAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTGAGCAGCATCTATGAAGATCTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAGCTGCTCATGGACCCCAAGCGGCAGATATTCCTCGACCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAGACGGTGCCCCAGAAGAGCAGCCTGGAGGAGCCAGATTTCTACAAAACCAAGATCAAGCTCTGCATCTTATTACATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_010TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTTGTCATCTCCTGGTTTTCTCTTGTCTTCCTCGCTTCTCCTCTTGTGGCCNO: 64)ATCTGGGAGCTGAAGAAAGACGTCTACGTAGTAGAGTTGGATTGGTACCCGGACGCTCCTGGAGAAATGGTGGTTCTCACCTGCGACACTCCTGAAGAAGACGGTATCACCTGGACGCTGGACCAAAGCAGCGAAGTTTTAGGCTCTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGCGACGCTGGCCAGTACACGTGCCACAAAGGAGGAGAAGTTTTAAGCCACAGTTTACTTCTTCTTCACAAGAAAGAAGATGGCATCTGGAGTACAGATATTTTAAAAGACCAGAAGGAGCCTAAGAACAAAACCTTCCTCCGCTGTGAAGCTAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTCACCACCATCTCCACTGACCTCACCTTCTCTGTAAAATCAAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCAGCGCTGAAAGAGTTCGAGGCGACAACAAGGAATATGAATATTCTGTGGAATGTCAAGAAGATTCTGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGACGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATTCGTGACATCATCAAACCAGACCCTCCTAAGAACCTTCAGTTAAAACCGCTGAAGAACAGCCGGCAGGTGGAAGTTTCCTGGGAGTACCCAGATACGTGGAGTACGCCGCACTCCTACTTCAGTTTAACCTTCTGTGTACAAGTACAAGGAAAATCAAAAAGAGAGAAGAAAGATCGTGTCTTCACTGACAAAACATCTGCCACGGTCATCTGCCGTAAGAACGCTTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTTCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCCGCAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTTCACCACTCGCAAAATCTTCTTCGTGCTGTTTCTAACATGCTGCAGAAGGCGCGGCAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATAGACCATGAAGATATCACCAAAGATAAAACCAGCACGGTGGAGGCCTGCCTTCCTTTAGAACTTACTAAGAACGAAAGTTGCCTTAACAGCCGTGAGACCAGCTTCATCACCAATGGCAGCTGCCTTGCTAGCAGGAAGACCAGCTTCATGATGGCGCTGTGCCTTTCTTCCATCTATGAAGATCTTAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAGCGGCAGATATTCCTCGACCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAAACTGTTCCCCAGAAGTCATCTTTAGAAGAACCAGATTTCTACAAAACAAAAATAAAACTCTGCATTCTTCTTCATGCCTTCCGCATCCGTGCTGTCACCATTGACCGTGTCATGTCCTACTTAAATGCTTCTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_011TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCNO: 65)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCGGACGCGCCGGGGGAGATGGTGGTGCTGACGTGCGACACGCCGGAGGAGGACGGGATCACGTGGACGCTGGACCAGAGCAGCGAGGTGCTGGGGAGCGGGAAGACGCTGACGATCCAGGTGAAGGAGTTCGGGGACGCGGGGCAGTACACGTGCCACAAGGGGGGGGAGGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGACGGGATCTGGAGCACAGATATCCTGAAGGACCAGAAGGAGCCGAAGAACAAGACGTTCCTGAGGTGCGAGGCGAAGAACTACAGCGGGAGGTTCACGTGCTGGTGGCTGACGACGATCAGCACGGACCTGACGTTCAGCGTGAAGAGCAGCAGGGGGAGCAGCGACCCGCAGGGGGTGACGTGCGGGGCGGCGACGCTGAGCGCGGAGAGGGTGAGGGGTGACAACAAGGAGTACGAGTACAGCGTGGAGTGCCAGGAAGATAGCGCGTGCCCGGCGGCGGAGGAGAGCCTGCCGATCGAGGTGATGGTGGACGCGGTGCACAAGCTGAAGTACGAGAACTACACGAGCAGCTTCTTCATCAGAGATATCATCAAGCCGGACCCGCCGAAGAACCTGCAGCTGAAGCCGCTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCAGATACGTGGAGCACGCCGCACAGCTACTTCAGCCTGACGTTCTGCGTGCAGGTGCAGGGGAAGAGCAAGAGGGAGAAGAAAGATAGGGTGTTCACAGATAAGACGAGCGCGACGGTGATCTGCAGGAAGAACGCGAGCATCAGCGTGAGGGCGCAAGATAGGTACTACAGCAGCAGCTGGAGCGAGTGGGCGAGCGTGCCGTGCAGCGGGGGGGGGGGGGGGGGGAGCAGGAACCTGCCGGTGGCGACGCCGGACCCGGGGATGTTCCCGTGCCTGCACCACAGCCAGAACCTGCTGAGGGCGGTGAGCAACATGCTGCAGAAGGCGAGGCAGACGCTGGAGTTCTACCCGTGCACGAGCGAGGAGATCGACCACGAAGATATCACGAAAGATAAGACGAGCACGGTGGAGGCGTGCCTGCCGCTGGAGCTGACGAAGAACGAGAGCTGCCTGAACAGCAGGGAGACGAGCTTCATCACGAACGGGAGCTGCCTGGCGAGCAGGAAGACGAGCTTCATGATGGCGCTGTGCCTGAGCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACGATGAACGCGAAGCTGCTGATGGACCCGAAGAGGCAGATCTTCCTGGACCAGAACATGCTGGCGGTGATCGACGAGCTGATGCAGGCGCTGAACTTCAACAGCGAGACGGTGCCGCAGAAGAGCAGCCTGGAGGAGCCAGATTTCTACAAGACGAAGATCAAGCTGTGCATCCTGCTGCACGCGTTCAGGATCAGGGCGGTGACGATCGACAGGGTGATGAGCTACCTGAACGCGAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_012TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTCGTGTTTCTGGCCAGCCCCCTGGTGGCCNO: 66)ATTTGGGAACTCAAGAAGGACGTGTACGTTGTGGAACTCGACTGGTACCCTGACGCCCCAGGCGAAATGGTGGTCTTAACCTGCGACACCCCTGAGGAGGACGGAATCACCTGGACCTTGGACCAGAGCTCCGAGGTCCTCGGCAGTGGCAAGACCCTGACCATACAGGTGAAAGAATTTGGAGACGCAGGGCAATACACATGTCACAAGGGCGGGGAGGTTCTTTCTCACTCCCTTCTGCTTCTACATAAAAAGGAAGACGGAATTTGGTCTACCGACATCCTCAAGGACCAAAAGGAGCCTAAGAATAAAACCTTCTTACGCTGTGAAGCTAAAAACTACAGCGGCAGATTCACTTGCTGGTGGCTCACCACCATTTCTACCGACCTGACCTTCTCGGTGAAGTCTTCAAGGGGCTCTAGTGATCCACAGGGAGTGACATGCGGGGCCGCCACACTGAGCGCTGAACGGGTGAGGGGCGATAACAAGGAGTATGAATACTCTGTCGAGTGTCAGGAGGATTCAGCTTGTCCCGCAGCTGAAGAGTCACTCCCCATAGAGGTTATGGTCGATGCTGTGCATAAACTGAAGTACGAAAACTACACCAGCAGCTTCTTCATTAGAGATATTATAAAACCTGACCCCCCCAAGAACCTGCAACTTAAACCCCTGAAAAACTCTCGGCAGGTCGAAGTTAGCTGGGAGTACCCTGATACTTGGTCCACCCCCCACTCGTACTTCTCACTGACTTTCTGTGTGCAGGTGCAGGGCAAGAGCAAGAGAGAGAAAAAAGATCGTGTATTCACAGATAAGACCTCTGCCACCGTGATCTGCAGAAAAAACGCTTCCATCAGTGTCAGAGCCCAAGACCGGTACTATAGTAGTAGCTGGAGCGAGTGGGCAAGTGTCCCCTGCTCTGGCGGCGGAGGGGGCGGCTCTCGAAACCTCCCCGTCGCTACCCCTGATCCAGGAATGTTCCCTTGCCTGCATCACTCACAGAATCTGCTGAGAGCGGTCAGCAACATGCTGCAGAAAGCTAGGCAAACACTGGAGTTTTATCCTTGTACCTCAGAGGAGATCGACCACGAGGATATTACCAAAGATAAGACCAGCACGGTGGAGGCCTGCTTGCCCCTGGAACTGACAAAGAATGAATCCTGCCTTAATAGCCGTGAGACCTCTTTTATAACAAACGGATCCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTCTGCCTGTCCTCAATCTACGAAGACCTGAAGATGTACCAGGTGGAATTTAAAACTATGAACGCCAAGCTGTTGATGGACCCCAAGCGGCAGATCTTTCTGGATCAAAATATGCTGGCTGTGATCGACGAACTGATGCAGGCCCTCAACTTTAACAGCGAGACCGTGCCACAAAAGAGCAGTCTTGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTCCTTCATGCCTTCAGGATAAGAGCTGTCACCATCGACAGAGTCATGAGTTACCTGAATGCATCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_013TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTCATCTCCTGGTTCAGTCTTGTCTTCCTGGCCTCGCCGCTGGTGGCCNO: 67)ATCTGGGAGCTGAAGAAAGACGTTTACGTAGTAGAGTTGGATTGGTACCCAGACGCACCTGGAGAAATGGTGGTCCTCACCTGTGACACGCCAGAAGAAGACGGTATCACCTGGACGCTGGACCAGAGCAGTGAAGTTCTTGGAAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGAGATGCTGGCCAGTACACCTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGTTTATTATTACTTCACAAGAAAGAAGATGGCATCTGGTCCACAGATATTTTAAAAGACCAGAAGGAGCCCAAAAATAAAACATTTCTTCGATGTGAGGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTGACCACCATCTCCACAGACCTCACCTTCAGTGTAAAAAGCAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCTCTGCAGAAAGAGTTCGAGGTGACAACAAAGAATATGAGTACTCGGTGGAATGTCAAGAAGATTCGGCCTGCCCAGCTGCTGAGGAGAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAACCTGACCCGCCCAAGAACTTACAGCTGAAGCCGCTGAAAAACAGCCGGCAGGTAGAAGTTTCCTGGGAGTACCCAGATACCTGGTCCACGCCGCACTCCTACTTCTCCCTCACCTTCTGTGTACAAGTACAAGGCAAGAGCAAGAGAGAGAAGAAAGATCGTGTCTTCACAGATAAAACATCAGCCACGGTCATCTGCAGGAAAAATGCCAGCATCTCGGTGCGGGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTGCCCTGCAGTGGTGGTGGGGGTGGTGGCAGCAGAAACCTTCCTGTGGCCACTCCAGACCCTGGCATGTTCCCGTGCCTTCACCACTCCCAAAATTTACTTCGAGCTGTTTCTAACATGCTGCAGAAAGCACGGCAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATTGACCATGAAGATATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTCTTCCTTTAGAGCTGACCAAAAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCTCCAGGAAAACCAGCTTCATGATGGCGCTCTGCCTCAGCTCCATCTATGAAGATTTGAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAGAGGCAGATATTTTTAGATCAAAACATGCTGGCAGTTATTGATGAGCTCATGCAAGCATTAAACTTCAACAGTGAGACGGTACCTCAAAAAAGCAGCCTTGAAGAGCCAGATTTCTACAAAACCAAGATCAAACTCTGCATTTTACTTCATGCCTTCCGCATCCGGGCGGTCACCATTGACCGTGTCATGTCCTACTTAAATGCCTCGTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_014TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTTGTGATTTCTTGGTTCTCTCTTGTGTTCCTTGCTTCTCCTCTTGTGGCTNO: 68)ATTTGGGAGTTAAAAAAGGACGTGTACGTGGTGGAGCTTGACTGGTACCCTGACGCACCTGGCGAGATGGTGGTGCTTACTTGTGACACTCCTGAGGAGGACGGCATTACTTGGACGCTTGACCAGTCTTCTGAGGTGCTTGGCTCTGGCAAAACACTTACTATTCAGGTGAAGGAGTTCGGGGATGCTGGCCAGTACACTTGCCACAAGGGCGGCGAGGTGCTTTCTCACTCTCTTCTTCTTCTTCACAAGAAGGAGGACGGCATTTGGTCTACTGACATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACATTCCTTCGTTGCGAGGCCAAGAACTACTCTGGCCGTTTCACTTGCTGGTGGCTTACTACTATTTCTACTGACCTTACTTTCTCTGTGAAGTCTTCTCGTGGCTCTTCTGACCCTCAGGGCGTGACTTGTGGGGCTGCTACTCTTTCTGCTGAGCGTGTGCGTGGTGACAACAAGGAGTACGAGTACTCTGTGGAGTGCCAGGAAGATTCTGCTTGCCCTGCTGCTGAGGAGTCTCTTCCTATTGAGGTGATGGTGGATGCTGTGCACAAGTTAAAATACGAGAACTACACTTCTTCTTTCTTCATTCGTGACATTATTAAGCCTGACCCTCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACTCTCGTCAGGTGGAGGTGTCTTGGGAGTACCCTGACACTTGGTCTACTCCTCACTCTTACTTCTCTCTTACTTTCTGCGTGCAGGTGCAGGGCAAGTCTAAGCGTGAGAAGAAGGACCGTGTGTTCACTGACAAAACATCTGCTACTGTGATTTGCAGGAAGAATGCATCTATTTCTGTGCGTGCTCAGGACCGTTACTACTCTTCTTCTTGGTCTGAGTGGGCTTCTGTGCCTTGCTCTGGCGGCGGCGGCGGCGGCTCCAGAAATCTTCCTGTGGCTACTCCTGACCCTGGCATGTTCCCTTGCCTTCACCACTCTCAGAACCTTCTTCGTGCTGTGAGCAACATGCTTCAGAAGGCTCGTCAAACTCTTGAGTTCTACCCTTGCACTTCTGAGGAGATTGACCACGAAGATATCACCAAAGATAAAACATCTACTGTGGAGGCTTGCCTTCCTCTTGAGCTTACCAAGAATGAATCTTGCTTAAATTCTCGTGAGACGTCTTTCATCACCAACGGCTCTTGCCTTGCCTCGCGCAAAACATCTTTCATGATGGCTCTTTGCCTTTCTTCTATTTACGAAGATTTAAAAATGTACCAGGTGGAGTTCAAAACAATGAATGCAAAGCTTCTTATGGACCCCAAGCGTCAGATTTTCCTTGACCAGAACATGCTTGCTGTGATTGACGAGCTTATGCAGGCTTTAAATTTCAACTCTGAGACGGTGCCTCAGAAGTCTTCTCTTGAGGAGCCTGACTTCTACAAGACCAAGATTAAGCTTTGCATTCTTCTTCATGCTTTCCGTATTCGTGCTGTGACTATTGACCGTGTGATGTCTTACTTAAATGCTTCTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_015TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAGCAGCTGGTGATCAGCTGGTTTAGCCTGGTGTTTCTGGCCAGCCCCCTGGTGGCCNO: 69)ATCTGGGAACTGAAGAAAGACGTGTACGTGGTAGAACTGGATTGGTATCCGGACGCTCCCGGCGAAATGGTGGTGCTGACCTGTGACACCCCCGAAGAAGACGGAATCACCTGGACCCTGGACCAGAGCAGCGAGGTGCTGGGCAGCGGCAAAACCCTGACCATCCAAGTGAAAGAGTTTGGCGATGCCGGCCAGTACACCTGTCACAAAGGCGGCGAGGTGCTAAGCCATTCGCTGCTGCTGCTGCACAAAAAGGAAGATGGCATCTGGAGCACCGATATCCTGAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATAGCGGCCGTTTCACCTGCTGGTGGCTGACGACCATCAGCACCGATCTGACCTTCAGCGTGAAAAGCAGCAGAGGCAGCAGCGACCCCCAAGGCGTGACGTGCGGCGCCGCCACCCTGAGCGCCGAGAGAGTGAGAGGCGACAACAAGGAGTATGAGTACAGCGTGGAGTGCCAGGAAGATAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGATGCCGTGCACAAGCTGAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAACCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAATAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCATAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAGAGAGAAAAGAAAGATAGAGTGTTCACAGATAAGACCAGCGCCACGGTGATCTGCAGAAAAAATGCCAGCATCAGCGTGAGAGCCCAAGATAGATACTATAGCAGCAGCTGGAGCGAATGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAAAACCTGCTGAGAGCCGTGAGCAACATGCTGCAGAAGGCCCGGCAGACCCTGGAATTTTACCCCTGCACCAGCGAAGAGATCGATCATGAAGATATCACCAAAGATAAAACCAGCACCGTGGAGGCCTGTCTGCCCCTGGAACTGACCAAGAATGAGAGCTGCCTAAATAGCAGAGAGACCAGCTTCATAACCAATGGCAGCTGCCTGGCCAGCAGAAAGACCAGCTTTATGATGGCCCTGTGCCTGAGCAGCATCTATGAAGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCCAAGCTGCTGATGGATCCCAAGCGGCAGATCTTTCTGGATCAAAACATGCTGGCCGTGATCGATGAGCTGATGCAGGCCCTGAATTTCAACAGCGAGACCGTGCCCCAAAAAAGCAGCCTGGAAGAACCGGATTTTTATAAAACCAAAATCAAGCTGTGCATACTGCTGCATGCCTTCAGAATCAGAGCCGTGACCATCGATAGAGTGATGAGCTATCTGAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_016TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTCATCAGCTGGTTCAGCCTGGTCTTCCTGGCCAGCCCCCTGGTGGCCNO: 70)ATCTGGGAGCTGAAGAAGGACGTATACGTAGTGGAGTTGGATTGGTACCCAGACGCTCCTGGGGAGATGGTGGTGCTGACCTGTGACACCCCAGAAGAGGACGGTATCACCTGGACCCTGGACCAGAGCTCAGAAGTGCTGGGCAGTGGAAAAACCCTGACCATCCAGGTGAAGGAGTTTGGAGATGCTGGCCAGTACACCTGCCACAAGGGTGGTGAAGTGCTGAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACAGATATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTTCGCTGTGAAGCCAAGAACTACAGTGGCCGCTTCACCTGCTGGTGGCTGACCACCATCAGCACAGACCTCACCTTCTCGGTGAAGAGCAGCAGAGGCAGCTCAGACCCCCAGGGTGTCACCTGTGGGGCGGCCACGCTGTCGGCGGAGAGAGTTCGAGGTGACAACAAGGAGTATGAATACTCGGTGGAGTGCCAGGAAGATTCGGCGTGCCCGGCGGCAGAAGAGAGCCTGCCCATAGAAGTGATGGTGGATGCTGTGCACAAGCTGAAGTATGAAAACTACACCAGCAGCTTCTTCATCAGAGATATCATCAAGCCAGACCCGCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAGGTTTCCTGGGAGTACCCAGATACGTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTCTGTGTCCAGGTGCAGGGCAAGAGCAAGAGAGAGAAGAAAGATAGAGTCTTCACAGATAAGACCTCGGCCACGGTCATCTGCAGAAAGAATGCCTCCATCTCGGTTCGAGCCCAAGATAGATACTACAGCAGCAGCTGGTCAGAATGGGCCTCGGTGCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCAGAAACCTGCCTGTTGCCACCCCAGACCCTGGGATGTTCCCCTGCCTGCACCACAGCCAGAACTTATTACGAGCTGTTTCTAACATGCTGCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGCACCTCAGAAGAGATTGACCATGAAGATATCACCAAAGATAAGACCAGCACTGTAGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAATGAAAGCTGCCTGAACAGCAGAGAGACCAGCTTCATCACCAATGGAAGCTGCCTGGCCAGCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTATGAAGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTGCTGATGGACCCCAAGCGGCAGATATTTTTGGACCAGAACATGCTGGCTGTCATTGATGAGCTGATGCAGGCCCTGAACTTCAACTCAGAAACTGTACCCCAGAAGAGCAGCCTGGAGGAGCCAGATTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTTCATGCTTTCAGAATCAGAGCTGTCACCATTGACCGCGTGATGAGCTACTTAAATGCCTCGTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_017TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTAATCAGCTGGTTTTCCCTCGTCTTTCTGGCATCACCCCTGGTGGCTNO: 71)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGATTGGTACCCTGACGCCCCGGGGGAAATGGTGGTGTTAACCTGCGACACGCCTGAGGAGGACGGCATCACCTGGACGCTGGACCAGAGCAGCGAGGTGCTTGGGTCTGGTAAAACTCTGACTATTCAGGTGAAAGAGTTCGGGGATGCCGGCCAATATACTTGCCACAAGGGTGGCGAGGTGCTTTCTCATTCTCTGCTCCTGCTGCACAAGAAAGAAGATGGCATTTGGTCTACTGATATTCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGATGCGAGGCTAAAAACTACAGCGGAAGATTTACCTGCTGGTGGCTGACCACAATCTCAACCGACCTGACATTTTCAGTGAAGTCCAGCAGAGGGAGCTCCGACCCTCAGGGCGTGACCTGCGGAGCCGCCACTCTGTCCGCAGAAAGAGTGAGAGGTGATAATAAGGAGTACGAGTATTCAGTCGAGTGCCAAGAAGATTCTGCCTGCCCAGCCGCCGAGGAGAGCCTGCCAATCGAGGTGATGGTAGATGCGGTACACAAGCTGAAGTATGAGAACTACACATCCTCCTTCTTCATAAGAGATATTATCAAGCCTGACCCACCTAAAAATCTGCAACTCAAGCCTTTGAAAAATTCACGGCAGGTGGAGGTGAGCTGGGAGTACCCTGATACTTGGAGCACCCCCCATAGCTACTTTTCGCTGACATTCTGCGTCCAGGTGCAGGGCAAGTCAAAGAGAGAGAAGAAGGATCGCGTGTTCACTGATAAAACAAGCGCCACAGTGATCTGCAGAAAAAACGCTAGCATTAGCGTCAGAGCACAGGACCGGTATTACTCCAGCTCCTGGAGCGAATGGGCATCTGTGCCCTGCAGCGGTGGGGGCGGAGGCGGATCCAGAAACCTCCCCGTTGCCACACCTGATCCTGGAATGTTCCCCTGTCTGCACCACAGCCAGAACCTGCTGAGAGCAGTGTCTAACATGCTCCAGAAGGCCAGGCAGACCCTGGAGTTTTACCCCTGCACCAGCGAGGAAATCGATCACGAAGATATCACCAAAGATAAAACCTCCACCGTGGAGGCCTGCCTGCCCCTGGAACTGACCAAAAACGAGAGCTGCCTGAATAGCAGGGAGACCTCCTTCATCACCAACGGCTCATGCCTTGCCAGCCGGAAAACTAGCTTCATGATGGCCCTGTGCCTGTCTTCGATCTATGAGGACCTGAAAATGTACCAGGTCGAATTTAAGACGATGAACGCAAAGCTGCTGATGGACCCCAAGCGGCAGATCTTTCTGGACCAGAACATGCTGGCAGTCATAGATGAGTTGATGCAGGCATTAAACTTCAACAGCGAGACCGTGCCTCAGAAGTCCAGCCTCGAGGAGCCAGATTTTTATAAGACCAAGATCAAACTATGCATCCTGCTGCATGCTTTCAGGATTAGAGCCGTCACCATCGATCGAGTCATGTCTTACCTGAATGCTAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_018TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAACAGTTAGTAATCTCCTGGTTTTCTCTGGTGTTTCTGGCCAGCCCCCTCGTGGCCNO: 72)ATCTGGGAGCTTAAAAAGGACGTTTACGTGGTGGAGTTGGATTGGTATCCCGACGCTCCAGGCGAAATGGTCGTGCTGACCTGCGATACCCCTGAAGAAGACGGTATCACCTGGACGCTGGACCAGTCTTCCGAGGTGCTTGGATCTGGCAAAACACTGACAATACAAGTTAAGGAGTTCGGGGACGCAGGGCAGTACACCTGCCACAAAGGCGGCGAGGTCCTGAGTCACTCCCTGTTACTGCTCCACAAGAAAGAGGACGGCATTTGGTCCACCGACATTCTGAAGGACCAGAAGGAGCCTAAGAATAAAACTTTCCTGAGATGCGAGGCAAAAAACTATAGCGGCCGCTTTACTTGCTGGTGGCTTACAACAATCTCTACCGATTTAACTTTCTCCGTGAAGTCTAGCAGAGGATCCTCTGACCCGCAAGGAGTGACTTGCGGAGCCGCCACCTTGAGCGCCGAAAGAGTCCGTGGCGATAACAAAGAATACGAGTACTCCGTGGAGTGCCAGGAAGATTCCGCCTGCCCAGCTGCCGAGGAGTCCCTGCCCATTGAAGTGATGGTGGATGCCGTCCACAAGCTGAAGTACGAAAACTATACCAGCAGCTTCTTCATCCGGGATATCATTAAGCCCGACCCTCCTAAAAACCTGCAACTTAAGCCCCTAAAGAATAGTCGGCAGGTTGAGGTCAGCTGGGAATATCCTGACACATGGAGCACCCCCCACTCTTATTTCTCCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGTAAACGGGAGAAAAAAGATAGGGTCTTTACCGATAAAACCAGCGCTACGGTTATCTGTCGGAAGAACGCTTCCATCTCCGTCCGCGCTCAGGATCGTTACTACTCGTCCTCATGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGTGGAGGCGGATCCAGAAATCTGCCTGTTGCCACACCAGACCCTGGCATGTTCCCCTGTCTGCATCATAGCCAGAACCTGCTCAGAGCCGTGAGCAACATGCTCCAGAAGGCCAGGCAAACTTTGGAGTTCTACCCGTGTACATCTGAGGAAATCGATCACGAAGATATAACCAAAGATAAAACCTCTACAGTAGAGGCTTGTTTGCCCCTGGAGTTGACCAAAAACGAGAGTTGCCTGAACAGTCGCGAGACGAGCTTCATTACTAACGGCAGCTGTCTCGCCTCCAGAAAAACATCCTTCATGATGGCCCTGTGTCTTTCCAGCATATACGAAGACCTGAAAATGTACCAGGTCGAGTTCAAAACAATGAACGCCAAGCTGCTTATGGACCCCAAGCGGCAGATCTTCCTCGACCAAAACATGCTCGCTGTGATCGATGAGCTGATGCAGGCTCTCAACTTCAATTCCGAAACAGTGCCACAGAAGTCCAGTCTGGAAGAACCCGACTTCTACAAGACCAAGATTAAGCTGTGTATTTTGCTGCATGCGTTTAGAATCAGAGCCGTGACCATTGATCGGGTGATGAGCTACCTGAACGCCTCGTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_019TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTTGTCATCTCCTGGTTTTCTCTTGTCTTCCTGGCCTCGCCGCTGGTGGCCNO: 73)ATCTGGGAGCTGAAGAAAGACGTTTACGTAGTAGAGTTGGATTGGTACCCAGACGCACCTGGAGAAATGGTGGTTCTCACCTGTGACACTCCTGAAGAAGACGGTATCACCTGGACGCTGGACCAAAGCTCAGAAGTTCTTGGCAGTGGAAAAACGCTGACCATACAAGTAAAAGAATTTGGGGATGCTGGCCAGTACACGTGCCACAAAGGAGGAGAAGTTCTCAGCCACAGTTTACTTCTTCTTCACAAGAAAGAAGATGGCATCTGGTCCACAGATATTTTAAAAGACCAGAAGGAGCCCAAGAACAAAACCTTCCTCCGCTGTGAGGCCAAGAACTACAGTGGTCGTTTCACCTGCTGGTGGCTCACCACCATCTCCACTGACCTCACCTTCTCTGTAAAAAGCAGCCGTGGTTCTTCTGACCCCCAAGGAGTCACCTGTGGGGCTGCCACGCTCTCGGCAGAAAGAGTTCGAGGTGACAACAAGGAATATGAATATTCTGTGGAATGTCAAGAAGATTCTGCCTGCCCGGCGGCAGAAGAAAGTCTTCCCATAGAAGTCATGGTGGATGCTGTTCACAAATTAAAATATGAAAACTACACCAGCAGCTTCTTCATTCGTGACATCATCAAACCAGACCCGCCCAAGAACCTTCAGTTAAAACCTTTAAAAAACAGCCGGCAGGTAGAAGTTTCCTGGGAGTACCCAGATACGTGGTCCACGCCGCACTCCTACTTCAGTTTAACCTTCTGTGTACAAGTACAAGGAAAATCAAAAAGAGAGAAGAAAGATCGTGTCTTCACTGACAAAACATCTGCCACGGTCATCTGCAGGAAGAATGCCTCCATCTCGGTTCGAGCCCAGGACCGCTACTACAGCAGCAGCTGGAGTGAGTGGGCATCTGTTCCCTGCAGTGGTGGCGGCGGCGGCGGCAGCCGCAACCTTCCTGTGGCCACGCCGGACCCTGGCATGTTCCCGTGCCTTCACCACTCCCAAAATCTTCTTCGTGCTGTTTCTAACATGCTGCAGAAGGCGCGCCAAACTTTAGAATTCTACCCGTGCACTTCTGAAGAAATAGACCATGAAGATATCACCAAAGATAAAACCAGCACGGTGGAGGCCTGCCTTCCTTTAGAGCTGACCAAGAATGAATCCTGCCTCAACAGCAGAGAGACCAGCTTCATCACCAATGGCAGCTGCCTGGCCTCGCGCAAGACCAGCTTCATGATGGCGCTGTGCCTTTCTTCCATCTATGAAGATTTAAAGATGTACCAAGTAGAATTTAAAACCATGAATGCCAAATTATTAATGGACCCCAAACGGCAGATATTTTTGGATCAAAACATGCTGGCTGTCATTGATGAGCTCATGCAAGCATTAAACTTCAACTCAGAAACTGTTCCCCAGAAGTCATCTTTAGAAGAGCCAGATTTCTACAAAACAAAAATAAAACTCTGCATTCTTCTTCATGCCTTCCGCATCCGTGCTGTCACCATTGACCGTGTCATGTCCTACTTAAATGCTTCTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_020TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCTAGCCCTCTGGTGGCCNO: 74)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGTTGGATTGGTACCCCGACGCTCCCGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGGATCACCTGGACCCTGGATCAGTCAAGCGAGGTGCTGGGAAGCGGCAAGACCCTGACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAATACACTTGCCACAAGGGAGGCGAGGTGCTGTCCCACTCCCTCCTGCTGCTGCACAAAAAGGAAGACGGCATCTGGAGCACCGACATCCTGAAAGACCAGAAGGAGCCTAAGAACAAAACATTCCTCAGATGCGAGGCCAAGAATTACTCCGGGAGATTCACCTGTTGGTGGCTGACCACCATCAGCACAGACCTGACCTTCAGCGTGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGTGACCTGTGGCGCCGCCACCCTGAGCGCCGAAAGAGTGCGCGGCGACAACAAGGAGTACGAGTACTCCGTGGAATGCCAGGAAGATAGCGCCTGCCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCTCTAGCTTCTTCATCAGAGATATCATCAAGCCCGATCCCCCCAAGAACCTGCAGCTGAAACCCCTGAAGAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTATCCCGACACCTGGTCCACCCCCCACAGCTATTTTAGCCTGACCTTCTGCGTGCAAGTGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACCGCGTGTTCACCGACAAAACCAGCGCCACCGTGATCTGCAGAAAGAACGCCAGCATCAGCGTGAGGGCCCAGGATAGATACTACAGTTCCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGCGGCGGCGGGGGAGGCTCGAGAAACCTGCCCGTGGCTACCCCCGATCCCGGAATGTTCCCCTGCCTGCACCACAGCCAGAACCTGCTGAGGGCGGTGTCCAACATGCTTCAGAAGGCCCGGCAGACCCTGGAGTTCTACCCCTGTACCTCTGAGGAGATCGATCATGAAGATATCACAAAAGATAAAACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGCCTGAACTCCCGCGAGACCAGCTTCATCACGAACGGCAGCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAAATGTACCAGGTGGAGTTTAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGGCAAATCTTCCTGGACCAGAACATGCTGGCAGTGATCGACGAGCTCATGCAGGCCCTGAACTTCAATAGCGAGACGGTCCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTTTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTTAGAATCCGTGCCGTGACCATTGACAGAGTGATGAGCTACCTGAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_021TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCTCTGGTTGCCNO: 75)ATCTGGGAGCTGAAGAAAGACGTGTACGTCGTGGAACTGGACTGGTATCCGGACGCCCCGGGCGAGATGGTGGTGCTGACCTGTGACACCCCCGAGGAGGACGGCATCACCTGGACGCTGGACCAATCCTCCGAGGTGCTGGGAAGCGGCAAGACCCTGACCATCCAGGTGAAGGAATTCGGGGACGCCGGGCAGTACACCTGCCACAAGGGGGGCGAAGTGCTGTCCCACTCGCTGCTGCTCCTGCATAAGAAGGAGGATGGAATCTGGTCCACCGACATCCTCAAAGATCAGAAGGAGCCCAAGAACAAGACGTTCCTGCGCTGTGAAGCCAAGAATTATTCGGGGCGATTCACGTGCTGGTGGCTGACAACCATCAGCACCGACCTGACGTTTAGCGTGAAGAGCAGCAGGGGGTCCAGCGACCCCCAGGGCGTGACGTGCGGCGCCGCCACCCTCTCCGCCGAGAGGGTGCGGGGGGACAATAAGGAGTACGAGTACAGCGTGGAATGCCAGGAGGACAGCGCCTGCCCCGCCGCGGAGGAAAGCCTCCCGATAGAGGTGATGGTGGACGCCGTGCACAAGCTCAAGTATGAGAATTACACCAGCAGCTTTTTCATCCGGGACATTATCAAGCCCGACCCCCCGAAGAACCTCCAGCTGAAGCCCCTGAAGAACAGCCGGCAGGTGGAAGTCTCCTGGGAGTATCCCGACACCTGGAGCACCCCGCACAGCTACTTCTCCCTGACCTTCTGTGTGCAGGTGCAGGGCAAGTCCAAGAGGGAAAAGAAGGACAGGGTTTTCACCGACAAGACCAGCGCGACCGTGATCTGCCGGAAGAACGCCAGCATAAGCGTCCGCGCCCAAGATAGGTACTACAGCAGCTCCTGGAGCGAGTGGGCTAGCGTGCCCTGCAGCGGGGGCGGGGGTGGGGGCTCCAGGAACCTGCCAGTGGCGACCCCCGACCCCGGCATGTTCCCCTGCCTCCATCACAGCCAGAACCTGCTGAGGGCCGTCAGCAATATGCTGCAGAAGGCCAGGCAGACCCTGGAATTCTACCCCTGCACGTCGGAGGAGATCGATCACGAGGATATCACAAAAGACAAGACTTCCACCGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAATGAGTCCTGTCTGAACTCCCGGGAAACCAGCTTCATCACCAACGGGTCCTGCCTGGCCAGCAGGAAGACCAGCTTTATGATGGCCCTGTGCCTGTCGAGCATCTACGAGGACCTGAAGATGTACCAGGTCGAGTTCAAGACAATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAAATCTTCCTGGACCAGAATATGCTTGCCGTCATCGACGAGCTCATGCAGGCCCTGAACTTCAACTCCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCGTTCAGGATCCGGGCAGTCACCATCGACCGTGTGATGTCCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_022TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTCCTCGCCTCTCCCCTGGTGGCCNO: 76)ATCTGGGAGCTCAAAAAGGACGTGTACGTGGTGGAGCTCGACTGGTACCCAGACGCCCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAAGAAGACGGCATCACGTGGACCCTCGACCAGTCCAGCGAGGTGCTGGGGAGCGGGAAGACTCTGACCATCCAGGTCAAGGAGTTCGGGGACGCCGGGCAGTACACGTGCCACAAGGGCGGCGAAGTCTTAAGCCACAGCCTGCTCCTGCTGCACAAGAAGGAGGACGGGATCTGGTCCACAGACATACTGAAGGACCAGAAGGAGCCGAAGAATAAAACCTTTCTGAGGTGCGAGGCCAAGAACTATTCCGGCAGGTTCACGTGCTGGTGGCTTACAACAATCAGCACAGACCTGACGTTCAGCGTGAAGTCCAGCCGCGGCAGCAGCGACCCCCAGGGGGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAGCGGGTGCGCGGGGACAACAAGGAGTACGAGTACTCCGTGGAGTGCCAGGAAGACAGCGCCTGTCCCGCCGCCGAAGAGAGCCTGCCTATCGAGGTCATGGTAGATGCAGTGCATAAGCTGAAGTACGAGAACTATACGAGCAGCTTTTTCATACGCGACATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTTAAGCCCCTGAAGAATAGCCGGCAGGTGGAGGTCTCCTGGGAGTACCCCGACACCTGGTCAACGCCCCACAGCTACTTCTCCCTGACCTTTTGTGTCCAAGTCCAGGGAAAGAGCAAGAGGGAGAAGAAAGATCGGGTGTTCACCGACAAGACCTCCGCCACGGTGATCTGCAGGAAGAACGCCAGCATCTCCGTGAGGGCGCAAGACAGGTACTACTCCAGCAGCTGGTCCGAATGGGCCAGCGTGCCCTGCTCCGGCGGCGGGGGCGGCGGCAGCCGAAACCTACCCGTGGCCACGCCGGATCCCGGCATGTTTCCCTGCCTGCACCACAGCCAGAACCTCCTGAGGGCCGTGTCCAACATGCTGCAGAAGGCCAGGCAGACTCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGATCACGAGGACATCACCAAGGATAAGACCAGCACTGTGGAGGCCTGCCTTCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTGAACTCCAGGGAGACCTCATTCATCACCAACGGCTCCTGCCTGGCCAGCAGGAAAACCAGCTTCATGATGGCCTTGTGTCTCAGCTCCATCTACGAGGACCTGAAGATGTATCAGGTCGAGTTCAAGACAATGAACGCCAAGCTGCTGATGGACCCCAAAAGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTCATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACGGTGCCCCAGAAAAGCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCAGGATCAGGGCAGTGACCATCGACCGGGTGATGTCATACCTTAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_023TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTGATCTCCTGGTTCAGCCTGGTGTTTCTGGCCTCGCCCCTGGTCGCCNO: 77)ATCTGGGAGCTGAAGAAAGACGTGTACGTCGTCGAACTGGACTGGTACCCCGACGCCCCCGGGGAGATGGTGGTGCTGACCTGCGACACGCCGGAGGAGGACGGCATCACCTGGACCCTGGATCAAAGCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATCCAAGTGAAGGAATTCGGCGATGCCGGCCAGTACACCTGTCACAAAGGGGGCGAGGTGCTCAGCCACAGCCTGCTGCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACCGATATCCTGAAGGACCAGAAAGAGCCCAAGAACAAGACGTTCCTGAGGTGCGAGGCCAAGAACTACAGCGGTAGGTTCACGTGTTGGTGGCTGACCACCATCAGCACCGACCTGACGTTCAGCGTGAAGAGCTCCAGGGGCAGCTCCGACCCACAGGGGGTGACGTGCGGGGCCGCAACCCTCAGCGCCGAAAGGGTGCGGGGGGACAACAAGGAGTACGAATACTCCGTGGAGTGCCAGGAAGATTCGGCCTGCCCCGCCGCGGAGGAGAGCCTCCCCATCGAGGTAATGGTGGACGCCGTGCATAAGCTGAAGTACGAGAACTACACCAGCTCGTTCTTCATCCGAGACATCATCAAACCCGACCCGCCCAAAAATCTGCAGCTCAAGCCCCTGAAGAACTCCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCGCACAGCTACTTCTCCCTGACATTCTGCGTGCAGGTGCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCCGAAAGAACGCCAGCATCTCGGTGCGCGCCCAGGATAGGTACTATTCCAGCTCCTGGAGCGAGTGGGCCTCGGTACCCTGCAGCGGCGGCGGGGGCGGCGGCAGTAGGAATCTGCCCGTGGCTACCCCGGACCCGGGCATGTTCCCCTGCCTCCACCACAGCCAGAACCTGCTGAGGGCCGTGAGCAACATGCTGCAGAAGGCCAGACAGACGCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGACCACGAGGACATCACCAAGGATAAAACTTCCACCGTCGAGGCCTGCCTGCCCTTGGAGCTGACCAAGAATGAATCCTGTCTGAACAGCAGGGAGACCTCGTTTATCACCAATGGCAGCTGCCTCGCCTCCAGGAAGACCAGCTTCATGATGGCCCTCTGTCTGAGCTCCATCTATGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGCTGCTGATGGACCCCAAGAGGCAGATCTTCCTGGATCAGAATATGCTGGCGGTGATCGACGAGCTCATGCAGGCCCTCAATTTCAATAGCGAGACAGTGCCCCAGAAGTCCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGTATCCTGCTGCACGCCTTCCGGATCCGGGCCGTCACCATCGACCGGGTCATGAGCTACCTCAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_024TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATCTCCTGGTTCTCCCTGGTGTTCCTGGCCTCGCCCCTGGTGGCCNO: 78)ATCTGGGAGCTGAAGAAGGACGTGTACGTCGTGGAGCTCGACTGGTACCCCGACGCCCCTGGCGAGATGGTGGTGCTGACCTGCGACACCCCAGAGGAGGATGGCATCACCTGGACCCTGGATCAGTCCTCCGAGGTGCTGGGCTCCGGCAAGACGCTGACCATCCAAGTGAAGGAGTTCGGTGACGCCGGACAGTATACCTGCCATAAGGGCGGCGAGGTCCTGTCCCACAGCCTCCTCCTCCTGCATAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGGTGCGAGGCCAAGAACTACAGCGGCCGATTCACCTGCTGGTGGCTCACCACCATATCCACCGACCTGACTTTCTCCGTCAAGTCCTCCCGGGGGTCCAGCGACCCCCAGGGAGTGACCTGCGGCGCCGCCACCCTCAGCGCCGAGCGGGTGCGGGGGGACAACAAGGAGTACGAATACTCCGTCGAGTGCCAGGAGGACTCCGCCTGCCCGGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTCGACGCGGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGTTTCTTCATCAGGGATATCATCAAGCCAGATCCCCCGAAGAATCTGCAACTGAAGCCGCTGAAAAACTCACGACAGGTGGAGGTGAGCTGGGAGTACCCCGACACGTGGAGCACCCCACATTCCTACTTCAGCCTGACCTTCTGCGTGCAGGTCCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACGGATAAGACCAGTGCCACCGTGATCTGCAGGAAGAACGCCTCTATTAGCGTGAGGGCCCAGGATCGGTATTACTCCTCGAGCTGGAGCGAATGGGCCTCCGTGCCCTGCAGTGGGGGGGGTGGAGGCGGGAGCAGGAACCTGCCCGTAGCAACCCCCGACCCCGGGATGTTCCCCTGTCTGCACCACTCGCAGAACCTGCTGCGCGCGGTGAGCAACATGCTCCAAAAAGCCCGTCAGACCTTAGAGTTCTACCCCTGCACCAGCGAAGAAATCGACCACGAAGACATCACCAAGGACAAAACCAGCACCGTGGAGGCGTGCCTGCCGCTGGAGCTGACCAAGAACGAGAGCTGCCTCAACTCCAGGGAGACCAGCTTTATCACCAACGGCTCGTGCCTAGCCAGCCGGAAAACCAGCTTCATGATGGCCCTGTGCCTGAGCTCCATTTACGAGGACCTGAAGATGTATCAGGTGGAGTTCAAGACCATGAATGCCAAACTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCGGTGATCGATGAGCTGATGCAGGCCCTGAACTTTAATAGCGAGACCGTGCCCCAGAAAAGCAGCCTGGAGGAGCCGGACTTCTACAAGACCAAAATCAAGCTGTGCATCCTGCTCCACGCCTTCCGCATCCGGGCCGTGACCATCGACAGGGTGATGAGCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_025TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTGATTTCCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTCGTGGCGNO: 79)ATCTGGGAGCTAAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCACCCGGCGAGATGGTCGTTCTGACCTGCGATACGCCAGAGGAGGACGGCATCACCTGGACCCTCGATCAGAGCAGCGAGGTCCTGGGGAGCGGAAAGACCCTGACCATCCAGGTCAAGGAGTTCGGCGACGCCGGCCAGTACACCTGCCACAAAGGTGGCGAGGTCCTGAGCCACTCGCTGCTGCTCCTGCATAAGAAGGAGGACGGAATCTGGAGCACAGACATCCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAGAACTACAGCGGGCGCTTCACGTGCTGGTGGCTGACCACCATCAGCACGGACCTCACCTTCTCCGTGAAGAGCAGCCGGGGATCCAGCGATCCCCAAGGCGTCACCTGCGGCGCGGCCACCCTGAGCGCGGAGAGGGTCAGGGGCGATAATAAGGAGTATGAGTACAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCGGCCGCCGAGGAGTCCCTGCCAATCGAAGTGATGGTCGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCCGGGATATCATCAAGCCCGATCCCCCGAAGAACCTGCAGCTGAAGCCCCTCAAGAACAGCCGGCAGGTGGAGGTGAGTTGGGAGTACCCCGACACCTGGTCAACGCCCCACAGCTACTTCTCCCTGACCTTCTGTGTGCAGGTGCAGGGAAAGAGCAAGAGGGAGAAGAAAGACCGGGTCTTCACCGACAAGACCAGCGCCACGGTGATCTGCAGGAAGAACGCAAGCATCTCCGTGAGGGCCCAGGACAGGTACTACAGCTCCAGCTGGTCCGAATGGGCCAGCGTGCCCTGTAGCGGCGGCGGGGGCGGTGGCAGCCGCAACCTCCCAGTGGCCACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAATCTGCTGAGGGCCGTGAGTAACATGCTGCAGAAGGCAAGGCAAACCCTCGAATTCTATCCCTGCACCTCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCAGCACCGTCGAGGCCTGTCTCCCCCTGGAGCTGACCAAGAATGAGAGCTGCCTGAACAGCCGGGAGACCAGCTTCATCACCAACGGGAGCTGCCTGGCCTCCAGGAAGACCTCGTTCATGATGGCGCTGTGCCTCTCAAGCATATACGAGGATCTGAAGATGTACCAGGTGGAGTTTAAGACGATGAACGCCAAGCTGCTGATGGACCCGAAGAGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATAGACGAGCTCATGCAGGCCCTGAACTTCAACTCCGAGACCGTGCCGCAGAAGTCATCCCTCGAGGAGCCCGACTTCTATAAGACCAAGATCAAGCTGTGCATCCTGCTCCACGCCTTCCGGATAAGGGCCGTGACGATCGACAGGGTGATGAGCTACCTTAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_026TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCCCTGGTGTTTCTCGCCAGCCCCCTGGTGGCCNO: 80)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCTGACGCCCCGGGGGAGATGGTCGTGCTGACCTGCGACACCCCCGAAGAGGACGGTATCACCTGGACCCTGGACCAGTCCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACTATTCAAGTCAAGGAGTTCGGAGACGCCGGCCAGTACACCTGCCACAAGGGTGGAGAGGTGTTATCACACAGCCTGCTGCTGCTGCACAAGAAGGAAGACGGGATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAAAACAAGACCTTCCTGCGGTGCGAGGCCAAGAACTATTCGGGCCGCTTTACGTGCTGGTGGCTGACCACCATCAGCACTGATCTCACCTTCAGCGTGAAGTCCTCCCGGGGGTCGTCCGACCCCCAGGGGGTGACCTGCGGGGCCGCCACCCTGTCCGCCGAGAGAGTGAGGGGCGATAATAAGGAGTACGAGTACAGCGTTGAGTGCCAGGAAGATAGCGCCTGTCCCGCCGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTATGAGAACTACACCTCAAGCTTCTTCATCAGGGACATCATCAAACCCGATCCGCCCAAGAATCTGCAGCTGAAGCCCCTGAAAAATAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCCCATAGCTATTTCTCCCTGACGTTCTGCGTGCAGGTGCAAGGGAAGAGCAAGCGGGAGAAGAAGGACCGGGTGTTCACCGACAAGACCTCCGCCACCGTGATCTGTAGGAAGAACGCGTCGATCTCGGTCAGGGCCCAGGACAGGTATTACAGCAGCAGCTGGAGCGAGTGGGCGAGCGTGCCCTGCTCGGGCGGCGGCGGCGGCGGGAGCAGAAATCTGCCCGTGGCCACCCCAGACCCCGGAATGTTCCCCTGCCTGCACCATTCGCAGAACCTCCTGAGGGCCGTGAGCAACATGCTGCAGAAGGCCCGCCAGACGCTGGAGTTCTACCCCTGCACGAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAAACCAGCACCGTGGAGGCCTGCCTGCCCCTGGAGCTGACCAAAAACGAATCCTGCCTCAACAGCCGGGAGACCAGCTTCATCACCAACGGCAGCTGCCTGGCCAGCCGAAAGACCTCCTTCATGATGGCCCTCTGCCTGAGCAGCATCTATGAGGATCTGAAGATGTATCAGGTGGAGTTCAAGACCATGAATGCCAAGCTGCTGATGGACCCCAAGAGGCAGATATTCCTGGACCAGAATATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAGACCGTCCCCCAGAAGTCCAGCCTGGAGGAGCCGGACTTTTACAAAACGAAGATCAAGCTGTGCATACTGCTGCACGCCTTCAGGATCCGGGCCGTGACAATCGACAGGGTGATGTCCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_027TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAGCAGCTGGTGATCAGCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCNO: 81)ATCTGGGAGCTCAAGAAGGACGTCTACGTCGTGGAGCTGGATTGGTACCCCGACGCTCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACGCTGGACCAGAGCTCAGAGGTGCTGGGAAGCGGAAAGACACTGACCATCCAGGTGAAGGAGTTCGGGGATGCCGGGCAGTATACCTGCCACAAGGGCGGCGAAGTGCTGAGCCATTCCCTGCTGCTGCTGCACAAGAAGGAGGACGGCATATGGTCCACCGACATCCTGAAGGATCAGAAGGAGCCGAAGAATAAAACCTTCCTGAGGTGCGAGGCCAAGAATTACAGCGGCCGATTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGTGTGAAGTCCTCACGGGGCAGCTCAGATCCCCAGGGCGTGACCTGCGGGGCCGCGACACTCAGCGCCGAGCGGGTGAGGGGTGATAACAAGGAGTACGAGTATTCTGTGGAGTGCCAGGAAGACTCCGCCTGTCCCGCCGCCGAGGAGTCCCTGCCCATCGAGGTGATGGTGGACGCCGTGCATAAACTGAAGTACGAGAACTACACCTCCAGCTTCTTCATCCGGGATATAATCAAGCCCGACCCTCCGAAAAACCTGCAGCTGAAGCCCCTTAAAAACAGCCGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGAGCACCCCCCATAGCTATTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGGAAGTCCAAGCGCGAGAAAAAGGACCGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCCGGAAGAACGCCAGTATAAGCGTAAGGGCCCAGGATAGGTACTACAGCTCCAGCTGGTCGGAGTGGGCCTCCGTGCCCTGTTCCGGCGGCGGGGGGGGTGGCAGCAGGAACCTCCCCGTGGCCACGCCGGACCCCGGCATGTTCCCGTGCCTGCACCACTCCCAAAACCTCCTGCGGGCCGTCAGCAACATGCTGCAAAAGGCGCGGCAGACCCTGGAGTTTTACCCCTGTACCTCCGAAGAGATCGACCACGAGGATATCACCAAGGATAAGACCTCCACCGTGGAGGCCTGTCTCCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTTAACAGCAGAGAGACCTCGTTCATAACGAACGGCTCCTGCCTCGCTTCCAGGAAGACGTCGTTCATGATGGCGCTGTGCCTGTCCAGCATCTACGAGGACCTGAAGATGTATCAGGTCGAGTTCAAAACCATGAACGCCAAGCTGCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTCAACAGCGAAACCGTGCCCCAGAAGTCAAGCCTGGAGGAGCCGGACTTCTATAAGACCAAGATCAAGCTGTGTATCCTGCTACACGCTTTTCGTATCCGGGCCGTGACCATCGACAGGGTTATGTCGTACTTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_028TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAACAGCTCGTGATCAGCTGGTTCAGCCTGGTGTTCCTGGCCAGCCCGCTGGTGGCCNO: 82)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCCGACGCCCCCGGCGAGATGGTGGTCCTGACCTGCGACACGCCGGAAGAGGACGGCATCACCTGGACCCTGGATCAGTCCAGCGAGGTGCTGGGCTCCGGCAAGACCCTGACCATTCAGGTGAAGGAGTTCGGCGACGCCGGTCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGAGCCACAGCCTACTGCTCCTGCACAAAAAGGAGGATGGAATCTGGTCCACCGACATCCTCAAGGACCAGAAGGAGCCGAAGAACAAGACGTTCCTCCGGTGCGAGGCCAAGAACTACAGCGGCAGGTTTACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACATTTTCCGTGAAGAGCAGCCGCGGCAGCAGCGATCCCCAGGGCGTGACCTGCGGGGCGGCCACCCTGTCCGCCGAGCGTGTGAGGGGCGACAACAAGGAGTACGAGTACAGCGTGGAATGCCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGAGCCTGCCAATCGAGGTCATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACGAGCAGCTTCTTCATCAGGGACATCATCAAACCGGACCCGCCCAAGAACCTGCAGCTGAAACCCTTGAAAAACAGCAGGCAGGTGGAAGTGTCTTGGGAGTACCCCGACACCTGGTCCACCCCCCACAGCTACTTTAGCCTGACCTTCTGTGTGCAGGTCCAGGGCAAGTCCAAGAGGGAGAAGAAGGACAGGGTGTTCACCGACAAAACCAGCGCCACCGTGATCTGCAGGAAGAACGCCTCCATCAGCGTGCGGGCCCAGGACAGGTATTACAGCTCGTCGTGGAGCGAGTGGGCCAGCGTGCCCTGCTCCGGGGGAGGCGGCGGCGGAAGCCGGAATCTGCCCGTGGCCACCCCCGATCCCGGCATGTTCCCGTGTCTGCACCACAGCCAGAACCTGCTGCGGGCCGTGAGCAACATGCTGCAGAAGGCCCGCCAAACCCTGGAGTTCTACCCCTGTACAAGCGAGGAGATCGACCATGAGGACATTACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTGCCCCTCGAGCTCACAAAGAACGAATCCTGCCTGAATAGCCGCGAGACCAGCTTTATCACGAACGGGTCCTGCCTCGCCAGCCGGAAGACAAGCTTCATGATGGCCCTGTGCCTGAGCAGCATCTACGAGGACCTGAAAATGTACCAAGTGGAGTTCAAAACGATGAACGCCAAGCTGCTGATGGACCCCAAGCGCCAGATCTTCCTGGACCAGAACATGCTGGCCGTCATCGACGAGCTCATGCAGGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTACAAGACGAAGATCAAGCTCTGCATCCTGCTGCACGCTTTCCGCATCCGCGCGGTGACCATCGACCGGGTGATGAGCTACCTCAACGCCAGTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_029TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAACAGCTGGTGATCAGCTGGTTCAGCCTGGTGTTTCTGGCCTCCCCTCTGGTGGCCNO: 83)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTACCCTGACGCCCCCGGCGAAATGGTGGTGCTGACGTGCGACACCCCCGAGGAGGATGGCATCACCTGGACCCTGGACCAAAGCAGCGAGGTCCTCGGAAGCGGCAAGACCCTCACTATCCAAGTGAAGGAGTTCGGGGATGCGGGCCAGTACACCTGCCACAAGGGCGGCGAGGTGCTGTCTCATAGCCTGCTGCTCCTGCATAAGAAGGAAGACGGCATCTGGAGCACCGACATACTGAAGGATCAGAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAGAACTACTCCGGGCGCTTCACCTGTTGGTGGCTGACCACCATCTCCACCGACCTGACCTTCAGCGTGAAGAGCAGCAGGGGGAGCAGCGACCCCCAGGGGGTGACCTGCGGAGCCGCGACCTTGTCGGCCGAGCGGGTGAGGGGCGACAATAAGGAGTACGAGTACTCGGTCGAATGCCAGGAGGACTCCGCCTGCCCCGCCGCCGAGGAGTCCCTCCCCATCGAAGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATACGGGATATCATCAAGCCCGACCCCCCGAAGAACCTGCAGCTGAAACCCTTGAAGAACTCCAGGCAGGTGGAGGTGAGCTGGGAGTACCCCGACACCTGGTCCACCCCGCACTCATACTTCAGCCTGACCTTCTGTGTACAGGTCCAGGGCAAGAGCAAGAGGGAAAAGAAGGATAGGGTGTTCACCGACAAGACCTCCGCCACGGTGATCTGTCGGAAAAACGCCAGCATCTCCGTGCGGGCCCAGGACAGGTACTATTCCAGCAGCTGGAGCGAGTGGGCCTCCGTCCCCTGCTCCGGCGGCGGTGGCGGGGGCAGCAGGAACCTCCCCGTGGCCACCCCCGATCCCGGGATGTTCCCATGCCTGCACCACAGCCAAAACCTGCTGAGGGCCGTCTCCAATATGCTGCAGAAGGCGAGGCAGACCCTGGAGTTCTACCCCTGTACCTCCGAGGAGATCGACCACGAGGATATCACCAAGGACAAGACCTCCACGGTCGAGGCGTGCCTGCCCCTGGAGCTCACGAAGAACGAGAGCTGCCTTAACTCCAGGGAAACCTCGTTTATCACGAACGGCAGCTGCCTGGCGTCACGGAAGACCTCCTTTATGATGGCCCTATGTCTGTCCTCGATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGATCCCAAGAGGCAGATTTTCCTGGACCAGAACATGCTGGCCGTGATTGACGAGCTGATGCAGGCGCTGAACTTCAACAGCGAGACAGTGCCGCAGAAGAGCTCCCTGGAGGAGCCGGACTTTTACAAGACCAAGATAAAGCTGTGCATCCTGCTCCACGCCTTCAGAATACGGGCCGTCACCATCGATAGGGTGATGTCTTACCTGAACGCCTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_030TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTGGTGATTAGCTGGTTTAGCCTGGTGTTCCTGGCAAGCCCCCTGGTGGCCNO: 84)ATCTGGGAACTGAAAAAGGACGTGTACGTGGTCGAGCTGGATTGGTACCCCGACGCCCCCGGCGAAATGGTGGTGCTGACGTGTGATACCCCCGAGGAGGACGGGATCACCTGGACCCTGGATCAGAGCAGCGAGGTGCTGGGGAGCGGGAAGACCCTGACGATCCAGGTCAAGGAGTTCGGCGACGCTGGGCAGTACACCTGTCACAAGGGCGGGGAGGTGCTGTCCCACTCCCTGCTGCTCCTGCATAAGAAAGAGGACGGCATCTGGTCCACCGACATCCTCAAGGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGCGGTGTGAGGCGAAGAACTACAGCGGCCGTTTCACCTGCTGGTGGCTGACGACAATCAGCACCGACTTGACGTTCTCCGTGAAGTCCTCCAGAGGCAGCTCCGACCCCCAAGGGGTGACGTGCGGCGCGGCCACCCTGAGCGCCGAGCGGGTGCGGGGGGACAACAAGGAGTACGAGTACTCCGTGGAGTGCCAGGAGGACAGCGCCTGTCCCGCAGCCGAGGAGTCCCTGCCCATCGAAGTCATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGCAGCTTCTTCATCCGCGATATCATCAAGCCCGATCCCCCCAAAAACCTGCAACTGAAGCCGCTGAAGAATAGCAGGCAGGTGGAGGTGTCCTGGGAGTACCCGGACACCTGGAGCACGCCCCACAGCTATTTCAGCCTGACCTTTTGCGTGCAGGTCCAGGGGAAGAGCAAGCGGGAGAAGAAGGACCGCGTGTTTACGGACAAAACCAGCGCCACCGTGATCTGCAGGAAGAACGCCAGCATCAGCGTGAGGGCCCAGGACAGGTACTACAGCAGCTCCTGGAGCGAGTGGGCCTCCGTGCCCTGTTCCGGAGGCGGCGGGGGCGGTTCCCGGAACCTCCCGGTGGCCACCCCCGACCCGGGCATGTTCCCGTGCCTGCACCACTCACAGAATCTGCTGAGGGCCGTGAGCAATATGCTGCAGAAGGCAAGGCAGACCCTGGAGTTTTATCCCTGCACCAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAGACCAGCACAGTGGAGGCCTGCCTGCCCCTGGAACTGACCAAGAACGAGTCCTGTCTGAACTCCCGGGAAACCAGCTTCATAACCAACGGCTCCTGTCTCGCCAGCAGGAAGACCAGCTTCATGATGGCCCTGTGCCTCAGCTCCATCTACGAGGACCTCAAGATGTACCAGGTTGAGTTCAAGACCATGAACGCCAAGCTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAATATGCTGGCCGTGATCGATGAGTTAATGCAGGCGCTGAACTTCAACAGCGAGACGGTGCCCCAAAAGTCCTCGCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTCCTGCACGCCTTCCGAATCCGGGCCGTAACCATCGACAGGGTGATGAGCTATCTCAACGCCTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_031TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCGCTTGTGTTCCTGGCCTCCCCCCTCGTCGCCNO: 85)ATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCGGGGGAGATGGTGGTGCTGACCTGCGACACCCCGGAAGAGGACGGCATCACCTGGACGCTCGACCAGTCGTCCGAAGTGCTGGGGTCGGGCAAGACCCTCACCATCCAGGTGAAGGAGTTCGGAGACGCCGGCCAGTACACCTGTCATAAGGGGGGGGAGGTGCTGAGCCACAGCCTCCTGCTCCTGCACAAAAAGGAGGACGGCATCTGGAGCACCGATATCCTCAAGGACCAGAAGGAGCCCAAGAACAAGACGTTCCTGAGGTGTGAGGCCAAGAACTACAGCGGGCGGTTCACGTGTTGGTGGCTCACCACCATCTCCACCGACCTCACCTTCTCCGTGAAGTCAAGCAGGGGCAGCTCCGACCCCCAAGGCGTCACCTGCGGCGCCGCCACCCTGAGCGCCGAGAGGGTCAGGGGGGATAACAAGGAATACGAGTACAGTGTGGAGTGCCAAGAGGATAGCGCCTGTCCCGCCGCCGAAGAGAGCCTGCCCATCGAAGTGATGGTGGACGCCGTGCACAAGCTGAAGTACGAGAACTACACCTCCAGCTTCTTCATCAGGGATATCATCAAGCCCGATCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTATCCCGACACGTGGAGCACCCCGCACAGCTACTTCTCGCTGACCTTCTGCGTGCAGGTGCAAGGGAAGTCCAAGAGGGAGAAGAAGGATAGGGTGTTCACCGACAAAACGAGCGCCACCGTGATCTGCCGGAAGAATGCCAGCATCTCTGTGAGGGCCCAGGACAGGTACTATTCCAGCTCCTGGTCGGAGTGGGCCAGCGTGCCCTGTAGCGGCGGGGGCGGGGGCGGCAGCAGGAACCTCCCGGTTGCCACCCCCGACCCCGGCATGTTTCCGTGCCTGCACCACTCGCAAAACCTGCTGCGCGCGGTCTCCAACATGCTGCAAAAAGCGCGCCAGACGCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGATCATGAAGATATCACCAAAGACAAGACCTCGACCGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAGAACGAAAGCTGCCTGAACAGCAGGGAGACAAGCTTCATCACCAACGGCAGCTGCCTGGCCTCCCGGAAGACCAGCTTCATGATGGCCCTGTGCCTGTCCAGCATCTACGAGGATCTGAAGATGTACCAAGTGGAGTTTAAGACCATGAACGCCAAGCTGTTAATGGACCCCAAAAGGCAGATCTTCCTGGATCAGAACATGCTGGCCGTCATCGACGAGCTGATGCAAGCCCTGAACTTCAACAGCGAGACGGTGCCCCAGAAGAGCAGCCTCGAGGAGCCCGACTTCTATAAGACCAAGATAAAGCTGTGCATTCTGCTGCACGCCTTCAGAATCAGGGCCGTGACCATCGATAGGGTGATGAGCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_032TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGTCACCAGCAGCTGGTGATTTCCTGGTTCAGTCTGGTGTTTCTTGCCAGCCCCCTGGTGGCCNO: 86)ATCTGGGAGCTGAAGAAAGACGTATACGTCGTGGAGCTGGACTGGTATCCCGACGCTCCCGGCGAGATGGTGGTCCTCACCTGCGACACCCCAGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCTCCGAGGTCCTGGGCAGCGGTAAGACCCTCACCATCCAGGTGAAGGAGTTTGGTGATGCCGGGCAGTATACCTGCCACAAGGGCGGCGAGGTGCTGTCCCACAGCCTCCTGTTACTGCATAAGAAGGAGGATGGCATCTGGAGCACCGACATCCTCAAGGACCAGAAAGAGCCCAAGAACAAGACCTTTCTGCGGTGCGAGGCGAAAAATTACTCCGGCCGGTTCACCTGCTGGTGGCTGACCACCATCAGCACGGACCTGACGTTCTCCGTGAAGTCGAGCAGGGGGAGCTCCGATCCCCAGGGCGTGACCTGCGGCGCGGCCACCCTGAGCGCCGAGCGCGTCCGCGGGGACAATAAGGAATACGAATATAGCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCGGCCGAGGAGAGCCTCCCGATCGAGGTGATGGTGGATGCCGTCCACAAGCTCAAATACGAAAACTACACCAGCAGCTTCTTCATTAGGGACATCATCAAGCCCGACCCCCCCAAAAACCTGCAGCTGAAGCCCCTGAAGAACAGCCGCCAGGTCGAGGTGTCATGGGAGTACCCAGACACCTGGAGCACCCCCCACTCCTACTTCAGCCTGACCTTCTGCGTCCAGGTGCAGGGAAAGTCCAAACGGGAGAAGAAGGATAGGGTCTTTACCGATAAGACGTCGGCCACCGTCATCTGCAGGAAGAACGCCAGCATAAGCGTGCGGGCGCAGGATCGGTACTACAGCTCGAGCTGGTCCGAATGGGCCTCCGTGCCCTGTAGCGGAGGGGGTGGCGGGGGCAGCAGGAACCTGCCCGTGGCCACCCCGGACCCGGGCATGTTTCCCTGCCTGCATCACAGTCAGAACCTGCTGAGGGCCGTGAGCAACATGCTCCAGAAGGCCCGCCAGACCCTGGAGTTTTACCCCTGCACCAGCGAAGAGATCGATCACGAAGACATCACCAAAGACAAGACCTCCACCGTGGAGGCCTGTCTGCCCCTGGAGCTGACCAAGAACGAGAGCTGTCTGAACAGCAGGGAGACCTCCTTCATCACCAACGGCTCCTGCCTGGCATCCCGGAAGACCAGCTTCATGATGGCCCTGTGTCTGAGCTCTATCTACGAGGACCTGAAGATGTACCAGGTCGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGACCCCAAGCGACAGATATTCCTGGACCAGAACATGCTCGCCGTGATCGATGAACTGATGCAAGCCCTGAACTTCAATAGCGAGACCGTGCCCCAGAAAAGCAGCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAACTGTGCATACTGCTGCACGCGTTCAGGATCCGGGCCGTCACCATCGACCGGGTGATGTCCTATCTGAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_033TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTCGTGATTAGCTGGTTTTCGCTGGTGTTCCTGGCCAGCCCTCTCGTGGCCNO: 87)ATCTGGGAGCTGAAAAAAGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCCCCCGGCGAGATGGTGGTGCTGACGTGCGACACCCCGGAAGAGGACGGCATCACCTGGACCCTGGACCAGTCATCCGAGGTCCTGGGCAGCGGCAAGACGCTCACCATCCAGGTGAAGGAGTTCGGCGACGCCGGCCAGTACACATGCCATAAGGGCGGGGAGGTGCTGAGCCACAGCCTGCTCCTCCTGCACAAGAAGGAGGATGGCATCTGGTCTACAGACATCCTGAAGGACCAGAAAGAGCCCAAGAACAAGACCTTCCTCCGGTGCGAGGCCAAGAACTACTCCGGGCGGTTTACTTGTTGGTGGCTGACCACCATCAGCACCGACCTCACCTTCAGCGTGAAGAGCTCCCGAGGGAGCTCCGACCCCCAGGGGGTCACCTGCGGCGCCGCCACCCTGAGCGCCGAGCGGGTGAGGGGCGACAACAAGGAGTATGAATACAGCGTGGAATGCCAAGAGGACAGCGCCTGTCCCGCGGCCGAGGAAAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAACTCAAGTACGAGAACTACACCAGCAGTTTCTTCATTCGCGACATCATCAAGCCGGACCCCCCCAAAAACCTGCAGCTCAAACCCCTGAAGAACAGCAGGCAGGTGGAGGTCAGCTGGGAGTACCCGGACACCTGGAGCACCCCCCATAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGCAAGAGCAAACGCGAGAAGAAGGACCGGGTGTTTACCGACAAGACCAGCGCCACGGTGATCTGCCGAAAGAATGCAAGCATCTCCGTGAGGGCGCAGGACCGCTACTACTCTAGCAGCTGGAGCGAGTGGGCCAGCGTGCCCTGCAGCGGTGGCGGCGGAGGCGGCAGCCGTAACCTCCCCGTGGCCACCCCCGACCCCGGCATGTTCCCGTGTCTGCACCACTCCCAGAACCTGCTGAGGGCCGTCAGCAATATGCTGCAGAAGGCCCGGCAGACGCTGGAGTTCTACCCCTGCACCTCCGAGGAGATCGACCATGAGGACATTACCAAGGACAAGACGAGCACTGTGGAGGCCTGCCTGCCCCTGGAGCTCACCAAAAACGAGAGCTGCCTGAATAGCAGGGAGACGTCCTTCATCACCAACGGCAGCTGTCTGGCCAGCAGGAAGACCAGCTTCATGATGGCCCTGTGCCTCTCCTCCATATATGAGGATCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCCAAGCTGCTGATGGATCCCAAGAGGCAGATCTTCCTGGACCAGAATATGCTGGCCGTGATTGACGAGCTGATGCAGGCCCTGAACTTTAATAGCGAGACCGTCCCCCAGAAGAGCAGCCTGGAGGAGCCCGACTTCTATAAGACCAAGATCAAGCTGTGCATACTGCTGCACGCGTTTAGGATAAGGGCCGTCACCATCGACAGGGTGATGAGCTACCTGAATGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_034TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAACAGCTGGTGATCTCCTGGTTCAGCCTGGTGTTCCTCGCCAGCCCCCTGGTGGCCNO: 88)ATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCCGGCGAGATGGTCGTGCTGACCTGCGACACCCCGGAGGAGGACGGCATCACCTGGACCCTGGATCAGTCCTCCGAGGTGCTGGGCAGCGGGAAGACCCTGACCATCCAGGTGAAAGAGTTCGGAGATGCCGGCCAGTATACCTGTCACAAGGGGGGTGAGGTGCTGAGCCATAGCCTCTTGCTTCTGCACAAGAAGGAGGACGGCATCTGGTCCACCGACATCCTCAAGGACCAAAAGGAGCCGAAGAATAAAACGTTCCTGAGGTGCGAAGCCAAGAACTATTCCGGACGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTCACCTTCTCCGTAAAGTCAAGCAGGGGCAGCTCCGACCCCCAGGGCGTGACCTGCGGAGCCGCCACCCTGAGCGCAGAGAGGGTGAGGGGCGACAACAAGGAGTACGAATACTCCGTCGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAAAGTCTGCCCATCGAGGTGATGGTGGACGCCGTGCACAAGCTCAAATACGAGAACTACACCAGCAGCTTCTTCATCCGGGATATCATCAAGCCCGACCCTCCAAAGAATCTGCAGCTGAAACCCCTTAAGAACAGCAGGCAGGTGGAGGTCAGCTGGGAGTACCCCGACACCTGGAGCACGCCCCACTCCTACTTTAGCCTGACCTTTTGCGTGCAGGTGCAGGGGAAAAGCAAGCGGGAGAAGAAGGACAGGGTGTTCACCGATAAGACCTCCGCTACCGTGATCTGCAGGAAGAACGCCTCAATCAGCGTGAGGGCCCAGGATCGGTACTACTCCAGCTCCTGGAGCGAGTGGGCCAGCGTGCCCTGCTCTGGCGGTGGCGGCGGGGGCAGCCGGAACCTGCCGGTGGCCACTCCCGACCCGGGCATGTTCCCGTGCCTCCACCATTCCCAGAACCTGCTGCGGGCCGTGTCCAATATGCTCCAGAAGGCAAGGCAGACCCTGGAGTTCTACCCCTGCACCAGCGAGGAGATCGATCACGAGGACATCACCAAAGACAAAACCAGCACGGTCGAGGCCTGCCTGCCCCTGGAACTCACCAAGAACGAAAGCTGTCTCAACAGCCGCGAGACCAGCTTCATAACCAACGGTTCCTGTCTGGCCTCCCGCAAGACCAGCTTTATGATGGCCCTCTGTCTGAGCTCCATCTATGAAGACCTGAAAATGTACCAGGTGGAGTTCAAAACCATGAACGCCAAGCTTCTGATGGACCCCAAGAGGCAGATCTTCCTGGATCAGAACATGCTGGCCGTGATCGACGAGCTGATGCAGGCCCTGAACTTTAACTCCGAGACCGTGCCCCAGAAAAGCAGCCTGGAAGAGCCCGATTTCTACAAAACGAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCCGGATCCGTGCGGTGACCATCGATAGGGTGATGAGCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_035TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAACAGCTGGTAATCAGCTGGTTCAGCCTGGTTTTCCTCGCGTCGCCCCTGGTGGCCNO: 89)ATCTGGGAGTTAAAGAAGGACGTGTACGTGGTGGAGCTGGATTGGTACCCCGACGCCCCGGGCGAGATGGTCGTGCTCACCTGCGATACCCCCGAGGAGGACGGGATCACCTGGACCCTGGACCAATCCAGCGAGGTGCTGGGCAGCGGCAAGACCCTGACCATACAGGTGAAGGAATTTGGGGACGCCGGGCAGTACACCTGCCACAAGGGCGGGGAAGTGCTGTCCCACTCCCTCCTGCTGCTGCATAAGAAGGAGGACGGCATCTGGAGCACCGACATCCTGAAGGACCAAAAGGAGCCCAAGAACAAGACCTTCCTGAGGTGCGAGGCCAAAAACTATTCCGGCCGCTTTACCTGTTGGTGGCTGACCACCATCTCCACCGATCTGACCTTCAGCGTGAAGTCGTCTAGGGGCTCCTCCGACCCCCAGGGCGTAACCTGCGGCGCCGCGACCCTGAGCGCCGAGAGGGTGCGGGGCGATAACAAAGAGTACGAGTACTCGGTGGAGTGCCAGGAGGACAGCGCCTGTCCGGCGGCCGAGGAGAGCCTGCCCATCGAGGTGATGGTGGACGCCGTCCACAAGCTGAAGTACGAGAACTACACCAGTTCGTTCTTCATCAGGGACATCATCAAGCCGGACCCCCCCAAGAACCTCCAGCTGAAGCCCCTGAAGAACAGCAGGCAGGTGGAAGTGTCCTGGGAGTATCCCGACACCTGGAGCACCCCCCACAGCTACTTCAGCCTGACCTTTTGCGTGCAGGTGCAGGGCAAAAGCAAGAGGGAAAAGAAGGACCGGGTGTTCACCGATAAGACGAGCGCCACCGTTATCTGCAGGAAGAACGCCTCCATAAGCGTGAGGGCGCAGGACCGTTACTACAGCAGCAGCTGGAGTGAGTGGGCAAGCGTGCCCTGTAGCGGCGGGGGCGGGGGCGGGTCCCGCAACCTCCCCGTCGCCACCCCCGACCCAGGCATGTTTCCGTGCCTGCACCACAGCCAGAACCTGCTGCGGGCCGTTAGCAACATGCTGCAGAAGGCCAGGCAGACCCTCGAGTTCTATCCCTGCACATCTGAGGAGATCGACCACGAAGACATCACTAAGGATAAGACCTCCACCGTGGAGGCCTGTCTGCCCCTCGAGCTGACCAAGAATGAATCCTGCCTGAACAGCCGAGAGACCAGCTTTATCACCAACGGCTCCTGCCTGGCCAGCAGGAAGACCTCCTTCATGATGGCCCTGTGCCTCTCCAGCATCTACGAGGATCTGAAGATGTACCAGGTAGAGTTCAAGACGATGAACGCCAAGCTCCTGATGGACCCCAAGAGGCAGATATTCCTGGACCAGAACATGCTGGCGGTGATCGACGAGCTGATGCAGGCCCTGAATTTCAACAGCGAGACGGTGCCACAGAAGTCCAGCCTGGAGGAGCCAGACTTCTACAAGACCAAGATCAAACTGTGCATCCTCCTGCACGCGTTCAGGATCCGCGCCGTCACCATAGACAGGGTGATGAGTTATCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_036TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTAATCAGCTGGTTTAGCCTGGTGTTCCTGGCCAGCCCACTGGTGGCCNO: 90)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAACTGGACTGGTACCCCGACGCCCCTGGCGAGATGGTGGTACTGACCTGTGACACCCCGGAGGAAGACGGTATCACCTGGACCCTGGATCAGAGCTCCGAGGTGCTGGGCTCCGGCAAGACACTGACCATCCAAGTTAAGGAATTTGGGGACGCCGGCCAGTACACCTGCCACAAGGGGGGCGAGGTGCTGTCCCACTCCCTGCTGCTTCTGCATAAGAAGGAGGATGGCATCTGGTCCACCGACATACTGAAGGACCAGAAGGAGCCCAAGAATAAGACCTTCCTGAGATGCGAGGCCAAGAACTACTCGGGAAGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCTCCGTGAAGAGCTCCCGGGGCAGCTCCGACCCCCAGGGCGTAACCTGTGGGGCCGCTACCCTGTCCGCCGAGAGGGTCCGGGGCGACAACAAGGAATACGAGTACAGCGTGGAGTGCCAGGAGGACTCCGCCTGCCCCGCCGCCGAGGAGTCGCTGCCCATAGAGGTGATGGTGGACGCCGTGCACAAGCTCAAGTACGAGAATTACACCAGCAGCTTCTTTATCAGGGACATAATTAAGCCGGACCCCCCAAAGAATCTGCAGCTGAAGCCCCTGAAGAATAGCCGGCAGGTGGAAGTGTCCTGGGAGTACCCCGACACCTGGAGCACCCCCCACTCCTATTTCTCACTGACATTCTGCGTGCAGGTGCAAGGGAAAAGCAAGAGGGAGAAGAAGGATAGGGTGTTCACCGACAAGACAAGCGCCACCGTGATCTGCCGAAAAAATGCCAGCATCAGCGTGAGGGCCCAGGATCGGTATTACAGCAGCTCCTGGAGCGAGTGGGCCAGCGTGCCCTGTTCCGGCGGGGGAGGGGGCGGCTCCCGGAACCTGCCGGTGGCCACCCCCGACCCTGGCATGTTCCCCTGCCTGCATCACAGCCAGAACCTGCTCCGGGCCGTGTCGAACATGCTGCAGAAGGCCCGGCAGACCCTCGAGTTTTACCCCTGCACCAGCGAAGAGATCGACCACGAAGACATAACCAAGGACAAGACCAGCACGGTGGAGGCCTGCCTGCCCCTGGAGCTTACCAAAAACGAGTCCTGCCTGAACAGCCGGGAAACCAGCTTCATAACGAACGGGAGCTGCCTGGCCTCCAGGAAGACCAGCTTCATGATGGCGCTGTGTCTGTCCAGCATATACGAGGATCTGAAGATGTATCAGGTGGAATTCAAAACTATGAATGCCAAGCTCCTGATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTAGCCGTGATCGACGAGCTGATGCAGGCCCTCAACTTCAACTCGGAGACGGTGCCCCAGAAGTCCAGCCTCGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATACTGCTGCATGCCTTCAGGATAAGGGCGGTGACTATCGACAGGGTCATGTCCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_037TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAACAACTGGTGATCAGCTGGTTCTCCCTGGTGTTCCTGGCCAGCCCCCTGGTGGCCNO: 91)ATCTGGGAGCTCAAAAAAGACGTGTACGTGGTGGAGCTCGATTGGTACCCAGACGCGCCGGGGGAAATGGTGGTGCTGACCTGCGACACCCCAGAGGAGGATGGCATCACGTGGACGCTGGATCAGTCCAGCGAGGTGCTGGGGAGCGGCAAGACGCTCACCATCCAGGTGAAGGAATTTGGCGACGCGGGCCAGTATACCTGTCACAAGGGCGGCGAGGTGCTGAGCCACTCCCTGCTGCTGCTGCACAAGAAGGAGGATGGGATCTGGTCAACCGATATCCTGAAAGACCAGAAGGAGCCCAAGAACAAGACCTTCCTGCGCTGCGAGGCCAAGAACTATAGCGGCAGGTTCACCTGCTGGTGGCTGACCACCATCAGCACCGACCTGACCTTCAGCGTGAAATCCTCCAGGGGCAGCAGCGACCCCCAGGGCGTGACCTGCGGTGCCGCCACGCTCTCCGCCGAGCGAGTGAGGGGTGACAACAAGGAGTACGAGTACAGCGTGGAATGTCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGTCGCTGCCCATCGAGGTGATGGTCGACGCGGTGCACAAGCTCAAATACGAGAATTACACCAGCAGCTTCTTCATCAGGGACATCATCAAGCCCGACCCCCCCAAGAACCTGCAGCTGAAGCCCTTGAAGAACAGCAGGCAGGTGGAGGTGAGCTGGGAGTACCCGGACACCTGGAGCACCCCCCACTCCTACTTCAGCCTGACGTTCTGTGTGCAGGTGCAGGGGAAGTCCAAGAGGGAGAAGAAGGACCGGGTGTTCACCGACAAGACCAGCGCCACCGTGATATGCCGCAAGAACGCGTCCATCAGCGTTCGCGCCCAGGACCGCTACTACAGCAGCTCCTGGTCCGAATGGGCCAGCGTGCCCTGCAGCGGTGGAGGGGGCGGGGGCTCCAGGAATCTGCCGGTGGCCACCCCCGACCCCGGGATGTTCCCGTGTCTGCATCACTCCCAGAACCTGCTGCGGGCCGTGAGCAATATGCTGCAGAAGGCCAGGCAGACGCTCGAGTTCTACCCCTGCACCTCCGAAGAGATCGACCATGAGGACATCACCAAGGACAAGACCAGCACCGTGGAGGCCTGCCTCCCCCTGGAGCTGACCAAAAACGAGAGCTGCCTGAACTCCAGGGAGACCAGCTTTATAACCAACGGCAGCTGCCTCGCCTCCAGGAAGACCTCGTTTATGATGGCCCTCTGCCTGTCCAGCATCTACGAGGACCTGAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGTTGCTCATGGACCCCAAGAGGCAGATCTTCCTGGACCAGAACATGCTCGCGGTGATCGACGAGCTGATGCAAGCCCTGAACTTCAACAGCGAGACCGTGCCCCAGAAGAGCAGCCTGGAAGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATCCTGCTGCACGCCTTCCGGATCCGGGCCGTGACCATCGACAGGGTGATGAGCTACCTCAACGCCTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_038TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTCGTGATCAGCTGGTTCTCCCTCGTCTTCCTGGCCTCCCCGCTGGTGGCCNO: 92)ATCTGGGAGCTGAAGAAGGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCCGGCGAGATGGTGGTGCTGACGTGCGACACACCAGAAGAGGACGGGATCACATGGACCCTGGATCAGTCGTCCGAGGTGCTGGGGAGCGGCAAGACCCTCACCATCCAAGTGAAGGAGTTCGGGGACGCCGGCCAGTACACCTGCCACAAGGGCGGGGAGGTGCTCTCCCATAGCCTGCTCCTCCTGCACAAAAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAGGAGCCCAAGAACAAGACATTTCTCAGGTGTGAGGCCAAGAACTATTCGGGCAGGTTTACCTGTTGGTGGCTCACCACCATCTCTACCGACCTGACGTTCTCCGTCAAGTCAAGCAGGGGGAGCTCGGACCCCCAGGGGGTGACATGTGGGGCCGCCACCCTGAGCGCGGAGCGTGTCCGCGGCGACAACAAGGAGTACGAGTATTCCGTGGAGTGCCAGGAGGACAGCGCCTGCCCCGCCGCCGAGGAGTCCCTGCCCATAGAGGTGATGGTGGACGCCGTCCACAAGTTGAAGTACGAAAATTATACCTCCTCGTTCTTCATTAGGGACATCATCAAGCCTGACCCCCCGAAGAACCTACAACTCAAGCCCCTCAAGAACTCCCGCCAGGTGGAGGTGTCCTGGGAGTACCCCGACACCTGGTCCACCCCGCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTCCAGGGGAAGAGCAAGCGTGAAAAGAAAGACAGGGTGTTCACCGACAAGACGAGCGCCACCGTGATCTGCAGGAAAAACGCCTCCATCTCCGTGCGCGCCCAGGACAGGTACTACAGTAGCTCCTGGAGCGAATGGGCCAGCGTGCCGTGCAGCGGCGGGGGAGGAGGCGGCAGTCGCAACCTGCCCGTGGCCACCCCCGACCCCGGCATGTTCCCATGCCTGCACCACAGCCAGAACCTGCTGAGGGCAGTCAGCAATATGCTGCAGAAGGCCAGGCAGACCCTGGAGTTTTATCCCTGCACCAGCGAGGAGATCGACCACGAGGACATCACCAAGGACAAGACCTCCACCGTCGAGGCCTGCCTGCCACTGGAGCTGACCAAAAACGAGAGCTGCCTGAACTCCAGGGAGACCTCCTTCATCACCAACGGGAGCTGCCTGGCCAGCCGGAAGACCAGCTTCATGATGGCGCTGTGCCTCAGCAGCATCTACGAGGATCTCAAGATGTACCAGGTGGAGTTCAAGACCATGAACGCGAAGCTGCTGATGGACCCCAAGCGGCAGATCTTCCTGGACCAGAACATGCTGGCCGTGATTGACGAGCTCATGCAGGCCCTGAACTTCAATAGCGAGACCGTCCCCCAAAAGAGCAGCCTGGAGGAACCCGACTTCTACAAAACGAAGATCAAGCTCTGCATCCTGCTGCACGCCTTCCGGATCCGGGCCGTGACCATCGATCGTGTGATGAGCTACCTGAACGCCTCGTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_039TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCACCAGCAGCTCGTCATCTCCTGGTTTAGCCTGGTGTTTCTGGCCTCCCCCCTGGTCGCCNO: 93)ATCTGGGAGCTGAAGAAAGACGTGTACGTGGTGGAGCTGGACTGGTACCCGGACGCTCCCGGGGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATCACCTGGACCCTGGACCAGAGCTCCGAGGTGCTGGGGAGCGGCAAGACCCTGACCATTCAGGTGAAAGAGTTCGGCGACGCCGGCCAATATACCTGCCACAAGGGGGGGGAGGTCCTGTCGCATTCCCTGCTGCTGCTTCACAAAAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGACCAGAAAGAACCCAAGAACAAGACGTTCCTGCGCTGCGAGGCCAAGAACTACAGCGGCCGGTTCACCTGTTGGTGGCTGACCACCATCTCCACCGACCTGACTTTCTCGGTGAAGAGCAGCCGCGGGAGCAGCGACCCCCAGGGAGTGACCTGCGGCGCCGCCACCCTGAGCGCCGAAAGGGTGAGGGGCGACAATAAAGAGTACGAGTATTCCGTGGAGTGCCAGGAGGACAGCGCCTGTCCCGCCGCCGAGGAGTCCCTGCCTATCGAGGTGATGGTCGACGCGGTGCACAAGCTCAAGTACGAAAACTACACCAGCAGCTTTTTCATCAGGGATATCATCAAACCAGACCCCCCCAAGAACCTGCAGCTGAAGCCCCTGAAAAACAGCAGGCAGGTGGAAGTGAGCTGGGAATACCCCGATACCTGGTCCACCCCCCACAGCTACTTCAGCCTGACCTTCTGCGTGCAGGTGCAGGGGAAGTCCAAGCGGGAGAAGAAAGATCGGGTGTTCACGGACAAGACCAGCGCCACCGTGATTTGCAGGAAAAACGCCAGCATCTCCGTGAGGGCTCAGGACAGGTACTACAGCTCCAGCTGGAGCGAGTGGGCCTCCGTGCCTTGCAGCGGGGGAGGAGGCGGCGGCAGCAGGAATCTGCCCGTCGCAACCCCCGACCCCGGCATGTTCCCCTGCCTGCACCACAGCCAGAATCTGCTGCGAGCCGTGAGCAACATGCTCCAGAAGGCCCGGCAGACGCTGGAGTTCTACCCCTGCACCTCCGAGGAGATCGACCACGAGGACATCACCAAGGATAAGACGAGCACCGTCGAGGCCTGTCTCCCCCTGGAGCTCACCAAGAACGAGTCCTGCCTGAATAGCAGGGAGACGTCCTTCATAACCAACGGCAGCTGTCTGGCGTCCAGGAAGACCAGCTTCATGATGGCCCTCTGCCTGAGCTCCATCTACGAGGACCTCAAGATGTACCAGGTCGAGTTCAAGACCATGAACGCAAAACTGCTCATGGATCCAAAGAGGCAGATCTTTCTGGACCAGAACATGCTGGCCGTGATCGATGAACTCATGCAGGCCCTGAATTTCAATTCCGAGACCGTGCCCCAGAAGAGCTCCCTGGAGGAACCCGACTTCTACAAAACAAAGATCAAGCTGTGTATCCTCCTGCACGCCTTCCGGATCAGGGCCGTCACCATTGACCGGGTGATGTCCTACCTGAACGCCAGCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC hIL12AB_040TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAA(SEQ IDTATAAGAGCCACCATGTGCCATCAGCAGCTGGTGATCAGCTGGTTCAGCCTCGTGTTCCTCGCCAGCCCCCTCGTGGCCNO: 94)ATCTGGGAGCTGAAAAAGGACGTGTACGTGGTGGAGCTGGACTGGTATCCCGACGCCCCGGGCGAGATGGTGGTGCTGACCTGCGACACCCCCGAGGAGGACGGCATTACCTGGACACTGGACCAGAGCAGCGAGGTCCTGGGCAGCGGGAAGACCCTGACAATTCAGGTGAAGGAGTTCGGCGACGCCGGACAGTACACGTGCCACAAGGGGGGGGAGGTGCTGTCCCACAGCCTCCTCCTGCTGCACAAGAAGGAGGATGGCATCTGGAGCACCGACATCCTGAAGGATCAGAAGGAGCCCAAGAACAAGACCTTTCTGAGATGCGAGGCCAAGAATTACAGCGGCCGTTTCACCTGCTGGTGGCTCACCACCATCAGCACCGACCTGACCTTCAGCGTGAAATCCTCCAGGGGCTCCTCCGACCCGCAGGGAGTGACCTGCGGCGCCGCCACACTGAGCGCCGAGCGGGTCAGAGGGGACAACAAGGAGTACGAGTACAGCGTTGAGTGCCAGGAGGACAGCGCCTGTCCCGCGGCCGAGGAATCCCTGCCCATCGAGGTGATGGTGGACGCAGTGCACAAGCTGAAGTACGAGAACTATACCTCGAGCTTCTTCATCCGGGATATCATTAAGCCCGATCCCCCGAAGAACCTGCAGCTCAAACCCCTGAAGAACAGCAGGCAGGTGGAGGTCTCCTGGGAGTACCCCGACACATGGTCCACCCCCCATTCCTATTTCTCCCTGACCTTTTGCGTGCAGGTGCAGGGCAAGAGCAAGAGGGAGAAAAAGGACAGGGTGTTCACCGACAAGACCTCCGCCACCGTGATCTGCCGTAAGAACGCTAGCATCAGCGTCAGGGCCCAGGACAGGTACTATAGCAGCTCCTGGTCCGAGTGGGCCAGCGTCCCGTGCAGCGGCGGGGGCGGTGGAGGCTCCCGGAACCTCCCCGTGGCCACCCCGGACCCCGGGATGTTTCCCTGCCTGCATCACAGCCAGAACCTGCTGAGGGCCGTGTCCAACATGCTGCAGAAGGCCAGGCAGACACTCGAGTTTTACCCCTGCACCAGCGAGGAGATCGACCACGAAGACATCACCAAGGACAAGACCTCCACCGTGGAGGCATGCCTGCCCCTGGAGCTGACCAAAAACGAAAGCTGTCTGAACTCCAGGGAGACCTCCTTTATCACGAACGGCTCATGCCTGGCCTCCAGAAAGACCAGCTTCATGATGGCCCTGTGCCTGAGCTCCATCTACGAGGACTTGAAAATGTACCAGGTCGAGTTCAAGACCATGAACGCCAAGCTGCTCATGGACCCCAAAAGGCAGATCTTTCTGGACCAGAATATGCTGGCCGTGATCGACGAGCTCATGCAAGCCCTGAATTTCAACAGCGAGACCGTGCCCCAGAAGTCCTCCCTGGAGGAGCCCGACTTCTACAAGACCAAGATCAAGCTGTGCATACTCCTGCACGCGTTTAGGATCAGGGCGGTGACCATCGATAGGGTGATGAGCTACCTGAATGCCTCCTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC

TABLE 4C mRNA Sequences (with T100 tail) hIL12AB_001G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAGCAGCUGGUCAUUAGCUGG(SEQ IDUUUAGCCUUGUGUUCCUGGCCUCCCCCCUUGUCGCUAUUUGGGAGCUCAAGAAGGACGUGUACGUGGUGGAGUUGGAUUNO: 95)GGUACCCAGACGCGCCCGGAGAGAUGGUAGUUCUGACCUGUGAUACCCCAGAGGAGGACGGCAUCACCUGGACGCUGGACCAAAGCAGCGAGGUUUUGGGCUCAGGGAAAACGCUGACCAUCCAGGUGAAGGAAUUCGGCGACGCCGGGCAGUACACCUGCCAUAAGGGAGGAGAGGUGCUGAGCCAUUCCCUUCUUCUGCUGCACAAGAAAGAGGACGGCAUCUGGUCUACCGACAUCCUGAAAGACCAGAAGGAGCCCAAGAACAAAACCUUCCUGAGGUGCGAGGCCAAGAACUACUCCGGCAGGUUCACUUGUUGGUGGCUGACCACCAUCAGUACAGACCUGACUUUUAGUGUAAAAAGCUCCAGAGGCUCGUCCGAUCCCCAAGGGGUGACCUGCGGCGCAGCCACUCUGAGCGCUGAGCGCGUGCGCGGUGACAAUAAAGAGUACGAGUACAGCGUUGAGUGUCAAGAAGAUAGCGCUUGCCCUGCCGCCGAGGAGAGCCUGCCUAUCGAGGUGAUGGUUGACGCAGUGCACAAGCUUAAGUACGAGAAUUACACCAGCUCAUUCUUCAUUAGAGAUAUAAUCAAGCCUGACCCACCCAAGAACCUGCAGCUGAAGCCACUGAAAAACUCACGGCAGGUCGAAGUGAGCUGGGAGUACCCCGACACCUGGAGCACUCCUCAUUCCUAUUUCUCUCUUACAUUCUGCGUCCAGGUGCAGGGCAAGAGCAAGCGGGAAAAGAAGGAUCGAGUCUUCACCGACAAAACAAGCGCGACCGUGAUUUGCAGGAAGAACGCCAGCAUCUCCGUCAGAGCCCAGGAUAGAUACUAUAGUAGCAGCUGGAGCGAGUGGGCAAGCGUGCCCUGUUCCGGCGGCGGGGGCGGGGGCAGCCGAAACUUGCCUGUCGCUACCCCGGACCCUGGAAUGUUUCCGUGUCUGCACCACAGCCAGAACCUGCUGAGAGCCGUGUCGAAUAUGCUCCAGAAGGCCCGGCAGACCCUUGAGUUCUACCCCUGUACCAGCGAAGAGAUCGAUCAUGAAGAUAUCACGAAAGAUAAAACAUCCACCGUCGAGGCUUGUCUCCCGCUGGAGCUGACCAAGAACGAGAGCUGUCUGAAUAGCCGGGAGACGUCUUUCAUCACGAAUGGUAGCUGUCUGGCCAGCAGGAAAACUUCCUUCAUGAUGGCUCUCUGCCUGAGCUCUAUCUAUGAAGAUCUGAAGAUGUAUCAGGUGGAGUUUAAAACAAUGAACGCCAAACUCCUGAUGGACCCAAAAAGGCAAAUCUUUCUGGACCAGAAUAUGCUGGCCGUGAUAGACGAGCUGAUGCAGGCACUGAACUUCAACAGCGAGACGGUGCCACAGAAAUCCAGCCUGGAGGAGCCUGACUUUUACAAAACUAAGAUCAAGCUGUGUAUCCUGCUGCACGCCUUUAGAAUCCGUGCCGUGACUAUCGACAGGGUGAUGUCAUACCUCAACGCUUCAUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_002G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGUUGGAUUNO: 96)GGUACCCCGACGCCCCCGGCGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGCAUCACCUGGACCCUGGACCAGAGCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACCAUCCAGGUGAAGGAGUUCGGCGACGCCGGCCAGUACACCUGCCACAAGGGCGGCGAGGUGCUGAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGACGGCAUCUGGAGCACCGACAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGAGAUGCGAGGCCAAGAACUACAGCGGCAGAUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACCUUCAGCGUGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGUGACCUGCGGCGCCGCCACCCUGAGCGCCGAGAGAGUGAGAGGCGACAACAAGGAGUACGAGUACAGCGUGGAGUGCCAGGAAGAUAGCGCCUGCCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUGCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCCGACCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGAGCACCCCCCACAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGCAAGAGAGAGAAGAAAGAUAGAGUGUUCACCGACAAGACCAGCGCCACCGUGAUCUGCAGAAAGAACGCCAGCAUCAGCGUGAGAGCCCAAGAUAGAUACUACAGCAGCAGCUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCUGCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAGAACCUGCUGAGAGCCGUGAGCAACAUGCUGCAGAAGGCCCGGCAGACCCUGGAGUUCUACCCCUGCACCAGCGAGGAGAUCGACCACGAAGAUAUCACCAAAGAUAAGACCAGCACCGUGGAGGCCUGCCUGCCCCUGGAGCUGACCAAGAACGAGAGCUGCCUGAACAGCAGAGAGACCAGCUUCAUCACCAACGGCAGCUGCCUGGCCAGCAGAAAGACCAGCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAGACCGUGCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCAGAAUCAGAGCCGUGACCAUCGACAGAGUGAUGAGCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_003G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAGCAGUUGGUCAUCUCUUGG(SEQ IDUUUUCCCUGGUUUUUCUGGCAUCUCCCCUCGUGGCCAUCUGGGAACUGAAGAAAGACGUUUACGUUGUAGAAUUGGAUUNO: 97)GGUAUCCGGACGCUCCUGGAGAAAUGGUGGUCCUCACCUGUGACACCCCUGAAGAAGACGGAAUCACCUGGACCUUGGACCAGAGCAGUGAGGUCUUAGGCUCUGGCAAAACCCUGACCAUCCAAGUCAAAGAGUUUGGAGAUGCUGGCCAGUACACCUGUCACAAAGGAGGCGAGGUUCUAAGCCAUUCGCUCCUGCUGCUUCACAAAAAGGAAGAUGGAAUUUGGUCCACUGAUAUUUUAAAGGACCAGAAAGAACCCAAAAAUAAGACCUUUCUAAGAUGCGAGGCCAAGAAUUAUUCUGGACGUUUCACCUGCUGGUGGCUGACGACAAUCAGUACUGAUUUGACAUUCAGUGUCAAAAGCAGCAGAGGCUCUUCUGACCCCCAAGGGGUGACGUGCGGAGCUGCUACACUCUCUGCAGAGAGAGUCAGAGGUGACAACAAGGAGUAUGAGUACUCAGUGGAGUGCCAGGAAGAUAGUGCCUGCCCAGCUGCUGAGGAGAGUCUGCCCAUUGAGGUCAUGGUGGAUGCCGUUCACAAGCUCAAGUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAACCUGACCCACCCAAGAACUUGCAGCUGAAGCCAUUAAAGAAUUCUCGGCAGGUGGAGGUCAGCUGGGAGUACCCUGACACCUGGAGUACUCCACAUUCCUACUUCUCCCUGACAUUCUGCGUUCAGGUCCAGGGCAAGAGCAAGAGAGAAAAGAAAGAUAGAGUCUUCACAGAUAAGACCUCAGCCACGGUCAUCUGCCGCAAAAAUGCCAGCAUUAGCGUGCGGGCCCAGGACCGCUACUAUAGCUCAUCUUGGAGCGAAUGGGCAUCUGUGCCCUGCAGUGGCGGAGGGGGCGGAGGGAGCAGAAACCUCCCCGUGGCCACUCCAGACCCAGGAAUGUUCCCAUGCCUUCACCACUCCCAAAACCUGCUGAGGGCCGUCAGCAACAUGCUCCAGAAGGCCCGGCAAACUUUAGAAUUUUACCCUUGCACUUCUGAAGAGAUUGAUCAUGAAGAUAUCACAAAAGAUAAAACCAGCACAGUGGAGGCCUGUUUACCAUUGGAAUUAACCAAGAAUGAGAGUUGCCUAAAUUCCAGAGAGACCUCUUUCAUAACUAAUGGGAGUUGCCUGGCCUCCAGAAAGACCUCUUUUAUGAUGGCCCUGUGCCUUAGUAGUAUUUAUGAAGAUUUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAAUGCAAAGCUUCUGAUGGAUCCUAAGAGGCAGAUCUUUUUAGAUCAAAACAUGCUGGCAGUUAUUGAUGAGCUGAUGCAGGCCCUGAAUUUCAACAGUGAGACGGUGCCACAAAAAUCCUCCCUUGAAGAACCAGAUUUCUACAAGACCAAGAUCAAGCUCUGCAUACUUCUUCAUGCUUUCAGAAUUCGGGCAGUGACUAUUGAUAGAGUGAUGAGCUAUCUGAAUGCUUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_004G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGGGCUGCCACCAGCAGCUGGUCAUCAGC(SEQ IDUGGUUCUCCCUGGUCUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUCUACGUAGUAGAGUUGGNO: 98)AUUGGUACCCAGACGCACCUGGAGAAAUGGUGGUUCUCACCUGUGACACGCCAGAAGAAGACGGUAUCACCUGGACGCUGGACCAGAGCUCAGAAGUUCUUGGCAGUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGGGAUGCUGGCCAGUACACCUGCCACAAAGGAGGAGAAGUUCUCAGCCACAGCCUGCUGCUGCUGCACAAGAAAGAAGAUGGCAUCUGGAGCACAGAUAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACCUUCCUUCGAUGUGAGGCCAAGAACUACAGUGGCCGCUUCACCUGCUGGUGGCUCACCACCAUCAGCACAGACCUCACCUUCUCGGUGAAGAGCAGCCGUGGCAGCUCAGACCCCCAAGGAGUCACCUGUGGGGCGGCCACGCUGUCGGCAGAAAGAGUUCGAGGUGACAACAAGGAAUAUGAAUACUCGGUGGAAUGUCAAGAAGAUUCGGCCUGCCCGGCGGCAGAAGAAAGUCUUCCCAUAGAAGUCAUGGUGGAUGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCAGACCCGCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAAGUUUCCUGGGAGUACCCAGAUACGUGGAGCACGCCGCACAGCUACUUCAGCCUCACCUUCUGUGUACAAGUACAAGGCAAGAGCAAGAGAGAGAAGAAAGAUCGUGUCUUCACAGAUAAAACCUCGGCGACGGUCAUCUGCAGGAAGAAUGCCUCCAUCUCGGUUCGAGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCCUCGGUGCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCAGAAACCUUCCUGUGGCCACGCCGGACCCUGGCAUGUUCCCGUGCCUGCACCACAGCCAAAAUUUACUUCGAGCUGUUUCUAACAUGCUGCAGAAAGCACGGCAAACUUUAGAAUUCUACCCCUGCACCUCAGAAGAAAUAGACCAUGAAGAUAUCACCAAAGAUAAAACCAGCACUGUAGAGGCCUGCCUGCCCCUGGAGCUCACCAAGAAUGAAUCCUGCCUCAACAGCAGAGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUGGCCAGCAGGAAAACCAGCUUCAUGAUGGCGCUCUGCCUGAGCAGCAUCUAUGAAGAUUUGAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAGCUGCUCAUGGACCCCAAGCGGCAGAUAUUUUUGGAUCAAAACAUGCUGGCUGUCAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACUCAGAGACGGUGCCCCAGAAGAGCAGCCUGGAGGAGCCAGAUUUCUACAAAACCAAGAUCAAGCUCUGCAUCUUAUUACAUGCCUUCCGCAUCCGGGCGGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_005G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUCAUCAGCUGG(SEQ IDUUCUCCCUGGUCUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUCUACGUAGUAGAGUUGGAUUNO: 99)GGUACCCAGACGCACCUGGAGAAAUGGUGGUUCUCACCUGUGACACGCCAGAAGAAGACGGUAUCACCUGGACGCUGGACCAGAGCUCAGAAGUUCUUGGCAGUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGGGAUGCUGGCCAGUACACCUGCCACAAAGGAGGAGAAGUUCUCAGCCACAGCCUGCUGCUGCUGCACAAGAAAGAAGAUGGCAUCUGGAGCACAGAUAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACCUUCCUUCGAUGUGAGGCCAAGAACUACAGUGGCCGCUUCACCUGCUGGUGGCUCACCACCAUCAGCACAGACCUCACCUUCUCGGUGAAGAGCAGCCGUGGCAGCUCAGACCCCCAAGGAGUCACCUGUGGGGCGGCCACGCUGUCGGCAGAAAGAGUUCGAGGUGACAACAAGGAAUAUGAAUACUCGGUGGAAUGUCAAGAAGAUUCGGCCUGCCCGGCGGCAGAAGAAAGUCUUCCCAUAGAAGUCAUGGUGGAUGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCAGACCCGCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAAGUUUCCUGGGAGUACCCAGAUACGUGGAGCACGCCGCACAGCUACUUCAGCCUCACCUUCUGUGUACAAGUACAAGGCAAGAGCAAGAGAGAGAAGAAAGAUCGUGUCUUCACAGAUAAAACCUCGGCGACGGUCAUCUGCAGGAAGAAUGCCUCCAUCUCGGUUCGAGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCCUCGGUGCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCAGAAACCUUCCUGUGGCCACGCCGGACCCUGGCAUGUUCCCGUGCCUGCACCACAGCCAAAAUUUACUUCGAGCUGUUUCUAACAUGCUGCAGAAAGCACGGCAAACUUUAGAAUUCUACCCCUGCACCUCAGAAGAAAUAGACCAUGAAGAUAUCACCAAAGAUAAAACCAGCACUGUAGAGGCCUGCCUGCCCCUGGAGCUCACCAAGAAUGAAUCCUGCCUCAACAGCAGAGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUGGCCAGCAGGAAAACCAGCUUCAUGAUGGCGCUCUGCCUGAGCAGCAUCUAUGAAGAUUUGAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAGCUGCUCAUGGACCCCAAGCGGCAGAUAUUUUUGGAUCAAAACAUGCUGGCUGUCAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACUCAGAGACGGUGCCCCAGAAGAGCAGCCUGGAGGAGCCAGAUUUCUACAAAACCAAGAUCAAGCUCUGCAUCUUAUUACAUGCCUUCCGCAUCCGGGCGGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_006G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGUUGGAUUNO: 100)GGUACCCCGACGCCCCCGGCGAGAUGGUGGUGCUGACCUGUGACACCCCCGAGGAGGACGGCAUCACCUGGACCCUGGACCAGAGCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACCAUCCAGGUGAAGGAGUUCGGGGACGCCGGCCAGUACACCUGCCACAAGGGCGGCGAGGUGCUGAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGACGGCAUCUGGAGCACAGAUAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGAGAUGCGAGGCCAAGAACUACAGCGGCAGAUUCACCUGCUGGUGGCUGACCACCAUCAGCACAGAUUUGACCUUCAGCGUGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGUGACCUGCGGCGCCGCCACCCUGAGCGCCGAGAGAGUGAGAGGUGACAACAAGGAGUACGAGUACAGCGUGGAGUGCCAGGAAGAUAGCGCCUGCCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUGCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCCGACCCGCCGAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGAGCACCCCCCACAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGCAAGAGAGAGAAGAAAGAUAGAGUGUUCACAGAUAAGACCAGCGCCACCGUGAUCUGCAGAAAGAACGCCAGCAUCAGCGUGAGAGCCCAAGAUAGAUACUACAGCAGCAGCUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCUGCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAGAACCUGCUGAGAGCCGUGAGCAACAUGCUGCAGAAGGCCCGGCAGACCCUGGAGUUCUACCCCUGCACCAGCGAGGAGAUCGACCACGAAGAUAUCACCAAAGAUAAGACCAGCACCGUGGAGGCCUGCCUGCCCCUGGAGCUGACCAAGAAUGAAAGCUGCCUGAACAGCAGAGAGACCAGCUUCAUCACCAACGGCAGCUGCCUGGCCAGCAGAAAGACCAGCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAGACCGUGCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCAGAAUCAGAGCCGUGACCAUCGACAGAGUGAUGAGCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_007G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUUGUCAUCUCCUGG(SEQ IDUUCUCUCUUGUCUUCCUUGCUUCUCCUCUUGUGGCCAUCUGGGAGCUGAAGAAGGACGUUUACGUAGUGGAGUUGGAUUNO: 101)GGUACCCUGACGCACCUGGAGAAAUGGUGGUUCUCACCUGUGACACUCCUGAGGAGGACGGUAUCACCUGGACGUUGGACCAGUCUUCUGAGGUUCUUGGCAGUGGAAAAACUCUUACUAUUCAGGUGAAGGAGUUUGGAGAUGCUGGCCAGUACACCUGCCACAAGGGUGGUGAAGUUCUCAGCCACAGUUUACUUCUUCUUCACAAGAAGGAGGAUGGCAUCUGGUCUACUGACAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACAUUCCUUCGUUGUGAAGCCAAGAACUACAGUGGUCGUUUCACCUGCUGGUGGCUUACUACUAUUUCUACUGACCUUACUUUCUCUGUGAAGUCUUCUCGUGGCUCUUCUGACCCUCAGGGUGUCACCUGUGGGGCUGCUACUCUUUCUGCUGAGCGUGUGCGUGGUGACAACAAGGAGUAUGAAUACUCGGUGGAGUGCCAGGAAGAUUCUGCCUGCCCUGCUGCUGAGGAGUCUCUUCCUAUUGAGGUGAUGGUGGAUGCUGUGCACAAGUUAAAAUAUGAAAACUACACUUCUUCUUUCUUCAUUCGUGACAUUAUAAAACCUGACCCUCCCAAGAACCUUCAGUUAAAACCUUUAAAAAACUCUCGUCAGGUGGAGGUGUCCUGGGAGUACCCUGACACGUGGUCUACUCCUCACUCCUACUUCUCUCUUACUUUCUGUGUCCAGGUGCAGGGCAAGUCCAAGCGUGAGAAGAAGGACCGUGUCUUCACUGACAAAACAUCUGCUACUGUCAUCUGCAGGAAGAAUGCAUCCAUCUCUGUGCGUGCUCAGGACCGUUACUACAGCUCUUCCUGGUCUGAGUGGGCUUCUGUGCCCUGCUCUGGCGGCGGCGGCGGCGGCAGCAGAAAUCUUCCUGUGGCUACUCCUGACCCUGGCAUGUUCCCCUGCCUUCACCACUCGCAGAACCUUCUUCGUGCUGUGAGCAACAUGCUUCAGAAGGCUCGUCAAACUUUAGAAUUCUACCCCUGCACUUCUGAGGAGAUUGACCAUGAAGAUAUCACCAAAGAUAAAACAUCUACUGUGGAGGCCUGCCUUCCUUUAGAGCUGACCAAGAAUGAAUCCUGCUUAAAUUCUCGUGAGACGUCUUUCAUCACCAAUGGCAGCUGCCUUGCCUCGCGCAAAACAUCUUUCAUGAUGGCUCUUUGCCUUUCUUCCAUCUAUGAAGAUUUAAAAAUGUACCAGGUGGAGUUCAAGACCAUGAAUGCAAAGCUUCUCAUGGACCCCAAGCGUCAGAUAUUUUUGGACCAGAACAUGCUUGCUGUCAUUGAUGAGCUCAUGCAGGCUUUAAACUUCAACUCUGAGACGGUGCCUCAGAAGUCUUCUUUAGAAGAGCCUGACUUCUACAAGACCAAGAUAAAACUUUGCAUUCUUCUUCAUGCUUUCCGCAUCCGUGCUGUGACUAUUGACCGUGUGAUGUCCUACUUAAAUGCUUCUUGAUAAUAGGCUGGAGCCUCGGUGGCCAAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_008G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCAUCAACAACUCGUGAUUAGCUGG(SEQ IDUUCAGUCUCGUGUUCCUGGCCUCUCCGCUGGUGGCCAUCUGGGAGCUUAAGAAGGACGUGUACGUGGUGGAGCUCGAUUNO: 102)GGUACCCCGACGCACCUGGCGAGAUGGUGGUGCUAACCUGCGAUACCCCCGAGGAGGACGGGAUCACUUGGACCCUGGAUCAGAGUAGCGAAGUCCUGGGCUCUGGCAAAACACUCACAAUCCAGGUGAAGGAAUUCGGAGACGCUGGUCAGUACACUUGCCACAAGGGGGGUGAAGUGCUGUCUCACAGCCUGCUGUUACUGCACAAGAAGGAGGAUGGGAUCUGGUCAACCGACAUCCUGAAGGAUCAGAAGGAGCCUAAGAACAAGACCUUUCUGAGGUGUGAAGCUAAGAACUAUUCCGGAAGAUUCACUUGCUGGUGGUUGACCACAAUCAGCACUGACCUGACCUUUUCCGUGAAGUCCAGCAGAGGAAGCAGCGAUCCUCAGGGCGUAACGUGCGGCGCGGCUACCCUGUCAGCUGAGCGGGUUAGAGGCGACAACAAAGAGUAUGAGUACUCCGUGGAGUGUCAGGAAGAUAGCGCCUGCCCCGCAGCCGAGGAGAGUCUGCCCAUCGAGGUGAUGGUGGACGCUGUCCAUAAGUUAAAAUACGAAAAUUACACAAGUUCCUUUUUCAUCCGCGAUAUUAUCAAACCCGAUCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAAUAGCCGACAGGUGGAAGUCUCUUGGGAGUAUCCUGACACCUGGUCCACGCCUCACAGCUACUUUAGUCUGACUUUCUGUGUCCAGGUCCAGGGCAAGAGCAAGAGAGAGAAAAAGGAUAGAGUGUUUACUGACAAAACAUCUGCUACAGUCAUCUGCAGAAAGAACGCCAGUAUCUCAGUGAGGGCGCAAGAUAGAUACUACAGUAGUAGCUGGAGCGAAUGGGCUAGCGUGCCCUGUUCAGGGGGCGGCGGAGGGGGCUCCAGGAAUCUGCCCGUGGCCACCCCCGACCCUGGGAUGUUCCCUUGCCUCCAUCACUCACAGAACCUGCUCAGAGCAGUGAGCAACAUGCUCCAAAAGGCCCGCCAGACCCUGGAGUUUUACCCUUGUACUUCAGAAGAGAUCGAUCACGAAGAUAUAACAAAGGAUAAAACCAGCACCGUGGAGGCCUGUCUGCCUCUGGAACUCACAAAGAAUGAAAGCUGUCUGAAUUCCAGGGAAACCUCCUUCAUUACUAACGGAAGCUGUCUCGCAUCUCGCAAAACAUCAUUCAUGAUGGCCCUCUGCCUGUCUUCUAUCUAUGAAGAUCUCAAGAUGUAUCAGGUGGAGUUCAAAACAAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUCCUGGACCAGAACAUGCUGGCAGUGAUCGAUGAGCUGAUGCAAGCCUUGAACUUCAACUCAGAGACGGUGCCGCAAAAGUCCUCGUUGGAGGAACCAGAUUUUUACAAAACCAAAAUCAAGCUGUGUAUCCUUCUUCACGCCUUUCGGAUCAGAGCCGUGACUAUCGACCGGGUGAUGUCAUACCUGAAUGCUUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_009G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUCAUCAGCUGG(SEQ IDUUUAGCCUGGUCUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUCUACGUAGUAGAGUUGGAUUNO: 103)GGUACCCAGACGCACCUGGAGAAAUGGUGGUUCUCACCUGCGACACGCCAGAAGAAGACGGUAUCACCUGGACGCUGGACCAGAGCAGCGAAGUACUGGGCAGUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGCGAUGCUGGCCAGUACACCUGCCACAAAGGAGGAGAAGUACUGAGCCACAGCCUGCUGCUGCUGCACAAGAAAGAAGAUGGCAUCUGGAGCACCGACAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACCUUCCUUCGAUGUGAGGCGAAGAACUACAGUGGCCGCUUCACCUGCUGGUGGCUCACCACCAUCAGCACCGACCUCACCUUCUCGGUGAAGAGCAGCCGUGGUAGCUCAGACCCCCAAGGAGUCACCUGUGGGGCGGCCACGCUGUCGGCAGAAAGAGUUCGAGGCGACAACAAGGAAUAUGAAUACUCGGUGGAAUGUCAAGAAGAUUCGGCCUGCCCGGCGGCAGAAGAAAGUCUGCCCAUAGAAGUCAUGGUGGAUGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCAGACCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAAGUUUCCUGGGAGUACCCAGAUACGUGGAGCACGCCGCACAGCUACUUCAGCCUCACCUUCUGUGUACAAGUACAAGGCAAGAGCAAGAGAGAGAAGAAAGAUCGUGUCUUCACCGACAAAACCUCGGCGACGGUCAUCUGCAGGAAGAAUGCAAGCAUCUCGGUUCGAGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCCUCGGUGCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCAGAAACCUUCCUGUGGCCACGCCGGACCCUGGCAUGUUUCCGUGCCUGCACCACAGCCAAAAUUUAUUACGAGCUGUUAGCAACAUGCUGCAGAAAGCACGGCAAACUUUAGAAUUCUACCCCUGCACCUCAGAAGAAAUAGACCAUGAAGAUAUCACCAAAGAUAAAACCAGCACUGUAGAGGCCUGCCUGCCCCUGGAGCUCACCAAGAACGAGAGCUGCCUCAAUAGCAGAGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUGGCCAGCAGGAAAACCAGCUUCAUGAUGGCGCUCUGCCUGAGCAGCAUCUAUGAAGAUCUGAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAGCUGCUCAUGGACCCCAAGCGGCAGAUAUUCCUCGACCAAAACAUGCUGGCUGUCAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACUCAGAGACGGUGCCCCAGAAGAGCAGCCUGGAGGAGCCAGAUUUCUACAAAACCAAGAUCAAGCUCUGCAUCUUAUUACAUGCCUUCCGCAUCCGGGCGGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_010G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUUGUCAUCUCCUGG(SEQ IDUUUUCUCUUGUCUUCCUCGCUUCUCCUCUUGUGGCCAUCUGGGAGCUGAAGAAAGACGUCUACGUAGUAGAGUUGGAUUNO: 104)GGUACCCGGACGCUCCUGGAGAAAUGGUGGUUCUCACCUGCGACACUCCUGAAGAAGACGGUAUCACCUGGACGCUGGACCAAAGCAGCGAAGUUUUAGGCUCUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGCGACGCUGGCCAGUACACGUGCCACAAAGGAGGAGAAGUUUUAAGCCACAGUUUACUUCUUCUUCACAAGAAAGAAGAUGGCAUCUGGAGUACAGAUAUUUUAAAAGACCAGAAGGAGCCUAAGAACAAAACCUUCCUCCGCUGUGAAGCUAAGAACUACAGUGGUCGUUUCACCUGCUGGUGGCUCACCACCAUCUCCACUGACCUCACCUUCUCUGUAAAAUCAAGCCGUGGUUCUUCUGACCCCCAAGGAGUCACCUGUGGGGCUGCCACGCUCAGCGCUGAAAGAGUUCGAGGCGACAACAAGGAAUAUGAAUAUUCUGUGGAAUGUCAAGAAGAUUCUGCCUGCCCGGCGGCAGAAGAAAGUCUUCCCAUAGAAGUCAUGGUGGACGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUUCGUGACAUCAUCAAACCAGACCCUCCUAAGAACCUUCAGUUAAAACCGCUGAAGAACAGCCGGCAGGUGGAAGUUUCCUGGGAGUACCCAGAUACGUGGAGUACGCCGCACUCCUACUUCAGUUUAACCUUCUGUGUACAAGUACAAGGAAAAUCAAAAAGAGAGAAGAAAGAUCGUGUCUUCACUGACAAAACAUCUGCCACGGUCAUCUGCCGUAAGAACGCUUCCAUCUCGGUUCGAGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCAUCUGUUCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCCGCAACCUUCCUGUGGCCACGCCGGACCCUGGCAUGUUCCCGUGCCUUCACCACUCGCAAAAUCUUCUUCGUGCUGUUUCUAACAUGCUGCAGAAGGCGCGGCAAACUUUAGAAUUCUACCCGUGCACUUCUGAAGAAAUAGACCAUGAAGAUAUCACCAAAGAUAAAACCAGCACGGUGGAGGCCUGCCUUCCUUUAGAACUUACUAAGAACGAAAGUUGCCUUAACAGCCGUGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUUGCUAGCAGGAAGACCAGCUUCAUGAUGGCGCUGUGCCUUUCUUCCAUCUAUGAAGAUCUUAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAAUUAUUAAUGGACCCCAAGCGGCAGAUAUUCCUCGACCAAAACAUGCUGGCUGUCAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACUCAGAAACUGUUCCCCAGAAGUCAUCUUUAGAAGAACCAGAUUUCUACAAAACAAAAAUAAAACUCUGCAUUCUUCUUCAUGCCUUCCGCAUCCGUGCUGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCUUCUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_011G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGUUGGAUUNO: 105)GGUACCCGGACGCGCCGGGGGAGAUGGUGGUGCUGACGUGCGACACGCCGGAGGAGGACGGGAUCACGUGGACGCUGGACCAGAGCAGCGAGGUGCUGGGGAGCGGGAAGACGCUGACGAUCCAGGUGAAGGAGUUCGGGGACGCGGGGCAGUACACGUGCCACAAGGGGGGGGAGGUGCUGAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGACGGGAUCUGGAGCACAGAUAUCCUGAAGGACCAGAAGGAGCCGAAGAACAAGACGUUCCUGAGGUGCGAGGCGAAGAACUACAGCGGGAGGUUCACGUGCUGGUGGCUGACGACGAUCAGCACGGACCUGACGUUCAGCGUGAAGAGCAGCAGGGGGAGCAGCGACCCGCAGGGGGUGACGUGCGGGGCGGCGACGCUGAGCGCGGAGAGGGUGAGGGGUGACAACAAGGAGUACGAGUACAGCGUGGAGUGCCAGGAAGAUAGCGCGUGCCCGGCGGCGGAGGAGAGCCUGCCGAUCGAGGUGAUGGUGGACGCGGUGCACAAGCUGAAGUACGAGAACUACACGAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCGGACCCGCCGAAGAACCUGCAGCUGAAGCCGCUGAAGAACAGCAGGCAGGUGGAGGUGAGCUGGGAGUACCCAGAUACGUGGAGCACGCCGCACAGCUACUUCAGCCUGACGUUCUGCGUGCAGGUGCAGGGGAAGAGCAAGAGGGAGAAGAAAGAUAGGGUGUUCACAGAUAAGACGAGCGCGACGGUGAUCUGCAGGAAGAACGCGAGCAUCAGCGUGAGGGCGCAAGAUAGGUACUACAGCAGCAGCUGGAGCGAGUGGGCGAGCGUGCCGUGCAGCGGGGGGGGGGGGGGGGGGAGCAGGAACCUGCCGGUGGCGACGCCGGACCCGGGGAUGUUCCCGUGCCUGCACCACAGCCAGAACCUGCUGAGGGCGGUGAGCAACAUGCUGCAGAAGGCGAGGCAGACGCUGGAGUUCUACCCGUGCACGAGCGAGGAGAUCGACCACGAAGAUAUCACGAAAGAUAAGACGAGCACGGUGGAGGCGUGCCUGCCGCUGGAGCUGACGAAGAACGAGAGCUGCCUGAACAGCAGGGAGACGAGCUUCAUCACGAACGGGAGCUGCCUGGCGAGCAGGAAGACGAGCUUCAUGAUGGCGCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACGAUGAACGCGAAGCUGCUGAUGGACCCGAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUGGCGGUGAUCGACGAGCUGAUGCAGGCGCUGAACUUCAACAGCGAGACGGUGCCGCAGAAGAGCAGCCUGGAGGAGCCAGAUUUCUACAAGACGAAGAUCAAGCUGUGCAUCCUGCUGCACGCGUUCAGGAUCAGGGCGGUGACGAUCGACAGGGUGAUGAGCUACCUGAACGCGAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_012G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUCGUGUUUCUGGCCAGCCCCCUGGUGGCCAUUUGGGAACUCAAGAAGGACGUGUACGUUGUGGAACUCGACUNO: 106)GGUACCCUGACGCCCCAGGCGAAAUGGUGGUCUUAACCUGCGACACCCCUGAGGAGGACGGAAUCACCUGGACCUUGGACCAGAGCUCCGAGGUCCUCGGCAGUGGCAAGACCCUGACCAUACAGGUGAAAGAAUUUGGAGACGCAGGGCAAUACACAUGUCACAAGGGCGGGGAGGUUCUUUCUCACUCCCUUCUGCUUCUACAUAAAAAGGAAGACGGAAUUUGGUCUACCGACAUCCUCAAGGACCAAAAGGAGCCUAAGAAUAAAACCUUCUUACGCUGUGAAGCUAAAAACUACAGCGGCAGAUUCACUUGCUGGUGGCUCACCACCAUUUCUACCGACCUGACCUUCUCGGUGAAGUCUUCAAGGGGCUCUAGUGAUCCACAGGGAGUGACAUGCGGGGCCGCCACACUGAGCGCUGAACGGGUGAGGGGCGAUAACAAGGAGUAUGAAUACUCUGUCGAGUGUCAGGAGGAUUCAGCUUGUCCCGCAGCUGAAGAGUCACUCCCCAUAGAGGUUAUGGUCGAUGCUGUGCAUAAACUGAAGUACGAAAACUACACCAGCAGCUUCUUCAUUAGAGAUAUUAUAAAACCUGACCCCCCCAAGAACCUGCAACUUAAACCCCUGAAAAACUCUCGGCAGGUCGAAGUUAGCUGGGAGUACCCUGAUACUUGGUCCACCCCCCACUCGUACUUCUCACUGACUUUCUGUGUGCAGGUGCAGGGCAAGAGCAAGAGAGAGAAAAAAGAUCGUGUAUUCACAGAUAAGACCUCUGCCACCGUGAUCUGCAGAAAAAACGCUUCCAUCAGUGUCAGAGCCCAAGACCGGUACUAUAGUAGUAGCUGGAGCGAGUGGGCAAGUGUCCCCUGCUCUGGCGGCGGAGGGGGCGGCUCUCGAAACCUCCCCGUCGCUACCCCUGAUCCAGGAAUGUUCCCUUGCCUGCAUCACUCACAGAAUCUGCUGAGAGCGGUCAGCAACAUGCUGCAGAAAGCUAGGCAAACACUGGAGUUUUAUCCUUGUACCUCAGAGGAGAUCGACCACGAGGAUAUUACCAAAGAUAAGACCAGCACGGUGGAGGCCUGCUUGCCCCUGGAACUGACAAAGAAUGAAUCCUGCCUUAAUAGCCGUGAGACCUCUUUUAUAACAAACGGAUCCUGCCUGGCCAGCAGGAAGACCUCCUUCAUGAUGGCCCUCUGCCUGUCCUCAAUCUACGAAGACCUGAAGAUGUACCAGGUGGAAUUUAAAACUAUGAACGCCAAGCUGUUGAUGGACCCCAAGCGGCAGAUCUUUCUGGAUCAAAAUAUGCUGGCUGUGAUCGACGAACUGAUGCAGGCCCUCAACUUUAACAGCGAGACCGUGCCACAAAAGAGCAGUCUUGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUCCUUCAUGCCUUCAGGAUAAGAGCUGUCACCAUCGACAGAGUCAUGAGUUACCUGAAUGCAUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_013G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUCAUCUCCUGG(SEQ IDUUCAGUCUUGUCUUCCUGGCCUCGCCGCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUUUACGUAGUAGAGUUGGAUUNO: 107)GGUACCCAGACGCACCUGGAGAAAUGGUGGUCCUCACCUGUGACACGCCAGAAGAAGACGGUAUCACCUGGACGCUGGACCAGAGCAGUGAAGUUCUUGGAAGUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGAGAUGCUGGCCAGUACACCUGCCACAAAGGAGGAGAAGUUCUCAGCCACAGUUUAUUAUUACUUCACAAGAAAGAAGAUGGCAUCUGGUCCACAGAUAUUUUAAAAGACCAGAAGGAGCCCAAAAAUAAAACAUUUCUUCGAUGUGAGGCCAAGAACUACAGUGGUCGUUUCACCUGCUGGUGGCUGACCACCAUCUCCACAGACCUCACCUUCAGUGUAAAAAGCAGCCGUGGUUCUUCUGACCCCCAAGGAGUCACCUGUGGGGCUGCCACGCUCUCUGCAGAAAGAGUUCGAGGUGACAACAAAGAAUAUGAGUACUCGGUGGAAUGUCAAGAAGAUUCGGCCUGCCCAGCUGCUGAGGAGAGUCUUCCCAUAGAAGUCAUGGUGGAUGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAACCUGACCCGCCCAAGAACUUACAGCUGAAGCCGCUGAAAAACAGCCGGCAGGUAGAAGUUUCCUGGGAGUACCCAGAUACCUGGUCCACGCCGCACUCCUACUUCUCCCUCACCUUCUGUGUACAAGUACAAGGCAAGAGCAAGAGAGAGAAGAAAGAUCGUGUCUUCACAGAUAAAACAUCAGCCACGGUCAUCUGCAGGAAAAAUGCCAGCAUCUCGGUGCGGGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCAUCUGUGCCCUGCAGUGGUGGUGGGGGUGGUGGCAGCAGAAACCUUCCUGUGGCCACUCCAGACCCUGGCAUGUUCCCGUGCCUUCACCACUCCCAAAAUUUACUUCGAGCUGUUUCUAACAUGCUGCAGAAAGCACGGCAAACUUUAGAAUUCUACCCGUGCACUUCUGAAGAAAUUGACCAUGAAGAUAUCACAAAAGAUAAAACCAGCACAGUGGAGGCCUGUCUUCCUUUAGAGCUGACCAAAAAUGAAUCCUGCCUCAACAGCAGAGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUGGCCUCCAGGAAAACCAGCUUCAUGAUGGCGCUCUGCCUCAGCUCCAUCUAUGAAGAUUUGAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAAUUAUUAAUGGACCCCAAGAGGCAGAUAUUUUUAGAUCAAAACAUGCUGGCAGUUAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACAGUGAGACGGUACCUCAAAAAAGCAGCCUUGAAGAGCCAGAUUUCUACAAAACCAAGAUCAAACUCUGCAUUUUACUUCAUGCCUUCCGCAUCCGGGCGGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCCUCGUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_014G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUUGUGAUUUCUUGG(SEQ IDUUCUCUCUUGUGUUCCUUGCUUCUCCUCUUGUGGCUAUUUGGGAGUUAAAAAAGGACGUGUACGUGGUGGAGCUUGACUNO: 108)GGUACCCUGACGCACCUGGCGAGAUGGUGGUGCUUACUUGUGACACUCCUGAGGAGGACGGCAUUACUUGGACGCUUGACCAGUCUUCUGAGGUGCUUGGCUCUGGCAAAACACUUACUAUUCAGGUGAAGGAGUUCGGGGAUGCUGGCCAGUACACUUGCCACAAGGGCGGCGAGGUGCUUUCUCACUCUCUUCUUCUUCUUCACAAGAAGGAGGACGGCAUUUGGUCUACUGACAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACAUUCCUUCGUUGCGAGGCCAAGAACUACUCUGGCCGUUUCACUUGCUGGUGGCUUACUACUAUUUCUACUGACCUUACUUUCUCUGUGAAGUCUUCUCGUGGCUCUUCUGACCCUCAGGGCGUGACUUGUGGGGCUGCUACUCUUUCUGCUGAGCGUGUGCGUGGUGACAACAAGGAGUACGAGUACUCUGUGGAGUGCCAGGAAGAUUCUGCUUGCCCUGCUGCUGAGGAGUCUCUUCCUAUUGAGGUGAUGGUGGAUGCUGUGCACAAGUUAAAAUACGAGAACUACACUUCUUCUUUCUUCAUUCGUGACAUUAUUAAGCCUGACCCUCCCAAGAACCUUCAGUUAAAACCUUUAAAAAACUCUCGUCAGGUGGAGGUGUCUUGGGAGUACCCUGACACUUGGUCUACUCCUCACUCUUACUUCUCUCUUACUUUCUGCGUGCAGGUGCAGGGCAAGUCUAAGCGUGAGAAGAAGGACCGUGUGUUCACUGACAAAACAUCUGCUACUGUGAUUUGCAGGAAGAAUGCAUCUAUUUCUGUGCGUGCUCAGGACCGUUACUACUCUUCUUCUUGGUCUGAGUGGGCUUCUGUGCCUUGCUCUGGCGGCGGCGGCGGCGGCUCCAGAAAUCUUCCUGUGGCUACUCCUGACCCUGGCAUGUUCCCUUGCCUUCACCACUCUCAGAACCUUCUUCGUGCUGUGAGCAACAUGCUUCAGAAGGCUCGUCAAACUCUUGAGUUCUACCCUUGCACUUCUGAGGAGAUUGACCACGAAGAUAUCACCAAAGAUAAAACAUCUACUGUGGAGGCUUGCCUUCCUCUUGAGCUUACCAAGAAUGAAUCUUGCUUAAAUUCUCGUGAGACGUCUUUCAUCACCAACGGCUCUUGCCUUGCCUCGCGCAAAACAUCUUUCAUGAUGGCUCUUUGCCUUUCUUCUAUUUACGAAGAUUUAAAAAUGUACCAGGUGGAGUUCAAAACAAUGAAUGCAAAGCUUCUUAUGGACCCCAAGCGUCAGAUUUUCCUUGACCAGAACAUGCUUGCUGUGAUUGACGAGCUUAUGCAGGCUUUAAAUUUCAACUCUGAGACGGUGCCUCAGAAGUCUUCUCUUGAGGAGCCUGACUUCUACAAGACCAAGAUUAAGCUUUGCAUUCUUCUUCAUGCUUUCCGUAUUCGUGCUGUGACUAUUGACCGUGUGAUGUCUUACUUAAAUGCUUCUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_015G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUUAGCCUGGUGUUUCUGGCCAGCCCCCUGGUGGCCAUCUGGGAACUGAAGAAAGACGUGUACGUGGUAGAACUGGAUUNO: 109)GGUAUCCGGACGCUCCCGGCGAAAUGGUGGUGCUGACCUGUGACACCCCCGAAGAAGACGGAAUCACCUGGACCCUGGACCAGAGCAGCGAGGUGCUGGGCAGCGGCAAAACCCUGACCAUCCAAGUGAAAGAGUUUGGCGAUGCCGGCCAGUACACCUGUCACAAAGGCGGCGAGGUGCUAAGCCAUUCGCUGCUGCUGCUGCACAAAAAGGAAGAUGGCAUCUGGAGCACCGAUAUCCUGAAGGACCAGAAAGAACCCAAAAAUAAGACCUUUCUAAGAUGCGAGGCCAAGAAUUAUAGCGGCCGUUUCACCUGCUGGUGGCUGACGACCAUCAGCACCGAUCUGACCUUCAGCGUGAAAAGCAGCAGAGGCAGCAGCGACCCCCAAGGCGUGACGUGCGGCGCCGCCACCCUGAGCGCCGAGAGAGUGAGAGGCGACAACAAGGAGUAUGAGUACAGCGUGGAGUGCCAGGAAGAUAGCGCCUGCCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGAUGCCGUGCACAAGCUGAAGUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAACCCGACCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAAUAGCCGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGAGCACCCCCCAUAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGCAAGAGAGAAAAGAAAGAUAGAGUGUUCACAGAUAAGACCAGCGCCACGGUGAUCUGCAGAAAAAAUGCCAGCAUCAGCGUGAGAGCCCAAGAUAGAUACUAUAGCAGCAGCUGGAGCGAAUGGGCCAGCGUGCCCUGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCUGCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAAAACCUGCUGAGAGCCGUGAGCAACAUGCUGCAGAAGGCCCGGCAGACCCUGGAAUUUUACCCCUGCACCAGCGAAGAGAUCGAUCAUGAAGAUAUCACCAAAGAUAAAACCAGCACCGUGGAGGCCUGUCUGCCCCUGGAACUGACCAAGAAUGAGAGCUGCCUAAAUAGCAGAGAGACCAGCUUCAUAACCAAUGGCAGCUGCCUGGCCAGCAGAAAGACCAGCUUUAUGAUGGCCCUGUGCCUGAGCAGCAUCUAUGAAGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAAUGCCAAGCUGCUGAUGGAUCCCAAGCGGCAGAUCUUUCUGGAUCAAAACAUGCUGGCCGUGAUCGAUGAGCUGAUGCAGGCCCUGAAUUUCAACAGCGAGACCGUGCCCCAAAAAAGCAGCCUGGAAGAACCGGAUUUUUAUAAAACCAAAAUCAAGCUGUGCAUACUGCUGCAUGCCUUCAGAAUCAGAGCCGUGACCAUCGAUAGAGUGAUGAGCUAUCUGAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_016G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUCAUCAGCUGG(SEQ IDUUCAGCCUGGUCUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUAUACGUAGUGGAGUUGGAUUNO: 110)GGUACCCAGACGCUCCUGGGGAGAUGGUGGUGCUGACCUGUGACACCCCAGAAGAGGACGGUAUCACCUGGACCCUGGACCAGAGCUCAGAAGUGCUGGGCAGUGGAAAAACCCUGACCAUCCAGGUGAAGGAGUUUGGAGAUGCUGGCCAGUACACCUGCCACAAGGGUGGUGAAGUGCUGAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGAUGGCAUCUGGAGCACAGAUAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACCUUCCUUCGCUGUGAAGCCAAGAACUACAGUGGCCGCUUCACCUGCUGGUGGCUGACCACCAUCAGCACAGACCUCACCUUCUCGGUGAAGAGCAGCAGAGGCAGCUCAGACCCCCAGGGUGUCACCUGUGGGGCGGCCACGCUGUCGGCGGAGAGAGUUCGAGGUGACAACAAGGAGUAUGAAUACUCGGUGGAGUGCCAGGAAGAUUCGGCGUGCCCGGCGGCAGAAGAGAGCCUGCCCAUAGAAGUGAUGGUGGAUGCUGUGCACAAGCUGAAGUAUGAAAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCAGACCCGCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAGGUUUCCUGGGAGUACCCAGAUACGUGGAGCACCCCCCACAGCUACUUCAGCCUGACCUUCUGUGUCCAGGUGCAGGGCAAGAGCAAGAGAGAGAAGAAAGAUAGAGUCUUCACAGAUAAGACCUCGGCCACGGUCAUCUGCAGAAAGAAUGCCUCCAUCUCGGUUCGAGCCCAAGAUAGAUACUACAGCAGCAGCUGGUCAGAAUGGGCCUCGGUGCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCAGAAACCUGCCUGUUGCCACCCCAGACCCUGGGAUGUUCCCCUGCCUGCACCACAGCCAGAACUUAUUACGAGCUGUUUCUAACAUGCUGCAGAAGGCCCGGCAGACCCUGGAGUUCUACCCCUGCACCUCAGAAGAGAUUGACCAUGAAGAUAUCACCAAAGAUAAGACCAGCACUGUAGAGGCCUGCCUGCCCCUGGAGCUGACCAAGAAUGAAAGCUGCCUGAACAGCAGAGAGACCAGCUUCAUCACCAAUGGAAGCUGCCUGGCCAGCAGAAAGACCAGCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUAUGAAGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAAUGCAAAGCUGCUGAUGGACCCCAAGCGGCAGAUAUUUUUGGACCAGAACAUGCUGGCUGUCAUUGAUGAGCUGAUGCAGGCCCUGAACUUCAACUCAGAAACUGUACCCCAGAAGAGCAGCCUGGAGGAGCCAGAUUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUUCAUGCUUUCAGAAUCAGAGCUGUCACCAUUGACCGCGUGAUGAGCUACUUAAAUGCCUCGUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_017G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUAAUCAGCUGG(SEQ IDUUUUCCCUCGUCUUUCUGGCAUCACCCCUGGUGGCUAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGCUGGAUUNO: 111)GGUACCCUGACGCCCCGGGGGAAAUGGUGGUGUUAACCUGCGACACGCCUGAGGAGGACGGCAUCACCUGGACGCUGGACCAGAGCAGCGAGGUGCUUGGGUCUGGUAAAACUCUGACUAUUCAGGUGAAAGAGUUCGGGGAUGCCGGCCAAUAUACUUGCCACAAGGGUGGCGAGGUGCUUUCUCAUUCUCUGCUCCUGCUGCACAAGAAAGAAGAUGGCAUUUGGUCUACUGAUAUUCUGAAAGACCAGAAGGAGCCCAAGAACAAGACCUUUCUGAGAUGCGAGGCUAAAAACUACAGCGGAAGAUUUACCUGCUGGUGGCUGACCACAAUCUCAACCGACCUGACAUUUUCAGUGAAGUCCAGCAGAGGGAGCUCCGACCCUCAGGGCGUGACCUGCGGAGCCGCCACUCUGUCCGCAGAAAGAGUGAGAGGUGAUAAUAAGGAGUACGAGUAUUCAGUCGAGUGCCAAGAAGAUUCUGCCUGCCCAGCCGCCGAGGAGAGCCUGCCAAUCGAGGUGAUGGUAGAUGCGGUACACAAGCUGAAGUAUGAGAACUACACAUCCUCCUUCUUCAUAAGAGAUAUUAUCAAGCCUGACCCACCUAAAAAUCUGCAACUCAAGCCUUUGAAAAAUUCACGGCAGGUGGAGGUGAGCUGGGAGUACCCUGAUACUUGGAGCACCCCCCAUAGCUACUUUUCGCUGACAUUCUGCGUCCAGGUGCAGGGCAAGUCAAAGAGAGAGAAGAAGGAUCGCGUGUUCACUGAUAAAACAAGCGCCACAGUGAUCUGCAGAAAAAACGCUAGCAUUAGCGUCAGAGCACAGGACCGGUAUUACUCCAGCUCCUGGAGCGAAUGGGCAUCUGUGCCCUGCAGCGGUGGGGGCGGAGGCGGAUCCAGAAACCUCCCCGUUGCCACACCUGAUCCUGGAAUGUUCCCCUGUCUGCACCACAGCCAGAACCUGCUGAGAGCAGUGUCUAACAUGCUCCAGAAGGCCAGGCAGACCCUGGAGUUUUACCCCUGCACCAGCGAGGAAAUCGAUCACGAAGAUAUCACCAAAGAUAAAACCUCCACCGUGGAGGCCUGCCUGCCCCUGGAACUGACCAAAAACGAGAGCUGCCUGAAUAGCAGGGAGACCUCCUUCAUCACCAACGGCUCAUGCCUUGCCAGCCGGAAAACUAGCUUCAUGAUGGCCCUGUGCCUGUCUUCGAUCUAUGAGGACCUGAAAAUGUACCAGGUCGAAUUUAAGACGAUGAACGCAAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUUCUGGACCAGAACAUGCUGGCAGUCAUAGAUGAGUUGAUGCAGGCAUUAAACUUCAACAGCGAGACCGUGCCUCAGAAGUCCAGCCUCGAGGAGCCAGAUUUUUAUAAGACCAAGAUCAAACUAUGCAUCCUGCUGCAUGCUUUCAGGAUUAGAGCCGUCACCAUCGAUCGAGUCAUGUCUUACCUGAAUGCUAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_018G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAACAGUUAGUAAUCUCCUGG(SEQ IDUUUUCUCUGGUGUUUCUGGCCAGCCCCCUCGUGGCCAUCUGGGAGCUUAAAAAGGACGUUUACGUGGUGGAGUUGGAUUNO: 112)GGUAUCCCGACGCUCCAGGCGAAAUGGUCGUGCUGACCUGCGAUACCCCUGAAGAAGACGGUAUCACCUGGACGCUGGACCAGUCUUCCGAGGUGCUUGGAUCUGGCAAAACACUGACAAUACAAGUUAAGGAGUUCGGGGACGCAGGGCAGUACACCUGCCACAAAGGCGGCGAGGUCCUGAGUCACUCCCUGUUACUGCUCCACAAGAAAGAGGACGGCAUUUGGUCCACCGACAUUCUGAAGGACCAGAAGGAGCCUAAGAAUAAAACUUUCCUGAGAUGCGAGGCAAAAAACUAUAGCGGCCGCUUUACUUGCUGGUGGCUUACAACAAUCUCUACCGAUUUAACUUUCUCCGUGAAGUCUAGCAGAGGAUCCUCUGACCCGCAAGGAGUGACUUGCGGAGCCGCCACCUUGAGCGCCGAAAGAGUCCGUGGCGAUAACAAAGAAUACGAGUACUCCGUGGAGUGCCAGGAAGAUUCCGCCUGCCCAGCUGCCGAGGAGUCCCUGCCCAUUGAAGUGAUGGUGGAUGCCGUCCACAAGCUGAAGUACGAAAACUAUACCAGCAGCUUCUUCAUCCGGGAUAUCAUUAAGCCCGACCCUCCUAAAAACCUGCAACUUAAGCCCCUAAAGAAUAGUCGGCAGGUUGAGGUCAGCUGGGAAUAUCCUGACACAUGGAGCACCCCCCACUCUUAUUUCUCCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGUAAACGGGAGAAAAAAGAUAGGGUCUUUACCGAUAAAACCAGCGCUACGGUUAUCUGUCGGAAGAACGCUUCCAUCUCCGUCCGCGCUCAGGAUCGUUACUACUCGUCCUCAUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGCGGCGGUGGAGGCGGAUCCAGAAAUCUGCCUGUUGCCACACCAGACCCUGGCAUGUUCCCCUGUCUGCAUCAUAGCCAGAACCUGCUCAGAGCCGUGAGCAACAUGCUCCAGAAGGCCAGGCAAACUUUGGAGUUCUACCCGUGUACAUCUGAGGAAAUCGAUCACGAAGAUAUAACCAAAGAUAAAACCUCUACAGUAGAGGCUUGUUUGCCCCUGGAGUUGACCAAAAACGAGAGUUGCCUGAACAGUCGCGAGACGAGCUUCAUUACUAACGGCAGCUGUCUCGCCUCCAGAAAAACAUCCUUCAUGAUGGCCCUGUGUCUUUCCAGCAUAUACGAAGACCUGAAAAUGUACCAGGUCGAGUUCAAAACAAUGAACGCCAAGCUGCUUAUGGACCCCAAGCGGCAGAUCUUCCUCGACCAAAACAUGCUCGCUGUGAUCGAUGAGCUGAUGCAGGCUCUCAACUUCAAUUCCGAAACAGUGCCACAGAAGUCCAGUCUGGAAGAACCCGACUUCUACAAGACCAAGAUUAAGCUGUGUAUUUUGCUGCAUGCGUUUAGAAUCAGAGCCGUGACCAUUGAUCGGGUGAUGAGCUACCUGAACGCCUCGUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_019G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUUGUCAUCUCCUGG(SEQ IDUUUUCUCUUGUCUUCCUGGCCUCGCCGCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUUUACGUAGUAGAGUUGGAUUNO: 113)GGUACCCAGACGCACCUGGAGAAAUGGUGGUUCUCACCUGUGACACUCCUGAAGAAGACGGUAUCACCUGGACGCUGGACCAAAGCUCAGAAGUUCUUGGCAGUGGAAAAACGCUGACCAUACAAGUAAAAGAAUUUGGGGAUGCUGGCCAGUACACGUGCCACAAAGGAGGAGAAGUUCUCAGCCACAGUUUACUUCUUCUUCACAAGAAAGAAGAUGGCAUCUGGUCCACAGAUAUUUUAAAAGACCAGAAGGAGCCCAAGAACAAAACCUUCCUCCGCUGUGAGGCCAAGAACUACAGUGGUCGUUUCACCUGCUGGUGGCUCACCACCAUCUCCACUGACCUCACCUUCUCUGUAAAAAGCAGCCGUGGUUCUUCUGACCCCCAAGGAGUCACCUGUGGGGCUGCCACGCUCUCGGCAGAAAGAGUUCGAGGUGACAACAAGGAAUAUGAAUAUUCUGUGGAAUGUCAAGAAGAUUCUGCCUGCCCGGCGGCAGAAGAAAGUCUUCCCAUAGAAGUCAUGGUGGAUGCUGUUCACAAAUUAAAAUAUGAAAACUACACCAGCAGCUUCUUCAUUCGUGACAUCAUCAAACCAGACCCGCCCAAGAACCUUCAGUUAAAACCUUUAAAAAACAGCCGGCAGGUAGAAGUUUCCUGGGAGUACCCAGAUACGUGGUCCACGCCGCACUCCUACUUCAGUUUAACCUUCUGUGUACAAGUACAAGGAAAAUCAAAAAGAGAGAAGAAAGAUCGUGUCUUCACUGACAAAACAUCUGCCACGGUCAUCUGCAGGAAGAAUGCCUCCAUCUCGGUUCGAGCCCAGGACCGCUACUACAGCAGCAGCUGGAGUGAGUGGGCAUCUGUUCCCUGCAGUGGUGGCGGCGGCGGCGGCAGCCGCAACCUUCCUGUGGCCACGCCGGACCCUGGCAUGUUCCCGUGCCUUCACCACUCCCAAAAUCUUCUUCGUGCUGUUUCUAACAUGCUGCAGAAGGCGCGCCAAACUUUAGAAUUCUACCCGUGCACUUCUGAAGAAAUAGACCAUGAAGAUAUCACCAAAGAUAAAACCAGCACGGUGGAGGCCUGCCUUCCUUUAGAGCUGACCAAGAAUGAAUCCUGCCUCAACAGCAGAGAGACCAGCUUCAUCACCAAUGGCAGCUGCCUGGCCUCGCGCAAGACCAGCUUCAUGAUGGCGCUGUGCCUUUCUUCCAUCUAUGAAGAUUUAAAGAUGUACCAAGUAGAAUUUAAAACCAUGAAUGCCAAAUUAUUAAUGGACCCCAAACGGCAGAUAUUUUUGGAUCAAAACAUGCUGGCUGUCAUUGAUGAGCUCAUGCAAGCAUUAAACUUCAACUCAGAAACUGUUCCCCAGAAGUCAUCUUUAGAAGAGCCAGAUUUCUACAAAACAAAAAUAAAACUCUGCAUUCUUCUUCAUGCCUUCCGCAUCCGUGCUGUCACCAUUGACCGUGUCAUGUCCUACUUAAAUGCUUCUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_020G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCUAGCCCUCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGUUGGAUUNO: 114)GGUACCCCGACGCUCCCGGCGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGGAUCACCUGGACCCUGGAUCAGUCAAGCGAGGUGCUGGGAAGCGGCAAGACCCUGACCAUCCAGGUGAAGGAGUUCGGCGACGCCGGCCAAUACACUUGCCACAAGGGAGGCGAGGUGCUGUCCCACUCCCUCCUGCUGCUGCACAAAAAGGAAGACGGCAUCUGGAGCACCGACAUCCUGAAAGACCAGAAGGAGCCUAAGAACAAAACAUUCCUCAGAUGCGAGGCCAAGAAUUACUCCGGGAGAUUCACCUGUUGGUGGCUGACCACCAUCAGCACAGACCUGACCUUCAGCGUGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGUGACCUGUGGCGCCGCCACCCUGAGCGCCGAAAGAGUGCGCGGCGACAACAAGGAGUACGAGUACUCCGUGGAAUGCCAGGAAGAUAGCGCCUGCCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUCCACAAGCUGAAGUACGAGAACUACACCUCUAGCUUCUUCAUCAGAGAUAUCAUCAAGCCCGAUCCCCCCAAGAACCUGCAGCUGAAACCCCUGAAGAACAGCCGGCAGGUGGAGGUGAGCUGGGAGUAUCCCGACACCUGGUCCACCCCCCACAGCUAUUUUAGCCUGACCUUCUGCGUGCAAGUGCAGGGCAAGAGCAAGAGAGAGAAGAAGGACCGCGUGUUCACCGACAAAACCAGCGCCACCGUGAUCUGCAGAAAGAACGCCAGCAUCAGCGUGAGGGCCCAGGAUAGAUACUACAGUUCCAGCUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGCGGCGGCGGGGGAGGCUCGAGAAACCUGCCCGUGGCUACCCCCGAUCCCGGAAUGUUCCCCUGCCUGCACCACAGCCAGAACCUGCUGAGGGCGGUGUCCAACAUGCUUCAGAAGGCCCGGCAGACCCUGGAGUUCUACCCCUGUACCUCUGAGGAGAUCGAUCAUGAAGAUAUCACAAAAGAUAAAACCAGCACCGUGGAGGCCUGCCUGCCCCUGGAGCUGACCAAGAACGAGAGCUGCCUGAACUCCCGCGAGACCAGCUUCAUCACGAACGGCAGCUGCCUGGCCAGCAGGAAGACCUCCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAAAUGUACCAGGUGGAGUUUAAGACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGGCAAAUCUUCCUGGACCAGAACAUGCUGGCAGUGAUCGACGAGCUCAUGCAGGCCCUGAACUUCAAUAGCGAGACGGUCCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUUUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUUAGAAUCCGUGCCGUGACCAUUGACAGAGUGAUGAGCUACCUGAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_021G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCCAGCCCUCUGGUUGCCAUCUGGGAGCUGAAGAAAGACGUGUACGUCGUGGAACUGGACUNO: 115)GGUAUCCGGACGCCCCGGGCGAGAUGGUGGUGCUGACCUGUGACACCCCCGAGGAGGACGGCAUCACCUGGACGCUGGACCAAUCCUCCGAGGUGCUGGGAAGCGGCAAGACCCUGACCAUCCAGGUGAAGGAAUUCGGGGACGCCGGGCAGUACACCUGCCACAAGGGGGGCGAAGUGCUGUCCCACUCGCUGCUGCUCCUGCAUAAGAAGGAGGAUGGAAUCUGGUCCACCGACAUCCUCAAAGAUCAGAAGGAGCCCAAGAACAAGACGUUCCUGCGCUGUGAAGCCAAGAAUUAUUCGGGGCGAUUCACGUGCUGGUGGCUGACAACCAUCAGCACCGACCUGACGUUUAGCGUGAAGAGCAGCAGGGGGUCCAGCGACCCCCAGGGCGUGACGUGCGGCGCCGCCACCCUCUCCGCCGAGAGGGUGCGGGGGGACAAUAAGGAGUACGAGUACAGCGUGGAAUGCCAGGAGGACAGCGCCUGCCCCGCCGCGGAGGAAAGCCUCCCGAUAGAGGUGAUGGUGGACGCCGUGCACAAGCUCAAGUAUGAGAAUUACACCAGCAGCUUUUUCAUCCGGGACAUUAUCAAGCCCGACCCCCCGAAGAACCUCCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAAGUCUCCUGGGAGUAUCCCGACACCUGGAGCACCCCGCACAGCUACUUCUCCCUGACCUUCUGUGUGCAGGUGCAGGGCAAGUCCAAGAGGGAAAAGAAGGACAGGGUUUUCACCGACAAGACCAGCGCGACCGUGAUCUGCCGGAAGAACGCCAGCAUAAGCGUCCGCGCCCAAGAUAGGUACUACAGCAGCUCCUGGAGCGAGUGGGCUAGCGUGCCCUGCAGCGGGGGCGGGGGUGGGGGCUCCAGGAACCUGCCAGUGGCGACCCCCGACCCCGGCAUGUUCCCCUGCCUCCAUCACAGCCAGAACCUGCUGAGGGCCGUCAGCAAUAUGCUGCAGAAGGCCAGGCAGACCCUGGAAUUCUACCCCUGCACGUCGGAGGAGAUCGAUCACGAGGAUAUCACAAAAGACAAGACUUCCACCGUGGAGGCCUGCCUGCCCCUGGAGCUCACCAAGAAUGAGUCCUGUCUGAACUCCCGGGAAACCAGCUUCAUCACCAACGGGUCCUGCCUGGCCAGCAGGAAGACCAGCUUUAUGAUGGCCCUGUGCCUGUCGAGCAUCUACGAGGACCUGAAGAUGUACCAGGUCGAGUUCAAGACAAUGAACGCCAAGCUGCUGAUGGACCCCAAGAGGCAAAUCUUCCUGGACCAGAAUAUGCUUGCCGUCAUCGACGAGCUCAUGCAGGCCCUGAACUUCAACUCCGAGACCGUGCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCGUUCAGGAUCCGGGCAGUCACCAUCGACCGUGUGAUGUCCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_022G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUCGCCUCUCCCCUGGUGGCCAUCUGGGAGCUCAAAAAGGACGUGUACGUGGUGGAGCUCGACUNO: 116)GGUACCCAGACGCCCCCGGGGAGAUGGUGGUGCUGACCUGCGACACCCCCGAAGAAGACGGCAUCACGUGGACCCUCGACCAGUCCAGCGAGGUGCUGGGGAGCGGGAAGACUCUGACCAUCCAGGUCAAGGAGUUCGGGGACGCCGGGCAGUACACGUGCCACAAGGGCGGCGAAGUCUUAAGCCACAGCCUGCUCCUGCUGCACAAGAAGGAGGACGGGAUCUGGUCCACAGACAUACUGAAGGACCAGAAGGAGCCGAAGAAUAAAACCUUUCUGAGGUGCGAGGCCAAGAACUAUUCCGGCAGGUUCACGUGCUGGUGGCUUACAACAAUCAGCACAGACCUGACGUUCAGCGUGAAGUCCAGCCGCGGCAGCAGCGACCCCCAGGGGGUGACCUGCGGCGCCGCCACCCUGAGCGCCGAGCGGGUGCGCGGGGACAACAAGGAGUACGAGUACUCCGUGGAGUGCCAGGAAGACAGCGCCUGUCCCGCCGCCGAAGAGAGCCUGCCUAUCGAGGUCAUGGUAGAUGCAGUGCAUAAGCUGAAGUACGAGAACUAUACGAGCAGCUUUUUCAUACGCGACAUCAUCAAGCCCGACCCCCCCAAGAACCUGCAGCUUAAGCCCCUGAAGAAUAGCCGGCAGGUGGAGGUCUCCUGGGAGUACCCCGACACCUGGUCAACGCCCCACAGCUACUUCUCCCUGACCUUUUGUGUCCAAGUCCAGGGAAAGAGCAAGAGGGAGAAGAAAGAUCGGGUGUUCACCGACAAGACCUCCGCCACGGUGAUCUGCAGGAAGAACGCCAGCAUCUCCGUGAGGGCGCAAGACAGGUACUACUCCAGCAGCUGGUCCGAAUGGGCCAGCGUGCCCUGCUCCGGCGGCGGGGGCGGCGGCAGCCGAAACCUACCCGUGGCCACGCCGGAUCCCGGCAUGUUUCCCUGCCUGCACCACAGCCAGAACCUCCUGAGGGCCGUGUCCAACAUGCUGCAGAAGGCCAGGCAGACUCUGGAGUUCUACCCCUGCACGAGCGAGGAGAUCGAUCACGAGGACAUCACCAAGGAUAAGACCAGCACUGUGGAGGCCUGCCUUCCCCUGGAGCUGACCAAGAACGAGAGCUGUCUGAACUCCAGGGAGACCUCAUUCAUCACCAACGGCUCCUGCCUGGCCAGCAGGAAAACCAGCUUCAUGAUGGCCUUGUGUCUCAGCUCCAUCUACGAGGACCUGAAGAUGUAUCAGGUCGAGUUCAAGACAAUGAACGCCAAGCUGCUGAUGGACCCCAAAAGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUCAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAGACGGUGCCCCAGAAAAGCUCCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCAGGAUCAGGGCAGUGACCAUCGACCGGGUGAUGUCAUACCUUAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_023G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUGAUCUCCUGG(SEQ IDUUCAGCCUGGUGUUUCUGGCCUCGCCCCUGGUCGCCAUCUGGGAGCUGAAGAAAGACGUGUACGUCGUCGAACUGGACUNO: 117)GGUACCCCGACGCCCCCGGGGAGAUGGUGGUGCUGACCUGCGACACGCCGGAGGAGGACGGCAUCACCUGGACCCUGGAUCAAAGCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACCAUCCAAGUGAAGGAAUUCGGCGAUGCCGGCCAGUACACCUGUCACAAAGGGGGCGAGGUGCUCAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGAUGGCAUCUGGAGCACCGAUAUCCUGAAGGACCAGAAAGAGCCCAAGAACAAGACGUUCCUGAGGUGCGAGGCCAAGAACUACAGCGGUAGGUUCACGUGUUGGUGGCUGACCACCAUCAGCACCGACCUGACGUUCAGCGUGAAGAGCUCCAGGGGCAGCUCCGACCCACAGGGGGUGACGUGCGGGGCCGCAACCCUCAGCGCCGAAAGGGUGCGGGGGGACAACAAGGAGUACGAAUACUCCGUGGAGUGCCAGGAAGAUUCGGCCUGCCCCGCCGCGGAGGAGAGCCUCCCCAUCGAGGUAAUGGUGGACGCCGUGCAUAAGCUGAAGUACGAGAACUACACCAGCUCGUUCUUCAUCCGAGACAUCAUCAAACCCGACCCGCCCAAAAAUCUGCAGCUCAAGCCCCUGAAGAACUCCAGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGUCCACCCCGCACAGCUACUUCUCCCUGACAUUCUGCGUGCAGGUGCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGUGUUCACCGACAAGACGAGCGCCACCGUGAUCUGCCGAAAGAACGCCAGCAUCUCGGUGCGCGCCCAGGAUAGGUACUAUUCCAGCUCCUGGAGCGAGUGGGCCUCGGUACCCUGCAGCGGCGGCGGGGGCGGCGGCAGUAGGAAUCUGCCCGUGGCUACCCCGGACCCGGGCAUGUUCCCCUGCCUCCACCACAGCCAGAACCUGCUGAGGGCCGUGAGCAACAUGCUGCAGAAGGCCAGACAGACGCUGGAGUUCUACCCCUGCACGAGCGAGGAGAUCGACCACGAGGACAUCACCAAGGAUAAAACUUCCACCGUCGAGGCCUGCCUGCCCUUGGAGCUGACCAAGAAUGAAUCCUGUCUGAACAGCAGGGAGACCUCGUUUAUCACCAAUGGCAGCUGCCUCGCCUCCAGGAAGACCAGCUUCAUGAUGGCCCUCUGUCUGAGCUCCAUCUAUGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCGAAGCUGCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGAUCAGAAUAUGCUGGCGGUGAUCGACGAGCUCAUGCAGGCCCUCAAUUUCAAUAGCGAGACAGUGCCCCAGAAGUCCUCCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGUAUCCUGCUGCACGCCUUCCGGAUCCGGGCCGUCACCAUCGACCGGGUCAUGAGCUACCUCAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_024G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUCUCCUGG(SEQ IDUUCUCCCUGGUGUUCCUGGCCUCGCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUCGUGGAGCUCGACUNO: 118)GGUACCCCGACGCCCCUGGCGAGAUGGUGGUGCUGACCUGCGACACCCCAGAGGAGGAUGGCAUCACCUGGACCCUGGAUCAGUCCUCCGAGGUGCUGGGCUCCGGCAAGACGCUGACCAUCCAAGUGAAGGAGUUCGGUGACGCCGGACAGUAUACCUGCCAUAAGGGCGGCGAGGUCCUGUCCCACAGCCUCCUCCUCCUGCAUAAGAAGGAGGACGGCAUCUGGAGCACCGACAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACCUUUCUGAGGUGCGAGGCCAAGAACUACAGCGGCCGAUUCACCUGCUGGUGGCUCACCACCAUAUCCACCGACCUGACUUUCUCCGUCAAGUCCUCCCGGGGGUCCAGCGACCCCCAGGGAGUGACCUGCGGCGCCGCCACCCUCAGCGCCGAGCGGGUGCGGGGGGACAACAAGGAGUACGAAUACUCCGUCGAGUGCCAGGAGGACUCCGCCUGCCCGGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUCGACGCGGUGCACAAGCUGAAGUACGAGAACUACACCAGCAGUUUCUUCAUCAGGGAUAUCAUCAAGCCAGAUCCCCCGAAGAAUCUGCAACUGAAGCCGCUGAAAAACUCACGACAGGUGGAGGUGAGCUGGGAGUACCCCGACACGUGGAGCACCCCACAUUCCUACUUCAGCCUGACCUUCUGCGUGCAGGUCCAGGGCAAGAGCAAGCGGGAGAAGAAGGACAGGGUGUUCACGGAUAAGACCAGUGCCACCGUGAUCUGCAGGAAGAACGCCUCUAUUAGCGUGAGGGCCCAGGAUCGGUAUUACUCCUCGAGCUGGAGCGAAUGGGCCUCCGUGCCCUGCAGUGGGGGGGGUGGAGGCGGGAGCAGGAACCUGCCCGUAGCAACCCCCGACCCCGGGAUGUUCCCCUGUCUGCACCACUCGCAGAACCUGCUGCGCGCGGUGAGCAACAUGCUCCAAAAAGCCCGUCAGACCUUAGAGUUCUACCCCUGCACCAGCGAAGAAAUCGACCACGAAGACAUCACCAAGGACAAAACCAGCACCGUGGAGGCGUGCCUGCCGCUGGAGCUGACCAAGAACGAGAGCUGCCUCAACUCCAGGGAGACCAGCUUUAUCACCAACGGCUCGUGCCUAGCCAGCCGGAAAACCAGCUUCAUGAUGGCCCUGUGCCUGAGCUCCAUUUACGAGGACCUGAAGAUGUAUCAGGUGGAGUUCAAGACCAUGAAUGCCAAACUCCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUCGCGGUGAUCGAUGAGCUGAUGCAGGCCCUGAACUUUAAUAGCGAGACCGUGCCCCAGAAAAGCAGCCUGGAGGAGCCGGACUUCUACAAGACCAAAAUCAAGCUGUGCAUCCUGCUCCACGCCUUCCGCAUCCGGGCCGUGACCAUCGACAGGGUGAUGAGCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_025G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUGAUUUCCUGG(SEQ IDUUCUCCCUGGUGUUCCUGGCCAGCCCCCUCGUGGCGAUCUGGGAGCUAAAGAAGGACGUGUACGUGGUGGAGCUGGACUNO: 119)GGUACCCGGACGCACCCGGCGAGAUGGUCGUUCUGACCUGCGAUACGCCAGAGGAGGACGGCAUCACCUGGACCCUCGAUCAGAGCAGCGAGGUCCUGGGGAGCGGAAAGACCCUGACCAUCCAGGUCAAGGAGUUCGGCGACGCCGGCCAGUACACCUGCCACAAAGGUGGCGAGGUCCUGAGCCACUCGCUGCUGCUCCUGCAUAAGAAGGAGGACGGAAUCUGGAGCACAGACAUCCUGAAAGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGAGGUGCGAGGCCAAGAACUACAGCGGGCGCUUCACGUGCUGGUGGCUGACCACCAUCAGCACGGACCUCACCUUCUCCGUGAAGAGCAGCCGGGGAUCCAGCGAUCCCCAAGGCGUCACCUGCGGCGCGGCCACCCUGAGCGCGGAGAGGGUCAGGGGCGAUAAUAAGGAGUAUGAGUACAGCGUGGAGUGCCAGGAGGACAGCGCCUGCCCGGCCGCCGAGGAGUCCCUGCCAAUCGAAGUGAUGGUCGACGCCGUGCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUCCGGGAUAUCAUCAAGCCCGAUCCCCCGAAGAACCUGCAGCUGAAGCCCCUCAAGAACAGCCGGCAGGUGGAGGUGAGUUGGGAGUACCCCGACACCUGGUCAACGCCCCACAGCUACUUCUCCCUGACCUUCUGUGUGCAGGUGCAGGGAAAGAGCAAGAGGGAGAAGAAAGACCGGGUCUUCACCGACAAGACCAGCGCCACGGUGAUCUGCAGGAAGAACGCAAGCAUCUCCGUGAGGGCCCAGGACAGGUACUACAGCUCCAGCUGGUCCGAAUGGGCCAGCGUGCCCUGUAGCGGCGGCGGGGGCGGUGGCAGCCGCAACCUCCCAGUGGCCACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAGAAUCUGCUGAGGGCCGUGAGUAACAUGCUGCAGAAGGCAAGGCAAACCCUCGAAUUCUAUCCCUGCACCUCCGAGGAGAUCGACCACGAGGAUAUCACCAAGGACAAGACCAGCACCGUCGAGGCCUGUCUCCCCCUGGAGCUGACCAAGAAUGAGAGCUGCCUGAACAGCCGGGAGACCAGCUUCAUCACCAACGGGAGCUGCCUGGCCUCCAGGAAGACCUCGUUCAUGAUGGCGCUGUGCCUCUCAAGCAUAUACGAGGAUCUGAAGAUGUACCAGGUGGAGUUUAAGACGAUGAACGCCAAGCUGCUGAUGGACCCGAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUGAUAGACGAGCUCAUGCAGGCCCUGAACUUCAACUCCGAGACCGUGCCGCAGAAGUCAUCCCUCGAGGAGCCCGACUUCUAUAAGACCAAGAUCAAGCUGUGCAUCCUGCUCCACGCCUUCCGGAUAAGGGCCGUGACGAUCGACAGGGUGAUGAGCUACCUUAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_026G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUCGUGAUCAGCUGG(SEQ IDUUCUCCCUGGUGUUUCUCGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGCUGGACUNO: 120)GGUACCCUGACGCCCCGGGGGAGAUGGUCGUGCUGACCUGCGACACCCCCGAAGAGGACGGUAUCACCUGGACCCUGGACCAGUCCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACUAUUCAAGUCAAGGAGUUCGGAGACGCCGGCCAGUACACCUGCCACAAGGGUGGAGAGGUGUUAUCACACAGCCUGCUGCUGCUGCACAAGAAGGAAGACGGGAUCUGGAGCACCGACAUCCUGAAGGACCAGAAGGAGCCCAAAAACAAGACCUUCCUGCGGUGCGAGGCCAAGAACUAUUCGGGCCGCUUUACGUGCUGGUGGCUGACCACCAUCAGCACUGAUCUCACCUUCAGCGUGAAGUCCUCCCGGGGGUCGUCCGACCCCCAGGGGGUGACCUGCGGGGCCGCCACCCUGUCCGCCGAGAGAGUGAGGGGCGAUAAUAAGGAGUACGAGUACAGCGUUGAGUGCCAGGAAGAUAGCGCCUGUCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUCCACAAGCUGAAGUAUGAGAACUACACCUCAAGCUUCUUCAUCAGGGACAUCAUCAAACCCGAUCCGCCCAAGAAUCUGCAGCUGAAGCCCCUGAAAAAUAGCAGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGUCCACCCCCCAUAGCUAUUUCUCCCUGACGUUCUGCGUGCAGGUGCAAGGGAAGAGCAAGCGGGAGAAGAAGGACCGGGUGUUCACCGACAAGACCUCCGCCACCGUGAUCUGUAGGAAGAACGCGUCGAUCUCGGUCAGGGCCCAGGACAGGUAUUACAGCAGCAGCUGGAGCGAGUGGGCGAGCGUGCCCUGCUCGGGCGGCGGCGGCGGCGGGAGCAGAAAUCUGCCCGUGGCCACCCCAGACCCCGGAAUGUUCCCCUGCCUGCACCAUUCGCAGAACCUCCUGAGGGCCGUGAGCAACAUGCUGCAGAAGGCCCGCCAGACGCUGGAGUUCUACCCCUGCACGAGCGAGGAGAUCGACCACGAAGACAUCACCAAGGACAAAACCAGCACCGUGGAGGCCUGCCUGCCCCUGGAGCUGACCAAAAACGAAUCCUGCCUCAACAGCCGGGAGACCAGCUUCAUCACCAACGGCAGCUGCCUGGCCAGCCGAAAGACCUCCUUCAUGAUGGCCCUCUGCCUGAGCAGCAUCUAUGAGGAUCUGAAGAUGUAUCAGGUGGAGUUCAAGACCAUGAAUGCCAAGCUGCUGAUGGACCCCAAGAGGCAGAUAUUCCUGGACCAGAAUAUGCUGGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAGACCGUCCCCCAGAAGUCCAGCCUGGAGGAGCCGGACUUUUACAAAACGAAGAUCAAGCUGUGCAUACUGCUGCACGCCUUCAGGAUCCGGGCCGUGACAAUCGACAGGGUGAUGUCCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_027G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCUCCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUCAAGAAGGACGUCUACGUCGUGGAGCUGGAUUNO: 121)GGUACCCCGACGCUCCCGGGGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGCAUCACCUGGACGCUGGACCAGAGCUCAGAGGUGCUGGGAAGCGGAAAGACACUGACCAUCCAGGUGAAGGAGUUCGGGGAUGCCGGGCAGUAUACCUGCCACAAGGGCGGCGAAGUGCUGAGCCAUUCCCUGCUGCUGCUGCACAAGAAGGAGGACGGCAUAUGGUCCACCGACAUCCUGAAGGAUCAGAAGGAGCCGAAGAAUAAAACCUUCCUGAGGUGCGAGGCCAAGAAUUACAGCGGCCGAUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACCUUCAGUGUGAAGUCCUCACGGGGCAGCUCAGAUCCCCAGGGCGUGACCUGCGGGGCCGCGACACUCAGCGCCGAGCGGGUGAGGGGUGAUAACAAGGAGUACGAGUAUUCUGUGGAGUGCCAGGAAGACUCCGCCUGUCCCGCCGCCGAGGAGUCCCUGCCCAUCGAGGUGAUGGUGGACGCCGUGCAUAAACUGAAGUACGAGAACUACACCUCCAGCUUCUUCAUCCGGGAUAUAAUCAAGCCCGACCCUCCGAAAAACCUGCAGCUGAAGCCCCUUAAAAACAGCCGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGAGCACCCCCCAUAGCUAUUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGGAAGUCCAAGCGCGAGAAAAAGGACCGGGUGUUCACCGACAAGACGAGCGCCACCGUGAUCUGCCGGAAGAACGCCAGUAUAAGCGUAAGGGCCCAGGAUAGGUACUACAGCUCCAGCUGGUCGGAGUGGGCCUCCGUGCCCUGUUCCGGCGGCGGGGGGGGUGGCAGCAGGAACCUCCCCGUGGCCACGCCGGACCCCGGCAUGUUCCCGUGCCUGCACCACUCCCAAAACCUCCUGCGGGCCGUCAGCAACAUGCUGCAAAAGGCGCGGCAGACCCUGGAGUUUUACCCCUGUACCUCCGAAGAGAUCGACCACGAGGAUAUCACCAAGGAUAAGACCUCCACCGUGGAGGCCUGUCUCCCCCUGGAGCUGACCAAGAACGAGAGCUGUCUUAACAGCAGAGAGACCUCGUUCAUAACGAACGGCUCCUGCCUCGCUUCCAGGAAGACGUCGUUCAUGAUGGCGCUGUGCCUGUCCAGCAUCUACGAGGACCUGAAGAUGUAUCAGGUCGAGUUCAAAACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUCGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAAACCGUGCCCCAGAAGUCAAGCCUGGAGGAGCCGGACUUCUAUAAGACCAAGAUCAAGCUGUGUAUCCUGCUACACGCUUUUCGUAUCCGGGCCGUGACCAUCGACAGGGUUAUGUCGUACUUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_028G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAACAGCUCGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUCCUGGCCAGCCCGCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGCUGGACUNO: 122)GGUACCCCGACGCCCCCGGCGAGAUGGUGGUCCUGACCUGCGACACGCCGGAAGAGGACGGCAUCACCUGGACCCUGGAUCAGUCCAGCGAGGUGCUGGGCUCCGGCAAGACCCUGACCAUUCAGGUGAAGGAGUUCGGCGACGCCGGUCAGUACACCUGCCACAAGGGCGGCGAGGUGCUGAGCCACAGCCUACUGCUCCUGCACAAAAAGGAGGAUGGAAUCUGGUCCACCGACAUCCUCAAGGACCAGAAGGAGCCGAAGAACAAGACGUUCCUCCGGUGCGAGGCCAAGAACUACAGCGGCAGGUUUACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACAUUUUCCGUGAAGAGCAGCCGCGGCAGCAGCGAUCCCCAGGGCGUGACCUGCGGGGCGGCCACCCUGUCCGCCGAGCGUGUGAGGGGCGACAACAAGGAGUACGAGUACAGCGUGGAAUGCCAGGAGGACAGCGCCUGUCCCGCCGCCGAGGAGAGCCUGCCAAUCGAGGUCAUGGUGGACGCCGUGCACAAGCUGAAGUACGAGAACUACACGAGCAGCUUCUUCAUCAGGGACAUCAUCAAACCGGACCCGCCCAAGAACCUGCAGCUGAAACCCUUGAAAAACAGCAGGCAGGUGGAAGUGUCUUGGGAGUACCCCGACACCUGGUCCACCCCCCACAGCUACUUUAGCCUGACCUUCUGUGUGCAGGUCCAGGGCAAGUCCAAGAGGGAGAAGAAGGACAGGGUGUUCACCGACAAAACCAGCGCCACCGUGAUCUGCAGGAAGAACGCCUCCAUCAGCGUGCGGGCCCAGGACAGGUAUUACAGCUCGUCGUGGAGCGAGUGGGCCAGCGUGCCCUGCUCCGGGGGAGGCGGCGGCGGAAGCCGGAAUCUGCCCGUGGCCACCCCCGAUCCCGGCAUGUUCCCGUGUCUGCACCACAGCCAGAACCUGCUGCGGGCCGUGAGCAACAUGCUGCAGAAGGCCCGCCAAACCCUGGAGUUCUACCCCUGUACAAGCGAGGAGAUCGACCAUGAGGACAUUACCAAGGACAAGACCAGCACCGUGGAGGCCUGCCUGCCCCUCGAGCUCACAAAGAACGAAUCCUGCCUGAAUAGCCGCGAGACCAGCUUUAUCACGAACGGGUCCUGCCUCGCCAGCCGGAAGACAAGCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAAAUGUACCAAGUGGAGUUCAAAACGAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGCCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUCAUCGACGAGCUCAUGCAGGCCCUGAACUUCAACAGCGAGACCGUGCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUACAAGACGAAGAUCAAGCUCUGCAUCCUGCUGCACGCUUUCCGCAUCCGCGCGGUGACCAUCGACCGGGUGAUGAGCUACCUCAACGCCAGUUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_029G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAACAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUGGUGUUUCUGGCCUCCCCUCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGCUGGACUNO: 123)GGUACCCUGACGCCCCCGGCGAAAUGGUGGUGCUGACGUGCGACACCCCCGAGGAGGAUGGCAUCACCUGGACCCUGGACCAAAGCAGCGAGGUCCUCGGAAGCGGCAAGACCCUCACUAUCCAAGUGAAGGAGUUCGGGGAUGCGGGCCAGUACACCUGCCACAAGGGCGGCGAGGUGCUGUCUCAUAGCCUGCUGCUCCUGCAUAAGAAGGAAGACGGCAUCUGGAGCACCGACAUACUGAAGGAUCAGAAGGAGCCCAAGAACAAGACCUUCCUGAGGUGCGAGGCCAAGAACUACUCCGGGCGCUUCACCUGUUGGUGGCUGACCACCAUCUCCACCGACCUGACCUUCAGCGUGAAGAGCAGCAGGGGGAGCAGCGACCCCCAGGGGGUGACCUGCGGAGCCGCGACCUUGUCGGCCGAGCGGGUGAGGGGCGACAAUAAGGAGUACGAGUACUCGGUCGAAUGCCAGGAGGACUCCGCCUGCCCCGCCGCCGAGGAGUCCCUCCCCAUCGAAGUGAUGGUGGACGCCGUCCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUACGGGAUAUCAUCAAGCCCGACCCCCCGAAGAACCUGCAGCUGAAACCCUUGAAGAACUCCAGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGUCCACCCCGCACUCAUACUUCAGCCUGACCUUCUGUGUACAGGUCCAGGGCAAGAGCAAGAGGGAAAAGAAGGAUAGGGUGUUCACCGACAAGACCUCCGCCACGGUGAUCUGUCGGAAAAACGCCAGCAUCUCCGUGCGGGCCCAGGACAGGUACUAUUCCAGCAGCUGGAGCGAGUGGGCCUCCGUCCCCUGCUCCGGCGGCGGUGGCGGGGGCAGCAGGAACCUCCCCGUGGCCACCCCCGAUCCCGGGAUGUUCCCAUGCCUGCACCACAGCCAAAACCUGCUGAGGGCCGUCUCCAAUAUGCUGCAGAAGGCGAGGCAGACCCUGGAGUUCUACCCCUGUACCUCCGAGGAGAUCGACCACGAGGAUAUCACCAAGGACAAGACCUCCACGGUCGAGGCGUGCCUGCCCCUGGAGCUCACGAAGAACGAGAGCUGCCUUAACUCCAGGGAAACCUCGUUUAUCACGAACGGCAGCUGCCUGGCGUCACGGAAGACCUCCUUUAUGAUGGCCCUAUGUCUGUCCUCGAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGAUCCCAAGAGGCAGAUUUUCCUGGACCAGAACAUGCUGGCCGUGAUUGACGAGCUGAUGCAGGCGCUGAACUUCAACAGCGAGACAGUGCCGCAGAAGAGCUCCCUGGAGGAGCCGGACUUUUACAAGACCAAGAUAAAGCUGUGCAUCCUGCUCCACGCCUUCAGAAUACGGGCCGUCACCAUCGAUAGGGUGAUGUCUUACCUGAACGCCUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_030G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUGGUGAUUAGCUGG(SEQ IDUUUAGCCUGGUGUUCCUGGCAAGCCCCCUGGUGGCCAUCUGGGAACUGAAAAAGGACGUGUACGUGGUCGAGCUGGAUUNO: 124)GGUACCCCGACGCCCCCGGCGAAAUGGUGGUGCUGACGUGUGAUACCCCCGAGGAGGACGGGAUCACCUGGACCCUGGAUCAGAGCAGCGAGGUGCUGGGGAGCGGGAAGACCCUGACGAUCCAGGUCAAGGAGUUCGGCGACGCUGGGCAGUACACCUGUCACAAGGGCGGGGAGGUGCUGUCCCACUCCCUGCUGCUCCUGCAUAAGAAAGAGGACGGCAUCUGGUCCACCGACAUCCUCAAGGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGCGGUGUGAGGCGAAGAACUACAGCGGCCGUUUCACCUGCUGGUGGCUGACGACAAUCAGCACCGACUUGACGUUCUCCGUGAAGUCCUCCAGAGGCAGCUCCGACCCCCAAGGGGUGACGUGCGGCGCGGCCACCCUGAGCGCCGAGCGGGUGCGGGGGGACAACAAGGAGUACGAGUACUCCGUGGAGUGCCAGGAGGACAGCGCCUGUCCCGCAGCCGAGGAGUCCCUGCCCAUCGAAGUCAUGGUGGACGCCGUCCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUCCGCGAUAUCAUCAAGCCCGAUCCCCCCAAAAACCUGCAACUGAAGCCGCUGAAGAAUAGCAGGCAGGUGGAGGUGUCCUGGGAGUACCCGGACACCUGGAGCACGCCCCACAGCUAUUUCAGCCUGACCUUUUGCGUGCAGGUCCAGGGGAAGAGCAAGCGGGAGAAGAAGGACCGCGUGUUUACGGACAAAACCAGCGCCACCGUGAUCUGCAGGAAGAACGCCAGCAUCAGCGUGAGGGCCCAGGACAGGUACUACAGCAGCUCCUGGAGCGAGUGGGCCUCCGUGCCCUGUUCCGGAGGCGGCGGGGGCGGUUCCCGGAACCUCCCGGUGGCCACCCCCGACCCGGGCAUGUUCCCGUGCCUGCACCACUCACAGAAUCUGCUGAGGGCCGUGAGCAAUAUGCUGCAGAAGGCAAGGCAGACCCUGGAGUUUUAUCCCUGCACCAGCGAGGAGAUCGACCACGAAGACAUCACCAAGGACAAGACCAGCACAGUGGAGGCCUGCCUGCCCCUGGAACUGACCAAGAACGAGUCCUGUCUGAACUCCCGGGAAACCAGCUUCAUAACCAACGGCUCCUGUCUCGCCAGCAGGAAGACCAGCUUCAUGAUGGCCCUGUGCCUCAGCUCCAUCUACGAGGACCUCAAGAUGUACCAGGUUGAGUUCAAGACCAUGAACGCCAAGCUCCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGACCAGAAUAUGCUGGCCGUGAUCGAUGAGUUAAUGCAGGCGCUGAACUUCAACAGCGAGACGGUGCCCCAAAAGUCCUCGCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUCCUGCACGCCUUCCGAAUCCGGGCCGUAACCAUCGACAGGGUGAUGAGCUAUCUCAACGCCUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_031G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUCGUGAUCAGCUGG(SEQ IDUUCUCGCUUGUGUUCCUGGCCUCCCCCCUCGUCGCCAUCUGGGAGCUGAAGAAAGACGUGUACGUGGUGGAGCUGGACUNO: 125)GGUAUCCCGACGCCCCGGGGGAGAUGGUGGUGCUGACCUGCGACACCCCGGAAGAGGACGGCAUCACCUGGACGCUCGACCAGUCGUCCGAAGUGCUGGGGUCGGGCAAGACCCUCACCAUCCAGGUGAAGGAGUUCGGAGACGCCGGCCAGUACACCUGUCAUAAGGGGGGGGAGGUGCUGAGCCACAGCCUCCUGCUCCUGCACAAAAAGGAGGACGGCAUCUGGAGCACCGAUAUCCUCAAGGACCAGAAGGAGCCCAAGAACAAGACGUUCCUGAGGUGUGAGGCCAAGAACUACAGCGGGCGGUUCACGUGUUGGUGGCUCACCACCAUCUCCACCGACCUCACCUUCUCCGUGAAGUCAAGCAGGGGCAGCUCCGACCCCCAAGGCGUCACCUGCGGCGCCGCCACCCUGAGCGCCGAGAGGGUCAGGGGGGAUAACAAGGAAUACGAGUACAGUGUGGAGUGCCAAGAGGAUAGCGCCUGUCCCGCCGCCGAAGAGAGCCUGCCCAUCGAAGUGAUGGUGGACGCCGUGCACAAGCUGAAGUACGAGAACUACACCUCCAGCUUCUUCAUCAGGGAUAUCAUCAAGCCCGAUCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCAGGCAGGUGGAGGUGAGCUGGGAGUAUCCCGACACGUGGAGCACCCCGCACAGCUACUUCUCGCUGACCUUCUGCGUGCAGGUGCAAGGGAAGUCCAAGAGGGAGAAGAAGGAUAGGGUGUUCACCGACAAAACGAGCGCCACCGUGAUCUGCCGGAAGAAUGCCAGCAUCUCUGUGAGGGCCCAGGACAGGUACUAUUCCAGCUCCUGGUCGGAGUGGGCCAGCGUGCCCUGUAGCGGCGGGGGCGGGGGCGGCAGCAGGAACCUCCCGGUUGCCACCCCCGACCCCGGCAUGUUUCCGUGCCUGCACCACUCGCAAAACCUGCUGCGCGCGGUCUCCAACAUGCUGCAAAAAGCGCGCCAGACGCUGGAGUUCUACCCCUGCACCAGCGAGGAGAUCGAUCAUGAAGAUAUCACCAAAGACAAGACCUCGACCGUGGAGGCCUGCCUGCCCCUGGAGCUCACCAAGAACGAAAGCUGCCUGAACAGCAGGGAGACAAGCUUCAUCACCAACGGCAGCUGCCUGGCCUCCCGGAAGACCAGCUUCAUGAUGGCCCUGUGCCUGUCCAGCAUCUACGAGGAUCUGAAGAUGUACCAAGUGGAGUUUAAGACCAUGAACGCCAAGCUGUUAAUGGACCCCAAAAGGCAGAUCUUCCUGGAUCAGAACAUGCUGGCCGUCAUCGACGAGCUGAUGCAAGCCCUGAACUUCAACAGCGAGACGGUGCCCCAGAAGAGCAGCCUCGAGGAGCCCGACUUCUAUAAGACCAAGAUAAAGCUGUGCAUUCUGCUGCACGCCUUCAGAAUCAGGGCCGUGACCAUCGAUAGGGUGAUGAGCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_032G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCACCAGCAGCUGGUGAUUUCCUGG(SEQ IDUUCAGUCUGGUGUUUCUUGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUAUACGUCGUGGAGCUGGACUNO: 126)GGUAUCCCGACGCUCCCGGCGAGAUGGUGGUCCUCACCUGCGACACCCCAGAGGAGGACGGCAUCACCUGGACCCUGGACCAGAGCUCCGAGGUCCUGGGCAGCGGUAAGACCCUCACCAUCCAGGUGAAGGAGUUUGGUGAUGCCGGGCAGUAUACCUGCCACAAGGGCGGCGAGGUGCUGUCCCACAGCCUCCUGUUACUGCAUAAGAAGGAGGAUGGCAUCUGGAGCACCGACAUCCUCAAGGACCAGAAAGAGCCCAAGAACAAGACCUUUCUGCGGUGCGAGGCGAAAAAUUACUCCGGCCGGUUCACCUGCUGGUGGCUGACCACCAUCAGCACGGACCUGACGUUCUCCGUGAAGUCGAGCAGGGGGAGCUCCGAUCCCCAGGGCGUGACCUGCGGCGCGGCCACCCUGAGCGCCGAGCGCGUCCGCGGGGACAAUAAGGAAUACGAAUAUAGCGUGGAGUGCCAGGAGGACAGCGCCUGCCCCGCGGCCGAGGAGAGCCUCCCGAUCGAGGUGAUGGUGGAUGCCGUCCACAAGCUCAAAUACGAAAACUACACCAGCAGCUUCUUCAUUAGGGACAUCAUCAAGCCCGACCCCCCCAAAAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGCCAGGUCGAGGUGUCAUGGGAGUACCCAGACACCUGGAGCACCCCCCACUCCUACUUCAGCCUGACCUUCUGCGUCCAGGUGCAGGGAAAGUCCAAACGGGAGAAGAAGGAUAGGGUCUUUACCGAUAAGACGUCGGCCACCGUCAUCUGCAGGAAGAACGCCAGCAUAAGCGUGCGGGCGCAGGAUCGGUACUACAGCUCGAGCUGGUCCGAAUGGGCCUCCGUGCCCUGUAGCGGAGGGGGUGGCGGGGGCAGCAGGAACCUGCCCGUGGCCACCCCGGACCCGGGCAUGUUUCCCUGCCUGCAUCACAGUCAGAACCUGCUGAGGGCCGUGAGCAACAUGCUCCAGAAGGCCCGCCAGACCCUGGAGUUUUACCCCUGCACCAGCGAAGAGAUCGAUCACGAAGACAUCACCAAAGACAAGACCUCCACCGUGGAGGCCUGUCUGCCCCUGGAGCUGACCAAGAACGAGAGCUGUCUGAACAGCAGGGAGACCUCCUUCAUCACCAACGGCUCCUGCCUGGCAUCCCGGAAGACCAGCUUCAUGAUGGCCCUGUGUCUGAGCUCUAUCUACGAGGACCUGAAGAUGUACCAGGUCGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGACAGAUAUUCCUGGACCAGAACAUGCUCGCCGUGAUCGAUGAACUGAUGCAAGCCCUGAACUUCAAUAGCGAGACCGUGCCCCAGAAAAGCAGCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAACUGUGCAUACUGCUGCACGCGUUCAGGAUCCGGGCCGUCACCAUCGACCGGGUGAUGUCCUAUCUGAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_033G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUCGUGAUUAGCUGG(SEQ IDUUUUCGCUGGUGUUCCUGGCCAGCCCUCUCGUGGCCAUCUGGGAGCUGAAAAAAGACGUGUACGUGGUGGAGCUGGACUNO: 127)GGUACCCGGACGCCCCCGGCGAGAUGGUGGUGCUGACGUGCGACACCCCGGAAGAGGACGGCAUCACCUGGACCCUGGACCAGUCAUCCGAGGUCCUGGGCAGCGGCAAGACGCUCACCAUCCAGGUGAAGGAGUUCGGCGACGCCGGCCAGUACACAUGCCAUAAGGGCGGGGAGGUGCUGAGCCACAGCCUGCUCCUCCUGCACAAGAAGGAGGAUGGCAUCUGGUCUACAGACAUCCUGAAGGACCAGAAAGAGCCCAAGAACAAGACCUUCCUCCGGUGCGAGGCCAAGAACUACUCCGGGCGGUUUACUUGUUGGUGGCUGACCACCAUCAGCACCGACCUCACCUUCAGCGUGAAGAGCUCCCGAGGGAGCUCCGACCCCCAGGGGGUCACCUGCGGCGCCGCCACCCUGAGCGCCGAGCGGGUGAGGGGCGACAACAAGGAGUAUGAAUACAGCGUGGAAUGCCAAGAGGACAGCGCCUGUCCCGCGGCCGAGGAAAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUCCACAAACUCAAGUACGAGAACUACACCAGCAGUUUCUUCAUUCGCGACAUCAUCAAGCCGGACCCCCCCAAAAACCUGCAGCUCAAACCCCUGAAGAACAGCAGGCAGGUGGAGGUCAGCUGGGAGUACCCGGACACCUGGAGCACCCCCCAUAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGCAAACGCGAGAAGAAGGACCGGGUGUUUACCGACAAGACCAGCGCCACGGUGAUCUGCCGAAAGAAUGCAAGCAUCUCCGUGAGGGCGCAGGACCGCUACUACUCUAGCAGCUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGUGGCGGCGGAGGCGGCAGCCGUAACCUCCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCGUGUCUGCACCACUCCCAGAACCUGCUGAGGGCCGUCAGCAAUAUGCUGCAGAAGGCCCGGCAGACGCUGGAGUUCUACCCCUGCACCUCCGAGGAGAUCGACCAUGAGGACAUUACCAAGGACAAGACGAGCACUGUGGAGGCCUGCCUGCCCCUGGAGCUCACCAAAAACGAGAGCUGCCUGAAUAGCAGGGAGACGUCCUUCAUCACCAACGGCAGCUGUCUGGCCAGCAGGAAGACCAGCUUCAUGAUGGCCCUGUGCCUCUCCUCCAUAUAUGAGGAUCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGAUCCCAAGAGGCAGAUCUUCCUGGACCAGAAUAUGCUGGCCGUGAUUGACGAGCUGAUGCAGGCCCUGAACUUUAAUAGCGAGACCGUCCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUAUAAGACCAAGAUCAAGCUGUGCAUACUGCUGCACGCGUUUAGGAUAAGGGCCGUCACCAUCGACAGGGUGAUGAGCUACCUGAAUGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_034G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAACAGCUGGUGAUCUCCUGG(SEQ IDUUCAGCCUGGUGUUCCUCGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAAGACGUGUACGUGGUGGAGCUGGACUNO: 128)GGUAUCCCGACGCCCCCGGCGAGAUGGUCGUGCUGACCUGCGACACCCCGGAGGAGGACGGCAUCACCUGGACCCUGGAUCAGUCCUCCGAGGUGCUGGGCAGCGGGAAGACCCUGACCAUCCAGGUGAAAGAGUUCGGAGAUGCCGGCCAGUAUACCUGUCACAAGGGGGGUGAGGUGCUGAGCCAUAGCCUCUUGCUUCUGCACAAGAAGGAGGACGGCAUCUGGUCCACCGACAUCCUCAAGGACCAAAAGGAGCCGAAGAAUAAAACGUUCCUGAGGUGCGAAGCCAAGAACUAUUCCGGACGGUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUCACCUUCUCCGUAAAGUCAAGCAGGGGCAGCUCCGACCCCCAGGGCGUGACCUGCGGAGCCGCCACCCUGAGCGCAGAGAGGGUGAGGGGCGACAACAAGGAGUACGAAUACUCCGUCGAGUGCCAGGAGGACAGCGCCUGCCCCGCCGCCGAGGAAAGUCUGCCCAUCGAGGUGAUGGUGGACGCCGUGCACAAGCUCAAAUACGAGAACUACACCAGCAGCUUCUUCAUCCGGGAUAUCAUCAAGCCCGACCCUCCAAAGAAUCUGCAGCUGAAACCCCUUAAGAACAGCAGGCAGGUGGAGGUCAGCUGGGAGUACCCCGACACCUGGAGCACGCCCCACUCCUACUUUAGCCUGACCUUUUGCGUGCAGGUGCAGGGGAAAAGCAAGCGGGAGAAGAAGGACAGGGUGUUCACCGAUAAGACCUCCGCUACCGUGAUCUGCAGGAAGAACGCCUCAAUCAGCGUGAGGGCCCAGGAUCGGUACUACUCCAGCUCCUGGAGCGAGUGGGCCAGCGUGCCCUGCUCUGGCGGUGGCGGCGGGGGCAGCCGGAACCUGCCGGUGGCCACUCCCGACCCGGGCAUGUUCCCGUGCCUCCACCAUUCCCAGAACCUGCUGCGGGCCGUGUCCAAUAUGCUCCAGAAGGCAAGGCAGACCCUGGAGUUCUACCCCUGCACCAGCGAGGAGAUCGAUCACGAGGACAUCACCAAAGACAAAACCAGCACGGUCGAGGCCUGCCUGCCCCUGGAACUCACCAAGAACGAAAGCUGUCUCAACAGCCGCGAGACCAGCUUCAUAACCAACGGUUCCUGUCUGGCCUCCCGCAAGACCAGCUUUAUGAUGGCCCUCUGUCUGAGCUCCAUCUAUGAAGACCUGAAAAUGUACCAGGUGGAGUUCAAAACCAUGAACGCCAAGCUUCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGAUCAGAACAUGCUGGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUUAACUCCGAGACCGUGCCCCAGAAAAGCAGCCUGGAAGAGCCCGAUUUCUACAAAACGAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCCGGAUCCGUGCGGUGACCAUCGAUAGGGUGAUGAGCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_035G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAACAGCUGGUAAUCAGCUGG(SEQ IDUUCAGCCUGGUUUUCCUCGCGUCGCCCCUGGUGGCCAUCUGGGAGUUAAAGAAGGACGUGUACGUGGUGGAGCUGGAUUNO: 129)GGUACCCCGACGCCCCGGGCGAGAUGGUCGUGCUCACCUGCGAUACCCCCGAGGAGGACGGGAUCACCUGGACCCUGGACCAAUCCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACCAUACAGGUGAAGGAAUUUGGGGACGCCGGGCAGUACACCUGCCACAAGGGCGGGGAAGUGCUGUCCCACUCCCUCCUGCUGCUGCAUAAGAAGGAGGACGGCAUCUGGAGCACCGACAUCCUGAAGGACCAAAAGGAGCCCAAGAACAAGACCUUCCUGAGGUGCGAGGCCAAAAACUAUUCCGGCCGCUUUACCUGUUGGUGGCUGACCACCAUCUCCACCGAUCUGACCUUCAGCGUGAAGUCGUCUAGGGGCUCCUCCGACCCCCAGGGCGUAACCUGCGGCGCCGCGACCCUGAGCGCCGAGAGGGUGCGGGGCGAUAACAAAGAGUACGAGUACUCGGUGGAGUGCCAGGAGGACAGCGCCUGUCCGGCGGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUCCACAAGCUGAAGUACGAGAACUACACCAGUUCGUUCUUCAUCAGGGACAUCAUCAAGCCGGACCCCCCCAAGAACCUCCAGCUGAAGCCCCUGAAGAACAGCAGGCAGGUGGAAGUGUCCUGGGAGUAUCCCGACACCUGGAGCACCCCCCACAGCUACUUCAGCCUGACCUUUUGCGUGCAGGUGCAGGGCAAAAGCAAGAGGGAAAAGAAGGACCGGGUGUUCACCGAUAAGACGAGCGCCACCGUUAUCUGCAGGAAGAACGCCUCCAUAAGCGUGAGGGCGCAGGACCGUUACUACAGCAGCAGCUGGAGUGAGUGGGCAAGCGUGCCCUGUAGCGGCGGGGGCGGGGGCGGGUCCCGCAACCUCCCCGUCGCCACCCCCGACCCAGGCAUGUUUCCGUGCCUGCACCACAGCCAGAACCUGCUGCGGGCCGUUAGCAACAUGCUGCAGAAGGCCAGGCAGACCCUCGAGUUCUAUCCCUGCACAUCUGAGGAGAUCGACCACGAAGACAUCACUAAGGAUAAGACCUCCACCGUGGAGGCCUGUCUGCCCCUCGAGCUGACCAAGAAUGAAUCCUGCCUGAACAGCCGAGAGACCAGCUUUAUCACCAACGGCUCCUGCCUGGCCAGCAGGAAGACCUCCUUCAUGAUGGCCCUGUGCCUCUCCAGCAUCUACGAGGAUCUGAAGAUGUACCAGGUAGAGUUCAAGACGAUGAACGCCAAGCUCCUGAUGGACCCCAAGAGGCAGAUAUUCCUGGACCAGAACAUGCUGGCGGUGAUCGACGAGCUGAUGCAGGCCCUGAAUUUCAACAGCGAGACGGUGCCACAGAAGUCCAGCCUGGAGGAGCCAGACUUCUACAAGACCAAGAUCAAACUGUGCAUCCUCCUGCACGCGUUCAGGAUCCGCGCCGUCACCAUAGACAGGGUGAUGAGUUAUCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_036G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUAAUCAGCUGG(SEQ IDUUUAGCCUGGUGUUCCUGGCCAGCCCACUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAACUGGACUNO: 130GGUACCCCGACGCCCCUGGCGAGAUGGUGGUACUGACCUGUGACACCCCGGAGGAAGACGGUAUCACCUGGACCCUGGAUCAGAGCUCCGAGGUGCUGGGCUCCGGCAAGACACUGACCAUCCAAGUUAAGGAAUUUGGGGACGCCGGCCAGUACACCUGCCACAAGGGGGGCGAGGUGCUGUCCCACUCCCUGCUGCUUCUGCAUAAGAAGGAGGAUGGCAUCUGGUCCACCGACAUACUGAAGGACCAGAAGGAGCCCAAGAAUAAGACCUUCCUGAGAUGCGAGGCCAAGAACUACUCGGGAAGGUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACCUUCUCCGUGAAGAGCUCCCGGGGCAGCUCCGACCCCCAGGGCGUAACCUGUGGGGCCGCUACCCUGUCCGCCGAGAGGGUCCGGGGCGACAACAAGGAAUACGAGUACAGCGUGGAGUGCCAGGAGGACUCCGCCUGCCCCGCCGCCGAGGAGUCGCUGCCCAUAGAGGUGAUGGUGGACGCCGUGCACAAGCUCAAGUACGAGAAUUACACCAGCAGCUUCUUUAUCAGGGACAUAAUUAAGCCGGACCCCCCAAAGAAUCUGCAGCUGAAGCCCCUGAAGAAUAGCCGGCAGGUGGAAGUGUCCUGGGAGUACCCCGACACCUGGAGCACCCCCCACUCCUAUUUCUCACUGACAUUCUGCGUGCAGGUGCAAGGGAAAAGCAAGAGGGAGAAGAAGGAUAGGGUGUUCACCGACAAGACAAGCGCCACCGUGAUCUGCCGAAAAAAUGCCAGCAUCAGCGUGAGGGCCCAGGAUCGGUAUUACAGCAGCUCCUGGAGCGAGUGGGCCAGCGUGCCCUGUUCCGGCGGGGGAGGGGGCGGCUCCCGGAACCUGCCGGUGGCCACCCCCGACCCUGGCAUGUUCCCCUGCCUGCAUCACAGCCAGAACCUGCUCCGGGCCGUGUCGAACAUGCUGCAGAAGGCCCGGCAGACCCUCGAGUUUUACCCCUGCACCAGCGAAGAGAUCGACCACGAAGACAUAACCAAGGACAAGACCAGCACGGUGGAGGCCUGCCUGCCCCUGGAGCUUACCAAAAACGAGUCCUGCCUGAACAGCCGGGAAACCAGCUUCAUAACGAACGGGAGCUGCCUGGCCUCCAGGAAGACCAGCUUCAUGAUGGCGCUGUGUCUGUCCAGCAUAUACGAGGAUCUGAAGAUGUAUCAGGUGGAAUUCAAAACUAUGAAUGCCAAGCUCCUGAUGGACCCCAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUAGCCGUGAUCGACGAGCUGAUGCAGGCCCUCAACUUCAACUCGGAGACGGUGCCCCAGAAGUCCAGCCUCGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUACUGCUGCAUGCCUUCAGGAUAAGGGCGGUGACUAUCGACAGGGUCAUGUCCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_037G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAACAACUGGUGAUCAGCUGG(SEQ IDUUCUCCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUCAAAAAAGACGUGUACGUGGUGGAGCUCGAUUNO: 131)GGUACCCAGACGCGCCGGGGGAAAUGGUGGUGCUGACCUGCGACACCCCAGAGGAGGAUGGCAUCACGUGGACGCUGGAUCAGUCCAGCGAGGUGCUGGGGAGCGGCAAGACGCUCACCAUCCAGGUGAAGGAAUUUGGCGACGCGGGCCAGUAUACCUGUCACAAGGGCGGCGAGGUGCUGAGCCACUCCCUGCUGCUGCUGCACAAGAAGGAGGAUGGGAUCUGGUCAACCGAUAUCCUGAAAGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGCGCUGCGAGGCCAAGAACUAUAGCGGCAGGUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACCUUCAGCGUGAAAUCCUCCAGGGGCAGCAGCGACCCCCAGGGCGUGACCUGCGGUGCCGCCACGCUCUCCGCCGAGCGAGUGAGGGGUGACAACAAGGAGUACGAGUACAGCGUGGAAUGUCAGGAGGACAGCGCCUGUCCCGCCGCCGAGGAGUCGCUGCCCAUCGAGGUGAUGGUCGACGCGGUGCACAAGCUCAAAUACGAGAAUUACACCAGCAGCUUCUUCAUCAGGGACAUCAUCAAGCCCGACCCCCCCAAGAACCUGCAGCUGAAGCCCUUGAAGAACAGCAGGCAGGUGGAGGUGAGCUGGGAGUACCCGGACACCUGGAGCACCCCCCACUCCUACUUCAGCCUGACGUUCUGUGUGCAGGUGCAGGGGAAGUCCAAGAGGGAGAAGAAGGACCGGGUGUUCACCGACAAGACCAGCGCCACCGUGAUAUGCCGCAAGAACGCGUCCAUCAGCGUUCGCGCCCAGGACCGCUACUACAGCAGCUCCUGGUCCGAAUGGGCCAGCGUGCCCUGCAGCGGUGGAGGGGGCGGGGGCUCCAGGAAUCUGCCGGUGGCCACCCCCGACCCCGGGAUGUUCCCGUGUCUGCAUCACUCCCAGAACCUGCUGCGGGCCGUGAGCAAUAUGCUGCAGAAGGCCAGGCAGACGCUCGAGUUCUACCCCUGCACCUCCGAAGAGAUCGACCAUGAGGACAUCACCAAGGACAAGACCAGCACCGUGGAGGCCUGCCUCCCCCUGGAGCUGACCAAAAACGAGAGCUGCCUGAACUCCAGGGAGACCAGCUUUAUAACCAACGGCAGCUGCCUCGCCUCCAGGAAGACCUCGUUUAUGAUGGCCCUCUGCCUGUCCAGCAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCGAAGUUGCUCAUGGACCCCAAGAGGCAGAUCUUCCUGGACCAGAACAUGCUCGCGGUGAUCGACGAGCUGAUGCAAGCCCUGAACUUCAACAGCGAGACCGUGCCCCAGAAGAGCAGCCUGGAAGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCCGGAUCCGGGCCGUGACCAUCGACAGGGUGAUGAGCUACCUCAACGCCUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_038G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUCGUGAUCAGCUGG(SEQ IDUUCUCCCUCGUCUUCCUGGCCUCCCCGCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGCUGGACUNO: 132)GGUAUCCCGACGCCCCCGGCGAGAUGGUGGUGCUGACGUGCGACACACCAGAAGAGGACGGGAUCACAUGGACCCUGGAUCAGUCGUCCGAGGUGCUGGGGAGCGGCAAGACCCUCACCAUCCAAGUGAAGGAGUUCGGGGACGCCGGCCAGUACACCUGCCACAAGGGCGGGGAGGUGCUCUCCCAUAGCCUGCUCCUCCUGCACAAAAAGGAGGAUGGCAUCUGGAGCACCGACAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACAUUUCUCAGGUGUGAGGCCAAGAACUAUUCGGGCAGGUUUACCUGUUGGUGGCUCACCACCAUCUCUACCGACCUGACGUUCUCCGUCAAGUCAAGCAGGGGGAGCUCGGACCCCCAGGGGGUGACAUGUGGGGCCGCCACCCUGAGCGCGGAGCGUGUCCGCGGCGACAACAAGGAGUACGAGUAUUCCGUGGAGUGCCAGGAGGACAGCGCCUGCCCCGCCGCCGAGGAGUCCCUGCCCAUAGAGGUGAUGGUGGACGCCGUCCACAAGUUGAAGUACGAAAAUUAUACCUCCUCGUUCUUCAUUAGGGACAUCAUCAAGCCUGACCCCCCGAAGAACCUACAACUCAAGCCCCUCAAGAACUCCCGCCAGGUGGAGGUGUCCUGGGAGUACCCCGACACCUGGUCCACCCCGCACAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUCCAGGGGAAGAGCAAGCGUGAAAAGAAAGACAGGGUGUUCACCGACAAGACGAGCGCCACCGUGAUCUGCAGGAAAAACGCCUCCAUCUCCGUGCGCGCCCAGGACAGGUACUACAGUAGCUCCUGGAGCGAAUGGGCCAGCGUGCCGUGCAGCGGCGGGGGAGGAGGCGGCAGUCGCAACCUGCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCAUGCCUGCACCACAGCCAGAACCUGCUGAGGGCAGUCAGCAAUAUGCUGCAGAAGGCCAGGCAGACCCUGGAGUUUUAUCCCUGCACCAGCGAGGAGAUCGACCACGAGGACAUCACCAAGGACAAGACCUCCACCGUCGAGGCCUGCCUGCCACUGGAGCUGACCAAAAACGAGAGCUGCCUGAACUCCAGGGAGACCUCCUUCAUCACCAACGGGAGCUGCCUGGCCAGCCGGAAGACCAGCUUCAUGAUGGCGCUGUGCCUCAGCAGCAUCUACGAGGAUCUCAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCGAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUGAUUGACGAGCUCAUGCAGGCCCUGAACUUCAAUAGCGAGACCGUCCCCCAAAAGAGCAGCCUGGAGGAACCCGACUUCUACAAAACGAAGAUCAAGCUCUGCAUCCUGCUGCACGCCUUCCGGAUCCGGGCCGUGACCAUCGAUCGUGUGAUGAGCUACCUGAACGCCUCGUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_039G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCACCAGCAGCUCGUCAUCUCCUGG(SEQ IDUUUAGCCUGGUGUUUCUGGCCUCCCCCCUGGUCGCCAUCUGGGAGCUGAAGAAAGACGUGUACGUGGUGGAGCUGGACUNO: 133)GGUACCCGGACGCUCCCGGGGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGCAUCACCUGGACCCUGGACCAGAGCUCCGAGGUGCUGGGGAGCGGCAAGACCCUGACCAUUCAGGUGAAAGAGUUCGGCGACGCCGGCCAAUAUACCUGCCACAAGGGGGGGGAGGUCCUGUCGCAUUCCCUGCUGCUGCUUCACAAAAAGGAGGAUGGCAUCUGGAGCACCGACAUCCUGAAGGACCAGAAAGAACCCAAGAACAAGACGUUCCUGCGCUGCGAGGCCAAGAACUACAGCGGCCGGUUCACCUGUUGGUGGCUGACCACCAUCUCCACCGACCUGACUUUCUCGGUGAAGAGCAGCCGCGGGAGCAGCGACCCCCAGGGAGUGACCUGCGGCGCCGCCACCCUGAGCGCCGAAAGGGUGAGGGGCGACAAUAAAGAGUACGAGUAUUCCGUGGAGUGCCAGGAGGACAGCGCCUGUCCCGCCGCCGAGGAGUCCCUGCCUAUCGAGGUGAUGGUCGACGCGGUGCACAAGCUCAAGUACGAAAACUACACCAGCAGCUUUUUCAUCAGGGAUAUCAUCAAACCAGACCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAAAACAGCAGGCAGGUGGAAGUGAGCUGGGAAUACCCCGAUACCUGGUCCACCCCCCACAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGGAAGUCCAAGCGGGAGAAGAAAGAUCGGGUGUUCACGGACAAGACCAGCGCCACCGUGAUUUGCAGGAAAAACGCCAGCAUCUCCGUGAGGGCUCAGGACAGGUACUACAGCUCCAGCUGGAGCGAGUGGGCCUCCGUGCCUUGCAGCGGGGGAGGAGGCGGCGGCAGCAGGAAUCUGCCCGUCGCAACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAGAAUCUGCUGCGAGCCGUGAGCAACAUGCUCCAGAAGGCCCGGCAGACGCUGGAGUUCUACCCCUGCACCUCCGAGGAGAUCGACCACGAGGACAUCACCAAGGAUAAGACGAGCACCGUCGAGGCCUGUCUCCCCCUGGAGCUCACCAAGAACGAGUCCUGCCUGAAUAGCAGGGAGACGUCCUUCAUAACCAACGGCAGCUGUCUGGCGUCCAGGAAGACCAGCUUCAUGAUGGCCCUCUGCCUGAGCUCCAUCUACGAGGACCUCAAGAUGUACCAGGUCGAGUUCAAGACCAUGAACGCAAAACUGCUCAUGGAUCCAAAGAGGCAGAUCUUUCUGGACCAGAACAUGCUGGCCGUGAUCGAUGAACUCAUGCAGGCCCUGAAUUUCAAUUCCGAGACCGUGCCCCAGAAGAGCUCCCUGGAGGAACCCGACUUCUACAAAACAAAGAUCAAGCUGUGUAUCCUCCUGCACGCCUUCCGGAUCAGGGCCGUCACCAUUGACCGGGUGAUGUCCUACCUGAACGCCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAGhIL12AB_040G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGCCAUCAGCAGCUGGUGAUCAGCUGG(SEQ IDUUCAGCCUCGUGUUCCUCGCCAGCCCCCUCGUGGCCAUCUGGGAGCUGAAAAAGGACGUGUACGUGGUGGAGCUGGACUNO: 134)GGUAUCCCGACGCCCCGGGCGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGCAUUACCUGGACACUGGACCAGAGCAGCGAGGUCCUGGGCAGCGGGAAGACCCUGACAAUUCAGGUGAAGGAGUUCGGCGACGCCGGACAGUACACGUGCCACAAGGGGGGGGAGGUGCUGUCCCACAGCCUCCUCCUGCUGCACAAGAAGGAGGAUGGCAUCUGGAGCACCGACAUCCUGAAGGAUCAGAAGGAGCCCAAGAACAAGACCUUUCUGAGAUGCGAGGCCAAGAAUUACAGCGGCCGUUUCACCUGCUGGUGGCUCACCACCAUCAGCACCGACCUGACCUUCAGCGUGAAAUCCUCCAGGGGCUCCUCCGACCCGCAGGGAGUGACCUGCGGCGCCGCCACACUGAGCGCCGAGCGGGUCAGAGGGGACAACAAGGAGUACGAGUACAGCGUUGAGUGCCAGGAGGACAGCGCCUGUCCCGCGGCCGAGGAAUCCCUGCCCAUCGAGGUGAUGGUGGACGCAGUGCACAAGCUGAAGUACGAGAACUAUACCUCGAGCUUCUUCAUCCGGGAUAUCAUUAAGCCCGAUCCCCCGAAGAACCUGCAGCUCAAACCCCUGAAGAACAGCAGGCAGGUGGAGGUCUCCUGGGAGUACCCCGACACAUGGUCCACCCCCCAUUCCUAUUUCUCCCUGACCUUUUGCGUGCAGGUGCAGGGCAAGAGCAAGAGGGAGAAAAAGGACAGGGUGUUCACCGACAAGACCUCCGCCACCGUGAUCUGCCGUAAGAACGCUAGCAUCAGCGUCAGGGCCCAGGACAGGUACUAUAGCAGCUCCUGGUCCGAGUGGGCCAGCGUCCCGUGCAGCGGCGGGGGCGGUGGAGGCUCCCGGAACCUCCCCGUGGCCACCCCGGACCCCGGGAUGUUUCCCUGCCUGCAUCACAGCCAGAACCUGCUGAGGGCCGUGUCCAACAUGCUGCAGAAGGCCAGGCAGACACUCGAGUUUUACCCCUGCACCAGCGAGGAGAUCGACCACGAAGACAUCACCAAGGACAAGACCUCCACCGUGGAGGCAUGCCUGCCCCUGGAGCUGACCAAAAACGAAAGCUGUCUGAACUCCAGGGAGACCUCCUUUAUCACGAACGGCUCAUGCCUGGCCUCCAGAAAGACCAGCUUCAUGAUGGCCCUGUGCCUGAGCUCCAUCUACGAGGACUUGAAAAUGUACCAGGUCGAGUUCAAGACCAUGAACGCCAAGCUGCUCAUGGACCCCAAAAGGCAGAUCUUUCUGGACCAGAAUAUGCUGGCCGUGAUCGACGAGCUCAUGCAAGCCCUGAAUUUCAACAGCGAGACCGUGCCCCAGAAGUCCUCCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUACUCCUGCACGCGUUUAGGAUCAGGGCGGUGACCAUCGAUAGGGUGAUGAGCUACCUGAAUGCCUCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG

TABLE 4D mRNA ORF Sequence > hIL12AB_002(SEQ ID NO: 237)AUGUGCCACCAGCAGCUGGUGAUCAGCUGGUUCAGCCUGGUGUUCCUGGCCAGCCCCCUGGUGGCCAUCUGGGAGCUGAAGAAGGACGUGUACGUGGUGGAGUUGGAUUGGUACCCCGACGCCCCCGGCGAGAUGGUGGUGCUGACCUGCGACACCCCCGAGGAGGACGGCAUCACCUGGACCCUGGACCAGAGCAGCGAGGUGCUGGGCAGCGGCAAGACCCUGACCAUCCAGGUGAAGGAGUUCGGCGACGCCGGCCAGUACACCUGCCACAAGGGCGGCGAGGUGCUGAGCCACAGCCUGCUGCUGCUGCACAAGAAGGAGGACGGCAUCUGGAGCACCGACAUCCUGAAGGACCAGAAGGAGCCCAAGAACAAGACCUUCCUGAGAUGCGAGGCCAAGAACUACAGCGGCAGAUUCACCUGCUGGUGGCUGACCACCAUCAGCACCGACCUGACCUUCAGCGUGAAGAGCAGCAGAGGCAGCAGCGACCCCCAGGGCGUGACCUGCGGCGCCGCCACCCUGAGCGCCGAGAGAGUGAGAGGCGACAACAAGGAGUACGAGUACAGCGUGGAGUGCCAGGAAGAUAGCGCCUGCCCCGCCGCCGAGGAGAGCCUGCCCAUCGAGGUGAUGGUGGACGCCGUGCACAAGCUGAAGUACGAGAACUACACCAGCAGCUUCUUCAUCAGAGAUAUCAUCAAGCCCGACCCCCCCAAGAACCUGCAGCUGAAGCCCCUGAAGAACAGCCGGCAGGUGGAGGUGAGCUGGGAGUACCCCGACACCUGGAGCACCCCCCACAGCUACUUCAGCCUGACCUUCUGCGUGCAGGUGCAGGGCAAGAGCAAGAGAGAGAAGAAAGAUAGAGUGUUCACCGACAAGACCAGCGCCACCGUGAUCUGCAGAAAGAACGCCAGCAUCAGCGUGAGAGCCCAAGAUAGAUACUACAGCAGCAGCUGGAGCGAGUGGGCCAGCGUGCCCUGCAGCGGCGGCGGCGGCGGCGGCAGCAGAAACCUGCCCGUGGCCACCCCCGACCCCGGCAUGUUCCCCUGCCUGCACCACAGCCAGAACCUGCUGAGAGCCGUGAGCAACAUGCUGCAGAAGGCCCGGCAGACCCUGGAGUUCUACCCCUGCACCAGCGAGGAGAUCGACCACGAAGAUAUCACCAAAGAUAAGACCAGCACCGUGGAGGCCUGCCUGCCCCUGGAGCUGACCAAGAACGAGAGCUGCCUGAACAGCAGAGAGACCAGCUUCAUCACCAACGGCAGCUGCCUGGCCAGCAGAAAGACCAGCUUCAUGAUGGCCCUGUGCCUGAGCAGCAUCUACGAGGACCUGAAGAUGUACCAGGUGGAGUUCAAGACCAUGAACGCCAAGCUGCUGAUGGACCCCAAGCGGCAGAUCUUCCUGGACCAGAACAUGCUGGCCGUGAUCGACGAGCUGAUGCAGGCCCUGAACUUCAACAGCGAGACCGUGCCCCAGAAGAGCAGCCUGGAGGAGCCCGACUUCUACAAGACCAAGAUCAAGCUGUGCAUCCUGCUGCACGCCUUCAGAAUCAGAGCCGUGACCAUCGACAGAGUGAUGAGCUACCUGAACGCCAGC

The sequence-optimized nucleotide sequences disclosed herein aredistinct from the corresponding wild type nucleotide acid sequences andfrom other known sequence-optimized nucleotide sequences, e.g., thesesequence-optimized nucleic acids have unique compositionalcharacteristics.

In some embodiments, the percentage of uracil or thymine nucleobases ina sequence-optimized nucleotide sequence (e.g., encoding an IL12B and/orIL12A polypeptide, a functional fragment, or a variant thereof) ismodified (e.g., reduced) with respect to the percentage of uracil orthymine nucleobases in the reference wild-type nucleotide sequence. Sucha sequence is referred to as a uracil-modified or thymine-modifiedsequence. The percentage of uracil or thymine content in a nucleotidesequence can be determined by dividing the number of uracils or thyminesin a sequence by the total number of nucleotides and multiplying by 100.In some embodiments, the sequence-optimized nucleotide sequence has alower uracil or thymine content than the uracil or thymine content inthe reference wild-type sequence. In some embodiments, the uracil orthymine content in a sequence-optimized nucleotide sequence of thedisclosure is greater than the uracil or thymine content in thereference wild-type sequence and still maintain beneficial effects,e.g., increased expression and/or reduced Toll-Like Receptor (TLR)response when compared to the reference wild-type sequence.

In some embodiments, the optimized sequences of the present disclosurecontain unique ranges of uracils or thymine (if DNA) in the sequence.The uracil or thymine content of the optimized sequences can beexpressed in various ways, e.g., uracil or thymine content of optimizedsequences relative to the theoretical minimum (% U_(TM) or % T_(TM)),relative to the wild-type (% U_(WT) or % T_(WT)), and relative to thetotal nucleotide content (% U_(TL) or % T_(TL)). For DNA it isrecognized that thymine is present instead of uracil, and one wouldsubstitute T where U appears. Thus, all the disclosures related to,e.g., % U_(TM), % U_(WT), or % U_(TL), with respect to RNA are equallyapplicable to % T_(TM), % T_(WT), or % T_(TL) with respect to DNA.

Uracil- or thymine-content relative to the uracil or thymine theoreticalminimum, refers to a parameter determined by dividing the number ofuracils or thymines in a sequence-optimized nucleotide sequence by thetotal number of uracils or thymines in a hypothetical nucleotidesequence in which all the codons in the hypothetical sequence arereplaced with synonymous codons having the lowest possible uracil orthymine content and multiplying by 100. This parameter is abbreviatedherein as % U_(TM) or % T_(TM)

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12B polypeptide of the disclosure is below 196%, below 195%, below190%, below 185%, below 180%, below 175%, below 170%, below 165%, below160%, below 155%, below 150%, below 145%, below 140%, below 139%, below138%, below 137%, below 136%, below 135%, below 134%, below 133%, below132%, below 131%, below 130%, below 129%, below 128%, below 127%, below126%, below 125%, below 124%, below 123%, below 122%, below 121%, below120%, below 119%, below 118%, below 117%, below 116%, or below 115%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12B polypeptide of the disclosure is below 196% and above 100%,above 101%, above 102%, above 103%, above 104%, above 105%, above 106%,above 107%, above 108%, above 109%, above 110%, above 111%, above 112%,above 113%, above 114%, above 115%, above 116%, above 117%, above 118%,above 119%, above 120%, above 121%, above 122%, above 123%, above 124%,above 125%, above 126%, above 127%, above 128%, above 129%, or above130%, above 135%, above 130%, above 131%, or above 132%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12B polypeptide of the disclosure is between 132% and 150%, between133% and 150%, between 134% and 150%, between 135% and 150%, between136% and 150%, between 137% and 150%, between 138% and 150%, between139% and 150%, between 140% and 150%, between 132% and 151%, between132% and 152%, between 132% and 153%, between 132% and 154%, between132% and 155%, between 132% and 156%, between 132% and 157%, between132% and 158%, between 132% and 159%, between 132% and 160%, between133% and 151%, between 134% and 152%, between 135% and 153%, between136% and 154%, between 137% and 155%, between 138% and 156%, between138% and 157%, between 139% and 158%, between 140% and 159%, or between141% and 160%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12B polypeptide of the disclosure is between about 133% and about152%, e.g., between 132.32% and 150.51%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12A polypeptide of the disclosure is below 198%, below 195%, below190%, below 185%, below 180%, below 175%, below 170%, below 165%, below160%, below 155%, below 150%, below 145%, below 140%, below 139%, below138%, below 137%, below 136%, below 135%, below 134%, below 133%, below132%, below 131%, below 130%, below 129%, below 128%, below 127%, below126%, below 125%, below 124%, below 123%, below 122%, below 121%, below120%, below 119%, below 118%, below 117%, below 116%, or below 115%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12A polypeptide of the disclosure is below 198% and above 100%,above 101%, above 102%, above 103%, above 104%, above 105%, above 106%,above 107%, above 108%, above 109%, above 110%, above 111%, above 112%,above 113%, above 114%, above 115%, above 116%, above 117%, above 118%,above 119%, above 120%, above 121%, above 122%, above 123%, above 124%,or above 125%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12A polypeptide of the disclosure is between 125% and 143%, between126% and 143%, between 127% and 143%, between 128% and 143%, between129% and 143%, between 130% and 143%, between 131% and 132%, between133% and 134%, between 135% and 143%, between 125% and 144%, between125% and 145%, between 125% and 146%, between 125% and 147%, between125% and 148%, between 125% and 149%, between 125% and 150%, between125% and 151%, between 125% and 152%, between 125% and 153%, between125% and 154%, between 125% and 155%, between 126% and 144%, between127% and 145%, between 128% and 146%, between 129% and 147%, between130% and 148%, between 131% and 149%, between 132% and 150%, or between133% and 151%.

In some embodiments, the % U_(TM) of a uracil-modified sequence encodingan IL12A polypeptide of the disclosure is between about 124% and about145%, e.g., between 125% and 144.42%.

A uracil- or thymine-modified sequence encoding an IL12B polypeptide,IL12A polypeptide, or both IL12B and IL12A polypeptides of thedisclosure can also be described according to its uracil or thyminecontent relative to the uracil or thymine content in the correspondingwild-type nucleic acid sequence (% U_(WT) or % T_(WT)).

The phrases “uracil or thymine content relative to the uracil or thyminecontent in the wild type nucleic acid sequence,” refers to a parameterdetermined by dividing the number of uracils or thymines in asequence-optimized nucleic acid by the total number of uracils orthymines in the corresponding wild-type nucleic acid sequence andmultiplying by 100. This parameter is abbreviated herein as % U_(WT) or% T_(WT).

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12B polypeptide of thedisclosure is above 50%, above 55%, above 60%, above 65%, above 70%,above 75%, above 80%, above 85%, above 90%, or above 95%.

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- or thyminemodified sequence encoding an IL12B polypeptide of the disclosure isbetween 55% and 88%, between 56% and 87%, between 57% and 86%, between58% and 85%, between 59% and 84%, between 60% and 83%, between 61% and82%, between 62% and 81%, between 63% and 80%, between 64% and 79%,between 65% and 78%, or between 65% and 77%.

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12B polypeptide of thedisclosure is between 66% and 78%, between 66% and 77%, between 67% and77%, between 67% and 76%, or between 65% and 77%.

In a particular embodiment, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12B polypeptide of thedisclosure is between about 66% and about 77%, e.g., between 67% and76%.

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12A polypeptide of thedisclosure is above 50%, above 55%, above 60%, above 65%, above 70%,above 75%, above 80%, above 85%, above 90%, or above 95%.

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- or thyminemodified sequence encoding an IL12A polypeptide of the disclosure isbetween 50% and 85%, between 51% and 84%, between 52% and 83%, between53% and 82%, between 54% and 81%, between 55% and 80%, between 56% and79%, between 57% and 78%, between 58% and 77%, between 59% and 76%,between 60% and 75%, between 61% and 74%, or between 62% and 73%.

In some embodiments, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12A polypeptide of thedisclosure is between 61% and 74%, between 61% and 73%, between 61% and72%, between 61% and 73%, between 62% and 73%, between 62% and 72%,between 62% and 74%, or between 63% and 72%.

In a particular embodiment, the % U_(WT) or % T_(WT) of a uracil- orthymine-modified sequence encoding an IL12A polypeptide of thedisclosure is between about 62% and about 73%, e.g., between 63% and72%.

The uracil or thymine content of wild-type IL12B relative to the totalnucleotide content (%) is about 21%. In some embodiments, the uracil orthymine content of a uracil- or thymine-modified sequence encoding anIL12B polypeptide relative to the total nucleotide content (%) (% U_(TL)or % T_(TL)) is less than 21%. In some embodiments, the % U_(TM) or %T_(TL) is less than 20%, less than 19%, less that 18%, less than 17%,less than 16%, less than 15%, less than 14%, less than 13%, less than12%, less than 11%, or less than 10%. In some embodiments, the % U_(TL)or % T_(TL) is not less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%.

In some embodiments, the uracil or thymine content of a uracil- orthymine-modified sequence encoding an IL12B polypeptide of thedisclosure relative to the total nucleotide content (% U_(TL) or %T_(TL)) is between 10% and 20%, between 11% and 20%, between 11.5% and19.5%, between 12% and 19%, between 12% and 18%, between 13% and 18%,between 13% and 17%, between 13% and 16%, between 13% and 16%, between14% and 16%, between 14% and 17%, or between 13% and 17%.

In a particular embodiment, the uracil or thymine content (% U_(TL) or %T_(TL)) of a uracil- or thymine modified sequence encoding an IL12Bpolypeptide of the disclosure is between about 13% and about 17%, e.g.,between 14% and 16%

The uracil or thymine content of wild-type IL12A relative to the totalnucleotide content (%) is about 26%. In some embodiments, the uracil orthymine content of a uracil- or thymine-modified sequence encoding anIL12A polypeptide relative to the total nucleotide content (%) (% U_(TL)or % T_(TL)) is less than 25%. In some embodiments, the % U_(TL) or %T_(TL) is less than 25%, less than 24%, less than 23%, less than 22%,less than 21%, less than 20%, less than 19%, less that 18%, less than17%, less than 16%, less than 15%, less than 14%, less than 13%, lessthan 12%, less than 11%, or less than 10%. In some embodiments, the %U_(TL) or % T_(TL) is not less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%,or 1%.

In some embodiments, the uracil or thymine content of a uracil- orthymine-modified sequence encoding an IL12A polypeptide of thedisclosure relative to the total nucleotide content (% U_(TL) or %T_(TL)) is between 10% and 25%, between 11% and 25%, between 12% and25%, between 13% and 25%, between 14% and 25%, between 15% and 25%,between 16% and 25%, between 10% and 24%, between 10% and 23%, between11% and 22%, between 11% and 21%, between 11% and 20%, between 11% and19%, between 11% and 18%, between 12% and 24%, between 12% and 23%,between 13% and 22%, between 14% and 21%, between 13% and 20%, between15% and 19%, between 15% and 20%, between 16% and 19%, between 16% and18%, or between 13% and 17%.

In a particular embodiment, the uracil or thymine content (% U_(TL) or %T_(TL)) of a uracil- or thymine modified sequence encoding an IL12Apolypeptide of the disclosure is between about 15% and about 19%, e.g.,between 16% and 18% In some embodiments, a uracil-modified sequenceencoding an IL12B polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides of the disclosure has a reduced number ofconsecutive uracils with respect to the corresponding wild-type nucleicacid sequence. For example, two consecutive leucines can be encoded bythe sequence CUUUUG, which includes a four uracil cluster. Such asubsequence can be substituted, e.g., with CUGCUC, which removes theuracil cluster.

Phenylalanine can be encoded by UUC or UUU. Thus, even if phenylalaninesencoded by UUU are replaced by UUC, the synonymous codon still containsa uracil pair (UU). Accordingly, the number of phenylalanines in asequence establishes a minimum number of uracil pairs (UU) that cannotbe eliminated without altering the number of phenylalanines in theencoded polypeptide.

In some embodiments, a uracil-modified sequence encoding an IL12B and/orIL12A polypeptide of the disclosure has a reduced number of uraciltriplets (UUU) with respect to the wild-type nucleic acid sequence. Insome embodiments, a uracil-modified sequence encoding an IL12B and/orIL12A polypeptide of the disclosure contains 4, 3, 2, 1 or no uraciltriplets (UUU).

In some embodiments, a uracil-modified sequence encoding an IL12B and/orIL12A polypeptide has a reduced number of uracil pairs (UU) with respectto the number of uracil pairs (UU) in the wild-type nucleic acidsequence. In some embodiments, a uracil-modified sequence encoding anIL12B and/or IL12A polypeptide of the disclosure has a number of uracilpairs (UU) corresponding to the minimum possible number of uracil pairs(UU) in the wild-type nucleic acid sequence.

In some embodiments, a uracil-modified sequence encoding an IL12Bpolypeptide of the disclosure has at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 uracil pairs(UU) less than the number of uracil pairs (UU) in the wild-type nucleicacid sequence. In some embodiments, a uracil-modified sequence encodingan IL12B polypeptide of the disclosure has between 7 and 13, between 8and 14, between 9 and 15, between 10 and 16, between 11 and 7, between12 and 18 uracil pairs (UU).

In some embodiments, a uracil-modified sequence encoding an IL12Bpolypeptide of the disclosure has at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 uracil pairs (UU) lessthan the number of uracil pairs (UU) in the wild-type nucleic acidsequence. In some embodiments, a uracil-modified sequence encoding anIL12A polypeptide of the disclosure has between 7 and 13, between 8 and14, between 9 and 15, between 10 and 16, between 11 and 7, between 12and 18 uracil pairs (UU).

The phrase “uracil pairs (UU) relative to the uracil pairs (UU) in thewild type nucleic acid sequence,” refers to a parameter determined bydividing the number of uracil pairs (UU) in a sequence-optimizednucleotide sequence by the total number of uracil pairs (UU) in thecorresponding wild-type nucleotide sequence and multiplying by 100. Thisparameter is abbreviated herein as % UU_(wt).

In some embodiments, a uracil-modified sequence encoding an IL12A orIL12B polypeptide of the disclosure has a % UU_(wt) less than 90%, lessthan 85%, less than 80%, less than 75%, less than 70%, less than 65%,less than 60%, less than 65%, less than 60%, less than 55%, less than50%, less than 40%, less than 30%, or less than 20%.

In some embodiments, a uracil-modified sequence encoding an IL12Bpolypeptide has a % UU_(wt) between 24% and 59%. In a particularembodiment, a uracil-modified sequence encoding an IL12B polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of thedisclosure has a % UU_(wt) between 29% and 55%.

In some embodiments, a uracil-modified sequence encoding an IL12Apolypeptide has a % UU_(wt) between 14% and 57%. In a particularembodiment, a uracil-modified sequence encoding an IL12B polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides of thedisclosure has a % UU_(wt) between 19% and 52%.

In some embodiments, the polynucleotide of the disclosure comprises auracil-modified sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides disclosedherein. In some embodiments, the uracil-modified sequence encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides comprises at least one chemically modified nucleobase,e.g., 5-methoxyuracil. In some embodiments, at least 95% of a nucleobase(e.g., uracil) in a uracil-modified sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides of the disclosure are modified nucleobases. In someembodiments, at least 95% of uracil in a uracil-modified sequenceencoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides is 5-methoxyuracil. In some embodiments, thepolynucleotide comprising a uracil-modified sequence further comprises amiRNA binding site, e.g., a miRNA binding site that binds to miR-122. Insome embodiments, the polynucleotide comprising a uracil-modifiedsequence is formulated with a delivery agent, e.g., a compound havingFormula (I), e.g., any of Compounds 1-147 or any of Compounds 1-232.

In some embodiments, the “guanine content of the sequence optimized ORFencoding IL12B and/or IL12A with respect to the theoretical maximumguanine content of a nucleotide sequence encoding the IL12B and/or IL12Apolypeptide,” abbreviated as % G_(TMX) is at least 69%, at least 70%, atleast 75%, at least about 80%, at least about 85%, at least about 90%,at least about 95%, or about 100%. In some embodiments, the % G_(TMX) isbetween about 70% and about 80%, between about 71% and about 79%,between about 71% and about 78%, or between about 71% and about 77%.

In some embodiments, the “cytosine content of the ORF relative to thetheoretical maximum cytosine content of a nucleotide sequence encodingthe IL12B and/or IL12A polypeptide,” abbreviated as % C_(TMX), is atleast 59%, at least 60%, at least about 65%, at least about 70%, atleast about 75%, at least about 80%, at least about 85%, at least about90%, at least about 95%, or about 100%. In some embodiments, the %C_(TMX) is between about 60% and about 80%, between about 62% and about80%, between about 63% and about 79%, or between about 68% and about76%.

In some embodiments, the “guanine and cytosine content (G/C) of the ORFrelative to the theoretical maximum G/C content in a nucleotide sequenceencoding the IL12B and/or IL12A polypeptide,” abbreviated as % G/C_(TMX)is at least about 81%, at least about 85%, at least about 90%, at leastabout 95%, or about 100%. The % G/C_(TMX) is between about 80% and about100%, between about 85% and about 99%, between about 90% and about 97%,or between about 91% and about 96%.

In some embodiments, the “G/C content in the ORF relative to the G/Ccontent in the corresponding wild-type ORF,” abbreviated as % G/C_(WT)is at least 102%, at least 103%, at least 104%, at least 105%, at least106%, at least 107%, at least 110%, at least 115%, or at least 120%.

In some embodiments, the average G/C content in the 3rd codon positionin the ORF is at least 20%, at least 21%, at least 22%, at least 23%, atleast 24%, at least 25%, at least 26%, at least 27%, at least 28%, atleast 29%, or at least 30% higher than the average G/C content in the3rd codon position in the corresponding wild-type ORF.

In some embodiments, the polynucleotide of the disclosure comprises anopen reading frame (ORF) encoding an IL12B and/or IL12A polypeptide,wherein the ORF has been sequence optimized, and wherein each of %U_(TL), % U_(WT), % U_(TM), % G_(TL), % G_(WT), % C_(TMX), % C_(TL), %C_(WT), % C_(TMX), % G/C_(TL), % G/C_(WT), or % G/C_(TMX), alone or in acombination thereof is in a range between (i) a maximum corresponding tothe parameter's maximum value (MAX) plus about 0.5, 1, 1.5, 2, 2.5, 3,3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 standarddeviations (STD DEV), and (ii) a minimum corresponding to theparameter's minimum value (MIN) less 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4,4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 standard deviations(STD DEV).

9. Methods for Sequence Optimization

In some embodiments, a polynucleotide of the disclosure (e.g., apolynucleotide comprising a nucleotide sequence, e.g., an ORF, encodingan IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12Bfusion polypeptides (e.g., the wild-type sequence, functional fragment,or variant thereof)) is sequence optimized. A sequence optimizednucleotide sequence (nucleotide sequence is also referred to as “nucleicacid” herein) comprises at least one codon modification with respect toa reference sequence (e.g., a wild-type sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides). Thus, in a sequence optimized nucleic acid, at least onecodon is different from a corresponding codon in a reference sequence(e.g., a wild-type sequence).

In general, sequence optimized nucleic acids are generated by at least astep comprising substituting codons in a reference sequence withsynonymous codons (i.e., codons that encode the same amino acid). Suchsubstitutions can be effected, for example, by applying a codonsubstitution map (i.e., a table providing the codons that will encodeeach amino acid in the codon optimized sequence), or by applying a setof rules (e.g., if glycine is next to neutral amino acid, glycine wouldbe encoded by a certain codon, but if it is next to a polar amino acid,it would be encoded by another codon). In addition to codonsubstitutions (i.e., “codon optimization”) the sequence optimizationmethods disclosed herein comprise additional optimization steps whichare not strictly directed to codon optimization such as the removal ofdeleterious motifs (destabilizing motif substitution). Compositions andformulations comprising these sequence optimized nucleic acids (e.g., aRNA, e.g., an mRNA) can be administered to a subject in need thereof tofacilitate in vivo expression of functionally active IL12.

The recombinant expression of large molecules in cell cultures can be achallenging task with numerous limitations (e.g., poor proteinexpression levels, stalled translation resulting in truncated expressionproducts, protein misfolding, etc.) These limitations can be reduced oravoided by administering the polynucleotides (e.g., a RNA, e.g., anmRNA), which encode a functionally active IL12 or compositions orformulations comprising the same to a patient suffering from cancer, sothe synthesis and delivery of the IL12 polypeptide to treat cancer takesplace endogenously.

Changing from an in vitro expression system (e.g., cell culture) to invivo expression requires the redesign of the nucleic acid sequenceencoding the therapeutic agent. Redesigning a naturally occurring genesequence by choosing different codons without necessarily altering theencoded amino acid sequence can often lead to dramatic increases inprotein expression levels (Gustafsson et al., 2004, Journal/TrendsBiotechnol 22, 346-53). Variables such as codon adaptation index (CAI),mRNA secondary structures, cis-regulatory sequences, GC content and manyother similar variables have been shown to somewhat correlate withprotein expression levels (Villalobos et al., 2006, “Journal/BMCBioinformatics 7, 285). However, due to the degeneracy of the geneticcode, there are numerous different nucleic acid sequences that can allencode the same therapeutic agent. Each amino acid is encoded by up tosix synonymous codons; and the choice between these codons influencesgene expression. In addition, codon usage (i.e., the frequency withwhich different organisms use codons for expressing a polypeptidesequence) differs among organisms (for example, recombinant productionof human or humanized therapeutic antibodies frequently takes place inhamster cell cultures).

In some embodiments, a reference nucleic acid sequence can be sequenceoptimized by applying a codon map. The skilled artisan will appreciatethat the T bases in the codon maps disclosed below are present in DNA,whereas the T bases would be replaced by U bases in corresponding RNAs.For example, a sequence optimized nucleic acid disclosed herein in DNAform, e.g., a vector or an in-vitro translation (IVT) template, wouldhave its T bases transcribed as U based in its corresponding transcribedmRNA. In this respect, both sequence optimized DNA sequences (comprisingT) and their corresponding RNA sequences (comprising U) are consideredsequence optimized nucleic acid of the present disclosure. A skilledartisan would also understand that equivalent codon-maps can begenerated by replaced one or more bases with non-natural bases. Thus,e.g., a TTC codon (DNA map) would correspond to a UUC codon (RNA map),which in turn may correspond to a ‘P’C codon (RNA map in which U hasbeen replaced with pseudouridine).

In one embodiment, a reference sequence encoding IL12A, IL12B, or bothIL12A and IL12B can be optimized by replacing all the codons encoding acertain amino acid with only one of the alternative codons provided in acodon map. For example, all the valines in the optimized sequence wouldbe encoded by GTG or GTC or GTT.

Sequence optimized polynucleotides of the disclosure can be generatedusing one or more codon optimization methods, or a combination thereof.Sequence optimization methods which may be used to sequence optimizenucleic acid sequences are described in detail herein. This list ofmethods is not comprehensive or limiting.

It will be appreciated that the design principles and rules describedfor each one of the sequence optimization methods discussed below can becombined in many different ways, for example high G/C content sequenceoptimization for some regions or uridine content sequence optimizationfor other regions of the reference nucleic acid sequence, as well astargeted nucleotide mutations to minimize secondary structure throughoutthe sequence or to eliminate deleterious motifs.

The choice of potential combinations of sequence optimization methodscan be, for example, dependent on the specific chemistry used to producea synthetic polynucleotide. Such a choice can also depend oncharacteristics of the protein encoded by the sequence optimized nucleicacid, e.g., a full sequence, a functional fragment, or a fusion proteincomprising IL12, etc. In some embodiments, such a choice can depend onthe specific tissue or cell targeted by the sequence optimized nucleicacid (e.g., a therapeutic synthetic mRNA).

The mechanisms of combining the sequence optimization methods or designrules derived from the application and analysis of the optimizationmethods can be either simple or complex. For example, the combinationcan be:

(i) Sequential: Each sequence optimization method or set of design rulesapplies to a different subsequence of the overall sequence, for examplereducing uridine at codon positions 1 to 30 and then selecting highfrequency codons for the remainder of the sequence;

(ii) Hierarchical: Several sequence optimization methods or sets ofdesign rules are combined in a hierarchical, deterministic fashion. Forexample, use the most GC-rich codons, breaking ties (which are common)by choosing the most frequent of those codons.

(iii) Multifactorial/Multiparametric: Machine learning or other modelingtechniques are used to design a single sequence that best satisfiesmultiple overlapping and possibly contradictory requirements. Thisapproach would require the use of a computer applying a number ofmathematical techniques, for example, genetic algorithms.

Ultimately, each one of these approaches can result in a specific set ofrules which in many cases can be summarized in a single codon table,i.e., a sorted list of codons for each amino acid in the target protein(i.e., an IL12A polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides), with a specific rule or set of rulesindicating how to select a specific codon for each amino acid position.

a. Uridine Content Optimization

The presence of local high concentrations of uridine in a nucleic acidsequence can have detrimental effects on translation, e.g., slow orprematurely terminated translation, especially when modified uridineanalogs are used in the production of synthetic mRNAs. Furthermore, highuridine content can also reduce the in vivo half-life of synthetic mRNAsdue to TLR activation.

Accordingly, a nucleic acid sequence can be sequence optimized using amethod comprising at least one uridine content optimization step. Such astep comprises, e.g., substituting at least one codon in the referencenucleic acid with an alternative codon to generate a uridine-modifiedsequence, wherein the uridine-modified sequence has at least one of thefollowing properties:

-   (i) increase or decrease in global uridine content;-   (ii) increase or decrease in local uridine content (i.e., changes in    uridine content are limited to specific subsequences);-   (iii) changes in uridine distribution without altering the global    uridine content;-   (iv) changes in uridine clustering (e.g., number of clusters,    location of clusters, or distance between clusters); or-   (v) combinations thereof.

In some embodiments, the sequence optimization process comprisesoptimizing the global uridine content, i.e., optimizing the percentageof uridine nucleobases in the sequence optimized nucleic acid withrespect to the percentage of uridine nucleobases in the referencenucleic acid sequence. For example, 30% of nucleobases may be uridinesin the reference sequence and 10% of nucleobases may be uridines in thesequence optimized nucleic acid.

In other embodiments, the sequence optimization process comprisesreducing the local uridine content in specific regions of a referencenucleic acid sequence, i.e., reducing the percentage of uridinenucleobases in a subsequence of the sequence optimized nucleic acid withrespect to the percentage of uridine nucleobases in the correspondingsubsequence of the reference nucleic acid sequence. For example, thereference nucleic acid sequence may have a 5′-end region (e.g., 30codons) with a local uridine content of 30%, and the uridine content inthat same region could be reduced to 10% in the sequence optimizednucleic acid.

In specific embodiments, codons can be replaced in the reference nucleicacid sequence to reduce or modify, for example, the number, size,location, or distribution of uridine clusters that could havedeleterious effects on protein translation. Although as a general ruleit is desirable to reduce the uridine content of the reference nucleicacid sequence, in certain embodiments the uridine content, and inparticular the local uridine content, of some subsequences of thereference nucleic acid sequence can be increased.

The reduction of uridine content to avoid adverse effects on translationcan be done in combination with other optimization methods disclosedhere to achieve other design goals. For example, uridine contentoptimization can be combined with ramp design, since using the rarestcodons for most amino acids will, with a few exceptions, reduce the Ucontent.

In some embodiments, the uridine-modified sequence is designed to inducea lower Toll-Like Receptor (TLR) response when compared to the referencenucleic acid sequence. Several TLRs recognize and respond to nucleicacids. Double-stranded (ds)RNA, a frequent viral constituent, has beenshown to activate TLR3. See Alexopoulou et al. (2001) Nature,413:732-738 and Wang et al. (2004) Nat. Med., 10:1366-1373.Single-stranded (ss)RNA activates TLR7. See Diebold et al. (2004)Science 303:1529-1531. RNA oligonucleotides, for example RNA withphosphorothioate internucleotide linkages, are ligands of human TLR8.See Heil et al. (2004) Science 303:1526-1529. DNA containingunmethylated CpG motifs, characteristic of bacterial and viral DNA,activate TLR9. See Hemmi et al. (2000) Nature, 408: 740-745.

As used herein, the term “TLR response” is defined as the recognition ofsingle-stranded RNA by a TLR7 receptor, and in some embodimentsencompasses the degradation of the RNA and/or physiological responsescaused by the recognition of the single-stranded RNA by the receptor.Methods to determine and quantitate the binding of an RNA to a TLR7 areknown in the art. Similarly, methods to determine whether an RNA hastriggered a TLR7-mediated physiological response (e.g., cytokinesecretion) are well known in the art. In some embodiments, a TLRresponse can be mediated by TLR3, TLR8, or TLR9 instead of TLR7.

Suppression of TLR7-mediated response can be accomplished via nucleosidemodification. RNA undergoes over hundred different nucleosidemodifications in nature (see the RNA Modification Database, available atmods.rna.albany.edu). Human rRNA, for example, has ten times morepseudouridine (Ψ) and 25 times more 2′-O-methylated nucleosides thanbacterial rRNA. Bacterial mRNA contains no nucleoside modifications,whereas mammalian mRNAs have modified nucleosides such as5-methylcytidine (m5C), N6-methyladenosine (m6A), inosine and many2′-O-methylated nucleosides in addition to N7-methylguanosine (m7G).

Uracil and ribose, the two defining features of RNA, are both necessaryand sufficient for TLR7 stimulation, and short single-stranded RNA(ssRNA) act as TLR7 agonists in a sequence-independent manner as long asthey contain several uridines in close proximity. See Diebold et al.(2006) Eur. J. Immunol. 36:3256-3267, which is herein incorporated byreference in its entirety. Accordingly, one or more of the optimizationmethods disclosed herein comprises reducing the uridine content (locallyand/or locally) and/or reducing or modifying uridine clustering toreduce or to suppress a TLR7-mediated response.

In some embodiments, the TLR response (e.g., a response mediated byTLR7) caused by the uridine-modified sequence is at least about 10%, atleast about 15%, at least about 20%, at least about 25%, at least about30%, at least about 35%, at least about 40%, at least about 45%, atleast about 50%, at least about 55%, at least about 60%, at least about65%, at least about 70%, at least about 75%, at least about 80%, atleast about 85%, at least about 90%, at least about 95%, or at leastabout 100% lower than the TLR response caused by the reference nucleicacid sequence.

In some embodiments, the TLR response caused by the reference nucleicacid sequence is at least about 1-fold, at least about 1.1-fold, atleast about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold,at least about 1.5-fold, at least about 1.6-fold, at least about1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at leastabout 2-fold, at least about 3-fold, at least about 4-fold, at leastabout 5-fold, at least about 6-fold, at least about 7-fold, at leastabout 8-fold, at least about 9-fold, or at least about 10-fold higherthan the TLR response caused by the uridine-modified sequence.

In some embodiments, the uridine content (average global uridinecontent) (absolute or relative) of the uridine-modified sequence ishigher than the uridine content (absolute or relative) of the referencenucleic acid sequence. Accordingly, in some embodiments, theuridine-modified sequence contains at least about 5%, at least about10%, at least about 15%, at least about 20%, at least about 25%, atleast about 30%, at least about 35%, at least about 40%, at least about45%, at least about 50%, at least about 55%, at least about 60%, atleast about 65%, at least about 70%, at least about 75%, at least about80%, at least about 85%, at least about 90%, at least about 95%, or atleast about 100% more uridine that the reference nucleic acid sequence.

In other embodiments, the uridine content (average global uridinecontent) (absolute or relative) of the uridine-modified sequence islower than the uridine content (absolute or relative) of the referencenucleic acid sequence. Accordingly, in some embodiments, theuridine-modified sequence contains at least about 5%, at least about10%, at least about 15%, at least about 20%, at least about 25%, atleast about 30%, at least about 35%, at least about 40%, at least about45%, at least about 50%, at least about 55%, at least about 60%, atleast about 65%, at least about 70%, at least about 75%, at least about80%, at least about 85%, at least about 90%, at least about 95%, or atleast about 100% less uridine that the reference nucleic acid sequence.

In some embodiments, the uridine content (average global uridinecontent) (absolute or relative) of the uridine-modified sequence is lessthan 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%,37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%,23%, 22%, 21%, 20%, 19%, 18%, 17%, 16^(%), 15%, 14%, 13%, 12%, 11%, 10%,9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the total nucleobases in theuridine-modified sequence. In some embodiments, the uridine content ofthe uridine-modified sequence is between about 10% and about 20%. Insome particular embodiments, the uridine content of the uridine-modifiedsequence is between about 12% and about 16%.

In some embodiments, the uridine content of the reference nucleic acidsequence can be measured using a sliding window. In some embodiments,the length of the sliding window is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34, 35, 36, 37, 38, 39, or 40 nucleobases. In some embodiments, thesliding window is over 40 nucleobases in length. In some embodiments,the sliding window is 20 nucleobases in length. Based on the uridinecontent measured with a sliding window, it is possible to generate ahistogram representing the uridine content throughout the length of thereference nucleic acid sequence and sequence optimized nucleic acids.

In some embodiments, a reference nucleic acid sequence can be modifiedto reduce or eliminate peaks in the histogram that are above or below acertain percentage value. In some embodiments, the reference nucleicacid sequence can be modified to eliminate peaks in the sliding-windowrepresentation which are above 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30%uridine. In another embodiment, the reference nucleic acid sequence canbe modified so no peaks are over 30% uridine in the sequence optimizednucleic acid, as measured using a 20 nucleobase sliding window. In someembodiments, the reference nucleic acid sequence can be modified so nomore or no less than a predetermined number of peaks in the sequenceoptimized nucleic sequence, as measured using a 20 nucleobase slidingwindow, are above or below a certain threshold value. For example, insome embodiments, the reference nucleic acid sequence can be modified sono peaks or no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 peaks in thesequence optimized nucleic acid are above 10%, 15%, 20%, 25% or 30%uridine. In another embodiment, the sequence optimized nucleic acidcontains between 0 peaks and 2 peaks with uridine contents 30% ofhigher.

In some embodiments, a reference nucleic acid sequence can be sequenceoptimized to reduce the incidence of consecutive uridines. For example,two consecutive leucines could be encoded by the sequence CUUUUG, whichwould include a four uridine cluster. Such subsequence could besubstituted with CUGCUC, which would effectively remove the uridinecluster. Accordingly, a reference nucleic sequence can be sequenceoptimized by reducing or eliminating uridine pairs (UU), uridinetriplets (UUU) or uridine quadruplets (UUUU). Higher order combinationsof U are not considered combinations of lower order combinations. Thus,for example, UUUU is strictly considered a quadruplet, not twoconsecutive U pairs; or UUUUUU is considered a sextuplet, not threeconsecutive U pairs, or two consecutive U triplets, etc.

In some embodiments, all uridine pairs (UU) and/or uridine triplets(UUU) and/or uridine quadruplets (UUUU) can be removed from thereference nucleic acid sequence. In other embodiments, uridine pairs(UU) and/or uridine triplets (UUU) and/or uridine quadruplets (UUUU) canbe reduced below a certain threshold, e.g., no more than 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 occurrences inthe sequence optimized nucleic acid. In a particular embodiment, thesequence optimized nucleic acid contains less than 20, 19, 18, 17, 16,15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 uridine pairs. Inanother particular embodiment, the sequence optimized nucleic acidcontains no uridine pairs and/or triplets.

Phenylalanine codons, i.e., UUC or UUU, comprise a uridine pair ortriples and therefore sequence optimization to reduce uridine contentcan at most reduce the phenylalanine U triplet to a phenylalanine Upair. In some embodiments, the occurrence of uridine pairs (UU) and/oruridine triplets (UUU) refers only to non-phenylalanine U pairs ortriplets. Accordingly, in some embodiments, non-phenylalanine uridinepairs (UU) and/or uridine triplets (UUU) can be reduced below a certainthreshold, e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 occurrences in the sequence optimizednucleic acid. In a particular embodiment, the sequence optimized nucleicacid contains less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9,8, 7, 6, 5, 4, 3, 2, or 1 non-phenylalanine uridine pairs and/ortriplets. In another particular embodiment, the sequence optimizednucleic acid contains no non-phenylalanine uridine pairs and/ortriplets.

In some embodiments, the reduction in uridine combinations (e.g., pairs,triplets, quadruplets) in the sequence optimized nucleic acid can beexpressed as a percentage reduction with respect to the uridinecombinations present in the reference nucleic acid sequence.

In some embodiments, a sequence optimized nucleic acid can contain about1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% ofthe total number of uridine pairs present in the reference nucleic acidsequence. In some embodiments, a sequence optimized nucleic acid cancontain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%,14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,60%, or 65% of the total number of uridine triplets present in thereference nucleic acid sequence. In some embodiments, a sequenceoptimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%,9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%,35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number of uridinequadruplets present in the reference nucleic acid sequence.

In some embodiments, a sequence optimized nucleic acid can contain about1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or 65% ofthe total number of non-phenylalanine uridine pairs present in thereference nucleic acid sequence. In some embodiments, a sequenceoptimized nucleic acid can contain about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%,9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%,35%, 40%, 45%, 50%, 55%, 60%, or 65% of the total number ofnon-phenylalanine uridine triplets present in the reference nucleic acidsequence.

In some embodiments, the uridine content in the sequence optimizedsequence can be expressed with respect to the theoretical minimumuridine content in the sequence. The term “theoretical minimum uridinecontent” is defined as the uridine content of a nucleic acid sequence asa percentage of the sequence's length after all the codons in thesequence have been replaced with synonymous codon with the lowesturidine content. In some embodiments, the uridine content of thesequence optimized nucleic acid is identical to the theoretical minimumuridine content of the reference sequence (e.g., a wild type sequence).In some aspects, the uridine content of the sequence optimized nucleicacid is about 90%, about 95%, about 100%, about 105%, about 110%, about115%, about 120%, about 125%, about 130%, about 135%, about 140%, about145%, about 150%, about 155%, about 160%, about 165%, about 170%, about175%, about 180%, about 185%, about 190%, about 195% or about 200% ofthe theoretical minimum uridine content of the reference sequence (e.g.,a wild type sequence).

In some embodiments, the uridine content of the sequence optimizednucleic acid is identical to the theoretical minimum uridine content ofthe reference sequence (e.g., a wild type sequence).

The reference nucleic acid sequence (e.g., a wild type sequence) cancomprise uridine clusters which due to their number, size, location,distribution or combinations thereof have negative effects ontranslation. As used herein, the term “uridine cluster” refers to asubsequence in a reference nucleic acid sequence or sequence optimizednucleic sequence with contains a uridine content (usually described as apercentage) which is above a certain threshold. Thus, in certainembodiments, if a subsequence comprises more than about 10%, 15%, 20%,25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or 65% uridine content, suchsubsequence would be considered a uridine cluster.

The negative effects of uridine clusters can be, for example, elicitinga TLR7 response. Thus, in some implementations of the nucleic acidsequence optimization methods disclosed herein it is desirable to reducethe number of clusters, size of clusters, location of clusters (e.g.,close to the 5′ and/or 3′ end of a nucleic acid sequence), distancebetween clusters, or distribution of uridine clusters (e.g., a certainpattern of cluster along a nucleic acid sequence, distribution ofclusters with respect to secondary structure elements in the expressedproduct, or distribution of clusters with respect to the secondarystructure of an mRNA).

In some embodiments, the reference nucleic acid sequence comprises atleast one uridine cluster, wherein said uridine cluster is a subsequenceof the reference nucleic acid sequence wherein the percentage of totaluridine nucleobases in said subsequence is above a predeterminedthreshold. In some embodiments, the length of the subsequence is atleast about 10, at least about 15, at least about 20, at least about 25,at least about 30, at least about 35, at least about 40, at least about45, at least about 50, at least about 55, at least about 60, at leastabout 65, at least about 70, at least about 75, at least about 80, atleast about 85, at least about 90, at least about 95, or at least about100 nucleobases. In some embodiments, the subsequence is longer than 100nucleobases. In some embodiments, the threshold is 1%, 2%, 3%, 4%, 5%,6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,21%, 22%, 23%, 24% or 25% uridine content. In some embodiments, thethreshold is above 25%.

For example, an amino acid sequence comprising A, D, G, S and R could beencoded by the nucleic acid sequence GCU, GAU, GGU, AGU, CGU. Althoughsuch sequence does not contain any uridine pairs, triplets, orquadruplets, one third of the nucleobases would be uridines. Such auridine cluster could be removed by using alternative codons, forexample, by using GCC, GAC, GGC, AGC, and CGC, which would contain nouridines.

In other embodiments, the reference nucleic acid sequence comprises atleast one uridine cluster, wherein said uridine cluster is a subsequenceof the reference nucleic acid sequence wherein the percentage of uridinenucleobases of said subsequence as measured using a sliding window thatis above a predetermined threshold. In some embodiments, the length ofthe sliding window is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,37, 38, 39, or 40 nucleobases. In some embodiments, the sliding windowis over 40 nucleobases in length. In some embodiments, the threshold is1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%,17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25% uridine content. In someembodiments, the threshold is above 25%.

In some embodiments, the reference nucleic acid sequence comprises atleast two uridine clusters. In some embodiments, the uridine-modifiedsequence contains fewer uridine-rich clusters than the reference nucleicacid sequence. In some embodiments, the uridine-modified sequencecontains more uridine-rich clusters than the reference nucleic acidsequence. In some embodiments, the uridine-modified sequence containsuridine-rich clusters with are shorter in length than correspondinguridine-rich clusters in the reference nucleic acid sequence. In otherembodiments, the uridine-modified sequence contains uridine-richclusters which are longer in length than the corresponding uridine-richcluster in the reference nucleic acid sequence.

See, Kariko et al. (2005) Immunity 23:165-175; Kormann et al. (2010)Nature Biotechnology 29:154-157; or Sahin et al. (2014) Nature ReviewsDrug Discovery|AOP, published online 19 Sep. 2014m doi:10.1038/nrd4278;all of which are herein incorporated by reference their entireties.

b. Guanine/Cytosine (G/C) Content

A reference nucleic acid sequence can be sequence optimized usingmethods comprising altering the Guanine/Cytosine (G/C) content (absoluteor relative) of the reference nucleic acid sequence. Such optimizationcan comprise altering (e.g., increasing or decreasing) the global G/Ccontent (absolute or relative) of the reference nucleic acid sequence;introducing local changes in G/C content in the reference nucleic acidsequence (e.g., increase or decrease G/C in selected regions orsubsequences in the reference nucleic acid sequence); altering thefrequency, size, and distribution of G/C clusters in the referencenucleic acid sequence, or combinations thereof.

In some embodiments, the sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides comprises an overall increase in G/C content (absolute orrelative) relative to the G/C content (absolute or relative) of thereference nucleic acid sequence. In some embodiments, the overallincrease in G/C content (absolute or relative) is at least about 5%, atleast about 10%, at least about 15%, at least about 20%, at least about25%, at least about 30%, at least about 35%, at least about 40%, atleast about 45%, at least about 50%, at least about 55%, at least about60%, at least about 65%, at least about 70%, at least about 75%, atleast about 80%, at least about 85%, at least about 90%, at least about95%, or at least about 100% relative to the G/C content (absolute orrelative) of the reference nucleic acid sequence.

In some embodiments, the sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides comprises an overall decrease in G/C content (absolute orrelative) relative to the G/C content of the reference nucleic acidsequence. In some embodiments, the overall decrease in G/C content(absolute or relative) is at least about 5%, at least about 10%, atleast about 15%, at least about 20%, at least about 25%, at least about30%, at least about 35%, at least about 40%, at least about 45%, atleast about 50%, at least about 55%, at least about 60%, at least about65%, at least about 70%, at least about 75%, at least about 80%, atleast about 85%, at least about 90%, at least about 95%, or at leastabout 100% relative to the G/C content (absolute or relative) of thereference nucleic acid sequence.

In some embodiments, the sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides comprises a local increase in Guanine/Cytosine (G/C)content (absolute or relative) in a subsequence (i.e., a G/C modifiedsubsequence) relative to the G/C content (absolute or relative) of thecorresponding subsequence in the reference nucleic acid sequence. Insome embodiments, the local increase in G/C content (absolute orrelative) is by at least about 5%, at least about 10%, at least about15%, at least about 20%, at least about 25%, at least about 30%, atleast about 35%, at least about 40%, at least about 45%, at least about50%, at least about 55%, at least about 60%, at least about 65%, atleast about 70%, at least about 75%, at least about 80%, at least about85%, at least about 90%, at least about 95%, or at least about 100%relative to the G/C content (absolute or relative) of the correspondingsubsequence in the reference nucleic acid sequence.

In some embodiments, the sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides comprises a local decrease in Guanine/Cytosine (G/C)content (absolute or relative) in a subsequence (i.e., a G/C modifiedsubsequence) relative to the G/C content (absolute or relative) of thecorresponding subsequence in the reference nucleic acid sequence. Insome embodiments, the local decrease in G/C content (absolute orrelative) is by at least about 5%, at least about 10%, at least about15%, at least about 20%, at least about 25%, at least about 30%, atleast about 35%, at least about 40%, at least about 45%, at least about50%, at least about 55%, at least about 60%, at least about 65%, atleast about 70%, at least about 75%, at least about 80%, at least about85%, at least about 90%, at least about 95%, or at least about 100%relative to the G/C content (absolute or relative) of the correspondingsubsequence in the reference nucleic acid sequence.

In some embodiments, the G/C content (absolute or relative) is increasedor decreased in a subsequence which is at least about 5, 10, 15, 20, 25,30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100nucleobases in length.

In some embodiments, the G/C content (absolute or relative) is increasedor decreased in a subsequence which is at least about 100, 110, 120,130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260,270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400,410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540,550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680,690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820,830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960,970, 980, 990, or 1000 nucleobases in length.

In some embodiments, the G/C content (absolute or relative) is increasedor decreased in a subsequence which is at least about 1100, 1200, 1300,1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500,2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700,3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900,5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100,6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300,7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500,8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700,9800, 9900, or 10000 nucleobases in length.

The increases or decreases in G and C content (absolute or relative)described herein can be conducted by replacing synonymous codons withlow G/C content with synonymous codons having higher G/C content, orvice versa. For example, L has 6 synonymous codons: two of them have 2G/C (CUC, CUG), 3 have a single G/C (UUG, CUU, CUA), and one has no G/C(UUA). So if the reference nucleic acid had a CUC codon in a certainposition, G/C content at that position could be reduced by replacing CUCwith any of the codons having a single G/C or the codon with no G/C.

See, U.S. Publ. Nos. US20140228558, US20050032730 A1; Gustafsson et al.(2012) Protein Expression and Purification 83: 37-46; all of which areincorporated herein by reference in their entireties.

c. Codon Frequency—Codon Usage Bias

Numerous codon optimization methods known in the art are based on thesubstitution of codons in a reference nucleic acid sequence with codonshaving higher frequencies. Thus, in some embodiments, a nucleic acidsequence encoding an IL12A polypeptide, an IL12B polypeptide, and/orIL12A and IL12B fusion polypeptides disclosed herein can be sequenceoptimized using methods comprising the use of modifications in thefrequency of use of one or more codons relative to other synonymouscodons in the sequence optimized nucleic acid with respect to thefrequency of use in the non-codon optimized sequence.

As used herein, the term “codon frequency” refers to codon usage bias,i.e., the differences in the frequency of occurrence of synonymouscodons in coding DNA/RNA. It is generally acknowledged that codonpreferences reflect a balance between mutational biases and naturalselection for translational optimization. Optimal codons help to achievefaster translation rates and high accuracy. As a result of thesefactors, translational selection is expected to be stronger in highlyexpressed genes. In the field of bioinformatics and computationalbiology, many statistical methods have been proposed and used to analyzecodon usage bias. See, e.g., Comeron & Aguadé (1998) J. Mol. Evol. 47:268-74. Methods such as the ‘frequency of optimal codons’ (Fop) (Ikemura(1981) J. Mol. Biol. 151 (3): 389-409), the Relative Codon Adaptation(RCA) (Fox & Eril (2010) DNA Res. 17 (3): 185-96) or the ‘CodonAdaptation Index’ (CAI) (Sharp & Li (1987) Nucleic Acids Res. 15 (3):1281-95) are used to predict gene expression levels, while methods suchas the ‘effective number of codons’ (Nc) and Shannon entropy frominformation theory are used to measure codon usage evenness.Multivariate statistical methods, such as correspondence analysis andprincipal component analysis, are widely used to analyze variations incodon usage among genes (Suzuki et al. (2008) DNA Res. 15 (6): 357-65;Sandhu et al., In Silico Biol. 2008; 8(2):187-92).

The nucleic acid sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides disclosed herein(e.g., a wild type nucleic acid sequence, a mutant nucleic acidsequence, a chimeric nucleic sequence, etc. which can be, for example,an mRNA), can be codon optimized using methods comprising substitutingat least one codon in the reference nucleic acid sequence with analternative codon having a higher or lower codon frequency in thesynonymous codon set; wherein the resulting sequence optimized nucleicacid has at least one optimized property with respect to the referencenucleic acid sequence.

In some embodiments, at least about 5%, at least about 10%, at leastabout 15%, at least about 20%, at least about 25%, at least about 30%,at least about 35%, at least about 40%, at least about 45%, at leastabout 50%, at least about 55%, at least about 60%, at least about 65%,at least about 70%, at least about 75%, at least about 80%, at leastabout 85%, at least about 90%, at least about 95%, at least about 99%,or 100% of the codons in the reference nucleic acid sequence encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides are substituted with alternative codons, each alternativecodon having a codon frequency higher than the codon frequency of thesubstituted codon in the synonymous codon set.

In some embodiments, at least one codon in the reference nucleic acidsequence encoding an IL12A polypeptide, an IL12B polypeptide, and/orIL12A and IL12B fusion polypeptides is substituted with an alternativecodon having a codon frequency higher than the codon frequency of thesubstituted codon in the synonymous codon set, and at least one codon inthe reference nucleic acid sequence is substituted with an alternativecodon having a codon frequency lower than the codon frequency of thesubstituted codon in the synonymous codon set.

In some embodiments, at least about 5%, at least about 10%, at leastabout 15%, at least about 20%, at least about 25%, at least about 30%,at least about 35%, at least about 40%, at least about 45%, at leastabout 50%, at least about 55%, at least about 60%, at least about 65%,at least about 70%, or at least about 75% of the codons in the referencenucleic acid sequence encoding IL12 are substituted with alternativecodons, each alternative codon having a codon frequency higher than thecodon frequency of the substituted codon in the synonymous codon set.

In some embodiments, at least one alternative codon having a highercodon frequency has the highest codon frequency in the synonymous codonset. In other embodiments, all alternative codons having a higher codonfrequency have the highest codon frequency in the synonymous codon set.

In some embodiments, at least one alternative codon having a lower codonfrequency has the lowest codon frequency in the synonymous codon set. Insome embodiments, all alternative codons having a higher codon frequencyhave the highest codon frequency in the synonymous codon set.

In some specific embodiments, at least one alternative codon has thesecond highest, the third highest, the fourth highest, the fifth highestor the sixth highest frequency in the synonymous codon set. In somespecific embodiments, at least one alternative codon has the secondlowest, the third lowest, the fourth lowest, the fifth lowest, or thesixth lowest frequency in the synonymous codon set.

Optimization based on codon frequency can be applied globally, asdescribed above, or locally to the reference nucleic acid sequenceencoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides. In some embodiments, when applied locally,regions of the reference nucleic acid sequence can modified based oncodon frequency, substituting all or a certain percentage of codons in acertain subsequence with codons that have higher or lower frequencies intheir respective synonymous codon sets. Thus, in some embodiments, atleast about 5%, at least about 10%, at least about 15%, at least about20%, at least about 25%, at least about 30%, at least about 35%, atleast about 40%, at least about 45%, at least about 50%, at least about55%, at least about 60%, at least about 65%, at least about 70%, atleast about 75%, at least about 80%, at least about 85%, at least about90%, at least about 95%, at least about 99%, or 100% of the codons in asubsequence of the reference nucleic acid sequence are substituted withalternative codons, each alternative codon having a codon frequencyhigher than the codon frequency of the substituted codon in thesynonymous codon set.

In some embodiments, at least one codon in a subsequence of thereference nucleic acid sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides is substitutedwith an alternative codon having a codon frequency higher than the codonfrequency of the substituted codon in the synonymous codon set, and atleast one codon in a subsequence of the reference nucleic acid sequenceis substituted with an alternative codon having a codon frequency lowerthan the codon frequency of the substituted codon in the synonymouscodon set.

In some embodiments, at least about 5%, at least about 10%, at leastabout 15%, at least about 20%, at least about 25%, at least about 30%,at least about 35%, at least about 40%, at least about 45%, at leastabout 50%, at least about 55%, at least about 60%, at least about 65%,at least about 70%, or at least about 75% of the codons in a subsequenceof the reference nucleic acid sequence encoding an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides aresubstituted with alternative codons, each alternative codon having acodon frequency higher than the codon frequency of the substituted codonin the synonymous codon set.

In some embodiments, at least one alternative codon substituted in asubsequence of the reference nucleic acid sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides and having a higher codon frequency has the highest codonfrequency in the synonymous codon set. In other embodiments, allalternative codons substituted in a subsequence of the reference nucleicacid sequence and having a lower codon frequency have the lowest codonfrequency in the synonymous codon set.

In some embodiments, at least one alternative codon substituted in asubsequence of the reference nucleic acid sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides and having a lower codon frequency has the lowest codonfrequency in the synonymous codon set. In some embodiments, allalternative codons substituted in a subsequence of the reference nucleicacid sequence and having a higher codon frequency have the highest codonfrequency in the synonymous codon set.

In specific embodiments, a sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides can comprise a subsequence having an overall codonfrequency higher or lower than the overall codon frequency in thecorresponding subsequence of the reference nucleic acid sequence at aspecific location, for example, at the 5′ end or 3′ end of the sequenceoptimized nucleic acid, or within a predetermined distance from thoseregion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30,35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 codons fromthe 5′ end or 3′ end of the sequence optimized nucleic acid).

In some embodiments, an sequence optimized nucleic acid encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides can comprise more than one subsequence having an overallcodon frequency higher or lower than the overall codon frequency in thecorresponding subsequence of the reference nucleic acid sequence. Askilled artisan would understand that subsequences with overall higheror lower overall codon frequencies can be organized in innumerablepatterns, depending on whether the overall codon frequency is higher orlower, the length of the subsequence, the distance between subsequences,the location of the subsequences, etc.

See, U.S. Pat. Nos. 5,082,767, 8,126,653, 7,561,973, 8,401,798; U.S.Publ. No. US 20080046192, US 20080076161; Int'l. Publ. No. WO2000018778;Welch et al. (2009) PLoS ONE 4(9): e7002; Gustafsson et al. (2012)Protein Expression and Purification 83: 37-46; Chung et al. (2012) BMCSystems Biology 6:134; all of which are incorporated herein by referencein their entireties.

d. Destabilizing Motif Substitution

There is a variety of motifs that can affect sequence optimization,which fall into various non-exclusive categories, for example:

-   (i) Primary sequence based motifs: Motifs defined by a simple    arrangement of nucleotides.-   (ii) Structural motifs: Motifs encoded by an arrangement of    nucleotides that tends to form a certain secondary structure.-   (iii) Local motifs: Motifs encoded in one contiguous subsequence.-   (iv) Distributed motifs: Motifs encoded in two or more disjoint    subsequences.-   (v) Advantageous motifs: Motifs which improve nucleotide structure    or function.-   (vi) Disadvantageous motifs: Motifs with detrimental effects on    nucleotide structure or function.

There are many motifs that fit into the category of disadvantageousmotifs. Some examples include, for example, restriction enzyme motifs,which tend to be relatively short, exact sequences such as therestriction site motifs for XbaI (TCTAGA (SEQ ID NO: 224)), EcoRI(GAATTC (SEQ ID NO: 225)), EcoRII (CCWGG (SEQ ID NO: 226), wherein Wmeans A or T, per the IUPAC ambiguity codes), or HindIII (AAGCTT (SEQ IDNO: 227)); enzyme sites, which tend to be longer and based on consensusnot exact sequence, such in the T7 RNA polymerase (GnnnnWnCRnCTCnCnnWnD(SEQ ID NO: 228), wherein n means any nucleotide, R means A or G, Wmeans A or T, D means A or G or T but not C); structural motifs, such asGGGG (SEQ ID NO: 229) repeats (Kim et al. (1991) Nature351(6324):331-2); or other motifs such as CUG-triplet repeats (Queridoet al. (2014) J. Cell Sci. 124:1703-1714).

Accordingly, the nucleic acid sequence encoding an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosedherein can be sequence optimized using methods comprising substitutingat least one destabilizing motif in a reference nucleic acid sequence,and removing such disadvantageous motif or replacing it with anadvantageous motif.

In some embodiments, the optimization process comprises identifyingadvantageous and/or disadvantageous motifs in the reference nucleicsequence, wherein such motifs are, e.g., specific subsequences that cancause a loss of stability in the reference nucleic acid sequence prioror during the optimization process. For example, substitution ofspecific bases during optimization may generate a subsequence (motif)recognized by a restriction enzyme. Accordingly, during the optimizationprocess the appearance of disadvantageous motifs can be monitored bycomparing the sequence optimized sequence with a library of motifs knownto be disadvantageous. Then, the identification of disadvantageousmotifs could be used as a post-hoc filter, i.e., to determine whether acertain modification which potentially could be introduced in thereference nucleic acid sequence should be actually implemented or not.

In some embodiments, the identification of disadvantageous motifs can beused prior to the application of the sequence optimization methodsdisclosed herein, i.e., the identification of motifs in the referencenucleic acid sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides and theirreplacement with alternative nucleic acid sequences can be used as apreprocessing step, for example, before uridine reduction.

In other embodiments, the identification of disadvantageous motifs andtheir removal is used as an additional sequence optimization techniqueintegrated in a multiparametric nucleic acid optimization methodcomprising two or more of the sequence optimization methods disclosedherein. When used in this fashion, a disadvantageous motif identifiedduring the optimization process would be removed, for example, bysubstituting the lowest possible number of nucleobases in order topreserve as closely as possible the original design principle(s) (e.g.,low U, high frequency, etc.).

See, e.g., U.S. Publ. Nos. US20140228558, US20050032730, orUS20140228558, which are herein incorporated by reference in theirentireties.

e. Limited Codon Set Optimization

In some particular embodiments, sequence optimization of a referencenucleic acid sequence encoding an L12A polypeptide, an IL12Bpolypeptide, and/or L12A and IL12B fusion polypeptides can be conductedusing a limited codon set, e.g., a codon set wherein less than thenative number of codons is used to encode the 20 natural amino acids, asubset of the 20 natural amino acids, or an expanded set of amino acidsincluding, for example, non-natural amino acids.

The genetic code is highly similar among all organisms and can beexpressed in a simple table with 64 entries which would encode the 20standard amino acids involved in protein translation plus start and stopcodons. The genetic code is degenerate, i.e., in general, more than onecodon specifies each amino acid. For example, the amino acid leucine isspecified by the UUA, UUG, CUU, CUC, CUA, or CUG codons, while the aminoacid serine is specified by UCA, UCG, UCC, UCU, AGU, or AGC codons(difference in the first, second, or third position). Native geneticcodes comprise 62 codons encoding naturally occurring amino acids. Thus,in some embodiments of the methods disclosed herein optimized codon sets(genetic codes) comprising less than 62 codons to encode 20 amino acidscan comprise 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47,46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 30,29, 28, 27, 26, 25, 24, 23, 22, 21, or 20 codons.

In some embodiments, the limited codon set comprises less than 20codons. For example, if a protein contains less than 20 types of aminoacids, such protein could be encoded by a codon set with less than 20codons. Accordingly, in some embodiments, an optimized codon setcomprises as many codons as different types of amino acids are presentin the protein encoded by the reference nucleic acid sequence. In someembodiments, the optimized codon set comprises 19, 18, 17, 16, 15, 14,13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or even 1 codon.

In some embodiments, at least one amino acid selected from the groupconsisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu,Lys, Phe, Pro, Ser, Thr, Tyr, and Val, i.e., amino acids which arenaturally encoded by more than one codon, is encoded with less codonsthan the naturally occurring number of synonymous codons. For example,in some embodiments, Ala can be encoded in the sequence optimizednucleic acid by 3, 2 or 1 codons; Cys can be encoded in the sequenceoptimized nucleic acid by 1 codon; Asp can be encoded in the sequenceoptimized nucleic acid by 1 codon; Glu can be encoded in the sequenceoptimized nucleic acid by 1 codon; Phe can be encoded in the sequenceoptimized nucleic acid by 1 codon; Gly can be encoded in the sequenceoptimized nucleic acid by 3 codons, 2 codons or 1 codon; His can beencoded in the sequence optimized nucleic acid by 1 codon; Ile can beencoded in the sequence optimized nucleic acid by 2 codons or 1 codon;Lys can be encoded in the sequence optimized nucleic acid by 1 codon;Leu can be encoded in the sequence optimized nucleic acid by 5 codons, 4codons, 3 codons, 2 codons or 1 codon; Asn can be encoded in thesequence optimized nucleic acid by 1 codon; Pro can be encoded in thesequence optimized nucleic acid by 3 codons, 2 codons, or 1 codon; Glncan be encoded in the sequence optimized nucleic acid by 1 codon; Argcan be encoded in the sequence optimized nucleic acid by 5 codons, 4codons, 3 codons, 2 codons, or 1 codon; Ser can be encoded in thesequence optimized nucleic acid by 5 codons, 4 codons, 3 codons, 2codons, or 1 codon; Thr can be encoded in the sequence optimized nucleicacid by 3 codons, 2 codons, or 1 codon; Val can be encoded in thesequence optimized nucleic acid by 3 codons, 2 codons, or 1 codon; and,Tyr can be encoded in the sequence optimized nucleic acid by 1 codon.

In some embodiments, at least one amino acid selected from the groupconsisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu,Lys, Phe, Pro, Ser, Thr, Tyr, and Val, i.e., amino acids which arenaturally encoded by more than one codon, is encoded by a single codonin the limited codon set.

In some specific embodiments, the sequence optimized nucleic acid is aDNA and the limited codon set consists of 20 codons, wherein each codonencodes one of 20 amino acids. In some embodiments, the sequenceoptimized nucleic acid is a DNA and the limited codon set comprises atleast one codon selected from the group consisting of GCT, GCC, GCA, andGCG; at least a codon selected from the group consisting of CGT, CGC,CGA, CGG, AGA, and AGG; at least a codon selected from AAT or ACC; atleast a codon selected from GAT or GAC; at least a codon selected fromTGT or TGC; at least a codon selected from CAA or CAG; at least a codonselected from GAA or GAG; at least a codon selected from the groupconsisting of GGT, GGC, GGA, and GGG; at least a codon selected from CATor CAC; at least a codon selected from the group consisting of ATT, ATC,and ATA; at least a codon selected from the group consisting of TTA,TTG, CTT, CTC, CTA, and CTG; at least a codon selected from AAA or AAG;an ATG codon; at least a codon selected from TTT or TTC; at least acodon selected from the group consisting of CCT, CCC, CCA, and CCG; atleast a codon selected from the group consisting of TCT, TCC, TCA, TCG,AGT, and AGC; at least a codon selected from the group consisting ofACT, ACC, ACA, and ACG; a TGG codon; at least a codon selected from TATor TAC; and, at least a codon selected from the group consisting of GTT,GTC, GTA, and GTG.

In other embodiments, the sequence optimized nucleic acid is an RNA(e.g., an mRNA) and the limited codon set consists of 20 codons, whereineach codon encodes one of 20 amino acids. In some embodiments, thesequence optimized nucleic acid is an RNA and the limited codon setcomprises at least one codon selected from the group consisting of GCU,GCC, GCA, and GCG; at least a codon selected from the group consistingof CGU, CGC, CGA, CGG, AGA, and AGG; at least a codon selected from AAUor ACC; at least a codon selected from GAU or GAC; at least a codonselected from UGU or UGC; at least a codon selected from CAA or CAG; atleast a codon selected from GAA or GAG; at least a codon selected fromthe group consisting of GGU, GGC, GGA, and GGG; at least a codonselected from CAU or CAC; at least a codon selected from the groupconsisting of AUU, AUC, and AUA; at least a codon selected from thegroup consisting of UUA, UUG, CUU, CUC, CUA, and CUG; at least a codonselected from AAA or AAG; an AUG codon; at least a codon selected fromUUU or UUC; at least a codon selected from the group consisting of CCU,CCC, CCA, and CCG; at least a codon selected from the group consistingof UCU, UCC, UCA, UCG, AGU, and AGC; at least a codon selected from thegroup consisting of ACU, ACC, ACA, and ACG; a UGG codon; at least acodon selected from UAU or UAC; and, at least a codon selected from thegroup consisting of GUU, GUC, GUA, and GUG.

In some specific embodiments, the limited codon set has been optimizedfor in vivo expression of a sequence optimized nucleic acid (e.g., asynthetic mRNA) following administration to a certain tissue or cell.

In some embodiments, the optimized codon set (e.g., a 20 codon setencoding 20 amino acids) complies at least with one of the followingproperties:

-   (i) the optimized codon set has a higher average G/C content than    the original or native codon set; or,-   (ii) the optimized codon set has a lower average U content than the    original or native codon set; or,-   (iii) the optimized codon set is composed of codons with the highest    frequency; or,-   (iv) the optimized codon set is composed of codons with the lowest    frequency; or,-   (v) a combination thereof.

In some specific embodiments, at least one codon in the optimized codonset has the second highest, the third highest, the fourth highest, thefifth highest or the sixth highest frequency in the synonymous codonset. In some specific embodiments, at least one codon in the optimizedcodon has the second lowest, the third lowest, the fourth lowest, thefifth lowest, or the sixth lowest frequency in the synonymous codon set.

As used herein, the term “native codon set” refers to the codon set usednatively by the source organism to encode the reference nucleic acidsequence. As used herein, the term “original codon set” refers to thecodon set used to encode the reference nucleic acid sequence before thebeginning of sequence optimization, or to a codon set used to encode anoptimized variant of the reference nucleic acid sequence at thebeginning of a new optimization iteration when sequence optimization isapplied iteratively or recursively.

In some embodiments, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in thecodon set are those with the highest frequency. In other embodiments,5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set are thosewith the lowest frequency.

In some embodiments, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in thecodon set are those with the highest uridine content. In someembodiments, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of codons in the codon set arethose with the lowest uridine content.

In some embodiments, the average G/C content (absolute or relative) ofthe codon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% higher than the averageG/C content (absolute or relative) of the original codon set. In someembodiments, the average G/C content (absolute or relative) of the codonset is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,70%, 75%, 80%, 85%, 90%, 95% or 100% lower than the average G/C content(absolute or relative) of the original codon set.

In some embodiments, the uracil content (absolute or relative) of thecodon set is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% higher than the average uracilcontent (absolute or relative) of the original codon set. In someembodiments, the uracil content (absolute or relative) of the codon setis 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 90%, 95% or 100% lower than the average uracil content(absolute or relative) of the original codon set.

See also U.S. Appl. Publ. No. 2011/0082055, and Int'l. Publ. No.WO2000018778, both of which are incorporated herein by reference intheir entireties.

10. Characterization of Sequence Optimized Nucleic Acids

In some embodiments of the disclosure, the polynucleotide (e.g., a RNA,e.g., an mRNA) comprising a sequence optimized nucleic acid (e.g., anORF) disclosed herein encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides can be can betested to determine whether at least one nucleic acid sequence property(e.g., stability when exposed to nucleases) or expression property hasbeen improved with respect to the non-sequence optimized nucleic acid.

As used herein, “expression property” refers to a property of a nucleicacid sequence either in vivo (e.g., translation efficacy of a syntheticmRNA after administration to a subject in need thereof) or in vitro(e.g., translation efficacy of a synthetic mRNA tested in an in vitromodel system). Expression properties include but are not limited to theamount of protein produced by an mRNA encoding an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides afteradministration, and the amount of soluble or otherwise functionalprotein produced. In some embodiments, sequence optimized nucleic acidsdisclosed herein can be evaluated according to the viability of thecells expressing a protein encoded by a sequence optimized nucleic acidsequence (e.g., a RNA, e.g., an mRNA) encoding an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides disclosedherein.

In a particular embodiment, a plurality of sequence optimized nucleicacids disclosed herein (e.g., a RNA, e.g., an mRNA) containing codonsubstitutions with respect to the non-optimized reference nucleic acidsequence can be characterized functionally to measure a property ofinterest, for example an expression property in an in vitro modelsystem, or in vivo in a target tissue or cell.

a. Optimization of Nucleic Acid Sequence Intrinsic Properties

In some embodiments of the disclosure, the desired property of thepolynucleotide is an intrinsic property of the nucleic acid sequence.For example, the nucleotide sequence (e.g., a RNA, e.g., an mRNA) can besequence optimized for in vivo or in vitro stability. In someembodiments, the nucleotide sequence can be sequence optimized forexpression in a particular target tissue or cell. In some embodiments,the nucleic acid sequence is sequence optimized to increase its plasmahalf by preventing its degradation by endo and exonucleases.

In other embodiments, the nucleic acid sequence is sequence optimized toincrease its resistance to hydrolysis in solution, for example, tolengthen the time that the sequence optimized nucleic acid or apharmaceutical composition comprising the sequence optimized nucleicacid can be stored under aqueous conditions with minimal degradation.

In other embodiments, the sequence optimized nucleic acid can beoptimized to increase its resistance to hydrolysis in dry storageconditions, for example, to lengthen the time that the sequenceoptimized nucleic acid can be stored after lyophilization with minimaldegradation.

b. Nucleic Acids Sequence Optimized for Protein Expression

In some embodiments of the disclosure, the desired property of thepolynucleotide is the level of expression of an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides encoded bya sequence optimized sequence disclosed herein. Protein expressionlevels can be measured using one or more expression systems. In someembodiments, expression can be measured in cell culture systems, e.g.,CHO cells or HEK293 cells. In some embodiments, expression can bemeasured using in vitro expression systems prepared from extracts ofliving cells, e.g., rabbit reticulocyte lysates, or in vitro expressionsystems prepared by assembly of purified individual components. In otherembodiments, the protein expression is measured in an in vivo system,e.g., mouse, rabbit, monkey, etc.

In some embodiments, protein expression in solution form can bedesirable. Accordingly, in some embodiments, a reference sequence can besequence optimized to yield a sequence optimized nucleic acid sequencehaving optimized levels of expressed proteins in soluble form. Levels ofprotein expression and other properties such as solubility, levels ofaggregation, and the presence of truncation products (i.e., fragmentsdue to proteolysis, hydrolysis, or defective translation) can bemeasured according to methods known in the art, for example, usingelectrophoresis (e.g., native or SDS-PAGE) or chromatographic methods(e.g., HPLC, size exclusion chromatography, etc.).

c. Optimization of Target Tissue or Target Cell Viability

In some embodiments, the expression of heterologous therapeutic proteinsencoded by a nucleic acid sequence can have deleterious effects in thetarget tissue or cell, reducing protein yield, or reducing the qualityof the expressed product (e.g., due to the presence of protein fragmentsor precipitation of the expressed protein in inclusion bodies), orcausing toxicity.

Accordingly, in some embodiments of the disclosure, the sequenceoptimization of a nucleic acid sequence disclosed herein, e.g., anucleic acid sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides, can be used toincrease the viability of target cells expressing the protein encoded bythe sequence optimized nucleic acid.

Heterologous protein expression can also be deleterious to cellstransfected with a nucleic acid sequence for autologous or heterologoustransplantation. Accordingly, in some embodiments of the presentdisclosure the sequence optimization of a nucleic acid sequencedisclosed herein can be used to increase the viability of target cellsexpressing the protein encoded by the sequence optimized nucleic acidsequence. Changes in cell or tissue viability, toxicity, and otherphysiological reaction can be measured according to methods known in theart.

d. Reduction of Immune and/or Inflammatory Response

In some cases, the administration of a sequence optimized nucleic acidencoding an IL12A polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides or a functional fragment thereof may triggeran immune response, which could be caused by (i) the therapeutic agent(e.g., an mRNA encoding an IL12A polypeptide, an IL12B polypeptide,and/or IL12A and IL12B fusion polypeptides), or (ii) the expressionproduct of such therapeutic agent (e.g., the IL12A polypeptide, IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides encoded by themRNA), or (iv) a combination thereof. Accordingly, in some embodimentsof the present disclosure the sequence optimization of nucleic acidsequence (e.g., an mRNA) disclosed herein can be used to decrease animmune or inflammatory response triggered by the administration of anucleic acid encoding an IL12A polypeptide, an IL12B polypeptide, and/orIL12A and IL12B fusion polypeptides or by the expression product ofIL12A, IL12B, and/or IL12A and IL12B fusion encoded by such nucleicacid.

In some aspects, an inflammatory response can be measured by detectingincreased levels of one or more inflammatory cytokines using methodsknown in the art, e.g., ELISA. The term “inflammatory cytokine” refersto cytokines that are elevated in an inflammatory response. Examples ofinflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine(C—X—C motif) ligand 1; also known as GROα, interferon-γ (IFNγ), tumornecrosis factor α (TNFα), interferon γ-induced protein 10 (IP-10), orgranulocyte-colony stimulating factor (G-CSF). The term inflammatorycytokines includes also other cytokines associated with inflammatoryresponses known in the art, e.g., interleukin-1 (IL-1), interleukin-8(IL-8), interleukin-13 (11-13), interferon α (IFN-α), etc.

11. Modified Nucleotide Sequences Encoding IL12 Polypeptides

In some embodiments, the polynucleotide (e.g., a RNA, e.g., an mRNA) ofthe disclosure comprises a chemically modified nucleobase, e.g.,5-methoxyuracil. In some embodiments, the mRNA is a uracil-modifiedsequence comprising an ORF encoding an IL12B polypeptide, IL12Apolypeptide, and/IL12B and IL12A fusion polypeptides, wherein the mRNAcomprises a chemically modified nucleobase, e.g., 5-methoxyuracil.

In certain aspects of the disclosure, when the 5-methoxyuracil base isconnected to a ribose sugar, as it is in polynucleotides, the resultingmodified nucleoside or nucleotide is referred to as 5-methoxyuridine. Insome embodiments, uracil in the polynucleotide is at least about 25%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least 90%, at least 95%,at least 99%, or about 100% 5-methoxyuracil. In one embodiment, uracilin the polynucleotide is at least 95% 5-methoxyuracil. In anotherembodiment, uracil in the polynucleotide is 100% 5-methoxyuracil.

In embodiments where uracil in the polynucleotide is at least 95%5-methoxyuracil, overall uracil content can be adjusted such that anmRNA provides suitable protein expression levels while inducing littleto no immune response. In some embodiments, the uracil content of theORF (% U_(TM)) is between about 105% and about 145%, about 105% andabout 140%, about 110% and about 140%, about 110% and about 145%, about115% and about 135%, about 105% and about 135%, about 110% and about135%, about 115% and about 145%, or about 115% and about 140%. In otherembodiments, the uracil content of the ORF is between about 117% andabout 134% or between 118% and 132% of the % U_(TM). In someembodiments, the % U_(TM) is about 115%, about 120%, about 125%, about130%, about 135%, about 140%, about 145%, or about 150%. In thiscontext, the term “uracil” can refer to 5-methoxyuracil and/or naturallyoccurring uracil.

In some embodiments, the uracil content in the ORF of the mRNA encodingan IL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12Bfusion polypeptides of the disclosure is less than about 50%, about 40%,about 30%, or about 20% of the total nucleobase content in the ORF. Insome embodiments, the uracil content in the ORF is between about 15% andabout 25% of the total nucleobase content in the ORF. In otherembodiments, the uracil content in the ORF is between about 20% andabout 30% of the total nucleobase content in the ORF. In one embodiment,the uracil content in the ORF of the mRNA encoding an IL12A polypeptide,an IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides is lessthan about 20% of the total nucleobase content in the open readingframe. In this context, the term “uracil” can refer to 5-methoxyuraciland/or naturally occurring uracil.

In further embodiments, the ORF of the mRNA encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides having 5-methoxyuracil and adjusted uracil content hasincreased Cytosine (C), Guanine (G), or Guanine/Cytosine (G/C) content(absolute or relative). In some embodiments, the overall increase in C,G, or G/C content (absolute or relative) of the ORF is at least about2%, at least about 3%, at least about 4%, at least about 5%, at leastabout 6%, at least about 7%, at least about 10%, at least about 15%, atleast about 20%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast about 95%, or at least about 100% relative to the G/C content(absolute or relative) of the wild-type ORF. In some embodiments, the G,the C, or the G/C content in the ORF is less than about 100%, less thanabout 90%, less than about 85%, or less than about 80% of thetheoretical maximum G, C, or G/C content of the corresponding wild typenucleotide sequence encoding the IL12A polypeptide, IL12B polypeptide,and/or IL12A and IL12B fusion polypeptides (% G_(TMX); % C_(TMX), or %G/C_(TMX)). In other embodiments, the G, the C, or the G/C content inthe ORF is between about 70% and about 80%, between about 71% and about79%, between about 71% and about 78%, or between about 71% and about 77%of the % G_(TMX), % C_(TMX), or % G/C_(TMX). In some embodiments, theincreases in G and/or C content (absolute or relative) described hereincan be conducted by replacing synonymous codons with low G, C, or G/Ccontent with synonymous codons having higher G, C, or G/C content. Inother embodiments, the increase in G and/or C content (absolute orrelative) is conducted by replacing a codon ending with U with asynonymous codon ending with G or C.

In further embodiments, the ORF of the mRNA encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides of the disclosure comprises 5-methoxyuracil and has anadjusted uracil content containing less uracil pairs (UU) and/or uraciltriplets (UUU) and/or uracil quadruplets (UUUU) than the correspondingwild-type nucleotide sequence encoding the IL12A polypeptide, IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides. In someembodiments, the ORF of the mRNA encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides of thedisclosure contains no uracil pairs and/or uracil triplets and/or uracilquadruplets. In some embodiments, uracil pairs and/or uracil tripletsand/or uracil quadruplets are reduced below a certain threshold, e.g.,no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, or 20 occurrences in the ORF of the mRNA encoding the IL12Apolypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides. In a particular embodiment, the ORF of the mRNA encodingthe IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides of the disclosure contains less than 20, 19, 18, 17, 16,15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-phenylalanineuracil pairs and/or triplets. In another embodiment, the ORF of the mRNAencoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides contains no non-phenylalanine uracil pairsand/or triplets.

In further embodiments, the ORF of the mRNA encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides of the disclosure comprises 5-methoxyuracil and has anadjusted uracil content containing less uracil-rich clusters than thecorresponding wild-type nucleotide sequence encoding the IL12Apolypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides. In some embodiments, the ORF of the mRNA encoding theIL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides of the disclosure contains uracil-rich clusters that areshorter in length than corresponding uracil-rich clusters in thecorresponding wild-type nucleotide sequence encoding the IL12Apolypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides.

In further embodiments, alternative lower frequency codons are employed.At least about 5%, at least about 10%, at least about 15%, at leastabout 20%, at least about 25%, at least about 30%, at least about 35%,at least about 40%, at least about 45%, at least about 50%, at leastabout 55%, at least about 60%, at least about 65%, at least about 70%,at least about 75%, at least about 80%, at least about 85%, at leastabout 90%, at least about 95%, at least about 99%, or 100% of the codonsin the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12Bfusion polypeptides-encoding ORF of the 5-methoxyuracil-comprising mRNAare substituted with alternative codons, each alternative codon having acodon frequency lower than the codon frequency of the substituted codonin the synonymous codon set. The ORF also has adjusted uracil content,as described above. In some embodiments, at least one codon in the ORFof the mRNA encoding the IL12A polypeptide, IL12B polypeptide, and/orIL12A and IL12B fusion polypeptides is substituted with an alternativecodon having a codon frequency lower than the codon frequency of thesubstituted codon in the synonymous codon set.

In some embodiments, the adjusted uracil content, IL12A polypeptide,IL12B polypeptide, and/or IL12A and IL12B fusion polypeptides-encodingORF of the 5-methoxyuracil-comprising mRNA exhibits expression levels ofIL12 when administered to a mammalian cell that are higher thanexpression levels of IL12 from the corresponding wild-type mRNA. Inother embodiments, the expression levels of IL12 when administered to amammalian cell are increased relative to a corresponding mRNA containingat least 95% 5-methoxyuracil and having a uracil content of about 160%,about 170%, about 180%, about 190%, or about 200% of the theoreticalminimum. In yet other embodiments, the expression levels of IL12 whenadministered to a mammalian cell are increased relative to acorresponding mRNA, wherein at least about 50%, at least about 60%, atleast about 70%, at least about 80%, at least about 90%, or about 100%of uracils are 1-methylpseudouracil or pseudouracils. In someembodiments, the mammalian cell is a mouse cell, a rat cell, or a rabbitcell. In other embodiments, the mammalian cell is a monkey cell or ahuman cell. In some embodiments, the human cell is a HeLa cell, a BJfibroblast cell, or a peripheral blood mononuclear cell (PBMC). In someembodiments, IL12 is expressed when the mRNA is administered to amammalian cell in vivo. In some embodiments, the mRNA is administered tomice, rabbits, rats, monkeys, or humans. In one embodiment, mice arenull mice. In some embodiments, the mRNA is administered to mice in anamount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, or about0.15 mg/kg. In some embodiments, the mRNA is administered intravenouslyor intramuscularly. In other embodiments, the IL12 polypeptide isexpressed when the mRNA is administered to a mammalian cell in vitro. Insome embodiments, the expression is increased by at least about 2-fold,at least about 5-fold, at least about 10-fold, at least about 50-fold,at least about 500-fold, at least about 1500-fold, or at least about3000-fold. In other embodiments, the expression is increased by at leastabout 10%, about 20%, about 30%, about 40%, about 50%, 60%, about 70%,about 80%, about 90%, or about 100%.

In some embodiments, adjusted uracil content, IL12A polypeptide, IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides-encoding ORF ofthe 5-methoxyuracil-comprising mRNA exhibits increased stability. Insome embodiments, the mRNA exhibits increased stability in a cellrelative to the stability of a corresponding wild-type mRNA under thesame conditions. In some embodiments, the mRNA exhibits increasedstability including resistance to nucleases, thermal stability, and/orincreased stabilization of secondary structure. In some embodiments,increased stability exhibited by the mRNA is measured by determining thehalf-life of the mRNA (e.g., in a plasma, cell, or tissue sample) and/ordetermining the area under the curve (AUC) of the protein expression bythe mRNA over time (e.g., in vitro or in vivo). An mRNA is identified ashaving increased stability if the half-life and/or the AUC is greaterthan the half-life and/or the AUC of a corresponding wild-type mRNAunder the same conditions.

In some embodiments, the mRNA of the present disclosure induces adetectably lower immune response (e.g., innate or acquired) relative tothe immune response induced by a corresponding wild-type mRNA under thesame conditions. In other embodiments, the mRNA of the presentdisclosure induces a detectably lower immune response (e.g., innate oracquired) relative to the immune response induced by an mRNA thatencodes for an L12B polypeptide, L12A polypeptide, and/or L12A and IL12Bfusion polypeptides but does not comprise 5-methoxyuracil under the sameconditions, or relative to the immune response induced by an mRNA thatencodes for an IL12A polypeptide, IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides and that comprises 5-methoxyuracil but thatdoes not have adjusted uracil content under the same conditions. Theinnate immune response can be manifested by increased expression ofpro-inflammatory cytokines, activation of intracellular PRRs (RIG-I,MDA5, etc), cell death, and/or termination or reduction in proteintranslation. In some embodiments, a reduction in the innate immuneresponse can be measured by expression or activity level of Type 1interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-6, IFN-ε, IFN-τ, IFN-ω, andIFN-ζ) or the expression of interferon-regulated genes such as thetoll-like receptors (e.g., TLR7 and TLR8), and/or by decreased celldeath following one or more administrations of the mRNA of thedisclosure into a cell.

In some embodiments, the expression of Type-1 interferons by a mammaliancell in response to the mRNA of the present disclosure is reduced by atleast 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, orgreater than 99.9% relative to a corresponding wild-type mRNA, to anmRNA that encodes an IL12A polypeptide, an IL12B polypeptide, and/orIL12A and IL12B fusion polypeptides but does not comprise5-methoxyuracil, or to an mRNA that encodes an IL12A polypeptide, anIL12B polypeptide, and/or IL12A and IL12B fusion polypeptides and thatcomprises 5-methoxyuracil but that does not have adjusted uracilcontent. In some embodiments, the interferon is IFN-β. In someembodiments, cell death frequency caused by administration of mRNA ofthe present disclosure to a mammalian cell is 10%, 25%, 50%, 75%, 85%,90%, 95%, or over 95% less than the cell death frequency observed with acorresponding wild-type mRNA, an mRNA that encodes for an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides but does not comprise 5-methoxyuracil, or an mRNA thatencodes for an IL12A polypeptide, an IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides and that comprises 5-methoxyuracil but thatdoes not have adjusted uracil content. In some embodiments, themammalian cell is a BJ fibroblast cell. In other embodiments, themammalian cell is a splenocyte. In some embodiments, the mammalian cellis that of a mouse or a rat. In other embodiments, the mammalian cell isthat of a human. In one embodiment, the mRNA of the present disclosuredoes not substantially induce an innate immune response of a mammaliancell into which the mRNA is introduced.

In some embodiments, the polynucleotide is an mRNA that comprises an ORFthat encodes an IL12A polypeptide, an IL12B polypeptide, and/or IL12Aand IL12B fusion polypeptides, wherein uracil in the mRNA is at leastabout 95% 5-methoxyuracil, wherein the uracil content of the ORF isbetween about 115% and about 135% of the theoretical minimum uracilcontent in the corresponding wild-type ORF, and wherein the uracilcontent in the ORF encoding the IL12A polypeptide, IL12B polypeptide,and/or IL12A and IL12B fusion polypeptides is less than about 30% of thetotal nucleobase content in the ORF. In some embodiments, the ORF thatencodes the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12Bfusion polypeptides is further modified to increase G/C content of theORF (absolute or relative) by at least about 40%, as compared to thecorresponding wild-type ORF. In yet other embodiments, the ORF encodingthe IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides contains less than 20 non-phenylalanine uracil pairs and/ortriplets. In some embodiments, at least one codon in the ORF of the mRNAencoding the IL12A polypeptide, IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides is further substituted with an alternativecodon having a codon frequency lower than the codon frequency of thesubstituted codon in the synonymous codon set. In some embodiments, theexpression of the IL12A polypeptide, IL12B polypeptide, and/or IL12A andIL12B fusion polypeptides encoded by an mRNA comprising an ORF whereinuracil in the mRNA is at least about 95% 5-methoxyuracil, and whereinthe uracil content of the ORF is between about 115% and about 135% ofthe theoretical minimum uracil content in the corresponding wild-typeORF, is increased by at least about 10-fold when compared to expressionof the IL12A polypeptide, IL12B polypeptide, and/or IL12A and IL12Bfusion polypeptides from the corresponding wild-type mRNA. In someembodiments, the mRNA comprises an open ORF wherein uracil in the mRNAis at least about 95% 5-methoxyuracil, and wherein the uracil content ofthe ORF is between about 115% and about 135% of the theoretical minimumuracil content in the corresponding wild-type ORF, and wherein the mRNAdoes not substantially induce an innate immune response of a mammaliancell into which the mRNA is introduced.

12. Methods for Modifying Polynucleotides

The disclosure includes modified polynucleotides comprising apolynucleotide described herein (e.g., a polynucleotide comprising anucleotide sequence encoding an IL12A polypeptide, an IL12B polypeptide,and/or IL12A and IL12B fusion polypeptides). The modifiedpolynucleotides can be chemically modified and/or structurally modified.When the polynucleotides of the present disclosure are chemically and/orstructurally modified the polynucleotides can be referred to as“modified polynucleotides.”

The present disclosure provides for modified nucleosides and nucleotidesof a polynucleotide (e.g., RNA polynucleotides, such as mRNApolynucleotides) encoding an IL12A polypeptide, an IL12B polypeptide,and/or IL12A and IL12B fusion polypeptides. A “nucleoside” refers to acompound containing a sugar molecule (e.g., a pentose or ribose) or aderivative thereof in combination with an organic base (e.g., a purineor pyrimidine) or a derivative thereof (also referred to herein as“nucleobase”). A “nucleotide” refers to a nucleoside including aphosphate group. Modified nucleotides may by synthesized by any usefulmethod, such as, for example, chemically, enzymatically, orrecombinantly, to include one or more modified or non-naturalnucleosides. Polynucleotides may comprise a region or regions of linkednucleosides. Such regions may have variable backbone linkages. Thelinkages may be standard phosphodiester linkages, in which case thepolynucleotides would comprise regions of nucleotides.

The modified polynucleotides disclosed herein can comprise variousdistinct modifications. In some embodiments, the modifiedpolynucleotides contain one, two, or more (optionally different)nucleoside or nucleotide modifications. In some embodiments, a modifiedpolynucleotide, introduced to a cell may exhibit one or more desirableproperties, e.g., improved protein expression, reduced immunogenicity,or reduced degradation in the cell, as compared to an unmodifiedpolynucleotide.

a. Structural Modifications

In some embodiments, a polynucleotide of the present disclosure (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides) is structurally modified. As used herein, a “structural”modification is one in which two or more linked nucleosides areinserted, deleted, duplicated, inverted or randomized in apolynucleotide without significant chemical modification to thenucleotides themselves. Because chemical bonds will necessarily bebroken and reformed to effect a structural modification, structuralmodifications are of a chemical nature and hence are chemicalmodifications. However, structural modifications will result in adifferent sequence of nucleotides. For example, the polynucleotide “ATCG(SEQ ID NO: 230)” can be chemically modified to “AT-5meC-G”. The samepolynucleotide can be structurally modified from “ATCG (SEQ ID NO: 230)”to “ATCCCG (SEQ ID NO: 231)”. Here, the dinucleotide “CC” has beeninserted, resulting in a structural modification to the polynucleotide.

b. Chemical Modifications

In some embodiments, the polynucleotides of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding anIL12A polypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides) are chemically modified. As used herein in reference to apolynucleotide, the terms “chemical modification” or, as appropriate,“chemically modified” refer to modification with respect to adenosine(A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribo- ordeoxyribonucleosides in one or more of their position, pattern, percentor population, including, but not limited to, its nucleobase, sugar,backbone, or any combination thereof. Generally, herein, these terms arenot intended to refer to the ribonucleotide modifications in naturallyoccurring 5′-terminal mRNA cap moieties.

In some embodiments, the polynucleotides of the disclosure (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Apolypeptide, an IL12B polypeptide, and/or IL12A and IL12B fusionpolypeptides) can have a uniform chemical modification of all or any ofthe same nucleoside type or a population of modifications produced bydownward titration of the same starting modification in all or any ofthe same nucleoside type, or a measured percent of a chemicalmodification of all any of the same nucleoside type but with randomincorporation, such as where all uridines are replaced by a uridineanalog, e.g., 5-methoxyuridine. In another embodiment, thepolynucleotides can have a uniform chemical modification of two, three,or four of the same nucleoside type throughout the entire polynucleotide(such as all uridines and/or all cytidines, etc. are modified in thesame way).

Modified nucleotide base pairing encompasses not only the standardadenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs,but also base pairs formed between nucleotides and/or modifiednucleotides comprising non-standard or modified bases, wherein thearrangement of hydrogen bond donors and hydrogen bond acceptors permitshydrogen bonding between a non-standard base and a standard base orbetween two complementary non-standard base structures. One example ofsuch non-standard base pairing is the base pairing between the modifiednucleotide inosine and adenine, cytosine or uracil. Any combination ofbase/sugar or linker may be incorporated into polynucleotides of thepresent disclosure.

The skilled artisan will appreciate that, except where otherwise noted,polynucleotide sequences set forth in the instant application willrecite “T”s in a representative DNA sequence but where the sequencerepresents RNA, the “T”s would be substituted for “U”s.

Modifications of polynucleotides (e.g., RNA polynucleotides, such asmRNA polynucleotides) that are useful in the composition of the presentdisclosure include, but are not limited to the following:2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine;2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonylcarbamoyladenosine; N6-glycinylcarbamoyladenosine;N6-isopentenyladenosine; N6-methyladenosine;N6-threonylcarbamoyladenosine; 1,2′-O-dimethyladenosine;1-methyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine(phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladenosine;2-methylthio-N6-hydroxynorvalyl carbamoyladenosine;2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate);Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine;N6,2′-O-dimethyladenosine; N6,2′-O-dimethyladenosine;N6,N6,2′-O-trimethyladenosine; N6,N6-dimethyladenosine;N6-acetyladenosine; N6-hydroxynorvalylcarbamoyladenosine;N6-methyl-N6-threonylcarbamoyladenosine; 2-methyladenosine;2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine;N1-methyl-adenosine; N6, N6 (dimethyl)adenine;N6-cis-hydroxy-isopentenyl-adenosine; α-thio-adenosine; 2(amino)adenine; 2 (aminopropyl)adenine; 2 (methylthio) N6(isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine;2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine;2-(propyl)adenine; 2′-Amino-2′-deoxy-ATP; 2′-Azido-2′-deoxy-ATP;2′-Deoxy-2′-a-aminoadenosine TP; 2′-Deoxy-2′-a-azidoadenosine TP; 6(alkyl)adenine; 6 (methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine;7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8(amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine;8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine;8-(hydroxyl)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine;8-azido-adenosine; aza adenine; deaza adenine; N6 (methyl)adenine;N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine;1-Deazaadenosine TP; 2′Fluoro-N6-Bz-deoxyadenosine TP;2′-OMe-2-Amino-ATP; 2′O-methyl-N6-Bz-deoxyadenosine TP;2′-a-Ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP;2-Amino-ATP; 2′-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP;2′-b-Ethynyladenosine TP; 2-Bromoadenosine TP;2′-b-Trifluoromethyladenosine TP; 2-Chloroadenosine TP;2′-Deoxy-2′,2′-difluoroadenosine TP; 2′-Deoxy-2′-a-mercaptoadenosine TP;2′-Deoxy-2′-a-thiomethoxyadenosine TP; 2′-Deoxy-2′-b-aminoadenosine TP;2′-Deoxy-2′-b-azidoadenosine TP; 2′-Deoxy-2′-b-bromoadenosine TP;2′-Deoxy-2′-b-chloroadenosine TP; 2′-Deoxy-2′-b-fluoroadenosine TP;2′-Deoxy-2′-b-iodoadenosine TP; 2′-Deoxy-2′-b-mercaptoadenosine TP;2′-Deoxy-2′-b-thiomethoxyadenosine TP; 2-Fluoroadenosine TP;2-Iodoadenosine TP; 2-Mercaptoadenosine TP; 2-methoxy-adenine;2-methylthio-adenine; 2-Trifluoromethyladenosine TP;3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloroadenosine TP;3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP;3-Deazaadenosine TP; 4′-Azidoadenosine TP; 4′-Carbocyclic adenosine TP;4′-Ethynyladenosine TP; 5′-Homo-adenosine TP; 8-Aza-ATP;8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-DeazaadenosineTP; 2-aminopurine; 7-deaza-2,6-diaminopurine;7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine;2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine;2-thiocytidine; 3-methylcytidine; 5-formylcytidine;5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine;2′-O-methylcytidine; 2′-O-methylcytidine; 5,2′-O-dimethylcytidine;5-formyl-2′-O-methylcytidine; Lysidine; N4,2′-O-dimethylcytidine;N4-acetyl-2′-O-methylcytidine; N4-methylcytidine;N4,N4-Dimethyl-2′-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine;Pseudo-iso-cytidine; pyrrolo-cytidine; α-thio-cytidine;2-(thio)cytosine; 2′-Amino-2′-deoxy-CTP; 2′-Azido-2′-deoxy-CTP;2′-Deoxy-2′-a-aminocytidine TP; 2′-Deoxy-2′-a-azidocytidine TP; 3(deaza) 5 (aza)cytosine; 3 (methyl)cytosine; 3-(alkyl)cytosine;3-(deaza) 5 (aza)cytosine; 3-(methyl)cytidine; 4,2′-O-dimethylcytidine;5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5(trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine;5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine;5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6-(azo)cytosine;6-aza-cytidine; aza cytosine; deaza cytosine; N4 (acetyl)cytosine;1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine;2-methoxy-5-methyl-cytidine; 2-methoxy-cytidine;2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine;4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine;4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine;5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine;Zebularine; (E)-5-(2-Bromo-vinyl)cytidine TP; 2,2′-anhydro-cytidine TPhydrochloride; 2′Fluor-N4-Bz-cytidine TP; 2′Fluoro-N4-Acetyl-cytidineTP; 2′-O-Methyl-N4-Acetyl-cytidine TP; 2′O-methyl-N4-Bz-cytidine TP;2′-a-Ethynylcytidine TP; 2′-a-Trifluoromethylcytidine TP;2′-b-Ethynylcytidine TP; 2′-b-Trifluoromethylcytidine TP;2′-Deoxy-2′,2′-difluorocytidine TP; 2′-Deoxy-2′-a-mercaptocytidine TP;2′-Deoxy-2′-α-thiomethoxycytidine TP; 2′-Deoxy-2′-b-aminocytidine TP;2′-Deoxy-2′-b-azidocytidine TP; 2′-Deoxy-2′-b-bromocytidine TP;2′-Deoxy-2′-b-chlorocytidine TP; 2′-Deoxy-2′-b-fluorocytidine TP;2′-Deoxy-2′-b-iodocytidine TP; 2′-Deoxy-2′-b-mercaptocytidine TP;2′-Deoxy-2′-b-thiomethoxycytidine TP; 2′-O-Methyl-5-(1-propynyl)cytidineTP; 3′-Ethynylcytidine TP; 4′-Azidocytidine TP; 4′-Carbocyclic cytidineTP; 4′-Ethynylcytidine TP; 5-(1-Propynyl)ara-cytidine TP;5-(2-Chloro-phenyl)-2-thiocytidine TP; 5-(4-Amino-phenyl)-2-thiocytidineTP; 5-Aminoallyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP;5-Ethynylcytidine TP; 5′-Homo-cytidine TP; 5-Methoxycytidine TP;5-Trifluoromethyl-Cytidine TP; N4-Amino-cytidine TP; N4-Benzoyl-cytidineTP; Pseudoisocytidine; 7-methylguanosine; N2,2′-O-dimethylguanosine;N2-methylguanosine; Wyosine; 1,2′-O-dimethylguanosine;1-methylguanosine; 2′-O-methylguanosine; 2′-O-ribosylguanosine(phosphate); 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate);7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine;Methylwyosine; N2,7-dimethylguanosine; N2,N2,2′-O-trimethylguanosine;N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine;N2,7,2′-O-trimethylguanosine; 6-thio-guanosine; 7-deaza-guanosine;8-oxo-guanosine; N1-methyl-guanosine; α-thio-guanosine; 2(propyl)guanine; 2-(alkyl)guanine; 2′-Amino-2′-deoxy-GTP;2′-Azido-2′-deoxy-GTP; 2′-Deoxy-2′-a-aminoguanosine TP;2′-Deoxy-2′-a-azidoguanosine TP; 6 (methyl)guanine; 6-(alkyl)guanine;6-(methyl)guanine; 6-methyl-guanosine; 7 (alkyl)guanine; 7(deaza)guanine; 7 (methyl)guanine; 7-(alkyl)guanine; 7-(deaza)guanine;7-(methyl)guanine; 8 (alkyl)guanine; 8 (alkynyl)guanine; 8(halo)guanine; 8 (thioalkyl)guanine; 8-(alkenyl)guanine;8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine;8-(hydroxyl)guanine; 8-(thioalkyl)guanine; 8-(thiol)guanine; azaguanine; deaza guanine; N (methyl)guanine; N-(methyl)guanine;1-methyl-6-thio-guanosine; 6-methoxy-guanosine;6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine;6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine;7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thio-guanosine;N2-methyl-6-thio-guanosine; 1-Me-GTP; 2′Fluoro-N2-isobutyl-guanosine TP;2′O-methyl-N2-isobutyl-guanosine TP; 2′-a-Ethynylguanosine TP;2′-a-Trifluoromethylguanosine TP; 2′-b-Ethynylguanosine TP;2′-b-Trifluoromethylguanosine TP; 2′-Deoxy-2′,2′-difluoroguanosine TP;2′-Deoxy-2′-a-mercaptoguanosine TP; 2′-Deoxy-2′-α-thiomethoxyguanosineTP; 2′-Deoxy-2′-b-aminoguanosine TP; 2′-Deoxy-2′-b-azidoguanosine TP;2′-Deoxy-2′-b-bromoguanosine TP; 2′-Deoxy-2′-b-chloroguanosine TP;2′-Deoxy-2′-b-fluoroguanosine TP; 2′-Deoxy-2′-b-iodoguanosine TP;2′-Deoxy-2′-b-mercaptoguanosine TP; 2′-Deoxy-2′-b-thiomethoxyguanosineTP; 4′-Azidoguanosine TP; 4′-Carbocyclic guanosine TP;4′-Ethynylguanosine TP; 5′-Homo-guanosine TP; 8-bromo-guanosine TP;9-Deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; Inosine;1,2′-O-dimethylinosine; 2′-O-methylinosine; 7-methylinosine;2′-O-methylinosine; Epoxyqueuosine; galactosyl-queuosine;Mannosylqueuosine; Queuosine; allyamino-thymidine; aza thymidine; deazathymidine; deoxy-thymidine; 2′-O-methyluridine; 2-thiouridine;3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine;5-methyluridine; 5-taurinomethyl-2-thiouridine; 5-taurinomethyluridine;Dihydrouridine; Pseudouridine; (3-(3-amino-3-carboxypropyl)uridine;1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine;1-methylpseduouridine; 1-methyl-pseudouridine; 2′-O-methyluridine;2′-O-methylpseudouridine; 2′-O-methyluridine; 2-thio-2′-O-methyluridine;3-(3-amino-3-carboxypropyl)uridine; 3,2′-O-dimethyluridine;3-Methyl-pseudo-Uridine TP; 4-thiouridine;5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methylester; 5,2′-O-dimethyluridine; 5,6-dihydro-uridine;5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2′-O-methyluridine;5-carbamoylmethyluridine; 5-carboxyhydroxymethyluridine;5-carboxyhydroxymethyluridine methyl ester;5-carboxymethylaminomethyl-2′-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine;5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine;5-Carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2′-O-methyluridine;5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine;5-methyluridine,), 5-methoxyuridine; 5-methyl-2-thiouridine;5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine;5-methyl aminomethyluridine; 5-Methyldihydrouridine; 5-Oxyaceticacid-Uridine TP; 5-Oxyacetic acid-methyl ester-Uridine TP;N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyaceticacid methyl ester; 3-(3-Amino-3-carboxypropyl)-Uridine TP;5-(iso-Pentenylaminomethyl)-2-thiouridine TP;5-(iso-Pentenylaminomethyl)-2′-O-methyluridine TP;5-(iso-Pentenylaminomethyl)uridine TP; 5-propynyl uracil;α-thio-uridine; 1(aminoalkylaminocarbonylethylenyl)-2(thio)-pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-4 (thio)pseudouracil; 1(aminoalkylaminocarbonylethylenyl)-pseudouracil; 1 (aminocarbonylethylenyl)-2(thio)-pseudouracil; 1(aminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1(aminocarbonylethylenyl)-4 (thio)pseudouracil; 1(aminocarbonylethylenyl)-pseudouracil; 1 substituted2(thio)-pseudouracil; 1 substituted 2,4-(dithio)pseudouracil; 1substituted 4 (thio)pseudouracil; 1 substituted pseudouracil;1-(aminoalkylaminocarbonylethylenyl)-2-(thio)-pseudouracil;1-Methyl-3-(3-amino-3-carboxypropyl) pseudouridine TP;1-Methyl-3-(3-amino-3-carboxypropyl)pseudo-UTP; 1-Methyl-pseudo-UTP; 2(thio)pseudouracil; 2′ deoxy uridine; 2′ fluorouridine; 2-(thio)uracil;2,4-(dithio)psuedouracil; 2′ methyl, 2′amino, 2′azido,2′fluro-guanosine; 2′-Amino-2′-deoxy-UTP; 2′-Azido-2′-deoxy-UTP;2′-Azido-deoxyuridine TP; 2′-O-methylpseudouridine; 2′ deoxy uridine; 2′fluorouridine; 2′-Deoxy-2′-a-aminouridine TP; 2′-Deoxy-2′-a-azidouridineTP; 2-methylpseudouridine; 3 (3 amino-3 carboxypropyl)uracil; 4(thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil;5 (1,3-diazole-1-alkyl)uracil; 5 (2-aminopropyl)uracil; 5(aminoalkyl)uracil; 5 (dimethyl aminoalkyl)uracil; 5(guanidiniumalkyl)uracil; 5 (methoxycarbonylmethyl)-2-(thio)uracil; 5(methoxycarbonyl-methyl)uracil; 5 (methyl) 2 (thio)uracil; 5 (methyl)2,4 (dithio)uracil; 5 (methyl) 4 (thio)uracil; 5 (methylaminomethyl)-2(thio)uracil; 5 (methylaminomethyl)-2,4 (dithio)uracil; 5(methylaminomethyl)-4 (thio)uracil; 5 (propynyl)uracil; 5(trifluoromethyl)uracil; 5-(2-aminopropyl)uracil;5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4 (dithio)pseudouracil;5-(alkyl)-4 (thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil;5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil;5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil;5-(guanidiniumalkyl)uracil; 5-(halo)uracil;5-(1,3-diazole-1-alkyl)uracil; 5-(methoxy)uracil;5-(methoxycarbonylmethyl)-2-(thio)uracil;5-(methoxycarbonyl-methyl)uracil; 5-(methyl) 2(thio)uracil; 5-(methyl)2,4 (dithio)uracil; 5-(methyl) 4 (thio)uracil;5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4 (dithio)pseudouracil;5-(methyl)-4 (thio)pseudouracil; 5-(methyl)pseudouracil;5-(methylaminomethyl)-2 (thio)uracil;5-(methylaminomethyl)-2,4(dithio)uracil;5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil;5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine;5-iodo-uridine; 5-uracil; 6 (azo)uracil; 6-(azo)uracil; 6-aza-uridine;allyamino-uracil; aza uracil; deaza uracil; N3 (methyl)uracil;Pseudo-UTP-1-2-ethanoic acid; Pseudouracil; 4-Thio-pseudo-UTP;1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine;1-propynyl-uridine; 1-taurinomethyl-1-methyl-uridine;1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine;2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine;2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine;2-thio-dihydropseudouridine; 2-thio-dihydrouridine;2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine;4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine;4-thio-pseudouridine; 5-aza-uridine; Dihydropseudouridine;(±)1-(2-Hydroxypropyl)pseudouridine TP;(2R)-1-(2-Hydroxypropyl)pseudouridine TP;(2S)-1-(2-Hydroxypropyl)pseudouridine TP;(E)-5-(2-Bromo-vinyl)ara-uridine TP; (E)-5-(2-Bromo-vinyl)uridine TP;(Z)-5-(2-Bromo-vinyl)ara-uridine TP; (Z)-5-(2-Bromo-vinyl)uridine TP;1-(2,2,2-Trifluoroethyl)-pseudo-UTP;1-(2,2,3,3,3-Pentafluoropropyl)pseudouridine TP;1-(2,2-Diethoxyethyl)pseudouridine TP;1-(2,4,6-Trimethylbenzyl)pseudouridine TP;1-(2,4,6-Trimethyl-benzyl)pseudo-UTP;1-(2,4,6-Trimethyl-phenyl)pseudo-UTP;1-(2-Amino-2-carboxyethyl)pseudo-UTP; 1-(2-Amino-ethyl)pseudo-UTP;1-(2-Hydroxyethyl)pseudouridine TP; 1-(2-Methoxyethyl)pseudouridine TP;1-(3,4-Bis-trifluoromethoxybenzyl)pseudouridine TP;1-(3,4-Dimethoxybenzyl)pseudouridine TP;1-(3-Amino-3-carboxypropyl)pseudo-UTP; 1-(3-Amino-propyl)pseudo-UTP;1-(3-Cyclopropyl-prop-2-ynyl)pseudouridine TP;1-(4-Amino-4-carboxybutyl)pseudo-UTP; 1-(4-Amino-benzyl)pseudo-UTP;1-(4-Amino-butyl)pseudo-UTP; 1-(4-Amino-phenyl)pseudo-UTP;1-(4-Azidobenzyl)pseudouridine TP; 1-(4-Bromobenzyl)pseudouridine TP;1-(4-Chlorobenzyl)pseudouridine TP; 1-(4-Fluorobenzyl)pseudouridine TP;1-(4-Iodobenzyl)pseudouridine TP;1-(4-Methanesulfonylbenzyl)pseudouridine TP;1-(4-Methoxybenzyl)pseudouridine TP; 1-(4-Methoxy-benzyl)pseudo-UTP;1-(4-Methoxy-phenyl)pseudo-UTP; 1-(4-Methylbenzyl)pseudouridine TP;1-(4-Methyl-benzyl)pseudo-UTP; 1-(4-Nitrobenzyl)pseudouridine TP;1-(4-Nitro-benzyl)pseudo-UTP; 1(4-Nitro-phenyl)pseudo-UTP;1-(4-Thiomethoxybenzyl)pseudouridine TP;1-(4-Trifluoromethoxybenzyl)pseudouridine TP;1-(4-Trifluoromethylbenzyl)pseudouridine TP;1-(5-Amino-pentyl)pseudo-UTP; 1-(6-Amino-hexyl)pseudo-UTP;1,6-Dimethyl-pseudo-UTP;1-[3-(2-{2-[2-(2-Aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridineTP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]-propionyl}pseudouridine TP;1-Acetylpseudouridine TP; 1-Alkyl-6-(1-propynyl)-pseudo-UTP;1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-Alkyl-6-allyl-pseudo-UTP;1-Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP;1-Alkyl-6-vinyl-pseudo-UTP; 1-Allylpseudouridine TP;1-Aminomethyl-pseudo-UTP; 1-Benzoylpseudouridine TP;1-Benzyloxymethylpseudouridine TP; 1-Benzyl-pseudo-UTP;1-Biotinyl-PEG2-pseudouridine TP; 1-Biotinylpseudouridine TP;1-Butyl-pseudo-UTP; 1-Cyanomethylpseudouridine TP;1-Cyclobutylmethyl-pseudo-UTP; 1-Cyclobutyl-pseudo-UTP;1-Cycloheptylmethyl-pseudo-UTP; 1-Cycloheptyl-pseudo-UTP;1-Cyclohexylmethyl-pseudo-UTP; 1-Cyclohexyl-pseudo-UTP;1-Cyclooctylmethyl-pseudo-UTP; 1-Cyclooctyl-pseudo-UTP;1-Cyclopentylmethyl-pseudo-UTP; 1-Cyclopentyl-pseudo-UTP;1-Cyclopropylmethyl-pseudo-UTP; 1-Cyclopropyl-pseudo-UTP;1-Ethyl-pseudo-UTP; 1-Hexyl-pseudo-UTP; 1-Homoallylpseudouridine TP;1-Hydroxymethylpseudouridine TP; 1-iso-propyl-pseudo-UTP;1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP;1-Me-alpha-thio-pseudo-UTP; 1-Methanesulfonylmethylpseudouridine TP;1-Methoxymethylpseudouridine TP;1-Methyl-6-(2,2,2-Trifluoroethyl)pseudo-UTP;1-Methyl-6-(4-morpholino)-pseudo-UTP;1-Methyl-6-(4-thiomorpholino)-pseudo-UTP; 1-Methyl-6-(substitutedphenyl)pseudo-UTP; 1-Methyl-6-amino-pseudo-UTP;1-Methyl-6-azido-pseudo-UTP; 1-Methyl-6-bromo-pseudo-UTP;1-Methyl-6-butyl-pseudo-UTP; 1-Methyl-6-chloro-pseudo-UTP;1-Methyl-6-cyano-pseudo-UTP; 1-Methyl-6-dimethylamino-pseudo-UTP;1-Methyl-6-ethoxy-pseudo-UTP; 1-Methyl-6-ethylcarboxylate-pseudo-UTP;1-Methyl-6-ethyl-pseudo-UTP; 1-Methyl-6-fluoro-pseudo-UTP;1-Methyl-6-formyl-pseudo-UTP; 1-Methyl-6-hydroxyamino-pseudo-UTP;1-Methyl-6-hydroxy-pseudo-UTP; 1-Methyl-6-iodo-pseudo-UTP;1-Methyl-6-iso-propyl-pseudo-UTP; 1-Methyl-6-methoxy-pseudo-UTP;1-Methyl-6-methylamino-pseudo-UTP; 1-Methyl-6-phenyl-pseudo-UTP;1-Methyl-6-propyl-pseudo-UTP; 1-Methyl-6-tert-butyl-pseudo-UTP;1-Methyl-6-trifluoromethoxy-pseudo-UTP;1-Methyl-6-trifluoromethyl-pseudo-UTP; 1-MorpholinomethylpseudouridineTP; 1-Pentyl-pseudo-UTP; 1-Phenyl-pseudo-UTP; 1-PivaloylpseudouridineTP; 1-Propargylpseudouridine TP; 1-Propyl-pseudo-UTP;1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-Butyl-pseudo-UTP;1-Thiomethoxymethylpseudouridine TP; 1-ThiomorpholinomethylpseudouridineTP; 1-Trifluoroacetylpseudouridine TP; 1-Trifluoromethyl-pseudo-UTP;1-Vinylpseudouridine TP; 2,2′-anhydro-uridine TP; 2′-bromo-deoxyuridineTP; 2′-F-5-Methyl-2′-deoxy-UTP; 2′-OMe-5-Me-UTP; 2′-OMe-pseudo-UTP;2′-a-Ethynyluridine TP; 2′-a-Trifluoromethyluridine TP;2′-b-Ethynyluridine TP; 2′-b-Trifluoromethyluridine TP;2′-Deoxy-2′,2′-difluorouridine TP; 2′-Deoxy-2′-a-mercaptouridine TP;2′-Deoxy-2′-α-thiomethoxyuridine TP; 2′-Deoxy-2′-b-aminouridine TP;2′-Deoxy-2′-b-azidouridine TP; 2′-Deoxy-2′-b-bromouridine TP;2′-Deoxy-2′-b-chlorouridine TP; 2′-Deoxy-2′-b-fluorouridine TP;2′-Deoxy-2′-b-iodouridine TP; 2′-Deoxy-2′-b-mercaptouridine TP;2′-Deoxy-2′-b-thiomethoxyuridine TP; 2-methoxy-4-thio-uridine;2-methoxyuridine; 2′-O-Methyl-5-(1-propynyl)uridine TP;3-Alkyl-pseudo-UTP; 4′-Azidouridine TP; 4′-Carbocyclic uridine TP;4′-Ethynyluridine TP; 5-(1-Propynyl)ara-uridine TP; 5-(2-Furanyl)uridineTP; 5-Cyanouridine TP; 5-Dimethylaminouridine TP; 5′-Homo-uridine TP;5-iodo-2′-fluoro-deoxyuridine TP; 5-Phenylethynyluridine TP;5-Trideuteromethyl-6-deuterouridine TP; 5-Trifluoromethyl-Uridine TP;5-Vinylarauridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP;6-(4-Morpholino)-pseudo-UTP; 6-(4-Thiomorpholino)-pseudo-UTP;6-(Substituted-Phenyl)-pseudo-UTP; 6-Amino-pseudo-UTP;6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP;6-Chloro-pseudo-UTP; 6-Cyano-pseudo-UTP; 6-Dimethylamino-pseudo-UTP;6-Ethoxy-pseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP;6-Fluoro-pseudo-UTP; 6-Formyl-pseudo-UTP; 6-Hydroxyamino-pseudo-UTP;6-Hydroxy-pseudo-UTP; 6-Iodo-pseudo-UTP; 6-iso-Propyl-pseudo-UTP;6-Methoxy-pseudo-UTP; 6-Methylamino-pseudo-UTP; 6-Methyl-pseudo-UTP;6-Phenyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP;6-tert-Butyl-pseudo-UTP; 6-Trifluoromethoxy-pseudo-UTP;6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudo-UTP; Pseudouridine1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1-(4-methylbenzoicacid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; PseudouridineTP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid;Pseudouridine TP1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionicacid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionicacid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}] propionic acid;Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP1-methylphosphonic acid diethyl ester; Pseudo-UTP-N1-3-propionic acid;Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid;Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid;Pseudo-UTP-N1-methyl-p-benzoic acid; Pseudo-UTP-N1-p-benzoic acid;Wybutosine; Hydroxywybutosine; Isowyosine; Peroxywybutosine;undermodified hydroxywybutosine; 4-demethylwyosine; 2,6-(diamino)purine;1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl:1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;1,3,5-(triaza)-2,6-(dioxa)-naphthalene; 2 (amino)purine;2,4,5-(trimethyl)phenyl; 2′ methyl, 2′amino, 2′azido, 2′fluro-cytidine;2′ methyl, 2′amino, 2′azido, 2′fluro-adenine; 2′methyl, 2′amino,2′azido, 2′fluro-uridine; 2′-amino-2′-deoxyribose;2-amino-6-Chloro-purine; 2-aza-inosinyl; 2′-azido-2′-deoxyribose;2′fluoro-2′-deoxyribose; 2′-fluoro-modified bases; 2′-O-methyl-ribose;2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidine-3-yl;2-pyridinone; 3 nitropyrrole; 3-(methyl)-7-(propynyl)isocarbostyrilyl;3-(methyl)isocarbostyrilyl; 4-(fluoro)-6-(methyl)benzimidazole;4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5nitroindole; 5 substituted pyrimidines; 5-(methyl)isocarbostyrilyl;5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine;6-(methyl)-7-(aza)indolyl; 6-chloro-purine;6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl;7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(aza)indolyl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazinl-yl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl;7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl;7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl;7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl;7-(propynyl)isocarbostyrilyl; 7-(propynyl)isocarbostyrilyl,propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidizopyridinyl;Aminoindolyl; Anthracenyl;bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl;Isocarbostyrilyl; Isoguanisine; N2-substituted purines;N6-methyl-2-amino-purine; N6-substituted purines; N-alkylatedderivative; Napthalenyl; Nitrobenzimidazolyl; Nitroimidazolyl;Nitroindazolyl; Nitropyrazolyl; Nubularine; 06-substituted purines;O-alkylated derivative;ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Oxoformycin TP;para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl;para-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Pentacenyl;Phenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl;pyridopyrimidin-3-yl; pyridopyrimidin-3-yl,2-oxo-7-amino-pyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-on-3-yl;Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Stilbenzyl; substituted1,2,4-triazoles; Tetracenyl; Tubercidine; Xanthine; Xanthosine-5′-TP;2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine;pyridin-4-one ribonucleoside; 2-Amino-riboside-TP; Formycin A TP;Formycin B TP; Pyrrolosine TP; 2′-OH-ara-adenosine TP;2′-OH-ara-cytidine TP; 2′-OH-ara-uridine TP; 2′-OH-ara-guanosine TP;5-(2-carbomethoxyvinyl)uridine TP; andN6-(19-Amino-pentaoxanonadecyl)adenosine TP.

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) includes a combination of at least two (e.g., 2,3, 4 or more) of the aforementioned modified nucleobases.

In some embodiments, the mRNA comprises at least one chemically modifiednucleoside. In some embodiments, the at least one chemically modifiednucleoside is selected from the group consisting of pseudouridine (ψ),N1-methylpseudouridine (m1ψ), 2-thiouridine (s2U), 4′-thiouridine,5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine,2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,2-thio-dihydropseudouridine, 2-thio-dihydrouridine,2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,5-methyluridine, 5-methoxyuridine, 2′-O-methyl uridine,1-methyl-pseudouridine (m1ψ), 5-methoxy-uridine (mo5U),5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyanouridine, 4′-thio uridine 7-deaza-adenine, 1-methyl-adenosine (m1A),2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and2,6-Diaminopurine, (I), 1-methyl-inosine (m1I), wyosine (imG),methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine(preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine(m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine,7-methyl-8-oxo-guanosine, 2,8-dimethyladenosine, 2-geranylthiouridine,2-lysidine, 2-selenouridine,3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine,3-(3-amino-3-carboxypropyl)pseudouridine, 3-methylpseudouridine,5-(carboxyhydroxymethyl)-2′-O-methyluridine methyl ester,5-aminomethyl-2-geranylthiouridine, 5-aminomethyl-2-selenouridine,5-aminomethyluridine, 5-carbamoylhydroxymethyluridine,5-carbamoylmethyl-2-thiouridine, 5-carboxymethyl-2-thiouridine,5-carboxymethylaminomethyl-2-geranylthiouridine,5-carboxymethylaminomethyl-2-selenouridine, 5-cyanomethyluridine,5-hydroxycytidine, 5-methylaminomethyl-2-geranylthiouridine,7-aminocarboxypropyl-demethylwyosine, 7-aminocarboxypropylwyosine,7-aminocarboxypropylwyosine methyl ester, 8-methyladenosine,N4,N4-dimethylcytidine, N6-formyladenosine, N6-hydroxymethyladenosine,agmatidine, cyclic N6-threonylcarbamoyladenosine, glutamyl-queuosine,methylated undermodified hydroxywybutosine,N4,N4,2′-O-trimethylcytidine, geranylated5-methylaminomethyl-2-thiouridine, geranylated5-carboxymethylaminomethyl-2-thiouridine, Qbase, preQ0base, preQ1base,and two or more combinations thereof. In some embodiments, the at leastone chemically modified nucleoside is selected from the group consistingof pseudouridine, N1-methylpseudouridine, 5-methylcytosine,5-methoxyuridine, and a combination thereof. In some embodiments, thepolynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide)includes a combination of at least two (e.g., 2, 3, 4 or more) of theaforementioned modified nucleobases. In one particular embodiment, theat least one chemically modified nucleoside is N1-methylpseudouridine.

(i) Base Modifications

In certain embodiments, the chemical modification is at nucleobases inthe polynucleotides (e.g., RNA polynucleotide, such as mRNApolynucleotide).

In some embodiments, a polynucleotide as disclosed herein comprises atleast one chemically modified nucleobase.

In some embodiments, the at least one chemically modified nucleobase isselected from the group consisting of pseudouracil (ψ),N1-methylpseudouracil (m1ψ), 2-thiouracil (s2U), 4′-thiouracil,5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouracil,2-thio-1-methyl-pseudouracil, 2-thio-5-aza-uracil,2-thio-dihydropseudouracil, 2-thio-dihydrouracil, 2-thio-pseudouracil,4-methoxy-2-thio-pseudouracil, 4-methoxy-pseudouracil,4-thio-1-methyl-pseudouracil, 4-thio-pseudouracil, 5-aza-uracil,dihydropseudouracil, 5-methyluracil, 5-methoxyuracil, 2′-O-methyluracil, 1-methyl-pseudouracil (m1ψ), 5-methoxy-uracil (mo5U),5-methyl-cytosine (m5C), α-thio-guanine, α-thio-adenine, 5-cyano uracil,4′-thio uracil, 7-deaza-adenine, 1-methyl-adenine (m1A),2-methyl-adenine (m2A), N6-methyl-adenine (m6A), and 2,6-Diaminopurine,(I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG),7-deaza-guanine, 7-cyano-7-deaza-guanine (preQ0),7-aminomethyl-7-deaza-guanine (preQ1), 7-methyl-guanine (m7G),1-methyl-guanine (m1G), 8-oxo-guanine, 7-methyl-8-oxo-guanine, and twoor more combinations thereof.

In some embodiments, the nucleobases in a polynucleotide as disclosedherein are chemically modified by at least about 10%, at least about20%, at least about 30%, at least about 40%, at least about 50%, atleast about 60%, at least about 70%, at least about 80%, at least about90%, at least 95%, at least 99%, or 100%.

In some embodiments, the chemically modified nucleobases are selectedfrom the group consisting of uracil, adenine, cytosine, guanine, and anycombination thereof.

In some embodiments, the uracils in a polynucleotide disclosed hereinare chemically modified by at least about 10%, at least about 20%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast 95%, at least 99%, or 100%.

In some embodiments, the adenines in a polynucleotide disclosed hereinare chemically modified by at least about 10%, at least about 20%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast 95%, at least 99%, or 100%.

In some embodiments, the cytosines in a polynucleotide disclosed hereinare chemically modified by at least about 10%, at least about 20%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast 95%, at least 99%, or 100%.

In some embodiments, the guanines in a polynucleotide disclosed hereinare chemically modified by at least about 10%, at least about 20%, atleast about 30%, at least about 40%, at least about 50%, at least about60%, at least about 70%, at least about 80%, at least about 90%, atleast 95%, at least 99%, or 100%.

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) includes a combination of at least two (e.g., 2,3, 4 or more) of modified nucleobases.

In some embodiments, modified nucleobases in the polynucleotide (e.g.,RNA polynucleotide, such as mRNA polynucleotide) are selected from thegroup consisting of 1-methyl-pseudouridine (m1ψ), 5-methoxy-uridine(mo5U), 5-methyl-cytidine (m5C), pseudouridine (ψ), α-thio-guanosine andα-thio-adenosine. In some embodiments, the polynucleotide includes acombination of at least two (e.g., 2, 3, 4 or more) of theaforementioned modified nucleobases.

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) comprises pseudouridine (ψ) and5-methyl-cytidine (m5C). In some embodiments, the polynucleotide (e.g.,RNA polynucleotide, such as mRNA polynucleotide) comprises1-methyl-pseudouridine (m1ψ). In some embodiments, the polynucleotide(e.g., RNA polynucleotide, such as mRNA polynucleotide) comprises1-methyl-pseudouridine (m1ψ) and 5-methyl-cytidine (m5C). In someembodiments, the polynucleotide (e.g., RNA polynucleotide, such as mRNApolynucleotide) comprises 2-thiouridine (s2U). In some embodiments, thepolynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide)comprises 2-thiouridine and 5-methyl-cytidine (m5C). In someembodiments, the polynucleotide (e.g., RNA polynucleotide, such as mRNApolynucleotide) comprises methoxy-uridine (mo5U). In some embodiments,the polynucleotide (e.g., RNA polynucleotide, such as mRNApolynucleotide) comprises 5-methoxy-uridine (mo5U) and 5-methyl-cytidine(m5C). In some embodiments, the polynucleotide (e.g., RNApolynucleotide, such as mRNA polynucleotide) comprises 2′-O-methyluridine. In some embodiments, the polynucleotide (e.g., RNApolynucleotide, such as mRNA polynucleotide) comprises 2′-O-methyluridine and 5-methyl-cytidine (m5C). In some embodiments, thepolynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide)comprises N6-methyl-adenosine (m6A). In some embodiments, thepolynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide)comprises N6-methyl-adenosine (m6A) and 5-methyl-cytidine (m5C).

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) is uniformly modified (e.g., fully modified,modified throughout the entire sequence) for a particular modification.For example, a polynucleotide can be uniformly modified with5-methyl-cytidine (m5C), meaning that all cytosine residues in the mRNAsequence are replaced with 5-methyl-cytidine (m5C). Similarly, apolynucleotide can be uniformly modified for any type of nucleosideresidue present in the sequence by replacement with a modified residuesuch as any of those set forth above.

In some embodiments, the chemically modified nucleosides in the openreading frame are selected from the group consisting of uridine,adenine, cytosine, guanine, and any combination thereof.

In some embodiments, the modified nucleobase is a modified cytosine.Examples of nucleobases and nucleosides having a modified cytosineinclude N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C),5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine(hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C),2-thio-5-methyl-cytidine.

In some embodiments, a modified nucleobase is a modified uridine.Example nucleobases and nucleosides having a modified uridine include5-cyano uridine or 4′-thio uridine.

In some embodiments, a modified nucleobase is a modified adenine.Example nucleobases and nucleosides having a modified adenine include7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A),N6-methyl-adenine (m6A), and 2,6-Diaminopurine.

In some embodiments, a modified nucleobase is a modified guanine.Example nucleobases and nucleosides having a modified guanine includeinosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine(mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0),7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G),1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.

In some embodiments, the nucleobase modified nucleotides in thepolynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide)are 5-methoxyuridine.

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) includes a combination of at least two (e.g., 2,3, 4 or more) of modified nucleobases.

In some embodiments, at least 95% of a type of nucleobases (e.g.,uracil) in a polynucleotide of the disclosure (e.g., an mRNApolynucleotide encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12A and IL12B fusion polypeptides) are modified nucleobases. Insome embodiments, at least 95% of uracil in a polynucleotide of thepresent disclosure (e.g., an mRNA polynucleotide encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusionpolypeptides) is 5-methoxyuracil.

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) comprises 5-methoxyuridine (5mo5U) and5-methyl-cytidine (m5C).

In some embodiments, the polynucleotide (e.g., RNA polynucleotide, suchas mRNA polynucleotide) is uniformly modified (e.g., fully modified,modified throughout the entire sequence) for a particular modification.For example, a polynucleotide can be uniformly modified with5-methoxyuridine, meaning that substantially all uridine residues in themRNA sequence are replaced with 5-methoxyuridine. Similarly, apolynucleotide can be uniformly modified for any type of nucleosideresidue present in the sequence by replacement with a modified residuesuch as any of those set forth above.

In some embodiments, the modified nucleobase is a modified cytosine.

In some embodiments, a modified nucleobase is a modified uracil. Examplenucleobases and nucleosides having a modified uracil include5-methoxyuracil.

In some embodiments, a modified nucleobase is a modified adenine.

In some embodiments, a modified nucleobase is a modified guanine.

In some embodiments, the nucleobases, sugar, backbone, or anycombination thereof in the open reading frame encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusionpolypeptides are chemically modified by at least 10%, at least 20%, atleast 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 95%, at least 99%, or 100%.

In some embodiments, the uridine nucleosides in the open reading frameencoding IL12B polypeptide, an IL12A polypeptide, and/or IL12A and IL12Bfusion polypeptides are chemically modified by at least 10%, at least20%, at least 30%, at least 40%, at least 50%, at least 60%, at least70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100%.

In some embodiments, the adenosine nucleosides in the open reading frameencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A andIL12B fusion polypeptides are chemically modified by at least 10%, atleast 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%, at least 99%, or100%.

In some embodiments, the cytidine nucleosides in the open reading frameencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A andIL12B fusion polypeptides are chemically modified by at least at least10%, at least 20%, at least 30%, at least 40%, at least 50%, at least60%, at least 70%, at least 80%, at least 90%, at least 95%, at least99%, or 100%.

In some embodiments, the guanosine nucleosides in the open reading frameencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12A andIL12B fusion polypeptides are chemically modified by at least at least10%, at least 20%, at least 30%, at least 40%, at least 50%, at least60%, at least 70%, at least 80%, at least 90%, at least 95%, at least99%, or 100%.

In some embodiments, the polynucleotides can include any useful linkerbetween the nucleosides, including subunit and heterologous polypeptidelinkers as disclosed elsewhere herein. Such linkers, including backbonemodifications, that are useful in the composition of the presentdisclosure include, but are not limited to the following: 3′-alkylenephosphonates, 3′-amino phosphoramidate, alkene containing backbones,aminoalkylphosphoramidates, aminoalkylphosphotriesters,boranophosphates, —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂—,—CH₂—NH—CH₂—, chiral phosphonates, chiral phosphorothioates, formacetyland thioformacetyl backbones, methylene (methylimino), methyleneformacetyl and thioformacetyl backbones, methyleneimino andmethylenehydrazino backbones, morpholino linkages, —N(CH₃)—CH₂—CH₂—,oligonucleosides with heteroatom internucleoside linkage, phosphinates,phosphoramidates, phosphorodithioates, phosphorothioate internucleosidelinkages, phosphorothioates, phosphotriesters, PNA, siloxane backbones,sulfamate backbones, sulfide sulfoxide and sulfone backbones, sulfonateand sulfonamide backbones, thionoalkylphosphonates,thionoalkylphosphotriesters, and thionophosphoramidates.

(ii) Sugar Modifications

The modified nucleosides and nucleotides (e.g., building blockmolecules), which can be incorporated into a polynucleotide (e.g., RNAor mRNA, as described herein), can be modified on the sugar of theribonucleic acid. For example, the 2′ hydroxyl group (OH) can bemodified or replaced with a number of different substituents. Exemplarysubstitutions at the 2′-position include, but are not limited to, H,halo, optionally substituted C₁₋₆ alkyl; optionally substituted C₁₋₆alkoxy; optionally substituted C₆₋₁₀ aryloxy; optionally substitutedC₃₋₈ cycloalkyl; optionally substituted C₃₋₈ cycloalkoxy; optionallysubstituted C₆₋₁₀ aryloxy; optionally substituted C₆₋₁₀ aryl-C₁₋₆alkoxy, optionally substituted C₁₋₁₂ (heterocyclyl)oxy; a sugar (e.g.,ribose, pentose, or any described herein); a polyethyleneglycol (PEG),—O(CH₂CH₂O)_(n)CH₂CH₂OR, where R is H or optionally substituted alkyl,and n is an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16,from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to20); “locked” nucleic acids (LNA) in which the 2′-hydroxyl is connectedby a C₁₋₆ alkylene or C₁₋₆ heteroalkylene bridge to the 4′-carbon of thesame ribose sugar, where exemplary bridges included methylene,propylene, ether, or amino bridges; aminoalkyl, as defined herein;aminoalkoxy, as defined herein; amino as defined herein; and amino acid,as defined herein

Generally, RNA includes the sugar group ribose, which is a 5-memberedring having an oxygen. Exemplary, non-limiting modified nucleotidesinclude replacement of the oxygen in ribose (e.g., with S, Se, oralkylene, such as methylene or ethylene); addition of a double bond(e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ringcontraction of ribose (e.g., to form a 4-membered ring of cyclobutane oroxetane); ring expansion of ribose (e.g., to form a 6- or 7-memberedring having an additional carbon or heteroatom, such as foranhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, andmorpholino that also has a phosphoramidate backbone); multicyclic forms(e.g., tricyclo; and “unlocked” forms, such as glycol nucleic acid (GNA)(e.g., R-GNA or S-GNA, where ribose is replaced by glycol units attachedto phosphodiester bonds), threose nucleic acid (TNA, where ribose isreplace with α-L-threofuranosyl-(3′-2′)), and peptide nucleic acid (PNA,where 2-amino-ethyl-glycine linkages replace the ribose andphosphodiester backbone). The sugar group can also contain one or morecarbons that possess the opposite stereochemical configuration than thatof the corresponding carbon in ribose. Thus, a polynucleotide moleculecan include nucleotides containing, e.g., arabinose, as the sugar. Suchsugar modifications are taught International Patent Publication Nos.WO2013052523 and WO2014093924, the contents of each of which areincorporated herein by reference in their entireties.

(iii) Combinations of Modifications

The polynucleotides of the disclosure (e.g., a polynucleotide comprisinga nucleotide sequence encoding an IL12A polypeptide, an IL12Bpolypeptide, and/or IL12A and IL12B fusion polypeptides or a functionalfragment or variant thereof) can include a combination of modificationsto the sugar, the nucleobase, and/or the internucleoside linkage. Thesecombinations can include any one or more modifications described herein.

Examples of modified nucleotides and modified nucleotide combinationsare provided below in Table 5. Combinations of modified nucleotides canbe used to form the polynucleotides of the disclosure. Unless otherwisenoted, the modified nucleotides can be completely substituted for thenatural nucleotides of the polynucleotides of the disclosure. As anon-limiting example, the natural nucleotide uridine can be substitutedwith a modified nucleoside described herein. In another non-limitingexample, the natural nucleotide uridine can be partially substituted orreplaced (e.g., about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%,45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99.9%) with atleast one of the modified nucleoside disclosed herein. Any combinationof base/sugar or linker can be incorporated into the polynucleotides ofthe disclosure and such modifications are taught in International PatentPublications WO2013052523 and WO2014093924, and U.S. Publ. Nos. US20130115272 and US20150307542, the contents of each of which areincorporated herein by reference in its entirety.

TABLE 5 Combinations Uracil Cytosine Adenine Guanine 5-Methoxy-UTP CTPATP GTP 5-Methoxy-UTP N4Ac-CTP ATP GTP 5-Methoxy-UTP 5-Methyl-CTP ATPGTP 5-Methoxy-UTP 5-Trifluoromethyl-CTP ATP GTP 5-Methoxy-UTP5-Hydroxymethyl-CTP ATP GTP 5-Methoxy-UTP 5-Bromo-CTP ATP GTP5-Methoxy-UTP N4Ac-CTP ATP GTP 5-Methoxy-UTP CTP ATP GTP 5-Methoxy-UTP5-Methyl-CTP ATP GTP 5-Methoxy-UTP 5-Trifluoromethyl-CTP ATP GTP5-Methoxy-UTP 5-Hydroxymethyl-CTP ATP GTP 5-Methoxy-UTP 5-Bromo-CTP ATPGTP 5-Methoxy-UTP N4-Ac-CTP ATP GTP 5-Methoxy-UTP 5-Iodo-CTP ATP GTP5-Methoxy-UTP 5-Bromo-CTP ATP GTP 5-Methoxy-UTP CTP ATP GTP5-Methoxy-UTP 5-Methyl-CTP ATP GTP 75% 5-Methoxy-UTP + 25% 5-Methyl-CTPATP GTP UTP 50% 5-Methoxy-UTP + 50% 5-Methyl-CTP ATP GTP UTP 25%5-Methoxy-UTP + 75% 5-Methyl-CTP ATP GTP UTP 5-Methoxy-UTP 75%5-Methyl-CTP + ATP GTP 25% CTP 5-Methoxy-UTP 50% 5-Methyl-CTP + ATP GTP50% CTP 5-Methoxy-UTP 25% 5-Methyl-CTP + ATP GTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 75%5-Methoxy-UTP + 25% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 50%5-Methoxy-UTP + 50% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 50%5-Methoxy-UTP + 50% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 50%5-Methoxy-UTP + 50% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 25%5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 25%5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% CTP ATP GTP UTP 50% 5-Methoxy-UTP + 50% CTP ATP GTPUTP 25% 5-Methoxy-UTP + 75% CTP ATP GTP UTP 5-Methoxy-UTP CTP ATP GTP5-Methoxy-UTP CTP ATP GTP 5-Methoxy-UTP CTP ATP GTP 5-Methoxy-UTP5-Methyl-CTP ATP GTP 5-Methoxy-UTP 5-Methyl-CTP ATP GTP 5-Methoxy-UTP5-Methyl-CTP ATP GTP 5-Methoxy-UTP CTP Alpha-thio- GTP ATP 5-Methoxy-UTP5-Methyl-CTP Alpha-thio- GTP ATP 5-Methoxy-UTP CTP ATP Alpha- thio-GTP5-Methoxy-UTP 5-Methyl-CTP ATP Alpha- thio-GTP 5-Methoxy-UTP CTP N6-Me-GTP ATP 5-Methoxy-UTP 5-Methyl-CTP N6-Me- GTP ATP 5-Methoxy-UTP CTP ATPGTP 5-Methoxy-UTP 5-Methyl-CTP ATP GTP 75% 5-Methoxy-UTP + 25%5-Methyl-CTP ATP GTP UTP 50% 5-Methoxy-UTP + 50% 5-Methyl-CTP ATP GTPUTP 25% 5-Methoxy-UTP + 75% 5-Methyl-CTP ATP GTP UTP 5-Methoxy-UTP 75%5-Methyl-CTP + ATP GTP 25% CTP 5-Methoxy-UTP 50% 5-Methyl-CTP + ATP GTP50% CTP 5-Methoxy-UTP 25% 5-Methyl-CTP + ATP GTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 75%5-Methoxy-UTP + 25% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 50%5-Methoxy-UTP + 50% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 50%5-Methoxy-UTP + 50% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 50%5-Methoxy-UTP + 50% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 25%5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 25%5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% CTP ATP GTP UTP 50% 5-Methoxy-UTP + 50% CTP ATP GTPUTP 25% 5-Methoxy-UTP + 75% CTP ATP GTP UTP 5-Methoxy-UTP 5-Ethyl-CTPATP GTP 5-Methoxy-UTP 5-Methoxy-CTP ATP GTP 5-Methoxy-UTP 5-Ethynyl-CTPATP GTP 5-Methoxy-UTP CTP ATP GTP 5-Methoxy-UTP 5-Methyl-CTP ATP GTP5-Methoxy-UTP CTP ATP GTP 5-Methoxy-UTP 5-Methyl-CTP ATP GTP 75%5-Methoxy-UTP + 25% 5-Methyl-CTP ATP GTP 1-Methyl-pseudo-UTP 50%5-Methoxy-UTP + 50% 5-Methyl-CTP ATP GTP 1-Methyl-pseudo-UTP 25%5-Methoxy-UTP + 75% 5-Methyl-CTP ATP GTP 1-Methyl-pseudo-UTP5-Methoxy-UTP 75% 5-Methyl-CTP + ATP GTP 25% CTP 5-Methoxy-UTP 50%5-Methyl-CTP + ATP GTP 50% CTP 5-Methoxy-UTP 25% 5-Methyl-CTP + ATP GTP75% CTP 75% 5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP1-Methyl-pseudo-UTP 25% CTP 75% 5-Methoxy-UTP + 25% 50% 5-Methyl-CTP +ATP GTP 1-Methyl-pseudo-UTP 50% CTP 75% 5-Methoxy-UTP + 25% 25%5-Methyl-CTP + ATP GTP 1-Methyl-pseudo-UTP 75% CTP 50% 5-Methoxy-UTP +50% 75% 5-Methyl-CTP + ATP GTP 1-Methyl-pseudo-UTP 25% CTP 50%5-Methoxy-UTP + 50% 50% 5-Methyl-CTP + ATP GTP 1-Methyl-pseudo-UTP 50%CTP 50% 5-Methoxy-UTP + 50% 25% 5-Methyl-CTP + ATP GTP1-Methyl-pseudo-UTP 75% CTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP +ATP GTP 1-Methyl-pseudo-UTP 25% CTP 25% 5-Methoxy-UTP + 75% 50%5-Methyl-CTP + ATP GTP 1-Methyl-pseudo-UTP 50% CTP 25% 5-Methoxy-UTP +75% 25% 5-Methyl-CTP + ATP GTP 1-Methyl-pseudo-UTP 75% CTP 75%5-Methoxy-UTP + 25% CTP ATP GTP 1-Methyl-pseudo-UTP 50% 5-Methoxy-UTP +50% CTP ATP GTP 1-Methyl-pseudo-UTP 25% 5-Methoxy-UTP + 75% CTP ATP GTP1-Methyl-pseudo-UTP 5-methoxy-UTP CTP ATP GTP 5-methoxy-UTP CTP ATP GTP5-methoxy-UTP 5-Methyl-CTP ATP GTP 5-Methoxy-UTP CTP ATP GTP5-Methoxy-UTP 5-Methyl-CTP ATP GTP 75% 5-Methoxy-UTP + 25% 5-Methyl-CTPATP GTP UTP 50% 5-Methoxy-UTP + 50% 5-Methyl-CTP ATP GTP UTP 25%5-Methoxy-UTP + 75% 5-Methyl-CTP ATP GTP UTP 5-Methoxy-UTP 75%5-Methyl-CTP + ATP GTP 25% CTP 5-Methoxy-UTP 50% 5-Methyl-CTP + ATP GTP50% CTP 5-Methoxy-UTP 25% 5-Methyl-CTP + ATP GTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 75%5-Methoxy-UTP + 25% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 50%5-Methoxy-UTP + 50% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 50%5-Methoxy-UTP + 50% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 50%5-Methoxy-UTP + 50% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 25%5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 25%5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% CTP ATP GTP UTP 50% 5-Methoxy-UTP + 50% CTP ATP GTPUTP 25% 5-Methoxy-UTP + 75% CTP ATP GTP UTP 5-Methoxy-UTP CTP ATP GTP5-Methoxy-UTP 5-Methyl-CTP ATP GTP 75% 5-Methoxy-UTP + 25% 5-Methyl-CTPATP GTP UTP 50% 5-Methoxy-UTP + 50% 5-Methyl-CTP ATP GTP UTP 25%5-Methoxy-UTP + 75% 5-Methyl-CTP ATP GTP UTP 5-Methoxy-UTP 75%5-Methyl-CTP + ATP GTP 25% CTP 5-Methoxy-UTP 50% 5-Methyl-CTP + ATP GTP50% CTP 5-Methoxy-UTP 25% 5-Methyl-CTP + ATP GTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 75%5-Methoxy-UTP + 25% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 50%5-Methoxy-UTP + 50% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 50%5-Methoxy-UTP + 50% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 50%5-Methoxy-UTP + 50% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 25%5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 25%5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% CTP ATP GTP UTP 50% 5-Methoxy-UTP + 50% CTP ATP GTPUTP 25% 5-Methoxy-UTP + 75% CTP ATP GTP UTP 5-Methoxy-UTP CTP ATP GTP25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 25%5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTPCTP ATP GTP 25% 5-Methoxy-UTP + 75% 75% 5-Methyl-CTP + ATP GTP UTP 25%CTP 25% 5-Methoxy-UTP + 75% 50% 5-Methyl-CTP + ATP GTP UTP 50% CTP 25%5-Methoxy-UTP + 75% 25% 5-Methyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Methyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTP5-Fluoro-CTP ATP GTP 5-Methoxy-UTP 5-Phenyl-CTP ATP GTP 5-Methoxy-UTPN4-Bz-CTP ATP GTP 5-Methoxy-UTP CTP N6- GTP Isopentenyl- ATP5-Methoxy-UTP N4-Ac-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25% N4-Ac-CTP +75% ATP GTP UTP CTP 25% 5-Methoxy-UTP + 75% 75% N4-Ac-CTP + 25% ATP GTPUTP CTP 75% 5-Methoxy-UTP + 25% 25% N4-Ac-CTP + 75% ATP GTP UTP CTP 75%5-Methoxy-UTP + 25% 75% N4-Ac-CTP + 25% ATP GTP UTP CTP 5-Methoxy-UTP5-Hydroxymethyl-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25% 5-Hydroxymethyl-ATP GTP UTP CTP + 75% CTP 25% 5-Methoxy-UTP + 75% 75% 5-Hydroxymethyl-ATP GTP UTP CTP + 25% CTP 75% 5-Methoxy-UTP + 25% 25% 5-Hydroxymethyl-ATP GTP UTP CTP + 75% CTP 75% 5-Methoxy-UTP + 25% 75% 5-Hydroxymethyl-ATP GTP UTP CTP + 25% CTP 5-Methoxy-UTP N4-Methyl CTP ATP GTP 25%5-Methoxy-UTP + 75% 25% N4-Methyl CTP + ATP GTP UTP 75% CTP 25%5-Methoxy-UTP + 75% 75% N4-Methyl CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 25% N4-Methyl CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% N4-Methyl CTP + ATP GTP UTP 25% CTP5-Methoxy-UTP 5-Trifluoromethyl-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25%5- ATP GTP UTP Trifluoromethyl-CTP + 75% CTP 25% 5-Methoxy-UTP + 75% 75%5- ATP GTP UTP Trifluoromethyl-CTP + 25% CTP 75% 5-Methoxy-UTP + 25% 25%5- ATP GTP UTP Trifluoromethyl-CTP + 75% CTP 75% 5-Methoxy-UTP + 25% 75%5- ATP GTP UTP Trifluoromethyl-CTP + 25% CTP 5-Methoxy-UTP 5-Bromo-CTPATP GTP 25% 5-Methoxy-UTP + 75% 25% 5-Bromo-CTP + ATP GTP UTP 75% CTP25% 5-Methoxy-UTP + 75% 75% 5-Bromo-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 25% 5-Bromo-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Bromo-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTP5-Iodo-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25% 5-Iodo-CTP + 75% ATP GTPUTP CTP 25% 5-Methoxy-UTP + 75% 75% 5-Iodo-CTP + 25% ATP GTP UTP CTP 75%5-Methoxy-UTP + 25% 25% 5-Iodo-CTP + 75% ATP GTP UTP CTP 75%5-Methoxy-UTP + 25% 75% 5-Iodo-CTP + 25% ATP GTP UTP CTP 5-Methoxy-UTP5-Ethyl-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25% 5-Ethyl-CTP + 75% ATPGTP UTP CTP 25% 5-Methoxy-UTP + 75% 75% 5-Ethyl-CTP + 25% ATP GTP UTPCTP 75% 5-Methoxy-UTP + 25% 25% 5-Ethyl-CTP + 75% ATP GTP UTP CTP 75%5-Methoxy-UTP + 25% 75% 5-Ethyl-CTP + 25% ATP GTP UTP CTP 5-Methoxy-UTP5-Methoxy-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25% 5-Methoxy-CTP + ATPGTP UTP 75% CTP 25% 5-Methoxy-UTP + 75% 75% 5-Methoxy-CTP + ATP GTP UTP25% CTP 75% 5-Methoxy-UTP + 25% 25% 5-Methoxy-CTP + ATP GTP UTP 75% CTP75% 5-Methoxy-UTP + 25% 75% 5-Methoxy-CTP + ATP GTP UTP 25% CTP5-Methoxy-UTP 5-Ethynyl-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25%5-Ethynyl-CTP + ATP GTP UTP 75% CTP 25% 5-Methoxy-UTP + 75% 75%5-Ethynyl-CTP + ATP GTP UTP 25% CTP 75% 5-Methoxy-UTP + 25% 25%5-Ethynyl-CTP + ATP GTP UTP 75% CTP 75% 5-Methoxy-UTP + 25% 75%5-Ethynyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTP 5-Pseudo-iso-CTP ATPGTP 25% 5-Methoxy-UTP + 75% 25% 5-Pseudo-iso-CTP + ATP GTP UTP 75% CTP25% 5-Methoxy-UTP + 75% 75% 5-Pseudo-iso-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 25% 5-Pseudo-iso-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Pseudo-iso-CTP + ATP GTP UTP 25% CTP5-Methoxy-UTP 5-Formyl-CTP ATP GTP 25% 5-Methoxy-UTP + 75% 25%5-Formyl-CTP + ATP GTP UTP 75% CTP 25% 5-Methoxy-UTP + 75% 75%5-Formyl-CTP + ATP GTP UTP 25% CTP 75% 5-Methoxy-UTP + 25% 25%5-Formyl-CTP + ATP GTP UTP 75% CTP 75% 5-Methoxy-UTP + 25% 75%5-Formyl-CTP + ATP GTP UTP 25% CTP 5-Methoxy-UTP 5-Aminoallyl-CTP ATPGTP 25% 5-Methoxy-UTP + 75% 25% 5-Aminoallyl-CTP + ATP GTP UTP 75% CTP25% 5-Methoxy-UTP + 75% 75% 5-Aminoallyl-CTP + ATP GTP UTP 25% CTP 75%5-Methoxy-UTP + 25% 25% 5-Aminoallyl-CTP + ATP GTP UTP 75% CTP 75%5-Methoxy-UTP + 25% 75% 5-Aminoallyl-CTP + ATP GTP UTP 25% CTP

13. Untranslated Regions (UTRS)

Untranslated regions (UTRs) are nucleic acid sections of apolynucleotide before a start codon (5′UTR) and after a stop codon(3′UTR) that are not translated. In some embodiments, a polynucleotide(e.g., a ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)) of thedisclosure comprising an open reading frame (ORF) encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12A and IL12B fusionpolypeptides further comprises UTR (e.g., a 5′UTR or functional fragmentthereof, a 3′UTR or functional fragment thereof, or a combinationthereof).

A UTR can be homologous or heterologous to the coding region in apolynucleotide. In some embodiments, the UTR is homologous to the ORFencoding the IL12 polypeptide. In some embodiments, the UTR isheterologous to the ORF encoding the IL12 polypeptide. In someembodiments, the polynucleotide comprises two or more 5′UTRs orfunctional fragments thereof, each of which have the same or differentnucleotide sequences. In some embodiments, the polynucleotide comprisestwo or more 3′UTRs or functional fragments thereof, each of which havethe same or different nucleotide sequences.

In some embodiments, the 5′UTR or functional fragment thereof, 3′ UTR orfunctional fragment thereof, or any combination thereof is sequenceoptimized.

In some embodiments, the 5′UTR or functional fragment thereof, 3′ UTR orfunctional fragment thereof, or any combination thereof comprises atleast one chemically modified nucleobase, e.g., 5-methoxyuracil.

UTRs can have features that provide a regulatory role, e.g., increasedor decreased stability, localization and/or translation efficiency. Apolynucleotide comprising a UTR can be administered to a cell, tissue,or organism, and one or more regulatory features can be measured usingroutine methods. In some embodiments, a functional fragment of a 5′UTRor 3′UTR comprises one or more regulatory features of a full length 5′or 3′ UTR, respectively.

Natural 5′UTRs bear features that play roles in translation initiation.They harbor signatures like Kozak sequences that are commonly known tobe involved in the process by which the ribosome initiates translationof many genes. Kozak sequences have the consensus CCR(A/G)CCAUGG (SEQ IDNO: 232), where R is a purine (adenine or guanine) three bases upstreamof the start codon (AUG), which is followed by another ‘G’. 5′UTRs alsohave been known to form secondary structures that are involved inelongation factor binding.

By engineering the features typically found in abundantly expressedgenes of specific target organs, one can enhance the stability andprotein production of a polynucleotide. For example, introduction of5′UTR of liver-expressed mRNA, such as albumin, serum amyloid A,Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, orFactor VIII, can enhance expression of polynucleotides in hepatic celllines or liver. Likewise, use of 5′UTR from other tissue-specific mRNAto improve expression in that tissue is possible for muscle (e.g., MyoD,Myosin, Myoglobin, Myogenin, Herculin), for endothelial cells (e.g.,Tie-1, CD36), for myeloid cells (e.g., C/EBP, AML1, G-CSF, GM-CSF,CD11b, MSR, Fr-1, i-NOS), for leukocytes (e.g., CD45, CD18), for adiposetissue (e.g., CD36, GLUT4, ACRP30, adiponectin) and for lung epithelialcells (e.g., SP-A/B/C/D).

In some embodiments, UTRs are selected from a family of transcriptswhose proteins share a common function, structure, feature or property.For example, an encoded polypeptide can belong to a family of proteins(i.e., that share at least one function, structure, feature,localization, origin, or expression pattern), which are expressed in aparticular cell, tissue or at some time during development. The UTRsfrom any of the genes or mRNA can be swapped for any other UTR of thesame or different family of proteins to create a new polynucleotide.

In some embodiments, the 5′UTR and the 3′UTR can be heterologous. Insome embodiments, the 5′UTR can be derived from a different species thanthe 3′UTR. In some embodiments, the 3′UTR can be derived from adifferent species than the 5′UTR.

Co-owned International Patent Application No. PCT/US2014/021522 (Publ.No. WO/2014/164253, incorporated herein by reference in its entirety)provides a listing of exemplary UTRs that can be utilized in thepolynucleotide of the present disclosure as flanking regions to an ORF.

Exemplary UTRs of the application include, but are not limited to, oneor more 5′UTR and/or 3′UTR derived from the nucleic acid sequence of: aglobin, such as an α- or β-globin (e.g., a Xenopus, mouse, rabbit, orhuman globin); a strong Kozak translational initiation signal; a CYBA(e.g., human cytochrome b-245 a polypeptide); an albumin (e.g., humanalbumin7); a HSD17B4 (hydroxysteroid (17-13) dehydrogenase); a virus(e.g., a tobacco etch virus (TEV), a Venezuelan equine encephalitisvirus (VEEV), a Dengue virus, a cytomegalovirus (CMV) (e.g., CMVimmediate early 1 (IE1)), a hepatitis virus (e.g., hepatitis B virus), asindbis virus, or a PAV barley yellow dwarf virus); a heat shock protein(e.g., hsp70); a translation initiation factor (e.g., elF4G); a glucosetransporter (e.g., hGLUT1 (human glucose transporter 1)); an actin(e.g., human α or β actin); a GAPDH; a tubulin; a histone; a citric acidcycle enzyme; a topoisomerase (e.g., a 5′UTR of a TOP gene lacking the5′ TOP motif (the oligopyrimidine tract)); a ribosomal protein Large 32(L32); a ribosomal protein (e.g., human or mouse ribosomal protein, suchas, for example, rps9); an ATP synthase (e.g., ATP5A1 or the 0 subunitof mitochondrial H⁺-ATP synthase); a growth hormone e (e.g., bovine(bGH) or human (hGH)); an elongation factor (e.g., elongation factor 1al (EEF1A1)); a manganese superoxide dismutase (MnSOD); a myocyteenhancer factor 2A (MEF2A); a β-F1-ATPase, a creatine kinase, amyoglobin, a granulocyte-colony stimulating factor (G-CSF); a collagen(e.g., collagen type I, alpha 2 (Col1A2), collagen type I, alpha 1(Col1A1), collagen type VI, alpha 2 (Col6A2), collagen type VI, alpha 1(Col6A1)); a ribophorin (e.g., ribophorin I (RPNI)); a low densitylipoprotein receptor-related protein (e.g., LRP1); a cardiotrophin-likecytokine factor (e.g., Nnt1); calreticulin (Calr); a procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (Plod1); and a nucleobindin (e.g.,Nucb1).

Other exemplary 5′ and 3′ UTRs include, but are not limited to, thosedescribed in Karikó et al., Mol. Ther. 2008 16(11):1833-1840; Karikó etal., Mol. Ther. 2012 20(5):948-953; Karikó et al., Nucleic Acids Res.2011 39(21):e142; Strong et al., Gene Therapy 1997 4:624-627; Hansson etal., J. Biol. Chem. 2015 290(9):5661-5672; Yu et al., Vaccine 200725(10):1701-1711; Cafri et al., Mol. Ther. 2015 23(8):1391-1400; Andrieset al., Mol. Pharm. 2012 9(8):2136-2145; Crowley et al., Gene Ther. 2015Jun. 30, doi:10.1038/gt.2015.68; Ramunas et al., FASEB J. 201529(5):1930-1939; Wang et al., Curr. Gene Ther. 2015 15(4):428-435;Holtkamp et al., Blood 2006 108(13):4009-4017; Kormann et al., Nat.Biotechnol. 2011 29(2):154-157; Poleganov et al., Hum. Gen. Ther. 201526(11):751-766; Warren et al., Cell Stem Cell 2010 7(5):618-630; Mandaland Rossi, Nat. Protoc. 2013 8(3):568-582; Holcik and Liebhaber, PNAS1997 94(6):2410-2414; Ferizi et al., Lab Chip. 2015 15(17):3561-3571;Thess et al., Mol. Ther. 2015 23(9):1456-1464; Boros et al., PLoS One2015 10(6):e0131141; Boros et al., J. Photochem. Photobiol. B. 2013129:93-99; Andries et al., J. Control. Release 2015 217:337-344;Zinckgraf et al., Vaccine 2003 21(15):1640-9; Garneau et al., J. Virol.2008 82(2):880-892; Holden and Harris, Virology 2004 329(1): 119-133;Chiu et al., J. Virol. 2005 79(13):8303-8315; Wang et al., EMBO J. 199716(13):4107-4116; Al-Zoghaibi et al., Gene 2007 391(1-2):130-9; Vivinuset al., Eur. J. Biochem. 2001 268(7):1908-1917; Gan and Rhoads, J. Biol.Chem. 1996 271(2):623-626; Boado et al., J. Neurochem. 199667(4):1335-1343; Knirsch and Clerch, Biochem. Biophys. Res. Commun. 2000272(1):164-168; Chung et al., Biochemistry 1998 37(46):16298-16306;Izquierdo and Cuevza, Biochem. J. 2000 346 Pt 3:849-855; Dwyer et al.,J. Neurochem. 1996 66(2):449-458; Black et al., Mol. Cell. Biol. 199717(5):2756-2763; Izquierdo and Cuevza, Mol. Cell. Biol. 199717(9):5255-5268; U.S. Pat. Nos. 8,278,036; 8,748,089; 8,835,108;9,012,219; US2010/0129877; US2011/0065103; US2011/0086904;US2012/0195936; US2014/020675; US2013/0195967; US2014/029490;US2014/0206753; WO2007/036366; WO2011/015347; WO2012/072096;WO2013/143555; WO2014/071963; WO2013/185067; WO2013/182623;WO2014/089486; WO2013/185069; WO2014/144196; WO2014/152659; 2014/152673;WO2014/152940; WO2014/152774; WO2014/153052; WO2014/152966,WO2014/152513; WO2015/101414; WO2015/101415; WO2015/062738; andWO2015/024667; the contents of each of which are incorporated herein byreference in their entirety.

In some embodiments, the 5′UTR is selected from the group consisting ofa 3-globin 5′UTR; a 5′UTR containing a strong Kozak translationalinitiation signal; a cytochrome b-245 a polypeptide (CYBA) 5′UTR; ahydroxysteroid (17-13) dehydrogenase (HSD17B4) 5′UTR; a Tobacco etchvirus (TEV) 5′UTR; a Venezuelen equine encephalitis virus (TEEV) 5′UTR;a 5′ proximal open reading frame of rubella virus (RV) RNA encodingnonstructural proteins; a Dengue virus (DEN) 5′UTR; a heat shock protein70 (Hsp70) 5′UTR; a eIF4G 5′UTR; a GLUT1 5′UTR; functional fragmentsthereof and any combination thereof.

In some embodiments, the 3′UTR is selected from the group consisting ofa β-globin 3′UTR; a CYBA 3′UTR; an albumin 3′UTR; a growth hormone (GH)3′UTR; a VEEV 3′UTR; a hepatitis B virus (HBV) 3′UTR; α-globin 3′UTR; aDEN 3′UTR; a PAV barley yellow dwarf virus (BYDV-PAV) 3′UTR; anelongation factor 1 al (EEF1A1) 3′UTR; a manganese superoxide dismutase(MnSOD) 3′UTR; a P subunit of mitochondrial H(+)-ATP synthase (β-mRNA)3′UTR; a GLUT1 3′UTR; a MEF2A 3′UTR; a β-F1-ATPase 3′UTR; functionalfragments thereof and combinations thereof.

Other exemplary UTRs include, but are not limited to, one or more of theUTRs, including any combination of UTRs, disclosed in WO2014/164253, thecontents of which are incorporated herein by reference in theirentirety. Shown in Table 21 of U.S. Provisional Application No.61/775,509 and in Table 22 of U.S. Provisional Application No.61/829,372, the contents of each are incorporated herein by reference intheir entirety, is a listing start and stop sites for 5′UTRs and 3′UTRs.In Table 21, each 5′UTR (5′-UTR-005 to 5′-UTR 68511) is identified byits start and stop site relative to its native or wild-type (homologous)transcript (ENST; the identifier used in the ENSEMBL database).

Wild-type UTRs derived from any gene or mRNA can be incorporated intothe polynucleotides of the disclosure. In some embodiments, a UTR can bealtered relative to a wild type or native UTR to produce a variant UTR,e.g., by changing the orientation or location of the UTR relative to theORF; or by inclusion of additional nucleotides, deletion of nucleotides,swapping or transposition of nucleotides. In some embodiments, variantsof 5′ or 3′ UTRs can be utilized, for example, mutants of wild typeUTRs, or variants wherein one or more nucleotides are added to orremoved from a terminus of the UTR.

Additionally, one or more synthetic UTRs can be used in combination withone or more non-synthetic UTRs. See, e.g., Mandal and Rossi, Nat.Protoc. 2013 8(3):568-82, the contents of which are incorporated hereinby reference in their entirety, and sequences available atwww.addgene.org/Derrick_Rossi/, last accessed Apr. 16, 2016. UTRs orportions thereof can be placed in the same orientation as in thetranscript from which they were selected or can be altered inorientation or location. Hence, a 5′ and/or 3′ UTR can be inverted,shortened, lengthened, or combined with one or more other 5′ UTRs or 3′UTRs.

In some embodiments, the polynucleotide comprises multiple UTRs, e.g., adouble, a triple or a quadruple 5′UTR or 3′UTR. For example, a doubleUTR comprises two copies of the same UTR either in series orsubstantially in series. For example, a double beta-globin 3′UTR can beused (see US2010/0129877, the contents of which are incorporated hereinby reference in its entirety).

In certain embodiments, the polynucleotides of the disclosure comprise a5′UTR and/or a 3′UTR selected from any of the UTRs disclosed herein. Insome embodiments, the 5′UTR comprises:

5′UTR-001 (Upstream UTR) (SEQ ID NO. 135)(GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC); 5′UTR-002 (UpstreamUTR) (SEQ ID NO. 136) (GGGAGATCAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC);5′UTR-003 (Upstream UTR) (SEQ ID NO. 137)(GGAATAAAAGTCTCAACACAACATATACAAAACAAACGAATCTCAAGCAATCAAGCATTCTACTTCTATTGCAGCAATTTAAATCATTTCTTTTAAAGCAAAAGCAATTTTCTGAAAATTTTCACCATTTACGAACGATAGCAAC); 5′UTR-004 (UpstreamUTR) (SEQ ID NO. 138) (GGGAGACAAGCUUGGCAUUCCGGUACUGUUGGUAAAGCCACC);5′UTR-005 (Upstream UTR) (SEQ ID NO. 139)(GGGAGATCAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC); 5′UTR-006 (UpstreamUTR) (SEQ ID NO. 140) (GGAATAAAAGTCTCAACACAACATATACAAAACAAACGAATCTCAAGCAATCAAGCATTCTACTTCTATTGCAGCAATTTAAATCATTTCTTTTAAAGCAAAAGCAATTTTCTGAAAATTTTCACCATTTACGAACGATAGCAAC); 5′UTR-007 (UpstreamUTR) (SEQ ID NO. 141) (GGGAGACAAGCUUGGCAUUCCGGUACUGUUGGUAAAGCCACC);5′UTR-008 (Upstream UTR) (SEQ ID NO. 142)(GGGAATTAACAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC); 5′UTR-009 (UpstreamUTR) (SEQ ID NO. 143) (GGGAAATTAGACAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC);5′UTR-010, Upstream (SEQ ID NO. 144)(GGGAAATAAGAGAGTAAAGAACAGTAAGAAGAAATATAAGAGCCACC); 5′UTR-011 (UpstreamUTR) (SEQ ID NO. 145) (GGGAAAAAAGAGAGAAAAGAAGACTAAGAAGAAATATAAGAGCCACC);5′UTR-012 (Upstream UTR) (SEQ ID NO. 146)(GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGATATATAAGAGCCACC); 5′UTR-013 (UpstreamUTR) (SEQ ID NO. 147) (GGGAAATAAGAGACAAAACAAGAGTAAGAAGAAATATAAGAGCCACC);5′UTR-014 (Upstream UTR) (SEQ ID NO. 148)(GGGAAATTAGAGAGTAAAGAACAGTAAGTAGAATTAAAAGAGCCACC); 5′UTR-15 (UpstreamUTR) (SEQ ID NO. 149) (GGGAAATAAGAGAGAATAGAAGAGTAAGAAGAAATATAAGAGCCACC);5′UTR-016 (Upstream UTR) (SEQ ID NO. 150)(GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAAATTAAGAGCCACC); 5′UTR-017 (UpstreamUTR) (SEQ ID NO. 151) (GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATTTAAGAGCCACC);5′UTR-018 (Upstream UTR) (SEQ ID NO. 152)(TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC); 142-3p 5′UTR-001 (UpstreamUTR including miR142-3p) (SEQ ID NO. 153)(TGATAATAGTCCATAAAGTAGGAAACACTACAGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); 142-3p 5′UTR-002 (UpstreamUTR including miR142-3p) (SEQ ID NO. 154)(TGATAATAGGCTGGAGCCTCGGTGGCTCCATAAAGTAGGAAACACTACACATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); 142-3p 5′UTR-003 (UpstreamUTR including miR142-3p) (SEQ ID NO. 155)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTCCATAAAGTAGGAAACACTACATGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); 142-3p 5′UTR-004 (UpstreamUTR including miR142-3p) (SEQ ID NO. 156)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGTCCATAAAGTAGGAAACACTACACCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); 142-3p 5′UTR-005 (UpstreamUTR including miR142-3p) (SEQ ID NO. 157)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCTCCATAAAGTAGGAAACACTACACTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); 142-3p 5′UTR-006 (UpstreamUTR including miR142-3p) (SEQ ID NO. 158)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCTCCATAAAGTAGGAAACACTACAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC); or 142-3p 5′UTR-007(Upstream UTR including miR142-3p) (SEQ ID NO. 159)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTTCCATAAAGTAGGAAACACTACACTGAGTGGGCGGC).

In some embodiments, the 3′UTR comprises:

3′UTR-001 (Creatine Kinase UTR) (SEQ ID NO. 160)(GCGCCTGCCCACCTGCCACCGACTGCTGGAACCCAGCCAGTGGGAGGGCCTGGCCCACCAGAGTCCTGCTCCCTCACTCCTCGCCCCGCCCCCTGTCCCAGAGTCCCACCTGGGGGCTCTCTCCACCCTTCTCAGAGTTCCAGTTTCAACCAGAGTTCCAACCAATGGGCTCCATCCTCTGGATTCTGGCCAATGAAATATCTCCCTGGCAGGGTCCTCTTCTTTTCCCAGAGCTCCACCCCAACCAGGAGCTCTAGTTAATGGAGAGCTCCCAGCACACTCGGAGCTTGTGCTTTGTCTCCACGCAAAGCGATAAATAAAAGCATTGGTGGCCTTTGGTCTTTGAATAAAGCCTGAGTAGGAAGTCTAGA); 3′UTR-002 (Myoglobin UTR) (SEQ ID NO. 161)(GCCCCTGCCGCTCCCACCCCCACCCATCTGGGCCCCGGGTTCAAGAGAGAGCGGGGTCTGATCTCGTGTAGCCATATAGAGTTTGCTTCTGAGTGTCTGCTTTGTTTAGTAGAGGTGGGCAGGAGGAGCTGAGGGGCTGGGGCTGGGGTGTTGAAGTTGGCTTTGCATGCCCAGCGATGCGCCTCCCTGTGGGATGTCATCACCCTGGGAACCGGGAGTGGCCCTTGGCTCACTGTGTTCTGCATGGTTTGGATCTGAATTAATTGTCCTTTCTTCTAAATCCCAACCGAACTTCTTCCAACCTCCAAACTGGCTGTAACCCCAAATCCAAGCCATTAACTACACCTGACAGTAGCAATTGTCTGATTAATCACTGGCCCCTTGAAGACAGCAGAATGTCCCTTTGCAATGAGGAGGAGATCTGGGCTGGGCGGGCCAGCTGGGGAAGCATTTGACTATCTGGAACTTGTGTGTGCCTCCTCAGGTATGGCAGTGACTCACCTGGTTTTAATAAAACAACCTGCAACATCTCATGGTCTTTGAATAAAG CCTGAGTAGGAAGTCTAGA);3′UTR-003 (α-actin UTR) (SEQ ID NO. 162)(ACACACTCCACCTCCAGCACGCGACTTCTCAGGACGACGAATCTTCTCAATGGGGGGGCGGCTGAGCTCCAGCCACCCCGCAGTCACTTTCTTTGTAACAACTTCCGTTGCTGCCATCGTAAACTGACACAGTGTTTATAACGTGTACATACATTAACTTATTACCTCATTTTGTTATTTTTCGAAACAAAGCCCTGTGGAAGAAAATGGAAAACTTGAAGAAGCATTAAAGTCATTCTGTTAAGCTGCGTAAATGGTCTTTGAATAAAGCCTGAGTAGGAAGTCTAGA); 3′UTR-004 (Albumin UTR) (SEQID NO. 163) (CATCACATTTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAATCTAATAGAGTGGTACAGCACTGTTATTTTTCAAAGATGTGTTGCTATCCTGAAAATTCTGTAGGTTCTGTGGAAGTTCCAGTGTTCTCTCTTATTCCACTTCGGTAGAGGATTTCTAGTTTCTTGTGGGCTAATTAAATAAATCATTAATACTCTTCTAATGGTCTTTGAATAAAGCCTGAGTAGGAAGTCTAGA); 3′UTR-005 (α-globin UTR) (SEQ ID NO.164) (GCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTCTCCCTTGCACCTGTACCTCTTGGTCTTTGAATAAAGCCTGAGTAGGAAGGCGGCC GCTCGAGCATGCATCTAGA);3′UTR-006 (G-CSF UTR) (SEQ ID NO. 165)(GCCAAGCCCTCCCCATCCCATGTATTTATCTCTATTTAATATTTATGTCTATTTAAGCCTCATATTTAAAGACAGGGAAGAGCAGAACGGAGCCCCAGGCCTCTGTGTCCTTCCCTGCATTTCTGAGTTTCATTCTCCTGCCTGTAGCAGTGAGAAAAAGCTCCTGTCCTCCCATCCCCTGGACTGGGAGGTAGATAGGTAAATACCAAGTATTTATTACTATGACTGCTCCCCAGCCCTGGCTCTGCAATGGGCACTGGGATGAGCCGCTGTGAGCCCCTGGTCCTGAGGGTCCCCACCTGGGACCCTTGAGAGTATCAGGTCTCCCACGTGGGAGACAAGAAATCCCTGTTTAATATTTAAACAGCAGTGTTCCCCATCTGGGTCCTTGCACCCCTCACTCTGGCCTCAGCCGACTGCACAGCGGCCCCTGCATCCCCTTGGCTGTGAGGCCCCTGGACAAGCAGAGGTGGCCAGAGCTGGGAGGCATGGCCCTGGGGTCCCACGAATTTGCTGGGGAATCTCGTTTTTCTTCTTAAGACTTTTGGGACATGGTTTGACTCCCGAACATCACCGACGCGTCTCCTGTTTTTCTGGGTGGCCTCGGGACACCTGCCCTGCCCCCACGAGGGTCAGGACTGTGACTCTTTTTAGGGCCAGGCAGGTGCCTGGACATTTGCCTTGCTGGACGGGGACTGGGGATGTGGGAGGGAGCAGACAGGAGGAATCATGTCAGGCCTGTGTGTGAAAGGAAGCTCCACTGTCACCCTCCACCTCTTCACCCCCCACTCACCAGTGTCCCCTCCACTGTCACATTGTAACTGAACTTCAGGATAATAAAGTGTTTGCCTCCATGGTCTTTGAATAAAGCCTGAGTAGGAAGGCGGCCGCTCGAGCAT GCATCTAGA); 3′UTR-007(Col1a2; collagen, type I, alpha 2 UTR) (SEQ ID NO. 166)(ACTCAATCTAAATTAAAAAAGAAAGAAATTTGAAAAAACTTTCTCTTTGCCATTTCTTCTTCTTCTTTTTTAACTGAAAGCTGAATCCTTCCATTTCTTCTGCACATCTACTTGCTTAAATTGTGGGCAAAAGAGAAAAAGAAGGATTGATCAGAGCATTGTGCAATACAGTTTCATTAACTCCTTCCCCCGCTCCCCCAAAAATTTGAATTTTTTTTTCAACACTCTTACACCTGTTATGGAAAATGTCAACCTTTGTAAGAAAACCAAAATAAAAATTGAAAAATAAAAACCATAAACATTTGCACCACTTGTGGCTTTTGAATATCTTCCACAGAGGGAAGTTTAAAACCCAAACTTCCAAAGGTTTAAACTACCTCAAAACACTTTCCCATGAGTGTGATCCACATTGTTAGGTGCTGACCTAGACAGAGATGAACTGAGGTCCTTGTTTTGTTTTGTTCATAATACAAAGGTGCTAATTAATAGTATTTCAGATACTTGAAGAATGTTGATGGTGCTAGAAGAATTTGAGAAGAAATACTCCTGTATTGAGTTGTATCGTGTGGTGTATTTTTTAAAAAATTTGATTTAGCATTCATATTTTCCATCTTATTCCCAATTAAAAGTATGCAGATTATTTGCCCAAATCTTCTTCAGATTCAGCATTTGTTCTTTGCCAGTCTCATTTTCATCTTCTTCCATGGTTCCACAGAAGCTTTGTTTCTTGGGCAAGCAGAAAAATTAAATTGTACCTATTTTGTATATGTGAGATGTTTAAATAAATTGTGAAAAAAATGAAATAAAGCATGTTTGGTTTTCCAAAAGAACATAT); 3′UTR-008 (Col6a2; collagen, typeVI, alpha 2 UTR) (SEQ ID NO. 167)(CGCCGCCGCCCGGGCCCCGCAGTCGAGGGTCGTGAGCCCACCCCGTCCATGGTGCTAAGCGGGCCCGGGTCCCACACGGCCAGCACCGCTGCTCACTCGGACGACGCCCTGGGCCTGCACCTCTCCAGCTCCTCCCACGGGGTCCCCGTAGCCCCGGCCCCCGCCCAGCCCCAGGTCTCCCCAGGCCCTCCGCAGGCTGCCCGGCCTCCCTCCCCCTGCAGCCATCCCAAGGCTCCTGACCTACCTGGCCCCTGAGCTCTGGAGCAAGCCCTGACCCAATAAAGGCTTTGAACCCAT); 3′UTR-009 (RPN1;ribophorin I UTR) (SEQ ID NO. 168)(GGGGCTAGAGCCCTCTCCGCACAGCGTGGAGACGGGGCAAGGAGGGGGGTTATTAGGATTGGTGGTTTTGTTTTGCTTTGTTTAAAGCCGTGGGAAAATGGCACAACTTTACCTCTGTGGGAGATGCAACACTGAGAGCCAAGGGGTGGGAGTTGGGATAATTTTTATATAAAAGAAGTTTTTCCACTTTGAATTGCTAAAAGTGGCATTTTTCCTATGTGCAGTCACTCCTCTCATTTCTAAAATAGGGACGTGGCCAGGCACGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCGGCTCACGAGGTCAGGAGATCGAGACTATCCTGGCTAACACGGTAAAACCCTGTCTCTACTAAAAGTACAAAAAATTAGCTGGGCGTGGTGGTGGGCACCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAAGGCATGAATCCAAGAGGCAGAGCTTGCAGTGAGCTGAGATCACGCCATTGCACTCCAGCCTGGGCAACAGTGTTAAGACTCTGTCTCAAATATAAATAAATAAATAAATAAATAAATAAATAAATAAAAATAAAGCGAGATGTTGCCCTC AAA); 3′UTR-010(LRP1; low density lipoprotein receptor-related protein 1 UTR) (SEQ IDNO. 169) (GGCCCTGCCCCGTCGGACTGCCCCCAGAAAGCCTCCTGCCCCCTGCCAGTGAAGTCCTTCAGTGAGCCCCTCCCCAGCCAGCCCTTCCCTGGCCCCGCCGGATGTATAAATGTAAAAATGAAGGAATTACATTTTATATGTGAGCGAGCAAGCCGGCAAGCGAGCACAGTATTATTTCTCCATCCCCTCCCTGCCTGCTCCTTGGCACCCCCATGCTGCCTTCAGGGAGACAGGCAGGGAGGGCTTGGGGCTGCACCTCCTACCCTCCCACCAGAACGCACCCCACTGGGAGAGCTGGTGGTGCAGCCTTCCCCTCCCTGTATAAGACACTTTGCCAAGGCTCTCCCCTCTCGCCCCATCCCTGCTTGCCCGCTCCCACAGCTTCCTGAGGGCTAATTCTGGGAAGGGAGAGTTCTTTGCTGCCCCTGTCTGGAAGACGTGGCTCTGGGTGAGGTAGGCGGGAAAGGATGGAGTGTTTTAGTTCTTGGGGGAGGCCACCCCAAACCCCAGCCCCAACTCCAGGGGCACCTATGAGATGGCCATGCTCAACCCCCCTCCCAGACAGGCCCTCCCTGTCTCCAGGGCCCCCACCGAGGTTCCCAGGGCTGGAGACTTCCTCTGGTAAACATTCCTCCAGCCTCCCCTCCCCTGGGGACGCCAAGGAGGTGGGCCACACCCAGGAAGGGAAAGCGGGCAGCCCCGTTTTGGGGACGTGAACGTTTTAATAATTTTTGCTGAATTCCTTTACAACTAAATAACACAGATATTGTTATAAATAAAATTGT); 3′UTR-011 (Nnt1;cardiotrophin-like cytokine factor 1 UTR) (SEQ ID NO. 170)(ATATTAAGGATCAAGCTGTTAGCTAATAATGCCACCTCTGCAGTTTTGGGAACAGGCAAATAAAGTATCAGTATACATGGTGATGTACATCTGTAGCAAAGCTCTTGGAGAAAATGAAGACTGAAGAAAGCAAAGCAAAAACTGTATAGAGAGATTTTTCAAAAGCAGTAATCCCTCAATTTTAAAAAAGGATTGAAAATTCTAAATGTCTTTCTGTGCATATTTTTTGTGTTAGGAATCAAAAGTATTTTATAAAAGGAGAAAGAACAGCCTCATTTTAGATGTAGTCCTGTTGGATTTTTTATGCCTCCTCAGTAACCAGAAATGTTTTAAAAAACTAAGTGTTTAGGATTTCAAGACAACATTATACATGGCTCTGAAATATCTGACACAATGTAAACATTGCAGGCACCTGCATTTTATGTTTTTTTTTTCAACAAATGTGACTAATTTGAAACTTTTATGAACTTCTGAGCTGTCCCCTTGCAATTCAACCGCAGTTTGAATTAATCATATCAAATCAGTTTTAATTTTTTAAATTGTACTTCAGAGTCTATATTTCAAGGGCACATTTTCTCACTACTATTTTAATACATTAAAGGACTAAATAATCTTTCAGAGATGCTGGAAACAAATCATTTGCTTTATATGTTTCATTAGAATACCAATGAAACATACAACTTGAAAATTAGTAATAGTATTTTTGAAGATCCCATTTCTAATTGGAGATCTCTTTAATTTCGATCAACTTATAATGTGTAGTACTATATTAAGTGCACTTGAGTGGAATTCAACATTTGACTAATAAAATGAGTTCATCATGTTGGCAAGTGATGTGGCAATTATCTCTGGTGACAAAAGAGTAAAATCAAATATTTCTGCCTGTTACAAATATCAAGGAAGACCTGCTACTATGAAATAGATGACATTAATCTGTCTTCACTGTTTATAATACGGATGGATTTTTTTTCAAATCAGTGTGTGTTTTGAGGTCTTATGTAATTGATGACATTTGAGAGAAATGGTGGCTTTTTTTAGCTACCTCTTTGTTCATTTAAGCACCAGTAAAGATCATGTCTTTTTATAGAAGTGTAGATTTTCTTTGTGACTTTGCTATCGTGCCTAAAGCTCTAAATATAGGTGAATGTGTGATGAATACTCAGATTATTTGTCTCTCTATATAATTAGTTTGGTACTAAGTTTCTCAAAAAATTATTAACACATGAAAGACAATCTCTAAACCAGAAAAAGAAGTAGTACAAATTTTGTTACTGTAATGCTCGCGTTTAGTGAGTTTAAAACACACAGTATCTTTTGGTTTTATAATCAGTTTCTATTTTGCTGTGCCTGAGATTAAGATCTGTGTATGTGTGTGTGTGTGTGTGTGCGTTTGTGTGTTAAAGCAGAAAAGACTTTTTTAAAAGTTTTAAGTGATAAATGCAATTTGTTAATTGATCTTAGATCACTAGTAAACTCAGGGCTGAATTATACCATGTATATTCTATTAGAAGAAAGTAAACACCATCTTTATTCCTGCCCTTTTTCTTCTCTCAAAGTAGTTGTAGTTATATCTAGAAAGAAGCAATTTTGATTTCTTGAAAAGGTAGTTCCTGCACTCAGTTTAAACTAAAAATAATCATACTTGGATTTTATTTATTTTTGTCATAGTAAAAATTTTAATTTATATATATTTTTATTTAGTATTATCTTATTCTTTGCTATTTGCCAATCCTTTGTCATCAATTGTGTTAAATGAATTGAAAATTCATGCCCTGTTCATTTTATTTTACTTTATTGGTTAGGATATTTAAAGGATTTTTGTATATATAATTTCTTAAATTAATATTCCAAAAGGTTAGTGGACTTAGATTATAAATTATGGCAAAAATCTAAAAACAACAAAAATGATTTTTATACATTCTATTTCATTATTCCTCTTTTTCCAATAAGTCATACAATTGGTAGATATGACTTATTTTATTTTTGTATTATTCACTATATCTTTATGATATTTAAGTATAAATAATTAAAAAAATTTATTGTACCTTATAGTCTGTCACCAAAAAAAAAAAATTATCTGTAGGTAGTGAAATGCTAATGTTGATTTGTCTTTAAGGGCTTGTTAACTATCCTTTATTTTCTCATTTGTCTTAAATTAGGAGTTTGTGTTTAAATTACTCATCTAAGCAAAAAATGTATATAAATCCCATTACTGGGTATATACCCAAAGGATTATAAATCATGCTGCTATAAAGACACATGCACACGTATGTTTATTGCAGCACTATTCACAATAGCAAAGACTTGGAACCAACCCAAATGTCCATCAATGATAGACTTGATTAAGAAAATGTGCACATATACACCATGGAATACTATGCAGCCATAAAAAAGGATGAGTTCATGTCCTTTGTAGGGACATGGATAAAGCTGGAAACCATCATTCTGAGCAAACTATTGCAAGGACAGAAAACCAAACACTGCATGTTCTCACTCATAGGTGGGAATTGAACAATGAGAACACTTGGACACAAGGTGGGGAACACCACACACCAGGGCCTGTCATGGGGTGGGGGGAGTGGGGAGGGATAGCATTAGGAGATATACCTAATGTAAATGATGAGTTAATGGGTGCAGCACACCAACATGGCACATGTATACATATGTAGCAAACCTGCACGTTGTGCACATGTACCCTAGAACTTAAAGTATAATTAAAAAAAAAAAGAAAACAGAAGCTATTTATAAAGAAGTTATTTGCTGAAATAAATGTGATCTTTCCCATTAAAAAAATAAAGAAATTTTGGGGTAAAAAAACACAATATATTGTATTCTTGAAAAATTCTAAGAGAGTGGATGTGAAGTGTTCTCACCACAAAAGTGATAACTAATTGAGGTAATGCACATATTAATTAGAAAGATTTTGTCATTCCACAATGTATATATACTTAAAAATATGTTATACACAATAAATACATACATTAAAAAATAAGTAAATG TA); 3′UTR-012(Col6a1; collagen, type VI, alpha 1 UTR) (SEQ ID NO. 171)(CCCACCCTGCACGCCGGCACCAAACCCTGTCCTCCCACCCCTCCCCACTCATCACTAAACAGAGTAAAATGTGATGCGAATTTTCCCGACCAACCTGATTCGCTAGATTTTTTTTAAGGAAAAGCTTGGAAAGCCAGGACACAACGCTGCTGCCTGCTTTGTGCAGGGTCCTCCGGGGCTCAGCCCTGAGTTGGCATCACCTGCGCAGGGCCCTCTGGGGCTCAGCCCTGAGCTAGTGTCACCTGCACAGGGCCCTCTGAGGCTCAGCCCTGAGCTGGCGTCACCTGTGCAGGGCCCTCTGGGGCTCAGCCCTGAGCTGGCCTCACCTGGGTTCCCCACCCCGGGCTCTCCTGCCCTGCCCTCCTGCCCGCCCTCCCTCCTGCCTGCGCAGCTCCTTCCCTAGGCACCTCTGTGCTGCATCCCACCAGCCTGAGCAAGACGCCCTCTCGGGGCCTGTGCCGCACTAGCCTCCCTCTCCTCTGTCCCCATAGCTGGTTTTTCCCACCAATCCTCACCTAACAGTTACTTTACAATTAAACTCAAAGCAAGCTCTTCTCCTCAGCTTGGGGCAGCCATTGGCCTCTGTCTCGTTTTGGGAAACCAAGGTCAGGAGGCCGTTGCAGACATAAATCTCGGCGACTCGGCCCCGTCTCCTGAGGGTCCTGCTGGTGACCGGCCTGGACCTTGGCCCTACAGCCCTGGAGGCCGCTGCTGACCAGCACTGACCCCGACCTCAGAGAGTACTCGCAGGGGCGCTGGCTGCACTCAAGACCCTCGAGATTAACGGTGCTAACCCCGTCTGCTCCTCCCTCCCGCAGAGACTGGGGCCTGGACTGGACATGAGAGCCCCTTGGTGCCACAGAGGGCTGTGTCTTACTAGAAACAACGCAAACCTCTCCTTCCTCAGAATAGTGATGTGTTCGACGTTTTATCAAAGGCCCCCTTTCTATGTTCATGTTAGTTTTGCTCCTTCTGTGTTTTTTTCTGAACCATATCCATGTTGCTGACTTTTCCAAATAAAGGTTTTCACTCCTCTC); 3′UTR-013 (Calr; calreticulinUTR) (SEQ ID NO. 172) (AGAGGCCTGCCTCCAGGGCTGGACTGAGGCCTGAGCGCTCCTGCCGCAGAGCTGGCCGCGCCAAATAATGTCTCTGTGAGACTCGAGAACTTTCATTTTTTTCCAGGCTGGTTCGGATTTGGGGTGGATTTTGGTTTTGTTCCCCTCCTCCACTCTCCCCCACCCCCTCCCCGCCCTTTTTTTTTTTTTTTTTTAAACTGGTATTTTATCTTTGATTCTCCTTCAGCCCTCACCCCTGGTTCTCATCTTTCTTGATCAACATCTTTTCTTGCCTCTGTCCCCTTCTCTCATCTCTTAGCTCCCCTCCAACCTGGGGGGCAGTGGTGTGGAGAAGCCACAGGCCTGAGATTTCATCTGCTCTCCTTCCTGGAGCCCAGAGGAGGGCAGCAGAAGGGGGTGGTGTCTCCAACCCCCCAGCACTGAGGAAGAACGGGGCTCTTCTCATTTCACCCCTCCCTTTCTCCCCTGCCCCCAGGACTGGGCCACTTCTGGGTGGGGCAGTGGGTCCCAGATTGGCTCACACTGAGAATGTAAGAACTACAAACAAAATTTCTATTAAATTAAATTTTGTGTCTCC); 3′UTR-014 (Col1a1; collagen, type I,alpha 1 UTR) (SEQ ID NO. 173)(CTCCCTCCATCCCAACCTGGCTCCCTCCCACCCAACCAACTTTCCCCCCAACCCGGAAACAGACAAGCAACCCAAACTGAACCCCCTCAAAAGCCAAAAAATGGGAGACAATTTCACATGGACTTTGGAAAATATTTTTTTCCTTTGCATTCATCTCTCAAACTTAGTTTTTATCTTTGACCAACCGAACATGACCAAAAACCAAAAGTGCATTCAACCTTACCAAAAAAAAAAAAAAAAAAAGAATAAATAAATAACTTTTTAAAAAAGGAAGCTTGGTCCACTTGCTTGAAGACCCATGCGGGGGTAAGTCCCTTTCTGCCCGTTGGGCTTATGAAACCCCAATGCTGCCCTTTCTGCTCCTTTCTCCACACCCCCCTTGGGGCCTCCCCTCCACTCCTTCCCAAATCTGTCTCCCCAGAAGACACAGGAAACAATGTATTGTCTGCCCAGCAATCAAAGGCAATGCTCAAACACCCAAGTGGCCCCCACCCTCAGCCCGCTCCTGCCCGCCCAGCACCCCCAGGCCCTGGGGGACCTGGGGTTCTCAGACTGCCAAAGAAGCCTTGCCATCTGGCGCTCCCATGGCTCTTGCAACATCTCCCCTTCGTTTTTGAGGGGGTCATGCCGGGGGAGCCACCAGCCCCTCACTGGGTTCGGAGGAGAGTCAGGAAGGGCCACGACAAAGCAGAAACATCGGATTTGGGGAACGCGTGTCAATCCCTTGTGCCGCAGGGCTGGGCGGGAGAGACTGTTCTGTTCCTTGTGTAACTGTGTTGCTGAAAGACTACCTCGTTCTTGTCTTGATGTGTCACCGGGGCAACTGCCTGGGGGCGGGGATGGGGGCAGGGTGGAAGCGGCTCCCCATTTTATACCAAAGGTGCTACATCTATGTGATGGGTGGGGTGGGGAGGGAATCACTGGTGCTATAGAAATTGAGATGCCCCCCCAGGCCAGCAAATGTTCCTTTTTGTTCAAAGTCTATTTTTATTCCTTGATATTTTTCTTTTTTTTTTTTTTTTTTTGTGGATGGGGACTTGTGAATTTTTCTAAAGGTGCTATTTAACATGGGAGGAGAGCGTGTGCGGCTCCAGCCCAGCCCGCTGCTCACTTTCCACCCTCTCTCCACCTGCCTCTGGCTTCTCAGGCCTCTGCTCTCCGACCTCTCTCCTCTGAAACCCTCCTCCACAGCTGCAGCCCATCCTCCCGGCTCCCTCCTAGTCTGTCCTGCGTCCTCTGTCCCCGGGTTTCAGAGACAACTTCCCAAAGCACAAAGCAGTTTTTCCCCCTAGGGGTGGGAGGAAGCAAAAGACTCTGTACCTATTTTGTATGTGTATAATAATTTGAGATGTTTTTAATTATTTTGATTGCTGGAATAAAGCATGTGGAAATGACCCAAACATAATCCGCAGTGGCCTCCTAATTTCCTTCTTTGGAGTTGGGGGAGGGGTAGACATGGGGAAGGGGCTTTGGGGTGATGGGCTTGCCTTCCATTCCTGCCCTTTCCCTCCCCACTATTCTCTTCTAGATCCCTCCATAACCCCACTCCCCTTTCTCTCACCCTTCTTATACCGCAAACCTTTCTACTTCCTCTTTCATTTTCTATTCTTGCAATTTCCTTGCACCTTTTCCAAATCCTCTTCTCCCCTGCAATACCATACAGGCAATCCACGTGCACAACACACACACACACTCTTCACATCTGGGGTTGTCCAAACCTCATACCCACTCCCCTTCAAGCCCATCCACTCTCCACCCCCTGGATGCCCTGCACTTGGTGGCGGTGGGATGCTCATGGATACTGGGAGGGTGAGGGGAGTGGAACCCGTGAGGAGGACCTGGGGGCCTCTCCTTGAACTGACATGAAGGGTCATCTGGCCTCTGCTCCCTTCTCACCCACGCTGACCTCCTGCCGAAGGAGCAACGCAACAGGAGAGGGGTCTGCTGAGCCTGGCGAGGGTCTGGGAGGGACCAGGAGGAAGGCGTGCTCCCTGCTCGCTGTCCTGGCCCTGGGGGAGTGAGGGAGACAGACACCTGGGAGAGCTGTGGGGAAGGCACTCGCACCGTGCTCTTGGGAAGGAAGGAGACCTGGCCCTGCTCACCACGGACTGGGTGCCTCGACCTCCTGAATCCCCAGAACACAACCCCCCTGGGCTGGGGTGGTCTGGGGAACCATCGTGCCCCCGCCTCCCGCCTACT CCTTTTTAAGCTT);3′UTR-015 (Plod1; procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1UTR) (SEQ ID NO. 174) (TTGGCCAGGCCTGACCCTCTTGGACCTTTCTTCTTTGCCGACAACCACTGCCCAGCAGCCTCTGGGACCTCGGGGTCCCAGGGAACCCAGTCCAGCCTCCTGGCTGTTGACTTCCCATTGCTCTTGGAGCCACCAATCAAAGAGATTCAAAGAGATTCCTGCAGGCCAGAGGCGGAACACACCTTTATGGCTGGGGCTCTCCGTGGTGTTCTGGACCCAGCCCCTGGAGACACCATTCACTTTTACTGCTTTGTAGTGACTCGTGCTCTCCAACCTGTCTTCCTGAAAAACCAAGGCCCCCTTCCCCCACCTCTTCCATGGGGTGAGACTTGAGCAGAACAGGGGCTTCCCCAAGTTGCCCAGAAAGACTGTCTGGGTGAGAAGCCATGGCCAGAGCTTCTCCCAGGCACAGGTGTTGCACCAGGGACTTCTGCTTCAAGTTTTGGGGTAAAGACACCTGGATCAGACTCCAAGGGCTGCCCTGAGTCTGGGACTTCTGCCTCCATGGCTGGTCATGAGAGCAAACCGTAGTCCCCTGGAGACAGCGACTCCAGAGAACCTCTTGGGAGACAGAAGAGGCATCTGTGCACAGCTCGATCTTCTACTTGCCTGTGGGGAGGGGAGTGACAGGTCCACACACCACACTGGGTCACCCTGTCCTGGATGCCTCTGAAGAGAGGGACAGACCGTCAGAAACTGGAGAGTTTCTATTAAAGGTCATTTAAACCA); 3′UTR-016 (Nucb1; nucleobindin 1 UTR)(SEQ ID NO. 175) (TCCTCCGGGACCCCAGCCCTCAGGATTCCTGATGCTCCAAGGCGACTGATGGGCGCTGGATGAAGTGGCACAGTCAGCTTCCCTGGGGGCTGGTGTCATGTTGGGCTCCTGGGGCGGGGGCACGGCCTGGCATTTCACGCATTGCTGCCACCCCAGGTCCACCTGTCTCCACTTTCACAGCCTCCAAGTCTGTGGCTCTTCCCTTCTGTCCTCCGAGGGGCTTGCCTTCTCTCGTGTCCAGTGAGGTGCTCAGTGATCGGCTTAACTTAGAGAAGCCCGCCCCCTCCCCTTCTCCGTCTGTCCCAAGAGGGTCTGCTCTGAGCCTGCGTTCCTAGGTGGCTCGGCCTCAGCTGCCTGGGTTGTGGCCGCCCTAGCATCCTGTATGCCCACAGCTACTGGAATCCCCGCTGCTGCTCCGGGCCAAGCTTCTGGTTGATTAATGAGGGCATGGGGTGGTCCCTCAAGACCTTCCCCTACCTTTTGTGGAACCAGTGATGCCTCAAAGACAGTGTCCCCTCCACAGCTGGGTGCCAGGGGCAGGGGATCCTCAGTATAGCCGGTGAACCCTGATACCAGGAGCCTGGGCCTCCCTGAACCCCTGGCTTCCAGCCATCTCATCGCCAGCCTCCTCCTGGACCTCTTGGCCCCCAGCCCCTTCCCCACACAGCCCCAGAAGGGTCCCAGAGCTGACCCCACTCCAGGACCTAGGCCCAGCCCCTCAGCCTCATCTGGAGCCCCTGAAGACCAGTCCCACCCACCTTTCTGGCCTCATCTGACACTGCTCCGCATCCTGCTGTGTGTCCTGTTCCATGTTCCGGTTCCATCCAAATACACTTTCTGGAACAAA); 3′UTR-017 (α-globin)(SEQ ID NO. 176) (GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCT GAGTGGGCGGC); or3′UTR-018 (SEQ ID NO. 177)(TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC).

In certain embodiments, the 5′UTR and/or 3′UTR sequence of thedisclosure comprises a nucleotide sequence at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,at least about 96%, at least about 97%, at least about 98%, at leastabout 99%, or about 100% identical to a sequence selected from the groupconsisting of 5′UTR sequences comprising any of the 5′UTR sequencesdisclosed herein and/or 3′UTR sequences comprises any of the 3′UTRsequences disclosed herein, and any combination thereof.

In certain embodiments, the 3′ UTR sequence comprises one or more miRNAbinding sites, e.g., miR-122 binding sites, or any other heterologousnucleotide sequences therein, without disrupting the function of the 3′UTR. Some examples of 3′ UTR sequences comprising a miRNA binding siteare listed in TABLE 6. In some embodiments, the 3′ UTR sequencecomprises a nucleotide sequence at least about 60%, at least about 70%,at least about 80%, at least about 90%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or about 100% identical to a sequence selected from the group consistingof SEQ ID NOs: 238-240. In certain embodiments, the 3′ UTR sequencecomprises a nucleotide sequence at least about 60%, at least about 70%,at least about 80%, at least about 90%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or about 100% identical to SEQ ID NO: 238. In certain embodiments, the3′ UTR sequence comprises a nucleotide sequence at least about 60%, atleast about 70%, at least about 80%, at least about 90%, at least about95%, at least about 96%, at least about 97%, at least about 98%, atleast about 99%, or about 100% identical to SEQ ID NO: 239. In certainembodiments, the 3′ UTR sequence comprises a nucleotide sequence atleast about 60%, at least about 70%, at least about 80%, at least about90%, at least about 95%, at least about 96%, at least about 97%, atleast about 98%, at least about 99%, or about 100% identical to SEQ IDNO: 240.

TABLE 6 Exemplary 3′ UTR with miRNA Binding Sites 3′ UTR Identifier/Name/ miRNA BS Description Sequence SEQ ID NO. 3UTR-018 + miR-122-5pbinding site Downstream URT

SEQ ID NO: 238 3UTR-018 + miR-122-3p binding site Downstream URT

SEQ ID NO: 239 3UTR-019 + DownstreamUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUU SEQ ID NO: 240 miR-122 URTGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUC binding siteCUGCACCCGUACCCCCCAAACACCAUUGUCACACUC CAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC*miRNA binding site is boxed or underlined.

The polynucleotides of the disclosure can comprise combinations offeatures. For example, the ORF can be flanked by a 5′UTR that comprisesa strong Kozak translational initiation signal and/or a 3′UTR comprisingan oligo(dT) sequence for templated addition of a poly-A tail. A 5′UTRcan comprise a first polynucleotide fragment and a second polynucleotidefragment from the same and/or different UTRs (see, e.g., US2010/0293625,herein incorporated by reference in its entirety).

It is also within the scope of the present disclosure to have patternedUTRs. As used herein “patterned UTRs” include a repeating or alternatingpattern, such as ABABAB or AABBAABBAABB or ABCABCABC or variants thereofrepeated once, twice, or more than 3 times. In these patterns, eachletter, A, B, or C represent a different UTR nucleic acid sequence.

Other non-UTR sequences can be used as regions or subregions within thepolynucleotides of the disclosure. For example, introns or portions ofintron sequences can be incorporated into the polynucleotides of thedisclosure. Incorporation of intronic sequences can increase proteinproduction as well as polynucleotide expression levels. In someembodiments, the polynucleotide of the disclosure comprises an internalribosome entry site (IRES) instead of or in addition to a UTR (see,e.g., Yakubov et al., Biochem. Biophys. Res. Commun. 2010394(1):189-193, the contents of which are incorporated herein byreference in their entirety). In some embodiments, the polynucleotide ofthe disclosure comprises 5′ and/or 3′ sequence associated with the 5′and/or 3′ ends of rubella virus (RV) genomic RNA, respectively, ordeletion derivatives thereof, including the 5′ proximal open readingframe of RV RNA encoding nonstructural proteins (e.g., see Pogue et al.,J. Virol. 67(12):7106-7117, the contents of which are incorporatedherein by reference in their entirety). Viral capsid sequences can alsobe used as a translational enhancer, e.g., the 5′ portion of a capsidsequence, (e.g., semliki forest virus and sindbis virus capsid RNAs asdescribed in Sjöberg et al., Biotechnology (NY) 1994 12(11):1127-1131,and Frolov and Schlesinger J. Virol. 1996 70(2): 1182-1190, the contentsof each of which are incorporated herein by reference in theirentirety). In some embodiments, the polynucleotide comprises an IRESinstead of a 5′UTR sequence. In some embodiments, the polynucleotidecomprises an ORF and a viral capsid sequence. In some embodiments, thepolynucleotide comprises a synthetic 5′UTR in combination with anon-synthetic 3′UTR.

In some embodiments, the UTR can also include at least one translationenhancer polynucleotide, translation enhancer element, or translationalenhancer elements (collectively, “TEE,” which refers to nucleic acidsequences that increase the amount of polypeptide or protein producedfrom a polynucleotide. As a non-limiting example, the TEE can includethose described in US2009/0226470, incorporated herein by reference inits entirety, and others known in the art. As a non-limiting example,the TEE can be located between the transcription promoter and the startcodon. In some embodiments, the 5′UTR comprises a TEE.

In one aspect, a TEE is a conserved element in a UTR that can promotetranslational activity of a nucleic acid such as, but not limited to,cap-dependent or cap-independent translation. The conservation of thesesequences has been shown across 14 species including humans. See, e.g.,Panek et al., “An evolutionary conserved pattern of 18S rRNA sequencecomplementarity to mRNA 5′UTRs and its implications for eukaryotic genetranslation regulation,” Nucleic Acids Research 2013, doi:10.1093/nar/gkt548, incorporated herein by reference in its entirety.

In one non-limiting example, the TEE comprises the TEE sequence in the5′-leader of the Gtx homeodomain protein. See Chappell et al., PNAS 2004101:9590-9594, incorporated herein by reference in its entirety.

In another non-limiting example, the TEE comprises a TEE having one ormore of the sequences of SEQ ID NOs: 1-35 in US2009/0226470,US2013/0177581, and WO2009/075886; SEQ ID NOs: 1-5 and 7-645 inWO2012/009644; and SEQ ID NO: 1 WO1999/024595, U.S. Pat. Nos. 6,310,197,and 6,849,405; the contents of each of which are incorporated herein byreference in their entirety.

In some embodiments, the TEE is an internal ribosome entry site (IRES),HCV-IRES, or an IRES element such as, but not limited to, thosedescribed in: U.S. Pat. No. 7,468,275, US2007/0048776, US2011/0124100,WO2007/025008, and WO2001/055369; the contents of each of which reincorporated herein by reference in their entirety. The IRES elementscan include, but are not limited to, the Gtx sequences (e.g., Gtx9-nt,Gtx8-nt, Gtx7-nt) as described by Chappell et al., PNAS 2004101:9590-9594, Zhou et al., PNAS 2005 102:6273-6278, US2007/0048776,US2011/0124100, and WO2007/025008; the contents of each of which areincorporated herein by reference in their entirety.

“Translational enhancer polynucleotide” or “translation enhancerpolynucleotide sequence” refer to a polynucleotide that includes one ormore of the TEE provided herein and/or known in the art (see. e.g., U.S.Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, US2009/0226470,US2007/0048776, US2011/0124100, US2009/0093049, US2013/0177581,WO2009/075886, WO2007/025008, WO2012/009644, WO2001/055371,WO1999/024595, EP2610341A1, and EP2610340A1; the contents of each ofwhich are incorporated herein by reference in their entirety), or theirvariants, homologs, or functional derivatives. In some embodiments, thepolynucleotide of the disclosure comprises one or multiple copies of aTEE. The TEE in a translational enhancer polynucleotide can be organizedin one or more sequence segments. A sequence segment can harbor one ormore of the TEEs provided herein, with each TEE being present in one ormore copies. When multiple sequence segments are present in atranslational enhancer polynucleotide, they can be homogenous orheterogeneous. Thus, the multiple sequence segments in a translationalenhancer polynucleotide can harbor identical or different types of theTEE provided herein, identical or different number of copies of each ofthe TEE, and/or identical or different organization of the TEE withineach sequence segment. In one embodiment, the polynucleotide of thedisclosure comprises a translational enhancer polynucleotide sequence.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure comprises at least one TEE or portion thereof that isdisclosed in: WO1999/024595, WO2012/009644, WO2009/075886,WO2007/025008, WO1999/024595, WO2001/055371, EP2610341A1, EP2610340A1,U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395,US2009/0226470, US2011/0124100, US2007/0048776, US2009/0093049, orUS2013/0177581, the contents of each are incorporated herein byreference in their entirety.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure comprises a TEE that is at least 5%, at least 10%, at least15%, at least 20%, at least 25%, at least 30%, at least 35%, at least40%, at least 45%, at least 50%, at least 55%, at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 85%, at least90%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or 100% identical to a TEE disclosed in: US2009/0226470,US2007/0048776, US2013/0177581, US2011/0124100, WO1999/024595,WO2012/009644, WO2009/075886, WO2007/025008, EP2610341A1, EP2610340A1,U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, Chappell etal., PNAS 2004 101:9590-9594, Zhou et al., PNAS 2005 102:6273-6278, andSupplemental Table 1 and in Supplemental Table 2 of Wellensiek et al.,“Genome-wide profiling of human cap-independent translation-enhancingelements,” Nature Methods 2013, DOI:10.1038/NMETH.2522; the contents ofeach of which are incorporated herein by reference in their entirety.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure comprises a TEE which is selected from a 5-30 nucleotidefragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15nucleotide fragment, or a 5-10 nucleotide fragment (including a fragmentof 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, or 30 nucleotides) of a TEE sequencedisclosed in: US2009/0226470, US2007/0048776, US2013/0177581,US2011/0124100, WO1999/024595, WO2012/009644, WO2009/075886,WO2007/025008, EP2610341A1, EP2610340A1, U.S. Pat. Nos. 6,310,197,6,849,405, 7,456,273, 7,183,395, Chappell et al., PNAS 2004101:9590-9594, Zhou et al., PNAS 2005 102:6273-6278, and SupplementalTable 1 and in Supplemental Table 2 of Wellensiek et al., “Genome-wideprofiling of human cap-independent translation-enhancing elements,”Nature Methods 2013, DOI: 10.103 8/NMETH.2522.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure comprises a TEE which is a transcription regulatory elementdescribed in any of U.S. Pat. Nos. 7,456,273, 7,183,395, US2009/0093049,and WO2001/055371, the contents of each of which are incorporated hereinby reference in their entirety. The transcription regulatory elementscan be identified by methods known in the art, such as, but not limitedto, the methods described in U.S. Pat. Nos. 7,456,273, 7,183,395,US2009/0093049, and WO2001/055371.

In some embodiments, a 5′UTR and/or 3′UTR comprising at least one TEEdescribed herein can be incorporated in a monocistronic sequence suchas, but not limited to, a vector system or a nucleic acid vector. Asnon-limiting examples, the vector systems and nucleic acid vectors caninclude those described in U.S. Pat. Nos. 7,456,273, 7,183,395,US2007/0048776, US2009/0093049, US2011/0124100, WO2007/025008, andWO2001/055371.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure comprises a TEE or portion thereof described herein. In someembodiments, the TEEs in the 3′UTR can be the same and/or different fromthe TEE located in the 5′UTR.

In some embodiments, a 5′UTR and/or 3′UTR of a polynucleotide of thedisclosure can include at least 1, at least 2, at least 3, at least 4,at least 5, at least 6, at least 7, at least 8, at least 9, at least 10,at least 11, at least 12, at least 13, at least 14, at least 15, atleast 16, at least 17, at least 18 at least 19, at least 20, at least21, at least 22, at least 23, at least 24, at least 25, at least 30, atleast 35, at least 40, at least 45, at least 50, at least 55 or morethan 60 TEE sequences. In one embodiment, the 5′UTR of a polynucleotideof the disclosure can include 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30,1-25, 1-20, 1-15, 1-10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 TEE sequences. TheTEE sequences in the 5′UTR of the polynucleotide of the disclosure canbe the same or different TEE sequences. A combination of different TEEsequences in the 5′UTR of the polynucleotide of the disclosure caninclude combinations in which more than one copy of any of the differentTEE sequences are incorporated. The TEE sequences can be in a patternsuch as ABABAB or AABBAABBAABB or ABCABCABC or variants thereof repeatedone, two, three, or more than three times. In these patterns, eachletter, A, B, or C represent a different TEE nucleotide sequence.

In some embodiments, the TEE can be identified by the methods describedin US2007/0048776, US2011/0124100, WO2007/025008, WO2012/009644, thecontents of each of which are incorporated herein by reference in theirentirety.

In some embodiments, the 5′UTR and/or 3′UTR comprises a spacer toseparate two TEE sequences. As a non-limiting example, the spacer can bea 15 nucleotide spacer and/or other spacers known in the art. As anothernon-limiting example, the 5′UTR and/or 3′UTR comprises a TEEsequence-spacer module repeated at least once, at least twice, at least3 times, at least 4 times, at least 5 times, at least 6 times, at least7 times, at least 8 times, at least 9 times, at least 10 times, or morethan 10 times in the 5′UTR and/or 3′UTR, respectively. In someembodiments, the 5′UTR and/or 3′UTR comprises a TEE sequence-spacermodule repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times.

In some embodiments, the spacer separating two TEE sequences can includeother sequences known in the art that can regulate the translation ofthe polynucleotide of the disclosure, e.g., miR sequences describedherein (e.g., miR binding sites and miR seeds). As a non-limitingexample, each spacer used to separate two TEE sequences can include adifferent miR sequence or component of a miR sequence (e.g., miR seedsequence).

In some embodiments, a polynucleotide of the disclosure comprises a miRand/or TEE sequence. In some embodiments, the incorporation of a miRsequence and/or a TEE sequence into a polynucleotide of the disclosurecan change the shape of the stem loop region, which can increase and/ordecrease translation. See e.g., Kedde et al., Nature Cell Biology 201012(10):1014-20, herein incorporated by reference in its entirety).

14. Microrna (miRNA) Binding Sites

Sensor sequences include, for example, microRNA (miRNA) binding sites,transcription factor binding sites, structured mRNA sequences and/ormotifs, artificial binding sites engineered to act as pseudo-receptorsfor endogenous nucleic acid binding molecules, and combinations thereof.Non-limiting examples of sensor sequences are described in U.S.Publication 2014/0200261, the contents of which are incorporated hereinby reference in their entirety.

In some embodiments, a polynucleotide (e.g., a ribonucleic acid (RNA),e.g., a messenger RNA (mRNA)) of the disclosure comprising an openreading frame (ORF) encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides further comprises a sensorsequence. In some embodiments, the sensor sequence is a miRNA bindingsite.

A miRNA is a 19-25 nucleotide long noncoding RNA that binds to apolynucleotide and down-regulates gene expression either by reducingstability or by inhibiting translation of the polynucleotide. A miRNAsequence comprises a “seed” region, i.e., a sequence in the region ofpositions 2-8 of the mature miRNA. A miRNA seed can comprise positions2-8 or 2-7 of the mature miRNA. In some embodiments, a miRNA seed cancomprise 7 nucleotides (e.g., nucleotides 2-8 of the mature miRNA),wherein the seed-complementary site in the corresponding miRNA bindingsite is flanked by an adenosine (A) opposed to miRNA position 1. In someembodiments, a miRNA seed can comprise 6 nucleotides (e.g., nucleotides2-7 of the mature miRNA), wherein the seed-complementary site in thecorresponding miRNA binding site is flanked by an adenosine (A) opposedto miRNA position 1. See, for example, Grimson A, Farh K K, Johnston WK, Garrett-Engele P, Lim L P, Bartel D P; Mol Cell. 2007 Jul. 6;27(1):91-105. miRNA profiling of the target cells or tissues can beconducted to determine the presence or absence of miRNA in the cells ortissues. In some embodiments, a polynucleotide (e.g., a ribonucleic acid(RNA), e.g., a messenger RNA (mRNA)) of the disclosure comprises one ormore microRNA target sequences, microRNA sequences, or microRNA seeds.Such sequences can correspond to any known microRNA such as those taughtin US Publication US2005/0261218 and US Publication US2005/0059005, thecontents of each of which are incorporated herein by reference in theirentirety.

As used herein, the term “microRNA (miRNA or miR) binding site” refersto a sequence within a polynucleotide, e.g., within a DNA or within anRNA transcript, including in the 5′UTR and/or 3′UTR, that has sufficientcomplementarity to all or a region of a miRNA to interact with,associate with or bind to the miRNA. In some embodiments, apolynucleotide of the disclosure comprising an ORF encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides further comprises a miRNA binding site. In exemplaryembodiments, a 5′UTR and/or 3′UTR of the polynucleotide (e.g., aribonucleic acid (RNA), e.g., a messenger RNA (mRNA)) comprises a miRNAbinding site.

A miRNA binding site having sufficient complementarity to a miRNA refersto a degree of complementarity sufficient to facilitate miRNA-mediatedregulation of a polynucleotide, e.g., miRNA-mediated translationalrepression or degradation of the polynucleotide. In exemplary aspects ofthe disclosure, a miRNA binding site having sufficient complementarityto the miRNA refers to a degree of complementarity sufficient tofacilitate miRNA-mediated degradation of the polynucleotide, e.g.,miRNA-guided RNA-induced silencing complex (RISC)-mediated cleavage ofmRNA. The miRNA binding site can have complementarity to, for example, a19-25 nucleotide miRNA sequence, to a 19-23 nucleotide miRNA sequence,or to a 22 nucleotide miRNA sequence. A miRNA binding site can becomplementary to only a portion of a miRNA, e.g., to a portion less than1, 2, 3, or 4 nucleotides of the full length of a naturally-occurringmiRNA sequence. Full or complete complementarity (e.g., fullcomplementarity or complete complementarity over all or a significantportion of the length of a naturally-occurring miRNA) is preferred whenthe desired regulation is mRNA degradation.

In some embodiments, a miRNA binding site includes a sequence that hascomplementarity (e.g., partial or complete complementarity) with anmiRNA seed sequence. In some embodiments, the miRNA binding siteincludes a sequence that has complete complementarity with a miRNA seedsequence. In some embodiments, a miRNA binding site includes a sequencethat has complementarity (e.g., partial or complete complementarity)with an miRNA sequence. In some embodiments, the miRNA binding siteincludes a sequence that has complete complementarity with a miRNAsequence. In some embodiments, a miRNA binding site has completecomplementarity with a miRNA sequence but for 1, 2, or 3 nucleotidesubstitutions, terminal additions, and/or truncations.

In some embodiments, the miRNA binding site is the same length as thecorresponding miRNA. In other embodiments, the miRNA binding site isone, two, three, four, five, six, seven, eight, nine, ten, eleven ortwelve nucleotide(s) shorter than the corresponding miRNA at the 5′terminus, the 3′ terminus, or both. In still other embodiments, themicroRNA binding site is two nucleotides shorter than the correspondingmicroRNA at the 5′ terminus, the 3′ terminus, or both. The miRNA bindingsites that are shorter than the corresponding miRNAs are still capableof degrading the mRNA incorporating one or more of the miRNA bindingsites or preventing the mRNA from translation.

In some embodiments, the miRNA binding site binds to the correspondingmature miRNA that is part of an active RISC containing Dicer. In anotherembodiment, binding of the miRNA binding site to the corresponding miRNAin RISC degrades the mRNA containing the miRNA binding site or preventsthe mRNA from being translated. In some embodiments, the miRNA bindingsite has sufficient complementarity to miRNA so that a RISC complexcomprising the miRNA cleaves the polynucleotide comprising the miRNAbinding site. In other embodiments, the miRNA binding site has imperfectcomplementarity so that a RISC complex comprising the miRNA inducesinstability in the polynucleotide comprising the miRNA binding site. Inanother embodiment, the miRNA binding site has imperfect complementarityso that a RISC complex comprising the miRNA represses transcription ofthe polynucleotide comprising the miRNA binding site.

In some embodiments, the miRNA binding site has one, two, three, four,five, six, seven, eight, nine, ten, eleven or twelve mismatch(es) fromthe corresponding miRNA.

In some embodiments, the miRNA binding site has at least about ten, atleast about eleven, at least about twelve, at least about thirteen, atleast about fourteen, at least about fifteen, at least about sixteen, atleast about seventeen, at least about eighteen, at least about nineteen,at least about twenty, or at least about twenty-one contiguousnucleotides complementary to at least about ten, at least about eleven,at least about twelve, at least about thirteen, at least about fourteen,at least about fifteen, at least about sixteen, at least aboutseventeen, at least about eighteen, at least about nineteen, at leastabout twenty, or at least about twenty-one, respectively, contiguousnucleotides of the corresponding miRNA.

By engineering one or more miRNA binding sites into a polynucleotide ofthe disclosure, the polynucleotide can be targeted for degradation orreduced translation, provided the miRNA in question is available. Thiscan reduce off-target effects upon delivery of the polynucleotide. Forexample, if a polynucleotide of the disclosure is not intended to bedelivered to a tissue or cell but ends up there, then a miRNA abundantin the tissue or cell can inhibit the expression of the gene of interestif one or multiple binding sites of the miRNA are engineered into the5′UTR and/or 3′UTR of the polynucleotide.

Conversely, miRNA binding sites can be removed from polynucleotidesequences in which they naturally occur in order to increase proteinexpression in specific tissues. For example, a binding site for aspecific miRNA can be removed from a polynucleotide to improve proteinexpression in tissues or cells containing the miRNA.

In one embodiment, a polynucleotide of the disclosure can include atleast one miRNA-binding site in the 5′UTR and/or 3′UTR in order todirect cytotoxic or cytoprotective mRNA therapeutics to specific cellssuch as, but not limited to, normal and/or cancerous cells. In anotherembodiment, a polynucleotide of the disclosure can include two, three,four, five, six, seven, eight, nine, ten, or more miRNA-binding sites inthe 5′-UTR and/or 3′-UTR in order to direct cytotoxic or cytoprotectivemRNA therapeutics to specific cells such as, but not limited to, normaland/or cancerous cells.

Regulation of expression in multiple tissues can be accomplished throughintroduction or removal of one or more miRNA binding sites. The decisionwhether to remove or insert a miRNA binding site can be made based onmiRNA expression patterns and/or their profilings in diseases.Identification of miRNAs, miRNA binding sites, and their expressionpatterns and role in biology have been reported (e.g., Bonauer et al.,Curr Drug Targets 2010 11:943-949; Anand and Cheresh Curr Opin Hematol2011 18:171-176; Contreras and Rao Leukemia 2012 26:404-413 (2011 Dec.20. doi: 10.1038/leu.2011.356); Bartel Cell 2009 136:215-233; Landgrafet al, Cell, 2007 129:1401-1414; Gentner and Naldini, Tissue Antigens.2012 80:393-403 and all references therein; each of which isincorporated herein by reference in its entirety).

miRNAs and miRNA binding sites can correspond to any known sequence,including non-limiting examples described in U.S. Publication Nos.2014/0200261, 2005/0261218, and 2005/0059005, each of which areincorporated herein by reference in their entirety.

Examples of tissues where miRNA are known to regulate mRNA, and therebyprotein expression, include, but are not limited to, liver (miR-122),muscle (miR-133, miR-206, miR-208), endothelial cells (miR-17-92,miR-126), myeloid cells (miR-142-3p, miR-142-5p, miR-16, miR-21,miR-223, miR-24, miR-27), adipose tissue (let-7, miR-30c), heart(miR-1d, miR-149), kidney (miR-192, miR-194, miR-204), and lungepithelial cells (let-7, miR-133, miR-126).

Some microRNAs, e.g., miR-122, are abundant in normal tissue but arepresent in much lower levels in cancer or tumor tissue. Thus,engineering microRNA target sequences (i.e., microRNA binding site) intothe polynucleotides encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides (e.g., in a 3′UTR like regionor other region) can effectively target the molecule for degradation orreduced translation in normal tissue (where the microRNA is abundant)while providing high levels of translation in the cancer or tumor tissue(where the microRNA is present in much lower levels). This provides atumor-targeting approach for the methods and compositions of thedisclosure.

Further examples of the miRNA binding sites that can be useful for thepresent disclosure include immune cell specific miRNAs including, butnot limited to, hsa-let-7a-2-3p, hsa-let-7a-3p, hsa-7a-5p, hsa-let-7c,hsa-let-7e-3p, hsa-let-7e-5p, hsa-let-7g-3p, hsa-let-7g-5p,hsa-let-7i-3p, hsa-let-7i-5p, miR-10a-3p, miR-10a-5p, miR-1184,hsa-let-7f-1-3p, hsa-let-7f-2-5p, hsa-let-7f-5p, miR-125b-1-3p,miR-125b-2-3p, miR-125b-5p, miR-1279, miR-130a-3p, miR-130a-5p,miR-132-3p, miR-132-5p, miR-142-3p, miR-142-5p, miR-143-3p, miR-143-5p,miR-146a-3p, miR-146a-5p, miR-146b-3p, miR-146b-5p, miR-147a, miR-147b,miR-148a-5p, miR-148a-3p, miR-150-3p, miR-150-5p, miR-151b, miR-155-3p,miR-155-5p, miR-15a-3p, miR-15a-5p, miR-15b-5p, miR-15b-3p, miR-16-1-3p,miR-16-2-3p, miR-16-5p, miR-17-5p, miR-181a-3p, miR-181a-5p,miR-181a-2-3p, miR-182-3p, miR-182-5p, miR-197-3p, miR-197-5p,miR-21-5p, miR-21-3p, miR-214-3p, miR-214-5p, miR-223-3p, miR-223-5p,miR-221-3p, miR-221-5p, miR-23b-3p, miR-23b-5p, miR-24-1-5p,miR-24-2-5p, miR-24-3p, miR-26a-1-3p, miR-26a-2-3p, miR-26a-5p,miR-26b-3p, miR-26b-5p, miR-27a-3p, miR-27a-5p, miR-27b-3p, miR-27b-5p,miR-28-3p, miR-28-5p, miR-2909, miR-29a-3p, miR-29a-5p, miR-29b-1-5p,miR-29b-2-5p, miR-29c-3p, miR-29c-5p, miR-30e-3p, miR-30e-5p,miR-331-5p, miR-339-3p, miR-339-5p, miR-345-3p, miR-345-5p, miR-346,miR-34a-3p, miR-34a-5p, miR-363-3p, miR-363-5p, miR-372, miR-377-3p,miR-377-5p, miR-493-3p, miR-493-5p, miR-542, miR-548b-5p, miR548c-5p,miR-548i, miR-548j, miR-548n, miR-574-3p, miR-598, miR-718, miR-935,miR-99a-3p, miR-99a-5p, miR-99b-3p, and miR-99b-5p. Furthermore, novelmiRNAs can be identified in immune cell through micro-arrayhybridization and microtome analysis (e.g., Jima D D et al, Blood, 2010,116:e118-e127; Vaz C et al., BMC Genomics, 2010, 11,288, the content ofeach of which is incorporated herein by reference in its entirety.)

MiRNAs that are known to be expressed in the liver include, but are notlimited to, miR-107, miR-122-3p, miR-122-5p, miR-1228-3p, miR-1228-5p,miR-1249, miR-129-5p, miR-1303, miR-151a-3p, miR-151a-5p, miR-152,miR-194-3p, miR-194-5p, miR-199a-3p, miR-199a-5p, miR-199b-3p,miR-199b-5p, miR-296-5p, miR-557, miR-581, miR-939-3p, and miR-939-5p.MiRNA binding sites from any liver specific miRNA can be introduced toor removed from a polynucleotide of the disclosure to regulateexpression of the polynucleotide in the liver. Liver specific miRNAbinding sites can be engineered alone or further in combination withimmune cell (e.g., APC) miRNA binding sites in a polynucleotide of thedisclosure.

MiRNAs that are known to be expressed in the lung include, but are notlimited to, let-7a-2-3p, let-7a-3p, let-7a-5p, miR-126-3p, miR-126-5p,miR-127-3p, miR-127-5p, miR-130a-3p, miR-130a-5p, miR-130b-3p,miR-130b-5p, miR-133a, miR-133b, miR-134, miR-18a-3p, miR-18a-5p,miR-18b-3p, miR-18b-5p, miR-24-1-5p, miR-24-2-5p, miR-24-3p, miR-296-3p,miR-296-5p, miR-32-3p, miR-337-3p, miR-337-5p, miR-381-3p, andmiR-381-5p. MiRNA binding sites from any lung specific miRNA can beintroduced to or removed from a polynucleotide of the disclosure toregulate expression of the polynucleotide in the lung. Lung specificmiRNA binding sites can be engineered alone or further in combinationwith immune cell (e.g., APC) miRNA binding sites in a polynucleotide ofthe disclosure.

MiRNAs that are known to be expressed in the heart include, but are notlimited to, miR-1, miR-133a, miR-133b, miR-149-3p, miR-149-5p,miR-186-3p, miR-186-5p, miR-208a, miR-208b, miR-210, miR-296-3p,miR-320, miR-451a, miR-451b, miR-499a-3p, miR-499a-5p, miR-499b-3p,miR-499b-5p, miR-744-3p, miR-744-5p, miR-92b-3p, and miR-92b-5p. MiRNAbinding sites from any heart specific microRNA can be introduced to orremoved from a polynucleotide of the disclosure to regulate expressionof the polynucleotide in the heart. Heart specific miRNA binding sitescan be engineered alone or further in combination with immune cell(e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.

MiRNAs that are known to be expressed in the nervous system include, butare not limited to, miR-124-5p, miR-125a-3p, miR-125a-5p, miR-125b-1-3p,miR-125b-2-3p, miR-125b-5p, miR-1271-3p, miR-1271-5p, miR-128,miR-132-5p, miR-135a-3p, miR-135a-5p, miR-135b-3p, miR-135b-5p, miR-137,miR-139-5p, miR-139-3p, miR-149-3p, miR-149-5p, miR-153, miR-181c-3p,miR-181c-5p, miR-183-3p, miR-183-5p, miR-190a, miR-190b, miR-212-3p,miR-212-5p, miR-219-1-3p, miR-219-2-3p, miR-23a-3p, miR-23a-5p,miR-30a-5p, miR-30b-3p, miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p,miR-30c-5p, miR-30d-3p, miR-30d-5p, miR-329, miR-342-3p, miR-3665,miR-3666, miR-380-3p, miR-380-5p, miR-383, miR-410, miR-425-3p,miR-425-5p, miR-454-3p, miR-454-5p, miR-483, miR-510, miR-516a-3p,miR-548b-5p, miR-548c-5p, miR-571, miR-7-1-3p, miR-7-2-3p, miR-7-5p,miR-802, miR-922, miR-9-3p, and miR-9-5p. MiRNAs enriched in the nervoussystem further include those specifically expressed in neurons,including, but not limited to, miR-132-3p, miR-132-3p, miR-148b-3p,miR-148b-5p, miR-151a-3p, miR-151a-5p, miR-212-3p, miR-212-5p, miR-320b,miR-320e, miR-323a-3p, miR-323a-5p, miR-324-5p, miR-325, miR-326,miR-328, miR-922 and those specifically expressed in glial cells,including, but not limited to, miR-1250, miR-219-1-3p, miR-219-2-3p,miR-219-5p, miR-23a-3p, miR-23a-5p, miR-3065-3p, miR-3065-5p,miR-30e-3p, miR-30e-5p, miR-32-5p, miR-338-5p, and miR-657. MiRNAbinding sites from any CNS specific miRNA can be introduced to orremoved from a polynucleotide of the disclosure to regulate expressionof the polynucleotide in the nervous system. Nervous system specificmiRNA binding sites can be engineered alone or further in combinationwith immune cell (e.g., APC) miRNA binding sites in a polynucleotide ofthe disclosure.

MiRNAs that are known to be expressed in the pancreas include, but arenot limited to, miR-105-3p, miR-105-5p, miR-184, miR-195-3p, miR-195-5p,miR-196a-3p, miR-196a-5p, miR-214-3p, miR-214-5p, miR-216a-3p,miR-216a-5p, miR-30a-3p, miR-33a-3p, miR-33a-5p, miR-375, miR-7-1-3p,miR-7-2-3p, miR-493-3p, miR-493-5p, and miR-944. MiRNA binding sitesfrom any pancreas specific miRNA can be introduced to or removed from apolynucleotide of the disclosure to regulate expression of thepolynucleotide in the pancreas. Pancreas specific miRNA binding sitescan be engineered alone or further in combination with immune cell (e.g.APC) miRNA binding sites in a polynucleotide of the disclosure.

MiRNAs that are known to be expressed in the kidney include, but are notlimited to, miR-122-3p, miR-145-5p, miR-17-5p, miR-192-3p, miR-192-5p,miR-194-3p, miR-194-5p, miR-20a-3p, miR-20a-5p, miR-204-3p, miR-204-5p,miR-210, miR-216a-3p, miR-216a-5p, miR-296-3p, miR-30a-3p, miR-30a-5p,miR-30b-3p, miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p, miR30c-5p,miR-324-3p, miR-335-3p, miR-335-5p, miR-363-3p, miR-363-5p, and miR-562.MiRNA binding sites from any kidney specific miRNA can be introduced toor removed from a polynucleotide of the disclosure to regulateexpression of the polynucleotide in the kidney. Kidney specific miRNAbinding sites can be engineered alone or further in combination withimmune cell (e.g., APC) miRNA binding sites in a polynucleotide of thedisclosure.

MiRNAs that are known to be expressed in the muscle include, but are notlimited to, let-7g-3p, let-7g-5p, miR-1, miR-1286, miR-133a, miR-133b,miR-140-3p, miR-143-3p, miR-143-5p, miR-145-3p, miR-145-5p, miR-188-3p,miR-188-5p, miR-206, miR-208a, miR-208b, miR-25-3p, and miR-25-5p. MiRNAbinding sites from any muscle specific miRNA can be introduced to orremoved from a polynucleotide of the disclosure to regulate expressionof the polynucleotide in the muscle. Muscle specific miRNA binding sitescan be engineered alone or further in combination with immune cell(e.g., APC) miRNA binding sites in a polynucleotide of the disclosure.

MiRNAs are also differentially expressed in different types of cells,such as, but not limited to, endothelial cells, epithelial cells, andadipocytes.

MiRNAs that are known to be expressed in endothelial cells include, butare not limited to, let-7b-3p, let-7b-5p, miR-100-3p, miR-100-5p,miR-101-3p, miR-101-5p, miR-126-3p, miR-126-5p, miR-1236-3p,miR-1236-5p, miR-130a-3p, miR-130a-5p, miR-17-5p, miR-17-3p, miR-18a-3p,miR-18a-5p, miR-19a-3p, miR-19a-5p, miR-19b-1-5p, miR-19b-2-5p,miR-19b-3p, miR-20a-3p, miR-20a-5p, miR-217, miR-210, miR-21-3p,miR-21-5p, miR-221-3p, miR-221-5p, miR-222-3p, miR-222-5p, miR-23a-3p,miR-23a-5p, miR-296-5p, miR-361-3p, miR-361-5p, miR-421, miR-424-3p,miR-424-5p, miR-513a-5p, miR-92a-1-5p, miR-92a-2-5p, miR-92a-3p,miR-92b-3p, and miR-92b-5p. Many novel miRNAs are discovered inendothelial cells from deep-sequencing analysis (e.g., Voellenkle C etal., RNA, 2012, 18, 472-484, herein incorporated by reference in itsentirety). MiRNA binding sites from any endothelial cell specific miRNAcan be introduced to or removed from a polynucleotide of the disclosureto regulate expression of the polynucleotide in the endothelial cells.

MiRNAs that are known to be expressed in epithelial cells include, butare not limited to, let-7b-3p, let-7b-5p, miR-1246, miR-200a-3p,miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p, miR-200c-5p,miR-338-3p, miR-429, miR-451a, miR-451b, miR-494, miR-802 and miR-34a,miR-34b-5p, miR-34c-5p, miR-449a, miR-449b-3p, miR-449b-5p specific inrespiratory ciliated epithelial cells, let-7 family, miR-133a, miR-133b,miR-126 specific in lung epithelial cells, miR-382-3p, miR-382-5pspecific in renal epithelial cells, and miR-762 specific in cornealepithelial cells. MiRNA binding sites from any epithelial cell specificmiRNA can be introduced to or removed from a polynucleotide of thedisclosure to regulate expression of the polynucleotide in theepithelial cells.

In addition, a large group of miRNAs are enriched in embryonic stemcells, controlling stem cell self-renewal as well as the developmentand/or differentiation of various cell lineages, such as neural cells,cardiac, hematopoietic cells, skin cells, osteogenic cells and musclecells (e.g., Kuppusamy K T et al., Curr. Mol Med, 2013, 13(5), 757-764;Vidigal J A and Ventura A, Semin Cancer Biol. 2012, 22(5-6), 428-436;Goff L A et al., PLoS One, 2009, 4:e7192; Morin R D et al., Genome Res,2008, 18, 610-621; Yoo J K et al., Stem Cells Dev. 2012, 21(11),2049-2057, each of which is herein incorporated by reference in itsentirety). MiRNAs abundant in embryonic stem cells include, but are notlimited to, let-7a-2-3p, let-a-3p, let-7a-5p, let7d-3p, let-7d-5p,miR-103a-2-3p, miR-103a-5p, miR-106b-3p, miR-106b-5p, miR-1246,miR-1275, miR-138-1-3p, miR-138-2-3p, miR-138-5p, miR-154-3p,miR-154-5p, miR-200c-3p, miR-200c-5p, miR-290, miR-301a-3p, miR-301a-5p,miR-302a-3p, miR-302a-5p, miR-302b-3p, miR-302b-5p, miR-302c-3p,miR-302c-5p, miR-302d-3p, miR-302d-5p, miR-302e, miR-367-3p, miR-367-5p,miR-369-3p, miR-369-5p, miR-370, miR-371, miR-373, miR-380-5p,miR-423-3p, miR-423-5p, miR-486-5p, miR-520c-3p, miR-548e, miR-548f,miR-548g-3p, miR-548g-5p, miR-548i, miR-548k, miR-5481, miR-548m,miR-548n, miR-548o-3p, miR-548o-5p, miR-548p, miR-664a-3p, miR-664a-5p,miR-664b-3p, miR-664b-5p, miR-766-3p, miR-766-5p, miR-885-3p,miR-885-5p, miR-93-3p, miR-93-5p, miR-941, miR-96-3p, miR-96-5p,miR-99b-3p and miR-99b-5p. Many predicted novel miRNAs are discovered bydeep sequencing in human embryonic stem cells (e.g., Morin R D et al.,Genome Res, 2008, 18, 610-621; Goff L A et al., PLoS One, 2009, 4:e7192;Bar M et al., Stem cells, 2008, 26, 2496-2505, the content of each ofwhich is incorporated herein by reference in its entirety).

In one embodiment, the binding sites of embryonic stem cell specificmiRNAs can be included in or removed from the 3′UTR of a polynucleotideof the disclosure to modulate the development and/or differentiation ofembryonic stem cells, to inhibit the senescence of stem cells in adegenerative condition (e.g. degenerative diseases), or to stimulate thesenescence and apoptosis of stem cells in a disease condition (e.g.cancer stem cells).

Many miRNA expression studies are conducted to profile the differentialexpression of miRNAs in various cancer cells/tissues and other diseases.Some miRNAs are abnormally over-expressed in certain cancer cells andothers are under-expressed. For example, miRNAs are differentiallyexpressed in cancer cells (WO2008/154098, US2013/0059015,US2013/0042333, WO2011/157294); cancer stem cells (US2012/0053224);pancreatic cancers and diseases (US2009/0131348, US2011/0171646,US2010/0286232, U.S. Pat. No. 8,389,210); asthma and inflammation (U.S.Pat. No. 8,415,096); prostate cancer (US2013/0053264); hepatocellularcarcinoma (WO2012/151212, US2012/0329672, WO2008/054828, U.S. Pat. No.8,252,538); lung cancer cells (WO2011/076143, WO2013/033640,WO2009/070653, US2010/0323357); cutaneous T cell lymphoma(WO2013/011378); colorectal cancer cells (WO2011/0281756,WO2011/076142); cancer positive lymph nodes (WO2009/100430,US2009/0263803); nasopharyngeal carcinoma (EP2112235); chronicobstructive pulmonary disease (US2012/0264626, US2013/0053263); thyroidcancer (WO2013/066678); ovarian cancer cells (US2012/0309645,WO2011/095623); breast cancer cells (WO2008/154098, WO2007/081740,US2012/0214699), leukemia and lymphoma (WO2008/073915, US2009/0092974,US2012/0316081, US2012/0283310, WO2010/018563, the content of each ofwhich is incorporated herein by reference in its entirety.)

As a non-limiting example, miRNA binding sites for miRNAs that areover-expressed in certain cancer and/or tumor cells can be removed fromthe 3′UTR of a polynucleotide of the disclosure, restoring theexpression suppressed by the over-expressed miRNAs in cancer cells, thusameliorating the corresponsive biological function, for instance,transcription stimulation and/or repression, cell cycle arrest,apoptosis and cell death. Normal cells and tissues, wherein miRNAsexpression is not up-regulated, will remain unaffected.

MiRNA can also regulate complex biological processes such asangiogenesis (e.g., miR-132) (Anand and Cheresh Curr Opin Hematol 201118:171-176). In the polynucleotides of the disclosure, miRNA bindingsites that are involved in such processes can be removed or introduced,in order to tailor the expression of the polynucleotides to biologicallyrelevant cell types or relevant biological processes. In this context,the polynucleotides of the disclosure are defined as auxotrophicpolynucleotides.

In some embodiments, the microRNA binding site (e.g., miR-122 bindingsite) is fully complementary to miRNA (e.g., miR-122), thereby degradingthe mRNA fused to the miRNA binding site. In other embodiments, themiRNA binding site is not fully complementary to the correspondingmiRNA. In certain embodiments, the miRNA binding site (e.g., miR-122binding site) is the same length as the corresponding miRNA (e.g.,miR-122). In other embodiments, the microRNA binding site (e.g., miR-122binding site) is one nucleotide shorter than the corresponding microRNA(e.g., miR-122, which has 22 nts) at the 5′ terminus, the 3′ terminus,or both. In still other embodiments, the microRNA binding site (e.g.,miR-122 binding site) is two nucleotides shorter than the correspondingmicroRNA (e.g., miR-122) at the 5′ terminus, the 3′ terminus, or both.In yet other embodiments, the microRNA binding site (e.g., miR-122binding site) is three nucleotides shorter than the correspondingmicroRNA (e.g., miR-122) at the 5′ terminus, the 3′ terminus, or both.In some embodiments, the microRNA binding site (e.g., miR-122 bindingsite) is four nucleotides shorter than the corresponding microRNA (e.g.,miR-122) at the 5′ terminus, the 3′ terminus, or both. In otherembodiments, the microRNA binding site (e.g., miR-122 binding site) isfive nucleotides shorter than the corresponding microRNA (e.g., miR-122)at the 5′ terminus, the 3′ terminus, or both. In some embodiments, themicroRNA binding site (e.g., miR-122 binding site) is six nucleotidesshorter than the corresponding microRNA (e.g., miR-122) at the 5′terminus, the 3′ terminus, or both. In other embodiments, the microRNAbinding site (e.g., miR-122 binding site) is seven nucleotides shorterthan the corresponding microRNA (e.g., miR-122) at the 5′ terminus orthe 3′ terminus. In other embodiments, the microRNA binding site (e.g.,miR-122 binding site) is eight nucleotides shorter than thecorresponding microRNA (e.g., miR-122) at the 5′ terminus or the 3′terminus. In other embodiments, the microRNA binding site (e.g., miR-122binding site) is nine nucleotides shorter than the correspondingmicroRNA (e.g., miR-122) at the 5′ terminus or the 3′ terminus. In otherembodiments, the microRNA binding site (e.g., miR-122 binding site) isten nucleotides shorter than the corresponding microRNA (e.g., miR-122)at the 5′ terminus or the 3′ terminus. In other embodiments, themicroRNA binding site (e.g., miR-122 binding site) is eleven nucleotidesshorter than the corresponding microRNA (e.g., miR-122) at the 5′terminus or the 3′ terminus. In other embodiments, the microRNA bindingsite (e.g., miR-122 binding site) is twelve nucleotides shorter than thecorresponding microRNA (e.g., miR-122) at the 5′ terminus or the 3′terminus. The miRNA binding sites that are shorter than thecorresponding miRNAs are still capable of degrading the mRNAincorporating one or more of the miRNA binding sites or preventing themRNA from translation.

In some embodiments, the microRNA binding site (e.g., miR-122 bindingsite) has sufficient complementarity to miRNA (e.g., miR-122) so that aRISC complex comprising the miRNA (e.g., miR-122) cleaves thepolynucleotide comprising the microRNA binding site. In otherembodiments, the microRNA binding site (e.g., miR-122 binding site) hasimperfect complementarity so that a RISC complex comprising the miRNA(e.g., miR-122) induces instability in the polynucleotide comprising themicroRNA binding site. In another embodiment, the microRNA binding site(e.g., miR-122 binding site) has imperfect complementarity so that aRISC complex comprising the miRNA (e.g., miR-122) repressestranscription of the polynucleotide comprising the microRNA bindingsite. In one embodiment, the miRNA binding site (e.g., miR-122 bindingsite) has one mismatch from the corresponding miRNA (e.g., miR-122). Inanother embodiment, the miRNA binding site has two mismatches from thecorresponding miRNA. In other embodiments, the miRNA binding site hasthree mismatches from the corresponding miRNA. In other embodiments, themiRNA binding site has four mismatches from the corresponding miRNA. Insome embodiments, the miRNA binding site has five mismatches from thecorresponding miRNA. In other embodiments, the miRNA binding site hassix mismatches from the corresponding miRNA. In certain embodiments, themiRNA binding site has seven mismatches from the corresponding miRNA. Inother embodiments, the miRNA binding site has eight mismatches from thecorresponding miRNA. In other embodiments, the miRNA binding site hasnine mismatches from the corresponding miRNA. In other embodiments, themiRNA binding site has ten mismatches from the corresponding miRNA. Inother embodiments, the miRNA binding site has eleven mismatches from thecorresponding miRNA. In other embodiments, the miRNA binding site hastwelve mismatches from the corresponding miRNA.

In certain embodiments, the miRNA binding site (e.g., miR-122 bindingsite) has at least about ten contiguous nucleotides complementary to atleast about ten contiguous nucleotides of the corresponding miRNA (e.g.,miR-122), at least about eleven contiguous nucleotides complementary toat least about eleven contiguous nucleotides of the corresponding miRNA,at least about twelve contiguous nucleotides complementary to at leastabout twelve contiguous nucleotides of the corresponding miRNA, at leastabout thirteen contiguous nucleotides complementary to at least aboutthirteen contiguous nucleotides of the corresponding miRNA, or at leastabout fourteen contiguous nucleotides complementary to at least aboutfourteen contiguous nucleotides of the corresponding miRNA. In someembodiments, the miRNA binding sites have at least about fifteencontiguous nucleotides complementary to at least about fifteencontiguous nucleotides of the corresponding miRNA, at least aboutsixteen contiguous nucleotides complementary to at least about sixteencontiguous nucleotides of the corresponding miRNA, at least aboutseventeen contiguous nucleotides complementary to at least aboutseventeen contiguous nucleotides of the corresponding miRNA, at leastabout eighteen contiguous nucleotides complementary to at least abouteighteen contiguous nucleotides of the corresponding miRNA, at leastabout nineteen contiguous nucleotides complementary to at least aboutnineteen contiguous nucleotides of the corresponding miRNA, at leastabout twenty contiguous nucleotides complementary to at least abouttwenty contiguous nucleotides of the corresponding miRNA, or at leastabout twenty one contiguous nucleotides complementary to at least abouttwenty one contiguous nucleotides of the corresponding miRNA.

In some embodiments, the polynucleotides comprise an mRNA encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides and at least one miR-122 binding site, at least two miR-122binding sites, at least three miR-122 binding sites, at least fourmiR-122 binding sites, or at least five miR-122 binding sites. In oneaspect, the miRNA binding site binds miR-122 or is complementary tomiR-122. In another aspect, the miRNA binding site binds to miR-122-3por miR-122-5p. In a particular aspect, the miRNA binding site comprisesa nucleotide sequence at least 80%, at least 85%, at least 90%, at least95%, or 100% identical to SEQ ID NO: 52 or 54, wherein the miRNA bindingsite binds to miR-122. In another particular aspect, the miRNA bindingsite comprises a nucleotide sequence at least 80%, at least 85%, atleast 90%, at least 95%, or 100% identical to SEQ ID NO: 54, wherein themiRNA binding site binds to miR-122. These sequences are shown below inTable 7.

TABLE 7 miR-122 and miR-122 binding sites SEQ ID NO. DescriptionSequence SEQ ID NO: 50 miR-122 CCUUAGCAGAGCUGUGGAGUGUGACAAUGGUGUUUGUGUCUAAACUAU CAAACGCCAUUAUCACACUAAAUA GCUACUGCUAGGC SEQ IDNO: 51 miR-122-3p AACGCCAUUAUCACACUAAAUA SEQ ID NO: 52 miR-122-3pUAUUUAGUGUGAUAAUGGCGUU binding site SEQ ID NO: 53 miR-122-5pUGGAGUGUGACAAUGGUGUUUG SEQ ID NO: 54 miR-122-5p CAAACACCAUUGUCACACUCCAbinding site

In some embodiments, a miRNA binding site (e.g., miR-122 binding site)is inserted in the polynucleotide of the disclosure in any position ofthe polynucleotide (e.g., 3′ UTR); the insertion site in thepolynucleotide can be anywhere in the polynucleotide as long as theinsertion of the miRNA binding site in the polynucleotide does notinterfere with the translation of the functional IL12B polypeptide,IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides in theabsence of the corresponding miRNA (e.g., miR-122); and in the presenceof the miRNA (e.g., miR-122), the insertion of the miRNA binding site inthe polynucleotide and the binding of the miRNA binding site to thecorresponding miRNA are capable of degrading the polynucleotide orpreventing the translation of the polynucleotide. In one embodiment, amiRNA binding site is inserted in a 3′UTR of the polynucleotide.

In certain embodiments, a miRNA binding site is inserted in at leastabout 30 nucleotides downstream from the stop codon of the an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides-encoding mRNA. In other embodiments, a miRNA binding siteis inserted in at least about 10 nucleotides, at least about 15nucleotides, at least about 20 nucleotides, at least about 25nucleotides, at least about 30 nucleotides, at least about 35nucleotides, at least about 40 nucleotides, at least about 45nucleotides, at least about 50 nucleotides, at least about 55nucleotides, at least about 60 nucleotides, at least about 65nucleotides, at least about 70 nucleotides, at least about 75nucleotides, at least about 80 nucleotides, at least about 85nucleotides, at least about 90 nucleotides, at least about 95nucleotides, or at least about 100 nucleotides downstream from the stopcodon of the polynucleotide, e.g., the IL12B polypeptide, IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides encoding mRNA.In other embodiments, a miRNA binding site is inserted in about 10nucleotides to about 100 nucleotides, about 20 nucleotides to about 90nucleotides, about 30 nucleotides to about 80 nucleotides, about 40nucleotides to about 70 nucleotides, about 50 nucleotides to about 60nucleotides, about 45 nucleotides to about 65 nucleotides downstreamfrom the stop codon of the polynucleotide, e.g., the IL12B polypeptide,IL12A polypeptide, and/or IL12B and IL12A fusion polypeptides-encodingmRNA. In some embodiments, the miRNA binding site is inserted downstreamof the stop codon in the nucleic acid sequence encoding an IL12polypeptide as disclosed herein. In some embodiments, the miRNA bindingsite is inserted downstream of the stop codon in the nucleic acidsequence encoding membrane domain as disclosed herein. In someembodiments, the miRNA binding site is inserted downstream of the stopcodon in the nucleic acid sequence encoding heterologous polypeptide asdisclosed herein.

In some embodiments, a miRNA binding site is inserted in thepolynucleotide of the disclosure in any position of the polynucleotide(e.g., the 5′UTR and/or 3′UTR). In some embodiments, the 5′UTR comprisesa miRNA binding site. In some embodiments, the 3′UTR comprises a miRNAbinding site. In some embodiments, the 5′UTR and the 3′UTR comprise amiRNA binding site. The insertion site in the polynucleotide can beanywhere in the polynucleotide as long as the insertion of the miRNAbinding site in the polynucleotide does not interfere with thetranslation of a functional polypeptide in the absence of thecorresponding miRNA; and in the presence of the miRNA, the insertion ofthe miRNA binding site in the polynucleotide and the binding of themiRNA binding site to the corresponding miRNA are capable of degradingthe polynucleotide or preventing the translation of the polynucleotide.

In some embodiments, a miRNA binding site is inserted in at least about30 nucleotides downstream from the stop codon of an ORF in apolynucleotide of the disclosure comprising the ORF. In someembodiments, a miRNA binding site is inserted in at least about 10nucleotides, at least about 15 nucleotides, at least about 20nucleotides, at least about 25 nucleotides, at least about 30nucleotides, at least about 35 nucleotides, at least about 40nucleotides, at least about 45 nucleotides, at least about 50nucleotides, at least about 55 nucleotides, at least about 60nucleotides, at least about 65 nucleotides, at least about 70nucleotides, at least about 75 nucleotides, at least about 80nucleotides, at least about 85 nucleotides, at least about 90nucleotides, at least about 95 nucleotides, or at least about 100nucleotides downstream from the stop codon of an ORF in a polynucleotideof the disclosure. In some embodiments, a miRNA binding site is insertedin about 10 nucleotides to about 100 nucleotides, about 20 nucleotidesto about 90 nucleotides, about 30 nucleotides to about 80 nucleotides,about 40 nucleotides to about 70 nucleotides, about 50 nucleotides toabout 60 nucleotides, about 45 nucleotides to about 65 nucleotidesdownstream from the stop codon of an ORF in a polynucleotide of thedisclosure.

MiRNA gene regulation can be influenced by the sequence surrounding themiRNA such as, but not limited to, the species of the surroundingsequence, the type of sequence (e.g., heterologous, homologous,exogenous, endogenous, or artificial), regulatory elements in thesurrounding sequence and/or structural elements in the surroundingsequence. The miRNA can be influenced by the 5′UTR and/or 3′UTR. As anon-limiting example, a non-human 3′UTR can increase the regulatoryeffect of the miRNA sequence on the expression of a polypeptide ofinterest compared to a human 3′UTR of the same sequence type.

In one embodiment, other regulatory elements and/or structural elementsof the 5′UTR can influence miRNA mediated gene regulation. One exampleof a regulatory element and/or structural element is a structured IRES(Internal Ribosome Entry Site) in the 5′UTR, which is necessary for thebinding of translational elongation factors to initiate proteintranslation. EIF4A2 binding to this secondarily structured element inthe 5′-UTR is necessary for miRNA mediated gene expression (Meijer H Aet al., Science, 2013, 340, 82-85, herein incorporated by reference inits entirety). The polynucleotides of the disclosure can further includethis structured 5′UTR in order to enhance microRNA mediated generegulation.

At least one miRNA binding site can be engineered into the 3′UTR of apolynucleotide of the disclosure. In this context, at least two, atleast three, at least four, at least five, at least six, at least seven,at least eight, at least nine, at least ten, or more miRNA binding sitescan be engineered into a 3′UTR of a polynucleotide of the disclosure.For example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1to 3, 2, or 1 miRNA binding sites can be engineered into the 3′UTR of apolynucleotide of the disclosure. In one embodiment, miRNA binding sitesincorporated into a polynucleotide of the disclosure can be the same orcan be different miRNA sites. A combination of different miRNA bindingsites incorporated into a polynucleotide of the disclosure can includecombinations in which more than one copy of any of the different miRNAsites are incorporated. In another embodiment, miRNA binding sitesincorporated into a polynucleotide of the disclosure can target the sameor different tissues in the body. As a non-limiting example, through theintroduction of tissue-, cell-type-, or disease-specific miRNA bindingsites in the 3′-UTR of a polynucleotide of the disclosure, the degree ofexpression in specific cell types (e.g., hepatocytes, myeloid cells,endothelial cells, cancer cells, etc.) can be reduced.

In one embodiment, a miRNA binding site can be engineered near the 5′terminus of the 3′UTR, about halfway between the 5′ terminus and 3′terminus of the 3′UTR and/or near the 3′ terminus of the 3′UTR in apolynucleotide of the disclosure. As a non-limiting example, a miRNAbinding site can be engineered near the 5′ terminus of the 3′UTR andabout halfway between the 5′ terminus and 3′ terminus of the 3′UTR. Asanother non-limiting example, a miRNA binding site can be engineerednear the 3′ terminus of the 3′UTR and about halfway between the 5′terminus and 3′ terminus of the 3′UTR. As yet another non-limitingexample, a miRNA binding site can be engineered near the 5′ terminus ofthe 3′UTR and near the 3′ terminus of the 3′UTR.

In another embodiment, a 3′UTR can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9,or 10 miRNA binding sites. The miRNA binding sites can be complementaryto a miRNA, miRNA seed sequence, and/or miRNA sequences flanking theseed sequence.

In one embodiment, a polynucleotide of the disclosure can be engineeredto include more than one miRNA site expressed in different tissues ordifferent cell types of a subject. As a non-limiting example, apolynucleotide of the disclosure can be engineered to include miR-192and miR-122 to regulate expression of the polynucleotide in the liverand kidneys of a subject. In another embodiment, a polynucleotide of thedisclosure can be engineered to include more than one miRNA site for thesame tissue.

In some embodiments, the therapeutic window and or differentialexpression associated with the polypeptide encoded by a polynucleotideof the disclosure can be altered with a miRNA binding site. For example,a polynucleotide encoding a polypeptide that provides a death signal canbe designed to be more highly expressed in cancer cells by virtue of themiRNA signature of those cells. Where a cancer cell expresses a lowerlevel of a particular miRNA, the polynucleotide encoding the bindingsite for that miRNA (or miRNAs) would be more highly expressed. Hence,the polypeptide that provides a death signal triggers or induces celldeath in the cancer cell. Neighboring noncancer cells, harboring ahigher expression of the same miRNA would be less affected by theencoded death signal as the polynucleotide would be expressed at a lowerlevel due to the effects of the miRNA binding to the binding site or“sensor” encoded in the 3′UTR. Conversely, cell survival orcytoprotective signals can be delivered to tissues containing cancer andnon-cancerous cells where a miRNA has a higher expression in the cancercells—the result being a lower survival signal to the cancer cell and alarger survival signal to the normal cell. Multiple polynucleotides canbe designed and administered having different signals based on the useof miRNA binding sites as described herein.

In some embodiments, the expression of a polynucleotide of thedisclosure can be controlled by incorporating at least one sensorsequence in the polynucleotide and formulating the polynucleotide foradministration. As a non-limiting example, a polynucleotide of thedisclosure can be targeted to a tissue or cell by incorporating a miRNAbinding site and formulating the polynucleotide in a lipid nanoparticlecomprising a cationic lipid, including any of the lipids describedherein.

A polynucleotide of the disclosure can be engineered for more targetedexpression in specific tissues, cell types, or biological conditionsbased on the expression patterns of miRNAs in the different tissues,cell types, or biological conditions. Through introduction oftissue-specific miRNA binding sites, a polynucleotide of the disclosurecan be designed for optimal protein expression in a tissue or cell, orin the context of a biological condition.

In some embodiments, a polynucleotide of the disclosure can be designedto incorporate miRNA binding sites that either have 100% identity toknown miRNA seed sequences or have less than 100% identity to miRNA seedsequences. In some embodiments, a polynucleotide of the disclosure canbe designed to incorporate miRNA binding sites that have at least: 60%,65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity toknown miRNA seed sequences. The miRNA seed sequence can be partiallymutated to decrease miRNA binding affinity and as such result in reduceddownmodulation of the polynucleotide. In essence, the degree of match ormis-match between the miRNA binding site and the miRNA seed can act as arheostat to more finely tune the ability of the miRNA to modulateprotein expression. In addition, mutation in the non-seed region of amiRNA binding site can also impact the ability of a miRNA to modulateprotein expression.

In one embodiment, a miRNA sequence can be incorporated into the loop ofa stem loop.

In another embodiment, a miRNA seed sequence can be incorporated in theloop of a stem loop and a miRNA binding site can be incorporated intothe 5′ or 3′ stem of the stem loop.

In one embodiment, a translation enhancer element (TEE) can beincorporated on the 5′end of the stem of a stem loop and a miRNA seedcan be incorporated into the stem of the stem loop. In anotherembodiment, a TEE can be incorporated on the 5′ end of the stem of astem loop, a miRNA seed can be incorporated into the stem of the stemloop and a miRNA binding site can be incorporated into the 3′ end of thestem or the sequence after the stem loop. The miRNA seed and the miRNAbinding site can be for the same and/or different miRNA sequences.

In one embodiment, the incorporation of a miRNA sequence and/or a TEEsequence changes the shape of the stem loop region which can increaseand/or decrease translation. (see e.g., Kedde et al., “A Pumilio-inducedRNA structure switch in p27-3′UTR controls miR-221 and miR-22accessibility.” Nature Cell Biology. 2010, incorporated herein byreference in its entirety).

In one embodiment, the 5′-UTR of a polynucleotide of the disclosure cancomprise at least one miRNA sequence. The miRNA sequence can be, but isnot limited to, a 19 or 22 nucleotide sequence and/or a miRNA sequencewithout the seed.

In one embodiment the miRNA sequence in the 5′UTR can be used tostabilize a polynucleotide of the disclosure described herein.

In another embodiment, a miRNA sequence in the 5′UTR of a polynucleotideof the disclosure can be used to decrease the accessibility of the siteof translation initiation such as, but not limited to a start codon.See, e.g., Matsuda et al., PLoS One. 2010 11(5):e15057; incorporatedherein by reference in its entirety, which used antisense locked nucleicacid (LNA) oligonucleotides and exon-junction complexes (EJCs) around astart codon (˜4 to +37 where the A of the AUG codons is +1) in order todecrease the accessibility to the first start codon (AUG). Matsudashowed that altering the sequence around the start codon with an LNA orEJC affected the efficiency, length and structural stability of apolynucleotide. A polynucleotide of the disclosure can comprise a miRNAsequence, instead of the LNA or EJC sequence described by Matsuda et al,near the site of translation initiation in order to decrease theaccessibility to the site of translation initiation. The site oftranslation initiation can be prior to, after or within the miRNAsequence. As a non-limiting example, the site of translation initiationcan be located within a miRNA sequence such as a seed sequence orbinding site. As another non-limiting example, the site of translationinitiation may be located within a miR-122 sequence such as the seedsequence or the mir-122 binding site.

In some embodiments, a polynucleotide of the disclosure can include atleast one miRNA in order to dampen expression of the encoded polypeptidein a tissue or cell of interest. As a non-limiting example, apolynucleotide of the disclosure can include at least one miR-122binding site in order to dampen expression of an encoded polypeptide ofinterest in the liver. As another non-limiting example a polynucleotideof the disclosure can include at least one miR-142-3p binding site,miR-142-3p seed sequence, miR-142-3p binding site without the seed,miR-142-5p binding site, miR-142-5p seed sequence, miR-142-5p bindingsite without the seed, miR-146 binding site, miR-146 seed sequenceand/or miR-146 binding site without the seed sequence.

In some embodiments, a polynucleotide of the disclosure can comprise atleast one miRNA binding site in the 3′UTR in order to selectivelydegrade mRNA therapeutics in the immune cells to subdue unwantedimmunogenic reactions caused by therapeutic delivery. As a non-limitingexample, the miRNA binding site can make a polynucleotide of thedisclosure more unstable in antigen presenting cells. Non-limitingexamples of these miRNAs include mir-122-5p or mir-122-3p.

In one embodiment, a polynucleotide of the disclosure comprises at leastone miRNA sequence in a region of the polynucleotide that can interactwith a RNA binding protein.

In some embodiments, the polynucleotide of the disclosure (e.g., a RNA,e.g., an mRNA) comprising (i) a sequence-optimized nucleotide sequence(e.g., an ORF) encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides (e.g., the wild-typesequence, functional fragment, or variant thereof) and (ii) a miRNAbinding site (e.g., a miRNA binding site that binds to miR-122).

In some embodiments, the polynucleotide of the disclosure comprises auracil-modified sequence encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides disclosed hereinand a miRNA binding site disclosed herein, e.g., a miRNA binding sitethat binds to miR-122. In some embodiments, the uracil-modified sequenceencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B andIL12A fusion polypeptides comprises at least one chemically modifiednucleobase, e.g., 5-methoxyuracil. In some embodiments, at least 95% ofa type of nucleobase (e.g., uracil) in a uracil-modified sequenceencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B andIL12A fusion polypeptides of the disclosure are modified nucleobases. Insome embodiments, at least 95% of uracil in a uracil-modified sequenceencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B andIL12A fusion polypeptides is 5-methoxyuridine. In some embodiments, thepolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides disclosed herein and a miRNA binding site is formulatedwith a delivery agent, e.g., a compound having the Formula (I), e.g.,any of Compounds 1-147 or any of Compounds 1-232.

15. 3′ UTR and the AU Rich Elements

In certain embodiments, a polynucleotide of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence (e.g., an ORF)encoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B andIL12A fusion polypeptides of the disclosure) further comprises a 3′ UTR.

3′-UTR is the section of mRNA that immediately follows the translationtermination codon and often contains regulatory regions thatpost-transcriptionally influence gene expression. Regulatory regionswithin the 3′-UTR can influence polyadenylation, translation efficiency,localization, and stability of the mRNA. In one embodiment, the 3′-UTRuseful for the disclosure comprises a binding site for regulatoryproteins or microRNAs. In some embodiments, the 3′-UTR has a silencerregion, which binds to repressor proteins and inhibits the expression ofthe mRNA. In other embodiments, the 3′-UTR comprises an AU-rich element.Proteins bind AREs to affect the stability or decay rate of transcriptsin a localized manner or affect translation initiation. In otherembodiments, the 3′-UTR comprises the sequence AAUAAA that directsaddition of several hundred adenine residues called the poly(A) tail tothe end of the mRNA transcript.

Natural or wild type 3′ UTRs are known to have stretches of Adenosinesand Uridines embedded in them. These AU rich signatures are particularlyprevalent in genes with high rates of turnover. Based on their sequencefeatures and functional properties, the AU rich elements (AREs) can beseparated into three classes (Chen et al, 1995): Class I AREs containseveral dispersed copies of an AUUUA motif within U-rich regions. C-Mycand MyoD contain class I AREs. Class II AREs possess two or moreoverlapping UUAUUUA(U/A)(U/A) nonamers. Molecules containing this typeof AREs include GM-CSF and TNF-α. Class III ARES are less well defined.These U rich regions do not contain an AUUUA motif. c-Jun and Myogeninare two well-studied examples of this class. Most proteins binding tothe AREs are known to destabilize the messenger, whereas members of theELAV family, most notably HuR, have been documented to increase thestability of mRNA. HuR binds to AREs of all the three classes.Engineering the HuR specific binding sites into the 3′ UTR of nucleicacid molecules will lead to HuR binding and thus, stabilization of themessage in vivo.

Introduction, removal or modification of 3′ UTR AU rich elements (AREs)can be used to modulate the stability of polynucleotides of thedisclosure. When engineering specific polynucleotides, one or morecopies of an ARE can be introduced to make polynucleotides of thedisclosure less stable and thereby curtail translation and decreaseproduction of the resultant protein. Likewise, AREs can be identifiedand removed or mutated to increase the intracellular stability and thusincrease translation and production of the resultant protein.Transfection experiments can be conducted in relevant cell lines, usingpolynucleotides of the disclosure and protein production can be assayedat various time points post-transfection. For example, cells can betransfected with different ARE-engineering molecules and by using anELISA kit to the relevant protein and assaying protein produced at 6hour, 12 hour, 24 hour, 48 hour, and 7 days post-transfection.

In certain embodiments, the 3′ UTR useful for the polynucleotides of thedisclosure comprises a 3′UTR selected from those shown in thisapplication.

In certain embodiments, the 3′ UTR sequence useful for the disclosurecomprises a nucleotide sequence at least about 60%, at least about 70%,at least about 80%, at least about 90%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or about 100% identical to a sequence selected from the group consistingof 3′UTR sequences listed herein and any combination thereof.

16. Regions Having a 5′ Cap

The disclosure also includes a polynucleotide that comprises both a 5′Cap and a polynucleotide of the present disclosure (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides).

The 5′ cap structure of a natural mRNA is involved in nuclear export,increasing mRNA stability and binds the mRNA Cap Binding Protein (CBP),which is responsible for mRNA stability in the cell and translationcompetency through the association of CBP with poly(A) binding proteinto form the mature cyclic mRNA species. The cap further assists theremoval of 5′ proximal introns during mRNA splicing.

Endogenous mRNA molecules can be 5′-end capped generating a5′-ppp-5′-triphosphate linkage between a terminal guanosine cap residueand the 5′-terminal transcribed sense nucleotide of the mRNA molecule.This 5′-guanylate cap can then be methylated to generate anN7-methyl-guanylate residue. The ribose sugars of the terminal and/oranteterminal transcribed nucleotides of the 5′ end of the mRNA canoptionally also be 2′-O-methylated. 5′-decapping through hydrolysis andcleavage of the guanylate cap structure can target a nucleic acidmolecule, such as an mRNA molecule, for degradation.

In some embodiments, the polynucleotides of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) incorporate a cap moiety.

In some embodiments, polynucleotides of the present disclosure (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) comprise a non-hydrolyzable cap structure preventingdecapping and thus increasing mRNA half-life. Because cap structurehydrolysis requires cleavage of 5′-ppp-5′ phosphorodiester linkages,modified nucleotides can be used during the capping reaction. Forexample, a Vaccinia Capping Enzyme from New England Biolabs (Ipswich,Mass.) can be used with α-thio-guanosine nucleotides according to themanufacturer's instructions to create a phosphorothioate linkage in the5′-ppp-5′ cap. Additional modified guanosine nucleotides can be usedsuch as α-methyl-phosphonate and seleno-phosphate nucleotides.

Additional modifications include, but are not limited to,2′-O-methylation of the ribose sugars of 5′-terminal and/or5′-anteterminal nucleotides of the polynucleotide (as mentioned above)on the 2′-hydroxyl group of the sugar ring. Multiple distinct 5′-capstructures can be used to generate the 5′-cap of a nucleic acidmolecule, such as a polynucleotide that functions as an mRNA molecule.Cap analogs, which herein are also referred to as synthetic cap analogs,chemical caps, chemical cap analogs, or structural or functional capanalogs, differ from natural (i.e., endogenous, wild-type orphysiological) 5′-caps in their chemical structure, while retaining capfunction. Cap analogs can be chemically (i.e., non-enzymatically) orenzymatically synthesized and/or linked to the polynucleotides of thedisclosure.

For example, the Anti-Reverse Cap Analog (ARCA) cap contains twoguanines linked by a 5′-5′-triphosphate group, wherein one guaninecontains an N7 methyl group as well as a 3′-O-methyl group (i.e.,N7,3′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine (m⁷G-3′mppp-G;which may equivalently be designated 3′ O-Me-m7G(5′)ppp(5′)G). The 3′-0atom of the other, unmodified, guanine becomes linked to the 5′-terminalnucleotide of the capped polynucleotide. The N7- and 3′-O-methlyatedguanine provides the terminal moiety of the capped polynucleotide.

Another exemplary cap is mCAP, which is similar to ARCA but has a2′-O-methyl group on guanosine (i.e.,N7,2′-O-dimethyl-guanosine-5′-triphosphate-5′-guanosine, m⁷Gm-ppp-G).

In some embodiments, the cap is a dinucleotide cap analog. As anon-limiting example, the dinucleotide cap analog can be modified atdifferent phosphate positions with a boranophosphate group or aphophoroselenoate group such as the dinucleotide cap analogs describedin U.S. Pat. No. 8,519,110, the contents of which are hereinincorporated by reference in its entirety.

In another embodiment, the cap is a cap analog is aN7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analogknown in the art and/or described herein. Non-limiting examples of aN7-(4-chlorophenoxyethyl) substituted dinucleotide form of a cap analoginclude a N7-(4-chlorophenoxyethyl)-G(5′)ppp(5′)G and aN7-(4-chlorophenoxyethyl)-m^(3′-O)G(5′)ppp(5′)G cap analog (See, e.g.,the various cap analogs and the methods of synthesizing cap analogsdescribed in Kore et al. Bioorganic & Medicinal Chemistry 201321:4570-4574; the contents of which are herein incorporated by referencein its entirety). In another embodiment, a cap analog of the presentdisclosure is a 4-chloro/bromophenoxyethyl analog.

While cap analogs allow for the concomitant capping of a polynucleotideor a region thereof, in an in vitro transcription reaction, up to 20% oftranscripts can remain uncapped. This, as well as the structuraldifferences of a cap analog from an endogenous 5′-cap structures ofnucleic acids produced by the endogenous, cellular transcriptionmachinery, can lead to reduced translational competency and reducedcellular stability.

Polynucleotides of the disclosure (e.g., a polynucleotide comprising anucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides) can also be cappedpost-manufacture (whether IVT or chemical synthesis), using enzymes, inorder to generate more authentic 5′-cap structures. As used herein, thephrase “more authentic” refers to a feature that closely mirrors ormimics, either structurally or functionally, an endogenous or wild typefeature. That is, a “more authentic” feature is better representative ofan endogenous, wild-type, natural or physiological cellular functionand/or structure as compared to synthetic features or analogs, etc., ofthe prior art, or which outperforms the corresponding endogenous,wild-type, natural or physiological feature in one or more respects.Non-limiting examples of more authentic 5′cap structures of the presentdisclosure are those that, among other things, have enhanced binding ofcap binding proteins, increased half-life, reduced susceptibility to 5′endonucleases and/or reduced 5′decapping, as compared to synthetic 5′capstructures known in the art (or to a wild-type, natural or physiological5′cap structure). For example, recombinant Vaccinia Virus Capping Enzymeand recombinant 2′-O-methyltransferase enzyme can create a canonical5′-5′-triphosphate linkage between the 5′-terminal nucleotide of apolynucleotide and a guanine cap nucleotide wherein the cap guaninecontains an N7 methylation and the 5′-terminal nucleotide of the mRNAcontains a 2′-O-methyl. Such a structure is termed the Cap1 structure.This cap results in a higher translational-competency and cellularstability and a reduced activation of cellular pro-inflammatorycytokines, as compared, e.g., to other 5′cap analog structures known inthe art. Cap structures include, but are not limited to,7mG(5′)ppp(5′)N,pN2p (cap 0), 7mG(5′)ppp(5′)NlmpNp (cap 1), and7mG(5′)-ppp(5′)NlmpN2mp (cap 2).

As a non-limiting example, capping chimeric polynucleotidespost-manufacture can be more efficient as nearly 100% of the chimericpolynucleotides can be capped. This is in contrast to ˜80% when a capanalog is linked to a chimeric polynucleotide in the course of an invitro transcription reaction.

According to the present disclosure, 5′ terminal caps can includeendogenous caps or cap analogs. According to the present disclosure, a5′ terminal cap can comprise a guanine analog. Useful guanine analogsinclude, but are not limited to, inosine, N1-methyl-guanosine,2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine,2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

In certain embodiments, the 5′ terminal cap structure is a Cap0, Cap1,ARCA, inosine, N1-methyl-guanosine, 2′fluoro-guanosine,7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine,2-azidoguanosine, Cap2, Cap4, 5′ methylG cap, or an analog thereof.

17. Poly-A Tails

In some embodiments, the polynucleotides of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) further comprise a poly-A tail. In further embodiments,terminal groups on the poly-A tail can be incorporated forstabilization. In other embodiments, a poly-A tail comprises des-3′hydroxyl tails.

During RNA processing, a long chain of adenine nucleotides (poly-A tail)can be added to a polynucleotide such as an mRNA molecule in order toincrease stability. Immediately after transcription, the 3′ end of thetranscript can be cleaved to free a 3′ hydroxyl. Then poly-A polymeraseadds a chain of adenine nucleotides to the RNA. The process, calledpolyadenylation, adds a poly-A tail that can be between, for example,approximately 80 to approximately 250 residues long, includingapproximately 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,200, 210, 220, 230, 240 or 250 residues long.

PolyA tails can also be added after the construct is exported from thenucleus.

According to the present disclosure, terminal groups on the poly A tailcan be incorporated for stabilization. Polynucleotides of the presentdisclosure can include des-3′ hydroxyl tails. They can also includestructural moieties or 2′-Omethyl modifications as taught by Junjie Li,et al. (Current Biology, Vol. 15, 1501-1507, Aug. 23, 2005, the contentsof which are incorporated herein by reference in its entirety).

The polynucleotides of the present disclosure can be designed to encodetranscripts with alternative polyA tail structures including histonemRNA. According to Norbury, “Terminal uridylation has also been detectedon human replication-dependent histone mRNAs. The turnover of thesemRNAs is thought to be important for the prevention of potentially toxichistone accumulation following the completion or inhibition ofchromosomal DNA replication. These mRNAs are distinguished by their lackof a 3′ poly(A) tail, the function of which is instead assumed by astable stem-loop structure and its cognate stem-loop binding protein(SLBP); the latter carries out the same functions as those of PABP onpolyadenylated mRNAs” (Norbury, “Cytoplasmic RNA: a case of the tailwagging the dog,” Nature Reviews Molecular Cell Biology; AOP, publishedonline 29 Aug. 2013; doi:10.1038/nrm3645) the contents of which areincorporated herein by reference in its entirety.

Unique poly-A tail lengths provide certain advantages to thepolynucleotides of the present disclosure. Generally, the length of apoly-A tail, when present, is greater than 30 nucleotides in length. Inanother embodiment, the poly-A tail is greater than 35 nucleotides inlength (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70,80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600,700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700,1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides).

In some embodiments, the polynucleotide or region thereof includes fromabout 30 to about 3,000 nucleotides (e.g., from 30 to 50, from 30 to100, from 30 to 250, from 30 to 500, from 30 to 750, from 30 to 1,000,from 30 to 1,500, from 30 to 2,000, from 30 to 2,500, from 50 to 100,from 50 to 250, from 50 to 500, from 50 to 750, from 50 to 1,000, from50 to 1,500, from 50 to 2,000, from 50 to 2,500, from 50 to 3,000, from100 to 500, from 100 to 750, from 100 to 1,000, from 100 to 1,500, from100 to 2,000, from 100 to 2,500, from 100 to 3,000, from 500 to 750,from 500 to 1,000, from 500 to 1,500, from 500 to 2,000, from 500 to2,500, from 500 to 3,000, from 1,000 to 1,500, from 1,000 to 2,000, from1,000 to 2,500, from 1,000 to 3,000, from 1,500 to 2,000, from 1,500 to2,500, from 1,500 to 3,000, from 2,000 to 3,000, from 2,000 to 2,500,and from 2,500 to 3,000).

In some embodiments, the poly-A tail is designed relative to the lengthof the overall polynucleotide or the length of a particular region ofthe polynucleotide. This design can be based on the length of a codingregion, the length of a particular feature or region or based on thelength of the ultimate product expressed from the polynucleotides.

In this context, the poly-A tail can be 10, 20, 30, 40, 50, 60, 70, 80,90, or 100% greater in length than the polynucleotide or featurethereof. The poly-A tail can also be designed as a fraction of thepolynucleotides to which it belongs. In this context, the poly-A tailcan be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the totallength of the construct, a construct region or the total length of theconstruct minus the poly-A tail. Further, engineered binding sites andconjugation of polynucleotides for Poly-A binding protein can enhanceexpression.

Additionally, multiple distinct polynucleotides can be linked togethervia the PABP (Poly-A binding protein) through the 3′-end using modifiednucleotides at the 3′-terminus of the poly-A tail. Transfectionexperiments can be conducted in relevant cell lines at and proteinproduction can be assayed by ELISA at 12 hr, 24 hr, 48 hr, 72 hr and day7 post-transfection.

In some embodiments, the polynucleotides of the present disclosure aredesigned to include a polyA-G Quartet region. The G-quartet is a cyclichydrogen bonded array of four guanine nucleotides that can be formed byG-rich sequences in both DNA and RNA. In this embodiment, the G-quartetis incorporated at the end of the poly-A tail. The resultantpolynucleotide is assayed for stability, protein production and otherparameters including half-life at various time points. It has beendiscovered that the polyA-G quartet results in protein production froman mRNA equivalent to at least 75% of that seen using a poly-A tail of120 nucleotides alone.

18. Start Codon Region

The disclosure also includes a polynucleotide that comprises both astart codon region and the polynucleotide described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides). In some embodiments, the polynucleotides of the presentdisclosure can have regions that are analogous to or function like astart codon region.

In some embodiments, the translation of a polynucleotide can initiate ona codon that is not the start codon AUG. Translation of thepolynucleotide can initiate on an alternative start codon such as, butnot limited to, ACG, AGG, AAG, CTG/CUG, GTG/GUG, ATA/AUA, ATT/AUU,TTG/UUG (see Touriol et al. Biology of the Cell 95 (2003) 169-178 andMatsuda and Mauro PLoS ONE, 2010 5:11; the contents of each of which areherein incorporated by reference in its entirety).

As a non-limiting example, the translation of a polynucleotide begins onthe alternative start codon ACG. As another non-limiting example,polynucleotide translation begins on the alternative start codon CTG orCUG. As yet another non-limiting example, the translation of apolynucleotide begins on the alternative start codon GTG or GUG.

Nucleotides flanking a codon that initiates translation such as, but notlimited to, a start codon or an alternative start codon, are known toaffect the translation efficiency, the length and/or the structure ofthe polynucleotide. (See, e.g., Matsuda and Mauro PLoS ONE, 2010 5:11;the contents of which are herein incorporated by reference in itsentirety). Masking any of the nucleotides flanking a codon thatinitiates translation can be used to alter the position of translationinitiation, translation efficiency, length and/or structure of apolynucleotide.

In some embodiments, a masking agent can be used near the start codon oralternative start codon in order to mask or hide the codon to reduce theprobability of translation initiation at the masked start codon oralternative start codon. Non-limiting examples of masking agents includeantisense locked nucleic acids (LNA) polynucleotides and exon-junctioncomplexes (EJCs) (See, e.g., Matsuda and Mauro describing masking agentsLNA polynucleotides and EJCs (PLoS ONE, 2010 5:11); the contents ofwhich are herein incorporated by reference in its entirety).

In another embodiment, a masking agent can be used to mask a start codonof a polynucleotide in order to increase the likelihood that translationwill initiate on an alternative start codon. In some embodiments, amasking agent can be used to mask a first start codon or alternativestart codon in order to increase the chance that translation willinitiate on a start codon or alternative start codon downstream to themasked start codon or alternative start codon.

In some embodiments, a start codon or alternative start codon can belocated within a perfect complement for a miR binding site. The perfectcomplement of a miR binding site can help control the translation,length and/or structure of the polynucleotide similar to a maskingagent. As a non-limiting example, the start codon or alternative startcodon can be located in the middle of a perfect complement for a miRNAbinding site. The start codon or alternative start codon can be locatedafter the first nucleotide, second nucleotide, third nucleotide, fourthnucleotide, fifth nucleotide, sixth nucleotide, seventh nucleotide,eighth nucleotide, ninth nucleotide, tenth nucleotide, eleventhnucleotide, twelfth nucleotide, thirteenth nucleotide, fourteenthnucleotide, fifteenth nucleotide, sixteenth nucleotide, seventeenthnucleotide, eighteenth nucleotide, nineteenth nucleotide, twentiethnucleotide or twenty-first nucleotide.

In another embodiment, the start codon of a polynucleotide can beremoved from the polynucleotide sequence in order to have thetranslation of the polynucleotide begin on a codon that is not the startcodon. Translation of the polynucleotide can begin on the codonfollowing the removed start codon or on a downstream start codon or analternative start codon. In a non-limiting example, the start codon ATGor AUG is removed as the first 3 nucleotides of the polynucleotidesequence in order to have translation initiate on a downstream startcodon or alternative start codon. The polynucleotide sequence where thestart codon was removed can further comprise at least one masking agentfor the downstream start codon and/or alternative start codons in orderto control or attempt to control the initiation of translation, thelength of the polynucleotide and/or the structure of the polynucleotide.

19. Stop Codon Region

The disclosure also includes a polynucleotide that comprises both a stopcodon region and the polynucleotide described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides). In some embodiments, the polynucleotides of the presentdisclosure can include at least two stop codons before the 3′untranslated region (UTR). The stop codon can be selected from TGA, TAAand TAG in the case of DNA, or from UGA, UAA and UAG in the case of RNA.In some embodiments, the polynucleotides of the present disclosureinclude the stop codon TGA in the case or DNA, or the stop codon UGA inthe case of RNA, and one additional stop codon. In a further embodimentthe addition stop codon can be TAA or UAA. In another embodiment, thepolynucleotides of the present disclosure include three consecutive stopcodons, four stop codons, or more.

20. Insertions and Substitutions

The disclosure also includes a polynucleotide of the present disclosurethat further comprises insertions and/or substitutions.

In some embodiments, the 5′UTR of the polynucleotide can be replaced bythe insertion of at least one region and/or string of nucleosides of thesame base. The region and/or string of nucleotides can include, but isnot limited to, at least 3, at least 4, at least 5, at least 6, at least7 or at least 8 nucleotides and the nucleotides can be natural and/orunnatural. As a non-limiting example, the group of nucleotides caninclude 5-8 adenine, cytosine, thymine, a string of any of the othernucleotides disclosed herein and/or combinations thereof.

In some embodiments, the 5′UTR of the polynucleotide can be replaced bythe insertion of at least two regions and/or strings of nucleotides oftwo different bases such as, but not limited to, adenine, cytosine,thymine, any of the other nucleotides disclosed herein and/orcombinations thereof. For example, the 5′UTR can be replaced byinserting 5-8 adenine bases followed by the insertion of 5-8 cytosinebases. In another example, the 5′UTR can be replaced by inserting 5-8cytosine bases followed by the insertion of 5-8 adenine bases.

In some embodiments, the polynucleotide can include at least onesubstitution and/or insertion downstream of the transcription start sitethat can be recognized by an RNA polymerase. As a non-limiting example,at least one substitution and/or insertion can occur downstream of thetranscription start site by substituting at least one nucleic acid inthe region just downstream of the transcription start site (such as, butnot limited to, +1 to +6). Changes to region of nucleotides justdownstream of the transcription start site can affect initiation rates,increase apparent nucleotide triphosphate (NTP) reaction constantvalues, and increase the dissociation of short transcripts from thetranscription complex curing initial transcription (Brieba et al,Biochemistry (2002) 41: 5144-5149; herein incorporated by reference inits entirety). The modification, substitution and/or insertion of atleast one nucleoside can cause a silent mutation of the sequence or cancause a mutation in the amino acid sequence.

In some embodiments, the polynucleotide can include the substitution ofat least 1, at least 2, at least 3, at least 4, at least 5, at least 6,at least 7, at least 8, at least 9, at least 10, at least 11, at least12 or at least 13 guanine bases downstream of the transcription startsite.

In some embodiments, the polynucleotide can include the substitution ofat least 1, at least 2, at least 3, at least 4, at least 5 or at least 6guanine bases in the region just downstream of the transcription startsite. As a non-limiting example, if the nucleotides in the region areGGGAGA, the guanine bases can be substituted by at least 1, at least 2,at least 3 or at least 4 adenine nucleotides (SEQ ID NO: 233). Inanother non-limiting example, if the nucleotides in the region areGGGAGA the guanine bases can be substituted by at least 1, at least 2,at least 3 or at least 4 cytosine bases (SEQ ID NO: 234). In anothernon-limiting example, if the nucleotides in the region are GGGAGA theguanine bases can be substituted by at least 1, at least 2, at least 3or at least 4 thymine, and/or any of the nucleotides described herein(SEQ ID NO: 235).

In some embodiments, the polynucleotide can include at least onesubstitution and/or insertion upstream of the start codon. For thepurpose of clarity, one of skill in the art would appreciate that thestart codon is the first codon of the protein coding region whereas thetranscription start site is the site where transcription begins. Thepolynucleotide can include, but is not limited to, at least 1, at least2, at least 3, at least 4, at least 5, at least 6, at least 7 or atleast 8 substitutions and/or insertions of nucleotide bases. Thenucleotide bases can be inserted or substituted at 1, at least 1, atleast 2, at least 3, at least 4 or at least 5 locations upstream of thestart codon. The nucleotides inserted and/or substituted can be the samebase (e.g., all A or all C or all T or all G), two different bases(e.g., A and C, A and T, or C and T), three different bases (e.g., A, Cand T or A, C and T) or at least four different bases.

As a non-limiting example, the guanine base upstream of the codingregion in the polynucleotide can be substituted with adenine, cytosine,thymine, or any of the nucleotides described herein. In anothernon-limiting example the substitution of guanine bases in thepolynucleotide can be designed so as to leave one guanine base in theregion downstream of the transcription start site and before the startcodon (see Esvelt et al. Nature (2011) 472(7344):499-503; the contentsof which is herein incorporated by reference in its entirety). As anon-limiting example, at least 5 nucleotides can be inserted at 1location downstream of the transcription start site but upstream of thestart codon and the at least 5 nucleotides can be the same base type.

21. Polynucleotide Comprising an mRNA Encoding an IL12 Polypeptide

In certain embodiments, a polynucleotide of the present disclosure, forexample a polynucleotide comprising an mRNA nucleotide sequence encodingan IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12Afusion polypeptides, comprises from 5′ to 3′ end:

-   (i) a 5′ cap provided above;-   (ii) a 5′ UTR, such as the sequences provided above;-   (iii) an open reading frame encoding an IL12B polypeptide, an IL12A    polypeptide, and/or IL12B and IL12A fusion polypeptides, e.g., a    sequence optimized nucleic acid sequence encoding IL12 disclosed    herein;-   (iv) at least one stop codon;-   (v) a 3′ UTR, such as the sequences provided above; and-   (vi) a poly-A tail provided above.

In some embodiments, the polynucleotide further comprises a miRNAbinding site, e.g., a miRNA binding site that binds to miRNA-142. Insome embodiments, the 5′UTR comprises the miRNA binding site.

In some embodiments, a polynucleotide of the present disclosurecomprises a nucleotide sequence encoding a polypeptide sequence at least70%, at least 80%, at least 81%, at least 82%, at least 83%, at least84%, at least 85%, at least 86%, at least 87%, at least 88%, at least89%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99%, or 100% identical to the protein sequence of a wild type IL12(e.g., isoform 1, 2, 3, or 4).

22. Methods of Making Polynucleotides

The present disclosure also provides methods for making a polynucleotideof the disclosure (e.g., a polynucleotide comprising a nucleotidesequence encoding an IL12B polypeptide, an IL12A polypeptide, and/orIL12B and IL12A fusion polypeptides) or a complement thereof.

In some aspects, a polynucleotide (e.g., a RNA, e.g., an mRNA) disclosedherein, and encoding an IL12B polypeptide, an IL12A polypeptide, and/orIL12B and IL12A fusion polypeptides, can be constructed using in vitrotranscription. In other aspects, a polynucleotide (e.g., a RNA, e.g., anmRNA) disclosed herein, and encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides, can beconstructed by chemical synthesis using an oligonucleotide synthesizer.

In other aspects, a polynucleotide (e.g., a RNA, e.g., an mRNA)disclosed herein, and encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides is made by usinga host cell. In certain aspects, a polynucleotide (e.g., a RNA, e.g., anmRNA) disclosed herein, and encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides is made by oneor more combination of the IVT, chemical synthesis, host cellexpression, or any other methods known in the art. In other embodiments,a host cell is a eukaryotic cell, e.g., in vitro mammalian cells.

Naturally occurring nucleosides, non-naturally occurring nucleosides, orcombinations thereof, can totally or partially naturally replaceoccurring nucleosides present in the candidate nucleotide sequence andcan be incorporated into a sequence-optimized nucleotide sequence (e.g.,a RNA, e.g., an mRNA) encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides. The resultantpolynucleotides, e.g., mRNAs, can then be examined for their ability toproduce protein and/or produce a therapeutic outcome.

a. In Vitro Transcription/Enzymatic Synthesis

The polynucleotides of the present disclosure disclosed herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) can be transcribed using an in vitro transcription (IVT)system. The system typically comprises a transcription buffer,nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase.The NTPs can be selected from, but are not limited to, those describedherein including natural and unnatural (modified) NTPs. The polymerasecan be selected from, but is not limited to, T7 RNA polymerase, T3 RNApolymerase and mutant polymerases such as, but not limited to,polymerases able to incorporate polynucleotides disclosed herein. SeeU.S. Publ. No. US20130259923, which is herein incorporated by referencein its entirety.

Any number of RNA polymerases or variants can be used in the synthesisof the polynucleotides of the present disclosure. RNA polymerases can bemodified by inserting or deleting amino acids of the RNA polymerasesequence. As a non-limiting example, the RNA polymerase can be modifiedto exhibit an increased ability to incorporate a 2′-modified nucleotidetriphosphate compared to an unmodified RNA polymerase (see InternationalPublication WO2008078180 and U.S. Pat. No. 8,101,385; hereinincorporated by reference in their entireties).

Variants can be obtained by evolving an RNA polymerase, optimizing theRNA polymerase amino acid and/or nucleic acid sequence and/or by usingother methods known in the art. As a non-limiting example, T7 RNApolymerase variants can be evolved using the continuous directedevolution system set out by Esvelt et al. (Nature 472:499-503 (2011);herein incorporated by reference in its entirety) where clones of T7 RNApolymerase can encode at least one mutation such as, but not limited to,lysine at position 93 substituted for threonine (K93T), I4M, A7T, E63V,V64D, A65E, D66Y, T76N, C125R, S128R, A136T, N165S, G175R, H176L, Y178H,F182L, L196F, G198V, D208Y, E222K, S228A, Q239R, T243N, G259D, M267I,G280C, H300R, D351A, A354S, E356D, L360P, A383V, Y385C, D388Y, S397R,M401T, N410S, K450R, P451T, G452V, E484A, H523L, H524N, G542V, E565K,K577E, K577M, N601S, S684Y, L699I, K713E, N748D, Q754R, E775K, A827V,D851N or L864F. As another non-limiting example, T7 RNA polymerasevariants can encode at least mutation as described in U.S. Pub. Nos.20100120024 and 20070117112; herein incorporated by reference in theirentireties. Variants of RNA polymerase can also include, but are notlimited to, substitutional variants, conservative amino acidsubstitution, insertional variants, deletional variants and/or covalentderivatives.

In one aspect, the polynucleotide can be designed to be recognized bythe wild type or variant RNA polymerases. In doing so, thepolynucleotide can be modified to contain sites or regions of sequencechanges from the wild type or parent chimeric polynucleotide.

Polynucleotide or nucleic acid synthesis reactions can be carried out byenzymatic methods utilizing polymerases. Polymerases catalyze thecreation of phosphodiester bonds between nucleotides in a polynucleotideor nucleic acid chain. Currently known DNA polymerases can be dividedinto different families based on amino acid sequence comparison andcrystal structure analysis. DNA polymerase I (pol I) or A polymerasefamily, including the Klenow fragments of E. coli, Bacillus DNApolymerase I, Thermus aquaticus (Taq) DNA polymerases, and the T7 RNAand DNA polymerases, is among the best studied of these families.Another large family is DNA polymerase α (pol α) or B polymerase family,including all eukaryotic replicating DNA polymerases and polymerasesfrom phages T4 and RB69. Although they employ similar catalyticmechanism, these families of polymerases differ in substratespecificity, substrate analog-incorporating efficiency, degree and ratefor primer extension, mode of DNA synthesis, exonuclease activity, andsensitivity against inhibitors.

DNA polymerases are also selected based on the optimum reactionconditions they require, such as reaction temperature, pH, and templateand primer concentrations. Sometimes a combination of more than one DNApolymerases is employed to achieve the desired DNA fragment size andsynthesis efficiency. For example, Cheng et al. increase pH, addglycerol and dimethyl sulfoxide, decrease denaturation times, increaseextension times, and utilize a secondary thermostable DNA polymerasethat possesses a 3′ to 5′ exonuclease activity to effectively amplifylong targets from cloned inserts and human genomic DNA. (Cheng et al.,PNAS 91:5695-5699 (1994), the contents of which are incorporated hereinby reference in their entirety). RNA polymerases from bacteriophage T3,T7, and SP6 have been widely used to prepare RNAs for biochemical andbiophysical studies. RNA polymerases, capping enzymes, and poly-Apolymerases are disclosed in the co-pending International PublicationNo. WO2014028429, the contents of which are incorporated herein byreference in their entirety.

In one aspect, the RNA polymerase which can be used in the synthesis ofthe polynucleotides of the present disclosure is a SynS RNA polymerase.(see Zhu et al. Nucleic Acids Research 2013, doi: 10.1093/nar/gkt1193,which is herein incorporated by reference in its entirety). The SynS RNApolymerase was recently characterized from marine cyanophage SynS by Zhuet al. where they also identified the promoter sequence (see Zhu et al.Nucleic Acids Research 2013, the contents of which is hereinincorporated by reference in its entirety). Zhu et al. found that SynSRNA polymerase catalyzed RNA synthesis over a wider range oftemperatures and salinity as compared to T7 RNA polymerase.Additionally, the requirement for the initiating nucleotide at thepromoter was found to be less stringent for SynS RNA polymerase ascompared to the T7 RNA polymerase making SynS RNA polymerase promisingfor RNA synthesis.

In one aspect, a SynS RNA polymerase can be used in the synthesis of thepolynucleotides described herein. As a non-limiting example, a SynS RNApolymerase can be used in the synthesis of the polynucleotide requiringa precise 3′-terminus.

In one aspect, a SynS promoter can be used in the synthesis of thepolynucleotides. As a non-limiting example, the SynS promoter can be5′-ATTGGGCACCCGTAAGGG-3′ (SEQ ID NO: 47) as described by Zhu et al.(Nucleic Acids Research 2013).

In one aspect, a SynS RNA polymerase can be used in the synthesis ofpolynucleotides comprising at least one chemical modification describedherein and/or known in the art (see e.g., the incorporation ofpseudo-UTP and 5Me-CTP described in Zhu et al. Nucleic Acids Research2013).

In one aspect, the polynucleotides described herein can be synthesizedusing a SynS RNA polymerase which has been purified using modified andimproved purification procedure described by Zhu et al. (Nucleic AcidsResearch 2013).

Various tools in genetic engineering are based on the enzymaticamplification of a target gene which acts as a template. For the studyof sequences of individual genes or specific regions of interest andother research needs, it is necessary to generate multiple copies of atarget gene from a small sample of polynucleotides or nucleic acids.Such methods can be applied in the manufacture of the polynucleotides ofthe disclosure.

Polymerase chain reaction (PCR) has wide applications in rapidamplification of a target gene, as well as genome mapping andsequencing. The key components for synthesizing DNA comprise target DNAmolecules as a template, primers complementary to the ends of target DNAstrands, deoxynucleoside triphosphates (dNTPs) as building blocks, and aDNA polymerase. As PCR progresses through denaturation, annealing andextension steps, the newly produced DNA molecules can act as a templatefor the next circle of replication, achieving exponentiallyamplification of the target DNA. PCR requires a cycle of heating andcooling for denaturation and annealing. Variations of the basic PCRinclude asymmetric PCR (Innis et al., PNAS 85: 9436-9440 (1988)),inverse PCR (Ochman et al., Genetics 120(3): 621-623, (1988)), reversetranscription PCR (RT-PCR) (Freeman et al., BioTechniques 26(1): 112-22,124-5 (1999), the contents of which are incorporated herein by referencein their entirety and so on). In RT-PCR, a single stranded RNA is thedesired target and is converted to a double stranded DNA first byreverse transcriptase.

A variety of isothermal in vitro nucleic acid amplification techniqueshave been developed as alternatives or complements of PCR. For example,strand displacement amplification (SDA) is based on the ability of arestriction enzyme to form a nick (Walker et al., PNAS 89: 392-396(1992), which is incorporated herein by reference in its entirety)). Arestriction enzyme recognition sequence is inserted into an annealedprimer sequence. Primers are extended by a DNA polymerase and dNTPs toform a duplex. Only one strand of the duplex is cleaved by therestriction enzyme. Each single strand chain is then available as atemplate for subsequent synthesis. SDA does not require the complicatedtemperature control cycle of PCR.

Nucleic acid sequence-based amplification (NASBA), also calledtranscription mediated amplification (TMA), is also an isothermalamplification method that utilizes a combination of DNA polymerase,reverse transcriptase, RNAse H, and T7 RNA polymerase. (Compton, Nature350:91-92 (1991)) the contents of which are incorporated herein byreference in their entirety. A target RNA is used as a template and areverse transcriptase synthesizes its complementary DNA strand. RNAse Hhydrolyzes the RNA template, making space for a DNA polymerase tosynthesize a DNA strand complementary to the first DNA strand which iscomplementary to the RNA target, forming a DNA duplex. T7 RNA polymerasecontinuously generates complementary RNA strands of this DNA duplex.These RNA strands act as templates for new cycles of DNA synthesis,resulting in amplification of the target gene.

Rolling-circle amplification (RCA) amplifies a single stranded circularpolynucleotide and involves numerous rounds of isothermal enzymaticsynthesis where Φ29 DNA polymerase extends a primer by continuouslyprogressing around the polynucleotide circle to replicate its sequenceover and over again. Therefore, a linear copy of the circular templateis achieved. A primer can then be annealed to this linear copy and itscomplementary chain can be synthesized. See Lizardi et al., NatureGenetics 19:225-232 (1998), the contents of which are incorporatedherein by reference in their entirety. A single stranded circular DNAcan also serve as a template for RNA synthesis in the presence of an RNApolymerase. (Daubendiek et al., JACS 117:7818-7819 (1995), the contentsof which are incorporated herein by reference in their entirety). Aninverse rapid amplification of cDNA ends (RACE) RCA is described byPolidoros et al. A messenger RNA (mRNA) is reverse transcribed intocDNA, followed by RNAse H treatment to separate the cDNA. The cDNA isthen circularized by CircLigase into a circular DNA. The amplificationof the resulting circular DNA is achieved with RCA. (Polidoros et al.,BioTechniques 41:35-42 (2006), the contents of which are incorporatedherein by reference in their entirety).

Any of the foregoing methods can be utilized in the manufacture of oneor more regions of the polynucleotides of the present disclosure.

Assembling polynucleotides or nucleic acids by a ligase is also widelyused. DNA or RNA ligases promote intermolecular ligation of the 5′ and3′ ends of polynucleotide chains through the formation of aphosphodiester bond. Ligase chain reaction (LCR) is a promisingdiagnosing technique based on the principle that two adjacentpolynucleotide probes hybridize to one strand of a target gene andcouple to each other by a ligase. If a target gene is not present, or ifthere is a mismatch at the target gene, such as a single-nucleotidepolymorphism (SNP), the probes cannot ligase. (Wiedmann et al., PCRMethods and Application, vol. 3 (4), s51-s64 (1994), the contents ofwhich are incorporated herein by reference in their entirety). LCR canbe combined with various amplification techniques to increasesensitivity of detection or to increase the amount of products if it isused in synthesizing polynucleotides and nucleic acids.

Several library preparation kits for nucleic acids are now commerciallyavailable. They include enzymes and buffers to convert a small amount ofnucleic acid samples into an indexed library for downstreamapplications. For example, DNA fragments can be placed in a NEBNEXT®ULTRA™ DNA Library Prep Kit by NEWENGLAND BIOLABS® for end preparation,ligation, size selection, clean-up, PCR amplification and finalclean-up.

Continued development is going on to improvement the amplificationtechniques. For example, U.S. Pat. No. 8,367,328 to Asada et al. thecontents of which are incorporated herein by reference in theirentirety, teaches utilizing a reaction enhancer to increase theefficiency of DNA synthesis reactions by DNA polymerases. The reactionenhancer comprises an acidic substance or cationic complexes of anacidic substance. U.S. Pat. No. 7,384,739 to Kitabayashi et al. thecontents of which are incorporated herein by reference in theirentirety, teaches a carboxylate ion-supplying substance that promotesenzymatic DNA synthesis, wherein the carboxylate ion-supplying substanceis selected from oxalic acid, malonic acid, esters of oxalic acid,esters of malonic acid, salts of malonic acid, and esters of maleicacid. U.S. Pat. No. 7,378,262 to Sobek et al. the contents of which areincorporated herein by reference in their entirety, discloses an enzymecomposition to increase fidelity of DNA amplifications. The compositioncomprises one enzyme with 3′ exonuclease activity but no polymeraseactivity and another enzyme that is a polymerase. Both of the enzymesare thermostable and are reversibly modified to be inactive at lowertemperatures.

U.S. Pat. No. 7,550,264 to Getts et al. teaches multiple round ofsynthesis of sense RNA molecules are performed by attachingoligodeoxynucleotides tails onto the 3′ end of cDNA molecules andinitiating RNA transcription using RNA polymerase, the contents of whichare incorporated herein by reference in their entirety. U.S. Pat. Pub.No. 2013/0183718 to Rohayem teaches RNA synthesis by RNA-dependent RNApolymerases (RdRp) displaying an RNA polymerase activity onsingle-stranded DNA templates, the contents of which are incorporatedherein by reference in their entirety. Oligonucleotides withnon-standard nucleotides can be synthesized with enzymaticpolymerization by contacting a template comprising non-standardnucleotides with a mixture of nucleotides that are complementary to thenucleotides of the template as disclosed in U.S. Pat. No. 6,617,106 toBenner, the contents of which are incorporated herein by reference intheir entirety.

b. Chemical Synthesis

Standard methods can be applied to synthesize an isolated polynucleotidesequence encoding an isolated polypeptide of interest, such as apolynucleotide of the disclosure (e.g., a polynucleotide comprising anucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides). For example, a single DNAor RNA oligomer containing a codon-optimized nucleotide sequence codingfor the particular isolated polypeptide can be synthesized. In otheraspects, several small oligonucleotides coding for portions of thedesired polypeptide can be synthesized and then ligated. In someaspects, the individual oligonucleotides typically contain 5′ or 3′overhangs for complementary assembly.

A polynucleotide disclosed herein (e.g., a RNA, e.g., an mRNA) can bechemically synthesized using chemical synthesis methods and potentialnucleobase substitutions known in the art. See, for example,International Publication Nos. WO2014093924, WO2013052523; WO2013039857,WO2012135805, WO2013151671; U.S. Publ. No. US20130115272; or U.S. Pat.No. 8,999,380 or 8,710,200, all of which are herein incorporated byreference in their entireties.

c. Purification of Polynucleotides Encoding IL12

Purification of the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) can include, but is not limited to, polynucleotideclean-up, quality assurance and quality control. Clean-up can beperformed by methods known in the arts such as, but not limited to,AGENCOURT® beads (Beckman Coulter Genomics, Danvers, Mass.), poly-Tbeads, LNA™ oligo-T capture probes (EXIQON® Inc., Vedbaek, Denmark) orHPLC based purification methods such as, but not limited to, stronganion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC(RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).

The term “purified” when used in relation to a polynucleotide such as a“purified polynucleotide” refers to one that is separated from at leastone contaminant. As used herein, a “contaminant” is any substance thatmakes another unfit, impure or inferior. Thus, a purified polynucleotide(e.g., DNA and RNA) is present in a form or setting different from thatin which it is found in nature, or a form or setting different from thatwhich existed prior to subjecting it to a treatment or purificationmethod.

In some embodiments, purification of a polynucleotide of the disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) removes impurities that can reduce or remove an unwantedimmune response, e.g., reducing cytokine activity.

In some embodiments, the polynucleotide of the disclosure (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) is purified prior to administration using columnchromatography (e.g., strong anion exchange HPLC, weak anion exchangeHPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC(HIC-HPLC), or (LCMS)).

In some embodiments, the polynucleotide of the disclosure (e.g., apolynucleotide comprising a nucleotide sequence an IL12B polypeptide, anIL12A polypeptide, and/or IL12B and IL12A fusion polypeptides) purifiedusing column chromatography (e.g., strong anion exchange HPLC, weakanion exchange HPLC, reverse phase HPLC (RP-HPLC, hydrophobicinteraction HPLC (HIC-HPLC), or (LCMS)) presents increased expression ofthe encoded IL12 protein compared to the expression level obtained withthe same polynucleotide of the present disclosure purified by adifferent purification method.

In some embodiments, a column chromatography (e.g., strong anionexchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC),hydrophobic interaction HPLC (HIC-HPLC), or (LCMS)) purifiedpolynucleotide comprises a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides comprising one or more of the point mutations known in theart.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases IL12 protein expression levels in cells when introduced intothose cells, e.g., by 10-100%, i.e., at least about 10%, at least about20%, at least about 25%, at least about 30%, at least about 35%, atleast about 40%, at least about 45%, at least about 50%, at least about55%, at least about 60%, at least about 65%, at least about 70%, atleast about 75%, at least about 80%, at least about 90%, at least about95%, or at least about 100% with respect to the expression levels ofIL12 protein in the cells before the RP-HPLC purified polynucleotide wasintroduced in the cells, or after a non-RP-HPLC purified polynucleotidewas introduced in the cells.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases functional IL12 protein expression levels in cells whenintroduced into those cells, e.g., by 10-100%, i.e., at least about 10%,at least about 20%, at least about 25%, at least about 30%, at leastabout 35%, at least about 40%, at least about 45%, at least about 50%,at least about 55%, at least about 60%, at least about 65%, at leastabout 70%, at least about 75%, at least about 80%, at least about 90%,at least about 95%, or at least about 100% with respect to thefunctional expression levels of IL12 protein in the cells before theRP-HPLC purified polynucleotide was introduced in the cells, or after anon-RP-HPLC purified polynucleotide was introduced in the cells.

In some embodiments, the use of RP-HPLC purified polynucleotideincreases detectable IL12 activity in cells when introduced into thosecells, e.g., by 10-100%, i.e., at least about 10%, at least about 20%,at least about 25%, at least about 30%, at least about 35%, at leastabout 40%, at least about 45%, at least about 50%, at least about 55%,at least about 60%, at least about 65%, at least about 70%, at leastabout 75%, at least about 80%, at least about 90%, at least about 95%,or at least about 100% with respect to the activity levels of functionalIL12 in the cells before the RP-HPLC purified polynucleotide wasintroduced in the cells, or after a non-RP-HPLC purified polynucleotidewas introduced in the cells.

In some embodiments, the purified polynucleotide is at least about 80%pure, at least about 85% pure, at least about 90% pure, at least about95% pure, at least about 96% pure, at least about 97% pure, at leastabout 98% pure, at least about 99% pure, or about 100% pure.

A quality assurance and/or quality control check can be conducted usingmethods such as, but not limited to, gel electrophoresis, UV absorbance,or analytical HPLC. In another embodiment, the polynucleotide can besequenced by methods including, but not limited toreverse-transcriptase-PCR.

d. Quantification of Expressed Polynucleotides Encoding IL12

In some embodiments, the polynucleotides of the present disclosure(e.g., a polynucleotide comprising a nucleotide sequence encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides), their expression products, as well as degradationproducts and metabolites can be quantified according to methods known inthe art.

In some embodiments, the polynucleotides of the present disclosure canbe quantified in exosomes or when derived from one or more bodily fluid.As used herein “bodily fluids” include peripheral blood, serum, plasma,ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow,synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk,broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid orpre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid,pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle,bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions,mucosal secretion, stool water, pancreatic juice, lavage fluids fromsinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, andumbilical cord blood. Alternatively, exosomes can be retrieved from anorgan selected from the group consisting of lung, heart, pancreas,stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast,prostate, brain, esophagus, liver, and placenta.

In the exosome quantification method, a sample of not more than 2 mL isobtained from the subject and the exosomes isolated by size exclusionchromatography, density gradient centrifugation, differentialcentrifugation, nanomembrane ultrafiltration, immunoabsorbent capture,affinity purification, microfluidic separation, or combinations thereof.In the analysis, the level or concentration of a polynucleotide can bean expression level, presence, absence, truncation or alteration of theadministered construct. It is advantageous to correlate the level withone or more clinical phenotypes or with an assay for a human diseasebiomarker.

The assay can be performed using construct specific probes, cytometry,qRT-PCR, real-time PCR, PCR, flow cytometry, electrophoresis, massspectrometry, or combinations thereof while the exosomes can be isolatedusing immunohistochemical methods such as enzyme linked immunosorbentassay (ELISA) methods. Exosomes may also be isolated by size exclusionchromatography, density gradient centrifugation, differentialcentrifugation, nanomembrane ultrafiltration, immunoabsorbent capture,affinity purification, microfluidic separation, or combinations thereof.

These methods afford the investigator the ability to monitor, in realtime, the level of polynucleotides remaining or delivered. This ispossible because the polynucleotides of the present disclosure differfrom the endogenous forms due to the structural or chemicalmodifications.

In some embodiments, the polynucleotide can be quantified using methodssuch as, but not limited to, ultraviolet visible spectroscopy (UV/Vis).A non-limiting example of a UV/Vis spectrometer is a NANODROP®spectrometer (ThermoFisher, Waltham, Mass.). The quantifiedpolynucleotide can be analyzed in order to determine if thepolynucleotide can be of proper size, check that no degradation of thepolynucleotide has occurred. Degradation of the polynucleotide can bechecked by methods such as, but not limited to, agarose gelelectrophoresis, HPLC based purification methods such as, but notlimited to, strong anion exchange HPLC, weak anion exchange HPLC,reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC(HIC-HPLC), liquid chromatography-mass spectrometry (LCMS), capillaryelectrophoresis (CE) and capillary gel electrophoresis (CGE).

23. Pharmaceutical Compositions and Formulations

The present disclosure provides pharmaceutical compositions andformulations that comprise any of the polynucleotides described above.In some embodiments, the composition or formulation further comprises adelivery agent.

In some embodiments, the composition or formulation can contain apolynucleotide comprising a sequence optimized nucleic acid sequencedisclosed herein which encodes an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides. In someembodiments, the composition or formulation can contain a polynucleotide(e.g., a RNA, e.g., an mRNA) comprising a polynucleotide (e.g., an ORF)having significant sequence identity to a sequence optimized nucleicacid sequence disclosed herein which encodes an IL12B polypeptide, anIL12A polypeptide, and/or IL12B and IL12A fusion polypeptides. In someembodiments, the polynucleotide further comprises a miRNA binding site,e.g., a miRNA binding site that binds miR-122.

Pharmaceutical compositions or formulation can optionally comprise oneor more additional active substances, e.g., therapeutically and/orprophylactically active substances. Pharmaceutical compositions orformulation of the present disclosure can be sterile and/orpyrogen-free. General considerations in the formulation and/ormanufacture of pharmaceutical agents can be found, for example, inRemington: The Science and Practice of Pharmacy 21^(st) ed., LippincottWilliams & Wilkins, 2005 (incorporated herein by reference in itsentirety). In some embodiments, compositions are administered to humans,human patients or subjects. For the purposes of the present disclosure,the phrase “active ingredient” generally refers to polynucleotides to bedelivered as described herein.

Formulations and pharmaceutical compositions described herein can beprepared by any method known or hereafter developed in the art ofpharmacology. In general, such preparatory methods include the step ofassociating the active ingredient with an excipient and/or one or moreother accessory ingredients, and then, if necessary and/or desirable,dividing, shaping and/or packaging the product into a desired single- ormulti-dose unit.

A pharmaceutical composition or formulation in accordance with thepresent disclosure can be prepared, packaged, and/or sold in bulk, as asingle unit dose, and/or as a plurality of single unit doses. As usedherein, a “unit dose” refers to a discrete amount of the pharmaceuticalcomposition comprising a predetermined amount of the active ingredient.The amount of the active ingredient is generally equal to the dosage ofthe active ingredient that would be administered to a subject and/or aconvenient fraction of such a dosage such as, for example, one-half orone-third of such a dosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition in accordance with the present disclosure mayvary, depending upon the identity, size, and/or condition of the subjectbeing treated and further depending upon the route by which thecomposition is to be administered. For example, the composition cancomprise between 0.1% and 99% (w/w) of the active ingredient. By way ofexample, the composition can comprise between 0.1% and 100%, e.g.,between 0.5 and 50%, between 1 and 30%, between 5 and 80%, or at least80% (w/w) active ingredient.

In some embodiments, the compositions and formulations described hereincan contain at least one polynucleotide of the disclosure. As anon-limiting example, the composition or formulation can contain 1, 2,3, 4 or 5 polynucleotides of the disclosure. In some embodiments, thecompositions or formulations described herein can comprise more than onetype of polynucleotide. In some embodiments, the composition orformulation can comprise a polynucleotide in linear and circular form.In another embodiment, the composition or formulation can comprise acircular polynucleotide and an IVT polynucleotide. In yet anotherembodiment, the composition or formulation can comprise an IVTpolynucleotide, a chimeric polynucleotide and a circular polynucleotide.

Although the descriptions of pharmaceutical compositions andformulations provided herein are principally directed to pharmaceuticalcompositions and formulations that are suitable for administration tohumans, it will be understood by the skilled artisan that suchcompositions are generally suitable for administration to any otheranimal, e.g., to non-human animals, e.g. non-human mammals. Modificationof pharmaceutical compositions or formulations suitable foradministration to humans in order to render the compositions suitablefor administration to various animals is well understood, and theordinarily skilled veterinary pharmacologist can design and/or performsuch modification with merely ordinary, if any, experimentation.Subjects to which administration of the pharmaceutical compositions orformulation is contemplated include, but are not limited to, humansand/or other primates; mammals, including commercially relevant mammalssuch as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats;and/or birds, including commercially relevant birds such as poultry,chickens, ducks, geese, and/or turkeys.

The present disclosure provides pharmaceutical formulations thatcomprise a polynucleotide described herein (e.g., a polynucleotidecomprising a nucleotide sequence encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides). Thepolynucleotides described herein can be formulated using one or moreexcipients to: (1) increase stability; (2) increase cell transfection;(3) permit the sustained or delayed release (e.g., from a depotformulation of the polynucleotide); (4) alter the biodistribution (e.g.,target the polynucleotide to specific tissues or cell types); (5)increase the translation of encoded protein in vivo; and/or (6) alterthe release profile of encoded protein in vivo. In some embodiments, thepharmaceutical formulation further comprises a delivery agent, (e.g., acompound having the Formula (I), e.g., any of Compounds 1-147 or any ofCompounds 1-232).

A pharmaceutically acceptable excipient, as used herein, includes, butare not limited to, any and all solvents, dispersion media, or otherliquid vehicles, dispersion or suspension aids, diluents, granulatingand/or dispersing agents, surface active agents, isotonic agents,thickening or emulsifying agents, preservatives, binders, lubricants oroil, coloring, sweetening or flavoring agents, stabilizers,antioxidants, antimicrobial or antifungal agents, osmolality adjustingagents, pH adjusting agents, buffers, chelants, cyoprotectants, and/orbulking agents, as suited to the particular dosage form desired. Variousexcipients for formulating pharmaceutical compositions and techniquesfor preparing the composition are known in the art (see Remington: TheScience and Practice of Pharmacy, 21st Edition, A. R. Gennaro(Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporatedherein by reference in its entirety).

Exemplary diluents include, but are not limited to, calcium or sodiumcarbonate, calcium phosphate, calcium hydrogen phosphate, sodiumphosphate, lactose, sucrose, cellulose, microcrystalline cellulose,kaolin, mannitol, sorbitol, etc., and/or combinations thereof.

Exemplary granulating and/or dispersing agents include, but are notlimited to, starches, pregelatinized starches, or microcrystallinestarch, alginic acid, guar gum, agar, poly(vinyl-pyrrolidone),(providone), cross-linked poly(vinyl-pyrrolidone) (crospovidone),cellulose, methylcellulose, carboxymethyl cellulose, cross-linked sodiumcarboxymethyl cellulose (croscarmellose), magnesium aluminum silicate(VEEGUM®), sodium lauryl sulfate, etc., and/or combinations thereof.

Exemplary surface active agents and/or emulsifiers include, but are notlimited to, natural emulsifiers (e.g., acacia, agar, alginic acid,sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin,gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin),sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monooleate[TWEEN®80], sorbitan monopalmitate [SPAN®40], glyceryl monooleate,polyoxyethylene esters, polyethylene glycol fatty acid esters (e.g.,CREMOPHOR®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether[BRIJ®30]), PLUORINC®F 68, POLOXAMER®188, etc. and/or combinationsthereof.

Exemplary binding agents include, but are not limited to, starch,gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses,lactose, lactitol, mannitol), amino acids (e.g., glycine), natural andsynthetic gums (e.g., acacia, sodium alginate), ethylcellulose,hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., andcombinations thereof.

Oxidation is a potential degradation pathway for mRNA, especially forliquid mRNA formulations. In order to prevent oxidation, antioxidantscan be added to the formulations. Exemplary antioxidants include, butare not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate,benzyl alcohol, butylated hydroxyanisole, m-cresol, methionine,butylated hydroxytoluene, monothioglycerol, sodium or potassiummetabisulfite, propionic acid, propyl gallate, sodium ascorbate, etc.,and combinations thereof.

Exemplary chelating agents include, but are not limited to,ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate,disodium edetate, fumaric acid, malic acid, phosphoric acid, sodiumedetate, tartaric acid, trisodium edetate, etc., and combinationsthereof.

Exemplary antimicrobial or antifungal agents include, but are notlimited to, benzalkonium chloride, benzethonium chloride, methylparaben, ethyl paraben, propyl paraben, butyl paraben, benzoic acid,hydroxybenzoic acid, potassium or sodium benzoate, potassium or sodiumsorbate, sodium propionate, sorbic acid, etc., and combinations thereof.

Exemplary preservatives include, but are not limited to, vitamin A,vitamin C, vitamin E, beta-carotene, citric acid, ascorbic acid,butylated hydroxyanisol, ethylenediamine, sodium lauryl sulfate (SLS),sodium lauryl ether sulfate (SLES), etc., and combinations thereof.

In some embodiments, the pH of polynucleotide solutions are maintainedbetween pH 5 and pH 8 to improve stability. Exemplary buffers to controlpH can include, but are not limited to sodium phosphate, sodium citrate,sodium succinate, histidine (or histidine-HCl), sodium malate, sodiumcarbonate, etc., and/or combinations thereof.

Exemplary lubricating agents include, but are not limited to, magnesiumstearate, calcium stearate, stearic acid, silica, talc, malt,hydrogenated vegetable oils, polyethylene glycol, sodium benzoate,sodium or magnesium lauryl sulfate, etc., and combinations thereof.

The pharmaceutical composition or formulation described here may containa cyroprotectant to stabilize a polynucleotide described herein duringfreezing. Exemplary cryoprotectants include, but are not limited tomannitol, sucrose, trehalose, lactose, glycerol, dextrose, etc., andcombinations thereof.

The pharmaceutical composition or formulation described here may containa bulking agent in lyophilized polynucleotide formulations to yield a“pharmaceutically elegant” cake, stabilize the lyophilizedpolynucleotides during long term (e.g., 36 month) storage. Exemplarybulking agents of the present disclosure can include, but are notlimited to sucrose, trehalose, mannitol, glycine, lactose, raffinose,and combinations thereof.

In some embodiments, the pharmaceutical composition or formulationfurther comprises a delivery agent. The delivery agent of the presentdisclosure can include, without limitation, liposomes, lipidnanoparticles, lipidoids, polymers, lipoplexes, microvesicles, exosomes,peptides, proteins, cells transfected with polynucleotides,hyaluronidase, nanoparticle mimics, nanotubes, conjugates, andcombinations thereof.

24. Delivery Agents

a. Lipid Compound

The present disclosure provides pharmaceutical compositions withadvantageous properties. In particular, the present application providespharmaceutical compositions comprising:

-   (a) a polynucleotide comprising a nucleotide sequence encoding an    IL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A    fusion polypeptides; and-   (b) a delivery agent.

In some embodiments, the delivery agent for the present disclosurecomprises any one or more compounds disclosed in InternationalApplication No. PCT/US2016/052352, filed on Sep. 16, 2016, and publishedas WO 2017/049245, which is incorporated herein by reference in itsentirety.

In some embodiments, the delivery agent comprises a compound having theformula (I)

wherein

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a carbocycle, heterocycle, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂,—OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR,—N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C-18alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or stereoisomers thereof.

In some embodiments, a subset of compounds of Formula (I) includes thosein which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a carbocycle, heterocycle, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, and—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or stereoisomers thereof, wherein alkyl and alkenyl groups maybe linear or branched.

In some embodiments, a subset of compounds of Formula (I) includes thosein which when R₄ is —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, or —CQ(R)₂, then(i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or7-membered heterocycloalkyl when n is 1 or 2.

In another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheteroaryl having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C (O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉) N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and a 5- to14-membered heterocycloalkyl having one or more heteroatoms selectedfrom N, O, and S which is substituted with one or more substituentsselected from oxo (═O), OH, amino, and C₁₋₃ alkyl, and each n isindependently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H; each R′ is independently selected from thegroup consisting of C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or stereoisomers thereof.

In another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheteroaryl having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, and a 5- to 14-membered heterocycloalkyl having one ormore heteroatoms selected from N, O, and S which is substituted with oneor more substituents selected from oxo (═O), OH, amino, and C₁₋₃ alkyl,and each n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In yet another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheterocycle having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR) C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CH R₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉)N(R)₂, andeach n is independently selected from 1, 2, 3, 4, and 5; and when Q is a5- to 14-membered heterocycle and (i) R₄ is —(CH₂)_(n)Q in which n is 1or 2, or (ii) R₄ is —(CH₂)_(n)CHQR in which n is 1, or (iii) R₄ is—CHQR, and —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or8- to 14-membered heterocycloalkyl;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In yet another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheterocycle having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5; and when Q is a 5- to 14-membered heterocycle and (i) R₄ is—(CH₂)_(n)Q in which n is 1 or 2, or (ii) R₄ is —(CH₂)_(n)CHQR in whichn is 1, or (iii) R₄ is —CHQR, and —CQ(R)₂, then Q is either a 5- to14-membered heteroaryl or 8- to 14-membered heterocycloalkyl;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In still another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheteroaryl having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_(n)OR, —N(R)C(═NR₉)N(R)₂,—N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R,—N(OR)C(O)OR, —N(OR)C (O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂,—N(OR)C(═CHR₉)N(R)₂, —C(═NR₉) R, —C(O)N(R)OR, and —C(═NR₉)N(R)₂, andeach n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

R₈ is selected from the group consisting of C₃₋₆ carbocycle andheterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C₁₋₆ alkyl, —OR,—S(O)₂R, —S(O)₂N(R)₂, C₂₋₆ alkenyl, C₃₋₆ carbocycle and heterocycle;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In still another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of a C₃₋₆ carbocycle,—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, —CQ(R)₂, and unsubstituted C₁₋₆alkyl, where Q is selected from a C₃₋₆ carbocycle, a 5- to 14-memberedheteroaryl having one or more heteroatoms selected from N, O, and S,—OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN,—C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—CRN(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₂₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In yet another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR, where Q is —N(R)₂, and n isselected from 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In yet another embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H,C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃,together with the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR, where Q is —N(R)₂, and n isselected from 3, 4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C-8alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In still other embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₃₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is selected from 1, 2, 3,4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In still other embodiments, another subset of compounds of Formula (I)includes those in which

R₁ is selected from the group consisting of C₅₋₂₀ alkyl, C₅₋₂₀ alkenyl,—R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of C₁₋₁₄alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, togetherwith the atom to which they are attached, form a heterocycle orcarbocycle;

R₄ is selected from the group consisting of —(CH₂)_(n)Q, —(CH₂)_(n)CHQR,—CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is selected from 1, 2, 3,4, and 5;

each R₅ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R₆ is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—,—S(O)₂—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C₁₋₃ alkyl, C₂₋₃ alkenyl,and H;

each R is independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃ alkenyl, and H;

each R′ is independently selected from the group consisting of C₁₋₁₈alkyl, C₂₋₁₈ alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl;

each R* is independently selected from the group consisting of C₁₋₁₂alkyl and C₁₋₁₂ alkenyl;

each Y is independently a C₃₋₆ carbocycle;

each X is independently selected from the group consisting of F, Cl, Br,and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts orstereoisomers thereof.

In certain embodiments, a subset of compounds of Formula (I) includesthose of Formula (IA):

or a salt or stereoisomer thereof, wherein 1 is selected from 1, 2, 3,4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,—NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈,—NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl,or heterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (IA), or a salt or stereoisomer thereof,

wherein

l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and9;

M₁ is a bond or M′;

R₄ is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which Q is OH,—NHC(S)N(R)₂, or —NHC(O)N(R)₂;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—P(O)(OR′)O—, an aryl group, and a heteroaryl group; and

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In certain embodiments, a subset of compounds of Formula (I) includesthose of Formula (II):

or a salt or stereoisomer thereof, wherein 1 is selected from 1, 2, 3,4, and 5; M₁ is a bond or M′; R₄ is unsubstituted C₁₋₃ alkyl, or—(CH₂)_(n)Q, in which n is 2, 3, or 4, and Q is OH, —NHC(S)N(R)₂,—NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂,—NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl, orheterocycloalkyl; M and M′ are independently selected from —C(O)O—,—OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and aheteroaryl group; and

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In some embodiments, a subset of compounds of Formula (I) includes thoseof Formula (II), or a salt or stereoisomer thereof, wherein

l is selected from 1, 2, 3, 4, and 5;

M₁ is a bond or M′;

R₄ is unsubstituted C₁₋₃ alkyl, or —(CH₂)_(n)Q, in which n is 2, 3, or4, and Q is OH, —NHC(S)N(R)₂, or —NHC(O)N(R)₂;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,—P(O)(OR′)O—, an aryl group, and a heteroaryl group; and

R₂ and R₃ are independently selected from the group consisting of H,C₁₋₁₄ alkyl, and C₂₋₁₄ alkenyl.

In some embodiments, the compound of formula (I) is of the formula(IIa),

or a salt thereof, wherein R₄ is as described above.

In some embodiments, the compound of formula (I) is of the formula(IIb),

or a salt thereof, wherein R₄ is as described above.

In some embodiments, the compound of formula (I) is of the formula(IIc),

or a salt thereof, wherein R₄ is as described above.

In some embodiments, the compound of formula (I) is of the formula(IIe):

or a salt thereof, wherein R₄ is as described above.

In some embodiments, the compound of formula (IIa), (IIb), (IIc), or(IIe) comprises an R₄ which is selected from —(CH₂)_(n)Q and—(CH₂)_(n)CHQR, wherein Q, R and n are as defined above.

In some embodiments, Q is selected from the group consisting of —OR,—OH, —O(CH₂)_(n)N(R)₂, —OC(O)R, —CX₃, —CN, —N(R)C(O)R, —N(H)C(O)R,—N(R)S(O)₂R, —N(H)S(O)₂R, —N(R)C(O)N(R)₂, —N(H)C(O)N(R)₂,—N(H)C(O)N(H)(R), —N(R)C(S)N(R)₂, —N(H)C(S)N(R)₂, —N(H)C(S)N(H)(R), anda heterocycle, wherein R is as defined above. In some aspects, n is 1 or2. In some embodiments, Q is OH, —NHC(S)N(R)₂, or —NHC(O)N(R)₂.

In some embodiments, the compound of formula (I) is of the formula(IId),

or a salt thereof, wherein R₂ and R₃ are independently selected from thegroup consisting of C₅₋₁₄ alkyl and C₅₋₁₄ alkenyl, n is selected from 2,3, and 4, and R′, R″, R₅, R₆ and m are as defined above.

In some aspects of the compound of formula (IId), R₂ is C₈ alkyl. Insome aspects of the compound of formula (IId), R₃ is C₅-C₉ alkyl. Insome aspects of the compound of formula (IId), m is 5, 7, or 9. In someaspects of the compound of formula (IId), each R₅ is H. In some aspectsof the compound of formula (IId), each R₆ is H.

In another aspect, the present application provides a lipid composition(e.g., a lipid nanoparticle (LNP)) comprising: (1) a compound having theformula (I); (2) optionally a helper lipid (e.g. a phospholipid); (3)optionally a structural lipid (e.g. a sterol); (4) optionally a lipidconjugate (e.g. a PEG-lipid); and (5) optionally a quaternary aminecompound. In exemplary embodiments, the lipid composition (e.g., LNP)further comprises a polynucleotide encoding an IL12B polypeptide, IL12Apolypeptide, or both IL12B and IL12A polypeptides, e.g., apolynucleotide encapsulated therein.

As used herein, the term “alkyl” or “alkyl group” means a linear orbranched, saturated hydrocarbon including one or more carbon atoms(e.g., one, two, three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen,eighteen, nineteen, twenty, or more carbon atoms).

The notation “C₁₋₁₄ alkyl” means a linear or branched, saturatedhydrocarbon including 1-14 carbon atoms. An alkyl group may beoptionally substituted.

As used herein, the term “alkenyl” or “alkenyl group” means a linear orbranched hydrocarbon including two or more carbon atoms (e.g., two,three, four, five, six, seven, eight, nine, ten, eleven, twelve,thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen,twenty, or more carbon atoms) and at least one double bond.

The notation “C₂₋₁₄ alkenyl” means a linear or branched hydrocarbonincluding 2-14 carbon atoms and at least one double bond. An alkenylgroup may include one, two, three, four, or more double bonds. Forexample, C₁₈ alkenyl may include one or more double bonds. A C₁₈ alkenylgroup including two double bonds may be a linoleyl group. An alkenylgroup may be optionally substituted.

As used herein, the term “carbocycle” or “carbocyclic group” means amono- or multi-cyclic system including one or more rings of carbonatoms. Rings may be three, four, five, six, seven, eight, nine, ten,eleven, twelve, thirteen, fourteen, or fifteen membered rings.

The notation “C₃₋₆ carbocycle” means a carbocycle including a singlering having 3-6 carbon atoms. Carbocycles may include one or more doublebonds and may be aromatic (e.g., aryl groups). Examples of carbocyclesinclude cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and1,2-dihydronaphthyl groups. Carbocycles may be optionally substituted.

As used herein, the term “heterocycle” or “heterocyclic group” means amono- or multi-cyclic system including one or more rings, where at leastone ring includes at least one heteroatom. Heteroatoms may be, forexample, nitrogen, oxygen, or sulfur atoms. Rings may be three, four,five, six, seven, eight, nine, ten, eleven, or twelve membered rings.Heterocycles may include one or more double bonds and may be aromatic(e.g., heteroaryl groups). Examples of heterocycles include imidazolyl,imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl,pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl,isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl,tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, andisoquinolyl groups. Heterocycles may be optionally substituted.

As used herein, a “biodegradable group” is a group that may facilitatefaster metabolism of a lipid in a subject. A biodegradable group may be,but is not limited to, —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—,—C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, anaryl group, and a heteroaryl group.

As used herein, an “aryl group” is a carbocyclic group including one ormore aromatic rings. Examples of aryl groups include phenyl and naphthylgroups.

As used herein, a “heteroaryl group” is a heterocyclic group includingone or more aromatic rings. Examples of heteroaryl groups includepyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Botharyl and heteroaryl groups may be optionally substituted. For example, Mand M′ can be selected from the non-limiting group consisting ofoptionally substituted phenyl, oxazole, and thiazole. In the formulasherein, M and M′ can be independently selected from the list ofbiodegradable groups above.

Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and heterocyclyl) groupsmay be optionally substituted unless otherwise specified. Optionalsubstituents may be selected from the group consisting of, but are notlimited to, a halogen atom (e.g., a chloride, bromide, fluoride, oriodide group), a carboxylic acid (e.g., —C(O)OH), an alcohol (e.g., ahydroxyl, —OH), an ester (e.g., —C(O)OR or —OC(O)R), an aldehyde (e.g.,—C(O)H), a carbonyl (e.g., —C(O)R, alternatively represented by C═O), anacyl halide (e.g., —C(O)X, in which X is a halide selected from bromide,fluoride, chloride, and iodide), a carbonate (e.g., —OC(O)OR), an alkoxy(e.g., —OR), an acetal (e.g., —C(OR)₂R″″, in which each OR are alkoxygroups that can be the same or different and R″″ is an alkyl or alkenylgroup), a phosphate (e.g., P(O)₄ ³⁻), a thiol (e.g., —SH), a sulfoxide(e.g., —S(O)R), a sulfinic acid (e.g., —S(O)OH), a sulfonic acid (e.g.,—S(O)₂OH), a thial (e.g., —C(S)H), a sulfate (e.g., S(O)₄ ²⁻), asulfonyl (e.g., —S(O)₂—), an amide (e.g., —C(O)NR₂, or —N(R)C(O)R), anazido (e.g., —N₃), a nitro (e.g., —NO₂), a cyano (e.g., —CN), anisocyano (e.g., —NC), an acyloxy (e.g., —OC(O)R), an amino (e.g., —NR₂,—NRH, or —NH₂), a carbamoyl (e.g., —OC(O)NR₂, —OC(O)NRH, or —OC(O)NH₂),a sulfonamide (e.g., —S(O)₂NR₂, —S(O)₂NRH, —S(O)₂NH₂, —N(R)S(O)₂R,—N(H)S(O)₂R, —N(R)S(O)₂H, or —N(H)S(O)₂H), an alkyl group, an alkenylgroup, and a cyclyl (e.g., carbocyclyl or heterocyclyl) group.

In any of the preceding, R is an alkyl or alkenyl group, as definedherein. In some embodiments, the substituent groups themselves may befurther substituted with, for example, one, two, three, four, five, orsix substituents as defined herein. For example, a C₁₋₆ alkyl group maybe further substituted with one, two, three, four, five, or sixsubstituents as described herein.

The compounds of any one of formulae (I), (IA), (II), (IIa), (IIb),(IIc), (IId), and (IIe) include one or more of the following featureswhen applicable.

In some embodiments, R₄ is selected from the group consisting of a C₃₋₆carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, where Q isselected from a C₃₋₆ carbocycle, 5- to 14-membered aromatic ornon-aromatic heterocycle having one or more heteroatoms selected from N,O, S, and P, —OR, —O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H,—CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂,—N(R)C(S)N(R)₂, and —C(R)N(R)₂C(O)OR, and each n is independentlyselected from 1, 2, 3, 4, and 5.

In another embodiment, R₄ is selected from the group consisting of aC₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, whereQ is selected from a C₃₋₆ carbocycle, a 5- to 14-membered heteroarylhaving one or more heteroatoms selected from N, O, and S, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—C(R)N(R)₂C(O)OR, and a 5- to 14-membered heterocycloalkyl having one ormore heteroatoms selected from N, O, and S which is substituted with oneor more substituents selected from oxo (═O), OH, amino, and C₁₋₃ alkyl,and each n is independently selected from 1, 2, 3, 4, and 5.

In another embodiment, R₄ is selected from the group consisting of aC₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, whereQ is selected from a C₃₋₆ carbocycle, a 5- to 14-membered heterocyclehaving one or more heteroatoms selected from N, O, and S, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5; and when Q is a 5- to 14-membered heterocycle and (i) R₄ is—(CH₂)_(n)Q in which n is 1 or 2, or (ii) R₄ is —(CH₂)_(n)CHQR in whichn is 1, or (iii) R₄ is —CHQR, and —CQ(R)₂, then Q is either a 5- to14-membered heteroaryl or 8- to 14-membered heterocycloalkyl.

In another embodiment, R₄ is selected from the group consisting of aC₃₋₆ carbocycle, —(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, whereQ is selected from a C₃₋₆ carbocycle, a 5- to 14-membered heteroarylhaving one or more heteroatoms selected from N, O, and S, —OR,—O(CH₂)_(n)N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂,—N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂,—C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4,and 5.

In another embodiment, R₄ is unsubstituted C₁₄ alkyl, e.g.,unsubstituted methyl.

In certain embodiments, the disclosure provides a compound having theFormula (I), wherein R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR, where Q is—N(R)₂, and n is selected from 3, 4, and 5.

In certain embodiments, the disclosure provides a compound having theFormula (I), wherein R₄ is selected from the group consisting of—(CH₂)_(n)Q, —(CH₂)_(n)CHQR, —CHQR, and —CQ(R)₂, where Q is —N(R)₂, andn is selected from 1, 2, 3, 4, and 5.

In certain embodiments, the disclosure provides a compound having theFormula (I), wherein R₂ and R₃ are independently selected from the groupconsisting of C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and —R*OR″, orR₂ and R₃, together with the atom to which they are attached, form aheterocycle or carbocycle, and R₄ is —(CH₂)_(n)Q or —(CH₂)_(n)CHQR,where Q is —N(R)₂, and n is selected from 3, 4, and 5.

In certain embodiments, R₂ and R₃ are independently selected from thegroup consisting of C₂₋₁₄ alkyl, C₂₋₁₄ alkenyl, —R*YR″, —YR″, and—R*OR″, or R₂ and R₃, together with the atom to which they are attached,form a heterocycle or carbocycle.

In some embodiments, R₁ is selected from the group consisting of C₅₋₂₀alkyl and C₅₋₂₀ alkenyl.

In other embodiments, R₁ is selected from the group consisting of—R*YR″, —YR″, and —R″M′R′.

In certain embodiments, R₁ is selected from —R*YR″ and —YR″. In someembodiments, Y is a cyclopropyl group. In some embodiments, R* is C₈alkyl or C₈ alkenyl. In certain embodiments, R″ is C₃₋₁₂ alkyl. Forexample, R″ may be C₃ alkyl. For example, R″ may be C₄₋₈ alkyl (e.g.,C₄, C₅, C₆, C₇, or C₈ alkyl).

In some embodiments, R₁ is C₅₋₂₀ alkyl. In some embodiments, R₁ is C₆alkyl. In some embodiments, R₁ is C₈ alkyl. In other embodiments, R₁ isC₉ alkyl. In certain embodiments, R₁ is C₁₄ alkyl. In other embodiments,R₁ is C₁₈ alkyl.

In some embodiments, R₁ is C₅₋₂₀ alkenyl. In certain embodiments, R₁ isC₁₈ alkenyl. In some embodiments, R₁ is linoleyl.

In certain embodiments, R₁ is branched (e.g., decan-2-yl, undecan-3-yl,dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl,2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, orheptadeca-9-yl). In certain embodiments, R₁ is

In certain embodiments, R₁ is unsubstituted C₅₋₂₀ alkyl or C₅₋₂₀alkenyl. In certain embodiments, R′ is substituted C₅₋₂₀ alkyl or C₅₋₂₀alkenyl (e.g., substituted with a C₃₋₆ carbocycle such as1-cyclopropylnonyl).

In other embodiments, R₁ is —R″M′R′.

In some embodiments, R′ is selected from —R*YR″ and —YR″. In someembodiments, Y is C₃₋₈ cycloalkyl. In some embodiments, Y is C₆₋₁₀ aryl.In some embodiments, Y is a cyclopropyl group. In some embodiments, Y isa cyclohexyl group. In certain embodiments, R* is C₁ alkyl.

In some embodiments, R″ is selected from the group consisting of C₃₋₁₂alkyl and C₃₋₁₂ alkenyl. In some embodiments, R″ adjacent to Y is C₁alkyl. In some embodiments, R″ adjacent to Y is C₄₋₉ alkyl (e.g., C₄,C₅, C₆, C₇ or C₈ or C₉ alkyl).

In some embodiments, R′ is selected from C₄ alkyl and C₄ alkenyl. Incertain embodiments, R′ is selected from C₅ alkyl and C₅ alkenyl. Insome embodiments, R′ is selected from C₆ alkyl and C₆ alkenyl. In someembodiments, R′ is selected from C₇ alkyl and C₇ alkenyl. In someembodiments, R′ is selected from C₉ alkyl and C₉ alkenyl.

In other embodiments, R′ is selected from C₁₁ alkyl and C₁₁ alkenyl. Inother embodiments, R′ is selected from C₁₂ alkyl, C₁₂ alkenyl, C₁₃alkyl, C₁₃ alkenyl, C₁₄ alkyl, C₁₄ alkenyl, C₁₅ alkyl, C₁₅ alkenyl, C₁₆alkyl, C₁₆ alkenyl, C₁₇ alkyl, C₁₇ alkenyl, C₁₈ alkyl, and C₁₈ alkenyl.In certain embodiments, R′ is branched (e.g., decan-2-yl, undecan-3-yl,dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl,2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl orheptadeca-9-yl). In certain embodiments, R′ is

In certain embodiments, R′ is unsubstituted C₁₋₁₈ alkyl. In certainembodiments, R′ is substituted C₁₋₁₈ alkyl (e.g., CI-15 alkylsubstituted with a C₃₋₆ carbocycle such as 1-cyclopropylnonyl).

In some embodiments, R″ is selected from the group consisting of C₃₋₁₄alkyl and C₃₋₁₄ alkenyl. In some embodiments, R″ is C₃ alkyl, C₄ alkyl,C₅ alkyl, C₆ alkyl, C₇ alkyl, or C₈ alkyl. In some embodiments, R″ is C₉alkyl, C₁₀ alkyl, C₁₁ alkyl, C₁₂ alkyl, C₁₃ alkyl, or C₁₄ alkyl.

In some embodiments, M′ is —C(O)O—. In some embodiments, M′ is —OC(O)—.

In other embodiments, M′ is an aryl group or heteroaryl group. Forexample, M′ may be selected from the group consisting of phenyl,oxazole, and thiazole.

In some embodiments, M is —C(O)O— In some embodiments, M is —OC(O)—. Insome embodiments, M is —C(O)N(R′)—. In some embodiments, M is—P(O)(OR′)O—.

In other embodiments, M is an aryl group or heteroaryl group. Forexample, M may be selected from the group consisting of phenyl, oxazole,and thiazole.

In some embodiments, M is the same as M′. In other embodiments, M isdifferent from M′.

In some embodiments, each R₅ is H. In certain such embodiments, each R₆is also H.

In some embodiments, R₇ is H. In other embodiments, R₇ is C₁₋₃ alkyl(e.g., methyl, ethyl, propyl, or i-propyl).

In some embodiments, R₂ and R₃ are independently C₅₋₁₄ alkyl or C₅₋₁₄alkenyl.

In some embodiments, R₂ and R₃ are the same. In some embodiments, R₂ andR₃ are C₈ alkyl. In certain embodiments, R₂ and R₃ are C₂ alkyl. Inother embodiments, R₂ and R₃ are C₃ alkyl. In some embodiments, R₂ andR₃ are C₄ alkyl. In certain embodiments, R₂ and R₃ are C₅ alkyl. Inother embodiments, R₂ and R₃ are C₆ alkyl. In some embodiments, R₂ andR₃ are C₇ alkyl.

In other embodiments, R₂ and R₃ are different. In certain embodiments,R₂ is C₈ alkyl. In some embodiments, R₃ is C₁₋₇(e.g., C₁, C₂, C₃, C₄,C₅, C₆, or C₇ alkyl) or C₉ alkyl.

In some embodiments, R₇ and R₃ are H.

In certain embodiments, R₂ is H.

In some embodiments, m is 5, 7, or 9.

In some embodiments, R₄ is selected from —(CH₂)_(n)Q and —(CH₂)_(n)CHQR.

In some embodiments, Q is selected from the group consisting of —OR,—OH, —O(CH₂)_(n)N(R)₂, —OC(O)R, —CX₃, —CN, —N(R)C(O)R, —N(H)C(O)R,—N(R)S(O)₂R, —N(H)S(O)₂R, —N(R)C(O)N(R)₂, —N(H)C(O)N(R)₂,—N(H)C(O)N(H)(R), —N(R)C(S)N(R)₂, —N(H)C(S)N(R)₂, —N(H)C(S)N(H)(R),—C(R)N(R)₂C(O)OR, a carbocycle, and a heterocycle.

In certain embodiments, Q is —OH.

In certain embodiments, Q is a substituted or unsubstituted 5- to10-membered heteroaryl, e.g., Q is an imidazole, a pyrimidine, a purine,2-amino-1,9-dihydro-6H-purin-6-one-9-yl (or guanin-9-yl), adenin-9-yl,cytosin-1-yl, or uracil-1-yl. In certain embodiments, Q is a substituted5- to 14-membered heterocycloalkyl, e.g., substituted with one or moresubstituents selected from oxo (═O), OH, amino, and C₁₋₃ alkyl. Forexample, Q is 4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, orisoindolin-2-yl-1,3-dione.

In certain embodiments, Q is an unsubstituted or substituted C₆₋₁₀ aryl(such as phenyl) or C₃₋₆ cycloalkyl.

In some embodiments, n is 1. In other embodiments, n is 2. In furtherembodiments, n is 3. In certain other embodiments, n is 4. For example,R₄ may be —(CH₂)₂OH. For example, R₄ may be —(CH₂)₃OH. For example, R₄may be —(CH₂)₄OH. For example, R₄ may be benzyl. For example, R₄ may be4-methoxybenzyl.

In some embodiments, R₄ is a C₃₋₆ carbocycle. In some embodiments, R₄ isa C₃₋₆ cycloalkyl. For example, R₄ may be cyclohexyl optionallysubstituted with e.g., OH, halo, C₁₋₆ alkyl, etc. For example, R₄ may be2-hydroxycyclohexyl.

In some embodiments, R is H.

In some embodiments, R is unsubstituted C₁₋₃ alkyl or unsubstituted C₂₋₃alkenyl. For example, R₄ may be —CH₂CH(OH)CH₃ or —CH₂CH(OH)CH₂CH₃.

In some embodiments, R is substituted C₁₋₃ alkyl, e.g., CH₂OH. Forexample, R₄ may be —CH₂CH(OH)CH₂OH.

In some embodiments, R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle. In some embodiments, R₂ andR₃, together with the atom to which they are attached, form a 5- to14-membered aromatic or non-aromatic heterocycle having one or moreheteroatoms selected from N, O, S, and P. In some embodiments, R₂ andR₃, together with the atom to which they are attached, form anoptionally substituted C₃₋₂₀ carbocycle (e.g., C₃₋₁₈ carbocycle, C₃₋₁₅carbocycle, C₃₋₁₂ carbocycle, or C₃₋₁₀ carbocycle), either aromatic ornon-aromatic. In some embodiments, R₂ and R₃, together with the atom towhich they are attached, form a C₃₋₆ carbocycle. In other embodiments,R₂ and R₃, together with the atom to which they are attached, form a C₆carbocycle, such as a cyclohexyl or phenyl group. In certainembodiments, the heterocycle or C₃₋₆ carbocycle is substituted with oneor more alkyl groups (e.g., at the same ring atom or at adjacent ornon-adjacent ring atoms). For example, R₂ and R₃, together with the atomto which they are attached, may form a cyclohexyl or phenyl groupbearing one or more C₅ alkyl substitutions. In certain embodiments, theheterocycle or C₃₋₆ carbocycle formed by R₂ and R₃, is substituted witha carbocycle groups. For example, R₂ and R₃, together with the atom towhich they are attached, may form a cyclohexyl or phenyl group that issubstituted with cyclohexyl. In some embodiments, R₂ and R₃, togetherwith the atom to which they are attached, form a C₇₋₁₅ carbocycle, suchas a cycloheptyl, cyclopentadecanyl, or naphthyl group.

In some embodiments, R₄ is selected from —(CH₂)_(n)Q and —(CH₂)_(n)CHQR.In some embodiments, Q is selected from the group consisting of —OR,—OH, —O(CH₂)_(n)N(R)₂, —OC(O)R, —CX₃, —CN, —N(R)C(O)R, —N(H)C(O)R,—N(R)S(O)₂R, —N(H)S(O)₂R, —N(R)C(O)N(R)₂, —N(H)C(O)N(R)₂,—N(H)C(O)N(H)(R), —N(R)C(S)N(R)₂, —N(H)C(S)N(R)₂, —N(H)C(S)N(H)(R), anda heterocycle. In other embodiments, Q is selected from the groupconsisting of an imidazole, a pyrimidine, and a purine.

In some embodiments, R₂ and R₃, together with the atom to which they areattached, form a heterocycle or carbocycle. In some embodiments, R₂ andR₃, together with the atom to which they are attached, form a C₃₋₆carbocycle, such as a phenyl group. In certain embodiments, theheterocycle or C₃₋₆ carbocycle is substituted with one or more alkylgroups (e.g., at the same ring atom or at adjacent or non-adjacent ringatoms). For example, R₂ and R₃, together with the atom to which they areattached, may form a phenyl group bearing one or more C₅ alkylsubstitutions.

In some embodiments, the pharmaceutical compositions of the presentdisclosure, the compound of formula (I) is selected from the groupconsisting of:

and salts or stereoisomers thereof.

In other embodiments, the compound of Formula (I) is selected from thegroup consisting of Compound 1-Compound 147, or salt or stereoisomersthereof.

Amine moieties of the lipid compounds disclosed herein can be protonatedunder certain conditions. For example, the central amine moiety of alipid according to formula (I) is typically protonated (i.e., positivelycharged) at a pH below the pKa of the amino moiety and is substantiallynot charged at a pH above the pKa. Such lipids may be referred toionizable amino lipids.

In one specific embodiment, the ionizable amino lipidis Compound 18.

In some embodiments, the amount the ionizable amino lipid, e.g.,compound of formula (I), ranges from about 1 mol % to 99 mol % in thelipid composition.

In one embodiment, the amount of the ionizable amino lipid, e.g.,compound of formula (I), is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or99 mol % in the lipid composition.

In one embodiment, the amount of the ionizable amino lipid, e.g., thecompound of formula (I), ranges from about 30 mol % to about 70 mol %,from about 35 mol % to about 65 mol %, from about 40 mol % to about 60mol %, and from about 45 mol % to about 55 mol % in the lipidcomposition.

In one specific embodiment, the amount of the ionizable amino lipid,e.g., compound of formula (I), is about 50 mol % in the lipidcomposition.

In addition to the ionizable amino lipid disclosed herein, e.g.,compound of formula (I), the lipid composition of the pharmaceuticalcompositions disclosed herein can comprise additional components such asphospholipids, structural lipids, quaternary amine compounds,PEG-lipids, and any combination thereof.

In other aspects, the lipid nanoparticle comprises a molar ratio ofabout 20-60% ionizable amino lipid:5-25% phospholipid lipid:25-55%sterol; and 0.5-15% PEG-modified lipid. In other aspects, the lipidnanoparticle carrier comprises a molar ratio of about 20-60% Compound18: 5-25% phospholipid:25-55% cholesterol; and 0.5-15% PEG-modifiedlipid. In other aspects, the lipid nanoparticle carrier comprises amolar ratio of about 50% ionizable amino lipid:about 10%phospholipid:about 38.5% cholesterol; and about 1.5% PEG-modified lipid.In other aspects, the lipid nanoparticle carrier comprises a molar ratioof about 50% Compound 18:about 10% phospholipid:about 38.5% cholesterol;and about 1.5% PEG-modified lipid. In other aspects, the lipidnanoparticle carrier comprises a molar ratio of about 49.83% ionizableamino lipid:about 9.83% phospholipid:about 30.33% cholesterol; and about2.0% PEG-modified lipid. In other aspects, the lipid nanoparticlecarrier comprises a molar ratio of about 49.83% Compound 18:about 9.83%phospholipid:about 30.33% cholesterol; and about 2.0% PEG-modifiedlipid.

b. Additional Components in the Lipid Composition

(i) Phospholipids

The lipid composition of the pharmaceutical composition disclosed hereincan comprise one or more phospholipids, for example, one or moresaturated or (poly)unsaturated phospholipids or a combination thereof.In general, phospholipids comprise a phospholipid moiety and one or morefatty acid moieties. For example, a phospholipid can be a lipidaccording to formula (VII):

in which R_(p) represents a phospholipid moiety and R₁ and R₂ representfatty acid moieties with or without unsaturation that may be the same ordifferent.

A phospholipid moiety may be selected, for example, from thenon-limiting group consisting of phosphatidyl choline, phosphatidylethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidicacid, 2-lysophosphatidyl choline, and a sphingomyelin.

A fatty acid moiety may be selected, for example, from the non-limitinggroup consisting of lauric acid, myristic acid, myristoleic acid,palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleicacid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid,arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoicacid, and docosahexaenoic acid.

Particular phospholipids may facilitate fusion to a membrane. Forexample, a cationic phospholipid may interact with one or morenegatively charged phospholipids of a membrane (e.g., a cellular orintracellular membrane). Fusion of a phospholipid to a membrane mayallow one or more elements (e.g., a therapeutic agent) of alipid-containing composition (e.g., LNPs) to pass through the membranepermitting, e.g., delivery of the one or more elements to a targettissue (e.g., tumoral tissue).

Non-natural phospholipid species including natural species withmodifications and substitutions including branching, oxidation,cyclization, and alkynes are also contemplated. For example, aphospholipid may be functionalized with or cross-linked to one or morealkynes (e.g., an alkenyl group in which one or more double bonds isreplaced with a triple bond). Under appropriate reaction conditions, analkyne group may undergo a copper-catalyzed cycloaddition upon exposureto an azide. Such reactions may be useful in functionalizing a lipidbilayer of a nanoparticle composition to facilitate membrane permeationor cellular recognition or in conjugating a nanoparticle composition toa useful component such as a targeting or imaging moiety (e.g., a dye).

Phospholipids include, but are not limited to, glycerophospholipids suchas phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines,phosphatidylinositols, phosphatidy glycerols, and phosphatidic acids.Phospholipids also include phosphosphingolipid, such as sphingomyelin.In some embodiments, a pharmaceutical composition for intratumoraldelivery disclosed herein can comprise more than one phospholipid. Whenmore than one phospholipid is used, such phospholipids can belong to thesame phospholipid class (e.g., MSPC and DSPC) or different classes(e.g., MSPC and MSPE).

Phospholipids may be of a symmetric or an asymmetric type. As usedherein, the term “symmetric phospholipid” includes glycerophospholipidshaving matching fatty acid moieties and sphingolipids in which thevariable fatty acid moiety and the hydrocarbon chain of the sphingosinebackbone include a comparable number of carbon atoms. As used herein,the term “asymmetric phospholipid” includes lysolipids,glycerophospholipids having different fatty acid moieties (e.g., fattyacid moieties with different numbers of carbon atoms and/orunsaturations (e.g., double bonds)), and sphingolipids in which thevariable fatty acid moiety and the hydrocarbon chain of the sphingosinebackbone include a dissimilar number of carbon atoms (e.g., the variablefatty acid moiety include at least two more carbon atoms than thehydrocarbon chain or at least two fewer carbon atoms than thehydrocarbon chain).

In some embodiments, the lipid composition of a pharmaceuticalcomposition disclosed herein comprises at least one symmetricphospholipid. Symmetric phospholipids may be selected from thenon-limiting group consisting of

-   1,2-dipropionyl-sn-glycero-3-phosphocholine (03:0 PC),-   1,2-dibutyryl-sn-glycero-3-phosphocholine (04:0 PC),-   1,2-dipentanoyl-sn-glycero-3-phosphocholine (05:0 PC),-   1,2-dihexanoyl-sn-glycero-3-phosphocholine (06:0 PC),-   1,2-diheptanoyl-sn-glycero-3-phosphocholine (07:0 PC),-   1,2-dioctanoyl-sn-glycero-3-phosphocholine (08:0 PC),-   1,2-dinonanoyl-sn-glycero-3-phosphocholine (09:0 PC),-   1,2-didecanoyl-sn-glycero-3-phosphocholine (10:0 PC),-   1,2-diundecanoyl-sn-glycero-3-phosphocholine (11:0 PC, DUPC),-   1,2-dilauroyl-sn-glycero-3-phosphocholine (12:0 PC),-   1,2-ditridecanoyl-sn-glycero-3-phosphocholine (13:0 PC),-   1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0 PC, DMPC),-   1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (15:0 PC),-   1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16:0 PC, DPPC),-   1,2-diphytanoyl-sn-glycero-3-phosphocholine (4ME 16:0 PC),-   1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (17:0 PC),-   1,2-distearoyl-sn-glycero-3-phosphocholine (18:0 PC, DSPC),-   1,2-dinonadecanoyl-sn-glycero-3-phosphocholine (19:0 PC),-   1,2-diarachidoyl-sn-glycero-3-phosphocholine (20:0 PC),-   1,2-dihenarachidoyl-sn-glycero-3-phosphocholine (21:0 PC),-   1,2-dibehenoyl-sn-glycero-3-phosphocholine (22:0 PC),-   1,2-ditricosanoyl-sn-glycero-3-phosphocholine (23:0 PC),-   1,2-dilignoceroyl-sn-glycero-3-phosphocholine (24:0 PC),-   1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (14:1 (Δ9-Cis) PC),-   1,2-dimyristelaidoyl-sn-glycero-3-phosphocholine (14:1 (Δ9-Trans)    PC),-   1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine (16:1 (Δ9-Cis) PC),-   1,2-dipalmitelaidoyl-sn-glycero-3-phosphocholine (16:1 (Δ9-Trans)    PC),-   1,2-dipetroselenoyl-sn-glycero-3-phosphocholine (18:1 (Δ6-Cis) PC),-   1,2-dioleoyl-sn-glycero-3-phosphocholine (18:1 (Δ9-Cis) PC, DOPC),-   1,2-dielaidoyl-sn-glycero-3-phosphocholine (18:1 (Δ9-Trans) PC),-   1,2-dilinoleoyl-sn-glycero-3-phosphocholine (18:2 (Cis) PC, DLPC),-   1,2-dilinolenoyl-sn-glycero-3-phosphocholine (18:3 (Cis) PC, DLnPC),-   1,2-dieicosenoyl-sn-glycero-3-phosphocholine (20:1 (Cis) PC),-   1,2-diarachidonoyl-sn-glycero-3-phosphocholine (20:4 (Cis) PC,    DAPC),-   1,2-dierucoyl-sn-glycero-3-phosphocholine (22:1 (Cis) PC),-   1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine (22:6 (Cis) PC,    DHAPC),-   1,2-dinervonoyl-sn-glycero-3-phosphocholine (24:1 (Cis) PC),-   1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine (06:0 PE),-   1,2-dioctanoyl-sn-glycero-3-phosphoethanolamine (08:0 PE),-   1,2-didecanoyl-sn-glycero-3-phosphoethanolamine (10:0 PE),-   1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (12:0 PE),-   1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (14:0 PE),-   1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine (15:0 PE),-   1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (16:0 PE),-   1,2-diphytanoyl-sn-glycero-3-phosphoethanol amine (4ME 16:0 PE),-   1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine (17:0 PE),-   1,2-distearoyl-sn-glycero-3-phosphoethanolamine (18:0 PE, DSPE),-   1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine (16:1 PE),-   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE,    DOPE),-   1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Trans)    PE),-   1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine (18:2 PE, DLPE),-   1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine (18:3 PE, DLnPE),-   1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine (20:4 PE, DAPE),-   1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine (22:6 PE,    DHAPE),-   1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),-   1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt    (DOPG), and    any combination thereof.

In some embodiments, the lipid composition of a pharmaceuticalcomposition disclosed herein comprises at least one symmetricphospholipid selected from the non-limiting group consisting of DLPC,DMPC, DOPC, DPPC, DSPC, DUPC, 18:0 Diether PC, DLnPC, DAPC, DHAPC, DOPE,4ME 16:0 PE, DSPE, DLPE, DLnPE, DAPE, DHAPE, DOPG, and any combinationthereof.

In some embodiments, the lipid composition of a pharmaceuticalcomposition disclosed herein comprises at least one asymmetricphospholipid. Asymmetric phospholipids may be selected from thenon-limiting group consisting of

-   1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC,    MPPC),-   1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC,    MSPC),-   1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-02:0 PC),-   1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC,    PMPC),-   1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC,    PSPC),-   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC,    POPC),-   1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC,    PLPC),-   1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4    PC),-   1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6    PC),-   1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC,    SMPC),-   1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC,    SPPC),-   1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC,    SOPC),-   1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0-18:2 PC),-   1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4    PC),-   1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0-22:6    PC),-   1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC,    OMPC),-   1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1-16:0 PC,    OPPC),-   1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1-18:0 PC,    OSPC),-   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE,    POPE),-   1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:2    PE),-   1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine    (16:0-20:4 PE),-   1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine    (16:0-22:6 PE),-   1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:1 PE),-   1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:2    PE),-   1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine    (18:0-20:4 PE),-   1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine    (18:0-22:6 PE),-   1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine    (OChemsPC), and    any combination thereof.

Asymmetric lipids useful in the lipid composition may also belysolipids. Lysolipids may be selected from the non-limiting groupconsisting of

-   1-hexanoyl-2-hydroxy-sn-glycero-3-phosphocholine (06:0 Lyso PC),-   1-heptanoyl-2-hydroxy-sn-glycero-3-phosphocholine (07:0 Lyso PC),-   1-octanoyl-2-hydroxy-sn-glycero-3-phosphocholine (08:0 Lyso PC),-   1-nonanoyl-2-hydroxy-sn-glycero-3-phosphocholine (09:0 Lyso PC),-   1-decanoyl-2-hydroxy-sn-glycero-3-phosphocholine (10:0 Lyso PC),-   1-undecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (11:0 Lyso PC),-   1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (12:0 Lyso PC),-   1-tridecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (13:0 Lyso PC),-   1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 Lyso PC),-   1-pentadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (15:0 Lyso    PC),-   1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (16:0 Lyso PC),-   1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (17:0 Lyso    PC),-   1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:0 Lyso PC),-   1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:1 Lyso PC),-   1-nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (19:0 Lyso PC),-   1-arachidoyl-2-hydroxy-sn-glycero-3-phosphocholine (20:0 Lyso PC),-   1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine (22:0 Lyso PC),-   1-lignoceroyl-2-hydroxy-sn-glycero-3-phosphocholine (24:0 Lyso PC),-   1-hexacosanoyl-2-hydroxy-sn-glycero-3-phosphocholine (26:0 Lyso PC),-   1-myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (14:0 Lyso    PE),-   1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (16:0 Lyso    PE),-   1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:0 Lyso    PE),-   1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:1 Lyso PE),-   1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), and    any combination thereof.

In some embodiment, the lipid composition of a pharmaceuticalcomposition disclosed herein comprises at least one asymmetricphospholipid selected from the group consisting of MPPC, MSPC, PMPC,PSPC, SMPC, SPPC, and any combination thereof. In some embodiments, theasymmetric phospholipid is1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC). In aparticular embodiment, the asymmetric phospholipid is one or morephospholipid disclosed in International Application No. PCT/US 17/27492,filed on Apr. 13, 2017, which is incorporated herein by reference in itsentireties.

In some embodiments, the lipid compositions disclosed herein may containone or more symmetric phospholipids, one or more asymmetricphospholipids, or a combination thereof. When multiple phospholipids arepresent, they can be present in equimolar ratios, or non-equimolarratios.

In one embodiment, the lipid composition of a pharmaceutical compositiondisclosed herein comprises a total amount of phospholipid (e.g., MSPC)which ranges from about 1 mol % to about 20 mol %, from about 5 mol % toabout 20 mol %, from about 10 mol % to about 20 mol %, from about 15 mol% to about 20 mol %, from about 1 mol % to about 15 mol %, from about 5mol % to about 15 mol %, from about 10 mol % to about 15 mol %, fromabout 5 mol % to about 10 mol % in the lipid composition. In oneembodiment, the amount of the phospholipid is from about 8 mol % toabout 15 mol % in the lipid composition. In one embodiment, the amountof the phospholipid (e.g., MSPC) is about 10 mol % in the lipidcomposition.

In some aspects, the amount of a specific phospholipid (e.g., MSPC) isat least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19 or 20 mol % in the lipid composition.

(ii) Quaternary Amine Compounds

The lipid composition of a pharmaceutical composition disclosed hereincan comprise one or more quaternary amine compounds (e.g., DOTAP). Theterm “quaternary amine compound” is used to include those compoundshaving one or more quaternary amine groups (e.g., trialkylamino groups)and permanently carrying a positive charge and existing in a form of asalt. For example, the one or more quaternary amine groups can bepresent in a lipid or a polymer (e.g., PEG). In some embodiments, thequaternary amine compound comprises (1) a quaternary amine group and (2)at least one hydrophobic tail group comprising (i) a hydrocarbon chain,linear or branched, and saturated or unsaturated, and (ii) optionally anether, ester, carbonyl, or ketal linkage between the quaternary aminegroup and the hydrocarbon chain. In some embodiments, the quaternaryamine group can be a trimethylammonium group. In some embodiments, thequaternary amine compound comprises two identical hydrocarbon chains. Insome embodiments, the quaternary amine compound comprises two differenthydrocarbon chains.

In some embodiments, the lipid composition of a pharmaceuticalcomposition disclosed herein comprises at least one quaternary aminecompound. Quaternary amine compound may be selected from thenon-limiting group consisting of

-   1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),-   N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride    (DOTMA),-   1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium    chloride (DOTIM),-   2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium    trifluoroacetate (DOSPA),-   N,N-distearyl-N,N-dimethylammonium bromide (DDAB),-   N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium    bromide (DMRIE),-   N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium    bromide (DORIE),-   N,N-dioleyl-N,N-dimethyl ammonium chloride (DODAC),-   1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC),-   1,2-distearoyl-3-trimethylammonium-propane (DSTAP),-   1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),-   1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP),-   1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP)-   1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC)-   1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC),-   1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC),-   1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC),-   1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1    EPC),-   1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0-18:1    EPC),    and any combination thereof.

In one embodiment, the quaternary amine compound is1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).

Quaternary amine compounds are known in the art, such as those describedin US 2013/0245107 A1, US 2014/0363493 A1, U.S. Pat. No. 8,158,601, WO2015/123264 A1, and WO 2015/148247 A1, which are incorporated herein byreference in their entirety.

In one embodiment, the amount of the quaternary amine compound (e.g.,DOTAP) in the lipid composition disclosed herein ranges from about 0.01mol % to about 20 mol %.

In one embodiment, the amount of the quaternary amine compound (e.g.,DOTAP) in the lipid composition disclosed herein ranges from about 0.5mol % to about 20 mol %, from about 0.5 mol % to about 15 mol %, fromabout 0.5 mol % to about 10 mol %, from about 1 mol % to about 20 mol %,from about 1 mol % to about 15 mol %, from about 1 mol % to about 10 mol%, from about 2 mol % to about 20 mol %, from about 2 mol % to about 15mol %, from about 2 mol % to about 10 mol %, from about 3 mol % to about20 mol %, from about 3 mol % to about 15 mol %, from about 3 mol % toabout 10 mol %, from about 4 mol % to about 20 mol %, from about 4 mol %to about 15 mol %, from about 4 mol % to about 10 mol %, from about 5mol % to about 20 mol %, from about 5 mol % to about 15 mol %, fromabout 5 mol % to about 10 mol %, from about 6 mol % to about 20 mol %,from about 6 mol % to about 15 mol %, from about 6 mol % to about 10 mol%, from about 7 mol % to about 20 mol %, from about 7 mol % to about 15mol %, from about 7 mol % to about 10 mol %, from about 8 mol % to about20 mol %, from about 8 mol % to about 15 mol %, from about 8 mol % toabout 10 mol %, from about 9 mol % to about 20 mol %, from about 9 mol %to about 15 mol %, from about 9 mol % to about 10 mol %.

In one embodiment, the amount of the quaternary amine compound (e.g.,DOTAP) in the lipid composition disclosed herein ranges from about 5 mol% to about 10 mol %.

In one embodiment, the amount of the quaternary amine compound (e.g.,DOTAP) in the lipid composition disclosed herein is about 5 mol %. Inone embodiment, the amount of the quaternary amine compound (e.g.,DOTAP) in the lipid composition disclosed herein is about 10 mol %.

In some embodiments, the amount of the quaternary amine compound (e.g.,DOTAP) is at least about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08,0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3,3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5,12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5,19, 19.5 or 20 mol % in the lipid composition disclosed herein.

In some embodiments, the lipid composition of the pharmaceuticalcompositions disclosed herein comprises a compound of formula (I). Inone embodiment, the mole ratio of the compound of formula (I) (e.g.,Compounds 18, 25, 26 or 48) to the quaternary amine compound (e.g.,DOTA) is about 100:1 to about 2.5:1. In one embodiment, the mole ratioof the compound of formula (I) (e.g., Compounds 18, 25, 26 or 48) to thequaternary amine compound (e.g., DOTAP) is about 90:1, about 80:1, about70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1,or about 2.5:1. In one embodiment, the mole ratio of the compound offormula (I) (e.g., Compounds 18, 25, 26 or 48) to the quaternary aminecompound (e.g., DOTAP) in the lipid composition disclosed herein isabout 10:1.

In some embodiments, the lipid composition of the pharmaceuticalcompositions disclosed herein comprises the lipid composition disclosedin International Application No. PCT/US2017/027492, filed Apr. 13, 2017,which is incorporated herein by reference in its entirety.

In some aspects, the lipid composition of the pharmaceuticalcompositions disclosed herein does not comprise a quaternary aminecompound. In some aspects, the lipid composition of the pharmaceuticalcompositions disclosed herein does not comprise DOTAP.

(iii) Structural Lipids

The lipid composition of a pharmaceutical composition disclosed hereincan comprise one or more structural lipids. As used herein, the term“structural lipid” refers to sterols and also to lipids containingsterol moieties. In some embodiments, the structural lipid is selectedfrom the group consisting of cholesterol, fecosterol, sitosterol,ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine,tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof. In someembodiments, the structural lipid is cholesterol.

In one embodiment, the amount of the structural lipid (e.g., an sterolsuch as cholesterol) in the lipid composition of a pharmaceuticalcomposition disclosed herein ranges from about 20 mol % to about 60 mol%, from about 25 mol % to about 55 mol %, from about 30 mol % to about50 mol %, or from about 35 mol % to about 45 mol %.

In one embodiment, the amount of the structural lipid (e.g., an sterolsuch as cholesterol) in the lipid composition disclosed herein rangesfrom about 25 mol % to about 30 mol %, from about 30 mol % to about 35mol %, or from about 35 mol % to about 40 mol %.

In one embodiment, the amount of the structural lipid (e.g., a sterolsuch as cholesterol) in the lipid composition disclosed herein is about23.5 mol %, about 28.5 mol %, about 33.5 mol %, or about 38.5 mol %.

In some embodiments, the amount of the structural lipid (e.g., an sterolsuch as cholesterol) in the lipid composition disclosed herein is atleast about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,53, 54, 55, 56, 57, 58, 59, or 60 mol %.

In some aspects, the lipid composition component of the pharmaceuticalcompositions for intratumoral delivery disclosed does not comprisecholesterol.

(iv) Polyethylene Glycol (PEG)-Lipids

The lipid composition of a pharmaceutical composition disclosed hereincan comprise one or more a polyethylene glycol (PEG) lipid.

As used herein, the term “PEG-lipid” refers to polyethylene glycol(PEG)-modified lipids. Non-limiting examples of PEG-lipids includePEG-modified phosphatidylethanolamine and phosphatidic acid,PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modifieddialkylamines and PEG-modified 1,2-diacyloxypropan-3-amines. Such lipidsare also referred to as PEGylated lipids. For example, a PEG lipid maybe PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPElipid.

In some embodiments, the PEG-lipid includes, but not limited to1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl,PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG),PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), orPEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA).

In one embodiment, the PEG-lipid is selected from the group consistingof a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidicacid, a PEG-modified ceramide, a PEG-modified dialkylamine, aPEG-modified diacylglycerol, a PEG-modified dialkylglycerol, andmixtures thereof.

In some embodiments, the lipid moiety of the PEG-lipids includes thosehaving lengths of from about C₁₄ to about C₂₂, preferably from about C₁₄to about C₁₆. In some embodiments, a PEG moiety, for example anmPEG-NH₂, has a size of about 1000, 2000, 5000, 10,000, 15,000 or 20,000daltons. In one embodiment, the PEG-lipid is PEG2k-DMG.

In one embodiment, the lipid nanoparticles described herein may comprisea PEG lipid which is a non-diffusible PEG. Non-limiting examples ofnon-diffusible PEGs include PEG-DSG and PEG-DSPE.

PEG-lipids are known in the art, such as those described in U.S. Pat.No. 8,158,601 and International Publ. No. WO 2015/130584 A2, which areincorporated herein by reference in their entirety.

In one embodiment, the amount of PEG-lipid in the lipid composition of apharmaceutical composition disclosed herein ranges from about 0.1 mol %to about 5 mol %, from about 0.5 mol % to about 5 mol %, from about 1mol % to about 5 mol %, from about 1.5 mol % to about 5 mol %, fromabout 2 mol % to about 5 mol % mol %, from about 0.1 mol % to about 4mol %, from about 0.5 mol % to about 4 mol %, from about 1 mol % toabout 4 mol %, from about 1.5 mol % to about 4 mol %, from about 2 mol %to about 4 mol %, from about 0.1 mol % to about 3 mol %, from about 0.5mol % to about 3 mol %, from about 1 mol % to about 3 mol %, from about1.5 mol % to about 3 mol %, from about 2 mol % to about 3 mol %, fromabout 0.1 mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %,from about 1 mol % to about 2 mol %, from about 1.5 mol % to about 2 mol%, from about 0.1 mol % to about 1.5 mol %, from about 0.5 mol % toabout 1.5 mol %, or from about 1 mol % to about 1.5 mol %.

In one embodiment, the amount of PEG-lipid in the lipid compositiondisclosed herein is about 1.5 mol %.

In one embodiment, the amount of PEG-lipid in the lipid compositiondisclosed herein is at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7,0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2,2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7,3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5 mol %.

In some aspects, the lipid composition of the pharmaceuticalcompositions disclosed herein does not comprise a PEG-lipid.

In some embodiments, the lipid composition disclosed herein comprises anionizable amino lipid, e.g., a compound of formula (I), and anasymmetric phospholipid. In some embodiments, the lipid compositioncomprises compound 18 and MSPC.

In some embodiments, the lipid composition disclosed herein comprises anionizable amino lipid, e.g., a compound of formula (I), and a quaternaryamine compound. In some embodiments, the lipid composition comprisescompound 18 and DOTAP.

In some embodiments, the lipid composition disclosed herein comprises anionizable amino lipid, e.g., a compound of formula (I), an asymmetricphospholipid, and a quaternary amine compound. In some embodiments, thelipid composition comprises compound 18, MSPC and DOTAP.

In one embodiment, the lipid composition comprises about 50 mol % of acompound of formula (I) (e.g. Compounds 18, 25, 26 or 48), about 10 mol% of DSPC or MSPC, about 33.5 mol % of cholesterol, about 1.5 mol % ofPEG-DMG, and about 5 mol % of DOTAP. In one embodiment, the lipidcomposition comprises about 50 mol % of a compound of formula (I) (e.g.Compounds 18, 25, 26 or 48), about 10 mol % of DSPC or MSPC, about 28.5mol % of cholesterol, about 1.5 mol % of PEG-DMG, and about 10 mol % ofDOTAP.

In some embodiments, the lipid nanoparticle comprises a molar ratio ofabout 20-60% ionizable amino lipid:5-25% phospholipid:25-55% sterol; and0.5-15% PEG-modified lipid. In other aspects, the lipid nanoparticlecarrier comprises a molar ratio of about 20-60% Compound 18: 5-25%phospholipid:25-55% cholesterol; and 0.5-15% PEG-modified lipid. Inother aspects, the lipid nanoparticle carrier comprises a molar ratio ofabout 50% ionizable amino lipid:about 10% phospholipid:about 38.5%cholesterol; and about 1.5% PEG-modified lipid. In other aspects, thelipid nanoparticle carrier comprises a molar ratio of about 50% Compound18: about 10% phospholipid:about 38.5% cholesterol; and about 1.5%PEG-modified lipid. In other aspects, the lipid nanoparticle carriercomprises a molar ratio of about 49.83% ionizable amino lipid:about9.83% phospholipid:about 30.33% cholesterol; and about 2.0% PEG-modifiedlipid. In other aspects, the lipid nanoparticle carrier comprises amolar ratio of about 49.83% Compound 18: about 9.83% phospholipid:about30.33% cholesterol; and about 2.0% PEG-modified lipid.

The components of the lipid nanoparticle may be tailored for optimaldelivery of the polynucleotides based on the desired outcome. As anon-limiting example, the lipid nanoparticle may comprise 40-60 mol % anionizable amino lipid (e.g., a compound of formula (I)), 8-16 mol %phospholipid, 30-45 mol % cholesterol, 1-5 mol % PEG lipid, andoptionally 1-15 mol % quaternary amine compound.

In some embodiments, the lipid nanoparticle may comprise 45-65 mol % ofan ionizable amino lipid (e.g., a compound of formula (I)), 5-10 mol %phospholipid, 25-40 mol % cholesterol, 0.5-5 mol % PEG lipid, andoptionally 1-15 mol % quaternary amine compound.

Non-limiting examples of nucleic acid lipid particles are disclosed inU.S. Patent Publication No. 20140121263, herein incorporated byreference in its entirety.

(v) Other Ionizable Amino Lipids

The lipid composition of the pharmaceutical composition disclosed hereincan comprise one or more ionizable lipids in addition to a lipidaccording to formula (I). As used herein, the term “ionizable lipid” hasits ordinary meaning in the art and may refer to a lipid comprising oneor more charged moieties. In some embodiments, an ionizable lipid may bepositively charged or negatively charged. An ionizable lipid may bepositively charged, in which case it can be referred to as ‘cationiclipid.” For example, an ionizable molecule may comprise an amine group,referred to as ionizable amino lipids.

Ionizable lipids may be selected from the non-limiting group consistingof 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10),N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine(KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25),1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA),2,2-dilinoleyl-4-dimethyl aminomethyl-[1,3]-dioxolane (DLin-K-DMA),heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate(DLin-MC3-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane(DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA),(13Z,165Z)—N,N-dimethyl-3-nonydocosa-13-16-dien-1-amine (L608),2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-di en-1-yloxy]propan-1-amine (Octyl-CLinDMA),(2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA (2R)), and(2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA (2S)). In addition tothese, an ionizable amino lipid may also be a lipid including a cyclicamine group.

Ionizable lipids can also be the compounds disclosed in InternationalPublication No. WO 2015/199952 A1, hereby incorporated by reference inits entirety. For example, the ionizable amino lipids include, but notlimited to:

and any combination thereof.

(vi) Other Lipid Composition Components

The lipid composition of a pharmaceutical composition disclosed hereinmay include one or more components in addition to those described above.For example, the lipid composition may include one or more permeabilityenhancer molecules, carbohydrates, polymers, surface altering agents(e.g., surfactants), or other components. For example, a permeabilityenhancer molecule may be a molecule described by U.S. Patent ApplicationPublication No. 2005/0222064. Carbohydrates may include simple sugars(e.g., glucose) and polysaccharides (e.g., glycogen and derivatives andanalogs thereof). The lipid composition may include a buffer such as,but not limited to, citrate or phosphate at a pH of 7, salt and/orsugar. Salt and/or sugar may be included in the formulations describedherein for isotonicity.

A polymer may be included in and/or used to encapsulate or partiallyencapsulate a pharmaceutical composition disclosed herein (e.g., apharmaceutical composition in lipid nanoparticle form). A polymer may bebiodegradable and/or biocompatible. A polymer may be selected from, butis not limited to, polyamines, polyethers, polyamides, polyesters,polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides,polysulfones, polyurethanes, polyacetylenes, polyethylenes,polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates,polyacrylonitriles, and polyarylates.

The ratio between the lipid composition and the polynucleotide range canbe from about 10:1 to about 60:1 (wt/wt).

In some embodiments, the ratio between the lipid composition and thepolynucleotide can be about 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1,17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1,29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1,41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, 51:1, 52:1,53:1, 54:1, 55:1, 56:1, 57:1, 58:1, 59:1 or 60:1 (wt/wt). In someembodiments, the wt/wt ratio of the lipid composition to thepolynucleotide encoding a therapeutic agent is about 20:1 or about 15:1.

In some embodiments, the pharmaceutical composition disclosed herein cancontain more than one polypeptides. For example, a pharmaceuticalcomposition disclosed herein can contain two or more polynucleotides(e.g., RNA, e.g., mRNA).

In one embodiment, the lipid nanoparticles described herein may comprisepolynucleotides (e.g., mRNA) in a lipid:polynucleotide weight ratio of5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1 or70:1, or a range or any of these ratios such as, but not limited to, 5:1to about 10:1, from about 5:1 to about 15:1, from about 5:1 to about20:1, from about 5:1 to about 25:1, from about 5:1 to about 30:1, fromabout 5:1 to about 35:1, from about 5:1 to about 40:1, from about 5:1 toabout 45:1, from about 5:1 to about 50:1, from about 5:1 to about 55:1,from about 5:1 to about 60:1, from about 5:1 to about 70:1, from about10:1 to about 15:1, from about 10:1 to about 20:1, from about 10:1 toabout 25:1, from about 10:1 to about 30:1, from about 10:1 to about35:1, from about 10:1 to about 40:1, from about 10:1 to about 45:1, fromabout 10:1 to about 50:1, from about 10:1 to about 55:1, from about 10:1to about 60:1, from about 10:1 to about 70:1, from about 15:1 to about20:1, from about 15:1 to about 25:1, from about 15:1 to about 30:1, fromabout 15:1 to about 35:1, from about 15:1 to about 40:1, from about 15:1to about 45:1, from about 15:1 to about 50:1, from about 15:1 to about55:1, from about 15:1 to about 60:1 or from about 15:1 to about 70:1.

In one embodiment, the lipid nanoparticles described herein may comprisethe polynucleotide in a concentration from approximately 0.1 mg/ml to 2mg/ml such as, but not limited to, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1.0 mg/ml,1.1 mg/ml, 1.2 mg/ml, 1.3 mg/ml, 1.4 mg/ml, 1.5 mg/ml, 1.6 mg/ml, 1.7mg/ml, 1.8 mg/ml, 1.9 mg/ml, 2.0 mg/ml or greater than 2.0 mg/ml.

In one embodiment, formulations comprising the polynucleotides and lipidnanoparticles described herein may comprise 0.15 mg/ml to 2 mg/ml of thepolynucleotide described herein (e.g., mRNA). In some embodiments, theformulation may further comprise 10 mM of citrate buffer and theformulation may additionally comprise up to 10% w/w of sucrose (e.g., atleast 1% w/w, at least 2% w/w, at least 3% w/w, at least 4% w/w, atleast 5% w/w, at least 6% w/w, at least 7% w/w, at least 8% w/w, atleast 9% w/w or 10% w/w).

(vii) Nanoparticle Compositions

In some embodiments, the pharmaceutical compositions disclosed hereinare formulated as lipid nanoparticles (LNP). Accordingly, the presentdisclosure also provides nanoparticle compositions comprising (i) alipid composition comprising a delivery agent such as a compound offormula (I) as described herein, and (ii) a polynucleotide encoding anIL12B polypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides. In such nanoparticle composition, the lipid compositiondisclosed herein can encapsulate the polynucleotide encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides.

Nanoparticle compositions are typically sized on the order ofmicrometers or smaller and may include a lipid bilayer. Nanoparticlecompositions encompass lipid nanoparticles (LNPs), liposomes (e.g.,lipid vesicles), and lipoplexes. For example, a nanoparticle compositionmay be a liposome having a lipid bilayer with a diameter of 500 nm orless.

Nanoparticle compositions include, for example, lipid nanoparticles(LNPs), liposomes, and lipoplexes. In some embodiments, nanoparticlecompositions are vesicles including one or more lipid bilayers. Incertain embodiments, a nanoparticle composition includes two or moreconcentric bilayers separated by aqueous compartments. Lipid bilayersmay be functionalized and/or crosslinked to one another. Lipid bilayersmay include one or more ligands, proteins, or channels.

Nanoparticle compositions of the present disclosure comprise at leastone compound according to formula (I). For example, the nanoparticlecomposition can include one or more of Compounds 1-147, or one or moreof Compounds 1-342. Nanoparticle compositions can also include a varietyof other components. For example, the nanoparticle composition mayinclude one or more other lipids in addition to a lipid according toformula (I), such as (i) at least one phospholipid, (ii) at least onequaternary amine compound, (iii) at least one structural lipid, (iv) atleast one PEG-lipid, or (v) any combination thereof.

In some embodiments, the nanoparticle composition comprises a compoundof formula (I), (e.g., Compounds 18, 25, 26 or 48). In some embodiments,the nanoparticle composition comprises a compound of formula (I) (e.g.,Compounds 18, 25, 26 or 48) and a phospholipid (e.g., DSPC or MSPC). Insome embodiments, the nanoparticle composition comprises a compound offormula (I) (e.g., Compounds 18, 25, 26 or 48), a phospholipid (e.g.,DSPC or MSPC), and a quaternary amine compound (e.g., DOTAP). In someembodiments, the nanoparticle composition comprises a compound offormula (I) (e.g., Compounds 18, 25, 26 or 48), and a quaternary aminecompound (e.g., DOTAP).

In some embodiments, the nanoparticle composition comprises a lipidcomposition consisting or consisting essentially of compound of formula(I) (e.g., Compounds 18, 25, 26 or 48). In some embodiments, thenanoparticle composition comprises a lipid composition consisting orconsisting essentially of a compound of formula (I) (e.g., Compounds 18,25, 26 or 48) and a phospholipid (e.g., DSPC or MSPC). In someembodiments, the nanoparticle composition comprises a lipid compositionconsisting or consisting essentially of a compound of formula (I) (e.g.,Compounds 18, 25, 26 or 48), a phospholipid (e.g., DSPC or MSPC), and aquaternary amine compound (e.g., DOTAP). In some embodiments, thenanoparticle composition comprises a lipid composition consisting orconsisting essentially of a compound of formula (I) (e.g., Compounds 18,25, 26 or 48), and a quaternary amine compound (e.g., DOTAP).

In one embodiment, the nanoparticle composition comprises (1) a lipidcomposition comprising about 50 mole % of a compound of formula (I)(e.g., Compounds 18, 25, 26 or 48); about 10 mole % of DSPC or MSPC;about 33.5 mole % of cholesterol; about 1.5 mole % of PEG-DMG (e.g.,PEG_(2k)-DMG); about 5 mole % of DOTAP; and (2) a polynucleotide.

In one embodiment, the nanoparticle composition comprises (1) a lipidcomposition comprising about 50 mole % of a compound of formula (I)(e.g., Compounds 18, 25, 26 or 48); about 10 mole % of DSPC or MSPC;about 28.5 mole % of cholesterol; about 1.5 mole % of PEG-DMG (e.g.,PEG_(2k)-DMG); about 10 mole % of DOTAP; and (2) a polynucleotide.

In one embodiment, the nanoparticle composition comprises (1) a lipidcomposition comprising about 50 mole % of a compound of formula (I)(e.g., Compounds 18, 25, 26 or 48); about 10 mole % of DSPC or MSPC;about 23.5 mole % of cholesterol; about 1.5 mole % of PEG-DMG (e.g.,PEG_(2k)-DMG); about 15 mole % of DOTAP; and (2) a polynucleotide.

Nanoparticle compositions may be characterized by a variety of methods.For example, microscopy (e.g., transmission electron microscopy orscanning electron microscopy) may be used to examine the morphology andsize distribution of a nanoparticle composition. Dynamic lightscattering or potentiometry (e.g., potentiometric titrations) may beused to measure zeta potentials. Dynamic light scattering may also beutilized to determine particle sizes. Instruments such as the ZetasizerNano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) may alsobe used to measure multiple characteristics of a nanoparticlecomposition, such as particle size, polydispersity index, and zetapotential.

As generally defined herein, the term “lipid” refers to a small moleculethat has hydrophobic or amphiphilic properties. Lipids may be naturallyoccurring or synthetic. Examples of classes of lipids include, but arenot limited to, fats, waxes, sterol-containing metabolites, vitamins,fatty acids, glycerolipids, glycerophospholipids, sphingolipids,saccharolipids, and polyketides, and prenol lipids. In some instances,the amphiphilic properties of some lipids leads them to form liposomes,vesicles, or membranes in aqueous media.

In some embodiments, a lipid nanoparticle (LNP) may comprise anionizable lipid. As used herein, the term “ionizable lipid” has itsordinary meaning in the art and may refer to a lipid comprising one ormore charged moieties. In some embodiments, an ionizable lipid may bepositively charged or negatively charged. An ionizable lipid may bepositively charged, in which case it can be referred to as “cationiclipid”. For example, an ionizable molecule may comprise an amine group,referred to as ionizable amino lipids. As used herein, a “chargedmoiety” is a chemical moiety that carries a formal electronic charge,e.g., monovalent (+1, or −1), divalent (+2, or −2), trivalent (+3, or−3), etc. The charged moiety may be anionic (i.e., negatively charged)or cationic (i.e., positively charged). Examples of positively-chargedmoieties include amine groups (e.g., primary, secondary, and/or tertiaryamines), ammonium groups, pyridinium group, guanidine groups, andimidizolium groups. In a particular embodiment, the charged moietiescomprise amine groups. Examples of negatively-charged groups orprecursors thereof, include carboxylate groups, sulfonate groups,sulfate groups, phosphonate groups, phosphate groups, hydroxyl groups,and the like. The charge of the charged moiety may vary, in some cases,with the environmental conditions, for example, changes in pH may alterthe charge of the moiety, and/or cause the moiety to become charged oruncharged. In general, the charge density of the molecule may beselected as desired.

It should be understood that the terms “charged” or “charged moiety”does not refer to a “partial negative charge” or “partial positivecharge” on a molecule. The terms “partial negative charge” and “partialpositive charge” are given its ordinary meaning in the art. A “partialnegative charge” may result when a functional group comprises a bondthat becomes polarized such that electron density is pulled toward oneatom of the bond, creating a partial negative charge on the atom. Thoseof ordinary skill in the art will, in general, recognize bonds that canbecome polarized in this way.

In some embodiments, the ionizable lipid is an ionizable amino lipid,sometimes referred to in the art as an “ionizable cationic lipid”. Inone embodiment, the ionizable amino lipid may have a positively chargedhydrophilic head and a hydrophobic tail that are connected via a linkerstructure.

The size of the nanoparticles can help counter biological reactions suchas, but not limited to, inflammation, or can increase the biologicaleffect of the polynucleotide.

As used herein, “size” or “mean size” in the context of nanoparticlecompositions refers to the mean diameter of a nanoparticle composition.

In one embodiment, the polynucleotide encoding an IL12B polypeptide, anIL12A polypeptide, and/or IL12B and IL12A fusion polypeptides areformulated in lipid nanoparticles having a diameter from about 10 toabout 100 nm such as, but not limited to, about 10 to about 20 nm, about10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm,about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 toabout 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about30 to about 60 nm, about 30 to about 70 nm, about 30 to about 80 nm,about 30 to about 90 nm, about 30 to about 100 nm, about 40 to about 50nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40 to about80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about 50 toabout 60 nm, about 50 to about 70 nm, about 50 to about 80 nm, about 50to about 90 nm, about 50 to about 100 nm, about 60 to about 70 nm, about60 to about 80 nm, about 60 to about 90 nm, about 60 to about 100 nm,about 70 to about 80 nm, about 70 to about 90 nm, about 70 to about 100nm, about 80 to about 90 nm, about 80 to about 100 nm and/or about 90 toabout 100 nm.

In one embodiment, the nanoparticles have a diameter from about 10 to500 nm. In one embodiment, the nanoparticle has a diameter greater than100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm,greater than 300 nm, greater than 350 nm, greater than 400 nm, greaterthan 450 nm, greater than 500 nm, greater than 550 nm, greater than 600nm, greater than 650 nm, greater than 700 nm, greater than 750 nm,greater than 800 nm, greater than 850 nm, greater than 900 nm, greaterthan 950 nm or greater than 1000 nm.

In some embodiments, the largest dimension of a nanoparticle compositionis 1 m or shorter (e.g., 1 μm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm,400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, orshorter).

A nanoparticle composition may be relatively homogenous. Apolydispersity index may be used to indicate the homogeneity of ananoparticle composition, e.g., the particle size distribution of thenanoparticle composition. A small (e.g., less than 0.3) polydispersityindex generally indicates a narrow particle size distribution. Ananoparticle composition may have a polydispersity index from about 0 toabout 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08,0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20,0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersityindex of a nanoparticle composition disclosed herein may be from about0.10 to about 0.20.

The zeta potential of a nanoparticle composition may be used to indicatethe electrokinetic potential of the composition. For example, the zetapotential may describe the surface charge of a nanoparticle composition.Nanoparticle compositions with relatively low charges, positive ornegative, are generally desirable, as more highly charged species mayinteract undesirably with cells, tissues, and other elements in thebody. In some embodiments, the zeta potential of a nanoparticlecomposition disclosed herein may be from about −10 mV to about +20 mV,from about −10 mV to about +15 mV, from about 10 mV to about +10 mV,from about −10 mV to about +5 mV, from about −10 mV to about 0 mV, fromabout −10 mV to about −5 mV, from about −5 mV to about +20 mV, fromabout −5 mV to about +15 mV, from about −5 mV to about +10 mV, fromabout −5 mV to about +5 mV, from about −5 mV to about 0 mV, from about 0mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV toabout +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about+20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about+10 mV.

In some embodiments, the zeta potential of the lipid nanoparticles maybe from about 0 mV to about 100 mV, from about 0 mV to about 90 mV, fromabout 0 mV to about 80 mV, from about 0 mV to about 70 mV, from about 0mV to about 60 mV, from about 0 mV to about 50 mV, from about 0 mV toabout 40 mV, from about 0 mV to about 30 mV, from about 0 mV to about 20mV, from about 0 mV to about 10 mV, from about 10 mV to about 100 mV,from about 10 mV to about 90 mV, from about 10 mV to about 80 mV, fromabout 10 mV to about 70 mV, from about 10 mV to about 60 mV, from about10 mV to about 50 mV, from about 10 mV to about 40 mV, from about 10 mVto about 30 mV, from about 10 mV to about 20 mV, from about 20 mV toabout 100 mV, from about 20 mV to about 90 mV, from about 20 mV to about80 mV, from about 20 mV to about 70 mV, from about 20 mV to about 60 mV,from about 20 mV to about 50 mV, from about 20 mV to about 40 mV, fromabout 20 mV to about 30 mV, from about 30 mV to about 100 mV, from about30 mV to about 90 mV, from about 30 mV to about 80 mV, from about 30 mVto about 70 mV, from about 30 mV to about 60 mV, from about 30 mV toabout 50 mV, from about 30 mV to about 40 mV, from about 40 mV to about100 mV, from about 40 mV to about 90 mV, from about 40 mV to about 80mV, from about 40 mV to about 70 mV, from about 40 mV to about 60 mV,and from about 40 mV to about 50 mV. In some embodiments, the zetapotential of the lipid nanoparticles may be from about 10 mV to about 50mV, from about 15 mV to about 45 mV, from about 20 mV to about 40 mV,and from about 25 mV to about 35 mV. In some embodiments, the zetapotential of the lipid nanoparticles may be about 10 mV, about 20 mV,about 30 mV, about 40 mV, about 50 mV, about 60 mV, about 70 mV, about80 mV, about 90 mV, and about 100 mV.

The term “encapsulation efficiency” of a polynucleotide describes theamount of the polynucleotide that is encapsulated by or otherwiseassociated with a nanoparticle composition after preparation, relativeto the initial amount provided. As used herein, “encapsulation” mayrefer to complete, substantial, or partial enclosure, confinement,surrounding, or encasement.

Encapsulation efficiency is desirably high (e.g., close to 100%). Theencapsulation efficiency may be measured, for example, by comparing theamount of the polynucleotide in a solution containing the nanoparticlecomposition before and after breaking up the nanoparticle compositionwith one or more organic solvents or detergents.

Fluorescence may be used to measure the amount of free polynucleotide ina solution. For the nanoparticle compositions described herein, theencapsulation efficiency of a polynucleotide may be at least 50%, forexample 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulationefficiency may be at least 80%. In certain embodiments, theencapsulation efficiency may be at least 90%.

The amount of a polynucleotide present in a pharmaceutical compositiondisclosed herein can depend on multiple factors such as the size of thepolynucleotide, desired target and/or application, or other propertiesof the nanoparticle composition as well as on the properties of thepolynucleotide.

For example, the amount of an mRNA useful in a nanoparticle compositionmay depend on the size (expressed as length, or molecular mass),sequence, and other characteristics of the mRNA. The relative amounts ofa polynucleotide in a nanoparticle composition may also vary.

The relative amounts of the lipid composition and the polynucleotidepresent in a lipid nanoparticle composition of the present disclosurecan be optimized according to considerations of efficacy andtolerability. For compositions including an mRNA as a polynucleotide,the N:P ratio can serve as a useful metric.

As the N:P ratio of a nanoparticle composition controls both expressionand tolerability, nanoparticle compositions with low N:P ratios andstrong expression are desirable. N:P ratios vary according to the ratioof lipids to RNA in a nanoparticle composition.

In general, a lower N:P ratio is preferred. The one or more RNA, lipids,and amounts thereof may be selected to provide an N:P ratio from about2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1,12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1. Incertain embodiments, the N:P ratio may be from about 2:1 to about 8:1.In other embodiments, the N:P ratio is from about 5:1 to about 8:1. Incertain embodiments, the N:P ratio is between 5:1 and 6:1. In onespecific aspect, the N:P ratio is about is about 5.67:1.

In addition to providing nanoparticle compositions, the presentdisclosure also provides methods of producing lipid nanoparticlescomprising encapsulating a polynucleotide. Such method comprises usingany of the pharmaceutical compositions disclosed herein and producinglipid nanoparticles in accordance with methods of production of lipidnanoparticles known in the art. See, e.g., Wang et al. (2015) “Deliveryof oligonucleotides with lipid nanoparticles” Adv. Drug Deliv. Rev.87:68-80; Silva et al. (2015) “Delivery Systems for Biopharmaceuticals.Part I: Nanoparticles and Microparticles” Curr. Pharm. Technol. 16:940-954; Naseri et al. (2015) “Solid Lipid Nanoparticles andNanostructured Lipid Carriers: Structure, Preparation and Application”Adv. Pharm. Bull. 5:305-13; Silva et al. (2015) “Lipid nanoparticles forthe delivery of biopharmaceuticals” Curr. Pharm. Biotechnol. 16:291-302,and references cited therein.

25. Other Delivery Agents

a. Liposomes, Lipoplexes, and Lipid Nanoparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise a delivery agent, e.g., a liposome, a lioplexes, alipid nanoparticle, or any combination thereof. The polynucleotidesdescribed herein (e.g., a polynucleotide comprising a nucleotidesequence encoding an IL12B polypeptide, an IL12A polypeptide, and/orIL12B and IL12A fusion polypeptides) can be formulated using one or moreliposomes, lipoplexes, or lipid nanoparticles. Liposomes, lipoplexes, orlipid nanoparticles can be used to improve the efficacy of thepolynucleotides directed protein production as these formulations canincrease cell transfection by the polynucleotide; and/or increase thetranslation of encoded protein. The liposomes, lipoplexes, or lipidnanoparticles can also be used to increase the stability of thepolynucleotides.

Liposomes are artificially-prepared vesicles that may primarily becomposed of a lipid bilayer and may be used as a delivery vehicle forthe administration of pharmaceutical formulations. Liposomes can be ofdifferent sizes. A multilamellar vesicle (MLV) may be hundreds ofnanometers in diameter, and may contain a series of concentric bilayersseparated by narrow aqueous compartments. A small unicellular vesicle(SUV) may be smaller than 50 nm in diameter, and a large unilamellarvesicle (LUV) may be between 50 and 500 nm in diameter. Liposome designmay include, but is not limited to, opsonins or ligands to improve theattachment of liposomes to unhealthy tissue or to activate events suchas, but not limited to, endocytosis. Liposomes may contain a low or ahigh pH value in order to improve the delivery of the pharmaceuticalformulations.

The formation of liposomes may depend on the pharmaceutical formulationentrapped and the liposomal ingredients, the nature of the medium inwhich the lipid vesicles are dispersed, the effective concentration ofthe entrapped substance and its potential toxicity, any additionalprocesses involved during the application and/or delivery of thevesicles, the optimal size, polydispersity and the shelf-life of thevesicles for the intended application, and the batch-to-batchreproducibility and scale up production of safe and efficient liposomalproducts, etc.

As a non-limiting example, liposomes such as synthetic membrane vesiclesmay be prepared by the methods, apparatus and devices described in U.S.Pub. Nos. US20130177638, US20130177637, US20130177636, US20130177635,US20130177634, US20130177633, US20130183375, US20130183373, andUS20130183372. In some embodiments, the polynucleotides described hereinmay be encapsulated by the liposome and/or it may be contained in anaqueous core that may then be encapsulated by the liposome as describedin, e.g., Intl. Pub. Nos. WO2012031046, WO2012031043, WO2012030901,WO2012006378, and WO2013086526; and U.S. Pub. Nos. US20130189351,US20130195969 and US20130202684. Each of the references in hereinincorporated by reference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a cationic oil-in-water emulsion where the emulsionparticle comprises an oil core and a cationic lipid that can interactwith the polynucleotide anchoring the molecule to the emulsion particle.In some embodiments, the polynucleotides described herein can beformulated in a water-in-oil emulsion comprising a continuoushydrophobic phase in which the hydrophilic phase is dispersed. Exemplaryemulsions can be made by the methods described in Intl. Pub. Nos.WO2012006380 and WO201087791, each of which is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a lipid-polycation complex. The formation of thelipid-polycation complex can be accomplished by methods as described in,e.g., U.S. Pub. No. US20120178702. As a non-limiting example, thepolycation can include a cationic peptide or a polypeptide such as, butnot limited to, polylysine, polyornithine and/or polyarginine and thecationic peptides described in Intl. Pub. No. WO2012013326 or U.S. Pub.No. US20130142818. Each of the references is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a lipid nanoparticle (LNP) such as those described inIntl. Pub. Nos. WO2013123523, WO2012170930, WO2011127255 andWO2008103276; and U.S. Pub. No. US20130171646, each of which is hereinincorporated by reference in its entirety.

Lipid nanoparticle formulations typically comprise one or more lipids.In some embodiments, the lipid is an ionizable lipid (e.g., an ionizableamino lipid). In some embodiments, the lipid is a cationic lipid. Insome embodiments, lipid nanoparticle formulations further comprise othercomponents, including a phospholipid, a structural lipid, a quaternaryamine compound, and a molecule capable of reducing particle aggregation,for example a PEG or PEG-modified lipid.

Cationic and ionizable lipids may include those as described in, e.g.,Intl. Pub. Nos. WO2015199952, WO 2015130584, WO 2015011633, andWO2012040184 WO2013126803, WO2011153120, WO2011149733, WO2011090965,WO2011043913, WO2011022460, WO2012061259, WO2012054365, WO2012044638,WO2010080724, WO201021865, WO2008103276, and WO2013086373; U.S. Pat.Nos. 7,893,302, 7,404,969, 8,283,333, and 8,466,122; and U.S. Pub. Nos.US20110224447, US20120295832, US20150315112, US20100036115,US20120202871, US20130064894, US20130129785, US20130150625,US20130178541, US20130123338 and US20130225836, each of which is hereinincorporated by reference in its entirety. In some embodiments, theamount of the cationic and ionizable lipids in the lipid compositionranges from about 0.01 mol % to about 99 mol %.

Exemplary ionizable lipids include, but not limited to, any one ofCompounds 1-147 disclosed herein, DLin-MC3-DMA (MC3), DLin-DMA, DLenDMA,DLin-D-DMA, DLin-K-DMA, DLin-M-C2-DMA, DLin-K-DMA, DLin-KC2-DMA,DLin-KC3-DMA, DLin-KC4-DMA, DLin-C2K-DMA, DLin-MP-DMA, DODMA, 98N12-5,C12-2000, DLin-C-DAP, DLin-DAC, DLinDAP, DLinAP, DLin-EG-DMA,DLin-2-DMAP, KL10, KL22, KL25, Octyl-CLinDMA, Octyl-CLinDMA (2R),Octyl-CLinDMA (2S), and any combination thereof. Other exemplaryionizable lipids include,(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (L608),(20Z,23Z)—N,N-dimethylnonacosa-20,23-dien-10-amine,(17Z,20Z)—N,N-dimemylhexacosa-17,20-dien-9-amine,(16Z,19Z)—N5N-dimethylpentacosa-16,19-dien-8-amine,(13Z,16Z)—N,N-dimethyldocosa-13,16-dien-5-amine,(12Z,15Z)—N,N-dimethylhenicosa-12,15-dien-4-amine,(14Z,17Z)—N,N-dimethyltricosa-14,17-dien-6-amine,(15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-7-amine,(18Z,21Z)—N,N-dimethylheptacosa-18,21-dien-10-amine,(15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-5-amine,(14Z,17Z)—N,N-dimethyltricosa-14,17-dien-4-amine,(19Z,22Z)—N,N-dimeihyloctacosa-19,22-dien-9-amine,(18Z,21Z)—N,N-dimethylheptacosa-18,21-dien-8-amine,(17Z,20Z)—N,N-dimethylhexacosa-17,20-dien-7-amine,(16Z,19Z)—N,N-dimethylpentacosa-16,19-dien-6-amine,(22Z,25Z)—N,N-dimethylhentriaconta-22,25-dien-10-amine,(21Z,24Z)—N,N-dimethyltriaconta-21,24-dien-9-amine,(18Z)—N,N-dimetylheptacos-18-en-10-amine,(17Z)—N,N-dimethylhexacos-17-en-9-amine,(19Z,22Z)—N,N-dimethyloctacosa-19,22-dien-7-amine,N,N-dimethylheptacosan-10-amine,(20Z,23Z)—N-ethyl-N-methylnonacosa-20,23-dien-10-amine,1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine,(20Z)—N,N-dimethylheptacos-20-en-10-amine, (15Z)—N,N-dimethyleptacos-15-en-10-amine, (14Z)—N,N-dimethylnonacos-14-en-10-amine,(17Z)—N,N-dimethylnonacos-17-en-10-amine,(24Z)—N,N-dimethyltritriacont-24-en-10-amine,(20Z)—N,N-dimethylnonacos-20-en-10-amine,(22Z)—N,N-dimethylhentriacont-22-en-10-amine,(16Z)—N,N-dimethylpentacos-16-en-8-amine,(12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl] eptadecan-8-amine,1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine,N,N-dimethyl-1-[(1 S,2R)-2-octylcyclopropyl]nonadecan-10-amine,N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimethyl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1 S,2R)-2-octylcyclopropyl]hexadecan-8-amine,N,N-dimethyl-[(1R,2 S)-2-undecylcyclopropyl]tetradecan-5-amine,N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine,1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine,R—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,S—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine,(2S)—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine,1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine,(2 S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine;(2S)—N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine,(2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine,(2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine,1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,(2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine,1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine,(2R)—N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,(2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine,N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]octyl}oxy)propan-2-amine,N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine,and (11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,2-trien-10-amine, and anycombination thereof.

Phospholipids include, but are not limited to, glycerophospholipids suchas phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines,phosphatidylinositols, phosphatidy glycerols, and phosphatidic acids.Phospholipids also include phosphosphingolipid, such as sphingomyelin.In some embodiments, the phospholipids are DLPC, DMPC, DOPC, DPPC, DSPC,DUPC, 18:0 Diether PC, DLnPC, DAPC, DHAPC, DOPE, 4ME 16:0 PE, DSPE,DLPE, DLnPE, DAPE, DHAPE, DOPG, and any combination thereof. In someembodiments, the phospholipids are MPPC, MSPC, PMPC, PSPC, SMPC, SPPC,DHAPE, DOPG, and any combination thereof. In some embodiments, theamount of phospholipids (e.g., DSPC and/or MSPC) in the lipidcomposition ranges from about 1 mol % to about 20 mol %.

The structural lipids include sterols and lipids containing sterolmoieties. In some embodiments, the structural lipids includecholesterol, fecosterol, sitosterol, ergosterol, campesterol,stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid,alpha-tocopherol, and mixtures thereof. In some embodiments, thestructural lipid is cholesterol. In some embodiments, the amount of thestructural lipids (e.g., cholesterol) in the lipid composition rangesfrom about 20 mol % to about 60 mol %.

The quaternary amine compound as described herein include1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA),1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride(DOTIM),2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide(DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE),N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammoniumbromide (DORIE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC),1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC),1,2-distearoyl-3-trimethyl ammonium-propane (DSTAP),1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP),1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP),1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC),1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC),1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC),1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC),1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC),1-palmitoyl-2-oleoyl-sn-glycero-3-ethylosphocholine (16:0-18:1 EPC), andany combination thereof. In some embodiments, the amount of thequaternary amine compounds (e.g., DOTAP) in the lipid composition rangesfrom about 0.01 mol % to about 20 mol %.

The PEG-modified lipids include PEG-modified phosphatidylethanolamineand phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 orPEG-CerC20), PEG-modified dialkylamines and PEG-modified1,2-diacyloxypropan-3-amines. Such lipids are also referred to asPEGylated lipids. For example, a PEG lipid may be PEG-c-DOMG, PEG-DMG,PEG-DLPE, PEG DMPE, PEG-DPPC, or a PEG-DSPE lipid. In some embodiments,the PEG-lipid are 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol(PEG-DMG),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl,PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG),PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), orPEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA). In some embodiments,the PEG moiety has a size of about 1000, 2000, 5000, 10,000, 15,000 or20,000 daltons. In some embodiments, the amount of PEG-lipid in thelipid composition ranges from about 0.1 mol % to about 5 mol %.

In some embodiments, the LNP formulations described herein canadditionally comprise a permeability enhancer molecule. Non-limitingpermeability enhancer molecules are described in U.S. Pub. No.US20050222064, herein incorporated by reference in its entirety.

The LNP formulations can further contain a phosphate conjugate. Thephosphate conjugate can increase in vivo circulation times and/orincrease the targeted delivery of the nanoparticle. Phosphate conjugatescan be made by the methods described in, e.g., Intl. Pub. No.WO2013033438 or U.S. Pub. No. US20130196948. The LNP formulation mayalso contain a polymer conjugate (e.g., a water soluble conjugate) asdescribed in, e.g., U.S. Pub. Nos. US20130059360, US20130196948, andUS20130072709. Each of the references is herein incorporated byreference in its entirety.

The LNP formulations can comprise a conjugate to enhance the delivery ofnanoparticles of the present disclosure in a subject. Further, theconjugate can inhibit phagocytic clearance of the nanoparticles in asubject. In some embodiments, the conjugate may be a “self” peptidedesigned from the human membrane protein CD47 (e.g., the “self”particles described by Rodriguez et al, Science 2013 339, 971-975,herein incorporated by reference in its entirety). As shown by Rodriguezet al. the self peptides delayed macrophage-mediated clearance ofnanoparticles which enhanced delivery of the nanoparticles.

The LNP formulations can comprise a carbohydrate carrier. As anon-limiting example, the carbohydrate carrier can include, but is notlimited to, an anhydride-modified phytoglycogen or glycogen-typematerial, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin,anhydride-modified phytoglycogen beta-dextrin (e.g., Intl. Pub. No.WO2012109121, herein incorporated by reference in its entirety).

The LNP formulations can be coated with a surfactant or polymer toimprove the delivery of the particle. In some embodiments, the LNP maybe coated with a hydrophilic coating such as, but not limited to, PEGcoatings and/or coatings that have a neutral surface charge as describedin U.S. Pub. No. US20130183244, herein incorporated by reference in itsentirety.

The LNP formulations can be engineered to alter the surface propertiesof particles so that the lipid nanoparticles may penetrate the mucosalbarrier as described in U.S. Pat. No. 8,241,670 or Intl. Pub. No.WO2013110028, each of which is herein incorporated by reference in itsentirety.

The LNP engineered to penetrate mucus can comprise a polymeric material(i.e., a polymeric core) and/or a polymer-vitamin conjugate and/or atri-block co-polymer. The polymeric material can include, but is notlimited to, polyamines, polyethers, polyamides, polyesters,polycarbamates, polyureas, polycarbonates, poly(styrenes), polyimides,polysulfones, polyurethanes, polyacetylenes, polyethylenes,polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates,polyacrylonitriles, and polyarylates.

LNP engineered to penetrate mucus can also include surface alteringagents such as, but not limited to, polynucleotides, anionic proteins(e.g., bovine serum albumin), surfactants (e.g., cationic surfactantssuch as for example dimethyldioctadecyl-ammonium bromide), sugars orsugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g.,heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g.,N-acetylcysteine, mugwort, bromelain, papain, clerodendrum,acetylcysteine, bromhexine, carbocisteine, eprazinone, mesna, ambroxol,sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin34 dornase alfa, neltenexine, erdosteine) and various DNases includingrhDNase.

In some embodiments, the mucus penetrating LNP can be a hypotonicformulation comprising a mucosal penetration enhancing coating. Theformulation can be hypotonic for the epithelium to which it is beingdelivered. Non-limiting examples of hypotonic formulations may be foundin, e.g., Intl. Pub. No. WO2013110028, herein incorporated by referencein its entirety.

In some embodiments, the polynucleotide described herein is formulatedas a lipoplex, such as, without limitation, the ATUPLEX™ system, theDACC system, the DBTC system and other siRNA-lipoplex technology fromSilence Therapeutics (London, United Kingdom), STEMFECT™ from STEMGENT®(Cambridge, Mass.), and polyethylenimine (PEI) or protamine-basedtargeted and non-targeted delivery of nucleic acids (Aleku et al. CancerRes. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 201250:76-78; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al.,Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 201023:334-344; Kaufmann et al. Microvasc Res 2010 80:286-293Weide et al. JImmunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31:180-188;Pascolo Expert Opin. Biol. Ther. 4:1285-1294; Fotin-Mleczek et al., 2011J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005,23:709-717; Peer et al., Proc Natl Acad Sci USA. 2007 6; 104:4095-4100;deFougerolles Hum Gene Ther. 2008 19:125-132; all of which areincorporated herein by reference in its entirety).

In some embodiments, the polynucleotides described herein are formulatedas a solid lipid nanoparticle (SLN), which may be spherical with anaverage diameter between 10 to 1000 nm. SLN possess a solid lipid corematrix that can solubilize lipophilic molecules and may be stabilizedwith surfactants and/or emulsifiers. Exemplary SLN can be those asdescribed in Intl. Pub. No. WO2013105101, herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated for controlled release and/or targeted delivery. As usedherein, “controlled release” refers to a pharmaceutical composition orcompound release profile that conforms to a particular pattern ofrelease to effect a therapeutic outcome. In one embodiment, thepolynucleotides can be encapsulated into a delivery agent describedherein and/or known in the art for controlled release and/or targeteddelivery. As used herein, the term “encapsulate” means to enclose,surround or encase. As it relates to the formulation of the compounds ofthe disclosure, encapsulation may be substantial, complete or partial.The term “substantially encapsulated” means that at least greater than50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.9 or greater than99.999% of the pharmaceutical composition or compound of the disclosuremay be enclosed, surrounded or encased within the delivery agent.“Partially encapsulation” means that less than 10, 10, 20, 30, 40 50 orless of the pharmaceutical composition or compound of the disclosure maybe enclosed, surrounded or encased within the delivery agent.

Advantageously, encapsulation can be determined by measuring the escapeor the activity of the pharmaceutical composition or compound of thedisclosure using fluorescence and/or electron micrograph. For example,at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98,99, 99.9, 99.99 or greater than 99.99% of the pharmaceutical compositionor compound of the disclosure are encapsulated in the delivery agent.

In some embodiments, the polynucleotide controlled release formulationcan include at least one controlled release coating (e.g., OPADRY®,EUDRAGIT RL®, EUDRAGIT RS® and cellulose derivatives such asethylcellulose aqueous dispersions (AQUACOAT® and SURELEASE®)). In someembodiments, the polynucleotide controlled release formulation cancomprise a polymer system as described in U.S. Pub. No. US20130130348,or a PEG and/or PEG related polymer derivative as described in U.S. Pat.No. 8,404,222, each of which is incorporated by reference in itsentirety.

In some embodiments, the polynucleotides described herein can beencapsulated in a therapeutic nanoparticle, referred to herein as“therapeutic nanoparticle polynucleotides.” Therapeutic nanoparticlesmay be formulated by methods described in, e.g., Intl. Pub. Nos.WO2010005740, WO2010030763, WO2010005721, WO2010005723, andWO2012054923; and U.S. Pub. Nos. US20110262491, US20100104645,US20100087337, US20100068285, US20110274759, US20100068286,US20120288541, US20120140790, US20130123351 and US20130230567; and U.S.Pat. Nos. 8,206,747, 8,293,276, 8,318,208 and 8,318,211, each of whichis herein incorporated by reference in its entirety.

In some embodiments, the therapeutic nanoparticle polynucleotide can beformulated for sustained release. As used herein, “sustained release”refers to a pharmaceutical composition or compound that conforms to arelease rate over a specific period of time. The period of time mayinclude, but is not limited to, hours, days, weeks, months and years. Asa non-limiting example, the sustained release nanoparticle of thepolynucleotides described herein can be formulated as disclosed in Intl.Pub. No. WO2010075072 and U.S. Pub. Nos. US20100216804, US20110217377,US20120201859 and US20130150295, each of which is herein incorporated byreference in their entirety.

In some embodiments, the therapeutic nanoparticle polynucleotide can beformulated to be target specific, such as those described in Intl. Pub.Nos. WO2008121949, WO2010005726, WO2010005725, WO2011084521 andWO2011084518; and U.S. Pub. Nos. US20100069426, US20120004293 andUS20100104655, each of which is herein incorporated by reference in itsentirety.

The LNPs can be prepared using microfluidic mixers or micromixers.Exemplary microfluidic mixers can include, but are not limited to, aslit interdigitial micromixer including, but not limited to thosemanufactured by Microinnova (Allerheiligen bei Wildon, Austria) and/or astaggered herringbone micromixer (SHM) (see Zhigaltsevet al., “Bottom-updesign and synthesis of limit size lipid nanoparticle systems withaqueous and triglyceride cores using millisecond microfluidic mixing,”Langmuir 28:3633-40 (2012); Belliveau et al., “Microfluidic synthesis ofhighly potent limit-size lipid nanoparticles for in vivo delivery ofsiRNA,” Molecular Therapy-Nucleic Acids. 1:e37 (2012); Chen et al.,“Rapid discovery of potent siRNA-containing lipid nanoparticles enabledby controlled microfluidic formulation,” J. Am. Chem. Soc.134(16):6948-51 (2012); each of which is herein incorporated byreference in its entirety). Exemplary micromixers include SlitInterdigital Microstructured Mixer (SIMM-V2) or a Standard SlitInterdigital Micro Mixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet(IJMM,) from the Institut für Mikrotechnik Mainz GmbH, Mainz Germany. Insome embodiments, methods of making LNP using SHM further comprisemixing at least two input streams wherein mixing occurs bymicrostructure-induced chaotic advection (MICA). According to thismethod, fluid streams flow through channels present in a herringbonepattern causing rotational flow and folding the fluids around eachother. This method can also comprise a surface for fluid mixing whereinthe surface changes orientations during fluid cycling. Methods ofgenerating LNPs using SHM include those disclosed in U.S. Pub. Nos.US20040262223 and US20120276209, each of which is incorporated herein byreference in their entirety.

In some embodiments, the polynucleotides described herein can beformulated in lipid nanoparticles using microfluidic technology (seeWhitesides, George M., “The Origins and the Future of Microfluidics,”Nature 442: 368-373 (2006); and Abraham et al., “Chaotic Mixer forMicrochannels,” Science 295: 647-651 (2002); each of which is hereinincorporated by reference in its entirety). In some embodiments, thepolynucleotides can be formulated in lipid nanoparticles using amicromixer chip such as, but not limited to, those from HarvardApparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). Amicromixer chip can be used for rapid mixing of two or more fluidstreams with a split and recombine mechanism.

In some embodiments, the polynucleotides described herein can beformulated in lipid nanoparticles having a diameter from about 1 nm toabout 100 nm such as, but not limited to, about 1 nm to about 20 nm,from about 1 nm to about 30 nm, from about 1 nm to about 40 nm, fromabout 1 nm to about 50 nm, from about 1 nm to about 60 nm, from about 1nm to about 70 nm, from about 1 nm to about 80 nm, from about 1 nm toabout 90 nm, from about 5 nm to about from 100 nm, from about 5 nm toabout 10 nm, about 5 nm to about 20 nm, from about 5 nm to about 30 nm,from about 5 nm to about 40 nm, from about 5 nm to about 50 nm, fromabout 5 nm to about 60 nm, from about 5 nm to about 70 nm, from about 5nm to about 80 nm, from about 5 nm to about 90 nm, about 10 to about 20nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 toabout 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm,about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 to about80 nm, about 30 to about 90 nm, about 30 to about 100 nm, about 40 toabout 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about50 to about 60 nm, about 50 to about 70 nm about 50 to about 80 nm,about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to about100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70 toabout 100 nm, about 80 to about 90 nm, about 80 to about 100 nm and/orabout 90 to about 100 nm.

In some embodiments, the lipid nanoparticles can have a diameter fromabout 10 to 500 nm. In one embodiment, the lipid nanoparticle may have adiameter greater than 100 nm, greater than 150 nm, greater than 200 nm,greater than 250 nm, greater than 300 nm, greater than 350 nm, greaterthan 400 nm, greater than 450 nm, greater than 500 nm, greater than 550nm, greater than 600 nm, greater than 650 nm, greater than 700 nm,greater than 750 nm, greater than 800 nm, greater than 850 nm, greaterthan 900 nm, greater than 950 nm or greater than 1000 nm.

In some embodiments, the polynucleotides can be delivered using smallerLNPs. Such particles may comprise a diameter from below 0.1 μm up to 100nm such as, but not limited to, less than 0.1 μm, less than 1.0 μm, lessthan 5 μm, less than 10 μm, less than 15 um, less than 20 um, less than25 um, less than 30 um, less than 35 um, less than 40 um, less than 50um, less than 55 um, less than 60 um, less than 65 um, less than 70 um,less than 75 um, less than 80 um, less than 85 um, less than 90 um, lessthan 95 um, less than 100 um, less than 125 um, less than 150 um, lessthan 175 um, less than 200 um, less than 225 um, less than 250 um, lessthan 275 um, less than 300 um, less than 325 um, less than 350 um, lessthan 375 um, less than 400 um, less than 425 um, less than 450 um, lessthan 475 um, less than 500 um, less than 525 um, less than 550 um, lessthan 575 um, less than 600 um, less than 625 um, less than 650 um, lessthan 675 um, less than 700 um, less than 725 um, less than 750 um, lessthan 775 um, less than 800 um, less than 825 um, less than 850 um, lessthan 875 um, less than 900 um, less than 925 um, less than 950 um, orless than 975 um.

The nanoparticles and microparticles described herein can begeometrically engineered to modulate macrophage and/or the immuneresponse. The geometrically engineered particles can have varied shapes,sizes and/or surface charges to incorporate the polynucleotidesdescribed herein for targeted delivery such as, but not limited to,pulmonary delivery (see, e.g., Intl. Pub. No. WO2013082111, hereinincorporated by reference in its entirety). Other physical features thegeometrically engineering particles can include, but are not limited to,fenestrations, angled arms, asymmetry and surface roughness, charge thatcan alter the interactions with cells and tissues.

In some embodiment, the nanoparticles described herein are stealthnanoparticles or target-specific stealth nanoparticles such as, but notlimited to, those described in U.S. Pub. No. US20130172406, hereinincorporated by reference in its entirety. The stealth ortarget-specific stealth nanoparticles can comprise a polymeric matrix,which may comprise two or more polymers such as, but not limited to,polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids,polypropylfumerates, polycaprolactones, polyamides, polyacetals,polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinylalcohols, polyurethanes, polyphosphazenes, polyacrylates,polymethacrylates, polycyanoacrylates, polyureas, polystyrenes,polyamines, polyesters, polyanhydrides, polyethers, polyurethanes,polymethacrylates, polyacrylates, polycyanoacrylates, or combinationsthereof.

b. Lipidoids

In some embodiments, the compositions or formulations of the presentdisclosure comprise a delivery agent, e.g., a lipidoid. Thepolynucleotides described herein (e.g., a polynucleotide comprising anucleotide sequence encoding an IL12B polypeptide, an IL12A polypeptide,and/or IL12B and IL12A fusion polypeptides) can be formulated withlipidoids. Complexes, micelles, liposomes or particles can be preparedcontaining these lipidoids and therefore to achieve an effectivedelivery of the polynucleotide, as judged by the production of anencoded protein, following the injection of a lipidoid formulation vialocalized and/or systemic routes of administration. Lipidoid complexesof polynucleotides can be administered by various means including, butnot limited to, intravenous, intramuscular, or subcutaneous routes.

The synthesis of lipidoids is described in literature (see Mahon et al.,Bioconjug. Chem. 2010 21:1448-1454; Schroeder et al., J Intern Med. 2010267:9-21; Akinc et al., Nat Biotechnol. 2008 26:561-569; Love et al.,Proc Natl Acad Sci USA. 2010 107:1864-1869; Siegwart et al., Proc NatlAcad Sci USA. 2011 108:12996-3001; all of which are incorporated hereinin their entireties).

Formulations with the different lipidoids, including, but not limited topenta[3-(1-laurylaminopropionyl)]-triethylenetetramine hydrochloride(TETA-5LAP; also known as 98N12-5, see Murugaiah et al., AnalyticalBiochemistry, 401:61 (2010)), C12-200 (including derivatives andvariants), and MD1, can be tested for in vivo activity. The lipidoid“98N12-5” is disclosed by Akinc et al., Mol Ther. 2009 17:872-879. Thelipidoid “C12-200” is disclosed by Love et al., Proc Natl Acad Sci USA.2010 107:1864-1869 and Liu and Huang, Molecular Therapy. 2010 669-670.Each of the references is herein incorporated by reference in itsentirety.

In one embodiment, the polynucleotides described herein can beformulated in an aminoalcohol lipidoid. Aminoalcohol lipidoids may beprepared by the methods described in U.S. Pat. No. 8,450,298 (hereinincorporated by reference in its entirety).

The lipidoid formulations can include particles comprising either 3 or 4or more components in addition to polynucleotides. Lipidoids andpolynucleotide formulations comprising lipidoids are described in Intl.Pub. No. WO 2015051214 (herein incorporated by reference in itsentirety.

c. Hyaluronidase

In some embodiments, the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) and hyaluronidase for injection (e.g., intramuscular orsubcutaneous injection). Hyaluronidase catalyzes the hydrolysis ofhyaluronan, which is a constituent of the interstitial barrier.Hyaluronidase lowers the viscosity of hyaluronan, thereby increasestissue permeability (Frost, Expert Opin. Drug Deliv. (2007) 4:427-440).Alternatively, the hyaluronidase can be used to increase the number ofcells exposed to the polynucleotides administered intramuscularly,intratumorally, or subcutaneously.

d. Nanoparticle Mimics

In some embodiments, the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) is encapsulated within and/or absorbed to a nanoparticlemimic. A nanoparticle mimic can mimic the delivery function organisms orparticles such as, but not limited to, pathogens, viruses, bacteria,fungus, parasites, prions and cells. As a non-limiting example, thepolynucleotides described herein can be encapsulated in a non-vironparticle that can mimic the delivery function of a virus (see e.g.,Intl. Pub. No. WO2012006376 and U.S. Pub. Nos. US20130171241 andUS20130195968, each of which is herein incorporated by reference in itsentirety).

e. Nanotubes

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) attached or otherwise bound to (e.g., through steric,ionic, covalent and/or other forces) at least one nanotube, such as, butnot limited to, rosette nanotubes, rosette nanotubes having twin baseswith a linker, carbon nanotubes and/or single-walled carbon nanotubes.Nanotubes and nanotube formulations comprising a polynucleotide aredescribed in, e.g., Intl. Pub. No. WO2014152211, herein incorporated byreference in its entirety.

f. Self-Assembled Nanoparticles, or Self-Assembled Macromolecules

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in self-assembled nanoparticles, or amphiphilicmacromolecules (AMs) for delivery. AMs comprise biocompatibleamphiphilic polymers that have an alkylated sugar backbone covalentlylinked to poly(ethylene glycol). In aqueous solution, the AMsself-assemble to form micelles. Nucleic acid self-assemblednanoparticles are described in Intl. Appl. No. PCT/US2014/027077, andAMs and methods of forming AMs are described in U.S. Pub. No.US20130217753, each of which is herein incorporated by reference in itsentirety.

g. Inorganic Nanoparticles, Semi-Conductive and Metallic Nanoparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in inorganic nanoparticles, or water-dispersiblenanoparticles comprising a semiconductive or metallic material. Theinorganic nanoparticles can include, but are not limited to, claysubstances that are water swellable. The water-dispersible nanoparticlescan be hydrophobic or hydrophilic nanoparticles. As a non-limitingexample, the inorganic, semi-conductive and metallic nanoparticles aredescribed in, e.g., U.S. Pat. Nos. 5,585,108 and 8,257,745; and U.S.Pub. Nos. US20120228565, US 20120265001 and US 20120283503, each ofwhich is herein incorporated by reference in their entirety.

h. Surgical Sealants: Gels and Hydrogels

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in a surgical sealant. Surgical sealants such as gels andhydrogels are described in Intl. Appl. No. PCT/US2014/027077, hereinincorporated by reference in its entirety.

i. Suspension Formulations

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in suspensions. In some embodiments, suspensions comprisea polynucleotide, water immiscible oil depots, surfactants and/orco-surfactants and/or co-solvents. Suspensions can be formed by firstpreparing an aqueous solution of a polynucleotide and an oil-based phasecomprising one or more surfactants, and then mixing the two phases(aqueous and oil-based).

Exemplary oils for suspension formulations can include, but are notlimited to, sesame oil and Miglyol (comprising esters of saturatedcoconut and palmkernel oil-derived caprylic and capric fatty acids andglycerin or propylene glycol), corn oil, soybean oil, peanut oil,beeswax and/or palm seed oil. Exemplary surfactants can include, but arenot limited to Cremophor, polysorbate 20, polysorbate 80, polyethyleneglycol, transcutol, Capmul®, labrasol, isopropyl myristate, and/or Span80. In some embodiments, suspensions can comprise co-solvents including,but not limited to ethanol, glycerol and/or propylene glycol.

In some embodiments, suspensions can provide modulation of the releaseof the polynucleotides into the surrounding environment by diffusionfrom a water immiscible depot followed by resolubilization into asurrounding environment (e.g., an aqueous environment).

In some embodiments, the polynucleotides can be formulated such thatupon injection, an emulsion forms spontaneously (e.g., when delivered toan aqueous phase), which may provide a high surface area to volume ratiofor release of polynucleotides from an oil phase to an aqueous phase. Insome embodiments, the polynucleotide is formulated in a nanoemulsion,which can comprise a liquid hydrophobic core surrounded by or coatedwith a lipid or surfactant layer. Exemplary nanoemulsions and theirpreparations are described in, e.g., U.S. Pat. No. 8,496,945, hereinincorporated by reference in its entirety.

j. Cations and Anions

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) and a cation or anion, such as Zn2+, Ca2+, Cu2+, Mg2+ andcombinations thereof. Exemplary formulations can include polymers and apolynucleotide complexed with a metal cation as described in, e.g., U.S.Pat. Nos. 6,265,389 and 6,555,525, each of which is herein incorporatedby reference in its entirety. In some embodiments, cationicnanoparticles can contain a combination of divalent and monovalentcations. The delivery of polynucleotides in cationic nanoparticles or inone or more depot comprising cationic nanoparticles may improvepolynucleotide bioavailability by acting as a long-acting depot and/orreducing the rate of degradation by nucleases.

k. Molded Nanoparticles and Microparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in molded nanoparticles in various sizes, shapes andchemistry. For example, the nanoparticles and/or microparticles can bemade using the PRINT® technology by LIQUIDA TECHNOLOGIES® (Morrisville,N.C.) (e.g., International Pub. No. WO2007024323, herein incorporated byreference in its entirety).

In some embodiments, the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) is formulated in microparticles. The microparticles maycontain a core of the polynucleotide and a cortex of a biocompatibleand/or biodegradable polymer, including but not limited to,poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, apolyorthoester and a polyanhydride. The microparticle may have adsorbentsurfaces to adsorb polynucleotides. The microparticles may have adiameter of from at least 1 micron to at least 100 microns (e.g., atleast 1 micron, at least 10 micron, at least 20 micron, at least 30micron, at least 50 micron, at least 75 micron, at least 95 micron, andat least 100 micron). In some embodiment, the compositions orformulations of the present disclosure are microemulsions comprisingmicroparticles and polynucleotides. Exemplary microparticles,microemulsions and their preparations are described in, e.g., U.S. Pat.Nos. 8,460,709, 8,309,139 and 8,206,749; U.S. Pub. Nos. US20130129830,US2013195923 and US20130195898; and Intl. Pub. No. WO2013075068, each ofwhich is herein incorporated by reference in its entirety.

l. NanoJackets and NanoLiposomes

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in NanoJackets and NanoLiposomes by Keystone Nano (StateCollege, Pa.). NanoJackets are made of materials that are naturallyfound in the body including calcium, phosphate and may also include asmall amount of silicates. Nanojackets may have a size ranging from 5 to50 nm.

NanoLiposomes are made of lipids such as, but not limited to, lipidsthat naturally occur in the body. NanoLiposomes may have a size rangingfrom 60-80 nm. In some embodiments, the polynucleotides disclosed hereinare formulated in a NanoLiposome such as, but not limited to, CeramideNanoLiposomes.

m. Cells or Minicells

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) that is transfected ex vivo into cells, which aresubsequently transplanted into a subject. Cell-based formulations of thepolynucleotide disclosed herein can be used to ensure cell transfection(e.g., in the cellular carrier), alter the biodistribution of thepolynucleotide (e.g., by targeting the cell carrier to specific tissuesor cell types), and/or increase the translation of encoded protein.

Exemplary cells include, but are not limited to, red blood cells,virosomes, and electroporated cells (see e.g., Godfrin et al., ExpertOpin Biol Ther. 2012 12:127-133; Fang et al., Expert Opin Biol Ther.2012 12:385-389; Hu et al., Proc Natl Acad Sci USA. 2011108:10980-10985; Lund et al., Pharm Res. 2010 27:400-420; Huckriede etal., J Liposome Res. 2007; 17:39-47; Cusi, Hum Vaccin. 2006 2:1-7; deJonge et al., Gene Ther. 2006 13:400-411; all of which are hereinincorporated by reference in its entirety).

A variety of methods are known in the art and are suitable forintroduction of nucleic acid into a cell, including viral and non-viralmediated techniques. Examples of typical non-viral mediated techniquesinclude, but are not limited to, electroporation, calcium phosphatemediated transfer, nucleofection, sonoporation, heat shock,magnetofection, liposome mediated transfer, microinjection,microprojectile mediated transfer (nanoparticles), cationic polymermediated transfer (DEAE-dextran, polyethylenimine, polyethylene glycol(PEG) and the like) or cell fusion.

In some embodiments, the polynucleotides described herein can bedelivered in synthetic virus-like particles (VLPs) synthesized by themethods as described in Intl. Pub Nos. WO2011085231 and WO2013116656;and U.S. Pub. No. 20110171248, each of which is herein incorporated byreference in its entirety.

The technique of sonoporation, or cellular sonication, is the use ofsound (e.g., ultrasonic frequencies) for modifying the permeability ofthe cell plasma membrane. Sonoporation methods are known to delivernucleic acids in vivo (Yoon and Park, Expert Opin Drug Deliv. 20107:321-330; Postema and Gilja, Curr Pharm Biotechnol. 2007 8:355-361;Newman and Bettinger, Gene Ther. 2007 14:465-475; U.S. Pub. Nos.US20100196983 and US20100009424; all herein incorporated by reference intheir entirety).

In some embodiments, the polynucleotides described herein can bedelivered by electroporation. Electroporation techniques are known todeliver nucleic acids in vivo and clinically (Andre et al., Curr GeneTher. 2010 10:267-280; Chiarella et al., Curr Gene Ther. 201010:281-286; Hojman, Curr Gene Ther. 2010 10:128-138; all hereinincorporated by reference in their entirety). Electroporation devicesare sold by many companies worldwide including, but not limited to BTX®Instruments (Holliston, Mass.) (e.g., the AgilePulse In vivo System) andInovio (Blue Bell, Pa.) (e.g., Inovio SP-5P intramuscular deliverydevice or the CELLECTRA® 3000 intradermal delivery device).

In some embodiments, the cells are selected from the group consisting ofmammalian cells, bacterial cells, plant, microbial, algal and fungalcells. In some embodiments, the cells are mammalian cells, such as, butnot limited to, human, mouse, rat, goat, horse, rabbit, hamster or cowcells. In a further embodiment, the cells can be from an establishedcell line, including, but not limited to, HeLa, NSO, SP2/0, KEK 293T,Vero, Caco, Caco-2, MDCK, COS-1, COS-7, K562, Jurkat, CHO-K1, DG44,CHOK1SV, CHO—S, Huvec, CV-1, Huh-7, NIH3T3, HEK293, 293, A549, HepG2,IMR-90, MCF-7, U-20S, Per.C6, SF9, SF21 or Chinese Hamster Ovary (CHO)cells.

In certain embodiments, the cells are fungal cells, such as, but notlimited to, Chrysosporium cells, Aspergillus cells, Trichoderma cells,Dictyostelium cells, Candida cells, Saccharomyces cells,Schizosaccharomyces cells, and Penicillium cells.

In certain embodiments, the cells are bacterial cells such as, but notlimited to, E. coli, B. subtilis, or BL21 cells. Primary and secondarycells to be transfected by the methods of the disclosure can be obtainedfrom a variety of tissues and include, but are not limited to, all celltypes that can be maintained in culture. The primary and secondary cellsinclude, but are not limited to, fibroblasts, keratinocytes, epithelialcells (e.g., mammary epithelial cells, intestinal epithelial cells),endothelial cells, glial cells, neural cells, formed elements of theblood (e.g., lymphocytes, bone marrow cells), muscle cells andprecursors of these somatic cell types. Primary cells may also beobtained from a donor of the same species or from another species (e.g.,mouse, rat, rabbit, cat, dog, pig, cow, bird, sheep, goat, horse).

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein in bacterialminicells. As a non-limiting example, bacterial minicells can be thosedescribed in Intl. Pub. No. WO2013088250 or U.S. Pub. No. US20130177499,each of which is herein incorporated by reference in its entirety.

n. Semi-Solid Compositions

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in a hydrophobic matrix to form a semi-solid or paste-likecomposition. As a non-limiting example, the semi-solid or paste-likecomposition can be made by the methods described in Intl. Pub. No.WO201307604, herein incorporated by reference in its entirety.

o. Exosomes

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in exosomes, which can be loaded with at least onepolynucleotide and delivered to cells, tissues and/or organisms. As anon-limiting example, the polynucleotides can be loaded in the exosomesas described in Intl. Pub. No. WO2013084000, herein incorporated byreference in its entirety.

p. Silk-Based Delivery

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) that is formulated for silk-based delivery. The silk-baseddelivery system can be formed by contacting a silk fibroin solution witha polynucleotide described herein. As a non-limiting example, asustained release silk-based delivery system and methods of making suchsystem are described in U.S. Pub. No. US20130177611, herein incorporatedby reference in its entirety.

q. Amino Acid Lipids

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) that is formulation with an amino acid lipid. Amino acidlipids are lipophilic compounds comprising an amino acid residue and oneor more lipophilic tails. Non-limiting examples of amino acid lipids andmethods of making amino acid lipids are described in U.S. Pat. No.8,501,824. The amino acid lipid formulations may deliver apolynucleotide in releasable form that comprises an amino acid lipidthat binds and releases the polynucleotides. As a non-limiting example,the release of the polynucleotides described herein can be provided byan acid-labile linker as described in, e.g., U.S. Pat. Nos. 7,098,032,6,897,196, 6,426,086, 7,138,382, 5,563,250, and 5,505,931, each of whichis herein incorporated by reference in its entirety.

r. Microvesicles

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an L12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in a microvesicle formulation. Exemplary microvesiclesinclude those described in U.S. Pub. No. US20130209544 (hereinincorporated by reference in its entirety). In some embodiments, themicrovesicle is an ARRDC1-mediated microvesicles (ARMMs) as described inIntl. Pub. No. WO2013119602 (herein incorporated by reference in itsentirety).

s. Interpolyelectrolyte Complexes

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an L12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in an interpolyelectrolyte complex. Interpolyelectrolytecomplexes are formed when charge-dynamic polymers are complexed with oneor more anionic molecules. Non-limiting examples of charge-dynamicpolymers and interpolyelectrolyte complexes and methods of makinginterpolyelectrolyte complexes are described in U.S. Pat. No. 8,524,368,herein incorporated by reference in its entirety.

t. Crystalline Polymeric Systems

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in crystalline polymeric systems. Crystalline polymericsystems are polymers with crystalline moieties and/or terminal unitscomprising crystalline moieties. Exemplary polymers are described inU.S. Pat. No. 8,524,259 (herein incorporated by reference in itsentirety).

u. Polymers, Biodegradable Nanoparticles, and Core-Shell Nanoparticles

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) and a natural and/or synthetic polymer. The polymersinclude, but not limited to, polyethenes, polyethylene glycol (PEG),poly(l-lysine)(PLL), PEG grafted to PLL, cationic lipopolymer,biodegradable cationic lipopolymer, polyethyleneimine (PEI),cross-linked branched poly(alkylene imines), a polyamine derivative, amodified poloxamer, elastic biodegradable polymer, biodegradablecopolymer, biodegradable polyester copolymer, biodegradable polyestercopolymer, multiblock copolymers, poly[α-(4-aminobutyl)-L-glycolic acid)(PAGA), biodegradable cross-linked cationic multi-block copolymers,polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates,polycaprolactones, polyamides, polyacetals, polyethers, polyesters,poly(orthoesters), polycyanoacrylates, polyvinyl alcohols,polyurethanes, polyphosphazenes, polyureas, polystyrenes, polyamines,polylysine, poly(ethylene imine), poly(serine ester),poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester),amine-containing polymers, dextran polymers, dextran polymer derivativesor combinations thereof.

Exemplary polymers include, DYNAMIC POLYCONJUGATE® (Arrowhead ResearchCorp., Pasadena, Calif.) formulations from MIRUS® Bio (Madison, Wis.)and Roche Madison (Madison, Wis.), PHASERX™ polymer formulations suchas, without limitation, SMARTT POLYMER TECHNOLOGY™ (PHASERX®, Seattle,Wash.), DMRI/DOPE, poloxamer, VAXFECTIN® adjuvant from Vical (San Diego,Calif.), chitosan, cyclodextrin from Calando Pharmaceuticals (Pasadena,Calif.), dendrimers and poly(lactic-co-glycolic acid) (PLGA) polymers.RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymers (ArrowheadResearch Corporation, Pasadena, Calif.) and pH responsive co-blockpolymers such as PHASERX® (Seattle, Wash.).

The polymer formulations allow a sustained or delayed release of thepolynucleotide (e.g., following intramuscular or subcutaneousinjection). The altered release profile for the polynucleotide canresult in, for example, translation of an encoded protein over anextended period of time. The polymer formulation can also be used toincrease the stability of the polynucleotide. Sustained releaseformulations can include, but are not limited to, PLGA microspheres,ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics,Inc. Alachua, Fla.), HYLENEX® (Halozyme Therapeutics, San Diego Calif.),surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia,Ga.), TISSELL® (Baxter International, Inc. Deerfield, Ill.), PEG-basedsealants, and COSEAL® (Baxter International, Inc. Deerfield, Ill.).

As a non-limiting example modified mRNA can be formulated in PLGAmicrospheres by preparing the PLGA microspheres with tunable releaserates (e.g., days and weeks) and encapsulating the modified mRNA in thePLGA microspheres while maintaining the integrity of the modified mRNAduring the encapsulation process. EVAc are non-biodegradable,biocompatible polymers that are used extensively in pre-clinicalsustained release implant applications (e.g., extended release productsOcusert a pilocarpine ophthalmic insert for glaucoma or progestasert asustained release progesterone intrauterine device; transdermal deliverysystems Testoderm, Duragesic and Selegiline; catheters). Poloxamer F-407NF is a hydrophilic, non-ionic surfactant triblock copolymer ofpolyoxyethylene-polyoxypropylene-polyoxyethylene having a low viscosityat temperatures less than 5° C. and forms a solid gel at temperaturesgreater than 15° C.

As a non-limiting example, the polynucleotides described herein can beformulated with the polymeric compound of PEG grafted with PLL asdescribed in U.S. Pat. No. 6,177,274. As another non-limiting example,the polynucleotides described herein can be formulated with a blockcopolymer such as a PLGA-PEG block copolymer (see e.g., U.S. Pub. No.US20120004293 and U.S. Pat. Nos. 8,236,330 and 8,246,968), or aPLGA-PEG-PLGA block copolymer (see e.g., U.S. Pat. No. 6,004,573). Eachof the references is herein incorporated by reference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated with at least one amine-containing polymer such as, but notlimited to polylysine, polyethylene imine, poly(amidoamine) dendrimers,poly(amine-co-esters) or combinations thereof. Exemplary polyaminepolymers and their use as delivery agents are described in, e.g., U.S.Pat. Nos. 8,460,696, 8,236,280, each of which is herein incorporated byreference in its entirety.

In some embodiments, the polynucleotides described herein can beformulated in a biodegradable cationic lipopolymer, a biodegradablepolymer, or a biodegradable copolymer, a biodegradable polyestercopolymer, a biodegradable polyester polymer, a linear biodegradablecopolymer, PAGA, a biodegradable cross-linked cationic multi-blockcopolymer or combinations thereof as described in, e.g., U.S. Pat. Nos.6,696,038, 6,517,869, 6,267,987, 6,217,912, 6,652,886, 8,057,821, and8,444,992; U.S. Pub. Nos. US20030073619, US20040142474, US20100004315,US2012009145 and US20130195920; and Intl Pub. Nos. WO2006063249 andWO2013086322, each of which is herein incorporated by reference in itsentirety.

In some embodiments, the polynucleotides described herein can beformulated in or with at least one cyclodextrin polymer as described inU.S. Pub. No. US20130184453. In some embodiments, the polynucleotidesdescribed herein can be formulated in or with at least one crosslinkedcation-binding polymers as described in Intl. Pub. Nos. WO2013106072,WO2013106073 and WO2013106086. In some embodiments, the polynucleotidesdescribed herein can be formulated in or with at least PEGylated albuminpolymer as described in U.S. Pub. No. US20130231287. Each of thereferences is herein incorporated by reference in its entirety.

In some embodiments, the polynucleotides disclosed herein can beformulated as a nanoparticle using a combination of polymers, lipids,and/or other biodegradable agents, such as, but not limited to, calciumphosphate. Components can be combined in a core-shell, hybrid, and/orlayer-by-layer architecture, to allow for fine-tuning of thenanoparticle for delivery (Wang et al., Nat Mater. 2006 5:791-796;Fuller et al., Biomaterials. 2008 29:1526-1532; DeKoker et al., Adv DrugDeliv Rev. 2011 63:748-761; Endres et al., Biomaterials. 201132:7721-7731; Su et al., Mol Pharm. 2011 Jun. 6; 8(3):774-87; hereinincorporated by reference in their entireties). As a non-limitingexample, the nanoparticle can comprise a plurality of polymers such as,but not limited to hydrophilic-hydrophobic polymers (e.g., PEG-PLGA),hydrophobic polymers (e.g., PEG) and/or hydrophilic polymers (Intl. Pub.No. WO20120225129, herein incorporated by reference in its entirety).

The use of core-shell nanoparticles has additionally focused on ahigh-throughput approach to synthesize cationic cross-linked nanogelcores and various shells (Siegwart et al., Proc Natl Acad Sci USA. 2011108:12996-13001; herein incorporated by reference in its entirety). Thecomplexation, delivery, and internalization of the polymericnanoparticles can be precisely controlled by altering the chemicalcomposition in both the core and shell components of the nanoparticle.For example, the core-shell nanoparticles may efficiently deliver siRNAto mouse hepatocytes after they covalently attach cholesterol to thenanoparticle.

In some embodiments, a hollow lipid core comprising a middle PLGA layerand an outer neutral lipid layer containing PEG can be used to deliveryof the polynucleotides as described herein. In some embodiments, thelipid nanoparticles can comprise a core of the polynucleotides disclosedherein and a polymer shell, which is used to protect the polynucleotidesin the core. The polymer shell can be any of the polymers describedherein and are known in the art, the polymer shell can be used toprotect the polynucleotides in the core.

Core-shell nanoparticles for use with the polynucleotides describedherein are described in U.S. Pat. No. 8,313,777 or Intl. Pub. No.WO2013124867, each of which is herein incorporated by reference in theirentirety.

v. Peptides and Proteins

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) that is formulated with peptides and/or proteins toincrease transfection of cells by the polynucleotide, and/or to alterthe biodistribution of the polynucleotide (e.g., by targeting specifictissues or cell types), and/or increase the translation of encodedprotein (e.g., Intl. Pub. Nos. WO2012110636 and WO2013123298. In someembodiments, the peptides can be those described in U.S. Pub. Nos.US20130129726, US20130137644 and US20130164219. Each of the referencesis herein incorporated by reference in its entirety.

w. Conjugates

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) that is covalently linked to a carrier or targeting group,or including two encoding regions that together produce a fusion protein(e.g., bearing a targeting group and therapeutic protein or peptide) asa conjugate. The conjugate can be a peptide that selectively directs thenanoparticle to neurons in a tissue or organism, or assists in crossingthe blood-brain barrier.

The conjugates include a naturally occurring substance, such as aprotein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL),high-density lipoprotein (HDL), or globulin); an carbohydrate (e.g., adextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronicacid); or a lipid. The ligand may also be a recombinant or syntheticmolecule, such as a synthetic polymer, e.g., a synthetic polyamino acid,an oligonucleotide (e.g., an aptamer). Examples of polyamino acidsinclude polyamino acid is a polylysine (PLL), poly L-aspartic acid, polyL-glutamic acid, styrene-maleic acid anhydride copolymer,poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydridecopolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA),polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane,poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, orpolyphosphazine. Example of polyamines include: polyethylenimine,polylysine (PLL), spermine, spermidine, polyamine,pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine,arginine, amidine, protamine, cationic lipid, cationic porphyrin,quaternary salt of a polyamine, or an alpha helical peptide.

In some embodiments, the conjugate can function as a carrier for thepolynucleotide disclosed herein. The conjugate can comprise a cationicpolymer such as, but not limited to, polyamine, polylysine,polyalkylenimine, and polyethylenimine that can be grafted to withpoly(ethylene glycol). Exemplary conjugates and their preparations aredescribed in U.S. Pat. No. 6,586,524 and U.S. Pub. No. US20130211249,each of which herein is incorporated by reference in its entirety.

The conjugates can also include targeting groups, e.g., a cell or tissuetargeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g.,an antibody, that binds to a specified cell type such as a kidney cell.A targeting group can be a thyrotropin, melanotropin, lectin,glycoprotein, surfactant protein A, Mucin carbohydrate, multivalentlactose, multivalent galactose, N-acetyl-galactosamine,N-acetyl-glucosamine multivalent mannose, multivalent fucose,glycosylated polyaminoacids, multivalent galactose, transferrin,bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, asteroid, bile acid, folate, vitamin B12, biotin, an RGD peptide, an RGDpeptide mimetic or an aptamer.

Targeting groups can be proteins, e.g., glycoproteins, or peptides,e.g., molecules having a specific affinity for a co-ligand, orantibodies e.g., an antibody, that binds to a specified cell type suchas a cancer cell, endothelial cell, or bone cell. Targeting groups mayalso include hormones and hormone receptors. They can also includenon-peptidic species, such as lipids, lectins, carbohydrates, vitamins,cofactors, multivalent lactose, multivalent galactose,N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose,multivalent fructose, or aptamers. The ligand can be, for example, alipopolysaccharide, or an activator of p38 MAP kinase.

The targeting group can be any ligand that is capable of targeting aspecific receptor. Examples include, without limitation, folate, GalNAc,galactose, mannose, mannose-6P, apatamers, integrin receptor ligands,chemokine receptor ligands, transferrin, biotin, serotonin receptorligands, PSMA, endothelin, GCPII, somatostatin, LDL, and HDL ligands. Inparticular embodiments, the targeting group is an aptamer. The aptamercan be unmodified or have any combination of modifications disclosedherein. As a non-limiting example, the targeting group can be aglutathione receptor (GR)-binding conjugate for targeted delivery acrossthe blood-central nervous system barrier as described in, e.g., U.S.Pub. No. US2013021661012 (herein incorporated by reference in itsentirety).

In some embodiments, the conjugate can be a synergisticbiomolecule-polymer conjugate, which comprises a long-actingcontinuous-release system to provide a greater therapeutic efficacy. Thesynergistic biomolecule-polymer conjugate can be those described in U.S.Pub. No. US20130195799. In some embodiments, the conjugate can be anaptamer conjugate as described in Intl. Pat. Pub. No. WO2012040524. Insome embodiments, the conjugate can be an amine containing polymerconjugate as described in U.S. Pat. No. 8,507,653. Each of thereferences is herein incorporated by reference in its entirety. In someembodiments, the polynucleotides can be conjugated to SMARTT POLYMERTECHNOLOGY® (PHASERX®, Inc. Seattle, Wash.).

In some embodiments, the polynucleotides described herein are covalentlyconjugated to a cell penetrating polypeptide, which can also include asignal sequence or a targeting sequence. The conjugates can be designedto have increased stability, and/or increased cell transfection; and/oraltered the biodistribution (e.g., targeted to specific tissues or celltypes).

In some embodiments, the polynucleotides described herein can beconjugated to an agent to enhance delivery. In some embodiments, theagent can be a monomer or polymer such as a targeting monomer or apolymer having targeting blocks as described in Intl. Pub. No.WO2011062965. In some embodiments, the agent can be a transport agentcovalently coupled to a polynucleotide as described in, e.g., U.S. Pat.Nos. 6,835,393 and 7,374,778. In some embodiments, the agent can be amembrane barrier transport enhancing agent such as those described inU.S. Pat. Nos. 7,737,108 and 8,003,129. Each of the references is hereinincorporated by reference in its entirety.

x. Micro-Organs

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in a micro-organ that can then express an encodedpolypeptide of interest in a long-lasting therapeutic formulation.Exemplary micro-organs and formulations are described in Intl. Pub. No.WO2014152211 (herein incorporated by reference in its entirety).

y. Pseudovirions

In some embodiments, the compositions or formulations of the presentdisclosure comprise the polynucleotides described herein (e.g., apolynucleotide comprising a nucleotide sequence encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides) in pseudovirions (e.g., pseudovirions developed by AuraBiosciences, Cambridge, Mass.).

In some embodiments, the pseudovirion used for delivering thepolynucleotides can be derived from viruses such as, but not limited to,herpes and papillomaviruses as described in, e.g., U.S. Pub. Nos.US20130012450, US20130012566, US21030012426 and US20120207840; and Intl.Pub. No. WO2013009717, each of which is herein incorporated by referencein its entirety.

The pseudovirion can be a virus-like particle (VLP) prepared by themethods described in U.S. Pub. Nos. US20120015899 and US20130177587, andIntl. Pub. Nos. WO2010047839, WO2013116656, WO2013106525 andWO2013122262. In one aspect, the VLP can be bacteriophages MS, Qβ, R17,fr, GA, Sp, MI, I, MXI, NL95, AP205, f2, PP7, and the plant virusesTurnip crinkle virus (TCV), Tomato bushy stunt virus (TBSV), Southernbean mosaic virus (SBMV) and members of the genus Bromovirus includingBroad bean mottle virus, Brome mosaic virus, Cassia yellow blotch virus,Cowpea chlorotic mottle virus (CCMV), Melandrium yellow fleck virus, andSpring beauty latent virus. In another aspect, the VLP can be derivedfrom the influenza virus as described in U.S. Pub. No. US20130177587 andU.S. Pat. No. 8,506,967. In one aspect, the VLP can comprise a B7-1and/or B7-2 molecule anchored to a lipid membrane or the exterior of theparticle such as described in Intl. Pub. No. WO2013116656. In oneaspect, the VLP can be derived from norovirus, rotavirus recombinant VP6protein or double layered VP2/VP6 such as the VLP as described in Intl.Pub. No. WO2012049366. Each of the references is herein incorporated byreference in its entirety.

In some embodiments, the pseudovirion can be a human papillomavirus-like particle as described in Intl. Pub. No. WO2010120266 and U.S.Pub. No. US20120171290. In some embodiments, the virus-like particle(VLP) can be a self-assembled particle. In one aspect, the pseudovirionscan be virion derived nanoparticles as described in U.S. Pub. Nos.US20130116408 and US20130115247; and Intl. Pub. No. WO2013119877. Eachof the references is herein incorporated by reference in their entirety.

Non-limiting examples of formulations and methods for formulating thepolynucleotides described herein are also provided in Intl. Pub. NoWO2013090648 (incorporated herein by reference in their entirety).

26. Compositions and Formulations for Use

Certain aspects of the disclosure are directed to compositions orformulations comprising any of the polynucleotides disclosed above.

In some embodiments, the composition or formulation comprises:

(i) a polynucleotide (e.g., a RNA, e.g., an mRNA) comprising asequence-optimized nucleotide sequence (e.g., an ORF) encoding an IL12Bpolypeptide, an IL12A polypeptide, and/or IL12B and IL12A fusionpolypeptides (e.g., the wild-type sequence, functional fragment, orvariant thereof), wherein the polynucleotide comprises at least onechemically modified nucleobase, e.g., 5-methoxyuracil (e.g., wherein atleast about 25%, at least about 30%, at least about 40%, at least about50%, at least about 60%, at least about 70%, at least about 80%, atleast about 90%, at least about 95%, at least about 99%, or 100% of theuracils are 5-methoxyuracils), and wherein the polynucleotide furthercomprises a miRNA binding site, e.g., a miRNA binding site that binds tomiR-122 (e.g., a miR-122-3p or miR-122-5p binding site); and

(ii) a delivery agent comprising a compound having Formula (I), e.g.,any of Compounds 1-147 (e.g., Compound 18, 25, 26 or 48) or any ofCompounds 1-232.

In some embodiments, the uracil or thymine content of the ORF relativeto the theoretical minimum uracil or thymine content of a nucleotidesequence encoding the IL12B polypeptide, the IL12A polypeptide, and/orIL12B and IL12A fusion polypeptides (% U_(TM) or % T_(TM)), is betweenabout 100% and about 150%.

In some embodiments, the polynucleotides, compositions or formulationsabove are used to treat and/or prevent an IL12-related diseases,disorders or conditions, e.g., cancer.

27. Forms of Administration

The polynucleotides, pharmaceutical compositions and formulations of thedisclosure described above can be administered by any route that resultsin a therapeutically effective outcome. These include, but are notlimited to enteral (into the intestine), gastroenteral, epidural (intothe dura matter), oral (by way of the mouth), transdermal, peridural,intracerebral (into the cerebrum), intracerebroventricular (into thecerebral ventricles), epicutaneous (application onto the skin),intradermal, (into the skin itself), subcutaneous (under the skin),nasal administration (through the nose), intravenous (into a vein),intravenous bolus, intravenous drip, intraarterial (into an artery),intramuscular (into a muscle), intracardiac (into the heart),intraosseous infusion (into the bone marrow), intrathecal (into thespinal canal), intraperitoneal, (infusion or injection into theperitoneum), intravesical infusion, intravitreal, (through the eye),intracavernous injection (into a pathologic cavity) intracavitary (intothe base of the penis), intravaginal administration, intrauterine,extra-amniotic administration, transdermal (diffusion through the intactskin for systemic distribution), transmucosal (diffusion through amucous membrane), transvaginal, insufflation (snorting), sublingual,sublabial, enema, eye drops (onto the conjunctiva), in ear drops,auricular (in or by way of the ear), buccal (directed toward the cheek),conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis,endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis,infiltration, interstitial, intra-abdominal, intra-amniotic,intra-articular, intrabiliary, intrabronchial, intrabursal,intracartilaginous (within a cartilage), intracaudal (within the caudaequine), intracisternal (within the cisterna magna cerebellomedularis),intracorneal (within the cornea), dental intracornal, intracoronary(within the coronary arteries), intracorporus cavernosum (within thedilatable spaces of the corporus cavernosa of the penis), intradiscal(within a disc), intraductal (within a duct of a gland), intraduodenal(within the duodenum), intradural (within or beneath the dura),intraepidermal (to the epidermis), intraesophageal (to the esophagus),intragastric (within the stomach), intragingival (within the gingivae),intraileal (within the distal portion of the small intestine),intralesional (within or introduced directly to a localized lesion),intraluminal (within a lumen of a tube), intralymphatic (within thelymph), intramedullary (within the marrow cavity of a bone),intrameningeal (within the meninges), intraocular (within the eye),intraovarian (within the ovary), intrapericardial (within thepericardium), intrapleural (within the pleura), intraprostatic (withinthe prostate gland), intrapulmonary (within the lungs or its bronchi),intrasinal (within the nasal or periorbital sinuses), intraspinal(within the vertebral column), intrasynovial (within the synovial cavityof a joint), intratendinous (within a tendon), intratesticular (withinthe testicle), intrathecal (within the cerebrospinal fluid at any levelof the cerebrospinal axis), intrathoracic (within the thorax),intratubular (within the tubules of an organ), intratumor (within atumor), intratympanic (within the aurus media), intravascular (within avessel or vessels), intraventricular (within a ventricle), iontophoresis(by means of electric current where ions of soluble salts migrate intothe tissues of the body), irrigation (to bathe or flush open wounds orbody cavities), laryngeal (directly upon the larynx), nasogastric(through the nose and into the stomach), occlusive dressing technique(topical route administration that is then covered by a dressing thatoccludes the area), ophthalmic (to the external eye), oropharyngeal(directly to the mouth and pharynx), parenteral, percutaneous,periarticular, peridural, perineural, periodontal, rectal, respiratory(within the respiratory tract by inhaling orally or nasally for local orsystemic effect), retrobulbar (behind the pons or behind the eyeball),intramyocardial (entering the myocardium), soft tissue, subarachnoid,subconjunctival, submucosal, topical, transplacental (through or acrossthe placenta), transtracheal (through the wall of the trachea),transtympanic (across or through the tympanic cavity), ureteral (to theureter), urethral (to the urethra), vaginal, caudal block, diagnostic,nerve block, biliary perfusion, cardiac perfusion, photopheresis orspinal. In specific embodiments, compositions can be administered in away that allows them cross the blood-brain barrier, vascular barrier, orother epithelial barrier. In some embodiments, a formulation for a routeof administration can include at least one inactive ingredient.

The polynucleotides of the present disclosure (e.g., a polynucleotidecomprising a nucleotide sequence encoding an IL12B polypeptide, an IL12Apolypeptide, and/or IL12B and IL12A fusion polypeptides or a functionalfragment or variant thereof) can be delivered to a cell naked. As usedherein in, “naked” refers to delivering polynucleotides free from agentsthat promote transfection. For example, the polynucleotides delivered tothe cell may contain no modifications. The naked polynucleotides can bedelivered to the cell using routes of administration known in the artand described herein.

The polynucleotides of the present disclosure (e.g., a polynucleotidecomprising a nucleotide sequence encoding an IL12B polypeptide, I anIL12A polypeptide, and/or IL12B and IL12A fusion polypeptides or afunctional fragment or variant thereof) can be formulated, using themethods described herein. The formulations can contain polynucleotidesthat can be modified and/or unmodified. The formulations may furtherinclude, but are not limited to, cell penetration agents, apharmaceutically acceptable carrier, a delivery agent, a bioerodible orbiocompatible polymer, a solvent, and a sustained-release deliverydepot. The formulated polynucleotides can be delivered to the cell usingroutes of administration known in the art and described herein.

The compositions can also be formulated for direct delivery to an organor tissue in any of several ways in the art including, but not limitedto, direct soaking or bathing, via a catheter, by gels, powder,ointments, creams, gels, lotions, and/or drops, by using substrates suchas fabric or biodegradable materials coated or impregnated with thecompositions, and the like.

The present disclosure encompasses the delivery of polynucleotides ofthe disclosure (e.g., a polynucleotide comprising a nucleotide sequenceencoding an IL12B polypeptide, an IL12A polypeptide, and/or IL12B andIL12A fusion polypeptides or a functional fragment or variant thereof)in forms suitable for parenteral and injectable administration. Liquiddosage forms for parenteral administration include, but are not limitedto, pharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups, and/or elixirs. In addition to active ingredients,liquid dosage forms can comprise inert diluents commonly used in the artsuch as, for example, water or other solvents, solubilizing agents andemulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol,1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed,groundnut, corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, oralcompositions can include adjuvants such as wetting agents, emulsifyingand suspending agents, sweetening, flavoring, and/or perfuming agents.In certain embodiments for parenteral administration, compositions aremixed with solubilizing agents such as CREMOPHOR®, alcohols, oils,modified oils, glycols, polysorbates, cyclodextrins, polymers, and/orcombinations thereof.

A pharmaceutical composition for parenteral administration can compriseat least one inactive ingredient. Any or none of the inactiveingredients used may have been approved by the US Food and DrugAdministration (FDA). A non-exhaustive list of inactive ingredients foruse in pharmaceutical compositions for parenteral administrationincludes hydrochloric acid, mannitol, nitrogen, sodium acetate, sodiumchloride and sodium hydroxide.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing agents, wetting agents, and/or suspendingagents. Sterile injectable preparations can be sterile injectablesolutions, suspensions, and/or emulsions in nontoxic parenterallyacceptable diluents and/or solvents, for example, as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that can beemployed are water, Ringer's solution, U.S.P., and isotonic sodiumchloride solution. Sterile, fixed oils are conventionally employed as asolvent or suspending medium. For this purpose any bland fixed oil canbe employed including synthetic mono- or diglycerides. Fatty acids suchas oleic acid can be used in the preparation of injectables. The sterileformulation may also comprise adjuvants such as local anesthetics,preservatives and buffering agents.

Injectable formulations can be sterilized, for example, by filtrationthrough a bacterial-retaining filter, and/or by incorporatingsterilizing agents in the form of sterile solid compositions that can bedissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

Injectable formulations can be for direct injection into a region of atissue, organ and/or subject. As a non-limiting example, a tissue, organand/or subject can be directly injected a formulation by intramyocardialinjection into the ischemic region. (See, e.g., Zangi et al. NatureBiotechnology 2013; the contents of which are herein incorporated byreference in its entirety).

In order to prolong the effect of an active ingredient, it is oftendesirable to slow the absorption of the active ingredient fromsubcutaneous or intramuscular injection. This can be accomplished by theuse of a liquid suspension of crystalline or amorphous material withpoor water solubility. The rate of absorption of the drug then dependsupon its rate of dissolution which, in turn, may depend upon crystalsize and crystalline form. Alternatively, delayed absorption of aparenterally administered drug form is accomplished by dissolving orsuspending the drug in an oil vehicle. Injectable depot forms are madeby forming microencapsule matrices of the drug in biodegradable polymerssuch as polylactide-polyglycolide. Depending upon the ratio of drug topolymer and the nature of the particular polymer employed, the rate ofdrug release can be controlled. Examples of other biodegradable polymersinclude poly(orthoesters) and poly(anhydrides). Depot injectableformulations are prepared by entrapping the drug in liposomes ormicroemulsions that are compatible with body tissues.

28. Kits and Devices

a. Kits

The disclosure provides a variety of kits for conveniently and/oreffectively using the claimed nucleotides of the present disclosure.Typically kits will comprise sufficient amounts and/or numbers ofcomponents to allow a user to perform multiple treatments of asubject(s) and/or to perform multiple experiments.

In one aspect, the present disclosure provides kits comprising themolecules (polynucleotides) of the disclosure.

Said kits can be for protein production, comprising a firstpolynucleotides comprising a translatable region. The kit may furthercomprise packaging and instructions and/or a delivery agent to form aformulation composition. The delivery agent can comprise a saline, abuffered solution, a lipidoid or any delivery agent disclosed herein.

In some embodiments, the buffer solution can include sodium chloride,calcium chloride, phosphate and/or EDTA. In another embodiment, thebuffer solution can include, but is not limited to, saline, saline with2 mM calcium, 5% sucrose, 5% sucrose with 2 mM calcium, 5% Mannitol, 5%Mannitol with 2 mM calcium, Ringer's lactate, sodium chloride, sodiumchloride with 2 mM calcium and mannose (See, e.g., U.S. Pub. No.20120258046; herein incorporated by reference in its entirety). In afurther embodiment, the buffer solutions can be precipitated or it canbe lyophilized. The amount of each component can be varied to enableconsistent, reproducible higher concentration saline or simple bufferformulations. The components may also be varied in order to increase thestability of modified RNA in the buffer solution over a period of timeand/or under a variety of conditions. In one aspect, the presentdisclosure provides kits for protein production, comprising: apolynucleotide comprising a translatable region, provided in an amounteffective to produce a desired amount of a protein encoded by thetranslatable region when introduced into a target cell; a secondpolynucleotide comprising an inhibitory nucleic acid, provided in anamount effective to substantially inhibit the innate immune response ofthe cell; and packaging and instructions.

In one aspect, the present disclosure provides kits for proteinproduction, comprising a polynucleotide comprising a translatableregion, wherein the polynucleotide exhibits reduced degradation by acellular nuclease, and packaging and instructions.

In one aspect, the present disclosure provides kits for proteinproduction, comprising a polynucleotide comprising a translatableregion, wherein the polynucleotide exhibits reduced degradation by acellular nuclease, and a mammalian cell suitable for translation of thetranslatable region of the first nucleic acid.

b. Devices

The present disclosure provides for devices that may incorporatepolynucleotides that encode polypeptides of interest. These devicescontain in a stable formulation the reagents to synthesize apolynucleotide in a formulation available to be immediately delivered toa subject in need thereof, such as a human patient

Devices for administration can be employed to deliver thepolynucleotides of the present disclosure according to single, multi- orsplit-dosing regimens taught herein. Such devices are taught in, forexample, International Application Publ. No. WO2013151666, the contentsof which are incorporated herein by reference in their entirety.

Method and devices known in the art for multi-administration to cells,organs and tissues are contemplated for use in conjunction with themethods and compositions disclosed herein as embodiments of the presentdisclosure. These include, for example, those methods and devices havingmultiple needles, hybrid devices employing for example lumens orcatheters as well as devices utilizing heat, electric current orradiation driven mechanisms.

According to the present disclosure, these multi-administration devicescan be utilized to deliver the single, multi- or split dosescontemplated herein. Such devices are taught for example in,International Application Publ. No. WO2013151666, the contents of whichare incorporated herein by reference in their entirety.

In some embodiments, the polynucleotide is administered subcutaneouslyor intramuscularly via at least 3 needles to three different, optionallyadjacent, sites simultaneously, or within a 60 minutes period (e.g.,administration to 4, 5, 6, 7, 8, 9, or 10 sites simultaneously or withina 60 minute period).

c. Methods and Devices Utilizing Catheters and/or Lumens

Methods and devices using catheters and lumens can be employed toadminister the polynucleotides of the present disclosure on a single,multi- or split dosing schedule. Such methods and devices are describedin International Application Publication No. WO2013151666, the contentsof which are incorporated herein by reference in their entirety.

d. Methods and Devices Utilizing Electrical Current

Methods and devices utilizing electric current can be employed todeliver the polynucleotides of the present disclosure according to thesingle, multi- or split dosing regimens taught herein. Such methods anddevices are described in International Application Publication No.WO2013151666, the contents of which are incorporated herein by referencein their entirety.

29. Definitions

In order that the present disclosure can be more readily understood,certain terms are first defined. As used in this application, except asotherwise expressly provided herein, each of the following terms shallhave the meaning set forth below. Additional definitions are set forththroughout the application.

The disclosure includes embodiments in which exactly one member of thegroup is present in, employed in, or otherwise relevant to a givenproduct or process. The disclosure includes embodiments in which morethan one, or all of the group members are present in, employed in, orotherwise relevant to a given product or process.

In this specification and the appended claims, the singular forms “a”,“an” and “the” include plural referents unless the context clearlydictates otherwise. The terms “a” (or “an”), as well as the terms “oneor more,” and “at least one” can be used interchangeably herein. Incertain aspects, the term “a” or “an” means “single.” In other aspects,the term “a” or “an” includes “two or more” or “multiple.”

Furthermore, “and/or” where used herein is to be taken as specificdisclosure of each of the two specified features or components with orwithout the other. Thus, the term “and/or” as used in a phrase such as“A and/or B” herein is intended to include “A and B,” “A or B,” “A”(alone), and “B” (alone). Likewise, the term “and/or” as used in aphrase such as “A, B, and/or C” is intended to encompass each of thefollowing aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; Aand C; A and B; B and C; A (alone); B (alone); and C (alone).

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure is related. For example, the ConciseDictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed.,2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed.,1999, Academic Press; and the Oxford Dictionary Of Biochemistry AndMolecular Biology, Revised, 2000, Oxford University Press, provide oneof skill with a general dictionary of many of the terms used in thisdisclosure.

Wherever aspects are described herein with the language “comprising,”otherwise analogous aspects described in terms of “consisting of” and/or“consisting essentially of” are also provided.

Units, prefixes, and symbols are denoted in their Système Internationalde Unites (SI) accepted form. Numeric ranges are inclusive of thenumbers defining the range. Where a range of values is recited, it is tobe understood that each intervening integer value, and each fractionthereof, between the recited upper and lower limits of that range isalso specifically disclosed, along with each subrange between suchvalues. The upper and lower limits of any range can independently beincluded in or excluded from the range, and each range where either,neither or both limits are included is also encompassed within thedisclosure. Where a value is explicitly recited, it is to be understoodthat values which are about the same quantity or amount as the recitedvalue are also within the scope of the disclosure. Where a combinationis disclosed, each subcombination of the elements of that combination isalso specifically disclosed and is within the scope of the disclosure.Conversely, where different elements or groups of elements areindividually disclosed, combinations thereof are also disclosed. Whereany element of an disclosure is disclosed as having a plurality ofalternatives, examples of that disclosure in which each alternative isexcluded singly or in any combination with the other alternatives arealso hereby disclosed; more than one element of an disclosure can havesuch exclusions, and all combinations of elements having such exclusionsare hereby disclosed.

Nucleotides are referred to by their commonly accepted single-lettercodes. Unless otherwise indicated, nucleic acids are written left toright in 5′ to 3′ orientation. Nucleobases are referred to herein bytheir commonly known one-letter symbols recommended by the IUPAC-IUBBiochemical Nomenclature Commission. Accordingly, A represents adenine,C represents cytosine, G represents guanine, T represents thymine, Urepresents uracil.

Amino acids are referred to herein by either their commonly known threeletter symbols or by the one-letter symbols recommended by the IUPAC-IUBBiochemical Nomenclature Commission. Unless otherwise indicated, aminoacid sequences are written left to right in amino to carboxyorientation.

About: The term “about” as used in connection with a numerical valuethroughout the specification and the claims denotes an interval ofaccuracy, familiar and acceptable to a person skilled in the art. Ingeneral, such interval of accuracy is +10%.

Where ranges are given, endpoints are included. Furthermore, unlessotherwise indicated or otherwise evident from the context andunderstanding of one of ordinary skill in the art, values that areexpressed as ranges can assume any specific value or subrange within thestated ranges in different embodiments of the disclosure, to the tenthof the unit of the lower limit of the range, unless the context clearlydictates otherwise.

Administered in combination: As used herein, the term “administered incombination” or “combined administration” means that two or more agentsare administered to a subject at the same time or within an intervalsuch that there can be an overlap of an effect of each agent on thepatient. In some embodiments, they are administered within about 60, 30,15, 10, 5, or 1 minute of one another. In some embodiments, theadministrations of the agents are spaced sufficiently closely togethersuch that a combinatorial (e.g., a synergistic) effect is achieved.

Amino acid substitution: The term “amino acid substitution” refers toreplacing an amino acid residue present in a parent or referencesequence (e.g., a wild type IL12 sequence) with another amino acidresidue. An amino acid can be substituted in a parent or referencesequence (e.g., a wild type IL12 polypeptide sequence), for example, viachemical peptide synthesis or through recombinant methods known in theart. Accordingly, a reference to a “substitution at position X” refersto the substitution of an amino acid present at position X with analternative amino acid residue. In some aspects, substitution patternscan be described according to the schema AnY, wherein A is the singleletter code corresponding to the amino acid naturally or originallypresent at position n, and Y is the substituting amino acid residue. Inother aspects, substitution patterns can be described according to theschema An(YZ), wherein A is the single letter code corresponding to theamino acid residue substituting the amino acid naturally or originallypresent at position X, and Y and Z are alternative substituting aminoacid residue, i.e.,

In the context of the present disclosure, substitutions (even when theyreferred to as amino acid substitution) are conducted at the nucleicacid level, i.e., substituting an amino acid residue with an alternativeamino acid residue is conducted by substituting the codon encoding thefirst amino acid with a codon encoding the second amino acid.

Animal: As used herein, the term “animal” refers to any member of theanimal kingdom. In some embodiments, “animal” refers to humans at anystage of development. In some embodiments, “animal” refers to non-humananimals at any stage of development. In certain embodiments, thenon-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit,a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In someembodiments, animals include, but are not limited to, mammals, birds,reptiles, amphibians, fish, and worms. In some embodiments, the animalis a transgenic animal, genetically-engineered animal, or a clone.

Approximately: As used herein, the term “approximately,” as applied toone or more values of interest, refers to a value that is similar to astated reference value. In certain embodiments, the term “approximately”refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%,16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%,or less in either direction (greater than or less than) of the statedreference value unless otherwise stated or otherwise evident from thecontext (except where such number would exceed 100% of a possiblevalue).

Associated with: As used herein with respect to a disease, the term“associated with” means that the symptom, measurement, characteristic,or status in question is linked to the diagnosis, development, presence,or progression of that disease. As association may, but need not, becausatively linked to the disease. For example, symptoms, sequelae, orany effects causing a decrease in the quality of life of a patient ofcancer are considered associated with cancer and in some embodiments ofthe present disclosure can be treated, ameliorated, or prevented byadministering the polynucleotides of the present disclosure to a subjectin need thereof.

When used with respect to two or more moieties, the terms “associatedwith,” “conjugated,” “linked,” “attached,” and “tethered,” when usedwith respect to two or more moieties, means that the moieties arephysically associated or connected with one another, either directly orvia one or more additional moieties that serves as a linking agent, toform a structure that is sufficiently stable so that the moieties remainphysically associated under the conditions in which the structure isused, e.g., physiological conditions. An “association” need not bestrictly through direct covalent chemical bonding. It may also suggestionic or hydrogen bonding or a hybridization based connectivitysufficiently stable such that the “associated” entities remainphysically associated.

Bifunctional: As used herein, the term “bifunctional” refers to anysubstance, molecule or moiety that is capable of or maintains at leasttwo functions. The functions may affect the same outcome or a differentoutcome. The structure that produces the function can be the same ordifferent. For example, bifunctional modified RNAs of the presentdisclosure may encode an IL12 peptide (a first function) while thosenucleosides that comprise the encoding RNA are, in and of themselves,capable of extending the half-life of the RNA (second function). In thisexample, delivery of the bifunctional modified RNA to a subjectsuffering from a protein deficiency would produce not only a peptide orprotein molecule that may ameliorate or treat a disease or conditions,but would also maintain a population modified RNA present in the subjectfor a prolonged period of time. In other aspects, a bifunctionallymodified mRNA can be a chimeric molecule comprising, for example, an RNAencoding an IL12 peptide (a first function) and a second protein eitherfused to first protein or co-expressed with the first protein.

Biocompatible: As used herein, the term “biocompatible” means compatiblewith living cells, tissues, organs or systems posing little to no riskof injury, toxicity or rejection by the immune system.

Biodegradable: As used herein, the term “biodegradable” means capable ofbeing broken down into innocuous products by the action of livingthings.

Biologically active: As used herein, the phrase “biologically active”refers to a characteristic of any substance that has activity in abiological system and/or organism. For instance, a substance that, whenadministered to an organism, has a biological effect on that organism,is considered to be biologically active. In particular embodiments, apolynucleotide of the present disclosure can be considered biologicallyactive if even a portion of the polynucleotide is biologically active ormimics an activity considered biologically relevant.

Chimera: As used herein, “chimera” is an entity having two or moreincongruous or heterogeneous parts or regions. For example, a chimericmolecule can comprise a first part comprising an IL12B polypeptide,IL12A polypeptide, or both IL12B and IL12A polypeptides, and a secondpart (e.g., genetically fused to the first part) comprising a secondtherapeutic protein (e.g., a protein with a distinct enzymatic activity,an antigen binding moiety, or a moiety capable of extending the plasmahalf-life of IL12, for example, an Fc region of an antibody).

Sequence Optimization: The term “sequence optimization” refers to aprocess or series of processes by which nucleobases in a referencenucleic acid sequence are replaced with alternative nucleobases,resulting in a nucleic acid sequence with improved properties, e.g.,improved protein expression or decreased immunogenicity.

In general, the goal in sequence optimization is to produce a synonymousnucleotide sequence than encodes the same polypeptide sequence encodedby the reference nucleotide sequence. Thus, there are no amino acidsubstitutions (as a result of codon optimization) in the polypeptideencoded by the codon optimized nucleotide sequence with respect to thepolypeptide encoded by the reference nucleotide sequence.

Codon substitution: The terms “codon substitution” or “codonreplacement” in the context of sequence optimization refer to replacinga codon present in a reference nucleic acid sequence with another codon.A codon can be substituted in a reference nucleic acid sequence, forexample, via chemical peptide synthesis or through recombinant methodsknown in the art. Accordingly, references to a “substitution” or“replacement” at a certain location in a nucleic acid sequence (e.g., anmRNA) or within a certain region or subsequence of a nucleic acidsequence (e.g., an mRNA) refer to the substitution of a codon at suchlocation or region with an alternative codon.

As used herein, the terms “coding region” and “region encoding” andgrammatical variants thereof, refer to an Open Reading Frame (ORF) in apolynucleotide that upon expression yields a polypeptide or protein.

Compound: As used herein, the term “compound,” is meant to include allstereoisomers and isotopes of the structure depicted. As used herein,the term “stereoisomer” means any geometric isomer (e.g., cis- andtrans-isomer), enantiomer, or diastereomer of a compound. The presentdisclosure encompasses any and all stereoisomers of the compoundsdescribed herein, including stereomerically pure forms (e.g.,geometrically pure, enantiomerically pure, or diastereomerically pure)and enantiomeric and stereoisomeric mixtures, e.g., racemates.Enantiomeric and stereomeric mixtures of compounds and means ofresolving them into their component enantiomers or stereoisomers arewell-known. “Isotopes” refers to atoms having the same atomic number butdifferent mass numbers resulting from a different number of neutrons inthe nuclei. For example, isotopes of hydrogen include tritium anddeuterium. Further, a compound, salt, or complex of the presentdisclosure can be prepared in combination with solvent or watermolecules to form solvates and hydrates by routine methods.

Contacting: As used herein, the term “contacting” means establishing aphysical connection between two or more entities. For example,contacting a mammalian cell with a nanoparticle composition means thatthe mammalian cell and a nanoparticle are made to share a physicalconnection. Methods of contacting cells with external entities both invivo and ex vivo are well known in the biological arts. For example,contacting a nanoparticle composition and a mammalian cell disposedwithin a mammal may be performed by varied routes of administration(e.g., intravenous, intramuscular, intradermal, and subcutaneous) andmay involve varied amounts of nanoparticle compositions. Moreover, morethan one mammalian cell may be contacted by a nanoparticle composition.

Conservative amino acid substitution: A “conservative amino acidsubstitution” is one in which the amino acid residue in a proteinsequence is replaced with an amino acid residue having a similar sidechain. Families of amino acid residues having similar side chains havebeen defined in the art, including basic side chains (e.g., lysine,arginine, or histidine), acidic side chains (e.g., aspartic acid orglutamic acid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, or cysteine), nonpolar sidechains (e.g., alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, or tryptophan), beta-branched side chains(e.g., threonine, valine, isoleucine) and aromatic side chains (e.g.,tyrosine, phenylalanine, tryptophan, or histidine). Thus, if an aminoacid in a polypeptide is replaced with another amino acid from the sameside chain family, the amino acid substitution is considered to beconservative. In another aspect, a string of amino acids can beconservatively replaced with a structurally similar string that differsin order and/or composition of side chain family members.

Non-conservative amino acid substitution: Non-conservative amino acidsubstitutions include those in which (i) a residue having anelectropositive side chain (e.g., Arg, His or Lys) is substituted for,or by, an electronegative residue (e.g., Glu or Asp), (ii) a hydrophilicresidue (e.g., Ser or Thr) is substituted for, or by, a hydrophobicresidue (e.g., Ala, Leu, Ile, Phe or Val), (iii) a cysteine or prolineis substituted for, or by, any other residue, or (iv) a residue having abulky hydrophobic or aromatic side chain (e.g., Val, His, Ile or Trp) issubstituted for, or by, one having a smaller side chain (e.g., Ala orSer) or no side chain (e.g., Gly).

Other amino acid substitutions can be readily identified by workers ofordinary skill. For example, for the amino acid alanine, a substitutioncan be taken from any one of D-alanine, glycine, beta-alanine,L-cysteine and D-cysteine. For lysine, a replacement can be any one ofD-lysine, arginine, D-arginine, homo-arginine, methionine, D-methionine,ornithine, or D-ornithine. Generally, substitutions in functionallyimportant regions that can be expected to induce changes in theproperties of isolated polypeptides are those in which (i) a polarresidue, e.g., serine or threonine, is substituted for (or by) ahydrophobic residue, e.g., leucine, isoleucine, phenylalanine, oralanine; (ii) a cysteine residue is substituted for (or by) any otherresidue; (iii) a residue having an electropositive side chain, e.g.,lysine, arginine or histidine, is substituted for (or by) a residuehaving an electronegative side chain, e.g., glutamic acid or asparticacid; or (iv) a residue having a bulky side chain, e.g., phenylalanine,is substituted for (or by) one not having such a side chain, e.g.,glycine. The likelihood that one of the foregoing non-conservativesubstitutions can alter functional properties of the protein is alsocorrelated to the position of the substitution with respect tofunctionally important regions of the protein: some non-conservativesubstitutions can accordingly have little or no effect on biologicalproperties.

Conserved: As used herein, the term “conserved” refers to nucleotides oramino acid residues of a polynucleotide sequence or polypeptidesequence, respectively, that are those that occur unaltered in the sameposition of two or more sequences being compared. Nucleotides or aminoacids that are relatively conserved are those that are conserved amongstmore related sequences than nucleotides or amino acids appearingelsewhere in the sequences.

In some embodiments, two or more sequences are said to be “completelyconserved” if they are 100% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are at least 70% identical, at least 80% identical, at least 90%identical, or at least 95% identical to one another. In someembodiments, two or more sequences are said to be “highly conserved” ifthey are about 70% identical, about 80% identical, about 90% identical,about 95%, about 98%, or about 99% identical to one another. In someembodiments, two or more sequences are said to be “conserved” if theyare at least 30% identical, at least 40% identical, at least 50%identical, at least 60% identical, at least 70% identical, at least 80%identical, at least 90% identical, or at least 95% identical to oneanother. In some embodiments, two or more sequences are said to be“conserved” if they are about 30% identical, about 40% identical, about50% identical, about 60% identical, about 70% identical, about 80%identical, about 90% identical, about 95% identical, about 98%identical, or about 99% identical to one another. Conservation ofsequence may apply to the entire length of an polynucleotide orpolypeptide or may apply to a portion, region or feature thereof.

Controlled Release: As used herein, the term “controlled release” refersto a pharmaceutical composition or compound release profile thatconforms to a particular pattern of release to effect a therapeuticoutcome.

Covalent Derivative: The term “covalent derivative” when referring topolypeptides include modifications of a native or starting protein withan organic proteinaceous or non-proteinaceous derivatizing agent, and/orpost-translational modifications. Covalent modifications aretraditionally introduced by reacting targeted amino acid residues of theprotein with an organic derivatizing agent that is capable of reactingwith selected side-chains or terminal residues, or by harnessingmechanisms of post-translational modifications that function in selectedrecombinant host cells. The resultant covalent derivatives are useful inprograms directed at identifying residues important for biologicalactivity, for immunoassays, or for the preparation of anti-proteinantibodies for immunoaffinity purification of the recombinantglycoprotein. Such modifications are within the ordinary skill in theart and are performed without undue experimentation.

Cyclic or Cyclized: As used herein, the term “cyclic” refers to thepresence of a continuous loop. Cyclic molecules need not be circular,only joined to form an unbroken chain of subunits. Cyclic molecules suchas the engineered RNA or mRNA of the present disclosure can be singleunits or multimers or comprise one or more components of a complex orhigher order structure.

Cytotoxic: As used herein, “cytotoxic” refers to killing or causinginjurious, toxic, or deadly effect on a cell (e.g., a mammalian cell(e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite,prion, or a combination thereof.

Delivering: As used herein, the term “delivering” means providing anentity to a destination. For example, delivering a polynucleotide to asubject may involve administering a nanoparticle composition includingthe polynucleotide to the subject (e.g., by an intravenous,intramuscular, intradermal, or subcutaneous route). Administration of ananoparticle composition to a mammal or mammalian cell may involvecontacting one or more cells with the nanoparticle composition.

Delivery Agent: As used herein, “delivery agent” refers to any substancethat facilitates, at least in part, the in vivo, in vitro, or ex vivodelivery of a polynucleotide to targeted cells.

Destabilized: As used herein, the term “destable,” “destabilize,” or“destabilizing region” means a region or molecule that is less stablethan a starting, wild-type or native form of the same region ormolecule.

Detectable label: As used herein, “detectable label” refers to one ormore markers, signals, or moieties that are attached, incorporated orassociated with another entity that is readily detected by methods knownin the art including radiography, fluorescence, chemiluminescence,enzymatic activity, absorbance and the like. Detectable labels includeradioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions,ligands such as biotin, avidin, streptavidin and haptens, quantum dots,and the like. Detectable labels can be located at any position in thepeptides or proteins disclosed herein. They can be within the aminoacids, the peptides, or proteins, or located at the N- or C-termini.

Diastereomer: As used herein, the term “diastereomer,” meansstereoisomers that are not mirror images of one another and arenon-superimposable on one another.

Digest: As used herein, the term “digest” means to break apart intosmaller pieces or components. When referring to polypeptides orproteins, digestion results in the production of peptides.

Distal: As used herein, the term “distal” means situated away from thecenter or away from a point or region of interest.

Domain: As used herein, when referring to polypeptides, the term“domain” refers to a motif of a polypeptide having one or moreidentifiable structural or functional characteristics or properties(e.g., binding capacity, serving as a site for protein-proteininteractions).

Dosing regimen: As used herein, a “dosing regimen” or a “dosing regimen”is a schedule of administration or physician determined regimen oftreatment, prophylaxis, or palliative care.

Effective Amount: As used herein, the term “effective amount” of anagent is that amount sufficient to effect beneficial or desired results,for example, clinical results, and, as such, an “effective amount”depends upon the context in which it is being applied. For example, inthe context of administering an agent that treats a protein deficiency(e.g., an IL12 deficiency), an effective amount of an agent is, forexample, an amount of mRNA expressing sufficient PBGF to ameliorate,reduce, eliminate, or prevent the symptoms associated with the IL12deficiency, as compared to the severity of the symptom observed withoutadministration of the agent. The term “effective amount” can be usedinterchangeably with “effective dose,” “therapeutically effectiveamount,” or “therapeutically effective dose.”

Enantiomer: As used herein, the term “enantiomer” means each individualoptically active form of a compound of the disclosure, having an opticalpurity or enantiomeric excess (as determined by methods standard in theart) of at least 80% (i.e., at least 90% of one enantiomer and at most10% of the other enantiomer), at least 90%, or at least 98%.

Encapsulate. As used herein, the term “encapsulate” means to enclose,surround or encase.

Encapsulation Efficiency: As used herein, “encapsulation efficiency”refers to the amount of a polynucleotide that becomes part of ananoparticle composition, relative to the initial total amount ofpolynucleotide used in the preparation of a nanoparticle composition.For example, if 97 mg of polynucleotide are encapsulated in ananoparticle composition out of a total 100 mg of polynucleotideinitially provided to the composition, the encapsulation efficiency maybe given as 97%. As used herein, “encapsulation” may refer to complete,substantial, or partial enclosure, confinement, surrounding, orencasement.

Encoded protein cleavage signal: As used herein, “encoded proteincleavage signal” refers to the nucleotide sequence that encodes aprotein cleavage signal.

Engineered: As used herein, embodiments of the disclosure are“engineered” when they are designed to have a feature or property,whether structural or chemical, that varies from a starting point, wildtype or native molecule.

Enhanced Delivery: As used herein, the term “enhanced delivery” meansdelivery of more (e.g., at least 1.5 fold more, at least 2-fold more, atleast 3-fold more, at least 4-fold more, at least 5-fold more, at least6-fold more, at least 7-fold more, at least 8-fold more, at least 9-foldmore, at least 10-fold more) of a polynucleotide by a nanoparticle to atarget tissue of interest (e.g., mammalian liver) compared to the levelof delivery of a polynucleotide by a control nanoparticle to a targettissue of interest (e.g., MC3, KC2, or DLinDMA). The level of deliveryof a nanoparticle to a particular tissue may be measured by comparingthe amount of protein produced in a tissue to the weight of said tissue,comparing the amount of polynucleotide in a tissue to the weight of saidtissue, comparing the amount of protein produced in a tissue to theamount of total protein in said tissue, or comparing the amount ofpolynucleotide in a tissue to the amount of total polynucleotide in saidtissue. It will be understood that the enhanced delivery of ananoparticle to a target tissue need not be determined in a subjectbeing treated, it may be determined in a surrogate such as an animalmodel (e.g., a rat model).

Exosome: As used herein, “exosome” is a vesicle secreted by mammaliancells or a complex involved in RNA degradation.

Expression: As used herein, “expression” of a nucleic acid sequencerefers to one or more of the following events: (1) production of an mRNAtemplate from a DNA sequence (e.g., by transcription); (2) processing ofan mRNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or3′ end processing); (3) translation of an mRNA into a polypeptide orprotein; and (4) post-translational modification of a polypeptide orprotein.

Ex Vivo: As used herein, the term “ex vivo” refers to events that occuroutside of an organism (e.g., animal, plant, or microbe or cell ortissue thereof). Ex vivo events may take place in an environmentminimally altered from a natural (e.g., in vivo) environment.

Feature: As used herein, a “feature” refers to a characteristic, aproperty, or a distinctive element. When referring to polypeptides,“features” are defined as distinct amino acid sequence-based componentsof a molecule. Features of the polypeptides encoded by thepolynucleotides of the present disclosure include surfacemanifestations, local conformational shape, folds, loops, half-loops,domains, half-domains, sites, termini or any combination thereof.

Formulation: As used herein, a “formulation” includes at least apolynucleotide and one or more of a carrier, an excipient, and adelivery agent.

Fragment: A “fragment,” as used herein, refers to a portion. Forexample, fragments of proteins can comprise polypeptides obtained bydigesting full-length protein isolated from cultured cells. In someembodiments, a fragment is a subsequences of a full length protein(e.g., IL12) wherein N-terminal, and/or C-terminal, and/or internalsubsequences have been deleted. In some preferred aspects of the presentdisclosure, the fragments of a protein of the present disclosure arefunctional fragments.

Functional: As used herein, a “functional” biological molecule is abiological molecule in a form in which it exhibits a property and/oractivity by which it is characterized. Thus, a functional fragment of apolynucleotide of the present disclosure is a polynucleotide capable ofexpressing a functional IL12 fragment. As used herein, a functionalfragment of IL12 refers to a fragment of wild type IL12 (i.e., afragment of any of its naturally occurring isoforms), or a mutant orvariant thereof, wherein the fragment retains a least about 10%, atleast about 15%, at least about 20%, at least about 25%, at least about30%, at least about 35%, at least about 40%, at least about 45%, atleast about 50%, at least about 55%, at least about 60%, at least about65%, at least about 70%, at least about 75%, at least about 80%, atleast about 85%, at least about 90%, or at least about 95% of thebiological activity of the corresponding full length protein.

Helper Lipid: As used herein, the term “helper lipid” refers to acompound or molecule that includes a lipidic moiety (for insertion intoa lipid layer, e.g., lipid bilayer) and a polar moiety (for interactionwith physiologic solution at the surface of the lipid layer). Typicallythe helper lipid is a phospholipid. A function of the helper lipid is to“complement” the amino lipid and increase the fusogenicity of thebilayer and/or to help facilitate endosomal escape, e.g., of nucleicacid delivered to cells. Helper lipids are also believed to be a keystructural component to the surface of the LNP.

Homology: As used herein, the term “homology” refers to the overallrelatedness between polymeric molecules, e.g. between nucleic acidmolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Generally, the term “homology” implies anevolutionary relationship between two molecules. Thus, two moleculesthat are homologous will have a common evolutionary ancestor. In thecontext of the present disclosure, the term homology encompasses both toidentity and similarity.

In some embodiments, polymeric molecules are considered to be“homologous” to one another if at least 25%, 30%, 35%, 40%, 45%, 50%,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the monomers inthe molecule are identical (exactly the same monomer) or are similar(conservative substitutions). The term “homologous” necessarily refersto a comparison between at least two sequences (polynucleotide orpolypeptide sequences).

Identity: As used herein, the term “identity” refers to the overallmonomer conservation between polymeric molecules, e.g., betweenpolynucleotide molecules (e.g. DNA molecules and/or RNA molecules)and/or between polypeptide molecules. Calculation of the percentidentity of two polynucleotide sequences, for example, can be performedby aligning the two sequences for optimal comparison purposes (e.g.,gaps can be introduced in one or both of a first and a second nucleicacid sequences for optimal alignment and non-identical sequences can bedisregarded for comparison purposes). In certain embodiments, the lengthof a sequence aligned for comparison purposes is at least 30%, at least40%, at least 50%, at least 60%, at least 70%, at least 80%, at least90%, at least 95%, or 100% of the length of the reference sequence. Thenucleotides at corresponding nucleotide positions are then compared.When a position in the first sequence is occupied by the same nucleotideas the corresponding position in the second sequence, then the moleculesare identical at that position. The percent identity between the twosequences is a function of the number of identical positions shared bythe sequences, taking into account the number of gaps, and the length ofeach gap, which needs to be introduced for optimal alignment of the twosequences. The comparison of sequences and determination of percentidentity between two sequences can be accomplished using a mathematicalalgorithm. When comparing DNA and RNA, thymine (T) and uracil (U) can beconsidered equivalent.

Suitable software programs are available from various sources, and foralignment of both protein and nucleotide sequences. One suitable programto determine percent sequence identity is bl2seq, part of the BLASTsuite of program available from the U.S. government's National Centerfor Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov).Bl2seq performs a comparison between two sequences using either theBLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acidsequences, while BLASTP is used to compare amino acid sequences. Othersuitable programs are, e.g., Needle, Stretcher, Water, or Matcher, partof the EMBOSS suite of bioinformatics programs and also available fromthe European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa.

Sequence alignments can be conducted using methods known in the art suchas MAFFT, Clustal (ClustalW, Clustal X or Clustal Omega), MUSCLE, etc.

Different regions within a single polynucleotide or polypeptide targetsequence that aligns with a polynucleotide or polypeptide referencesequence can each have their own percent sequence identity. It is notedthat the percent sequence identity value is rounded to the nearesttenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to80.2. It also is noted that the length value will always be an integer.

In certain aspects, the percentage identity “% ID” of a first amino acidsequence (or nucleic acid sequence) to a second amino acid sequence (ornucleic acid sequence) is calculated as % ID=100×(Y/Z), where Y is thenumber of amino acid residues (or nucleobases) scored as identicalmatches in the alignment of the first and second sequences (as alignedby visual inspection or a particular sequence alignment program) and Zis the total number of residues in the second sequence. If the length ofa first sequence is longer than the second sequence, the percentidentity of the first sequence to the second sequence will be higherthan the percent identity of the second sequence to the first sequence.

One skilled in the art will appreciate that the generation of a sequencealignment for the calculation of a percent sequence identity is notlimited to binary sequence-sequence comparisons exclusively driven byprimary sequence data. It will also be appreciated that sequencealignments can be generated by integrating sequence data with data fromheterogeneous sources such as structural data (e.g., crystallographicprotein structures), functional data (e.g., location of mutations), orphylogenetic data. A suitable program that integrates heterogeneous datato generate a multiple sequence alignment is T-Coffee, available atwww.tcoffee.org, and alternatively available, e.g., from the EBI. Itwill also be appreciated that the final alignment used to calculatepercent sequence identity can be curated either automatically ormanually.

Immune response: The term “immune response” refers to the action of, forexample, lymphocytes, antigen presenting cells, phagocytic cells,granulocytes, and soluble macromolecules produced by the above cells orthe liver (including antibodies, cytokines, and complement) that resultsin selective damage to, destruction of, or elimination from the humanbody of invading pathogens, cells or tissues infected with pathogens,cancerous cells, or, in cases of autoimmunity or pathologicalinflammation, normal human cells or tissues. In some cases, theadministration of a nanoparticle comprising a lipid component and anencapsulated therapeutic agent can trigger an immune response, which canbe caused by (i) the encapsulated therapeutic agent (e.g., an mRNA),(ii) the expression product of such encapsulated therapeutic agent(e.g., a polypeptide encoded by the mRNA), (iii) the lipid component ofthe nanoparticle, or (iv) a combination thereof.

Inflammatory response: “Inflammatory response” refers to immuneresponses involving specific and non-specific defense systems. Aspecific defense system reaction is a specific immune system reaction toan antigen. Examples of specific defense system reactions includeantibody responses. A non-specific defense system reaction is aninflammatory response mediated by leukocytes generally incapable ofimmunological memory, e.g., macrophages, eosinophils and neutrophils. Insome aspects, an immune response includes the secretion of inflammatorycytokines, resulting in elevated inflammatory cytokine levels.

Inflammatory cytokines: The term “inflammatory cytokine” refers tocytokines that are elevated in an inflammatory response. Examples ofinflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine(C—X—C motif) ligand 1; also known as GROα, interferon-γ (IFNγ), tumornecrosis factor α (TNFα), interferon γ-induced protein 10 (IP-10), orgranulocyte-colony stimulating factor (G-CSF). The term inflammatorycytokines includes also other cytokines associated with inflammatoryresponses known in the art, e.g., interleukin-1 (IL-1), interleukin-8(IL-8), interleukin-12 (IL12), interleukin-13 (11-13), interferon α(IFN-α), etc.

In Vitro: As used herein, the term “in vitro” refers to events thatoccur in an artificial environment, e.g., in a test tube or reactionvessel, in cell culture, in a Petri dish, etc., rather than within anorganism (e.g., animal, plant, or microbe).

In Vivo: As used herein, the term “in vivo” refers to events that occurwithin an organism (e.g., animal, plant, or microbe or cell or tissuethereof).

Insertional and deletional variants: “Insertional variants” whenreferring to polypeptides are those with one or more amino acidsinserted immediately adjacent to an amino acid at a particular positionin a native or starting sequence. “Immediately adjacent” to an aminoacid means connected to either the alpha-carboxy or alpha-aminofunctional group of the amino acid. “Deletional variants” when referringto polypeptides are those with one or more amino acids in the native orstarting amino acid sequence removed. Ordinarily, deletional variantswill have one or more amino acids deleted in a particular region of themolecule.

Intact: As used herein, in the context of a polypeptide, the term“intact” means retaining an amino acid corresponding to the wild typeprotein, e.g., not mutating or substituting the wild type amino acid.Conversely, in the context of a nucleic acid, the term “intact” meansretaining a nucleobase corresponding to the wild type nucleic acid,e.g., not mutating or substituting the wild type nucleobase.

Ionizable amino lipid: The term “ionizable amino lipid” includes thoselipids having one, two, three, or more fatty acid or fatty alkyl chainsand a pH-titratable amino head group (e.g., an alkylamino ordialkylamino head group). An ionizable amino lipid is typicallyprotonated (i.e., positively charged) at a pH below the pKa of the aminohead group and is substantially not charged at a pH above the pKa. Suchionizable amino lipids include, but are not limited to DLin-MC3-DMA(MC3) and (13Z,165Z)—N,N-dimethyl-3-nonydocosa-13-16-dien-1-amine(L608).

Isolated: As used herein, the term “isolated” refers to a substance orentity that has been separated from at least some of the components withwhich it was associated (whether in nature or in an experimentalsetting). Isolated substances (e.g., polynucleotides or polypeptides)can have varying levels of purity in reference to the substances fromwhich they have been isolated. Isolated substances and/or entities canbe separated from at least about 10%, about 20%, about 30%, about 40%,about 50%, about 60%, about 70%, about 80%, about 90%, or more of theother components with which they were initially associated. In someembodiments, isolated substances are more than about 80%, about 85%,about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about96%, about 97%, about 98%, about 99%, or more than about 99% pure. Asused herein, a substance is “pure” if it is substantially free of othercomponents.

Substantially isolated: By “substantially isolated” is meant that thecompound is substantially separated from the environment in which it wasformed or detected. Partial separation can include, for example, acomposition enriched in the compound of the present disclosure.Substantial separation can include compositions containing at leastabout 50%, at least about 60%, at least about 70%, at least about 80%,at least about 90%, at least about 95%, at least about 97%, or at leastabout 99% by weight of the compound of the present disclosure, or saltthereof.

A polynucleotide, vector, polypeptide, cell, or any compositiondisclosed herein which is “isolated” is a polynucleotide, vector,polypeptide, cell, or composition which is in a form not found innature. Isolated polynucleotides, vectors, polypeptides, or compositionsinclude those which have been purified to a degree that they are nolonger in a form in which they are found in nature. In some aspects, apolynucleotide, vector, polypeptide, or composition which is isolated issubstantially pure.

Isomer: As used herein, the term “isomer” means any tautomer,stereoisomer, enantiomer, or diastereomer of any compound of thedisclosure. It is recognized that the compounds of the disclosure canhave one or more chiral centers and/or double bonds and, therefore,exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Zisomers) or diastereomers (e.g., enantiomers (i.e., (+) or (−)) orcis/trans isomers). According to the disclosure, the chemical structuresdepicted herein, and therefore the compounds of the disclosure,encompass all of the corresponding stereoisomers, that is, both thestereomerically pure form (e.g., geometrically pure, enantiomericallypure, or diastereomerically pure) and enantiomeric and stereoisomericmixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures ofcompounds of the disclosure can typically be resolved into theircomponent enantiomers or stereoisomers by well-known methods, such aschiral-phase gas chromatography, chiral-phase high performance liquidchromatography, crystallizing the compound as a chiral salt complex, orcrystallizing the compound in a chiral solvent. Enantiomers andstereoisomers can also be obtained from stereomerically orenantiomerically pure intermediates, reagents, and catalysts bywell-known asymmetric synthetic methods.

Linker: As used herein, a “linker” (including a subunit linker and aheterologous polypeptide linker as referred to herein) refers to a groupof atoms, e.g., 10-1,000 atoms, and can be comprised of the atoms orgroups such as, but not limited to, carbon, amino, alkylamino, oxygen,sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker can beattached to a modified nucleoside or nucleotide on the nucleobase orsugar moiety at a first end, and to a payload, e.g., a detectable ortherapeutic agent, at a second end. The linker can be of sufficientlength as to not interfere with incorporation into a nucleic acidsequence. The linker can be used for any useful purpose, such as to formpolynucleotide multimers (e.g., through linkage of two or more chimericpolynucleotides molecules or IVT polynucleotides) or polynucleotidesconjugates, as well as to administer a payload, as described herein.Examples of chemical groups that can be incorporated into the linkerinclude, but are not limited to, alkyl, alkenyl, alkynyl, amido, amino,ether, thioether, ester, alkylene, heteroalkylene, aryl, orheterocyclyl, each of which can be optionally substituted, as describedherein. Examples of linkers include, but are not limited to, unsaturatedalkanes, polyethylene glycols (e.g., ethylene or propylene glycolmonomeric units, e.g., diethylene glycol, dipropylene glycol,triethylene glycol, tripropylene glycol, tetraethylene glycol, ortetraethylene glycol), and dextran polymers and derivatives thereof.Other examples include, but are not limited to, cleavable moietieswithin the linker, such as, for example, a disulfide bond (—S—S—) or anazo bond (—N═N—), which can be cleaved using a reducing agent orphotolysis. Non-limiting examples of a selectively cleavable bondinclude an amido bond can be cleaved for example by the use oftris(2-carboxyethyl)phosphine (TCEP), or other reducing agents, and/orphotolysis, as well as an ester bond can be cleaved for example byacidic or basic hydrolysis.

Methods of Administration: As used herein, “methods of administration”may include intravenous, intramuscular, intradermal, subcutaneous, orother methods of delivering a composition to a subject. A method ofadministration may be selected to target delivery (e.g., to specificallydeliver) to a specific region or system of a body.

Modified: As used herein “modified” refers to a changed state orstructure of a molecule of the disclosure. Molecules can be modified inmany ways including chemically, structurally, and functionally. In someembodiments, the mRNA molecules of the present disclosure are modifiedby the introduction of non-natural nucleosides and/or nucleotides, e.g.,as it relates to the natural ribonucleotides A, U, G, and C.Noncanonical nucleotides such as the cap structures are not considered“modified” although they differ from the chemical structure of the A, C,G, U ribonucleotides.

Mucus: As used herein, “mucus” refers to the natural substance that isviscous and comprises mucin glycoproteins.

Nanoparticle Composition: As used herein, a “nanoparticle composition”is a composition comprising one or more lipids. Nanoparticlecompositions are typically sized on the order of micrometers or smallerand may include a lipid bilayer. Nanoparticle compositions encompasslipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), andlipoplexes. For example, a nanoparticle composition may be a liposomehaving a lipid bilayer with a diameter of 500 nm or less.

Naturally occurring: As used herein, “naturally occurring” meansexisting in nature without artificial aid.

Non-human vertebrate: As used herein, a “non-human vertebrate” includesall vertebrates except Homo sapiens, including wild and domesticatedspecies. Examples of non-human vertebrates include, but are not limitedto, mammals, such as alpaca, banteng, bison, camel, cat, cattle, deer,dog, donkey, gayal, goat, guinea pig, horse, llama, mule, pig, rabbit,reindeer, sheep water buffalo, and yak.

Nucleic acid sequence: The terms “nucleic acid sequence,” “nucleotidesequence,” or “polynucleotide sequence” are used interchangeably andrefer to a contiguous nucleic acid sequence. The sequence can be eithersingle stranded or double stranded DNA or RNA, e.g., an mRNA.

The term “nucleic acid,” in its broadest sense, includes any compoundand/or substance that comprises a polymer of nucleotides. These polymersare often referred to as polynucleotides. Exemplary nucleic acids orpolynucleotides of the disclosure include, but are not limited to,ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleicacids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs),locked nucleic acids (LNAs, including LNA having a β-D-riboconfiguration, α-LNA having an α-L-ribo configuration (a diastereomer ofLNA), 2′-amino-LNA having a 2′-amino functionalization, and2′-amino-α-LNA having a 2′-amino functionalization), ethylene nucleicacids (ENA), cyclohexenyl nucleic acids (CeNA) or hybrids orcombinations thereof.

The phrase “nucleotide sequence encoding” refers to the nucleic acid(e.g., an mRNA or DNA molecule) coding sequence which encodes apolypeptide. The coding sequence can further include initiation andtermination signals operably linked to regulatory elements including apromoter and polyadenylation signal capable of directing expression inthe cells of an individual or mammal to which the nucleic acid isadministered. The coding sequence can further include sequences thatencode signal peptides.

Off-target: As used herein, “off target” refers to any unintended effecton any one or more target, gene, or cellular transcript.

Open reading frame: As used herein, “open reading frame” or “ORF” refersto a sequence which does not contain a stop codon in a given readingframe.

Operably linked: As used herein, the phrase “operably linked” refers toa functional connection between two or more molecules, constructs,transcripts, entities, moieties or the like.

Optionally substituted: Herein a phrase of the form “optionallysubstituted X” (e.g., optionally substituted alkyl) is intended to beequivalent to “X, wherein X is optionally substituted” (e.g., “alkyl,wherein said alkyl is optionally substituted”). It is not intended tomean that the feature “X” (e.g., alkyl) per se is optional.

Part: As used herein, a “part” or “region” of a polynucleotide isdefined as any portion of the polynucleotide that is less than theentire length of the polynucleotide.

Patient: As used herein, “patient” refers to a subject who may seek orbe in need of treatment, requires treatment, is receiving treatment,will receive treatment, or a subject who is under care by a trainedprofessional for a particular disease or condition.

Pharmaceutically acceptable: The phrase “pharmaceutically acceptable” isemployed herein to refer to those compounds, materials, compositions,and/or dosage forms that are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of human beingsand animals without excessive toxicity, irritation, allergic response,or other problem or complication, commensurate with a reasonablebenefit/risk ratio.

Pharmaceutically acceptable excipients: The phrase “pharmaceuticallyacceptable excipient,” as used herein, refers any ingredient other thanthe compounds described herein (for example, a vehicle capable ofsuspending or dissolving the active compound) and having the propertiesof being substantially nontoxic and non-inflammatory in a patient.Excipients can include, for example: antiadherents, antioxidants,binders, coatings, compression aids, disintegrants, dyes (colors),emollients, emulsifiers, fillers (diluents), film formers or coatings,flavors, fragrances, glidants (flow enhancers), lubricants,preservatives, printing inks, sorbents, suspensing or dispersing agents,sweeteners, and waters of hydration. Exemplary excipients include, butare not limited to: butylated hydroxytoluene (BHT), calcium carbonate,calcium phosphate (dibasic), calcium stearate, croscarmellose,crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine,ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol,methionine, methylcellulose, methyl paraben, microcrystalline cellulose,polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinizedstarch, propyl paraben, retinyl palmitate, shellac, silicon dioxide,sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate,sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide,vitamin A, vitamin E, vitamin C, and xylitol.

Pharmaceutically acceptable salts: The present disclosure also includespharmaceutically acceptable salts of the compounds described herein. Asused herein, “pharmaceutically acceptable salts” refers to derivativesof the disclosed compounds wherein the parent compound is modified byconverting an existing acid or base moiety to its salt form (e.g., byreacting the free base group with a suitable organic acid). Examples ofpharmaceutically acceptable salts include, but are not limited to,mineral or organic acid salts of basic residues such as amines; alkalior organic salts of acidic residues such as carboxylic acids; and thelike. Representative acid addition salts include acetate, acetic acid,adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate,camphorsulfonate, citrate, cyclopentanepropionate, digluconate,dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate,glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide,hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts,and the like. Representative alkali or alkaline earth metal saltsinclude sodium, lithium, potassium, calcium, magnesium, and the like, aswell as nontoxic ammonium, quaternary ammonium, and amine cations,including, but not limited to ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, ethylamine, and the like. The pharmaceutically acceptablesalts of the present disclosure include the conventional non-toxic saltsof the parent compound formed, for example, from non-toxic inorganic ororganic acids. The pharmaceutically acceptable salts of the presentdisclosure can be synthesized from the parent compound that contains abasic or acidic moiety by conventional chemical methods. Generally, suchsalts can be prepared by reacting the free acid or base forms of thesecompounds with a stoichiometric amount of the appropriate base or acidin water or in an organic solvent, or in a mixture of the two;generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol, or acetonitrile are used. Lists of suitable salts are foundin Remington's Pharmaceutical Sciences, 17^(th) ed., Mack PublishingCompany, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties,Selection, and Use, P. H. Stahl and C. G. Wermuth (eds.), Wiley-VCH,2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19(1977), each of which is incorporated herein by reference in itsentirety.

Pharmaceutically acceptable solvate: The term “pharmaceuticallyacceptable solvate,” as used herein, means a compound of the disclosurewherein molecules of a suitable solvent are incorporated in the crystallattice. A suitable solvent is physiologically tolerable at the dosageadministered. For example, solvates can be prepared by crystallization,recrystallization, or precipitation from a solution that includesorganic solvents, water, or a mixture thereof. Examples of suitablesolvents are ethanol, water (for example, mono-, di-, and tri-hydrates),N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO),N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC),1,3-dimethyl-2-imidazolidinone (DMEU),1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile(ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone,benzyl benzoate, and the like. When water is the solvent, the solvate isreferred to as a “hydrate.”

Pharmacokinetic: As used herein, “pharmacokinetic” refers to any one ormore properties of a molecule or compound as it relates to thedetermination of the fate of substances administered to a livingorganism. Pharmacokinetics is divided into several areas including theextent and rate of absorption, distribution, metabolism and excretion.This is commonly referred to as ADME where: (A) Absorption is theprocess of a substance entering the blood circulation; (D) Distributionis the dispersion or dissemination of substances throughout the fluidsand tissues of the body; (M) Metabolism (or Biotransformation) is theirreversible transformation of parent compounds into daughtermetabolites; and (E) Excretion (or Elimination) refers to theelimination of the substances from the body. In rare cases, some drugsirreversibly accumulate in body tissue.

Physicochemical: As used herein, “physicochemical” means of or relatingto a physical and/or chemical property.

Polynucleotide: The term “polynucleotide” as used herein refers topolymers of nucleotides of any length, including ribonucleotides,deoxyribonucleotides, analogs thereof, or mixtures thereof. This termrefers to the primary structure of the molecule. Thus, the term includestriple-, double- and single-stranded deoxyribonucleic acid (“DNA”), aswell as triple-, double- and single-stranded ribonucleic acid (“RNA”).It also includes modified, for example by alkylation, and/or by capping,and unmodified forms of the polynucleotide. More particularly, the term“polynucleotide” includes polydeoxyribonucleotides (containing2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), includingtRNA, rRNA, hRNA, siRNA and mRNA, whether spliced or unspliced, anyother type of polynucleotide which is an N- or C-glycoside of a purineor pyrimidine base, and other polymers containing normucleotidicbackbones, for example, polyamide (e.g., peptide nucleic acids “PNAs”)and polymorpholino polymers, and other synthetic sequence-specificnucleic acid polymers providing that the polymers contain nucleobases ina configuration which allows for base pairing and base stacking, such asis found in DNA and RNA. In particular aspects, the polynucleotidecomprises an mRNA. In other aspect, the mRNA is a synthetic mRNA. Insome aspects, the synthetic mRNA comprises at least one unnaturalnucleobase. In some aspects, all nucleobases of a certain class havebeen replaced with unnatural nucleobases (e.g., all uridines in apolynucleotide disclosed herein can be replaced with an unnaturalnucleobase, e.g., 5-methoxyuridine). In some aspects, the polynucleotide(e.g., a synthetic RNA or a synthetic DNA) comprises only naturalnucleobases, i.e., A (adenosine), G (guanosine), C (cytidine), and T(thymidine) in the case of a synthetic DNA, or A, C, G, and U (uridine)in the case of a synthetic RNA.

The skilled artisan will appreciate that the T bases in the codon mapsdisclosed herein are present in DNA, whereas the T bases would bereplaced by U bases in corresponding RNAs. For example, acodon-nucleotide sequence disclosed herein in DNA form, e.g., a vectoror an in-vitro translation (IVT) template, would have its T basestranscribed as U based in its corresponding transcribed mRNA. In thisrespect, both codon-optimized DNA sequences (comprising T) and theircorresponding mRNA sequences (comprising U) are consideredcodon-optimized nucleotide sequence of the present disclosure. A skilledartisan would also understand that equivalent codon-maps can begenerated by replaced one or more bases with non-natural bases. Thus,e.g., a TTC codon (DNA map) would correspond to a UUC codon (RNA map),which in turn would correspond to a ‘ ’C codon (RNA map in which U hasbeen replaced with pseudouridine).

Standard A-T and G-C base pairs form under conditions which allow theformation of hydrogen bonds between the N3-H and C4-oxy of thymidine andthe Ni and C6-NH2, respectively, of adenosine and between the C2-oxy, N3and C4-NH2, of cytidine and the C2-NH2, N′—H and C6-oxy, respectively,of guanosine. Thus, for example, guanosine(2-amino-6-oxy-9-β-D-ribofuranosyl-purine) can be modified to formisoguanosine (2-oxy-6-amino-9-β-D-ribofuranosyl-purine). Suchmodification results in a nucleoside base which will no longereffectively form a standard base pair with cytosine. However,modification of cytosine (1-3-D-ribofuranosyl-2-oxy-4-amino-pyrimidine)to form isocytosine (1-β3-D-ribofuranosyl-2-amino-4-oxy-pyrimidine-)results in a modified nucleotide which will not effectively base pairwith guanosine but will form a base pair with isoguanosine (U.S. Pat.No. 5,681,702 to Collins et al.). Isocytosine is available from SigmaChemical Co. (St. Louis, Mo.); isocytidine can be prepared by the methoddescribed by Switzer et al. (1993) Biochemistry 32:10489-10496 andreferences cited therein; 2′-deoxy-5-methyl-isocytidine can be preparedby the method of Tor et al., 1993, J. Am. Chem. Soc. 115:4461-4467 andreferences cited therein; and isoguanine nucleotides can be preparedusing the method described by Switzer et al., 1993, supra, and Mantschet al., 1993, Biochem. 14:5593-5601, or by the method described in U.S.Pat. No. 5,780,610 to Collins et al. Other nonnatural base pairs can besynthesized by the method described in Piccirilli et al., 1990, Nature343:33-37, for the synthesis of 2,6-diaminopyrimidine and its complement(1-methylpyrazolo-[4,3]pyrimidine-5,7-(4H,6H)-dione. Other such modifiednucleotide units which form unique base pairs are known, such as thosedescribed in Leach et al. (1992) J. Am. Chem. Soc. 114:3675-3683 andSwitzer et al., supra.

Polypeptide: The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer can comprise modified amino acids. The terms alsoencompass an amino acid polymer that has been modified naturally or byintervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids such as homocysteine, ornithine, p-acetylphenylalanine,D-amino acids, and creatine), as well as other modifications known inthe art.

The term, as used herein, refers to proteins, polypeptides, and peptidesof any size, structure, or function. Polypeptides include encodedpolynucleotide products, naturally occurring polypeptides, syntheticpolypeptides, homologs, orthologs, paralogs, fragments and otherequivalents, variants, and analogs of the foregoing. A polypeptide canbe a monomer or can be a multi-molecular complex such as a dimer, trimeror tetramer. They can also comprise single chain or multichainpolypeptides. Most commonly disulfide linkages are found in multichainpolypeptides. The term polypeptide can also apply to amino acid polymersin which one or more amino acid residues are an artificial chemicalanalogue of a corresponding naturally occurring amino acid. In someembodiments, a “peptide” can be less than or equal to 50 amino acidslong, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acidslong.

Polypeptide variant: As used herein, the term “polypeptide variant”refers to molecules that differ in their amino acid sequence from anative or reference sequence. The amino acid sequence variants canpossess substitutions, deletions, and/or insertions at certain positionswithin the amino acid sequence, as compared to a native or referencesequence. Ordinarily, variants will possess at least about 50% identity,at least about 60% identity, at least about 70% identity, at least about80% identity, at least about 90% identity, at least about 95% identity,at least about 99% identity to a native or reference sequence. In someembodiments, they will be at least about 80%, or at least about 90%identical to a native or reference sequence.

Polypeptide per unit drug (PUD): As used herein, a PUD or product perunit drug, is defined as a subdivided portion of total daily dose,usually 1 mg, pg, kg, etc., of a product (such as a polypeptide) asmeasured in body fluid or tissue, usually defined in concentration suchas pmol/mL, mmol/mL, etc. divided by the measure in the body fluid.

Preventing: As used herein, the term “preventing” refers to partially orcompletely delaying onset of an infection, disease, disorder and/orcondition; partially or completely delaying onset of one or moresymptoms, features, or clinical manifestations of a particularinfection, disease, disorder, and/or condition; partially or completelydelaying onset of one or more symptoms, features, or manifestations of aparticular infection, disease, disorder, and/or condition; partially orcompletely delaying progression from an infection, a particular disease,disorder and/or condition; and/or decreasing the risk of developingpathology associated with the infection, the disease, disorder, and/orcondition.

Prodrug: The present disclosure also includes prodrugs of the compoundsdescribed herein. As used herein, “prodrugs” refer to any substance,molecule or entity that is in a form predicate for that substance,molecule or entity to act as a therapeutic upon chemical or physicalalteration. Prodrugs may by covalently bonded or sequestered in some wayand that release or are converted into the active drug moiety prior to,upon or after administered to a mammalian subject. Prodrugs can beprepared by modifying functional groups present in the compounds in sucha way that the modifications are cleaved, either in routine manipulationor in vivo, to the parent compounds. Prodrugs include compounds whereinhydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any groupthat, when administered to a mammalian subject, cleaves to form a freehydroxyl, amino, sulfhydryl, or carboxyl group respectively. Preparationand use of prodrugs is discussed in T. Higuchi and V. Stella, “Pro-drugsas Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, andin Bioreversible Carriers in Drug Design, ed. Edward B. Roche, AmericanPharmaceutical Association and Pergamon Press, 1987, both of which arehereby incorporated by reference in their entirety.

Proliferate: As used herein, the term “proliferate” means to grow,expand or increase or cause to grow, expand or increase rapidly.“Proliferative” means having the ability to proliferate.“Anti-proliferative” means having properties counter to or inapposite toproliferative properties.

Prophylactic: As used herein, “prophylactic” refers to a therapeutic orcourse of action used to prevent the spread of disease.

Prophylaxis: As used herein, a “prophylaxis” refers to a measure takento maintain health and prevent the spread of disease. An “immuneprophylaxis” refers to a measure to produce active or passive immunityto prevent the spread of disease.

Protein cleavage site: As used herein, “protein cleavage site” refers toa site where controlled cleavage of the amino acid chain can beaccomplished by chemical, enzymatic or photochemical means.

Protein cleavage signal: As used herein “protein cleavage signal” refersto at least one amino acid that flags or marks a polypeptide forcleavage.

Protein of interest: As used herein, the terms “proteins of interest” or“desired proteins” include those provided herein and fragments, mutants,variants, and alterations thereof.

Proximal: As used herein, the term “proximal” means situated nearer tothe center or to a point or region of interest.

Pseudouridine: As used herein, pseudouridine (v) refers to theC-glycoside isomer of the nucleoside uridine. A “pseudouridine analog”is any modification, variant, isoform or derivative of pseudouridine.For example, pseudouridine analogs include but are not limited to1-carboxymethyl-pseudouridine, 1-propynyl-pseudouridine,1-taurinomethyl-pseudouridine, 1-taurinomethyl-4-thio-pseudouridine,1-methylpseudouridine (m¹ψ), 1-methyl-4-thio-pseudouridine (m¹s⁴ψ),4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m³ψ),2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine,2-thio-1-methyl-1-deaza-pseudouridine, dihydropseudouridine,2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine,4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine,N1-methyl-pseudouridine,1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ ψ), and2′-O-methyl-pseudouridine (ψm).

Purified: As used herein, “purify,” “purified,” “purification” means tomake substantially pure or clear from unwanted components, materialdefilement, admixture or imperfection.

Reference Nucleic Acid Sequence: The term “reference nucleic acidsequence” or “reference nucleic acid” or “reference nucleotide sequence”or “reference sequence” refers to a starting nucleic acid sequence(e.g., a RNA, e.g., an mRNA sequence) that can be sequence optimized. Insome embodiments, the reference nucleic acid sequence is a wild typenucleic acid sequence, a fragment or a variant thereof. In someembodiments, the reference nucleic acid sequence is a previouslysequence optimized nucleic acid sequence.

Repeated transfection: As used herein, the term “repeated transfection”refers to transfection of the same cell culture with a polynucleotide aplurality of times. The cell culture can be transfected at least twice,at least 3 times, at least 4 times, at least 5 times, at least 6 times,at least 7 times, at least 8 times, at least 9 times, at least 10 times,at least 11 times, at least 12 times, at least 13 times, at least 14times, at least 15 times, at least 16 times, at least 17 times at least18 times, at least 19 times, at least 20 times, at least 25 times, atleast 30 times, at least 35 times, at least 40 times, at least 45 times,at least 50 times or more.

Salts: In some aspects, the pharmaceutical composition for intratumoraldelivery disclosed herein and comprises salts of some of their lipidconstituents. The term “salt” includes any anionic and cationic complex.Non-limiting examples of anions include inorganic and organic anions,e.g., fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate),phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide,carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide,sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate,formate, acetate, benzoate, citrate, tartrate, lactate, acrylate,polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate,malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate,perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite,iodate, an alkylsulfonate, an arylsulfonate, arsenate, arsenite,chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide,peroxide, permanganate, and mixtures thereof.

Sample. As used herein, the term “sample” or “biological sample” refersto a subset of its tissues, cells or component parts (e.g., body fluids,including but not limited to blood, mucus, lymphatic fluid, synovialfluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood,urine, vaginal fluid and semen). A sample further can include ahomogenate, lysate or extract prepared from a whole organism or a subsetof its tissues, cells or component parts, or a fraction or portionthereof, including but not limited to, for example, plasma, serum,spinal fluid, lymph fluid, the external sections of the skin,respiratory, intestinal, and genitourinary tracts, tears, saliva, milk,blood cells, tumors, organs. A sample further refers to a medium, suchas a nutrient broth or gel, which may contain cellular components, suchas proteins or nucleic acid molecule.

Signal Sequence: As used herein, the phrases “signal sequence,” “signalpeptide,” and “transit peptide” are used interchangeably and refer to asequence that can direct the transport or localization of a protein to acertain organelle, cell compartment, or extracellular export. The termencompasses both the signal sequence polypeptide and the nucleic acidsequence encoding the signal sequence. Thus, references to a signalsequence in the context of a nucleic acid refer in fact to the nucleicacid sequence encoding the signal sequence polypeptide.

Signal transduction pathway: A “signal transduction pathway” refers tothe biochemical relationship between a variety of signal transductionmolecules that play a role in the transmission of a signal from oneportion of a cell to another portion of a cell. As used herein, thephrase “cell surface receptor” includes, for example, molecules andcomplexes of molecules capable of receiving a signal and thetransmission of such a signal across the plasma membrane of a cell.

Similarity: As used herein, the term “similarity” refers to the overallrelatedness between polymeric molecules, e.g. between polynucleotidemolecules (e.g. DNA molecules and/or RNA molecules) and/or betweenpolypeptide molecules. Calculation of percent similarity of polymericmolecules to one another can be performed in the same manner as acalculation of percent identity, except that calculation of percentsimilarity takes into account conservative substitutions as isunderstood in the art.

Single unit dose: As used herein, a “single unit dose” is a dose of anytherapeutic administered in one dose/at one time/single route/singlepoint of contact, i.e., single administration event.

Split dose: As used herein, a “split dose” is the division of singleunit dose or total daily dose into two or more doses.

Specific delivery: As used herein, the term “specific delivery,”“specifically deliver,” or “specifically delivering” means delivery ofmore (e.g., at least 1.5 fold more, at least 2-fold more, at least3-fold more, at least 4-fold more, at least 5-fold more, at least 6-foldmore, at least 7-fold more, at least 8-fold more, at least 9-fold more,at least 10-fold more) of a polynucleotide by a nanoparticle to a targettissue of interest (e.g., mammalian liver) compared to an off-targettissue (e.g., mammalian spleen). The level of delivery of a nanoparticleto a particular tissue may be measured by comparing the amount ofprotein produced in a tissue to the weight of said tissue, comparing theamount of polynucleotide in a tissue to the weight of said tissue,comparing the amount of protein produced in a tissue to the amount oftotal protein in said tissue, or comparing the amount of polynucleotidein a tissue to the amount of total polynucleotide in said tissue. Forexample, for renovascular targeting, a polynucleotide is specificallyprovided to a mammalian kidney as compared to the liver and spleen if1.5, 2-fold, 3-fold, 5-fold, 10-fold, 15 fold, or 20 fold morepolynucleotide per 1 g of tissue is delivered to a kidney compared tothat delivered to the liver or spleen following systemic administrationof the polynucleotide. It will be understood that the ability of ananoparticle to specifically deliver to a target tissue need not bedetermined in a subject being treated, it may be determined in asurrogate such as an animal model (e.g., a rat model).

Stable: As used herein “stable” refers to a compound that issufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture, and in some cases capable of formulation intoan efficacious therapeutic agent.

Stabilized: As used herein, the term “stabilize,” “stabilized,”“stabilized region” means to make or become stable.

Stereoisomer: As used herein, the term “stereoisomer” refers to allpossible different isomeric as well as conformational forms that acompound may possess (e.g., a compound of any formula described herein),in particular all possible stereochemically and conformationallyisomeric forms, all diastereomers, enantiomers and/or conformers of thebasic molecular structure. Some compounds of the present disclosure mayexist in different tautomeric forms, all of the latter being includedwithin the scope of the present disclosure.

Subject: By “subject” or “individual” or “animal” or “patient” or“mammal,” is meant any subject, particularly a mammalian subject, forwhom diagnosis, prognosis, or therapy is desired. Mammalian subjectsinclude, but are not limited to, humans, domestic animals, farm animals,zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs,rabbits, rats, mice, horses, cattle, cows; primates such as apes,monkeys, orangutans, and chimpanzees; canids such as dogs and wolves;felids such as cats, lions, and tigers; equids such as horses, donkeys,and zebras; bears, food animals such as cows, pigs, and sheep; ungulatessuch as deer and giraffes; rodents such as mice, rats, hamsters andguinea pigs; and so on. In certain embodiments, the mammal is a humansubject. In other embodiments, a subject is a human patient. In aparticular embodiment, a subject is a human patient in need oftreatment.

Substantially: As used herein, the term “substantially” refers to thequalitative condition of exhibiting total or near-total extent or degreeof a characteristic or property of interest. One of ordinary skill inthe biological arts will understand that biological and chemicalcharacteristics rarely, if ever, go to completion and/or proceed tocompleteness or achieve or avoid an absolute result. The term“substantially” is therefore used herein to capture the potential lackof completeness inherent in many biological and chemicalcharacteristics.

Substantially equal: As used herein as it relates to time differencesbetween doses, the term means plus/minus 2%.

Substantially simultaneous: As used herein and as it relates toplurality of doses, the term means within 2 seconds.

Suffering from: An individual who is “suffering from” a disease,disorder, and/or condition has been diagnosed with or displays one ormore symptoms of the disease, disorder, and/or condition.

Susceptible to: An individual who is “susceptible to” a disease,disorder, and/or condition has not been diagnosed with and/or may notexhibit symptoms of the disease, disorder, and/or condition but harborsa propensity to develop a disease or its symptoms. In some embodiments,an individual who is susceptible to a disease, disorder, and/orcondition (for example, cancer) can be characterized by one or more ofthe following: (1) a genetic mutation associated with development of thedisease, disorder, and/or condition; (2) a genetic polymorphismassociated with development of the disease, disorder, and/or condition;(3) increased and/or decreased expression and/or activity of a proteinand/or nucleic acid associated with the disease, disorder, and/orcondition; (4) habits and/or lifestyles associated with development ofthe disease, disorder, and/or condition; (5) a family history of thedisease, disorder, and/or condition; and (6) exposure to and/orinfection with a microbe associated with development of the disease,disorder, and/or condition. In some embodiments, an individual who issusceptible to a disease, disorder, and/or condition will develop thedisease, disorder, and/or condition. In some embodiments, an individualwho is susceptible to a disease, disorder, and/or condition will notdevelop the disease, disorder, and/or condition.

Sustained release: As used herein, the term “sustained release” refersto a pharmaceutical composition or compound release profile thatconforms to a release rate over a specific period of time.

Synthetic: The term “synthetic” means produced, prepared, and/ormanufactured by the hand of man. Synthesis of polynucleotides or othermolecules of the present disclosure can be chemical or enzymatic.

Targeted Cells: As used herein, “targeted cells” refers to any one ormore cells of interest. The cells can be found in vitro, in vivo, insitu or in the tissue or organ of an organism. The organism can be ananimal, for example a mammal, a human, a subject or a patient.

Target tissue: As used herein “target tissue” refers to any one or moretissue types of interest in which the delivery of a polynucleotide wouldresult in a desired biological and/or pharmacological effect. Examplesof target tissues of interest include specific tissues, organs, andsystems or groups thereof. In particular applications, a target tissuemay be a kidney, a lung, a spleen, vascular endothelium in vessels(e.g., intra-coronary or intra-femoral), or tumor tissue (e.g., viaintratumoral injection). An “off-target tissue” refers to any one ormore tissue types in which the expression of the encoded protein doesnot result in a desired biological and/or pharmacological effect. Inparticular applications, off-target tissues may include the liver andthe spleen.

The presence of a therapeutic agent in an off-target issue can be theresult of: (i) leakage of a polynucleotide from the administration siteto peripheral tissue or distant off-target tissue (e.g., liver) viadiffusion or through the bloodstream (e.g., a polynucleotide intended toexpress a polypeptide in a certain tissue would reach the liver and thepolypeptide would be expressed in the liver); or (ii) leakage of anpolypeptide after administration of a polynucleotide encoding suchpolypeptide to peripheral tissue or distant off-target tissue (e.g.,liver) via diffusion or through the bloodstream (e.g., a polynucleotidewould expressed a polypeptide in the target tissue, and the polypeptidewould diffuse to peripheral tissue).

Targeting sequence: As used herein, the phrase “targeting sequence”refers to a sequence that can direct the transport or localization of aprotein or polypeptide.

Terminus: As used herein the terms “termini” or “terminus,” whenreferring to polypeptides, refers to an extremity of a peptide orpolypeptide. Such extremity is not limited only to the first or finalsite of the peptide or polypeptide but can include additional aminoacids in the terminal regions. The polypeptide based molecules of thedisclosure can be characterized as having both an N-terminus (terminatedby an amino acid with a free amino group (NH₂)) and a C-terminus(terminated by an amino acid with a free carboxyl group (COOH)).Proteins of the disclosure are in some cases made up of multiplepolypeptide chains brought together by disulfide bonds or bynon-covalent forces (multimers, oligomers). These sorts of proteins willhave multiple N- and C-termini. Alternatively, the termini of thepolypeptides can be modified such that they begin or end, as the casecan be, with a non-polypeptide based moiety such as an organicconjugate.

Therapeutic Agent: The term “therapeutic agent” refers to an agent that,when administered to a subject, has a therapeutic, diagnostic, and/orprophylactic effect and/or elicits a desired biological and/orpharmacological effect. For example, in some embodiments, an mRNAencoding an IL12B polypeptide, IL12A polypeptide, or both IL12B andIL12A polypeptides can be a therapeutic agent.

Therapeutically effective amount: As used herein, the term“therapeutically effective amount” means an amount of an agent to bedelivered (e.g., nucleic acid, drug, therapeutic agent, diagnosticagent, prophylactic agent, etc.) that is sufficient, when administeredto a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition.

Therapeutically effective outcome: As used herein, the term“therapeutically effective outcome” means an outcome that is sufficientin a subject suffering from or susceptible to an infection, disease,disorder, and/or condition, to treat, improve symptoms of, diagnose,prevent, and/or delay the onset of the infection, disease, disorder,and/or condition.

Total daily dose: As used herein, a “total daily dose” is an amountgiven or prescribed in 24 hr. period. The total daily dose can beadministered as a single unit dose or a split dose.

Transcription factor: As used herein, the term “transcription factor”refers to a DNA-binding protein that regulates transcription of DNA intoRNA, for example, by activation or repression of transcription. Sometranscription factors effect regulation of transcription alone, whileothers act in concert with other proteins. Some transcription factor canboth activate and repress transcription under certain conditions. Ingeneral, transcription factors bind a specific target sequence orsequences highly similar to a specific consensus sequence in aregulatory region of a target gene. Transcription factors may regulatetranscription of a target gene alone or in a complex with othermolecules.

Transcription: As used herein, the term “transcription” refers tomethods to introduce exogenous nucleic acids into a cell. Methods oftransfection include, but are not limited to, chemical methods, physicaltreatments and cationic lipids or mixtures.

Transfection: As used herein, “transfection” refers to the introductionof a polynucleotide into a cell wherein a polypeptide encoded by thepolynucleotide is expressed (e.g., mRNA) or the polypeptide modulates acellular function (e.g., siRNA, miRNA). As used herein, “expression” ofa nucleic acid sequence refers to translation of a polynucleotide (e.g.,an mRNA) into a polypeptide or protein and/or post-translationalmodification of a polypeptide or protein.

Treating, treatment, therapy: As used herein, the term “treating” or“treatment” or “therapy” refers to partially or completely alleviating,ameliorating, improving, relieving, delaying onset of, inhibitingprogression of, reducing severity of, and/or reducing incidence of oneor more symptoms or features of a disease, e.g., acute intermittentporphyria. For example, “treating” acute intermittent porphyria canrefer to diminishing symptoms associate with the disease, prolong thelifespan (increase the survival rate) of patients, reducing the severityof the disease, preventing or delaying the onset of the disease, etc.Treatment can be administered to a subject who does not exhibit signs ofa disease, disorder, and/or condition and/or to a subject who exhibitsonly early signs of a disease, disorder, and/or condition for thepurpose of decreasing the risk of developing pathology associated withthe disease, disorder, and/or condition.

Unmodified: As used herein, “unmodified” refers to any substance,compound or molecule prior to being changed in some way. Unmodified can,but does not always, refer to the wild type or native form of abiomolecule. Molecules can undergo a series of modifications wherebyeach modified molecule can serve as the “unmodified” starting moleculefor a subsequent modification.

Uracil: Uracil is one of the four nucleobases in the nucleic acid ofRNA, and it is represented by the letter U. Uracil can be attached to aribose ring, or more specifically, a ribofuranose via a 3-Ni-glycosidicbond to yield the nucleoside uridine. The nucleoside uridine is alsocommonly abbreviated according to the one letter code of its nucleobase,i.e., U. Thus, in the context of the present disclosure, when a monomerin a polynucleotide sequence is U, such U is designated interchangeablyas a “uracil” or a “uridine.”

Uridine Content: The terms “uridine content” or “uracil content” areinterchangeable and refer to the amount of uracil or uridine present ina certain nucleic acid sequence. Uridine content or uracil content canbe expressed as an absolute value (total number of uridine or uracil inthe sequence) or relative (uridine or uracil percentage respect to thetotal number of nucleobases in the nucleic acid sequence).

Uridine-Modified Sequence: The terms “uridine-modified sequence” refersto a sequence optimized nucleic acid (e.g., a synthetic mRNA sequence)with a different overall or local uridine content (higher or loweruridine content) or with different uridine patterns (e.g., gradientdistribution or clustering) with respect to the uridine content and/oruridine patterns of a candidate nucleic acid sequence. In the content ofthe present disclosure, the terms “uridine-modified sequence” and“uracil-modified sequence” are considered equivalent andinterchangeable.

A “high uridine codon” is defined as a codon comprising two or threeuridines, a “low uridine codon” is defined as a codon comprising oneuridine, and a “no uridine codon” is a codon without any uridines. Insome embodiments, a uridine-modified sequence comprises substitutions ofhigh uridine codons with low uridine codons, substitutions of highuridine codons with no uridine codons, substitutions of low uridinecodons with high uridine codons, substitutions of low uridine codonswith no uridine codons, substitution of no uridine codons with lowuridine codons, substitutions of no uridine codons with high uridinecodons, and combinations thereof. In some embodiments, a high uridinecodon can be replaced with another high uridine codon. In someembodiments, a low uridine codon can be replaced with another lowuridine codon. In some embodiments, a no uridine codon can be replacedwith another no uridine codon. A uridine-modified sequence can beuridine enriched or uridine rarefied.

Uridine Enriched: As used herein, the terms “uridine enriched” andgrammatical variants refer to the increase in uridine content (expressedin absolute value or as a percentage value) in an sequence optimizednucleic acid (e.g., a synthetic mRNA sequence) with respect to theuridine content of the corresponding candidate nucleic acid sequence.Uridine enrichment can be implemented by substituting codons in thecandidate nucleic acid sequence with synonymous codons containing lessuridine nucleobases. Uridine enrichment can be global (i.e., relative tothe entire length of a candidate nucleic acid sequence) or local (i.e.,relative to a subsequence or region of a candidate nucleic acidsequence).

Uridine Rarefied: As used herein, the terms “uridine rarefied” andgrammatical variants refer to a decrease in uridine content (expressedin absolute value or as a percentage value) in an sequence optimizednucleic acid (e.g., a synthetic mRNA sequence) with respect to theuridine content of the corresponding candidate nucleic acid sequence.Uridine rarefication can be implemented by substituting codons in thecandidate nucleic acid sequence with synonymous codons containing lessuridine nucleobases. Uridine rarefication can be global (i.e., relativeto the entire length of a candidate nucleic acid sequence) or local(i.e., relative to a subsequence or region of a candidate nucleic acidsequence).

Variant: The term variant as used in present disclosure refers to bothnatural variants (e.g., polymorphisms, isoforms, etc) and artificialvariants in which at least one amino acid residue in a native orstarting sequence (e.g., a wild type sequence) has been removed and adifferent amino acid inserted in its place at the same position. Thesevariants can be described as “substitutional variants.” Thesubstitutions can be single, where only one amino acid in the moleculehas been substituted, or they can be multiple, where two or more aminoacids have been substituted in the same molecule. If amino acids areinserted or deleted, the resulting variant would be an “insertionalvariant” or a “deletional variant” respectively.

The terms “invention” and “disclosure” can be used interchangeably whendescribing or used, for example, in the phrases “the present invention”or “the present disclosure.”

30. Equivalents and Scope

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments in accordance with the disclosure described herein. Thescope of the present disclosure is not intended to be limited to theabove Description, but rather is as set forth in the appended claims.

In the claims, articles such as “a,” “an,” and “the” may mean one ormore than one unless indicated to the contrary or otherwise evident fromthe context. Claims or descriptions that include “or” between one ormore members of a group are considered satisfied if one, more than one,or all of the group members are present in, employed in, or otherwiserelevant to a given product or process unless indicated to the contraryor otherwise evident from the context. The disclosure includesembodiments in which exactly one member of the group is present in,employed in, or otherwise relevant to a given product or process. Thedisclosure includes embodiments in which more than one, or all of thegroup members are present in, employed in, or otherwise relevant to agiven product or process.

It is also noted that the term “comprising” is intended to be open andpermits but does not require the inclusion of additional elements orsteps. When the term “comprising” is used herein, the term “consistingof” is thus also encompassed and disclosed.

Where ranges are given, endpoints are included. Furthermore, it is to beunderstood that unless otherwise indicated or otherwise evident from thecontext and understanding of one of ordinary skill in the art, valuesthat are expressed as ranges can assume any specific value or subrangewithin the stated ranges in different embodiments of the disclosure, tothe tenth of the unit of the lower limit of the range, unless thecontext clearly dictates otherwise.

In addition, it is to be understood that any particular embodiment ofthe present disclosure that falls within the prior art can be explicitlyexcluded from any one or more of the claims. Since such embodiments aredeemed to be known to one of ordinary skill in the art, they can beexcluded even if the exclusion is not set forth explicitly herein. Anyparticular embodiment of the compositions of the disclosure (e.g., anynucleic acid or protein encoded thereby; any method of production; anymethod of use; etc.) can be excluded from any one or more claims, forany reason, whether or not related to the existence of prior art.

All cited sources, for example, references, publications, databases,database entries, and art cited herein, are incorporated into thisapplication by reference, even if not expressly stated in the citation.In case of conflicting statements of a cited source and the instantapplication, the statement in the instant application shall control.

Section and table headings are not intended to be limiting. The presentdisclosure is further described in the following examples, which do notlimit the scope of the disclosure described in the claims.

EXAMPLES Example 1: In Vivo Anti-Tumor Efficacy of IL12 Modified mRNA ina Colon Adenocarcinoma (MC38) Syngeneic Model (IntravenousAdministration)

The in vivo anti-tumor efficacy of IL12 mRNA, administered as a singleintravenous (IV) dose in mice bearing M38 adenocarcinoma tumors, wasassessed.

A. Preparation of IL12 Modified mRNA and Control

A polynucleotide (mRNA) comprising a codon-optimized nucleotide sequenceencoding a wild-type murine IL12 polypeptide (murine IL12) and a miRNAbinding site (miR-122) in its 3′ UTR were prepared (mIL12_miR122)(sequence set forth below).

(SEQ ID NO: 241) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCCUCAGAAGCUAACCAUCUCCUGGUUUGCCAUCGUUUUGCUGGUGUCUCCACUCAUGGCCAUGUGGGAGCUGGAGAAAGACGUUUAUGUUGUAGAGGUGGACUGGACUCCCGAUGCCCCUGGAGAAACAGUGAACCUCACCUGUGACACGCCUGAAGAAGAUGACAUCACCUGGACCUCAGACCAGAGACAUGGAGUCAUAGGCUCUGGAAAGACCCUGACCAUCACUGUCAAAGAGUUCCUAGAUGCUGGCCAGUACACCUGCCACAAAGGAGGCGAGACUCUGAGCCACUCACAUCUGCUGCUCCACAAGAAGGAAAAUGGAAUUUGGUCCACUGAAAUUUUAAAAAAUUUCAAAAACAAGACUUUCCUGAAGUGUGAAGCACCAAAUUACUCCGGACGGUUCACGUGCUCAUGGCUGGUGCAAAGAAACAUGGACUUGAAGUUCAACAUCAAGAGCAGUAGCAGUUCCCCUGACUCUCGGGCAGUGACAUGUGGAAUGGCGUCUCUGUCUGCAGAGAAGGUCACACUGGACCAAAGGGACUAUGAGAAGUAUUCAGUGUCCUGCCAGGAGGAUGUCACCUGCCCAACUGCCGAGGAGACCCUGCCCAUUGAACUGGCGUUGGAAGCACGGCAGCAGAAUAAAUAUGAGAACUACAGCACCAGCUUCUUCAUCAGGGACAUCAUCAAACCAGACCCGCCCAAGAACUUGCAGAUGAAGCCUUUGAAGAACUCACAGGUGGAGGUCAGCUGGGAGUACCCUGACUCCUGGAGCACUCCCCAUUCCUACUUCUCCCUCAAGUUCUUUGUUCGAAUCCAGCGCAAGAAAGAAAAGAUGAAGGAGACAGAGGAGGGGUGUAACCAGAAAGGUGCGUUCCUCGUAGAGAAGACAUCUACCGAAGUCCAAUGCAAAGGCGGGAAUGUCUGCGUGCAAGCUCAGGAUCGCUAUUACAAUUCCUCAUGCAGCAAGUGGGCAUGUGUUCCCUGCAGGGUCCGAUCCGGAGGCGGAGGGAGCGGAGGCGGAGGGAGCGGAGGCGGAGGGAGCAGGGUCAUUCCAGUCUCUGGACCUGCCAGGUGUCUUAGCCAGUCCCGAAACCUGCUGAAGACCACAGAUGACAUGGUGAAGACGGCCAGAGAAAAACUGAAACAUUAUUCCUGCACUGCUGAAGACAUCGAUCAUGAAGACAUCACACGGGACCAAACCAGCACAUUGAAGACCUGUUUACCACUGGAACUACACAAGAACGAGAGUUGCCUGGCUACUAGAGAGACUUCUUCCACAACAAGAGGGAGCUGCCUGCCCCCACAGAAGACGUCUUUGAUGAUGACCCUGUGCCUUGGUAGCAUCUAUGAGGACUUGAAGAUGUACCAGACAGAGUUCCAGGCCAUCAACGCAGCACUUCAGAAUCACAACCAUCAGCAGAUCAUUUUAGACAAGGGCAUGCUGGUGGCCAUCGAUGAGCUGAUGCAGUCUCUGAAUCAUAAUGGCGAGACUCUGCGCCAGAAACCUCCUGUGGGAGAAGCAGACCCUUACAGAGUGAAAAUGAAGCUCUGCAUCCUGCUUCACGCCUUCAGCACCCGCGUCGUGACCAUCAACAGGGUGAUGGGCUAUCUGAGCUCCGCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUA AAGUCUGAGUGGGCGGC

The miR-122 binding element was incorporated to decrease proteinproduction from the liver. A negative control mRNA was also prepared(non-translatable version of mRNAs), e.g., NST-FIX. The mRNAs were fullymodified with N1-methylpseudouridine. Both modified mRNAs wereformulated in MC3 lipid nanoparticles (LNP).

B. MC-38 Colon Adenocarcinoma Mouse Model

MC-38 colon adenocarcinoma tumors were implanted subcutaneously in miceas described in Rosenberg et al., Science 233:1318-1321 (1986)).

Eleven days after tumor implantation, two groups of animals wereadministered a single intravenous dose of LNP-formulated IL12 modifiedmRNA (at a dose of either 0.1 mg/kg (Group 4) or 0.05 mg/kg (Group 5).Two groups of control animals were treated with equivalent doses ofnegative control mRNA (NST-FIX LNP) (Group 7 and Group 8), PBS (Group1), or recombinant murine IL12 protein, 1 μg (Group 2).

Tumor volume was measured using manual calipers. Mean tumor volume today 24 (FIG. 5) was recorded in cubic millimeters (mm³).

C. Results

Intravenous administration of murine IL12 mRNA resulted in dosedependent plasma IL12 (FIG. 2A) and IFNγ (FIG. 2B) levels and increasedIL12 and IFNγ AUC (Table 8), each of which were higher than those levelsfollowing administration of a comparable amount of recombinant IL12protein by intraperitoneal injection (FIGS. 2A-2B).

TABLE 8 AUC levels for IL12 and IFNγ plasma levels. IL12 AUC (ng/mL) *IFNγ AUC (ng/mL) * Treatment hr_(0.5-196) hr_(0.5-196) 0.1 mpk IL12 mRNA18805 5290 (↑10.4x) (↑21.3x) 0.05 mpk IL12 mRNA 7500 1856 (↑4.1x)(↑7.5x) ~0.05 mpk IL12 1801 248 protein The numbers in parenthesesindicate the x-fold increase for mRNA over protein.

FIG. 3 depicts the robust efficacy of a single intravenous (IV) dose ofmurine IL12 mRNA in lipid nanoparticle (LNP), at doses of 0.1 mg/kg(Group 4) and 0.05 mg/kg (Group 5) (as indicated by lines with theinverted triangles), compared to Groups 1 (PBS), 2 (IL12 protein), 7 and8 (controls NST-FIX, 0.1 mg/kg and 0.05 mg/kg, respectively).

FIGS. 4A-4F depict the mean tumor volume and the number of completeresponses (CR) seen following administration of a single intravenous(IV) dose of: murine IL12 mRNA in lipid nanoparticle (LNP), at doses of0.1 mg/kg (Group 4)(FIG. 4F) and 0.05 mg/kg (Group 5)(FIG. 4E), PBS(Group 1)(FIG. 4A), IL12 protein (Group 2)(FIG. 4D), controls NST-FIX,0.1 mg/kg and 0.05 mg/kg (Groups 7 and 8, respectively) (FIGS. 4C and4B, respectively). Complete responses (CRs) are shown in FIGS. 4E and 4Fonly. FIG. 4E shows that 6 of 8 CRs (i.e., 75% CR) were seen in Group 5(IL12 mRNA in lipid nanoparticle (LNP), at a dose of 0.05 mg/kg). FIG.4F shows that 5 of 9 CRs (i.e., 56% CR) were seen in Group 4 (IL12 mRNAin lipid nanoparticle (LNP), at a dose of 0.1 mg/kg). Aside from theIL12 mRNA groups, no other group observed any CRs.

FIG. 5 depicts the survival benefit at day 47 post tumor-implantationfrom a single intravenous (IV) dose of murine IL12 mRNA in lipidnanoparticle (LNP) at a dose of 0.05 mg/kg (Group 5) and at a dose of0.1 mg/kg (Group 4).

Notably, FIGS. 3-5 demonstrate the advantage of administeringintravenous murine IL12 mRNA over protein in terms of improvedpharmacokinetics (PK), pharmacodynamics (PD), and therapeutic efficacy,with a single IV dose.

Table 9 depicts the tolerability advantage of local (intratumoral)administration of IL12 mRNA over systemic (intravenous) administration.Nine (9) of 10 mice intratumorally administered IL12 mRNA were viable atday 20 compared to 3 of 12 mice intravenously administered IL12 mRNA.

TABLE 9 Intravenous and intratumoral tolerability of murine IL12administration. IL12 Treatment tolerability Plasma levels mRNA in LNPoutcome of IL12 24 hr Route (mg/kg) (to Day 20) post dose (ng/ml)Intravenous 0.2 3/12 viable 1592 Intratumoral ~0.2   9/10 viable 89 (4μg fixed)

Example 2: In Vivo Anti-Tumor Efficacy of Murine IL12 Modified mRNA in aColon Adenocarcinoma (MC38) Model (Intratumoral Administration)

The in vivo anti-tumor efficacy of murine IL12 mRNA, administeredintratumorally in mice bearing M38 adenocarcinoma tumors, was assessed.

A. Preparation of IL12 Modified mRNA and Control

The mIL12_miR122 polynucleotide as described in Example 1 was prepared.A negative control mRNA, NST-FIX mRNA, was also prepared. Both modifiedmRNAs were formulated in MC3 lipid nanoparticles (LNP) as described inExample 1.

B. MC-38 Colon Adenocarcinoma Mouse Model

MC-38 colon adenocarcinoma tumors were implanted subcutaneously in miceas described in Rosenberg et al., Science 233:1318-1321 (1986)).

Eleven days after tumor implantation, animals were administered a singleintratumoral dose of MC3 LNP-formulated murine IL12 modified mRNA (4 μgmRNA per dose). Two groups of control animals were treated with anequivalent dose and regimen of negative control mRNA (NST-FIX LNP) orPBS.

Tumor volume was measured at the indicated time points in FIG. 6B usingmanual calipers. Tumor volume mean to day 24 (FIG. 6A) and individualtumor volume to day 47 (FIG. 6B) were recorded in cubic millimeters(mm³). Endpoints in the study were either death of the animal or a tumorvolume reaching 1500 mm³.

C. Results

FIG. 6A shows that mean tumor volume was reduced when MC3 LNP-formulatedmurine IL12 modified mRNA was administered. In contrast, administering acontrol modified mRNA (NST-FIX) or PBS to the mice had little effect onreducing the tumor volume mean when assessed up to day 24.

FIG. 6B shows that administering about 4 μg MC3 LNP-formulated murineIL12 modified mRNA per animal to the mice decreased individual tumorvolumes in some animals compared to animals administered controlmodified mRNA (NST-FIX) or PBS. Complete responses (CRs) were seen in 3of 7 animals (44%), with 3 animals removed due to ulceration. These datashow that mIL12_miR122 polynucleotides have anti-tumor efficacy whenadministered intratumorally in vivo.

Example 3: In Vivo Anti-Tumor Efficacy of IL12 Modified mRNA in a B-CellLymphoma (A20) Syngeneic Model

The in vivo anti-tumor efficacy of murine IL12 mRNA, administeredintratumorally in mice bearing A20 B-cell lymphoma tumors, was assessed.

A. Preparation of IL12 modified mRNAs and controls

A polynucleotide comprising a codon-optimized nucleotide sequenceencoding an IL12 polypeptide (murine IL12) without a miRNA binding site(miRless) was prepared (IL12 miRless) (sequence set forth below).

(SEQ ID NO: 242) GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACCAUGUGUCCUCAGAAGCUAACCAUCUCCUGGUUUGCCAUCGUUUUGCUGGUGUCUCCACUCAUGGCCAUGUGGGAGCUGGAGAAAGACGUUUAUGUUGUAGAGGUGGACUGGACUCCCGAUGCCCCUGGAGAAACAGUGAACCUCACCUGUGACACGCCUGAAGAAGAUGACAUCACCUGGACCUCAGACCAGAGACAUGGAGUCAUAGGCUCUGGAAAGACCCUGACCAUCACUGUCAAAGAGUUCCUAGAUGCUGGCCAGUACACCUGCCACAAAGGAGGCGAGACUCUGAGCCACUCACAUCUGCUGCUCCACAAGAAGGAAAAUGGAAUUUGGUCCACUGAAAUUUUAAAAAAUUUCAAAAACAAGACUUUCCUGAAGUGUGAAGCACCAAAUUACUCCGGACGGUUCACGUGCUCAUGGCUGGUGCAAAGAAACAUGGACUUGAAGUUCAACAUCAAGAGCAGUAGCAGUUCCCCUGACUCUCGGGCAGUGACAUGUGGAAUGGCGUCUCUGUCUGCAGAGAAGGUCACACUGGACCAAAGGGACUAUGAGAAGUAUUCAGUGUCCUGCCAGGAGGAUGUCACCUGCCCAACUGCCGAGGAGACCCUGCCCAUUGAACUGGCGUUGGAAGCACGGCAGCAGAAUAAAUAUGAGAACUACAGCACCAGCUUCUUCAUCAGGGACAUCAUCAAACCAGACCCGCCCAAGAACUUGCAGAUGAAGCCUUUGAAGAACUCACAGGUGGAGGUCAGCUGGGAGUACCCUGACUCCUGGAGCACUCCCCAUUCCUACUUCUCCCUCAAGUUCUUUGUUCGAAUCCAGCGCAAGAAAGAAAAGAUGAAGGAGACAGAGGAGGGGUGUAACCAGAAAGGUGCGUUCCUCGUAGAGAAGACAUCUACCGAAGUCCAAUGCAAAGGCGGGAAUGUCUGCGUGCAAGCUCAGGAUCGCUAUUACAAUUCCUCAUGCAGCAAGUGGGCAUGUGUUCCCUGCAGGGUCCGAUCCGGAGGCGGAGGGAGCGGAGGCGGAGGGAGCGGAGGCGGAGGGAGCAGGGUCAUUCCAGUCUCUGGACCUGCCAGGUGUCUUAGCCAGUCCCGAAACCUGCUGAAGACCACAGAUGACAUGGUGAAGACGGCCAGAGAAAAACUGAAACAUUAUUCCUGCACUGCUGAAGACAUCGAUCAUGAAGACAUCACACGGGACCAAACCAGCACAUUGAAGACCUGUUUACCACUGGAACUACACAAGAACGAGAGUUGCCUGGCUACUAGAGAGACUUCUUCCACAACAAGAGGGAGCUGCCUGCCCCCACAGAAGACGUCUUUGAUGAUGACCCUGUGCCUUGGUAGCAUCUAUGAGGACUUGAAGAUGUACCAGACAGAGUUCCAGGCCAUCAACGCAGCACUUCAGAAUCACAACCAUCAGCAGAUCAUUUUAGACAAGGGCAUGCUGGUGGCCAUCGAUGAGCUGAUGCAGUCUCUGAAUCAUAAUGGCGAGACUCUGCGCCAGAAACCUCCUGUGGGAGAAGCAGACCCUUACAGAGUGAAAAUGAAGCUCUGCAUCCUGCUUCACGCCUUCAGCACCCGCGUCGUGACCAUCAACAGGGUGAUGGGCUAUCUGAGCUCCGCCUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC

The mIL12_miR122 polynucleotide as described in Example 1 was prepared.A negative control mRNA (NST) was also prepared (non-translatableversion of the same mRNA) (NST IL12_miRless). All modified mRNAs wereformulated in MC3 lipid nanoparticles (LNP) as described in Example 1.

B. A20 B-Cell Lymphoma Tumor Model

Mouse models of B-cell lymphoma using the A20 cell line are useful foranalyzing tumors. (Kim et al., Journal of Immunology 122:549-554 (1979);Donnou et al., Advances in Hematology 2012:701704 (2012), incorporatedherein by reference in their entirety). A20 cells are derived from a Bcell lymphoma from a BALB/c mouse and are typically grown in syngeneicmice as a subcutaneous implant. 500,000 A20 cells were implantedsubcutaneously in BALB/c mice to generate subcutaneous tumors. Tumorswere monitored for size and palpability.

Once the tumors reached an average size of 100 mm³, the mice werecohorted into three groups. One test group was administeredintratumorally mIL12_miRless in MC3-based lipid nanoparticles (LNP) at adose of 5 μg mRNA per animal. The second test group was administeredintratumorally mIL12_miR122 in MC3-based lipid nanoparticles (LNP) at adose of 5 μg mRNA per animal. The control group was administered anequivalent dose of non-translated control mRNA (NST). Animals were dosedon day 10 post implantation. Results are shown in FIGS. 7A-7C.

The study was carried out through day 50 post implantation. Endpoints inthe study were either death of the animal or a pre-determined endpointof 2000 mm³ tumor volume.

C. Results

FIG. 7A shows that tumor volume (measured in mm³) increased over time inall 12 animals treated with 5 μg control NST mRNA. FIG. 7B shows thattumor volume decreased over time in some animals treated withmIL12_miRless compared to animals administered control mRNA (NST).Complete responses (CRs) were seen in 5 of 12 animals (42%). Therefore,the intratumoral administration of murine IL12 mRNAs is efficacious inthe A20 tumor model.

FIG. 7C shows changes in tumor volume in animals treated with 5 μgmIL12-miR122 (FIG. 7C). Complete responses (CR) were achieved in 6 outof 12 mice in the IL12-miR122 group (FIG. 7C).

The data in FIGS. 7A-7C show that mIL12_miRless and mIL12-miR122polynucleotides have comparable anti-tumor efficacy when administeredintratumorally in vivo.

Example 4: Single and Multidose In Vivo Anti-Tumor Efficacy of aModified IL12 mRNA

The in vivo anti-tumor efficacy of a modified murine IL12 mRNA,administered as a single 0.5 μg dose and a multidose (0.5 μg for 7days×6), was studied in BALB/C mice bearing A20 B-cell lymphoma tumors.

A. Modified IL12 mRNA

The mIL12_miR122 polynucleotide and mIL12_miRless polynucleotide asdescribed in Examples 1 and 3, respectively, were prepared. One group ofmIL12_miR122 mRNA was formulated in MC3-based lipid nanoparticles (LNP)as described in Example 1. Another group of mIL12_miR122 mRNA wasformulated in Compound 18-based lipid nanoparticles (LNP).

B. Dosing

On day 10 post implantation, two groups of mice bearing A20 tumors (n=12in each group) were administered a single 0.5 μg dose of murine IL12mRNA in the form of IL12 miRless- or IL12 miR122-mRNA in MC3-based LNP.

Also on day 10 post implantation, another group of mice bearing A20tumors was intratumorally administered weekly dosing of 0.5 μg of IL12miR122 mRNA in MC3-based LNP for 7 days×6.

Also on day 10 post implantation, another group of mice bearing A20tumors was intratumorally administered weekly dosing of 0.5 μg of IL12miR122 mRNA in Compound 18-based LNP for 7 days×6.

Finally, 10 days post implantation, another group of mice bearing A20tumors (n=12 per group) was administered weekly dosing of 0.5 μgnon-translated negative control mRNA (NST) in either MC3-based LNP orCompound 18-based LNP for 7 days×6.

C. Results

As shown in FIGS. 8A-8B, in vivo anti-tumor efficacy in a B-celllymphoma tumor model (A20) was achieved after mice bearing A20 tumorswere administered a single dose of 0.5 μg murine IL12 mRNA in MC3-basedlipid nanoparticle (LNP). FIG. 8A depicts decreased tumor volume in somemice administered IL12 miRless (0.5 g), and that four (4) completeresponses (CR) were achieved. FIG. 8B depicts decreased tumor volume insome mice administered IL12 miR122 (0.5 μg), and that three (3) completeresponses (CR) were achieved.

As shown in FIG. 8C, in vivo anti-tumor efficacy was enhanced with aweekly dosing regimen of IL12 miR122 mRNA in MC3-based LNP (0.5 μg mRNAfor 7 days×6), compared to single dosing (see FIG. 8B). FIG. 8C showsthat five (5) CRs were achieved in the 12 A20-bearing mice administeredweekly dosing of 0.5 μg IL12 miR122 mRNA for seven (7) days×6.

In vivo anti-tumor efficacy of IL12 mRNA in Compound-18 LNPs wasenhanced as compared to the in vivo tumor efficacy of IL12 mRNA in MC3LNPs, as can be seen by delay in tumor growth (FIG. 8D). FIG. 8D showsthe individual tumor volumes for 12 mice administered 0.5 μg of murineIL12 mRNA in compound 18-based LNP for 7 days×6. Complete responses (CR)were also achieved in 5 out of 12 animals.

As shown in FIGS. 8E-8F, tumor growth was observed in mice bearing A20tumors administered weekly dosing (7 days×6) of 0.5 μg non-translatednegative control mRNA (NST) in MC3-based lipid nanoparticle (LNP) (FIG.8E) and 0.5 μg NST in Compound 18-based LNP (FIG. 8F).

This data shows that polynucleotides comprising modified murine IL12mRNA (both miR122 and miRless) show anti-tumor efficacy at low doses(0.5 μg). It also shows that in vivo anti-tumor efficacy can potentiallybe enhanced with a multiple dosing regimen. Finally, the data shows invivo anti-tumor efficacy when 0.5 μg IL12 miR122 mRNA in MC3-based andCompound 18-based LNP is administered intratumorally weekly (for 7days×6). In contrast, tumor growth was observed in mice bearing A20tumors administered weekly dosing (7 days×6) of 0.5 μg non-translatednegative control mRNA (NST) in MC3-based lipid nanoparticle (LNP) and inCompound 18-based LNP.

Example 5: Analysis of Levels of IL12 p70, IFNγ, IP10, IL6, GCSF, andGROα in Plasma and Tumors of A20-Bearing Mice Following Administrationof Murine IL12 mRNA

On day 10 post implantation, groups of mice bearing A20 tumors (n=12 ineach group) were administered a dose of miR122 IL12 mRNA (at 5 μg, 2.5μg, or 0.5 μg) in MC3-based LNP or Compound 18-based LNP, NST or IL12protein at the same dosages, or PBS.

The levels of tumor and plasma IL12 p70, as well as the level of othercytokines, were determined at 6 and 24 hours after administration of thedosages. The levels of IL12 (p70) were determined using a sandwich ELISAcommercial kit (R&D Systems, Minneapolis, Minn., USA). The levels ofIFNγ, IP10, IL6, G-CSF, and GROα were also determined.

Results:

FIGS. 9A-9B show dose-dependent levels of IL12 in plasma (FIG. 9A) andtumor (FIG. 9B) at 6 hours and 24 hours following administration of theindicated doses of murine IL12 mRNA in an MC3-based LNP to mice bearingA20 tumors.

FIGS. 9C-9D show elevated levels of IL12 in plasma and tumor followingadministration of the indicated doses of murine IL12 mRNA in Compound18-based LNPs compared to murine IL12 mRNA in MC3-based LNPs. FIG. 9Cshows plasma IL12 levels at 6 hours and 24 hours; FIG. 9D shows tumorIL12 levels at 6 hours and 24 hours. Table 10 shows the fold increase ofIL12 in plasma and tumor after the murine IL12 mRNA administration (6hrs and 24 hrs).

TABLE 10 Fold increase of IL12 from Compound 18 compared to MC3. mRNAdose 6 hr 24 hr Plasma 0.5 μg 9.3 2.8 2.5 μg 2.7 7.2 Tumor 0.5 μg 1.82.9 2.5 μg 2.3 2.1

FIGS. 9E-9F show increased levels of IFNγ at 6 hours and 24 hours inplasma (FIG. 9E) and in tumor (FIG. 9F) following administration ofmurine IL12 mRNA to mice bearing A20 tumors.

FIGS. 9G-9H show increased levels of IP10 at 6 hours and 24 hours inplasma (FIG. 9G) and in tumor (FIG. 911) following administration ofmurine IL12 mRNA to mice bearing A20 tumors.

FIGS. 9I-9J show decreased levels of IL6 at 6 hours and 24 hours inplasma (FIG. 9I) and in tumor (FIG. 9J) following administration ofmurine IL12 mRNA in Compound 18-based LNP compared to murine IL12 mRNAin MC3-based LNP.

FIGS. 9K-9L show decreased levels of G-CSF at 6 hours and 24 hours inplasma (FIG. 9K) and in tumor (FIG. 9L) following administration ofmurine IL12 mRNA in Compound 18-based LNP compared to murine IL12 mRNAin MC3-based LNP.

FIGS. 9M-9N show decreased levels of GROα at 6 hours and at 24 hours inplasma (FIG. 9M) and tumor (FIG. 9N) following administration of murineIL12 mRNA in Compound 18-based LNP compared to murine IL12 mRNA inMC3-based LNP.

The data in this example show dose dependent levels of IL12 in plasmaand tumor with intratumoral administration of murine IL12 mRNA (FIGS. 9Aand 9B). The data also show increased IL12 levels in plasma and tumorfrom Compound 18-based LNPs compared to MC3-based LNP (FIGS. 9C and 9D),as well as increased IFNγ and IP10 levels, attributable toadministration of murine IL12 mRNA (FIGS. 9E-9H). Finally, this exampleshows decreased levels of IL6, G-CSF, and GROα in plasma and tumor withCompound 18-formulated murine IL12 mRNA compared to MC3-formulatedmurine IL12 mRNA (FIGS. 91-9N).

Example 6: In Vivo Anti-Tumor Efficacy of Intravenous (IV)Administration of IL12 miR122 mRNA in a Subcutaneous A20 Model

A. Study Design

500,000 A20 cells were implanted subcutaneously in BALB/c mice. A20tumor-bearing mice were cohorted into 2 treatment groups (N=10) whentumor averages reached approximately −100 mm³. Mice were IV dosed with0.5 mg/kg murine mRNA in a Compound 18 PEG containing LNP every 7 days(Q7D).

The control group were treated with negative control mRNA formulated inLNP, whereas the treatment group were dosed with LNPs containing murineIL12 mRNA with a miR122 binding element with in the 3′ UTR. Use of theCompound 18-containing LNP and incorporation of the miR122 bindingelement were meant to mitigate potential protein production from theliver.

Tumor volumes and body weights were measured twice a week, and generalclinical observations made in accordance with an accepted IACUC protocoluntil a pre-determined endpoint of 2000 mm³ tumor volume was reached.

B. Efficacy Data

The individual tumor volumes from mice treated with weekly dosing ofmurine IL12 mRNA plus a miR122 binding element formulated in a Compound18 PEG-containing LNP are shown in FIG. 10B compared to appropriatenegative controls in FIG. 10A. Dosing days are indicated by vertical redhashed lines, and the pre-determined endpoint of 2000 mm³ tumor volumeindicated by horizontal black hashed line.

C. Assessment of Side Effects/Toxicity

The individual body weights from mice treated with weekly dosing ofmurine IL12 mRNA plus a miR122 binding element formulated in a Compound18 PEG-containing LNP are shown in FIG. 10D compared to appropriatenegative controls in FIG. 10C.

D. Conclusion

The intravenous administration of murine IL12 mRNA delayed the growth ofA20 tumors as compared to an appropriate negative control (i.e., IVtreatment of identically formulated mRNA with a miR122 binding elementthat had no start “NST” codons). The efficacious dosing of 0.5 mg/kg Q7Dwas well-tolerated as determined by general clinical observations andmore quantitatively by body weight measurements.

Example 7: In Vivo Anti-Tumor Efficacy of Intraperitoneal (IP)Administration of Murine IL12 Modified mRNA in an IP MC38 Model

A. Study Design

The luciferase reporter gene was integrated within the MC-38 colon cellline to enable measurement of bioluminescence from these cells if grownin a context that tumor burden could not be assessed by caliper in liveanimals. The light output from these cells has been correlated withtumor burden.

500,000 MC-38 luciferase-enabled (MC38-luc) cells were inoculated in theperitoneal cavity as a model of colon cancer metastasis to this space.Mice were assigned to various treatment groups based on bioluminescentsignal, and treatment started 7 days post disease induction.

Mice were treated with a single intraperitoneal (IP) dose of murine mRNAformulated in a LNP (MC3:cholesterol:DSPC:PEG-DMGat mol % s of50:38.5:10:1.5) and compared to a single IP dose of 1 μg recombinantmouse IL12 protein. A single dose of 2 fixed dose levels of mRNA (2 μgand 4 μg) were administered at day 7 post disease induction, and murineIL12 mRNAs with and without a miR122 binding element were assessed indifferent treatment groups compared to appropriate negative controls(non-start NST mRNA with a miR122 binding element encapsulated in anidentically formulated LNP).

Tumor volumes and body weights were frequently measured, and generalclinical observations made in accordance with appropriate IACUCprotocols.

B. Efficacy Data

Bioluminescence (BL) was used as a surrogate for tumor burden andmeasured on several days including day 22 post disease induction asdepicted in FIG. 11A. Treatment groups and dose levels are indicated inFIG. 11B. Mice were administered no treatment, 2 μg mIL12_miRless, 2 μgmIL12_miR122, 2 μg NST_OX40L_122, 4 μg mIL12_miRless, 4 μg mIL12_miR122,4 g NST_OX40L_122, and 1 μg rm IL12. Mice treated with murine IL12 mRNAin all arms exhibited lower BL signal than negative controls.

C. Assessment of Side Effects/Toxicity:

The treatments were generally well tolerated, and no treatment groupsexhibited a body weight loss average of over 10% (FIG. 11B).

D. Conclusion

As shown in FIGS. 11A and 11B, mice treated out to 150 days postimplantation with both fixed doses of murine IL12 mRNA exhibited lowerlevels of BL signal as a measure of tumor burden compared to negativecontrols, and this inhibited BL level was associated with an apparentsurvival benefit of intraperitoneally-dosed murine IL12 mRNA. MurineIL12 mRNA that contained a miR122 binding domain within the 3′ UTRexhibited similar efficacy to mRNA without this regulatory element(miR-less). The effective doses employed were considered generallywell-tolerated.

Mice treated with fixed doses of murine IL12 mRNA exhibited lower levelsof BL signal as a measure of tumor burden compared to negative controls,and this inhibited BL level was associated with an apparent survivalbenefit of intraperitoneally-dosed murine IL12 mRNA.

Example 8: Analysis of Levels of IL12 and IFNγ in Mice FollowingAdministration of Murine IL12 mRNA

Mice bearing MC38 tumors were administered one or more doses of murinemiR122 IL12 mRNA in standard Compound 18-based LNP intratumorally (iTu).In particular, mice were given a single intratumoral (iTu) dose ofmurine miR122 L12 mRNA (at 0.05 μg, 0.5 μg, or 5.0 μg) in LNP, multipleiTu doses (4×) of murine miR122 IL12 mRNA at the same levels, or 5.0 μgNST as a control.

The levels of plasma IL12 and IFNγ were determined at 24 hours afteradministration of the dosages. The levels of IL12 and IFNγ weredetermined using a Luminex-based multiplex panel (ProcartaPlex MouseCytokine & Chemokine Panel 1A 36 plex, Affymetrix eBioscience).

FIG. 17A shows dose-dependent levels of IL12 in plasma at 24 hoursfollowing administration of the indicated doses of murine IL12 mRNA tomice bearing tumors. The plasma concentration of IL12 (ng/ml) is shownbelow in Table 11.

TABLE 11 IL12 protein levels in plasma (ng/ml). Dose 1^(st) 2^(nd)3^(rd) 4^(th)   5 ug NST  0.007 ± 0.0008  0.001 ± 0.0012 0.006 ± n/a  —0.05 ug IL12_122 0.320 ± 0.117 0.165 ± 0.095 0.559 ± 0.725 0.143 ± 0.054 0.5 ug IL12_122 1.59 ± 1.65 2.02 ± 1.49 5.30 ± 9.57 1.21 ± 1.21   5 ugIL12_122 195.8 ± 123.3 176.8 ± 221.4 86.61 ± 40.53 69.87 ± 62.50

FIG. 17B shows increased levels of IFNγ at 24 hours in plasma followingadministration of murine IL12 mRNA to mice bearing tumors. This figuretherefore shows that administration of murine IL12 mRNA induces IFNγexpression over multiple doses.

Alternatively, mice bearing MC38 colon adenocarcinoma cells within theperitoneal cavity as a model of carcinomatosis were given a single fixedintraperitoneal (IP) dose of murine miR122 IL12 mRNA (at 2 μg or 4 μg),murine miRless IL12 mRNA (at 2 μg or 4 μg), or recombinant IL12 protein(rmIL12) (at 1 μg), on day 7 after MC38 cells were seeded. The levels ofplasma IL12 and IFNγ were determined after administration of the dosageusing standard techniques.

FIGS. 18A-18B show increased levels of IL12 in plasma (FIG. 18A) andIFNγ in plasma (FIG. 18B) following intraperitoneal (IP) administrationof murine IL12 mRNA to mice bearing MC38 tumors.

These data show that both intratumoral and intraperitonealadministration of IL-12 induces increased plasma levels of IFNγ.Additionally, multiple dosing of IL-12 in an MC38 tumor model inducesrepeated levels of both plasma IL-12 and IFNγ.

Example 9: In Vivo Anti-Tumor Efficacy of Intratumoral (iTu)Administration of IL12 miR122 mRNA in an A20 Model

A20 tumor cells were implanted subcutaneously in mice. A20 tumor-bearingmice were cohorted into 2 treatment groups (N=12). Mice were iTu dosedwith 0.5 μg mRNA in Compound 18-LNP, every 7 days (Q7D).

The control group was treated with negative control mRNA formulated inthe same LNP, whereas the treatment group was dosed with LNPs containingmurine IL12 mRNA with a miR122 binding site in the 3′ UTR(mIL12-miR122).

Tumor volumes were measured over the course of 90 days afterimplantation with A20 cells, and general clinical observations made inaccordance with an accepted IACUC protocol until a pre-determinedendpoint of 2000 mm³ tumor volume was reached.

The individual tumor volumes from mice treated with iTu dosing ofmL12-miR122 formulated in Compound 18-LNP are shown in FIG. 19B comparedto the negative control in FIG. 19A. FIG. 19B shows that four miceachieved complete response by Day 90.

Apparent complete responders (4/12) from FIG. 19B were re-challengedwith A20 tumor cells. Individual tumor volumes from re-challenged miceare shown in FIG. 19D compared to tumor growth in naïve mice challengedwith A20 in FIG. 19C. FIG. 19C shows that 9 out of 10 control micebearing newly implanted tumors reached its end point (2000 mm³ tumorvolume) by Day 45. However, FIG. 19D shows that all four completeresponders from FIG. 19B rechalleged with A20 tumor did not show anytumor growth through Day 60. This indicates that the mIL12-miR122 mRNAadministration provided the mice an immune memory response that issufficient to prevent tumor growth upon rechallenge.

Example 10: In Vivo Anti-Tumor Efficacy of Intratumoral (iTu)Administration of IL12 miR122 mRNA in an MC38-S Model

MC38-S cells were implanted into mice. Generally, MC38-S, also describedas MC38-2, is a more sensitive cell line to therapy. Without being boundby theory, one explanation for this observation is the increased levelsof CD45+ T cells, CD8+ Treg cells, Tumor associated macrophages (TAMs),and DCs observed as well as observations that MC38-S tumors are slowergrowing and more sensitive to tested IMTs. All of these characteristicsof MC38-S tumors are by comparison to MC38-R tumors (also described asMC38-1 or MC38-M) and both are useful models.

MC38-S tumor-bearing mice were cohorted into 4 treatment groups (N=15).Mice were iTu dosed with 0.05 μg, 0.5 μg, or 5 μg murine IL12 mRNA inCompound-18 LNP. As a negative control, mice were iTu dosed with NST-FIXmRNA or untreated. In single and multiple dose studies, mice in theexperimental and control groups received the same dosing regimen.

Tumor volumes and survival were measured in each group over the courseof 80 days after implantation with MC38-S cells and general clinicalobservations made in accordance with an accepted protocol until apre-determined endpoint of 1500 mm³ tumor volume was reached.

The individual tumor volumes from mice treated with a single iTu dose of0.05 μg murine IL12 mRNA are shown in FIG. 20A and FIG. 21A, micetreated with a single iTu dose of 0.5 μg murine IL12 mRNA are shown inFIG. 20B and FIG. 21B, mice treated with a single iTu dose of 5 μgmurine IL12 mRNA formulated are shown in FIG. 20C and FIG. 21C, comparedto appropriate negative controls in FIG. 20D. The pre-determinedendpoint of 1500 mm³ tumor volume indicated by horizontal black hashedline. FIGS. 20A and 21A show that six out of 15 mice achieved completeresponse. FIGS. 20B, 21B, 20C, and 21C show that 13 out of 15 miceachieved complete response, indicating that a low dose of 0.5 μg may besufficient to exert a maximally effective response given the similarresponse seen with 5 μg.

The individual tumor volumes from mice treated with two iTu doses of0.05 μg murine IL12 mRNA are shown in FIG. 21D, mice treated with twoiTu doses of 0.5 μg murine IL12 mRNA are shown in FIG. 21E, and micetreated with two iTu doses of 5 μg murine IL12 mRNA are shown in FIG.21F. The pre-determined endpoint of 1500 mm³ tumor volume indicated byhorizontal black hashed line. FIG. 21D shows that 9 out of 15 miceachieved complete response. FIGS. 21E and 21F show that 14 out of 15mice achieved a complete response. This data shows that in some tumortypes, a single administration of murine IL12 mRNA can achieve ananti-tumor effect that is sufficient to reduce or eliminate the tumor.

A dose response trend was clear between 0.05 and 0.5 μg dose levels. Athreshold appeared to be achieved ≤0.5 μg murine IL12 mRNA. Two doses ofIL12 mRNA were also beneficial above a single dose. All miceadministered any dose of murine IL12 mRNA displayed a survival benefit(FIG. 22). Therefore, the intratumoral administration of murine IL12mRNA delayed or reduced the growth or size of MC38-S tumors as comparedto an appropriate negative control and provided a survival benefit.

Example 11: In Vivo Anti-Tumor Efficacy of Intratumoral (iTu)Administration of IL12 miR122 mRNA in an MC38-R Model

MC38-R cells were implanted into mice. Generally, MC38-R, also referredto herein as MC38-1 or MC38-M, is a more resistant cell line to therapy.Without being bound by theory, one explanation for this observation isthe reduced levels of CD45+ T cells, CD8+ Treg cells, and DCs, and morecells that bear markers of “myeloid derived suppressor cells” wereobserved, as well as observations that MC38-R tumors are faster growingand generally less sensitive to tested immune-mediated therapies. All ofthese characteristics of MC38-R tumors are by comparison to MC38-Stumors and both are useful models.

MC38-R tumor-bearing mice were cohorted into 4 treatment groups (N=13).Mice were iTu dosed with 0.05 μg, 0.5 μg, or 5 μg murine IL12 mRNA inCompound-18 LNP. As a negative control, mice were iTu dosed with NST-FIXmRNA or untreated. In single and multiple dose studies, mice in theexperimental and control groups received the same dosing regimen.

Tumor volumes and survival were measured in each group over the courseof 75 days after implantation with MC38-R cells.

The individual tumor volumes from mice treated with a single iTu dose of0.05 μg murine IL12 mRNA are shown in FIG. 23A and FIG. 23E, micetreated with a single iTu dose of 0.5 μg murine IL12 mRNA formulated inan LNP are shown in FIG. 23B and FIG. 23F, mice treated with a singleiTu dose of 5 μg murine IL12 mRNA formulated in an LNP are shown in FIG.23C and FIG. 23G, compared to appropriate negative controls in FIG. 23D.The pre-determined endpoint of 2000 mm³ tumor volume indicated byhorizontal black hashed line. FIGS. 23A and 23E show that no micebearing MC38-R tumor after administration of 0.05 μg of murine IL12 mRNAachieved complete response. FIGS. 23B and 23F show that two mice bearingMC38-R tumor after administration of 0.5 μg of murine IL12 mRNA achievedcomplete response. FIGS. 23C and 23G show that four mice bearing MC38-Rtumor after administration of 5 μg of murine IL12 mRNA achieved completeresponse.

The individual tumor volumes from mice treated with multiple iTu dosesof 0.05 g murine IL12 mRNA are shown in FIG. 23H, mice treated with twoiTu doses of 0.5 g murine IL12 mRNA formulated in an LNP are shown inFIG. 23I, and mice treated with two iTu doses of 5 μg murine IL12 mRNAformulated in an LNP are shown in FIG. 23J. The pre-determined endpointof 2000 mm³ tumor volume indicated by horizontal black hashed line.FIGS. 23H-23J show that multiple administrations have similar efficacyas single administration.

These results indicate that despite the demonstrated resistance ofMC38-R tumors to other immune mediated therapies, such as anti-PD1 andanti-PD-L1 antagonist antibodies, mice administered murine IL12 mRNAdisplayed a survival benefit (FIG. 24). Survival events included tumorburden endpoints and animals off study due to ulceration/eschar whichoccurred in treated and non-treated mice. The intratumoraladministration of murine IL12 mRNA delayed the growth of MC38-R tumorsas compared to an appropriate negative control and provided a survivalbenefit and was generally well tolerated.

The levels of tumor and plasma IL12 p70, as well as the level of othercytokines, were determined at 24 hours after administration of thedosages. The results show dose dependent levels of IL12 in plasma withintratumoral administration of murine IL12 mRNA as shown previously. Theresults also show sustained dose-dependent expression of TNFα, IL-10,IL-13, IL-15/15R, IL-27, MIP-113, MIP-1α, MCP-1, MCP-3, M-CSF, IL-4, andIL-5 after multiple murine IL12 dosing (data not shown). GM-CSF, IL-18,IL-3, RANTES and IL-6 had elevated expression levels only following 5 μgmurine IL12 dosing (data not shown).

Example 12: CD8+ T Cells Involved in IL12 mRNA Efficacy

To evaluate the role of CD8+ T cells in mediating IL12 mRNA inducedefficacy, MC38-R cells were implanted into mice, the CD8+ Tcell-depleting clone 24.3 was used to deplete CD8+ T cells and CD8+ Tcell levels were monitored in blood to confirm depletion over the courseof the efficacy study. The 24.3 clone or a control antibody was given tomice 2 days prior to administration of murine IL12 mRNA. The depletingor control antibody was given at 0.5 mg daily for 3 consecutive days, 3days off, then another five antibody doses at 0.2 mg given every 4 days.Flow cytometry was performed throughout the experiment to confirm CD8+ Tcell depletion.

Using the 24.3 clone, CD8+ T cells were depleted over the course of 28days, whereas an antibody control did not deplete CD8+ T cells (FIG.25). CD8+ T cell numbers in blood were significantly decreased at alltime points examined by flow cytometry, thus confirming effectivedepletion.

Mice given 0.5 μg murine IL12 mRNA after CD8+ T cell depletion via clone24.3 displayed increased tumor volume (FIG. 26D) compared to mice given0.5 μg murine IL12 mRNA after mock CD8+ T cell depletion (FIG. 26B).Likewise, mice given 0.5 μg murine IL12 mRNA after CD8+ T cell depletiondisplayed poor survival compared to mice given 0.5 μg murine IL12 mRNAafter mock CD8+ T cell depletion (FIG. 26E). FIG. 26A shows tumor volumein mice treated with negative control mRNA after mock CD8+ T celldepletion, and FIG. 26C shows tumor volume in mice treated with negativecontrol mRNA after CD8+ T cell depletion. Although murine IL12 mRNAtreatment appeared to result in some delay in tumor growth even withCD8+ T cell depletion, there were no complete responders in the absenceof cytotoxic T cells in contrast to the clear survival benefit observedwith murine IL12 mRNA treatment and mock depletion. The results indicatethat CD8+ T cells play an essential role in IL12 mRNA mediated efficacy.

Example 13: Significant Changes in the Immune Infiltrate in MC38-R andB16F10-AP3 Tumors Following Intratumoral Administration of IL12 mRNA

Significant changes occurred in the immune cell infiltrate in bothMC38-R and B16F10-AP3 tumors following treatment with IL12 mRNA. MC38-Rtumors were treated intratumorally with 0.05 μg or 0.5 μg murine IL12mRNA and B16F10-AP3 tumors were treated intratumorally with 0.1 μg or0.5 μg murine IL12 mRNA.

In both the MC38-R and B16F10-AP3 models the percentage of CD11b+myeloid cells within the tumor staining positive for PDL1 expressionincreased significantly at most time points, following IL12 mRNAtreatment (FIG. 27A and FIG. 27B).

IL12 mRNA treatment further correlated with an increase in CD8+ T cellwithin tumors in both MC38-R and B16F10-AP3 mouse models at late timepoints. In particular, the percent of T cells, as evidenced by theproportion of CD8+ T cells out of the immune infiltrate (CD45+ cells)and the number of CD8+ positive cells per mg of tumor tissue, wasstatistically higher 7 days after administration of 0.5 μg murine IL12mRNA in both mouse models (FIGS. 28A and 28B). Furthermore, asignificantly higher number of T cells were observed in tumors inB16F10-AP3 mice treated with 0.1 μg murine IL12 mRNA, as evidenced bythe proportion of CD8+ T cells out of the immune infiltrate (CD45+cells) (FIG. 28B). Both the percent of CD45 positive cells and the cellsper mg are informative. At day 7, tumors in treatment groups are smallerthan controls, particularly for the 0.1 μg and 0.5 μg groups.

An increased ratio of CD8+ cells to T regulatory (Treg) cells (CD8:Treg)was seen in both MC38-R (FIG. 29A) and B16F10-AP3 (FIG. 29B) mousemodels, demonstrating an improved effector to suppressor ratio. Inparticular, MC38-R mice treated with 0.05 μg or 0.5 μg murine IL12 mRNAexhibited statistically significant higher ratios of CD8+ T cells toTreg cells as compared to negative controls, resulting from both anincrease in CD8+ cells and a decrease in Treg cells in tumor tissue atday 7 (FIG. 29A). Similarly, B16F10-AP3 mice treated with 0.1 μg or 0.5μg murine IL12 mRNA exhibited statistically higher ratios of CD8+ Tcells to Treg cells as compared to negative controls, resulting from anincrease in CD8+ cells (FIG. 29B).

Expression of CD69, which is indicative of activation of T lymphocytesand NK cells, was increased on CD8+ T cells in both MC38-R andB16F10-AP3 tumors (FIGS. 30A-30B).

Activation of natural killer (NK) cells was also seen in both MC38-R andB16F10-AP3 tumors treated with IL-12 mRNA (FIGS. 31A and 31B).

An increase in cross-presenting dendritic cells was observed in bothMC38-R and B16F10-AP3 tumor models. CD103+ cDC increases were observedin both MC38-R (FIG. 32A) and B16F10-AP3 tumors (FIG. 32B) at day 7. Inaddition, a greater percent of activated CD8+ cDCs were found in thedraining lymph node following treatment with murine IL12 mRNA at each of24 hrs, 72 hrs, and day 7 as compared to controls in B16F10-AP3 tumors(FIG. 32C).

Example 14: In Vivo Anti-Tumor Efficacy of IL12 Modified mRNA inCombination with Anti-PD-L1 Antibody in an MC38-R Model

Given the increased expression of PD-L1 (see Example 11 above) afteradministration of murine IL12 mRNA, the efficacy of a combinationtherapy of murine IL12 mRNA and an anti-PD-L1 antibody was studied. Toevaluate the efficacy of anti-PD-L1 antibody monotherapy, mice bearingMC38-R tumor were administered a murine anti-PD-L1 antibody obtainedfrom clone 80. FIG. 33A shows tumor volume changes in mice afteradministration of an antibody control. FIG. 33B shows tumor volumechanges after administration of the anti-PD-L1 antibody. All micereached the end point (i.e., 2000 mm³ tumor) demonstrating insensitivityof this model to anti-PD-L1 treatment.

Mice bearing MC38-R tumor were administered iTu either (i) murine IL12mRNA alone, or (ii) murine IL12 mRNA and a murine anti-PD-L1 antibody incombination. Three dosages of mRNA were tested, i.e., 0.05 μg (data notshown), 0.5 μg, and 5 μg. Tumor volumes and survival were measured ineach group (n=15) over the course of 90 days after implantation withMC38-R cells and general clinical observations made in accordance withan accepted protocol until a pre-determined endpoint of 2000 mm³ tumorvolume was reached.

FIGS. 33C and 33E show that the combination therapy with 0.5 μg murineIL12 mRNA resulted in complete response in 6 out of 15 mice while only 1out of 15 mice achieved complete response after administration of murineIL12 mRNA alone. FIGS. 33D and 33F show that 11 out of 15 mice achievedcomplete response in the combination therapy with 5 μg murine IL12 mRNAwhile only 5 out of 15 mice achieved complete response afteradministration of murine IL12 mRNA alone. FIG. 33G shows data thatconfirm a murine anti-PD-L1 antibody alone did not have any anti-tumorefficacy in mice bearing MC38-R in this study. The results show that thecombination therapy of murine IL12 mRNA and a checkpoint inhibitor,e.g., an anti-PD-L1 antibody, can display synergistic efficacy in tumorsotherwise resistant to checkpoint inhibitor therapy, e.g., MC38-R.

Example 15: In Vivo Anti-Tumor Efficacy of Intratumoral Administrationof IL12 Modified mRNA in Combination with an Anti-PD-L1 Antibody

MC-38 colon adenocarcinoma tumors were implanted subcutaneously in miceas described in Rosenberg et al., Science 233:1318-1321 (1986)).

MC38-R or B16F10-AP3 mice tumor bearing-mice were administered a singleintratumoral dose of LNP-formulated murine IL12 modified mRNA (IL12 mRNAwith miR122 formulated with Compound 18-based LNP) at a dose of either0.05 μg, 0.5 μg, or 5 μg, alone or in combination with anintraperitoneal dose of anti-PD-L1 antibody (clone 80). Additional doseswere administered as indicated below.

A. Results

To test the effect of combined treatment with a murine IL12 mRNA and ananti-PD-L1 antibody (αPD-L1), MC38-R mice were treated eleven days postimplant with a murine anti-PD-L1 antibody alone (FIG. 34A), 0.5 μgmurine IL12 mRNA alone (FIG. 34B), or both a murine anti-PD-L1 antibodyand 0.5 μg murine IL12 mRNA (FIG. 34C). Treatment using an anti-PD-L1antibody alone had little effect on tumor growth (FIG. 34A), andtreatment with a single dose of 0.5 μg murine IL12 mRNA resulted in oneCR (FIG. 34B). When murine IL12 mRNA intratumoral treatment was combinedwith anti-PD-L1 administration (administered in six doses), there was alarge increase in the number of CRs observed. Eight out of fifteen mice(53%) exhibited a complete response following a single dose of 0.5 μgmurine IL12 mRNA in combination with an anti-PD-L1 antibody (FIG. 34C),

The synergistic effect of combination treatment using murine IL12 mRNAand an anti-PD-L1 antibody was further observed in B16F10-AP3 mice,which are thought to be immunologically barren and are also resistant tocheckpoint blockade therapies such as anti-PDL1. While untreatedB16F10-AP3 mice (FIG. 35A) and B16F10-AP3 treated with an anti-PD-L1antibody alone (FIG. 35B) or a single dose of 0.5 μg murine IL12 mRNAalone (FIG. 35C) yielded no CRs, mice treated with a single dose of 0.5μg murine IL12 mRNA in combination with an anti-PD-L1 antibody(administered in six doses on days 11, 14, 18, 21, 25, and 28) resultedin two CRs out of fifteen mice (FIG. 35D).

Example 16: Abscopal Effect Following Murine IL12 mRNA Administrationwithin a Distal Tumor

To investigate potential abscopal effects of murine IL12 mRNAintratumoral administration, MC38 colon adenocarcinoma tumors wereimplanted bilaterally in mice (MC38-S; FIG. 36A). In an ongoing study,17/20 MC38-S tumors treated with 0.5 μg murine IL12 mRNA (FIG. 36D) and19/20 MC38-S tumors treated with 5 μg murine IL12 mRNA (FIG. 36F) havethus far exhibited a complete response after about 50 months. Inaddition, 3/20 distal tumors in the 0.5 μg murine IL12 mRNA-treated mice(FIG. 36E) and 16/20 distal tumors in the 5 μg murine IL12 mRNA-treatedmice have thus far exhibited a complete response after about 50 months(FIG. 36G). The results with negative control are shown in FIGS. 36B and36C.

These abscopal effects are amplified when murine IL12 mRNA treatment iscombined with anti-PD-L1 treatment, in an ongoing study. Mice implantedwith bilateral MC38 tumors were administered intratumorally into onetumor either 0.5 μg murine L12 mRNA (FIG. 37C-37D) or 5 μg murine IL12mRNA (FIG. 37E-37F) either as a monotherapy (FIGS. 37C and 37E) orcombined with an anti-PD-L1 antibody (administered by IP injection of 20mg/kg twice per week for two weeks; FIGS. 37D and 37F). Thus far, 3/20CRs and 16/20 CRs were observed bilaterally in the 0.5 μg (FIG. 37C) and5 μg (FIG. 37E) murine IL12 mRNA-treated mice, and 8/20 CRs and 20/20CRs were observed bilaterally in the mice treated with a combination ofanti-PD-L1 and 0.5 μg (FIG. 37D) or 5 μg (FIG. 37F) murine IL12 mRNA.The results with negative control are shown in FIGS. 37A and 37B.

Example 17: Evaluation of Codon-Optimized mRNAs Encoding Human IL12

In addition to the mIL12_miR122 construct generated in Example 1, 20codon-optimized mRNAs encoding human IL12 polypeptide (hIL12AB_001-020)were prepared. These mRNAs also had a miR-122 binding site in the 3′UTR.

The mRNAs were fully modified with N1-methylpseudouridine. The modifiedmRNAs were formulated in MC3 lipid nanoparticles (LNP) for screening.HeLa cells were transfected using a standard transfection protocol andexpression was determined ˜22 hours post-transfection. Expression wasnormalized to that from the wild-type muIL12 construct. Most constructstested had expression equal to or up to ˜2-fold over the miL12 miR122construct.

Constructs having high expression in HeLa cells were also tested forexpression in MC38 cells, Heb3B cells and A20 cells to confirmexpression in various tumor cell lines.

Variants hIL12AB_002, hIL12AB_006 and hIL12AB_021 were further selectedfor testing in vivo. C57B16 mice were implanted subcutaneously with A20cells (A20 tumor model). Tumors were allowed to grow and tumorssubsequently injected intratumorally with LNP-encapsulated mRNAs.Plasma, tumor, liver and spleen were collected 6 and 24 hourspost-administration of a single intratumoral dose of mRNA. (n=6 pergroup.) Variants hIL12AB_002 and hIL12AB_006, in particular, showed goodexpression as compared to mIL12_miR122 mRNA, e.g., in plasma and tumor.

Based on the collective screening in vitro and in vivo, hIL12AB_002 wasselected as a preferred mRNA encoding hIL12AB (FIG. 38).

Other Embodiments

It is to be understood that the words which have been used are words ofdescription rather than limitation, and that changes can be made withinthe purview of the appended claims without departing from the true scopeand spirit of the disclosure in its broader aspects.

While the present disclosure has been described at some length and withsome particularity with respect to the several described embodiments, itis not intended that it should be limited to any such particulars orembodiments or any particular embodiment, but it is to be construed withreferences to the appended claims so as to provide the broadest possibleinterpretation of such claims in view of the prior art and, therefore,to effectively encompass the intended scope of the disclosure.

All publications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety. Incase of conflict, the present specification, including definitions, willcontrol. In addition, section headings, the materials, methods, andexamples are illustrative only and not intended to be limiting.

It is to be appreciated that the Detailed Description section, and notthe Summary and Abstract sections, is intended to be used to interpretthe claims. The Summary and Abstract sections may set forth one or morebut not all exemplary embodiments of the present disclosure ascontemplated by the inventor(s), and thus, are not intended to limit thepresent disclosure and the appended claims in any way.

The present disclosure has been described above with the aid offunctional building blocks illustrating the implementation of specifiedfunctions and relationships thereof. The boundaries of these functionalbuilding blocks have been arbitrarily defined herein for the convenienceof the description. Alternate boundaries can be defined so long as thespecified functions and relationships thereof are appropriatelyperformed.

The foregoing description of the specific embodiments will so fullyreveal the general nature of the disclosure that others can, by applyingknowledge within the skill of the art, readily modify and/or adapt forvarious applications such specific embodiments, without undueexperimentation, without departing from the general concept of thepresent disclosure. Therefore, such adaptations and modifications areintended to be within the meaning and range of equivalents of thedisclosed embodiments, based on the teaching and guidance presentedherein. It is to be understood that the phraseology or terminologyherein is for the purpose of description and not of limitation, suchthat the terminology or phraseology of the present specification is tobe interpreted by the skilled artisan in light of the teachings andguidance.

The breadth and scope of the present disclosure should not be limited byany of the above-described exemplary embodiments, but should be definedonly in accordance with the following claims and their equivalents.

What is claimed is:
 1. A method for treating cancer in a subject byinducing an anti-tumor immune response, comprising administeringintratumorally to the subject a lipid nanoparticle (LNP) encapsulatedmessenger RNA (mRNA) comprising an open reading frame (ORF) encoding ahuman IL-12 polypeptide, wherein the LNP comprises a molar ratio ofabout 20-60% ionizable amino lipid; 5-25% phospholipid; 25-55% sterol;and 0.5-15% PEG-modified lipid.
 2. The method of claim 1, wherein theORF encodes a human IL-12B polypeptide operably linked to a human IL-12Apolypeptide.
 3. The method of claim 2, wherein the IL-12B polypeptide isoperably linked to the IL-12A polypeptide by a peptide linker, andwherein the peptide linker comprises a Gly/Ser linker.
 4. The method ofclaim 1, wherein the human IL12 polypeptide comprises an amino acidsequence set forth in SEQ ID NO:
 48. 5. The method of claim 1, whereinthe anti-tumor response comprises a T-cell response, IFNγ production, orboth a T-cell response and IFNγ production.
 6. A method for treatingcancer in a subject by inducing an anti-tumor immune response,comprising administering intratumorally to the subject a LNPencapsulated mRNA comprising an ORF encoding a human IL-12 polypeptide,wherein the LNP comprises an ionizable amino lipid; a phospholipid; asterol; and a PEG-modified lipid, and wherein the mRNA comprises an ORFcomprising a nucleotide sequence at least 90% identical to SEQ ID NO:237.
 7. The method of claim 6, wherein the mRNA comprises the nucleotidesequence as set forth in SEQ ID NO:
 237. 8. The method of claim 7,wherein the mRNA comprises a 3′ UTR comprising a microRNA binding site,wherein the microRNA binding site is a miR-122-3p or a miR-122-5pbinding site.
 9. The method of claim 8, wherein the miR-122-5p bindingsite comprises the sequence set forth in SEQ ID NO:
 54. 10. The methodof claim 7, wherein the mRNA comprises a 3′ UTR comprising the sequenceset forth in SEQ ID NO:
 240. 11. The method of claim 10, wherein themRNA comprises a 5′ UTR comprising the sequence set forth in SEQ ID NO:135.
 12. The method of claim 7, wherein the mRNA is fully modified withchemically-modified uridines.
 13. The method of claim 12, wherein thechemically-modified uridines are N1-methylpseudouridines (m1ψ).
 14. Themethod of claim 6, wherein the anti-tumor response comprises a T-cellresponse, IFNγ production, or both a T-cell response and IFNγproduction.
 15. The method of claim 1, wherein the mRNA comprises anucleotide sequence at least 90% to SEQ ID NO:
 96. 16. The method ofclaim 15, wherein the mRNA comprises the nucleotide sequence as setforth in SEQ ID NO:
 96. 17. The method of claim 16, wherein the mRNA isfully modified with N1-methylpseudouridines (m1ψ).
 18. The method ofclaim 1, wherein the ionizable amino lipid comprises a compound havingthe formula


19. The method of claim 1, wherein the LNP comprises a molar ratio ofabout 50% ionizable amino lipid; 10% phospholipid; 38.5% cholesterol;and 1.5% PEG-modified lipid.
 20. The method of claim 19, wherein theionizable amino lipid comprises a compound having the formula